

Program at a Glance

CROI 2016

Conference on Retroviruses
and Opportunistic Infections

February 22-25, 2016
Boston, Massachusetts



 **IAS-USA**
International Antiviral Society-USA

CONTENTS

CROI FOUNDATION	2
IAS—USA	2
CROI 2016 PROGRAM COMMITTEE	3
Scientific Program Committee	3
Community Liaison Subcommittee	4
EXTERNAL REVIEWERS	5
SCHOLARSHIP AWARDEES	7
Young Investigators	7
International Scholars	11
Community Educators	12
CONTINUING MEDICAL EDUCATION	13
Accreditation Statement	13
Objectives	13
Statement of Need	13
CME Credit Information	13
Claiming CME Credits or a Certificate of Participation	13
Disclosure of Financial Relationships	13
Drug and Product Disclaimer	13
GENERAL INFORMATION	14
Overview	14
Commercial Support	6
Americans with Disabilities Act	14
Emergency Services	14
Embargo Policies / Social Media	14
Welcome Reception	14
Wi-Fi	14
Meals	14
Overflow Accommodations for Session Rooms	15
Website	15
Webcasts and Podcasts	15
Affiliated Activity Policies	15
Mobile App	15
Badges	15
Child Care	15
Conference Etiquette	15
CONFERENCE SERVICES	16
HOTEL INFORMATION	17
ABSTRACT PROCESS	19
ORAL SESSIONS	21
POSTER SESSIONS, BY CATEGORY	50
DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS ..	128
INDEX OF STUDIES RELATED TO WOMEN	134
AUTHOR INDEX	137
KEYWORD INDEX	165
CONFERENCE SCHEDULE OVERVIEW	Inside Back Cover
CONVENTION CENTER FLOOR PLANS	Back Cover

CROI FOUNDATION

The CROI Foundation is a 501(c)(3) tax-exempt organization in the United States that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and IAS-USA to accomplish the mission of CROI
- Approves nominations annually for members of the CROI PC and the CROI Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with IAS-USA

- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

Composition of the CROI Foundation Board of Directors

The Board of Directors comprises current and previous CROI Chairs and Vice Chairs and selected members of the CROI PC.

CROI Foundation Board of Directors

Constance A. Benson, MD, President

University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD, Secretary-Treasurer

Tufts University
Boston, MA, United States

Elaine J. Abrams, MD

International Center for AIDS Care and Treatment Programs
Columbia University
New York, NY, United States

Susan P. Buchbinder, MD

San Francisco Department of Public Health
University of California San Francisco
San Francisco, CA, United States

Judith S. Currier, MD, MSc

University of California Los Angeles
Los Angeles, CA, United States

Kevin M. De Cock, MD

Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD

Columbia University Medical Center/New York—Presbyterian Hospital
New York, NY, United States

John W. Mellors, MD

University of Pittsburgh
Pittsburgh, PA, United States

Julie M. Overbaugh, PhD

Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Robert T. Schooley, MD

University of California San Diego
San Diego, CA, United States

Richard A. Koup, MD

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD, United States

IAS—USA

The International Antiviral Society—USA is a 501(c)(3) not-for-profit professional education organization. The IAS—USA serves as the Conference Secretariat for CROI.

The mission of the IAS—USA is to improve the treatment, care, and quality of life for people with HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Contact: Executive Director, Donna M. Jacobsen

Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120

Phone: 415-544-9400

Website: www.iasusa.org



CROI 2016 SCIENTIFIC PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The "goodwill ambassadors" of CROI, PC members are also responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, and convening workshops, symposia, and special sessions.

Scientific Program Committee



Julie M. Overbaugh, PhD
CROI 2016 Chair
Fred Hutchinson Cancer
Research Center
Seattle, WA,
United States



Susan P. Buchbinder, MD
CROI 2016 Vice Chair
San Francisco Department
of Public Health
University of California
San Francisco
San Francisco, CA,
United States



Judith S. Currier, MD, MSc
CROI 2016 Vice Chair
University of California
Los Angeles
Los Angeles, CA,
United States



Elaine J. Abrams, MD
ICAP at Columbia University
New York, NY, United States



John M. Coffin, PhD
Tufts University
Boston, MA, United States



Scott M. Hammer, MD
Columbia University Medical
Center
New York-Presbyterian Hospital
New York, NY, United States



Galit Alter, PhD
Ragon Institute of MGH, MIT,
and Harvard
Cambridge, MA, United States



Kevin M. De Cock, MD
Centers for Disease Control
and Prevention
Nairobi, Kenya



Diane V. Havlir, MD
University of California
San Francisco
San Francisco, CA,
United States



Constance A. Benson, MD
University of California
San Diego
San Diego, CA, United States



**Wafaa M. El-Sadr,
MD, MPH**
ICAP at Columbia University
New York, NY, United States



Sharon L. Hillier, PhD
Magee-Womens Hospital
of University of Pittsburgh
Medical Center
Pittsburgh, PA, United States



Bruce J. Brew, MD, MBBS
St. Vincent's Hospital
Sydney, Australia



**Courtney V. Fletcher,
PharmD**
University of Nebraska
Medical Center
College of Pharmacy
Omaha, NE, United States



James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA,
United States



Ellen G. Chadwick, MD
Northwestern University
Ann & Robert H. Lurie
Children's Hospital of Chicago
Chicago, IL, United States



Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland



Peter W. Hunt, MD
University of California
San Francisco
San Francisco, CA,
United States



Richard E. Chaisson, MD
The Johns Hopkins University
Baltimore, MD, United States



Timothy Hallett, PhD
Imperial College London
London, United Kingdom



Harold W. Jaffe, MD
Centers for Disease Control
and Prevention
Atlanta, GA, United States



Ilesh V. Jani, MD, PhD
Instituto Nacional de Saúde
Maputo, Mozambique



Frank Kirchoff, PhD
Institute of Molecular Virology
Ulm, Germany



Dennis L. Kolson, MD, PhD
University of Pennsylvania
Philadelphia, PA,
United States



Richard A. Koup, MD
Vaccine Research Center
National Institute of Allergy
and Infectious Diseases
National Institutes of Health
Bethesda, MD, United States



Hermione Lyall, MD
Imperial College Healthcare
National Health Service Trust
London, England



**James A. McIntyre,
MBChB, FRCOG**
Anova Health Institute
Johannesburg, South Africa



John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, United States



Ronald T. Mitsuyasu, MD
University of California
Los Angeles
Los Angeles, CA, United States



Andrew N. Phillips, PhD
University College London
London, England



Peter Reiss, MD, PhD
University of Amsterdam
Amsterdam, Netherlands



Douglas D. Richman, MD
University of California
San Diego
La Jolla, CA, United States



Jürgen K. Rockstroh, MD
University of Bonn
Bonn, Germany



Robert T. Schooley, MD
University of California
San Diego
La Jolla, CA, United States



Guido Silvestri, MD
Emory University and Yerkes
National Primate Research
Center
Atlanta, GA, United States



Serena S. Spudich, MD, MA
Yale University
New Haven, CT, United States



Mario Stevenson, PhD
University of Miami
Miami, FL, United States



Wesley I. Sundquist, PhD
University of Utah
School of Medicine
Salt Lake City, UT,
United States



Amalio Telenti, MD, PhD
The J. Craig Venter Institute
La Jolla, CA, United States



David L. Thomas, MD
The Johns Hopkins University
Baltimore, MD, United States



Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland

Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.



Mark Hubbard
Tennessee Association of
People With AIDS
Nashville, TN, United States



**Morenike Ukpong-Folayan,
FWACS, MBA, BChD**
Obafemi Awolowo University
Ile-Ife, Nigeria



Jeff Taylor
AIDS Treatment
Activists Coalition
Palm Springs, CA,
United States



Steven F. Wakefield
HIV Vaccine Trials Network
Fred Hutchinson Cancer
Research Center
Seattle, WA, United States

EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2016 .

Edward P. Acosta, PharmD

University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD

University of Colorado
Aurora, CO, United States

Till Bärnighausen, MD, PhD, ScD, MSc

Harvard University
Boston, MA, United States

John M. Blandford, PhD

Centers for Disease Control and Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD

Chelsea and Westminster Hospital and
National Health Service Foundation Trust
London, United Kingdom

Jacob Bor, PhD

Boston University School of Public Health
Boston, MA, United States

William Borkowsky, MD

New York University School of Medicine
New York, NY, United States

John T. Brooks, MD

Centers for Disease Control and Prevention
Atlanta, GA, United States

Todd T. Brown, MD, PhD

Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD

Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Nicolas Chomont, PhD

Vaccine and Gene Therapy Institute of Florida
Port St Lucie, FL, United States

David B. Clifford, MD

Washington University School of Medicine
Saint Louis, MO, United States

Susan E. Cohn, MD

Northwestern University
Chicago, IL, United States

Elizabeth Connick, MD

University of Colorado Denver
Aurora, CO, United States

Elizabeth Connick, MD

University of Colorado Denver
Aurora, CO, United States

Eric S. Daar, MD

Harbor—University of California Los Angeles
Medical Center
Torrance, CA, United States

David Evans, PhD

University of Wisconsin—Madison
Madison, WI, United States

Charles W. Flexner, MD

The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD

St. Jude Children's Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD

Case Western Reserve University
Cleveland, OH, United States

Dana Gabuzda, MD

Dana-Farber Cancer Institute
Boston, MA, United States

Monica Gandhi, MD, MPH

University of California San Francisco
San Francisco, CA, United States

Elvin H. Geng, MD, MPH

University of California San Francisco
San Francisco, CA, United States

J. Gerardo Garcia-Lerma, PhD

Centers for Disease Control and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD

University of Padova
Padova, Italy

Francisco Gonzalez-Scarano, MD

University of Texas
San Antonio, TX, United States

Steven K. Grinspoon, MD

Massachusetts General Hospital and
Harvard University
Boston, MA, United States

Beatrice H. Hahn, MD

University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD

University of Zimbabwe
Harare, Zimbabwe

Timothy Hallett, PhD

Imperial College London
London, United Kingdom

P. Richard Harrigan, MD

British Columbia Centre for Excellence in
HIV/AIDS
Vancouver, BC, Canada

Diane V. Havlir, MD

University of California San Francisco
San Francisco, CA, United States

Priscilla Y. Hsue, MD

University of California San Francisco
San Francisco, CA, United States

Roger Kouyos, PhD

University Hospital Zurich
Zurich, Switzerland

Susan E. Krown, MD

AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD, MSc

University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledergerber, PhD

University of Zurich
Zurich, Switzerland

Scott L. Letendre, MD

University of California San Diego
San Diego, CA, United States

Sharon R. Lewin, MD

The Doherty Institute for Infection
and Immunity
Melbourne, Australia

Anne F. Luetkemeyer, MD

University of California San Francisco
San Francisco, CA, United States

Patrick Mallon, PhD, MBBS

University College Dublin
Dublin, Ireland

Natasha Martin, DPhil

University of California San Diego
San Diego, CA, United States

Nelly R. Mugo, MPH, MBChB, MMed
Kenya Medical Research Institute
Thika, Kenya

Victor Musiime, PhD, MBChB
Makerere University College of Health
Sciences
Kampala, Uganda

Landon Myer, MD, PhD
University of Cape Town
Cape Town, South Africa

Susanna Naggie, MD, MHS
Duke Clinical Research Institute
Durham, NC, United States

Ariela Noy, MD
Memorial Sloan Kettering Cancer Research
Center
New York, NY, United States

Jean-Michel Pawlotsky, MD, PhD
Henri Mondor University Hospital
Creteil, France

**Martina Penazzato, MD, PhD,
MSc, DTMH**
World Health Organization
Geneva, Switzerland

Paul Revill, MSc
University of York
York, United Kingdom

Sharon A. Riddler, MD
University of Pittsburgh
Pittsburgh, PA, United States

Lesley Scott, MD
National Health Laboratory Service
Johannesburg, South Africa

Kenneth E. Sherman, MD
University of Cincinnati
Cincinnati, OH, United States

Davey M. Smith, MD
University of California San Diego
San Diego, CA, United States

Magdalena Sobieszczyk, MD, MPH
Columbia University
New York, NY, United States

Serena S. Spudich, MD, MA
Yale University
Guilford, CT, United States

David L. Wyles, MD
University of California San Diego
San Diego, CA, United States

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, United States

Michael T. Yin, MD
Columbia University Medical Center
New York, NY, United States

Clement Zeh, PhD, MPH
Centers for Disease Control and Prevention
Atlanta, GA, United States

COMMERCIAL SUPPORT

CROI is largely supported by participant registration fees. In addition, the organizers seek grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations.

Please note, CROI registration fees cover all attendee meals (including the welcome reception) and travel expenses for selected invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.

CROI 2016 received grant support commitments from the following commercial companies:

Platinum

Merck & Co, Inc
ViiV Healthcare

Gold

Bristol-Myers Squibb
Gilead Sciences, Inc
Janssen Therapeutics

Additional support has been provided by AbbVie and Mylan, Inc.

YOUNG INVESTIGATOR SCHOLARSHIP AWARDEES

Enass Abdel-Hameed

University of Cincinnati

Mohamed Abdel-Mohsen

University of California San Francisco

Shaheed Abdulhaqq

Oregon Health and Science University

Kristina Adachi

University of California Los Angeles

Emily Adland

University of Oxford

Sama Adnan

Emory University

Hisashi Akiyama

Boston University

Melanie Alvarado

University of Alaska Anchorage

Brett Anderson

University of Minnesota

Sophie Andrews

University of Oxford

Kaitlin Anstett

McGill University

Prabhu Arunachalam

Jawaharlal Nehru Centre for Advanced Scientific Research

Sara Auld

Emory University

Roger Badia

IrsiCaixa

Ester Ballana

IrsiCaixa

Riddhma Banga

Centre Hospitalier Universitaire Vaudois

Linda Battalora

Colorado School of Mines

Fatai Bello

Lagos University Teaching Hospital

Priya Bhagwat

University of California Los Angeles

Tamara Sonia Boender

Amsterdam Institute for Global Health and Development

David Boettiger

University of New South Wales

Andrea Bonito

University of Brescia

Denali Boon

Johns Hopkins University

Alvaro Borges

University of Copenhagen

Alana Brennan

Boston University

Yann Breton

Université Laval-CHU de Québec

Katherine Bruner

Johns Hopkins University

Matthew Budd

University of British Columbia

Marcus Buggert

University of Pennsylvania

Ellsworth Campbell

Oak Ridge Institute of Science and Education

Margaret Caplan

University of California Los Angeles

Emily Cartwright

Emory University

Javier Cepeda

Johns Hopkins University

Maddalena Cerrone

University of Milan

Antoine Chaillon

University of California San Diego

Jingxian Chen

University of North Carolina at Chapel Hill

Sukrutha Chettimada

Dana-Farber Cancer Institute

Christopher Ching

University of California Los Angeles

Avantika Chitre

University of California San Francisco

Calvin Chiu

University of the Witwatersrand

Aaron Christensen-Quick

University of California San Diego

Shang-Lin Chung

Yale University

Nicoletta Ciccarelli

Catholic University of Rome

Anthony Cillo

University of Pittsburgh

Meredith Clement

Duke University Hospital

Dami Collier

University College London

Paul Collini

University of Sheffield

Nicola Cotugno

Children Hospital Bambino Gesù

Richard Court

University of Cape Town

Subathira Dakshina

Barts Health NHS Trust

Abderaouf Damouche

University Paris Sud

Jennifer Dan

University of California San Diego

Alessandro D'Avino

Università Cattolica del Sacro Cuore

Thibaut Davy

University of North Carolina at Chapel Hill

Laura de la Fuente Soro

Barcelona Institute for Global Health

Christine Paula de los Angeles

Northwestern University

Eric Declodet

Stellenbosch University

Nicholas DeGroot

Centers for Disease Control and Prevention

Michelino Di Rosa

University of Catania

David Dolling

University College London

Maggie Dorr

George Washington University

Yimin Du

University of Alabama at Birmingham

Léa Duchesne

INSERM U1136

Adam Ericson

University of Wisconsin-Madison

Zelda Euler

Ragon Institute of MGH, MIT, and Harvard

Amanda Fabra García

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Michelli Faria de Oliveira

University of California San Diego

Alison Feder

Stanford University

Michael Freeman

Case Western Reserve University

Mario Frías

Instituto Maimonides de
Investigación Biomédica
de Córdoba

Matthew Gagne

Boston University

Carolina Garrido

University of North Carolina at
Chapel Hill

Pascal Geldsetzer

Harvard University

Varghese George

University of Miami

Matine Ghadrshenas

University of Washington

Joshua Gini

Federal Ministry of
Health Nigeria

Julia Goldberg Raifman

Johns Hopkins University

Monica Golumbeanu

ETH Zürich

Elisabet Gómez-Mora

IrsiCaixa

Anda Gonciulea

Johns Hopkins University

Morgane Gossez

University of Oxford

Charitha Gowda

University of Pennsylvania

Marielle Goyette

University of Washington

Heather Grome

Vanderbilt University School
of Medicine

Analise Gruenewald

University of Pennsylvania

Carolina Gutiérrez

Hospital Ramon y Cajal

Ahmad Haeri Mazanderani

National Institute for
Communicable Diseases

Chiraz Hamimi

Institut National de la Santé et
de la Recherche Médicale

Lisa Hamzah

King's College London

Jason Hataye

National Institutes of Health

Camilla Hatleberg

University of Copenhagen

Xuan He

Chinese Center for Disease
Control and Prevention

Joanna Hellmuth

University of California
San Francisco

Matthew Hernandez

Icahn School of Medicine at
Mount Sinai

Alison Hill

Harvard University

Mira Hleyhel

INSERM U1018

Martin Hoenig

University of California
San Diego

Louise Hogan

University of California
San Francisco

Feiyu Hong

University of Pittsburgh

Julia Hood

Public Health Seattle &
King County

Louisa Howard

National Institutes of Health

Sebastiaan Hulleig

Erasmus University
Medical Center

Andrea Introini

Karolinska Institutet

Jeffrey Jenks

University of California
San Diego

Erica Johnson

Emory University

Firmin Kabore

Centre Hospitalier Universitaire
Souré Sanou

Palwasha Khan

London School of Hygiene &
Tropical Medicine

Catherine Kiama

Kenya Ministry of Health

Marion Kiguoya

University of KwaZulu-Natal

Allison Kirkpatrick

NIAID

Maja Kiselinova

Ghent University

Christian Körner

Heinrich Pette Institut, Leibniz
Institute for Virology

Catherine Koss

University of California
San Francisco

Rebecca Krakora

National Institutes of Health

Nitasha Kumar

Emory University, The University
of Melbourne

Nathan Lachowsky

University of British Columbia

Steven Lada

University of California
San Diego

Jessica Lakritz

Boston College

Camille Lange

National Institutes of Health

Sarah Laskey

Johns Hopkins University

Guinevere Lee

Massachusetts General Hospital

Ellen Leitman

University of Oxford

Matthew Levy

George Washington University

Xiaojun Li

Jilin University

Yijia Li

Peking Union Medical
College Hospital

Danny Li

University of California
San Francisco

Weizhe Li

University of Nebraska
Medical Center

Xiang Li

Yale University

Naomi Lin

University College London

Pamela Lincez

Children's Hospital of
Los Angeles

Claire Loiseau

INSERM U1043

Elisa López Varela

Barcelona Institute for
Global Health

Jesús Luévano

Ragon Institute of MGH, MIT,
and Harvard

Christine MacBrayne

University of Colorado Denver

Edith Majonga

Biomedical Research and
Training Institute

Thokozile Malaba

University of Cape Town

Jaclyn Mallard

Boston College

Lara Manganaro

Icahn School of Medicine at
Mount Sinai

Jennifer Manuzak

University of Washington

Christian Manzardo

University of Barcelona

Julia Marcus

Kaiser Permanente

Marianne Martinello

Kirby Institute, UNSW

Enrique Martin-Gayo

Ragon Institute of MGH, MIT,
and Harvard

Gloria Martrus

Heinrich Pette Institut, Leibniz
Institute for Virology

Alex Marzel

University Hospital Zurich

Michela Masetti

University of Milan

Yusuke Matsui

Kyoto University

Robert Maughan

University College Dublin

Carla Mavian

University of Florida

Padraig McGettrick

University College Dublin

Jessica McGillen

Imperial College London

Bindiya MeggiInstituto Nacional de Saúde
de Mocambique**Vikram Mehraj**Research Institute of the McGill
University Health Centre**Inna Menkova-Garnier**

INSERM U955

Sabrina Merat

AIMM Therapeutics

Nicolás Merchante

Hospital Universitario de Valme

Marco MerliVita-Salute San Raffaele
University**Luca Micci**

Emory University

Brodie Miles

University of Colorado Denver

Caitlin MillerBoston University School
of Medicine**Shannon Miller**

University of Colorado Denver

Raphael Mohr

University Hospital Bonn

Blandine MonelHoward Hughes Medical
Institute**Matias Moragas**Hospital de Pediatria SAMIC
"Prof Dr Juan P. Garrahan"**Bozena Morawski**

University of Minnesota

Masahiko Mori

University of Oxford

Beatriz Mothe

IrsiCaixa

Eirini Moysi

University of Miami

Kenneth Mugwanya

University of Washington

Andrew Mujugira

University of Washington

Daniel MurrayThe Kirby Institute of Infection
and Immunity in Society**Zibusiso Ndlovu**

Médecins Sans Frontières

Megan Neary

University of Liverpool

Karin Neukam

Valme University Hospital

Astrid NewsomPublic Health Service
of Amsterdam**Thao Nguyen**

Case Western Reserve University

Brooke NicholsErasmus University Medical
Center**Mariia Novikova**

National Cancer Institute

Piotr Nowak

Karolinska Institutet

Jasanthia Odayar

University of Cape Town

Jane O'Halloran

University College Dublin

Adeniyi Olagunju

University of Liverpool

Catherine Oldenburg

Harvard University

Alexandra Ozanne

Université de Bordeaux

Iain Page

The University of Manchester

Riya Palchaudhuri

Burnet Institute

David PaleschEmory University and Yerkes
National Primate Research
Center**Laurence Palk**University of California
Los Angeles**Gary Parker**KwaZulu-Natal Research
Institute for TB-HIV**Dana Pasquale**UNC Gillings School of Global
Public Health**Monita Patel**Centers for Disease Control
and Prevention**Eshan Patel**

National Institutes of Health

Paolo Pavone

Sapienza University of Rome

Maria Pernas

Instituto de Salud Carlos III

Tanit PhupitakpholHIV-NAT, Thai Red Cross AIDS
Research Centre**Rosalie Ponte**Research Institute of the McGill
University Health Centre**Robert Power**

Wellcome Trust Africa Centre

Christina PsomasUniversity Hospital of
Montpellier**Rajith Kumar Reddy Rajoli**

University of Liverpool

Anton Reepalu

Lund University

Ludy Registre

Boston University

Eugene Richardson

Stanford University

Eva Riveira-Muñoz

AIDS Research Institute IrsiCaixa

Javier Rivera Pinto

IrsiCaixa

Owain Roberts

University of Liverpool

Sarah Roberts

University of Washington

Muntsa Rocafort

AIDS Research Institute IrsiCaixa

Eduardo Rodríguez-ArbolíVirgen del Rocío University
Hospital**Eliane Rohner**

University of Bern

Molly Rosenberg

Harvard University

Carmine RossiResearch Institute of the McGill
University Health Centre**Cristina Rovelli**Vita-Salute San Raffaele
University**Maria Ruperez**Barcelona Institute for Global
Health**Lene Ryom**

University of Copenhagen

Brenda Salantes

University of Pennsylvania

Maria Salgado

AIDS Research Institute IrsiCaixa

Ayesha Sania

Columbia University

Irma Saulle

University of Milan

Stein SchalkwijkRadboud University Medical
Center**Alexandra Scherrer**

University Hospital Zürich

Ivan Schietroma

Sapienza University of Rome

Luca Schifanella

National Institutes of Health

Erica SchlesingerUniversity of California
San Francisco**Gundolf Schuettfort**University Hospital Frankfurt
am Main**Anna Schultze**

University College London

Joseph Sharp

University of Cape Town

Leah Shepherd

University College London

Stephanie ShiauColumbia University Medical
Center

Carey Shive

Cleveland VA Medical Center

Joshua ShorensteinUniversity of California
San Diego**Jeanne Sibiude**

INSERM U1018

Francesco Simonetti

University of Milan

Cassandra SimonichFred Hutchinson Cancer
Research Center**Ravesh Singh**

University of KwaZulu-Natal

Urisha Singh

University of KwaZulu-Natal

Arjun SinhaUniversity of California
San Francisco**Magdalena Sips**Ragon Institute of MGH, MIT,
and Harvard**Shauna Stahlman**

Johns Hopkins University

Arjen StamUniversity Medical Center
Utrecht**Gaby Steba**Academic Medical Center
Amsterdam**Karl Stefcik**Centre Hospitalier Universitaire
de Tours**Natalia Stella Ascariz**

Hospital Universitario La Paz

Tavitiya Sudjaritruk

Johns Hopkins University

Tahmina Sultana

Osaka University

Sara SunshineBrigham and Women's Hospital,
Harvard Medical School**Talia Swartz**Icahn School of Medicine at
Mount Sinai**Jori Symons**Doherty Institute for Infection
and Immunity**Laura Tarancón**

Biomedicine Institute of Sevilla

Sushama Telwatte

Burnet Institute

Aurielle Thomas

National Institutes of Health

Corbin ThompsonUniversity of North Carolina at
Chapel Hill**Thierry Tiendrebeogo**

INSERM U897

Graham TreasureBrigham and Women's Hospital,
Harvard Medical School**Ming-Han Tsai**

University of Oxford

Damien TullyRagon Institute of MGH, MIT,
and Harvard**Jonathan Underwood**

Imperial College London

Priyanka Uprety

Johns Hopkins University

Emiko Urano

National Cancer Institute

Kimyata Valere

Rutgers University

Christina Valiaveettil

University of Toronto

Joost VanhommerigPublic Health Service of
Amsterdam**M.J. Vivancos-Gallego**Hospital Universitario Ramón
y Cajal**Thomas Vollbrecht**University of California
San Diego**Catriona Waitt**

University of Liverpool

Naomi Walker

Imperial College London

Victoria Walker-SperlingJohns Hopkins School of
Medicine**Jiayi Wang**

University of Minnesota

Bernard WeigelUniversity of California San
Francisco**Kevin Weiss**

Emory University

Katherine Wetzel

University of Pennsylvania

Darcy White

University of Washington

Kate Wilson

University of Washington

Anni Winkelmann

Aarhus University Hospital

Joanne Winter

University College London

Sarah Wood

University of Pennsylvania

Yuanfei WuUniversity of Massachusetts
Medical School**Beiqing Wu**University of Nebraska Medical
Center**Shu Yang**

Harvard University

Emine YaylaliCenters for Disease Control and
Prevention**Christina Yek**

University of Texas Southwestern

Mehwish Younas

Institute of Human Genetics

Rebecca ZashBeth Israel Deaconess Medical
Center**Jennifer Zerbato**

University of Pittsburgh

Wenjing ZhengUniversity of California
San Francisco

INTERNATIONAL SCHOLARSHIP AWARDEES

Gbolahan Ajibola

Botswana Harvard AIDS Institute Partnership

Rita Atugonza

Baylor College of Medicine Children's
Foundation Uganda

Vivian Avelino-Silva

University of Sao Paulo

Anchalee Avihingsanon

The HIV Netherlands Australia Thailand
Research Collaboration

James Ayieko

Kenya Medical Research Institute

Andrzej Bienczak

University of Cape Town

Peter Cherutich

University of Washington

Diana Faini

Ifakara Health Institute

Colette Guiteau Moise

Les Centres GHESKIO

Agibothu Kupparam Hemanth Kumar

National Institute for Research in Tuberculosis

Cheryl Hendrickson

Health Economics and Epidemiology
Research Office

Mbae Japhet

Consolata Hospital Mathari

Kevin Kadede

Kenya Medical Research Institute

Patrick Karugaba

Makerere University - Johns Hopkins
University Research Collaboration

Cissy Kityo

Joint Clinical Research Centre

Dalsone Kwarisiima

Makerere University-University of California
San Francisco Research Collaboration

Stanzi le Roux

University of Cape Town

Sikhulile Moyo

Botswana Harvard AIDS Institute Partnership

Florence Mwangwa

Infectious Diseases Research Collaboration

Landon Myer

University of Cape Town

Damalie Nakanjako

Makerere University College of Health
Sciences

Nicaise Ndembu

Institute of Human Virology, Nigeria

Fredrick Odongo

Kenya Medical Research Institute

Stephen Okoboi

The AIDS Support Organization

Eric Remera

Institute of HIV/AIDS Disease Prevention
and Control

Muhayimpundu Ribakare

Rwanda Bio Medical Center

Charlotte Schutz

University of Cape Town

Mazvita Sengayi

National Health Laboratory Service

Sarah Jane Steele

Médecins Sans Frontières

Omar Sued

Fundación Huésped

Gilles Van Culsem

Médecins Sans Frontières

COMMUNITY EDUCATOR SCHOLARSHIP AWARDEES

Joshua Agee

My Brother's Keeper

Josephine Ayankoya

Bridge HIV, San Francisco Department of Public Health

Giorgio Barbareschi

European AIDS Treatment Group

Tamas Bereczky

European AIDS Treatment Group

Aisuluu Bolotbaeva

Central Asian HIV Foundation

Danette Brown

Volunteers of America Greater Baton Rouge

Danielle Campbell

Black Treatment Advocates Network

Caitlit Conyngham

Philadelphia FIGHT

Giulio Corbelli

PLUS Onlus

Michael Dorosh

Treatment Education Network

Florita Durueke

New HIV Vaccine and Microbicides Advocacy Society

Mardrequis Harris

Friends for Life Corporation

Brandon Harrison

National Black Leadership Commission on AIDS, Inc

Angel Hernández

Community Scientific Subcommittee, ACTG

Shalarey Jones

University of California Los Angeles

Tapiwanashe Kujinga

Pan-African Treatment Access Movement

Marreo McDonald

My Brother's Keeper, Inc

Michael Meulbroek

Asociación para el Trasplante de Órganos a Seropositivos

Kennedy Mupeli

Centre for Youth of Hope

Jane Mwirumubi

Makerere University Business School

Robert Newells

AIDS Project of the East Bay

Definate Nhamo

Pangaea Zimbabwe AIDS Trust

Simon Ondiek

Jaramogi Oginga Odinga University of Science and Technology

Julia Patterson

Case Western Reserve University

Elias Phiri

Addington Afro-Ethnic Health Promotion Group

Juan Pierce

Black AIDS Institute African American HIV University Science and Treatment College

Ferran Pujol Roca

Projecte dels NOMS-Hispanosida

Yvette Raphael

Damelin College

Jorge Saz Berges

Joves Positius

Cissy Ssuuna

Baylor College of Medicine Children's Foundation Uganda

Nsubuga Supercharger

Pina Uganda and Joint Clinical Research Centre

Harry Tembo

Zambia Community Advisory Platform

DaShawn Usher

New York Blood Center's Project ACHIEVE

Lisa White

SisterLove, Inc.

Ntando Yola

Desmond Tutu HIV Foundation

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS—USA designates this live activity for a maximum of **17 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Since 2006, the IAS—USA has held Accreditation with Commendation. As such, the IAS—USA belongs to an elite group of organizations in the United States that have been awarded this prestigious status, which, in the words of the ACCME, is “reserved for programs that are truly exceptional.”

CME credits can be claimed for plenary lectures, symposia, opening session lectures, and special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions.

Objectives

After participating in CROI 2016, participants will be able to:

- Describe new current basic science research on the pathogenesis of HIV and on advances toward a cure
- List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
- Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research on different facets of HIV and its complications.

CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI 2016. Other practitioners

and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

Claiming CME Credits or a Certificate of Participation

During the conference, daily evaluations will be e-mailed to all CROI participants to the e-mail account they used to register for the conference. On Thursday, February 25, 2016, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. To obtain CME credits or a Certificate of Participation for CROI, this final evaluation must be completed by Thursday, March 31, 2016. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits or hours that you can claim, calculate your time spent attending the relevant sessions, including plenary sessions, symposia, and workshops. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), a themed discussion (1:45 PM to 2:45 PM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 4 hours to apply toward CME credits for that day. At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of **17 AMA PRA Category 1 Credits™** for this activity.

A CME hour worksheet can be found here: http://www.croiconference.org/sites/default/files/uploads/croi2016_cme_worksheet.pdf

Disclosure of Financial Relationships

It is the policy of the IAS—USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS—USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS—USA audience aware of speaker and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

GENERAL INFORMATION

Overview

CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and attracts more than 4000 HIV and AIDS research leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans with Disabilities Act

CROI 2016 endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Attendee Services booth on the Plaza level during the conference.

Emergency Services

In the event of an emergency please contact the command center, open 24 hours daily, or notify CROI staff. The command center can be reached at (617) 954-2111 and is located by the Boylston Street entrance. In addition, security offices are located throughout the building and at each of the building's entrances. A nurse is available on-site and is accessible by contacting the command center, notifying CROI staff, or visiting the nurse's office in the registration area.

Embargo Policy

The research presented at CROI 2016 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 1:45 PM to 2:00 PM as part of a session that ends at 2:45 PM, the embargo on that study lifts at 2:45 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2016 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which that study is featured.

Social Media

CROI embargo policies apply to any public dissemination of research information presented at the conference, including through electronic publications (eg, blogs) or social media (eg, Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Welcome Reception

All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Reception on February 22, 2016. The reception will be held in Hall C and Hall D and the corresponding pre-function areas.

This unique Welcome Reception will offer attendees the opportunity to network with colleagues.

Wi-Fi

Complimentary wireless internet is provided at the Hynes Convention Center. As a courtesy to your fellow attendees please disable the Wi-Fi function on your unused devices. For example, if you have a tablet, laptop, and a Wi-Fi enabled phone, please use one device at a time to access Wi-Fi and disable the others. There are several Wi-Fi hot spots throughout the convention center. Please visit Attendee Services for a list of the hot spots.

Meals

Morning coffee and light continental breakfast will be available to conference attendees in the Auditorium from 8:00 AM – 8:30 AM Tuesday to Thursday. An afternoon snack break will be available at 2:30 PM in Poster Hall A. Attendees are on their own for lunch and dinner each day. Below is a list of food service options located in the Convention Center or within a short walking distance.

CROI registration fees cover all food and beverage above provided by the conference at the convention center. Attendees are responsible for all other meal expenses. Selected restaurants and food outlets:

At the Convention Center

Towne Stove and Spirits
The Capital Grill

At the Prudential Center

(next to the South Lobby main entrance of the Convention Center)

5 Napkin Burger	Au Bon Pain
Barnes & Noble Cafe	California Pizza Kitchen
Cheesecake Factory	Cold Stone Creamery
Crazy Dough's Pizza	Dunkin' Donuts
Fruitata	Godiva
Haru	L'Espalier
P.F. Chang's	Pinkberry
Star Market	Teavana
Top of the Hub	Wagamama

At the Sheraton Boston

SideBar & Grille
Starbucks

Back Bay Neighborhood

(within 1-3 blocks, listed by distance from the convention center)

Bukowski Tavern	Summer Shack
Dillon's	Dunkin Donuts
Boloco	Whiskey's
Trader Joe's	Lir
The Pour House	McGreevy's Boston
Atlantic Fish Company	Abe & Louie's
Starbucks	DeLuca's Market
Dirty Water Dough Company	Chipotle
Scissors and Pie	B. Good
Sweetgreen	

At the Marriott Copley, Copley Place Mall, and Westin Copley Place

(within 1 block of the Convention Center)

Bar 10	Champion's Sports Bar
The Huntington at the Westin	Osushi
Legal Sea Foods	Turner Fisheries

Overflow Accommodations for Session Rooms

Simultaneous overflow with 5 concurrently streamed sessions will be set up in Hall C. Audio for each session will be played through headphones set up at each seat. Additional overflow accommodations will be set up in rooms 309, 310, and 313. The assignment of sessions to each overflow room will be determined on-site as necessary.

Website

For additional information about the conference please visit the website at www.CROIconference.org.



Webcasts and Podcasts

Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions will be webcast and podcast. Webcasts are also available as streaming video for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI 2016 webcasts and podcasts. Webcasts will be available within 24 hours of the end of the relevant session.

Affiliated Activity Policies

The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies, not-for-profit groups, government agencies, etc) have been approved to host Affiliated Activities occurring outside CROI session times. Affiliated Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2016.

If an affiliated activity is found to have violated the Guidelines for Affiliated Activities (above), the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an affiliated activity at future CROI conferences, may have their current registration revoked, non-compliance may be subject to fines and damages, and could negatively impact the registration/status/attendance of those attending an unapproved affiliated activity.

Mobile App

CROI 2016 has a Mobile App to enhance your conference experience. The App enables you to schedule sessions, view abstracts, e-mail other participants, receive announcements, and more. Search "CROI 2016" in your mobile device App store, and download the conference App. The mobile App supports iOS and Android devices. Access is restricted to registered attendees only. Your log-in information and password will be provided to you on site with your registration materials.

Badges

Badge pickup will be available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. **DO NOT LOSE YOUR BADGE. Unfortunately, payment of an additional registration fee (\$750) will be required to replace a lost badge.** Also, if you notice that your affiliation or the affiliations of other attendees are incorrect, please inform conference staff in the office of the Conference Secretariat.

Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel.

Conference Etiquette

Please ensure all cell phones and pagers are off or are placed in **SILENT** mode. No flash photography is permitted in session rooms.

CONFERENCE SERVICES

Services	Location	Hours	Notes
Boston Information	Registration Area on Plaza Level	Sunday: 2:30 PM – 7:30 PM Monday: 8:30 AM – 7:35 PM Tuesday: 8:00 AM – 7:45 PM Wednesday: 8:00 AM – 6:30 PM Thursday: 8:00 AM – 6:30 PM	Local information and reservations assistance.
Bag and Coat Check	Plaza Level	Monday: 8:00 AM – 10:30 PM Tuesday: 7:30 AM – 8:15 PM Wednesday: 7:30 AM – 6:30 PM Thursday: 7:30 AM – 6:30 PM	Bag and coat check are free of charge.
Cyber Cafe	Boylston Hallway 3rd Floor Prefunction Hall A	Regular Conference Hours	Two Cyber Cafés with Internet access are available to download electronic materials and for webcasts, abstract searches, and messages.
Media Center	Room 210	Monday: 10:00 AM–5:00 PM, Tuesday to Thursday: 8:00 AM–6:30 PM	The Media Center is a work space with Wi-Fi and is the location of the daily press conferences open exclusively to registered, accredited media.
Badge Pickup • Speakers, Conveners, and Presenters • Attendees • Scholarship Recipients • Media Housing Information	Registration Area on the Plaza Level	Sunday: 3:00 PM–6:00 PM Monday: 8:00 AM–7:00 PM Tuesday: 7:00 AM–6:00 PM Wednesday: 8:00 AM–6:00 PM Thursday: 8:00 AM–12:00 PM	Location to pick up badges and conference materials. There is no on-site registration for attendees or media.
Speaker Ready Room	Room 200	Sunday: 3:00 PM–6:00 PM Monday to Thursday: 7:30 AM–6:00 PM	The speaker ready room is a space for presenters to load their slides and rehearse their presentations. Use of the rehearsal services is on a first-come, first-served basis. Oral abstract, invited, and themed discussion session speakers must drop off presentations at the speaker ready room at least 24 hours before their presentation.
Electronic Poster Drop-off	Room 200	Sunday: 3:00 PM–6:00 PM Monday to Thursday: 7:30 AM–6:00 PM	Poster presenters must submit an electronic version of their poster for placement on the CROI website. Upon submission of an electronic poster, presenters will be issued a special badge for early access to the poster halls for setup. Only badge holders and their assistants will be granted early access.
New Mother's Room	Room 307	Sunday: 3:00 PM–6:00 PM Monday: 9:00 AM–6:00 PM Tuesday to Thursday: 8:30 AM–6:00 PM	The New Mother's Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis.
Personal Considerations Room	Room 308	Sunday: 3:00 PM–6:00 PM Monday: 9:00 AM–6:00 PM Tuesday to Thursday: 8:30 AM–6:00 PM	The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is on a first-come, first-served basis.
Lost and Found	Attendee Services counter in the Registration Area on the Plaza Level	Regular Conference Hours	You may inquire about lost or stolen items at Lost and Found. Please turn in any found items to CROI staff at the Attendee Services counter in the registration area. During the course of the conference, lost items will be held at the registration area. After the conference, lost items will be held by the Convention Center's command center.

HOTEL INFORMATION

CROI 2016 hotels are listed below. For more detailed housing information, please visit the CROI 2016 conference website: www.CROIConference.org/housing. Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Boston area (ie, within a 50-mile radius of the Hynes Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system.

Boston Marriott Copley Place

Headquarter Hotel
110 Huntington Avenue
Boston, MA 02116
PH: +1 617 236 5800
Distance: 0.3 mi / 0.5 km

Westin Copley Place

10 Huntington Avenue
Boston, MA, 02116
PH: +1 617 262 9600
Distance: 0.4 mi / 0.6 km

Hilton Boston Back Bay

40 Dalton Street
Boston, MA 02115
PH: +1 617 236 1100
Distance: 0.2 mi / 0.3 km

The Colonnade Hotel

120 Huntington Avenue
Boston, MA 02116
PH: +1 617 424 7000
Distance: 0.3 mi / 0.5 km

The Midtown Hotel

220 Huntington Avenue
Boston, MA 02115
PH: +1 617 262 1000
Distance: 0.5 mi / 0.8 km

Hampton Inn & Suites

811 Massachusetts Avenue
Boston, MA 02118
PH: +1 617 445 6400
Distance: 1.6 mi / 2.6 km
A daily shuttle service to and from the Convention Center is provided.
Please check with the hotel for times.
Public Transportation: Take bus route 1 to the Hynes.

Sheraton Boston Hotel

39 Dalton Street
Boston, MA 02199
PH: +1 617 236 2000
Distance: 0.1 mi / 0.2 km

Mandarin Oriental, Boston

776 Boylston Street
Boston, MA 02199
PH: +1 617 535 8888
Distance: 0.1 mi / 0.2 km

The Lenox

61 Exeter Street
Boston, MA 02116
PH: +1 617 536 5300
Distance: 0.2 mi / 0.3 km


Fairmont Copley Plaza

138 St. James Avenue
Boston, MA 02116
PH: +1 617 267 5300
Distance : 0.4 mi / 0.6 km

Boston Park Plaza Hotel

50 Park Plaza
Boston, MA 02116
PH: +1 617 427 2000
Distance: 0.8 mi / 1.3 km
Distance to T at Arlington Station: 500 ft / 150 m
Take the green line to Copley Station (1 stop).
Exit onto Boylston Street and turn left.
Continue on Boylston Street for 0.2 miles and enter the Convention Center on the left.


General Information



- 7 Hilton Boston Back Bay
- 8 Lenox
- 9 Mandarin Oriental
- 10 MidTown Hotel
- 11 Sheraton Boston Hotel
- 12 Westin / Copley Place Boston

- 1 John B. Hynes Convention Center
- 2 Boston Marriott Copley Place
- 3 Boston Park Plaza Hotel & Towers
- 4 Colomade Hotel
- 5 Fairmont Copley Plaza Hotel
- 6 Hampton Inn & Suites Boston Crosstown Center (1.6 miles from the Convention Center; Inset)

FACILITIES



- Massachusetts Bay Transportation Authority
- Rapid Transit

ABSTRACT PROCESS

Scientific Categories

- A. Virology
- B. Molecular Epidemiology and HIV/SIV Evolution
- C. Pathogenesis: Human Studies and Animal Models
- (D. Pathogenesis: Animal Models has been combined with Category C)
- E. Host Immune Responses to Infection, Vaccines, and Immunotherapy
- F. HIV Persistence, Reservoirs, Latency, Eradication, Including Gene Therapy
- G. Neuropathogenesis
- H. Clinical Pharmacology
- I. Antiretroviral Therapy: Preclinical Studies
- J. Antiretroviral Therapy: Randomized Clinical Trials
- K. Antiretroviral Therapy: Observational Studies
- L. HIV Drug Resistance
- M. HIV Diagnostics
- N. Hepatitis Viruses
- O. HIV-related and Non-HIV-Related Malignancies
- P. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
- Q. Other Complications of HIV Infection and Antiretroviral Therapy
- R. Tuberculosis and Other Opportunistic Infections
- S. Maternal/Fetal HIV
- T. Pediatrics and Adolescents
- U. Contraception and Reproductive and Sexual Health in Women
- V. Prevention and Intervention Studies
- W. Epidemiology
- X. Implementation Science and Health Care Delivery
- Y. Population and Economic Modeling

Abstract Content

Author names, institutions, abstract titles, and abstracts in the Program and Abstracts eBook are generally presented as submitted by the corresponding author.

Abstract Review Process

The PC and a panel of volunteer external reviewers reviewed approximately 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster

presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).

Common Reasons for Abstract Rejection


- Information is not new enough
- Methodology is inadequate or insufficient to support conclusions
- Background does not summarize the hypothesis
- Submission is poorly written
- Abstract is duplicative of other submissions
- Abstract is not appropriate for CROI
- Controls are absent or inadequate
- Statistical evaluation is inadequate or absent
- Summary of essential results is inadequate or absent
- Data are inadequate or insufficient to support conclusions
- Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
- Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts

Total general abstract submitted	1936
Total general abstracts accepted	951
General oral abstracts	94
General poster abstracts	857
Total late-breaking abstracts submitted	198
Total late-breaking abstracts accepted	52
Late-breaking oral abstracts	25
Late-breaking poster abstracts	27

All Authors on Accepted Abstracts

Region	N	Percent
Africa	652	13.5
Asia	222	4.6
Australia	84	1.7
Europe	1140	22.7
Latin/South America	77	1.6
North America	2644	54.9



ORAL SESSIONS

MONDAY, FEBRUARY 22, 2016

Session W1 Workshop **CME**
9:00 AM-12:30 PM

Ballroom B/C

Program Committee Workshop for New Investigators and Trainees

Target audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). It is open to all CROI attendees, however.

Level of knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:

- Describe the current state-of-the-art of selected areas of HIV basic and clinical research
- List the leading research themes being presented at CROI 2016
- Better navigate CROI 2016, maximize the knowledge gained, and pursue interactions with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and CROI 2016 overall

Conveners

Scott M. Hammer, *Columbia University College of Physicians and Surgeons, New York, NY, USA*

John W. Mellors, *University of Pittsburgh, Pittsburgh, PA, USA*



1 Program Committee Workshop for New Investigators and Trainees: Session Summary



Molecular Virology: Advances in the Understanding of HIV

Richard A. Sundquist, *University of Utah School of Medicine, Salt Lake City, UT, USA*



Immunology and Vaccines

Richard A. Koup, *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA*



The HIV Latent Reservoir: Obstacles and Strategies to a Cure

Huldrych F. Günthard, *University Hospital Zurich, Zurich, Switzerland*



The Rapidly Changing Landscape of HIV Prevention

Sharon L. Hillier, *Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA, USA*



Unraveling the Complexities of Long-Term Complications of Treated HIV Infection

Judith S. Currier, *David Geffen School of Medicine of UCLA, Los Angeles, CA, USA*

Session MD **CME**
1:00 PM-2:00 PM

Ballroom B/C

The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Scholars and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research. The Martin Delaney Presentation is customized to the Community Liaison Subcommittee and is presented as a panel discussion.

Moderator

Morenike Ukpong-Folayan, *Obafemi Awolowo University, Ile-Ife, Nigeria*



2 Panel Discussion on Stigma, Trauma, and Stress: Considerations for HIV Research and Programs

Panelists



Limits and Complexity Research on Stigma and HIV

Laurel Sprague, *The Sero Project, Milford, PA, USA*



Women's Rights and Decision Making in Hormonal Contraception

Sethemiso Mthembu, *International Community of Women Living with HIV/AIDS, Southern Africa, Durban, South Africa*



Engaging Young Men of Color in Community HIV Prevention Studies

Keith Green, *Univ of Chicago School of Social Service Administration, Chicago, IL, USA*

Session W2 Workshop
2:15 PM-4:00 PM

CME

Ballroom B/C

Clinical Trial Design and Analysis Workshop

Target audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:

- Provide examples of big data and how these data can be used to improve program impact
- Describe approaches to incorporating pharmacokinetic and pharmacodynamics measures into clinical trials
- Describe how sexual and social network data can be used to evaluate HIV transmission patterns

Conveners

Susan P. Buchbinder, *San Francisco Department of Public Health, San Francisco, CA, USA*

Richard E. Chaisson, *The Johns Hopkins University School of Medicine, Baltimore, MD, USA*



3 Key Considerations in Studies of Antiviral Pharmacokinetics and Pharmacodynamics

Jennifer Kiser, *Univ of Colorado, Denver, CO, USA*



4 Using Big Data to Improve the HIV Care and Prevention Continuum

Patrick Sullivan, *Emory Univ, Atlanta, GA, USA*



5 HIV Transmission Networks and HIV Prevention in the Era of TasP and PrEP

Martina Morris, *Univ of Washington, Seattle, WA, USA*



Session W3 Workshop
2:15 PM-4:00 PM

CME

Ballroom A

Frontiers in Laboratory Science Workshop

Target audience: This session is directed to investigators and clinicians interested in learning about the main technological and conceptual developments in life sciences that are influencing HIV research or hold a significant potential for research.

Level of knowledge: It is assumed that participants are familiar with the main technological and data analysis approaches used in HIV research.

Objectives: At the completion of the session, participants will be able to:

- Recognize the potential of and directions in the field proteome analysis.
- Describe novel microfluidic approaches to single-cell analyses.
- Visualize and learn of the establishment of organs-on-chips.

Conveners

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA*

Amalio Telenti, *University of California San Diego, San Diego, CA, USA*



6 Deciphering Mucosal Barrier Functionality and HIV Immunity by Mass Spectrometry

Adam Burgener, *Univ of Manitoba, Winnipeg, MB, Canada*



7 Drop-Based Microfluidics for Single-Cell Studies

David A. Weitz, *Harvard Univ, Boston, MA, USA*



8 Integration of Systems Biology with Tissue Engineering and Organs-On-Chips

Linda Griffith, *Massachusetts Inst of Tech, Boston, MA, USA*



Session W4 Workshop
2:15 PM-4:00 PM



Room 304/306

Interactive Case-Based Workshop on Hepatitis C

Target audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.

Level of knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:

- Describe the diagnosis and staging of patients with HCV infection
- Describe the effective treatment of HCV infection according to HCV genotype and state of liver disease
- Recognize how treatment differs for persons with cirrhosis

Conveners

Susanna Naggie, *Duke University School of Medicine, Durham, NC, USA*

David L. Wyles, *University of California San Diego, San Diego, CA, USA*



9 Treatment for HCV Genotype 1-Infected Patients With HIV/HCV Coinfection

Anne F. Luetkemeyer, *Univ of California San Francisco, San Francisco, CA, USA*



10 Treatment for Cirrhotic HCV Genotype 3-Infected Patients With Prior Treatment Failure

Karine LaCombe, *Sorbonne Univs, Paris, France*



11 HCV Infection Treatment Before and After Liver Transplant

Elizabeth C. Verna, *Columbia Univ, New York, NY, USA*



12 Treatment of HCV Infection in Groups at High Risk for Reinfection

Oluwaseun Falade-Nwulia, *Johns Hopkins Univ, Baltimore, MD, USA*



Session OS
5:00 PM-7:00 PM




Auditorium


Opening Session

Opening Session Hosts

Julie M. Overbaugh, *Fred Hutchinson Cancer Research Center, Seattle, WA, USA*



Susan P. Buchbinder *San Francisco Department of Public Health, San Francisco, CA, USA*



Judith S. Currier, *David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA*



Bernard Fields Lecture

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

13 T Cell Control of HIV: Implications for Vaccines and Cure

Bruce D. Walker, *Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA*



N'Galy-Mann Lecture

The N'Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N'Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

14 Confronting HIV and TB From the Bronx, NY, to Tugela Ferry, South Africa

Gerald H. Friedland, *Yale University School of Med, New Haven, CT, USA*



CROI Foundation Special Event

A unique programming segment that will honor achievement, inform, and surprise. It should not be missed.

Fighting AIDS With Style

Kenneth Cole, *Kenneth Cole Productions, Inc, and Chairman of the Board of amFAR*



Monday, February 22, 2016 • Oral Sessions

TUESDAY, FEBRUARY 23, 2016

Tuesday Plenary Session



Auditorium

8:30 AM-9:30 AM

8:30 15 Harnessing Antibodies for HIV-1 Prevention and Treatment

John R. Mascola, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA



9:00 16 Antiretroviral Therapy: Where Are We Now? Where Are We Going?

Joseph J. Eron, Jr., University of North Carolina at Chapel Hill, Chapel Hill, NC, USA



Session 0-1 Oral Abstracts

Room 302

10:00 AM-12:00 PM

SIV and HIV Pathogenesis

Oral Abstract Moderators

Netanya S. Utay, University of Texas Medical Branch at Galveston, Galveston, TX, USA

James B. Whitney, Beth Israel Deaconess Medical Center, Harvard, Boston, MA, USA

10:00 17 Rare Host Genetic Variation Influencing Risk of Heterosexual HIV-1 Acquisition

Rommel D. Mackelprang¹; Mary Emond¹; Michael J. Bamshad¹; Xuanlin Hou¹; Jessica Chong¹; Kati Buckingham¹; Nelly R. Mugo²; Jared M. Baeten³; Connie M. Celum³; Jairam R. Lingappa⁴; for the Partners in Prevention HSV/HIV Transmission and Partners PrEP Studies
¹Univ of Washington, Seattle, WA, USA; ²Kenya Med Rsr Inst, Thika, Kenya

10:15 18LB HIV-1 Laboratory Contagion During Recombination Procedures With Defective Constructs

Claudia Alteri¹; Alessandro Soria²; Ada Bertoli¹; Alessandra Bandera³; Gabriella Scarlatti⁴; Monica Tolazzi⁵; Emanuela Balestra⁶; Andrea Gori⁷; Francesca Ceccherini-Silberstein¹; Carlo Federico Perno²
¹Univ of Rome Tor Vergata, Rome, Italy; ²San Gerardo Hosp, Monza, Italy; ³San Gerardo General Hosp, Monza, Italy; ⁴San Raffaele Scientific Inst, Milan, Italy; ⁵Univ of Rome Tor Vergata, Roma, Italy

10:30 19 Identification of a Highly Functional DC Subset in Controllers by Single-Cell RNA-Seq

Enrique Martin-Gayo¹; Michael Cole²; Kellie E. Kolb²; Zhengyu Ouyang¹; Sam W. Kazer¹; Bruce D. Walker¹; Nir Yosef¹; Alex K. Shalek¹; Xu G. Yu¹
¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ²Electrical Engineering & Computer Sci, Berkeley, CA, USA; ³MIT Inst for Med Engineering & Sci (IMES), Cambridge, MA, USA

10:45 20 The Sooty Mangabey Genome Sequence Reveals New Insights in Natural SIV Infections

David J. Palesch¹; Steven E. Bosinger¹; Gregory Tharp¹; Yue Liu¹; Muthuswamy Raveendran¹; Donna Muzny¹; Richard Gibbs¹; Kim C. Worley¹; Jeffrey Rogers¹; Guido Silvestri¹
¹Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA; ²Emory Univ, Atlanta, GA, USA; ³Baylor Coll of Med, Houston, TX, USA

11:00 21 Hyperacute Microbial Translocation During Pathogenic SIV Infection

Adam J. Ericson¹; Michael Lauck¹; Mariel S. Mohns¹; Sarah R. DiNapoli¹; James P. Mutschler¹; Justin M. Greene¹; Benjamin J. Burwitz¹; Jonah B. Sacha¹; Thomas C. Friedrich¹; Jason M. Brenchley¹; David H. O'Connor¹
¹Univ of Wisconsin-Madison, Madison, WI, USA; ²NIH, Bethesda, MD, USA; ³Oregon Hlth & Sci Univ, Beaverton, OR, USA; ⁴Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA

11:15 22 CD8 T Cells Are Required to Suppress Viremia in SIV-Infected ART Treated Macaques

Emily K. Cartwright¹; Thomas H. Vanderford¹; Kirk A. Easley¹; Joern E. Schmitz¹; Ann Chahroudi²; Steven E. Bosinger¹; Mirko Paiardini³; Jacob D. Estes⁴; Guido Silvestri²
¹Emory Univ, Atlanta, GA, USA; ²Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA; ³Emory Univ Rollins Sch of PH, Atlanta, GA, USA; ⁴Beth Israel Deaconess Med Cntr, Harvard Med Sch, Boston, MA, USA; ⁵Emory Univ Sch of Med, Atlanta, GA, USA; ⁶Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA

11:30 23 Lack of CTL Attenuates, but Does Not Ablate Compartmentalization of SIV Replication

Joy M. Folkvord¹; Melissa Thomas¹; Eva Rakasz²; Shengbin Li²; Pamela Skinner²; Elizabeth Connick¹
¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ²Wisconsin Natl Primate Rsr Cntr, Madison, WI, USA; ³Univ of Minnesota, Minneapolis, MN, USA; ⁴Univ of Colorado, Denver, CO, USA

11:45 24 Sooty Mangabey CD4+ T Cells Express the SIVsmm Coreceptor CXCR6

Katherine Wetzel¹; Emily Roberts¹; Yanjie Yi¹; Michael R. Betts¹; Guido Silvestri¹; Mirko Paiardini¹; Ronald Collman¹
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA

Session O-2 Oral Abstracts

10:00 AM-12:00 PM

Viral Reservoirs/Antiretroviral Therapy Randomized Clinical Trials

Oral Abstract Moderators

Alexandra L. Calmy, University Hospital Geneva, University of Geneva, Geneva, Switzerland

Christine Durand, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Ballroom B/C

11:00 29 Switching Tenofovir DF to Tenofovir Alafenamide in Virologically Suppressed Adults

Joel E. Gallant¹; Eric Daar²; Francois Raffi³; Cynthia Brinson⁴; Peter Ruane⁵; Edwin DeJesus⁶; Mingjin Yan⁷; Andrew Plummer⁸; Andrew Cheng⁹; Martin S. Rhee⁷

¹Southwest Care Cntr, Santa Fe, NM, USA; ²Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ³Chu Hotel Dieu-Chu De Nantes, Nantes, France; ⁴Central Texas Clinical Rsr, Austin, TX, USA; ⁵Peter J Ruane MD, Inc, Los Angeles, CA, USA; ⁶Orlando Immunology Cntr, Orlando, FL, USA; ⁷Gilead Scis, Inc, Foster City, CA, USA

11:15 30 ACTG 5273 Randomized Trial of Second-Line ART Supports WHO Guidance

Alberto M. La Rosa¹; Linda J. Harrison²; Babafemi Taiwo³; Carole L. Wallis⁴; Lu Zheng⁵; Peter S. Kim⁶; Nagalingeswaran Kumarasamy⁷; Mina Hosseinipour⁸; John W. Mellors⁹; Ann Collier⁹

¹Asociación Civil Impacta Salud y Educación, Lima, Peru; ²Harvard Sch of PH, Boston, MA, USA; ³Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA; ⁴BAR SA and Lancet Lab, Johannesburg, South Africa; ⁵DAIDS, NIAID, NIH, Rockville, MD, USA; ⁶YRG Cntr for AIDS Rsr and Educ, Chennai, India; ⁷Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁸Univ of Pittsburgh, Pittsburgh, PA, USA; ⁹Univ of Washington, Seattle, WA, USA

10:00 25 Safety, Immunologic and Virologic Activity of Anti-PD-L1 in HIV-1 Participants on ART

Joseph J. Eron, Jr.¹; Cynthia Gay²; Ronald Bosch³; Justin Ritz²; Jason M. Hataye⁴; Carey Hwang⁵; Randall L. Tressler⁶; Stephen W. Mason⁷; Richard A. Koup⁸; John W. Mellors⁹; for the ACTG A5326 Study Team

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Harvard Sch of PH, Boston, MA, USA; ³NIH, Bethesda, MD, USA; ⁴Bristol-Myers Squibb, Princeton, NJ, USA; ⁵DAIDS, NIAID, NIH, Rockville, MD, USA; ⁶Bristol-Myers Squibb, Wallingford, CT, USA; ⁷VRC, NIAID, NIH, Bethesda, MD, USA; ⁸Univ of Pittsburgh, Pittsburgh, PA, USA

10:15 26LB Effect of Sequential Vacc-4x/GM-CSF Immunization and Romidepsin on the HIV Reservoir

Steffen Leth¹; Jesper Højen¹; Mariane Schleimann¹; Sara Nissen²; Alejandra Mork³; Maja Sommerfelt⁴; Lars Østergaard⁵; Thomas Rasmussen⁶; Martin Tolstrup⁷; **Ole S. Søgaard**⁸

¹Aarhus Univ Hosp, Aarhus, Denmark; ²Bionor Pharma, Oslo, Norway; ³Aarhus Univ Hosp, Aarhus Nord, Denmark

10:30 27 A Patient Navigation/Contingency Management RCT for Hospitalized HIV+ Substance Users

Lisa Metsch¹; Daniel Feaster²; Lauren Gooden³; Moupali Das⁴; Tim Matheson⁵; Maxine Stitzer⁶; Mamta Jain⁷; Allan Rodriguez²; Raul Mandler⁸; Carlos del Rio⁹

¹Columbia Univ Mailman Sch of PH, New York, NY, USA; ²Miller Sch of Med, Univ of Miami, Miami, FL, USA; ³Columbia Univ Mailman Sch of PH, Miami, FL, USA; ⁴Gilead Scis, Inc, Foster City, CA, USA; ⁵San Francisco Dept of PH, San Francisco, CA, USA; ⁶Johns Hopkins Bayview Med Cntr, Baltimore, MD, USA; ⁷Univ of Texas Southwestern Med Cntr, Dallas, TX, USA; ⁸Natl Inst on Drug Abuse, NIH, Rockville, MD, USA; ⁹Emory Univ Sch of Med, Atlanta, GA, USA

10:45 28 Initiating ART at a Patient's First Clinic Visit: The RapIT Randomized Trial

Sydney Rosen¹; Mhairi Maskew²; Matthew P. Fox³; Cynthia Nyoni⁴; Constance Mongwenyana⁵; Given Malete⁶; Ian Sanne⁷; Lawrence Long⁸

¹Boston Univ, Boston, MA, USA; ²Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa

11:30 31LB Cabotegravir+Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results

David A. Margolis¹; Juan González-García²; Hans-Jürgen Stellbrink³; Joseph J. Eron⁴; Yazdan Yazdanpanah⁵; Sandy Griffith⁶; David Dorey⁷; Kimberley Y. Smith⁸; Peter Williams⁹; William Spreen¹

¹ViiV Hlthcare, Research Triangle Park, NC, USA; ²Inst for Hlth Rsr of La Paz Univ Hosp, Madrid, Spain; ³ICH Study Cntr, Hamburg, Germany; ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁵INSERM U1137, Paris, France; ⁶ViiV Hlthcare, Durham, NC, USA; ⁷GSK, Mississauga, ON, Canada; ⁸Janssen, Beerse, Belgium

11:45 32LB ACTG 5340: The Effect of VRC01 on Viral Kinetics After Analytic Treatment Interruption

Katharine J. Bar¹; Linda J. Harrison²; Edgar T. Overton³; Mark Bardsley⁴; Michael Messer⁵; Edmund Capparelli⁶; Barney Graham⁷; Richard A. Koup⁸; James A. Hoxie⁹; Pablo Tebas¹⁰; for the AIDS Clinical Trials Group (A5340 team)

¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁴Univ of Alabama School of Medicine, Birmingham, AL, USA; ⁵Univ of California San Diego, San Diego, CA, USA; ⁶NIAID, NIH, Bethesda, MD, USA; ⁷VRC, NIAID, NIH, Bethesda, MD, USA

Session O-3 Oral Abstracts
10:00 AM-12:00 PM

Room 304/306

Prevention and Treatment of Pediatric HIV Infections

Oral Abstract Moderators

Jason Brophy, *Children's Hospital of Eastern Ontario, Ottawa, ON, Canada*
Karin Nielsen-Saines, *University of California Los Angeles, Los Angeles, CA, USA*

10:00 33 Breast Milk and In Utero HIV-1 Transmission Select for Unique Envelope Signatures

Thomas A. Wilkinson¹; Kyle J. Nakamura¹; Laura M. Heath²; Katherine Semrau³; Chipepo Kankasa⁴; Nicholas E. Webb⁵; Benhur Lee⁶; Louise Kuhn⁷; James I. Mullins⁸; Grace M. Aldrovandi¹

¹*Children's Hosp of Los Angeles, Los Angeles, CA, USA*; ²*Univ of Washington, Seattle, WA, USA*; ³*Boston Univ Sch of PH, Boston, MA, USA*; ⁴*Univ Teaching Hosp, Lusaka, Zambia*; ⁵*Univ of California Los Angeles, Los Angeles, CA, USA*; ⁶*Columbia Univ, New York, NY, USA*

10:15 34 Impact of Option B+ on ART Uptake and Retention in Swaziland: A Stepped-Wedge Trial

Elaine J. Abrams¹; Nontokozi Langwenya²; Averie Gachuhi³; Allison Zerbe⁴; Thabo Hlophe⁵; Simangele Mthethwa-Hleta⁶; Harriet Nuwagaba-Biribonwoha⁷; Ruben Sahabo⁸; Velephi Okello⁹; Landon Myer²

¹*CAP, Columbia Univ Mailman Sch of PH, New York, NY, USA*; ²*Univ of Cape Town, Cape Town, South Africa*; ³*ICAP at Columbia Univ, New York, NY, USA*; ⁴*ICAP at Columbia Univ, Mbabane, Swaziland*; ⁵*Ministry of Hlth, Mbabane, Swaziland*

10:30 35LB National HIV Transmission in 4-12 Week Olds in Malawi's PMTCT Option B+ Program

Beth Tippett Barr¹; Erik Schouten²; Joep van Oosterhout³; Sundeep K. Gupta⁴; Happy Phiri⁵; Deus Thindwa⁶; Christopher Blair⁷; Andreas Jahn⁸; Monique von Lettow⁹; for the NEMAPP Consortium

¹*CDC, Harare, Zimbabwe*; ²*Management Sciences for Hlth, Lilongwe, Malawi*; ³*Dignitas Intl, Zomba, Malawi*; ⁴*CDC, Lilongwe, Malawi*; ⁵*Ministry of Hlth, Lilongwe, Malawi*; ⁶*Dignitas International, Lilongwe, Malawi*

10:45 36 Impact of Maternal Tenofovir Use on HIV-Exposed Newborn Bone Mineral

George K. Siberry¹; Camlin Tierney²; Lynda Stranix-Chibanda³; Caroline Marr⁴; John A. Shepherd⁵; Renee Browning⁶; Heidi J. Kalkwarf⁷; Kathleen George⁸; Mary G. Fowler⁹; for the IMPAACT P1084s Study Team

¹*Eunice Kennedy Shriver NICHD, Bethesda, MD, USA*; ²*Harvard Sch of PH, Boston, MA, USA*; ³*Univ of Zimbabwe, Harare, Zimbabwe*; ⁴*Univ of California San Francisco, San Francisco, CA, USA*; ⁵*NIH, Rockville, MD, USA*; ⁶*Cincinnati Children's Hosp Med Ctr, Cincinnati, OH, USA*; ⁷*IMPAACT Operations, Durham, NC, USA*; ⁸*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*

11:00 37 Similar Mortality With Cotrimoxazole vs Placebo in HIV-Exposed Uninfected Children

Roger L. Shapiro¹; Michael Hughes²; Kathleen Powis³; Gbolahan Ajibola⁴; Kara Bennett⁵; Sikhulile Moyo⁶; Joseph Makhema⁷; Sheryl Zwierski⁸; M. Essex⁹; Shahin Lockman⁶
¹*Harvard Sch of PH, Boston, MA, USA*; ²*Massachusetts General Hosp, Boston, MA, USA*; ³*Botsswana Harvard AIDS Inst Partnership, Gaborone, Botswana*; ⁴*Bennett Statistical Consulting, Inc., Ballston Lake, NY, USA*; ⁵*NIH, Bethesda, MD, USA*; ⁶*Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA*

11:15 38 Urgent Versus Post-Stabilization ART in Hospitalized Children: A Randomized Trial

Irene N. Njuguna¹; Lisa M. Cranmer²; Vincent O. Otieno³; Helen M. Okinyi⁴; Sarah Benki-Nugent⁵; Joshua Stern⁶; Ken Tapia⁷; Elizabeth Maleche-Obimbo⁸; Dalton Wamalwa⁹; Grace C. John-Stewart⁴

¹*Univ of Nairobi, Nairobi, Kenya*; ²*Emory Univ Sch of Med, Atlanta, GA, USA*; ³*Univ of Washington, Seattle, WA, USA*

11:30 39 Three-Year Outcomes in PMTCT-Exposed Children Switched to EFV Once Suppressed on LPVr

Pamela Murnane¹; Renate Strehlau²; Stephanie Shiau³; Sarah Ramteke⁴; Faezah Patel⁵; Elaine J. Abrams⁶; Ashraf Coovadia⁷; Louise Kuhn⁸; for the NEVEREST III Study Team

¹*Columbia Univ, Johannesburg, South Africa*; ²*Univ of the Witwatersrand, Johannesburg, South Africa*; ³*Columbia Univ Med Ctr, New York, NY, USA*; ⁴*Columbia Univ, New York, NY, USA*; ⁵*ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA*

11:45 40 Efavirenz Is Associated With Higher Bone Mass in South African Children With HIV

Stephen M. Arpadi¹; Stephanie Shiau²; Renate Strehlau³; Faezah Patel⁴; Louise Kuhn⁵; Ashraf Coovadia⁶; Don McMahon⁷; Jonathan J. Kaufman⁸; Michael T. Yin⁹; for the CHANGES Bone Study Team

¹*Columbia Univ Med Ctr, New York, NY, USA*; ²*Univ of the Witwatersrand, Johannesburg, South Africa*; ³*Columbia Univ, New York, NY, USA*; ⁴*Mount Sinai Sch of Med, New York, NY, USA*

Session O-4 Oral Abstracts
10:00 AM-12:00 PM

Auditorium

Complications from Head to Toe

Oral Abstract Moderators

Kristine M. Erlandson, *University of Colorado, Denver, CO, US*
Chris T. Longenecker, *Case Western Reserve University, Cleveland, OH, US*

10:00 41 Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy

Jason V. Baker¹; Katherine Huppler Hullsiek²; Nicole Wyman Engen³; Daniel Duprez⁴; for the INSIGHT START (Strategic Timing of Antiretroviral Treatment) Arterial Elasticity Substudy Team
¹*Hennepin County Med Ctr, Univ of Minnesota, Minneapolis, MN, USA*; ²*Univ of Minnesota, Minneapolis, MN, USA*

10:15 42 Comparing Cardiovascular Disease Risk Scores for Use in HIV-Infected Individuals

Heidi M. Crane¹; Robin Nance¹; Joseph A. Delaney²; Daniel Drozd³; Susan Heckbert⁴; Rebekah Young⁵; Matthew J. Feinstein⁶; Richard Moore⁷; Michael S. Saag⁸; Mari Kitahata¹
¹Univ of Washington, Seattle, WA, USA; ²Univ of Washington Sch of PH, Seattle, WA, USA; ³Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Univ of Alabama at Birmingham, Birmingham, AL, USA

10:30 43 Stroke Incidence Highest in Women and Black HIV-Infected Participants in ALLRT Cohort

Felicia Chow¹; Michael R. Wilson¹; Kunling Wu²; Ron Ellis³; Ronald Bosch⁴; Benjamin P. Linares⁵
¹Univ of California San Francisco, San Francisco, CA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of California San Diego, San Diego, CA, USA; ⁴Boston Univ Sch of Med, Boston, MA, USA

10:45 44LB Aspirin Fails to Impact Immune Activation or Endothelial Function in Treated HIV

Meagan K. O'Brien¹; Douglas Kitch²; Peter W. Hunt³; Karin Klingman⁴; James H. Stein⁵; Nicholas T. Funderburg⁶; Jeffrey S. Berger⁷; Pablo Tebas⁸; Judith Aberg⁹; for the ACTG A5331 Study Team
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴NIAID, NIH, Bethesda, MD, USA; ⁵Univ of Wisconsin-Madison, Madison, WI, USA; ⁶Ohio State Univ, Columbus, OH, USA; ⁷New York Univ School of Med, New York, NY, USA; ⁸Univ of Pennsylvania, Philadelphia, PA, USA

11:00 45 Body Composition Changes on DRV/r + Either RAL or TDF/FTC As First-Line ART

Jose I. Bernardino¹; Amanda Mcroft²; Cedrick Wallet³; Jean-Michel Molina⁴; Hernando Knobel⁵; Jacques Reynes⁶; Abdel Babiker⁷; François Raffi⁸; Jose R. Arribas⁹; for the NEAT 001/ANRS 143 Study group
¹Inst for Hlth Rsr of La Paz Univ Hosp, Madrid, Spain; ²Univ Coll London, London, UK; ³INSERM U897, Univ de Bordeaux, Bordeaux, France; ⁴Hopital Saint-Louis, Paris, France; ⁵Hosp del Mar Barcelona, Barcelona, Spain; ⁶Univ Hosp Montpellier, Montpellier, France; ⁷Univ Hosp Nantes, Nantes, France

11:15 46 Antiretrovirals, Fractures, and Osteonecrosis in a Large European HIV Cohort

Alvaro H. Borges¹; Jennifer Hoy²; Eric Florence³; Dalibor Sedlacek⁴; Hans-Jürgen Stellbrink⁵; Vilma Uzdaviniene⁶; Tomaz Janez⁷; Panagiotis Gargalianos-Kakolyris⁸; Jens D. Lundgren⁹; Amanda Mcroft¹⁰; for the EuroSIDA in EuroCOORD
¹CHP, Rigshospet, Univ of Copenhagen, Copenhagen, Denmark; ²Alfred Hosp, Melbourne, Australia; ³Inst of Trop Med Antwerp, Antwerp, Belgium; ⁴Charles Univ Hosp Plzen, Plzen, Czech Republic; ⁵ICH Study Cntr, Hamburg, Germany; ⁶Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania; ⁷Univ Med Cntr Ljubljana, Ljubljana, Slovenia; ⁸General Hosp of Athens "G. Gennimatas", Athens, Greece; ⁹Rigshospet, Univ of Copenhagen, Copenhagen, Denmark; ¹⁰Univ Coll London, London, UK

11:30 47 A Single Dose Zoledronic Acid Prevents Antiretroviral-Induced Bone Loss

Ighoverhera Ofotokun¹; Kehmia Titanji¹; Aswani Vunnava¹; Antonina Foster²; Anandi N. Shethi³; Cecile D. Lahiri⁴; Jeffrey L. Lennox⁵; Andrea Knezevic⁶; Kirk A. Easley⁷; M. N. Weitzmann¹
¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Emory Univ Rollins Sch of PH, Atlanta, GA, USA

11:45 48LB Recovery of Bone Mineral Density After Stopping Oral HIV Preexposure Prophylaxis

Robert Grant¹; Kathleen Mulligan²; Vanessa McMahan³; Albert Y. Liu⁴; Juan Guanira⁵; Suwat Chariyalertsak⁶; Linda-Gail Bekker⁷; Mauro Schechter⁸; Valdilea G. Veloso⁹; David V. Glidden¹⁰; for the iPrEx study team.
¹Univ of California San Francisco, San Francisco, CA, USA; ²Gladstone Insts, San Francisco, CA, USA; ³San Francisco Dept of PH, San Francisco, CA, USA; ⁴Investigaciones Médicas en Salud, Lima, Peru; ⁵Univ of Chiang Mai, Chiang Mai, Thailand; ⁶Desmond Tutu HIV Cntr, Cape Town, South Africa; ⁷Projeto Praça Onze, Universidade Fed do Rio de Janeiro, Rio de Janeiro, Brazil; ⁸Fiocruz, Rio de Janeiro, Brazil

Session 0-5 Oral Abstracts**Ballroom A****10:00 AM-12:00 PM****Strategies for Testing and Linkage to Care: Are We Closing the Gap?****Oral Abstract Moderators**

Demetre C. Daskalakis, New York City Department of Health and Mental Hygiene, Queens, NY, USA

Heidi van Rooyen, Human Sciences Research Council, Durban, South Africa

10:00 49 Male Partner Home HIV Testing vs Clinic

Invitation in Pregnancy: A Randomized Trial
 Daisy Krakowiak¹; John Kinuthia²; Alfred Osoti³; Victor Asila⁴; Molly Ann Gone⁵; Jennifer Mark⁶; Monisha Sharma⁷; Ruanne V. Barnabas⁸; **Carey Farquhar**¹
¹Univ of Washington, Seattle, WA, USA; ²Kenya Natl Hosp, Nairobi, Kenya; ³Univ of Nairobi, Nairobi, Kenya

10:15 50 Effectiveness of Partner Services for HIV in Kenya: A Cluster Randomized Trial

Peter Cherutich¹; Mathew R. Golden²; Beatrice Wamuti³; Barbra A. Richardson⁴; Kristjana H. Ásbjörnsdóttir⁵; Felix A. Otieno⁶; Betsy Samba⁷; Matt Dunbar⁸; **Carey Farquhar**⁹; for the aPS Study Group
¹Univ of Washington, Seattle, WA, USA; ²Univ of Washington Sch of Med, Seattle, WA, USA; ³Kenya Natl Hosp, Nairobi, Kenya

10:30 51 Optimal Timing of Home-Based HIV Testing in Western Kenya

Jack J. Olney¹; Paula Braitsstein²; Jeffrey W. Eaton³; Edwin Sang⁴; Monicha Nyambura⁵; Sylvester Kimaiyo⁶; Ellen McRobie⁷; Joseph Hogan⁸; Timothy Hallett¹
¹Imperial Coll London, London, UK; ²Univ of Toronto, Toronto, ON, Canada; ³Academic Model Providing Access to Hlthcare, Eldoret, Kenya; ⁴Moi Univ, Eldoret, Kenya; ⁵Brown Univ, Providence, RI, USA

10:45 52 Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States

Kristen Hess; Xiaohong Hu; Amy Lansky; Jonathan Mermin; H. Irene Hall
CDC, Atlanta, GA, USA

11:00 53 Increased HIV Viral Suppression Among US Adults Receiving Medical Care, 2009-2013

Heather Bradley; Christine Mattson; Linda Beer; Ping Huang; Roy L. Shouse
CDC, Atlanta, GA, USA

11:15 54 Narrowing the Gap in Life Expectancy for HIV+ Compared With HIV- Individuals

Julia L. Marcus¹; Chun Chao²; Wendy Leyden³; Lanfang Xu²; Charles P. Quesenberry¹; Daniel B. Klein¹; William J. Townner²; Michael A. Horberg⁴; Michael J. Silverberg¹
¹*Kaiser Permanente Northern California, Oakland, CA, USA*;
²*Kaiser Permanente Southern California, Pasadena, CA, USA*;
³*Kaiser Permanente San Leandro Med Cntr, San Leandro, CA, USA*;
⁴*Mid-Atlantic Permanente Med Group, Rockville, MD, USA*

11:30 55 Perception of Infectiousness in HIV-Infected Persons After Initiating ART: ACTG A5257

Raphael J. Landovitz¹; Thuy T. Tran²; Susan E. Cohn³; Ighovwerha Ofotokun⁴; George A. Bishopric⁵; Jeffrey L. Lennox⁶; Judith S. Currier¹; Heather J. Ribaud⁷
¹*David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA*;
²*Harvard Sch of PH, Boston, MA, USA*;
³*Northwestern Univ, Chicago, IL, USA*;
⁴*Emory Univ Sch of Med, Atlanta, GA, USA*;
⁵*Univ of Miami, Miami, FL, USA*

Session TD-1 Themed Discussion

Room 311

1:45 PM-2:45 PM

Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions

Themed Discussion Leader

David M. Burger, *Radboud University Medical Center, Nijmegen, Netherlands*

438 Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women

Nikki Mulligan¹; Brookie M. Best²; Edmund Capparelli¹; Alice Stek²; Emily Barr³; Elizabeth Smith⁴; Nahida Chakhtoura⁵; Jiajia Wang⁶; Sandra Burchett⁷; Mark Mirochnick⁸
¹*Univ of California San Diego, San Diego, CA, USA*;
²*Univ of Southern California, Los Angeles, CA, USA*;
³*Univ of Colorado Anschutz Med Campus, Aurora, CO, USA*;
⁴*NIAID, NIH, Bethesda, MD, USA*;
⁵*Eunice Kennedy Shriver NICHD, Bethesda, MD, USA*;
⁶*Harvard Sch of PH, Boston, MA, USA*;
⁷*Children's Hosp Boston, Boston, MA, USA*;
⁸*Boston Univ Sch of Med, Boston, MA, USA*

439 Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women

Mark Mirochnick¹; Brookie M. Best²; Angela Kashuba³; Craig Sykes⁴; Amanda Schauer⁵; Jiajia Wang⁶; Alice Stek⁷; Elizabeth Smith⁸; Nahida Chakhtoura⁹; Edmund Capparelli¹⁰
¹*Boston Univ Sch of Med, Boston, MA, USA*;
²*Univ of California San Diego, San Diego, CA, USA*;
³*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*;
⁴*Harvard Sch of PH, Boston, MA, USA*;
⁵*Univ of Southern California, Los Angeles, CA, USA*;
⁶*NIAID, NIH, Bethesda, MD, USA*;
⁷*Eunice Kennedy Shriver NICHD, Bethesda, MD, USA*

440 Nevirapine Dosing for Treatment in the First Month of Life

Mark Mirochnick¹; Karin Nielsen-Saines²; Jose H. Pilotto³; Philippa Musoke⁴; Avinash Shetty⁵; Katherine Luzuriaga⁶; Edmund Capparelli⁷
¹*Boston Univ Sch of Med, Boston, MA, USA*;
²*Univ of California Los Angeles, Los Angeles, CA, USA*;
³*Hosp Geral de Nova Iguaçu, Rio de Janeiro, Brazil*;
⁴*Makerere Univ, Kampala, Uganda*;
⁵*Wake Forest Univ, Winston Salem, NC, USA*;
⁶*Univ of Massachusetts Med Sch, Worcester, MA, USA*;
⁷*Univ of California San Diego, San Diego, CA, USA*

441 Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling

Adeniyi Olagunju¹; Rajith Kumar Reddy Rajoli¹; Oluseye Bolaji²; David J. Back³; Saye Khoo⁴; Andrew Owen⁵; Marco Siccardi⁶
¹*Univ of Liverpool, Liverpool, UK*;
²*Obafemi Awolowo Univ, Ile-Ife, Nigeria*

442 Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models

Rajith Kumar Reddy Rajoli; David Back; Steve Rannard; Andrew Owen; Marco Siccardi
Univ of Liverpool, Liverpool, UK

Session TD-2 Themed Discussion

Room 312

1:45 PM-2:45 PM

Global Burden and Mortality of Cancer in HIV

Themed Discussion Leader

William A. Blattner, *Institute of Human Virology, Baltimore, MD, USA*

616 Excess Mortality Rates Among HIV-Infected Cancer Patients in the United States

Anna Coghill; Ruth Pfeiffer; Meredith Shiels; Eric Engels
NCI, Rockville, MD, USA

617 Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy

Eliane Rohner¹; Lukas Bütikofer²; Mhairi Maskev³; Yi-Ming A. Chen⁴; Ruth Friedman⁵; Gypsamber D. Souza⁶; Matthias Egger⁷; Julia Bohlius⁸; for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
¹*Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland*;
²*Univ of Bern, Bern, Switzerland*;
³*Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa*;
⁴*Kaohsiung Med Univ, Kaohsiung, Taiwan*;
⁵*Inst Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil*;
⁶*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*;
⁷*Univ Hosp Bern, Bern, Switzerland*

613 Risk of Cancer in HIV-Positive Adults on ART in South Africa: A Record Linkage Study

Mazvita M. Sengayi¹; Adrian Spoorri²; Matthias Egger³; Janet Giddy⁴; Mhairi Maskev⁵; Elvira Singh⁶; Julia Bohlius⁷; for the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA)
¹*Natl Cancer Registry, NHLS, Johannesburg, South Africa*;
²*Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland*;
³*Univ Hosp Bern, Bern, Switzerland*;
⁴*McCord Hosp, Durban, South Africa*;
⁵*Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa*

615 Cancer Versus Tuberculosis Mortality Among HIV-Infected Individuals in Botswana

Scott Dryden-Peterson¹; Gita Suneja²; Heluf Medhin³; Memory Bvochora-Nsingo⁴; Mukendi K. Kayembe⁵; Neo Tapela⁶; Shahin Lockman¹

¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Univ of Utah Sch of Med, Salt Lake City, UT, USA; ³Botswana Ministry of Hlth, Gaborone, Botswana; ⁴Gaborone Private Hosp, Gaborone, Botswana; ⁵Natl Hlth Lab, Gaborone, Botswana

Session TD-3 Themed Discussion

1:45 PM-2:45 PM

Rants About HCV RAVS

Themed Discussion Leader

Gary P. Wang, North Florida/South Georgia Veterans Health System, Gainesville, FL, US

Ballroom B/C

579 Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance

Wei Huang; Alicia Newton; Arne Frantzell; Jennifer Cook; Dongmei Yang; Joseph M. Volpe; Charles M. Walworth; Jeannette M. Whitcomb; Jacqueline D. Reeves; Christos Petropoulos
Monogram BioScis, South San Francisco, CA, USA

577 HCV Resistance to Daclatasvir/Sofosbuvir Across Different Genotypes in the Real Life

Slim Fourati¹; Christophe Hezode¹; Alexandre Soulier¹; Lila Poiteau¹; Marion Lavert¹; Christophe Rodriguez²; Stephane Chevaliez³; Jean-Michel Pawlotsky¹
¹INSERM U955, Créteil, France; ²Inst Mondor de Recherche Biomédicale INSERM U955, Créteil, France

543 Tracing the Origin of HCV NS3 Q80K Among HIV-Infected MSM in the Netherlands

Astrid M. Newsom¹; Cynthia K. Ho²; Faydra I. Lieveeld³; Thijs J. van de Laar⁴; Jan T. van der Meer⁵; Anne M. Wensing⁶; Greet J. Boland⁷; Joop E. Arends⁸; Maria Prins¹; Janke Schinkel⁹
¹PH Service of Amsterdam, Amsterdam, Netherlands; ²Academic Med Cntr, Amsterdam, Netherlands; ³Univ Med Cntr Utrecht, Utrecht, Netherlands; ⁴Sanquin Blood Supply Fndn, Amsterdam, Netherlands; ⁵Cntr of Infectious Diseases and Immunology Amsterdam, Academic Med Cntr, Amsterdam, Netherlands

578 Polymorphisms at Codon 28 of HCV NS5A Impact NS5A Inhibitor Susceptibility

Alicia Newton; Arne Frantzell; Christos Petropoulos; Wei Huang
Monogram BioScis, South San Francisco, CA, USA

580 Resistance Associated Variants: Data From the NIAID SYNERGY Trial

Eleanor M. Wilson¹; Sarah Kattakuzhy²; Hongmei Mo³; Anuoluwapo Osinusi⁴; Henry Masur⁵; Anita Kohlf⁶; Shyam Kottillil⁶
¹Inst of Human Virology, Baltimore, MD, USA; ²Inst of Human Virology, Bethesda, MD, USA; ³Gilead Scis, Inc, Foster City, CA, USA; ⁴NIH, Bethesda, MD, USA; ⁵Dignity Hlth, St. Joseph's Hosp, Phoenix, AZ, USA; ⁶Univ of Maryland Med Cntr, Baltimore, MD, USA

Session TD-4 Themed Discussion

1:45 PM-2:45 PM

Room 304/306

Learning from Experience: Shaping the Future of Antiretroviral Therapy in Sub-Saharan Africa

Themed Discussion Leader

Tsitsi Mutasa-Apollo, University of Zimbabwe, Harare, Zimbabwe

1015 6-Year Retention and Immunological Response to ART by Gender: leDEA West Africa

Thierry Tiendrebeogo¹; Juan Burgos-Soto¹; Eugene Messou²; Aristophane Tanon³; Vivian Kwaghue⁴; Marcel Zannou⁵; Albert Minga⁶; Nathalie De Rekeneire¹; Francois Dabis⁷; Renaud Bequet¹
¹INSERM U897, Bordeaux, France; ²CePreF, ACONDA, Abidjan, Côte d'Ivoire; ³CHU de Treichville, Abidjan, Côte d'Ivoire; ⁴Univ of Abuja Teaching Hosp, Abuja, Nigeria; ⁵Cntr de Prise en Charge des Personnes Vivant Avec le VIH, CHNU, Cotonou, Benin; ⁶Cntr Médical de Suivi de Donneurs de Sang /CNTS/PRIMO-CI, Abidjan, Côte d'Ivoire; ⁷INSERM U897, ISPEP, Univ de Bordeaux, Bordeaux, France

1021 Declining Mortality in Patients on ART Lost to Follow-up in Sub-Saharan Africa

Matthias Egger¹; Anne Mooser²; Kathrin Zürcher³; Denis Nash⁴; Olga Tymejczyk⁵; Margaret Couvillon⁶; for the leDEA and MESH Consortia
¹Univ of Bern, Bern, Switzerland; ²Sch of PH, City Univ of New York, New York, NY, USA

1029 Comparing Adherence Methods: Which Best Predicts Virological and Resistance Outcome?

Catherine Orrell¹; Karen Cohen¹; Rory Leisegang²; David R. Bangsberg³; Gary Maartens⁴; Robin Wood¹
¹Univ of Cape Town, Cape Town, South Africa; ²Harvard Med Sch, Boston, MA, USA

1027 High Rate of Viral Suppression in Late Mortality on First-Line ART in Uganda/Zimbabwe

David I. Dolling¹; Pontiano Kaleebu²; Peter Nkurunziza³; Moira Spyer⁴; Charles Gilks⁵; Deenan Pillay⁶; Ruth Goodall⁷; for the DART Virology Group
¹Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ²Med Rsr Council/Uganda Virus Rsr Inst Uganda Rsr Unit on AIDS, Entebbe, Uganda; ³Sch of Pop Hlth, Univ of Queensland, Herston, Australia; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

1030 Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa

Dami A. Collier¹; Kathy Baisley²; Dickman Garet³; Deenan Pillay³; Ravindra K. Gupta¹
¹Univ Coll London, London, UK; ²London Sch of Hygiene & Trop Med, London, UK; ³Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

Session TD-5 Themed Discussion
1:45 PM-2:45 PM

Room 302

HIV Testing: A Crucial Foundation

Themed Discussion Leader

Cheryl C. Johnson, *World Health Organization, Geneva, Switzerland*

- 975 Home-Based HIV Testing and New HIV Diagnoses in Chókwe District, Mozambique**
Isabelle Casavant¹; Duncan MacKellar²; Ricardo Thompson³; Robert Nelson²; Juvenio Bonzela⁴; Bertur Alfaced⁵; Stanley Wei¹; Daniel Shodell⁶; Judite Cardoso⁵; Nely Honwana¹
¹*CDC, Maputo, Mozambique*; ²*CDC, Atlanta, GA, USA*; ³*Natl Inst of Hlth Mozambique, Maputo, Mozambique*; ⁴*CIISC, Chókwe, Mozambique*; ⁵*Provincial Directorate of PH, Xaixai, Mozambique*; ⁶*Colorado Dept of PH and Environment, Denver, CO, USA*; ⁷*Jhpiego, Maputo, Mozambique*
- 988 Home-Based HIV Counseling and Testing Using Index Patients in Lesotho**
Abby L. DiCarlo¹; Allison Zerbe¹; Zach Peters²; Koen Frederix³; Joanne E. Mantell¹; Robert Remien¹; **Wafaa M. El-Sadr¹**
¹*ICAP at Columbia Univ, New York, NY, USA*; ²*ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA*; ³*HIV Cntr for Clinical and Behavioral Studies, Columbia Univ and New York State Psychiatric Inst, New York, NY, USA*
- 978 Effective, High-Yield HIV Testing for Partners of Newly Diagnosed Persons in Tanzania**
Marya Plotkin¹; Catherine Kahabuka²; Mbaraka Amuni³; Mustafa Njazi⁴; Werner Maokola⁵; Erick Mlangwa⁵; Mary Drake⁶; Kelly Curran⁷; Charlene Brown⁷; Vincent Wong⁷
¹*Jhpiego, Chapel Hill, NC, USA*; ²*Kahabuka Consulting, Dar es Salaam, Tanzania*; ³*Jhpiego, Dar es Salaam, Tanzania*; ⁴*Natl AIDS Control Prog, Dar es Salaam, Tanzania*; ⁵*US Agency for Intl Develop-Tanzania, Dar es Salaam, Tanzania*; ⁶*Jhpiego, Baltimore, MD, USA*; ⁷*US Agency for Intl Develop, Washington, DC, USA*
- 983 HIV Testing and Linkage to Care in the Botswana Combination Prevention Project**
Pamela J. Bachanas¹; Mary G. Alwano²; Stephanie K. Behel¹; John Wen¹; Winnie Sento³; **Jan S. Moore¹**; Molly Pretorius Holme⁴; Tendani Gaolethe⁵; Refeletswe Lebelonyane⁶; Lisa A. Mills²
¹*CDC, Atlanta, GA, USA*; ²*CDC, Gaborone, Botswana*; ³*Tebelopele Counseling and Testing Cntr, Gaborone, Botswana*; ⁴*Harvard Sch of PH, Boston, MA, USA*; ⁵*Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana*; ⁶*Ministry of Hlth, Gaborone, Botswana*
- 979 94% Population HIV Testing Coverage With Repeat Hybrid Mobile Testing in East Africa**
Gabriel Chamie¹; Jane Kabami²; Emmanuel Ssemmondo²; Tamara Clark¹; Elizabeth Bukusi¹; Maya Petersen³; Moses R. Kamya²; Diane V. Havlir¹; Edwin Charlebois¹; for the Sustainable East Africa Research for Community Health (SEARCH) team
¹*Univ of California San Francisco, San Francisco, CA, USA*; ²*Makerere Univ- Univ of California Rsr Collab, Kampala, Uganda*; ³*Cntr for Microbiology Rsr, Kenya Med Rsr Inst, Kisumu, Kenya*; ⁴*Univ of California Berkeley, Berkeley, CA, USA*; ⁵*Makerere Univ Coll of Hlth Scis, Kampala, Uganda*

Session TD-6 Themed Discussion
1:45 PM-2:45 PM

Ballroom A

HIV Persistence and Latency Reversal

Themed Discussion Leader

Sharon R. Lewin, *Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia*

- 377 Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent HIV-1**
Jennifer Zerbato¹; Deborah McMahon¹; Michele D. Sobolewski¹; John W. Mellors¹; Nicolas Sluis-Cremer
Univ of Pittsburgh, Pittsburgh, PA, USA
- 378 Follicular Tregs Reduce HIV Replication and Reactivation From Latency Ex Vivo**
Brodie Miles¹; Elizabeth Connick
Univ of Colorado, Denver, CO, USA
- 375 Dendritic Cell-T-Cell Culture Facilitates HIV Latency in Proliferating CD4+ T Cells**
Nitasha A. Kumar¹; Renee M. van der Sluis²; Talia Mota²; Sharon R. Lewin³; Paul U. Cameron³
¹*Emory Univ, Atlanta, GA, USA*; ²*The Peter Doherty Inst, Univ of Melbourne, Melbourne, Australia*; ³*Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia*
- 379 A Subset of Infectious Proviruses Persist and Expand Following Activation Ex Vivo**
John K. Bui¹; Elias Halvas²; Elizabeth Fyne¹; Michele D. Sobolewski¹; Dianna Koonitz²; Mary F. Kearney³; Wei Shao⁴; Feiyu Hong¹; John W. Mellors¹
¹*Univ of Pittsburgh, Pittsburgh, PA, USA*; ²*Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA*; ³*NCI, Frederick, MD, USA*; ⁴*Leidos Biomed Rsr, Inc, Frederick, MD, USA*
- 380 Transcription of Novel HIV-1 RNA Species in the Setting of Undetectable Virus**
Hiromi Imamichi¹; Robin Dewar²; Joseph A. Adelsberger³; Catherine A. Rehm⁴; Catherine Seaman⁴; Gregg Roby⁵; Alice Pau⁶; H. Clifford Lane⁶
¹*NIAID, NIH, Frederick, MD, USA*; ²*Frederick Cancer Rsr and Develop Cntr, Frederick, MD, USA*; ³*Leidos Biomed Rsr, Inc, Frederick, MD, USA*; ⁴*NIAID, NIH, Bethesda, MD, USA*; ⁵*NIAID, NIH, Rockville, MD, USA*

Session S-1 Symposium
4:00 PM-6:00 PM

CME

Room 304/306

Molecular Interplay from Virus to Host

Target audience: This session is directed to clinicians and scientists who are interested in understanding HIV and its interactions with innate immune factors in mechanistic detail.

Level of knowledge: It is assumed that participants are familiar with basic stages of the viral life cycle and the fundamentals of innate immunity.

Objectives: At the completion of the session, participants will be able to:

- Describe how HIV selects and packages its RNA genome
- Describe how the viral Nef protein subverts clathrin and clathrin adaptor proteins to remove antagonizing cellular proteins from the plasma membrane
- Describe the antiviral activity of the SERINC protein and how this protein is antagonized by HIV Nef and other retroviral proteins
- Describe how the viral Vif protein recognizes antiviral APOBEC3 proteins for degradation

Conveners

Celia A. Schiffer, *University of Massachusetts Medical School, Worcester, MA, USA*

Jonathan P. Stoye, *Francis Crick Institute, USA*




4:00 56 Structure of the HIV-1 RNA Packaging Signal

Michael F. Summers, *Howard Hughes Med Inst, Minneapolis, MN, USA*



4:30 57 The Antiretroviral Activity of the SERINC Gene Family

Massimo Pizzato, *Univ of Trento, Trento, Italy*



5:00 58 How HIV-1 Nef Downregulation Hijacks Clathrin-Coated Vesicles

James H. Hurley, *Univ of California Berkeley, Berkeley, CA, USA*



5:30 59 APOBEC3F-Vif Binding Interface Elucidated by Numerous Experimental Approaches

Reuben S. Harris, *Howard Hughes Med Inst, Minneapolis, MN, USA*



Session S-2 Symposium
4:00 PM-6:00 PM

CME

Ballroom A

A Beautiful Mind: Keeping It

Target audience: This session is directed to clinicians and scientists who are interested in understanding the pathogenesis of HIV's effect on the brain and its clinical implications.

Level of knowledge: It is assumed that participants are familiar with basic and clinical concepts of how HIV impacts the CNS.

Objectives: At the completion of the session, participants will be able to:

- Describe the implications of viral reservoirs in the CNS for systemic and neurologic disease
- Be familiar with CNS biomarkers of HIV immune activation
- Describe the impact of antiretroviral therapies on the CNS
- Critically evaluate CNS biomarkers of HIV brain disease

Conveners

Andrea Antinori, *Istituto Nazionale Malattie Infettive "L. Spallanzani", Rome, Italy*

Dana H. Gabuzda, *Dana-Farber Cancer Institute, Boston, MA, USA*



4:00 60 CNS HIV Infection: Cerebrospinal Fluid and Blood Biomarkers

Magnus Gisslén, *Univ of Gothenburg, Gothenburg, Sweden*



4:30 61 Neuroimaging of HIV in the Brain

Beau M. Ances, *Washington Univ in St. Louis, St Louis, MO, USA*



5:00 62 CNS as an HIV Reservoir

Ronald I. Swanstrom, *Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*



5:30 63 Therapeutics of the CNS With HIV Infection

Andrea Calcagno, *Univ of Torino, Torino, Italy*



Session S-3 Symposium



Ballroom B/C

4:00 PM-6:00 PM

Global Impact of Hepatitis

Target audience: This session is directed to investigators and clinicians who are interested in the epidemiology, basic science, public health impact, and future trends in hepatitis B and hepatitis C therapy.

Level of knowledge: It is assumed that participants are familiar with the general principles of hepatitis B and hepatitis C virology and treatment.

Objectives: At the completion of the session, participants will be able to:

- Compare the global burden and epidemiology of hepatitis B and C
- Describe Egypt as a model for hepatitis C transmission around the world and the approaches to disease eradication
- Identify the mechanism of antiviral activity of hepatitis C medications including those effective against all genotypes
- Compare immunologic and virologic mechanisms for eradication of hepatitis B

Conveners

Gottfried Hirschall, *World Health Organization, Geneva, Switzerland*

Andri Rauch, *Bern University Hospital and University of Bern, Bern, Switzerland*



4:00 64 Hepatitis C: Global Epidemiology
Imam Waked, *Natl Liver Inst, Shebeen El Kom, Egypt*



4:30 65 Refer to the CROI Mobile App and the CROI website for updates on this presentation

5:00 66 Hepatitis C Therapeutics: Pangenotypic Therapeutics on the Horizon
Karine LaCombe, *Sorbonne Univs, Paris, France*



5:30 67 Hepatitis B Virus: Is a Cure Possible?
Chloe Thio, *Johns Hopkins Univ, Baltimore, MD, USA*



Session S-4 Symposium



Auditorium

4:00 PM-6:00 PM

Innovations in PrEP

Target audience: This session is directed to clinicians and scientists who are interested in understanding antiretroviral preexposure prophylaxis (PrEP) for HIV prevention.

Level of knowledge: It is assumed that participants are familiar with basic concepts of how PrEP is used for HIV prevention.

Objectives: At the completion of the session, participants will be able to:

- Describe the current experience in PrEP delivery models
- Describe the potential increases in sexually transmitted infections associated with PrEP programs
- Describe approaches to promoting the use of PrEP
- List the potential advantages and disadvantages of current and future potential PrEP modalities
- Describe opportunities for other prevention modalities in light of low uptake of PrEP in some populations

Conveners

Albert Y. Liu, *San Francisco Department of Public Health, San Francisco, CA, USA*

Dawn K. Smith, *Centers for Disease Control and Prevention, Atlanta, Georgia, USA*



4:00 68 Delivery of PrEP: From Evidence to Practice
C. Bradley Hare, *Kaiser Permanente Northern California, San Francisco, CA, USA*



4:30 69 Sexually Transmitted Infection Control in the Era of PrEP
Sheena McCormack, *Univ Coll London, London, UK*



5:00 70 PrEP-4-Love: Transmitting Desire Across Chicago
James Pickett, *AIDS Fndn of Chicago, Chicago, IL, USA*



5:30 71 The Promise and Challenges of Sustained Delivery of PrEP
Ian McGowan, *Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA*



Special Session SS Oral Abstracts
6:15 PM-7:45 PM

Ebola: One Year Later

Oral Abstract Moderators

Kevin M. De Cock, *Centers for Disease Control and Prevention, Nairobi, Kenya*
Nancy Sullivan, *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA*

72LB Unreported Cases and Asymptomatic Infection in an Ebola “Hotspot”

Eugene T. Richardson¹; J. Daniel Kelly²; Mohamed B. Barrie³; Annelies W. Mesman³; Komba Quiwa³; Sahr Karku³; George Rutherford³; James H. Jones³; Megan Murray³; Paul Farmer¹
¹Stanford Univ, Stanford, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Partners In Hlth, Freetown, Sierra Leone; ⁴Harvard Med School, Boston, MA, USA

73LB Sequelae of Ebola Virus Disease in Surviving Patients in Guinea: Postebogui Cohort

Jean-François Etard¹; Mamadou Saliou Sow²; Sandrine Leroy¹; Philippe Msellati³; Abdoulaye I. Toure⁴; Bernard Taverne⁵; Ibrahima Savane⁶; Moumié Barry⁷; Eric Delaporte⁸; for the Postebogui study group
¹Institut de Recherche Pour le Développement, Montpellier, France; ²Donka National Hosp, Conakry, Guinea; ³Inst Recherche et Développement, France, Montpellier, Cameroon; ⁴Institut de Recherche Pour le Développement UMI 233, INSERM U1176, Montpellier, France; ⁵Institut de Recherche Pour le Développement UMI 233, INSERM U1175, Montpellier, France; ⁶Macenta Prectoral Hosp, Macenta, Guinea; ⁷CHU de Conakry, Conakry, Guinea; ⁸UMI 233-IRD/U1175-INSERM/Montpellier Univ, Montpellier, France

Ballroom B/C

74LB A Cohort Study of Survivors of Ebola Virus Infection in Liberia (PREVAIL III)

Mosoka Fallah; for the Prevail III Research Team, *Ministry of Hlth, Monrovia, Liberia*

75LB Dynamics of Ebola Virus Clearance in Semen in Guinea

Daouda Sissoko¹; Sophie Duraffour²; Jacques Kolie³; Abdoul H. Beavogui⁴; Thi Huyen Tram Nguyen⁵; Jeremie Guedj⁶; Denis Malvy⁷; Miles W. Carroll⁸; Xavier Anglaret⁹; Stephan Gunther¹⁰
¹INSERM U897, Bordeaux, France; ²Bernhard-Nocht Inst for Tropical Medicine, Hamburg, Germany; ³Ministry of Hlth Guinea, Conakry, Guinea; ⁴Cntr de Recherche en Santé Rurale de Maferinyah, Conakry, Guinea; ⁵UMR 1137, INSERM, Université Paris Diderot, Paris, France; ⁶French National Inst of Hlth and Med Rsr, Paris, France; ⁷CHU de Bordeaux, Bordeaux, France; ⁸Public Hlth England, Salisbury, UK; ⁹INSERM, Abidjan, Côte d'Ivoire (Ivory Coast); ¹⁰European Mobile Laboratory Project, Hamburg, Germany

76LB A Randomized Controlled Trial of the Safety and Immunogenicity of Two Ebola Vaccines

Fatorma Bolay; for the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL 1) Team, *Liberian Inst of BioMed Rsr/NIH Partnership, Bethesda, MD, USA*

77LB PREVAIL II: A Randomized Controlled Trial of ZMapp™ in Acute Ebola Virus Infection

Richard T. Davey; for the Multi-National PREVAIL II Study Team, *NIAID, Bethesda, MD, USA*

WEDNESDAY, FEBRUARY 24, 2016

Wednesday Plenary Sessions



Auditorium

8:30 AM-9:30 AM

8:30 78 Progress in Gene Therapy for HIV Cure

Paula M. Cannon, *University of Southern California, Los Angeles, CA, USA*



9:00 79 HIV in Transgender Populations: Charted and Uncharted Waters

Tonia C. Poteat, *The Johns Hopkins University, Baltimore, MD, USA*



Session 0-6 Oral Abstracts

10:00 AM-12:00 PM

Ballroom B/C

Reservoirs, Relapse, and Remission

Oral Abstract Moderators

Carolina Gutiérrez, *Ramón y Cajal Hospital, IRYCIS, Madrid, Spain*

Jonathan Z. Li, *Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA*

10:00 80 Investigating the Mechanisms that Control HIV Transcription and Latency In Vivo

Steven A. Yukl¹; Philipp Kaiser¹; Peggy Kim¹; Sunil K. Joshi¹; Nicholas Kim¹; Peilin Li¹; Harry Lampiris¹; Hongbing Liu¹; Andrew Rice²; Joseph K. Wong³; for the DARE Study Group
¹San Francisco VA Med Cntr, San Francisco, CA, USA; ²Baylor Coll of Med, Houston, TX, USA

10:15 81 Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation

Mohamed Abdel-Mohsen¹; Leonard Chavez²; Glen M. Chew²; Xutao Deng³; Ali Danesh³; Sheila M. Keating³; Rebecca Hoh³; Steven G. Deeks³; Lishomwa C. Ndhlovu³; Satish Pillai¹
¹Blood Systems Rsr Inst, San Francisco, CA, USA; ²Univ of Hawaii, Honolulu, HI, USA; ³Univ of California San Francisco, San Francisco, CA, USA

10:30 82 PD-1+ and Tfh Cells Represent the Major Source of HIV-1 Replication-Competent Virus

Riddhima Banga¹; Francesco Procopio¹; Matthias Cavassini²; Jean-Marc Corpataux³; Giuseppe Pantaleo³; Matthieu Perreau¹
¹CHUV, Epalinges, Switzerland; ²Univ Hosp Lausanne, Univ of Lausanne, Lausanne, Switzerland; ³CHU Vaudois, Lausanne, Switzerland

10:45 83 Rapid Accumulation of Defective Proviruses Complicates HIV-1 Reservoir Measurements

Katherine M. Bruner¹; Ross Pollack²; Alexandra Murray¹; Mary Soliman¹; Sarah B. Laskey³; Matt F. Strain⁴; Douglas D. Richman⁵; Steven G. Deeks⁶; Janet Siliciano⁷; Robert Siliciano⁸
¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Univ of California San Diego, San Diego, CA, USA; ⁴University of California San Francisco, San Francisco, CA, USA; ⁵Howard Hughes Med Inst, Baltimore, MD, USA

11:00 84 Clones of SIV-Infected Cells Are Present in Spleen and Lymph Nodes in Rhesus Macaques

Andrea Ferris¹; Gregory Q. Del Prete²; Brandon Keele²; Xiaolin Wu²; Jeffrey Lifson²; **Stephen H. Hughes**¹
¹NCI, Frederick, MD, USA; ²Frederick Natl Lab, Frederick, MD, USA

11:15 85 ART Reduces Cellular HIV RNA but Not the Fraction of Proviruses Transcribing RNA

Feiyu Hong¹; Jonathan Spindler¹; Andrew Musick¹; Anthony R. Cillo¹; Michael Bale¹; Wei Shao¹; John M. Coffin¹; John W. Mellors¹; **Mary F. Kearney**²
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²HIV Dynamics and Replication Prog, Natl Cancer Inst, Frederick, MD, USA; ³NCI, Frederick, MD, USA; ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA; ⁵Tufts Univ, Boston, MA, USA

11:30 86 Restricted HIV-1 Diversity and Clonal Expansion Following Cytoreductive Chemotherapy

Timothy J. Henrich¹; Eileen P. Scully¹; Kristen S. Hobbs¹; Emily Hanhauser¹; Louise Hogan¹; Christine D. Palmer²; Yvonne P. Robles³; Kaitlyn S. Leadabrand¹; Ann S. LaCasce⁴; Daniel Kuritzkes⁵
¹Univ of California San Francisco, San Francisco, CA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ⁴Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ⁵Dana-Farber Cancer Inst, Boston, MA, USA; ⁶Harvard Med Sch, Boston, MA, USA

11:45 87 Virological Remission After ART Interruption in African HIV-1 Seroconverters

Morgane Gossez¹; Gita Ramjee²; Jacob Hurst¹; Pontiano Kaleebu³; Helen Rees⁴; Kholoud Porter⁵; Abdel Babiker⁶; Sarah J. Fidler⁷; John Frater⁸; for the SPARTAC Trial Investigators
¹Univ of Oxford, Oxford, UK; ²South African Med Rsr Council, Cape Town, South Africa; ³Med Rsr Council/Uganda Virus Rsr Inst Uganda Rsr Unit on AIDS, Entebbe, Uganda; ⁴Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa; ⁵Med Rsr Council, London, UK; ⁶Univ Coll London, London, UK; ⁷Imperial Coll London, London, UK

Session 0-7 Oral Abstracts

10:00 AM-12:00 PM

Room 304/306

Pushing Frontiers of Adaptive Immunity

Oral Abstract Moderators

Gregory Q. Del Prete, *Frederick National Laboratory, Frederick, MD, USA*

Peter D. Kwong, *Vaccine Research Center, NIAID/NIH, Bethesda, MD, USA*

10:00 88 An Infant bNAbs With Low Somatic Hypermutation Contributes to Polyclonal Breadth

Cassandra Simonich¹; Katherine Williams¹; Theodore Gobillot²; Hadega Aamer³; Stephanie Rainwater³; Ruth Nduati⁴; Julie M. Overbaugh¹
¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ²Univ of Washington, Seattle, WA, USA; ³Seattle Children's Rsr Inst, Seattle, WA, USA; ⁴Univ of Nairobi, Nairobi, Kenya

10:15 89L Virus, Host, and Disease Factors Govern HIV-1 Broadly Neutralizing Antibody Induction

Peter Rusert¹; Roger Kouyos²; Claus Kadelka³; Hanna Ebner¹; Merle Schanz¹; Michael Huber¹; Dominique L. Braun¹; Huldrych F. Günthard¹; **Alexandra Trkola¹**; for the the Swiss HIV Cohort Study

¹*Inst of Med Virology, Univ of Zurich, Zurich, Switzerland;*

²*Univ Hosp Zurich, Zurich, Switzerland;* ³*Univ of Zurich, Zurich, Switzerland*

10:30 90 Clinical Safety and Pharmacokinetics of IV and SC VRC01, a Broadly Neutralizing mAb

Kenneth H. Mayer¹; Kelly Seaton²; Yunda Huang³; Nicole Grunenberg⁴; John Hural⁵; Julie Ledgerwood⁶; Robert Bailor⁷; Richard A. Koup⁸; Mary Allen⁹; Barney Graham⁹

¹*The Fenway Inst, Fenway Hlth, Boston, MA, USA;* ²*Duke Univ, Durham, NC, USA;* ³*Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA;* ⁴*NIAID, NIH, Bethesda, MD, USA;* ⁵*NIAID, NIH, Bethesda, MD, USA*

10:45 91 Neutrophil Functions Induced by Gp-120 Specific IgA and IgG; Clues for Immunotherapy

Magdalena Sips¹; Marina Krykbaeva¹; Anne Sophie Dugast¹; Fernanda Cerqueira¹; Peter Brouckaert²; Galit Alter¹

¹*Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA;*

²*Ghent Univ, Gent, Belgium*

11:00 92 Potency and Kinetics of Autologous HIV-1 Neutralizing Antibody Responses During ATI

Brenda Salantes¹; Benjamin Scheinfeld¹; Katharine J. Bar

Univ of Pennsylvania, Philadelphia, PA, USA

11:15 93L PD-1 Blockade as an Adjunct Therapy to ART and Potential to Destabilize SIV Reservoir

Geetha Mylvaganam¹; Sakeenah Hicks¹; Benton Lawson¹; Melon Nega²; Vijayakumar Velu¹; Rafi Ahmed¹; Gordon J. Freeman¹; Rama Amara³

¹*Emory Univ, Atlanta, GA, USA;* ²*Dana-Farber Cancer Inst, Boston, MA, USA;* ³*Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA*

11:30 94 Follicular CTL Accumulate in SIV-Infected Lymph Nodes Due to Immune Activation

Costantino Petrovas¹; Sara Ferrando-Martinez¹; Amarendra Pegu¹; Sarah F. Andrews¹; David Ambrozak¹; Adrian B. McDermott¹; Jason M. Brechley¹; John R. Mascola¹; Richard A. Koup³

¹*NIH, Bethesda, MD, USA;* ²*Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA;* ³*VRC, NIAID, NIH, Bethesda, MD, USA*

11:45 95L Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission

James B. Whitney¹; So-Yon Lim¹; Christa E. Osuna¹; Srisowmya Sanisetty¹; Tiffany L. Barnes²; Tomas Cihlar²; Michael Miller²; Romas Gelezianas²; Joseph Hesselgesser²

¹*Beth Israel Deaconess Med Cntr/Harvard, Boston, MA, USA;*

²*Gilead Sciences, Inc, Foster City, CA, USA;* *Gilead Scis, Inc, Foster City, CA, USA*

Session 0-8 Oral Abstracts

Room 302

10:00 AM-12:00 PM

Drugs: From Discovery to Challenges in Clinical Use

Oral Abstract Moderators

Peter L. Anderson¹, *University of Colorado, Denver, CO, USA*

Anne-Marie Taburet², *Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France*

10:00 96 Pharmacologic Measures of Adherence and Relationship to Drug Response

Peter L. Anderson¹, *Univ of Colorado, Denver, CO, USA*

10:30 97 HIV-1 Combinaectin BMS-986197: A Long-Acting Inhibitor With Multiple Modes of Action

Mark Krystal¹; David Wensel²; Yongnian Sun³; Jonathan Davis²; Zhufang Li¹; Thomas McDonagh²; Sharon Zhang¹; Matt Soars¹; Mark Cockett¹; for the Combinaectin Working Group

¹*Bristol-Myers Squibb, Wallingford, CT, USA;* ²*Bristol-Myers Squibb, Waltham, MA, USA*

10:45 98 Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis

Jay Grobler¹; Evan Friedman²; Stephanie E. Barrett³; Sandra L. Wood⁴; Wendy Ankrom⁵; Kerry L. Fillgrove⁶; Ming-Tain Lai⁷; Marian Gindy⁸; Marian Iwamoto⁹; Daria J. Hazuda¹⁰; for the MK-8591 Early Development Team

¹*Merck & Co, Inc, West Point, PA, USA;* ²*Merck & Co, Inc, Rahway, NJ, USA;* ³*Merck & Co, Inc, Kenilworth, NJ, USA*

11:00 99 Lower Ribavirin Exposures in HIV+ Patients That Relapsed to Acute HCV Treatment

Christine E. MacBrayne¹; Michael Hughes²; Kimberly M. Hollabaugh³; Jhoanna C. Roa³; Xinhui Chen⁴; Diana M. Brainard⁵; Raymond T. Chung⁶; Susanna Naggie⁷; Jennifer Kiser⁸; for the A5327 Study Team

¹*Univ of Colorado, Denver, CO, USA;* ²*Harvard Sch of PH, Boston, MA, USA;* ³*Social & Scientific Systems, Inc., Silver Spring, MD, USA;* ⁴*Univ of Colorado, Aurora, CO, USA;* ⁵*Gilead Scis, Inc, Foster City, CA, USA;* ⁶*Harvard Med Sch, Boston, MA, USA;* ⁷*Duke Univ Sch of Med, Durham, NC, USA*

11:15 100 Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens

Erik Mogalian¹; Luisa M. Stamm¹; Anuoluwapo Osinusi; Gong Shen; Karim Sajwani; John McNally; John Ling; Anita Mathias

Gilead Scis, Inc, Foster City, CA, USA

11:30 101 EFV Reduced PK of Piperazine for Malaria Prevention in HIV+ Ugandan Pregnant Women

Richard Kajubi¹; Liusheng Huang²; Norah Mwebaza³; Abel Kakuru⁴; Prasanna Jagannathan⁵; Philip Rosenthal⁶; Moses R. Kamya⁷; Grant Dorsey⁸; Diane V. Havlir⁹; Francesca Aweeka² ¹*Makerere Univ, Kampala, Uganda;* ²*Univ of California San Francisco, San Francisco, CA, USA;* ³*Infectious Diseases Rsr Collab and Makerere Univ, Kampala, Uganda;* ⁴*Infectious Diseases Rsr Collab and Makerere Univ, Kampala, Uganda;* ⁵*Makerere Univ Coll of Hlth Scis, KAMPALA, Uganda*

11:45 102LB Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF

Katy L. Garrett¹; Mackenzie L. Cottrell¹; Heather M. Prince¹; Craig Sykes¹; Amanda Schauer¹; Anne Peery¹; James Rooney²; Scott McCallister²; Cynthia Gay¹; Angela Kashuba¹
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
²Gilead Scis, Inc, Foster City, CA, USA

Session 0-9 Oral Abstracts

Auditorium

10:00 AM-12:00 PM

Expanding the Toolbox for Prevention

Oral Abstract Moderators

Sinéad Delany-Moretlwe, *Wits Reproductive Health and HIV Institute, Johannesburg, South Africa*

Nyaradzo Mgodi, *Medical Research Council of Zimbabwe, Zimbabwe*

10:00 103 HPTN 069/ACTG 5305: Phase II Study of Maraviroc-Based Regimens for HIV PrEP in MSM

Roy Gulick¹; Timothy J. Wilkin¹; Ying Chen²; Raphael J. Landovitz³; K. R. Amico⁴; Alicia Young⁵; Paul Richardson⁶; Mark A. Marzinko⁷; Marybeth McCauley⁸; Kenneth H. Mayer⁹
¹Weill Cornell Med Coll, New York, NY, USA; ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ⁴Univ of Michigan Sch of PH, Ann Arbor, MI, USA; ⁵SCHARP, Seattle, WA, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA; ⁷FHI 360, Washington, DC, USA; ⁸The Fenway Inst, Fenway Hlth, Boston, MA, USA

10:15 104 PrEP Impact on T-Cell Activation and Explant Infection: HPTN 069/ACTG 5305 Substudy

Ian McGowan¹; Alexiy Nikiforov²; Alicia Young³; Ross Cranston⁴; Raphael J. Landovitz⁵; Rahul Bakshi⁶; Adriana Andrade⁶; Kenneth H. Mayer⁷; Timothy J. Wilkin⁸; Roy Gulick⁹
¹Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ²Magee-Womens Hosp of the Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA; ³SCHARP, Seattle, WA, USA; ⁴David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁷The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁸Weill Cornell Med Coll, New York, NY, USA

10:30 105 Cabotegravir Long-Acting Injection Protects Macaques Against Intravenous Challenge

Chasity D. Andrews¹; Leslie St. Bernard¹; Amanda Poon¹; William Spreen²; Agegnehu Gettie³; Kasi Russell-Lodrigue⁴; Zhi Hong⁵; David D. Ho¹; Martin Markowitz¹
¹Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ²ViiV Hlthcare, Research Triangle Park, NC, USA; ³Tulane Natl Primate Rsr Cntr, Covington, LA, USA; ⁴GSK, Research Triangle Park, NC, USA

10:45 106 ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men

Martin Markowitz¹; Ian Frank²; Robert Grant³; Kenneth H. Mayer⁴; David A. Margolis⁵; Krischan J. Hudson⁶; Britt S. Stancil⁷; Susan L. Ford⁸; Alex R. Rinehart⁹; William Spreen¹⁰
¹Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ²Perelman Sch of Med, Univ of Pennsylvania, Philadelphia, PA, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁵ViiV Hlthcare, Research Triangle Park, NC, USA

11:00 107 Chemoprophylaxis With Oral FTC/TAF Protects Macaques From Rectal SHIV Infection

Ivana Massud¹; James Mitchell¹; Darius Babusis²; Frank Deyoukns³; Adrian Ray⁴; James Rooney⁵; Walid Heneine⁶; Michael Miller⁷; **Gerardo Garcia-Lerma**¹
¹CDC, Atlanta, GA, USA; ²Gilead Scis, Inc, Foster City, CA, USA

11:15 108LB MTN-017: Rectal Phase 2 Extended Safety and Acceptability Study of 1% Tenofovir Gel

Ross Cranston¹; Javier Lama²; Barbra A. Richardson³; Alex Carballo-Diéguez⁴; Ratiya Kunjara Na Ayudhya⁵; Cindy Jacobson⁶; Mark A. Marzinko⁷; Sherri Johnson⁸; Jeanna Piper⁹; Ian McGowan¹
¹Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ²Impacta Peru, Barranco, Lima, Peru; ³Univ of Washington, Seattle, WA, USA; ⁴New York State Psychiatric Inst., New York, NY, USA; ⁵Magee-Womens Rsr Inst, Pittsburgh, PA, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA; ⁷FHI 360, Washington DC, DC, USA; ⁸NIAID, NIH, Bethesda, MD, USA

11:30 109LB A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women

Jared M. Baeten¹; Thesla Palanee-Phillips²; Elizabeth R. Brown³; Katie Schwartz⁴; Lydia E. Soto-Torres⁵; Annalene Nel⁶; Zeda Rosenberg⁷; Ian McGowan⁸; Sharon L. Hillier⁹; for the MTN-020/ASPIRE Study Team
¹Univ of Washington, Seattle, WA, USA; ²Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa; ³Statistical Cntr for HIV/AIDS Rsr & Prevention, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁴FHI 360, Durham, NC, USA; ⁵NIAID, NIH, Bethesda, MD, USA; ⁶Intl Partnership for Microbicides, Paarl, South Africa; ⁷International Partnership for Microbicides, Silver Spring, MD, USA; ⁸Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ⁹Magee-Womens Hosp of the Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA

11:45 110LB Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women

Annalene Nel¹; Saidi Kapiga²; Linda-Gail Bekker³; Brid Devlin⁴; Maarten Borremans⁵; Zeda Rosenberg⁶; for the IPM 027/Ring Study Research Center Teams
¹Intl Partnership for Microbicides, Paarl, South Africa; ²London Sch of Hygiene & Trop Med, London, United Kingdom; ³Desmond Tutu HIV Cntr, Cape Town, South Africa; ⁴International Partnership for Microbicides, Silver Spring, MD, USA; ⁵SGS Life Science Services, Mechelen, Belgium

Session 0-10 Oral Abstracts

10:00 AM-12:00 PM

Getting to 90-90-90

Oral Abstract Moderators

Lisa J. Nelson, U.S. Department of State, Washington, DC, USA

Marco Vitoria, World Health Organization, Geneva, Switzerland

Ballroom A

10:00 111 Botswana Is Close to Meeting UNAIDS 2020 Goals of 90-90-90 Coverage

Tendani Gaolathe¹; Kathleen Wirth²; Molly Pretorius Holme²; Joseph Makhema³; Sikhulile Moyo³; Eric Tchetgen Tchetgen²; Refeletse Lebelonyane⁴; Lisa A. Mills⁵; M. Essex²; Shahin Lockman⁶

¹Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana;

²Harvard Sch of PH, Boston, MA, USA; ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁴Ministry of Hlth, Gaborone, Botswana; ⁵CDC, Gaborone, Botswana; ⁶Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

10:15 112 Streamlining Antiretroviral Therapy Uptake: A Stepped-Wedge Cluster Randomized Trial

Gideon Amanyiye¹; Fred Collins Semitala¹; Jennifer Namusobya¹; Richard Katuramu¹; Leatitia Kampiire²; Jeanna Wallenta³; David V. Glidden³; Moses R. Kanya; Diane V. Havlir; **Elvin H. Geng**⁴

¹Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ²Infectious Diseases Rsr Collab, Kampala, Uganda; ³Univ of California San Francisco, San Francisco, CA, USA

10:30 113LB A Randomized Trial to Accelerate HIV Care and ART Initiation Following HIV Diagnosis

Christopher Hoffmann¹; Tonderai Mabuto²; Sibuse Ginindza²; Katherine L. Fielding³; Griffiths Kubeka²; David Dowdy⁴; Gavin Churchyard⁵; Salome Charalambous⁶

¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Aurum Inst, Johannesburg, South Africa; ³London Sch of Hygiene & Trop Med, London, UK; ⁴Johns Hopkins Univ Bloomberg School of Public Hlth, Baltimore, MD, USA; ⁵The Aurum Inst, Johannesburg, South Africa

10:45 114 Towards the Second UNAIDS Target: Population-Level ART Coverage in HPTN 071 (PopART)

Sarah J. Fidler¹; Sian Floyd²; Blia Yang³; Kwame Shanaube⁴; Peter Bock⁵; Ab Schaap⁶; Kaplana Sabapathy⁷; Helen Ayles⁸; Richard Hayes⁹; for the HPTN 071 (PopART) study team

¹Imperial Coll London, London, UK; ²London Sch of Hygiene & Trop Med, London, UK; ³Univ of Stellenbosch, Cape Town, South Africa; ⁴ZAMBART, Lusaka, Zambia

11:00 115 Optimising South Africa's HIV Response: Results of the HIV and TB Investment Case

Calvin Chiu¹; Gesine Meyer-Rath²; Leigh F. Johnson³; Tom Sumner⁴; Teresa Guthrie⁵; Yogan Pillay⁶; Fareed Abdullah⁷; Eva Kiwango⁸; for the South African HIV and TB Investment Case Task Team and Steering Committee

¹Univ of the Witwatersrand, Johannesburg, South Africa; ²Boston Univ, Boston, MA, USA; ³Univ of Cape Town, Cape Town, South Africa; ⁴London Sch of Hygiene & Trop Med, London, UK; ⁵Guthrie Hlth Financing Consult, Cape Town, South Africa; ⁶Natl Dept of Hlth, Pretoria, South Africa; ⁷South African Natl AIDS Council, Pretoria, South Africa; ⁸UNAIDS-South Africa, Pretoria, South Africa

11:15 116 Virologic Efficacy of ART Begun at High CD4+ Counts via Streamlined Care in East Africa

Dalsone Kwarisiima¹; Vivek Jain²; Asiphas Owaraganise³; Florence Mwangwa⁴; Dathan Byonanebye⁵; James Ayiteko⁶; Maya Petersen⁷; Diane V. Havlir⁸; Moses R. Kanya; for the SEARCH Collaboration

¹Makerere Univ-Univ of California San Francisco Rsr Collab, Kampala, Uganda; ²Univ of California San Francisco, San Francisco, CA, USA; ³Infectious Diseases Rsr Collab, Kampala, Uganda; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁵Kenya Med Rsr Inst, Kisumu, Kenya; ⁶Univ of California Berkeley, Berkeley, CA, USA

11:30 117 HIV Mortality by Care Cascade Stage and Implications for Universal ART Eligibility

Erin Bendavid¹; Anna Bershteyn²; Andrew Boulle³; **Jeffrey W. Eaton**⁴; Timothy Hallett⁵; Daniel J. Klein⁶; Jack J. Olney⁷; Andrew N. Phillips⁸; Emma Slaymaker⁹; for the HIV Modelling Consortium Writing Group on ART Eligibility Guidelines

¹Stanford Univ, Stanford, CA, USA; ²Inst for Disease Modeling, Bellevue, WA, USA; ³Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa; ⁴Imperial Coll London, London, UK; ⁵Univ Coll London, London, UK; ⁶London Sch of Hygiene & Trop Med, London, UK

11:45 118 Trends in ART Discontinuation by Age in Malawi, 2004–2014

Catrina A. Mugglin¹; Andreas Haas²; Joep van Oosterhout³; Frank Chimbandira³; Lyson Tenthanii¹; Malango Msukwa⁴; Oliver Gadabu⁵; Janne Estill⁶; Matthias Egger⁷; Olivia Keiser⁸

¹Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland; ²Dignitas Intl, Zomba, Malawi; ³Malawi Ministry of Hlth, Lilongwe, Malawi; ⁴Inst of Social and Preventive Med, Univ of Bern, Lilongwe, Malawi; ⁵Baobab Hlth Trust, Lilongwe, Malawi; ⁶Univ Hosp Bern, Bern, Switzerland

Session TD-7 Themed Discussion

1:45 PM-2:45 PM

Stroke: Incidence and Risk Factors

Themed Discussion Leader

Richard W. Price, University of California San Francisco, San Francisco, CA, USA

636 Design, Implementation, and Findings of Next-Generation Stroke Adjudication in HIV

Heidi M. Crane¹; Felicia Chow²; Kyra J. Becker³; Christina Marra⁴; Joseph Zunt⁵; Emily L. Ho⁶; Rizwan Kilani⁷; Robin Nance⁸; Joseph A. Delaney⁹; David Tirschwell¹⁰

¹Univ of Washington, Seattle, WA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Washington Sch of PH and Community Med, Seattle, WA, USA

637 Differences in Predictors for Ischaemic and Haemorrhagic Strokes in HIV+ Individuals
Camilla I. Hatleberg¹; David Kamara²; Lene Ryom³; Stephane de Wit⁴; Matthew Law⁵; Peter Reiss⁶; Antonella d'Amminio Monforte⁷; Jens D. Lundgren⁸; Caroline Sabin⁹; for the The Data Collection on Adverse events of Anti-HIV drugs
¹Rigshospet, Univ of Copenhagen, Copenhagen, Denmark; ²Univ Coll London, London, UK; ³St Pierre Univ Hosp, Brussels, Belgium; ⁴Univ of New South Wales, Sydney, Australia; ⁵Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ⁶Infectious Diseases Clinic, San Paolo Hosp, Univ of Milan, Milan, Italy

638 Persistently Increased Ischemic Stroke Risk in HIV-Infected Women
Felicia Chow¹; Susan Regan²; Sara E. Looby³; Markella V. Zanni⁴; James B. Meigs⁵; Cheryl D. Bushnell⁶; Steven K. Feske⁷; Steven Grinspoon⁸; Virginia A. Triant⁹
¹Univ of California San Francisco, San Francisco, CA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³Wake Forest Baptist Med Ctr, Winston Salem, NC, USA; ⁴Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

639 Stroke in HIV-Infected Patients in the Combination Antiretroviral Therapy Era
Juan Berenguer¹; Alejandro Alvaro-Meca²; Asuncion Diaz³; Dariela Micheloud⁴; Salvador Resino⁵
¹Hosp General Universitario Gregorio Marañón, Madrid, Spain; ²Univ Rey Juan Carlos, Alcorcón, Spain; ³Inst de Salud Carlos III, Madrid, Spain

640 Incidental Carotid Plaque in HIV Is Associated With Subsequent Cerebrovascular Events
Sumbal Janjua¹; Pedro Staziaki²; Richard Takx³; Orla Hennessy⁴; Michael Lu⁵; Markella V. Zanni⁶; Steven Grinspoon⁷; Udo Hoffmann⁸; Tomas G. Neilan⁹
 Massachusetts General Hosp, Boston, MA, USA

Session TD-8 Themed Discussion Room 302
1:45 PM-2:45 PM
HIV and Microbiomes
Themed Discussion Leader
Nichole Klatt, University of Washington, Seattle, WA, US

260 Distinct Gut Microbiota Composition in Gay Men
Muntsa Rocafort¹; Marc Noguera-Julian²; Yolanda Guillen³; Mariona Parera⁴; Piotr Nowak⁵; Falk Hildebrand⁶; Georg Zeller⁷; Anders Sönnnerborg⁸; Peer Bork⁹; Roger Paredes¹⁰
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²IrsiCaixa Inst for AIDS Rsr, Barcelona, Spain; ³Karolinska Inst, Stockholm, Sweden; ⁴Structural and Computational Biology, European Molecular Biology Lab, Heidelberg, Germany

261 Impact of HIV-Associated Changes in the Gut Microbiome on Disease Progression
Jesús Luévano¹; David B. Gootenberg²; Jeffrey M. Paer³; Bruce D. Walker⁴; Douglas S. Kwon⁵
 Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA

262 Altered Gut Microbes Enhance Mucosal CD4 T Cell Infection and Depletion Ex Vivo
Stephanie M. Dillon¹; Eric L. Lee²; Andrew M. Donovan³; Kejun Guo⁴; Michael S. Harper⁵; Daniel N. Frank⁶; Martin D. McCarter⁷; Mario L. Santiago⁸; Cara Wilson⁹
¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ²Univ of Colorado Hosp, Aurora, Aurora, CO, USA

263 Enhancement of Microbiota in Macaques Leads to Beneficial Immune Function Modulation
Jennifer A. Manuzak¹; Tiffany Hensley-McBain²; Charlene Miller³; Alexander Zevin⁴; Jason M. Brechnley⁵; Jacob D. Estes⁶; Stanley Langevin⁷; R. Keith Reeves⁸; Elias Haddad⁹; Nichole Klatt¹⁰
¹Univ of Washington, Seattle, WA, USA; ²Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA; ³Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA; ⁴Harvard Univ, Boston, MA, USA; ⁵Drexel Univ, Philadelphia, PA, USA

264 Fecal Microbial Transplantation: Safety and Engraftment During Treated HIV Infection
Ma Somsouk¹; Ivan Vujkovic-Cvijin²; Montha Pao³; Peter W. Hunt⁴; Susan V. Lynch⁵; Joseph M. McCune⁶
¹Univ of California San Francisco, San Francisco, CA, USA; ²NIH, Bethesda, MD, USA

Session TD-9 Themed Discussion Room 312
1:45 PM-2:45 PM
Cryptococcal Disease: Detection and Complications
Themed Discussion Leader

Ian M. Sanne, University of the Witwatersrand, Wits Health Consortium, Johannesburg, South Africa

760 Maximizing Detection and Improving Outcomes of Cryptococcosis in Rural Tanzania
Diana Faini¹; Aneth V. Kalinjuma²; Julie Neborak³; Alexa King⁴; Dorcas Mnzava⁵; Tracy Glass⁶; Hansjakob Furrer⁷; Christoph Hatz⁸; David R. Boulware⁹; Emilio Letang¹⁰
¹Ifakara Hlth Inst, Dar es Salaam, Tanzania; ²Ifakara Hlth Inst, Morogoro, Tanzania; ³Univ of Minnesota, Minneapolis, MN, USA; ⁴Swiss Trop Inst of PH, Basel, Switzerland; ⁵Bern Univ Hosp and Univ of Bern, Bern, Switzerland

759 Evaluation of Provider-Initiated Cryptococcal Antigen Screening, South Africa
Nicky Longley¹; Snigdh Vallabhaneni²; Mariette Smith³; Rachel Smith⁴; Meg Osler⁵; Nicola Kelly⁶; Anna Cross⁷; Andrew Boulle⁸; Graeme Meintjes⁹; Neshesh Govender¹⁰
¹St George's Univ of London, London, UK; ²CDC, Atlanta, GA, USA; ³Univ of Cape Town, Cape Town, South Africa; ⁴Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa; ⁵Natl Inst of Communicable Diseases, Johannesburg, South Africa

762 Immunologic Discrimination of Cryptococcal IRIS From Culture-Positive Relapse
David R. Boulware¹; Joshua R. Rhein²; Edward N. Janoff³; Abdu Musubire⁴; Andrew Kambugu⁵; Paul Bohjanen⁶; David B. Meya⁷; for the COAT Trial Team
¹Univ of Minnesota, Minneapolis, MN, USA; ²Univ of Colorado, Denver, CO, USA; ³Infectious Diseases Inst, Kampala, Uganda

761 Neurocognitive Function in HIV-Infected Persons With Cryptococcal Antigenemia

Martha P. Montgomery¹; Noeline Nakasujja²; Bozena M. Morawski¹; Radha Rajasingham¹; Elizabeth Nalintya²; Renee Donahue Carlson¹; Jona E. Kaplan¹; Andrew Kambugu³; David B. Meya⁴; David R. Boulware⁵; for the COAT and ORCAS Trial Teams

¹Univ of Minnesota, Minneapolis, MN, USA; ²Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ³Infectious Diseases Inst, Kampala, Uganda; ⁴Emory Univ Sch of Med, Atlanta, GA, USA; ⁵CDC, Atlanta, GA, USA

Session TD-10 Themed Discussion

1:45 PM-2:45 PM

New Drugs for Kids: What's Taking so Long?

Themed Discussion Leader

Martina Penazzato, World Health Organization, Geneva, Switzerland

815 Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Edmund Capparelli¹; Kenneth Maswabi²; Steven Rossi¹; Muchaneta Bhondai³; Sikhulile Moyo⁴; Patrick Jean-Philippe⁵; Michael Hughes⁶; Mathias Lichterfeld⁷; Daniel Kuritzkes⁸; Roger L. Shapiro⁹

¹Univ of California San Diego, San Diego, CA, USA; ²Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ³Henry M. Jackson Fndn for the Advancement of Military Med, Inc, Rockville, MD, USA; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ⁶Harvard Med Sch, Boston, MA, USA

816 IMPAACT 1093: Dolutegravir in 6- to 12-Year-Old HIV-Infected Children: 48-Week Results

Allen Wiznia¹; Carmelita Alvero²; Terry Fenton³; Kathleen George⁴; Ellen Townley⁵; Rohan Hazra⁶; Bobbie Graham⁷; Annie Buchanan⁸; Cindy Vavro⁹; Rolando Viani¹⁰; for the IMPAACT P1093

¹Albert Einstein Coll of Med, Bronx, NY, USA; ²Harvard Sch of PH, Boston, MA, USA; ³SDAC, Harvard Sch of PH, Boston, MA, USA; ⁴IMPAACT Operations, Durham, NC, USA; ⁵NIH, Rockville, MD, USA; ⁶Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁷Frontier Sci & Tech Rsr Fndn, Inc, Buffalo, NY, USA; ⁸GSK, Research Triangle Park, NC, USA; ⁹ViiV Hlthcare, Research Triangle Park, NC, USA; ¹⁰Univ of California San Diego, San Diego, CA, USA

817 Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Treatment-Naïve Adolescents

Aditya Gaur¹; Hilda Kizito²; Rana Chakraborty³; Jagmohan Batra⁴; Pope Kosalaraksa⁵; Wicharn Luesombonk; Yongwu Shao⁶; Devi SenGupta⁷; Martin S. Rhee⁸; Erin Quirk⁹

¹St Jude Children's Rsr Hosp, Memphis, TN, USA; ²Joint Clinical Rsr Cntr, Kampala, Uganda; ³Emory Univ, Atlanta, GA, USA; ⁴Miller Children's Hosp, Long Beach, CA, USA; ⁵Khon Kaen Univ, Khon Kaen, Thailand; ⁶Queen Savang Vadhana Memorial Hosp, Chon Buri, Thailand; ⁷Gilead Scis, Inc, Foster City, CA, USA

1120 Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Carlo Giaquinto¹; Muthuhadini P. Mawela²; Kulkanya Chokephaibulkit³; Annie Fang⁴; Elna van der Ryst⁵; Srinivas Rao Valluri⁶; Manoli Vourvahis⁷; Rebecca Zhang-Roper⁸; Lynn McFadyen⁹; Jayvant Heera⁸

¹Univ of Padova, Padova, Italy; ²Sefako Makgatho Hlth Scis Univ, Pretoria, South Africa; ³Sriraj Hosp, Mahidol Univ, Bangkok, Thailand; ⁴Pfizer, Inc, New York, NY, USA; ⁵Pfizer Inc, The Rsr Network, Sandwich, UK; ⁶GSK, Stockley Park, UK; ⁷Pfizer, Inc, Sandwich, UK; ⁸Pfizer, Inc, Groton, CT, USA

819 Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study

Vania Giacometti¹; Katia Maruca²; Paola Erba³; Maria Puzovizzo²; Pilar Nannini⁴; Silvia Capelli⁵; Alessandro Ambrosi⁶; Gianvincenzo Zuccotti⁷; Stefano Mora²

¹Luigi Sacco Hosp, Univ of Milan, Milan, Italy; ²San Raffaele Scientific Inst, Milan, Italy; ³Univ of Milan, Milan, Italy; ⁴Ospedale Buzzi, Univ of Milan, Milan, Italy

Session TD-11 Themed Discussion

1:45 PM-2:45 PM

Innovations to Enhance Treatment Outcomes

Themed Discussion Leader

Moses R. Kamya, Makerere University College of Health Sciences, Kampala, Uganda

1011 The Real-World Impact of CD4-Eligibility Criteria on Retention in HIV Care

Jacob Bor¹; Matthew P. Fox²; Sydney Rosen³; Atheendar Venkataramani⁴; Frank Tanser⁵; Deenan Pillay⁶; Till Bärnighausen⁵

¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Massachusetts General Hosp, Boston, MA, USA; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁵Harvard Sch of PH, Boston, MA, USA

1012 Do ART Eligibility Expansions Crowd out the Sickest? Evidence From South Africa

Sheryl A. Kluber¹; Matthew P. Fox²; Michael LaValley³; Till Bärnighausen⁴; Deenan Pillay⁵; Jacob Bor¹

¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Harvard Sch of PH, Boston, MA, USA; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

1018 Evaluating Appointment Patterns to Improve Sustainability of HIV Treatment in Zambia

Monika Roy¹; Charles Holmes²; Izukanji Sikazwe³; The Savory⁴; Mwanza Mwanza⁵; Carolyn Moore⁶; Kafula Mulenga⁷; Nancy L. Czaicki⁸; Nancy Padian⁹; Elvin H. Geng¹⁰

¹Univ of California San Francisco, San Francisco, CA, USA; ²Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ³Univ of California Berkeley, Berkeley, CA, USA

1031 Outcomes of Patients Enrolled in ART Adherence Clubs After Viral Respression

Joseph T. Sharp¹; Lynne Wilkinson²; Vivian Cox³; Carol Cragg⁴; Gilles Van Cutsem⁵; Anna Grimsrud⁶

¹Univ of Cape Town, Cape Town, South Africa; ²Médecins Sans Frontières, Khayelitsha, South Africa; ³Western Cape Dept of Hlth, Cape Town, South Africa; ⁴Médecins Sans Frontières, Cape Town, South Africa; ⁵IAS, Cape Town, South Africa

1016 Barriers to Care and 1-Year Mortality in Newly Diagnosed HIV+ Persons in South Africa

Ingrid V. Bassett¹; Sharon M. Coleman²; Janet Giddy³; Laura M. Bogart⁴; Christine E. Chaisson⁵; Douglas Ross⁶; Tessa Govender⁷; Rochelle P. Walensky⁸; Kenneth A. Freedberg⁹; Elena Losina⁶

¹Massachusetts General Hosp, Boston, MA, USA; ²Boston Univ Sch of PH, Boston, MA, USA; ³McCord Hosp, Durban, South Africa; ⁴Boston Children's Hosp, Harvard Med Sch, Boston, MA, USA; ⁵Midlands Med Cntr, Pietermaritzburg, South Africa; ⁶Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

Session TD-12 Themed Discussion
1:45 PM-2:45 PM

Ballroom B/C

It's Complicated: Renal Function and STIs in PrEP Users
Themed Discussion Leader

Amanda Mocroft, *University College London, London, United Kingdom*

866 Higher Cumulative TDF/FTC Levels in PrEP Associated With Decline in Renal Function

Monica Gandhi¹; David V. Glidden²; Albert Y. Liu³; Howard Horng⁴; K. R. Amico⁵; Kathleen Mulligan¹; Sybil Hosek⁶; Mauro Schechter⁷; Kenneth H. Mayer⁸; Robert Grant⁹; for the iPrEx Study Team
¹Univ of California San Francisco, San Francisco, CA, USA; ²San Francisco Dept of PH, San Francisco, CA, USA; ³Univ of Michigan Sch of PH, Ann Arbor, MI, USA; ⁴John H. Stroger Jr Hosp of Cook County, Chicago, IL, USA; ⁵Projeto Praça Onze, Universidade Fed do Rio de Janeiro, Rio de Janeiro, Brazil; ⁶The Fenway Inst, Fenway Hlth, Boston, MA, USA

867 Changes in Renal Function Associated With TDF/FTC PrEP Use in the US Demo Project

Albert Y. Liu¹; Eric Vittinghoff²; Peter L. Anderson³; Stephanie Cohen⁴; Susanne Doblecki-Lewis⁵; Oliver Bacon⁶; Wairimu Chege⁷; Susan P. Buchbinder⁸; Michael Kolber⁹; Richard Elion⁹; for the Demo Project Team
¹San Francisco Dept of PH, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Colorado, Denver, CO, USA; ⁴Univ of Miami, Miami, FL, USA; ⁵DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁶George Washington Univ Sch of Med, Washington, DC, USA

868 Rare Incidence of Proximal Tubular Dysfunction With Tenofovir-Based Chemoprophylaxis

Kenneth K. Mugwanya¹; Jared M. Baeten²; Connie M. Celum³; Deborah Donnell⁴; Thomas Nickolas⁵; Nelly R. Mugoo⁶; Andrea Branch⁷; James K. Kairie⁸; Allan Ronald⁹; Christina Wyatt⁹; for the Partners PrEP Study Team
¹Univ of Washington, Seattle, WA, USA; ²SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³Columbia Univ, New York, NY, USA; ⁴Kenya Med Rsr Inst, Thika, Kenya; ⁵Icahn Sch of Med at Mount Sinai, New York, NY, USA; ⁶Univ of Nairobi, Nairobi, Kenya; ⁷Univ of Manitoba, Winnipeg, MB, Canada

869 STI Data From Community-Based PrEP Implementation Suggest Changes to CDC Guidelines

Sarit A. Golub¹; Stephanie Pena²; Kailip Boonrai³; Nora Douglas⁴; Machel Hunt⁵; Asa Radix⁶
¹Hunter Coll and the Grad Cntr, City Univ of New York, New York, NY, USA; ²Callen-Lorde Community Hlth Cntr, New York, NY, USA; ³Hunter HIV/AIDS Rsr Team, Hunter Coll, New York, NY, USA

870 Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project

Stephanie Cohen¹; Eric Vittinghoff²; Susan S. Philip³; Susanne Doblecki-Lewis⁴; Oliver Bacon⁵; Wairimu Chege⁶; Richard Elion⁷; Susan P. Buchbinder⁸; Michael Kolber⁹; Albert Y. Liu⁹
¹San Francisco Dept of PH, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Miami, Miami, FL, USA; ⁴DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁵George Washington Univ Sch of Med, Washington, DC, USA

Session S-5 Symposium
4:00 PM-6:00 PM



Ballroom A

Reaching 90-90-90 and Beyond: Challenges and Innovations

Target audience: This session is directed to clinicians, scientists, and public health practitioners who are interested in understanding the global HIV response targets, current status in terms of progress towards these targets and strategies that may enable their achievement.

Level of knowledge: It is assumed that participants are familiar with basic concepts of the HIV global response and key elements of HIV programming.

Objectives: At the completion of the session, participants will be able to:

- Describe the issues to be addressed in order to achieve global targets for HIV diagnosis and ART initiation, adherence and retention
- Describe innovations to help overcome the implementation challenges
- Assess progress toward achievement of targets over time

Conveners

Serge Eholie, *Treichville University Teaching Hospital, Abidjan, Ivory Coast*

Catherine A. Hankins, *Amsterdam Institute for Global Health and Development, Amsterdam Netherlands*



4:00 119 Option B+ : A Stepping Stone to Universal Treatment

Andreas Jahn, *Ministry of Hlth, Lilongwe, Malawi*



4:30 120 Missing But in Action: Where Are the Men?

Helen Ayles, *London Sch of Hygiene & Trop Med, London, UK*



5:00 121 Antiretroviral Therapy for Life: Understanding and Improving Retention

Elvin H. Geng, *Univ of California San Francisco, San Francisco, CA, USA*



5:30 122 Innovations in Antiretroviral Therapy Delivery

Anna Grimsrud, *IAS, Cape Town, South Africa*



Session S-6 Symposium
4:00 PM-6:00 PM

CME

Ballroom B/C

Pathogenesis and Consequences of Metabolic Complications

Target audience: This session is directed to clinicians and scientists who are interested in understanding the pathogenesis and consequences of metabolic complications in patients with HIV infection.

Level of knowledge: It is assumed that participants are familiar with the basic concept that HIV may cause immune activation and that HIV may increase the risk of metabolic complications.

Objectives: At the completion of the session, participants will be able to:

- Describe immunologic mechanisms thought to drive metabolic complications in HIV infected adults and children
- Describe the current understanding of the pathogenesis and clinical consequences of visceral adiposity, NASH/NAFLD, and bone disease in HIV infected adults and children

Conveners

Todd T. Brown, *The Johns Hopkins University, Baltimore, MD, USA*

Allison R. Eckard, *Medical University of South Carolina, Charleston, SC, USA*



4:00 123 Visceral Adiposity in the Modern HIV Treatment Era

Grace A. McComsey, *Case Western Reserve Univ, Cleveland, OH, USA*



4:30 124 NAFLD and NASH in HIV Infection

Elizabeth C. Verna, *Columbia Univ, New York, NY, USA*



5:00 125 Immunopathogenesis of Metabolic Complications in Treated HIV Infection

Suzanne M. Crowe, *Burnet Inst, Melbourne, Australia*



5:30 126 What Exactly Does Antiretroviral Therapy Do to Bone?

Patrick Mallon, *for the UCD HIV Molecular Research Group, Univ Coll Dublin, Dublin, Ireland*



Session S-7 Symposium
4:00 PM-6:00 PM

CME

Room 304/306

Location, Location, Location: The Lymph Node

Target audience: This session is directed to clinicians and scientists who are interested in understanding HIV/SIV immunology, virology, and pathogenesis.

Level of knowledge: It is assumed that participants are familiar with basic concepts of how immune responses are generated to infections or vaccines, and how HIV/SIV replicates.

Objectives: At the completion of the session, participants will be able to:

- Describe the architecture of the lymph node, and where immune responses are generated
- Describe how antigen presenting cells within lymph nodes are involved in orchestrating immune responses
- Describe where HIV/SIV replicates in lymph nodes
- Describe why antiviral CD8 T cells have difficulty suppressing HIV/SIV replication in lymph nodes

Symposium Conveners

Susan Moir, *National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA*

Ashley T. Hasse, *University of Minnesota, Minneapolis, MN, USA*



4:00 127 Visualizing the Early Events of Antigen Recognition by B Cells

Facundo Batista, *Francis Crick Inst, London, UK*



4:30 128 Are Follicular Dendritic Cells a Reservoir for HIV?

Michael C. Carroll, *Harvard Univ, Boston, MA, USA*



5:00 129 Imaging Lymphoid Tissues to Understand Viral Persistence and Impaired Function

Jacob D. Estes, *Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA*



5:30 130 The Lymph Node, Cytotoxic T cell, and HIV/SIV Infections

Elizabeth Connick, *Univ of Colorado, Denver, CO, USA*



Wednesday, February 24, 2016 - Oral Sessions

THURSDAY, FEBRUARY 25, 2016

Thursday Plenary Session


8:30 AM-9:30 AM



Auditorium

8:30 131 Tuberculosis: Why Do I Have to Take So Many Pills?

Eric J. Rubin, *Harvard School of Public Health, Boston, MA, USA*



9:00 132 The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015

John T. Brooks, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



Session 0-11 Oral Abstracts

Room 312

10:00 AM-12:00 PM

HIV Virology: Putting It All Together

Oral Abstract Moderators

Javier Martinez-Picado, *IrsiCaixa Institute for AIDS Research, Badalona, Spain*

Manish Sagar, *Boston University, Boston, MA, USA*

10:00 133 Type 1 Interferon Resistance Is a Hallmark of Mucosally Transmitted HIV-1

Frederic Bibollet-Ruche¹; Shilpa Iyer¹; Ronnie Russell¹; Andrew G. Smith¹; Christiana M. Shaw¹; Yingying Li¹; Timothy Decker¹; George M. Shaw²; Persephone Borrow³; Beatrice Hahn¹
¹*Univ of Pennsylvania, Philadelphia, PA, USA*; ²*Perelman Sch of Med, Univ of Pennsylvania, Philadelphia, PA, USA*; ³*Univ of Oxford, Oxford, UK*

10:15 134 Expression and Potency of IFNα Subtypes in an Ex Vivo Model of Acute HIV-1 Infection

Mario L. Santiago¹; Michael S. Harper¹; Kejun Guo¹; Kathrin Gibbert²; Eric L. Lee¹; Stephanie M. Dillon¹; Martin D. McCarter¹; Kim J. Hasenkrug³; Ulf Dittmer²; Cara Wilson⁴
¹*Univ of Colorado Anschutz Med Campus, Aurora, CO, USA*; ²*Univ of Duisburg-Essen, Essen, Germany*; ³*NIAID, NIH, Hamilton, MT, USA*; ⁴*Univ of Colorado Hosp, Aurora, Aurora, CO, USA*

10:30 135 Novel Mechanism of Interferon Restriction of HIV-1 in Humans

Ramy El-Diwany¹; Michael Chattergoon¹; Justin R. Bailey¹; Stuart C. Ray¹; Sarah J. Wheelan¹; Joel N. Blankson²; Robert Siliciano³; David L. Thomas³; Ashwin Balagopal¹
¹*Johns Hopkins Univ, Baltimore, MD, USA*; ²*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ³*Howard Hughes Med Inst, Baltimore, MD, USA*

10:45 136 SERINC3 and SERINC5 Are Novel Antiviral Proteins Antagonized by HIV-1 Nef

Yuanfei Wu; Yoshiko Usami; Heinrich G. Gottlinger
Univ of Massachusetts Med Sch, Worcester, MA, USA

11:00 137 The PPIP122-125 Motif in HIV-1 CA Is an Essential Assembly and Maturation Element

Maria Novikova¹; Muthukumar Balasubramaniam¹; Sagar Kudchodkar²; Ferri Soheilian³; Anna T. Gres³; Karen A. Kirby³; Stefan G. Sarafianos³; Eric O. Freed¹
¹*NCI, Frederick, MD, USA*; ²*Leidos Biomed Rsr, Inc, Frederick, MD, USA*; ³*Univ of Missouri, Columbia, MO, USA*; ⁴*Univ of Missouri Sch of Med, Columbia, MO, USA*

11:15 138 Characterization of 2 CCR5 Tropic HIV-1 Viruses Exhibiting High Env Content

Sean P. O'Brien¹; Terra M. Ireland¹; Julian W. Bess²; James D. Roser²; Elena N. Chertova³; Gregory Q. Del Prete²; Brandon Keele²; Jeffrey Lifson²
¹*Leidos Biomed Rsr, Inc, Frederick, MD, USA*; ²*Frederick Natl Lab, Frederick, MD, USA*

11:30 139 Nuclear Entry of HIV Requires Reshaping of Integrase Multimers

Frauke Christ¹; Lieve Dirix²; Doortje Borrenberghs²; Flore De Wit¹; Jolien Blokken²; Susana Rocha¹; Jelle Hendrix¹; **Zeger Debysse**¹; Johan Hofkens²
¹*Katholieke Universiteit Leuven, Leuven, Belgium*; ²*Katholieke Universiteit Leuven, Heverlee, Belgium*

11:45 140 1970s HIV-1 Genomes Reveal the Early History of the North American HIV/AIDS Epidemic

Michael Worobey¹; Thomas D. Watts²; Richard A. McKay²; Timothy Granade³; Beryl A. Koblin¹; Walid Heneine¹; Harold W. Jaffe¹
¹*Univ of Arizona, Tucson, AZ, USA*; ²*Univ of Cambridge, Cambridge, UK*; ³*CDC, Atlanta, GA, USA*; ⁴*New York Blood Cntr, New York, NY, USA*

Session 0-12 Oral Abstracts

Room 304/306

10:00 AM-12:00 PM

Central Nervous System: Viral Dynamics, Biomarkers, and Cognition

Oral Abstract Moderators

Paola Cinque, *San Raffaele Scientific Institute, Milano, Italy*

Renaud Du Pasquier, *Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland*

10:00 141 SIV-Infected Brain Macrophages Leave the Central Nervous System

Xavier Alvarez¹; Cecily Midkiff²; Andrew Lackner¹; Kenneth C. Williams²
¹*Tulane Natl Primate Rsr Cntr, Covington, LA, USA*; ²*Boston Coll, Chestnut Hill, MA, USA*

10:15 142 CSF Lymphocyte and Monocyte Activation and Trafficking in Primary HIV Infection

Xiang Li¹; Fangyong Li²; Anji Yi³; Julia Peterson³; Brinda Emu¹; Richard W. Price¹; Elizabeth Sinclair¹; Serena S. Spudich¹
¹*Yale Univ Sch of Med, New Haven, CT, USA*; ²*Yale Univ Sch of PH, New Haven, CT, USA*; ³*Univ of California San Francisco, San Francisco, CA, USA*

10:30 143 Compartmentalized HIV DNA Populations Persist in CSF Despite Suppressive ART

Michelli Faria de Oliveira; Antoine Chaillon; Scott R. Letendre; Matt F. Strain; Ron Ellis; Sheldon R. Morris; Susan J. Little; Davey M. Smith; Sara Gianella
Univ of California San Diego, San Diego, CA, USA

10:45 144 Mitochondrial DNA Copy Number and Neurocognitive Impairment in HIV-Infected Persons

David Samuels¹; Asha R. Kallianpur²; Yan Guo³; Todd T. Brown⁴; Sanjay R. Mehta⁵; Ron Ellis⁶; Scott R. Letendre⁷; Todd Hulgan⁸; for the CHARTER study group
¹*Vanderbilt Univ Sch of Med, Nashville, TN, USA*; ²*Cleveland Clinic/ Lerner Rsr Inst, Cleveland, OH, USA*; ³*Vanderbilt Univ, Nashville, TN, USA*; ⁴*Johns Hopkins Univ, Baltimore, MD, USA*; ⁵*Univ of California San Diego, San Diego, CA, USA*

11:00 145 Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV+ Men on ART

Shibani S. Mukerji¹; Joseph Locascio²; Vikas Misra³; Lorenz David⁴; Alexander Holman⁵; Anupriya Dutta⁶; Sudhir Penugonda⁷; Steven Wolinsky⁸; Dana Gabuzda⁹
¹*Massachusetts General Hosp, Boston, MA, USA*; ²*Dana-Farber Cancer Inst, Boston, MA, USA*; ³*Dana-Farber Cancer Inst, Brookline, MA, USA*; ⁴*Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA*

11:15 146 Paroxetine and Fluconazole Therapy for HAND: A Double-Blind, Placebo-Controlled Trial

Ned Sacktor¹; Richard L. Skolasky²; Norman Haughey³; Cynthia Munro⁴; Richard Moxley⁵; Joseph Steiner⁶; Avindra Nath⁷; Justin McArthur⁸
¹*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ²*NIH, Bethesda, MD, USA*

11:30 147 MVC and TDF Reduce Neurocognitive Impairment in Initial ART: ACTG A5303

Kevin R. Robertson¹; Sachiko Miyahara²; Anthony Lee³; Todd T. Brown⁴; Ellen S. Chan⁵; Baiba Berzins⁶; David Rusin⁷; Joseph J. Eron⁸; Babafemi Taiwo⁹; for the AIDS Clinical Trials Group Team 5303
¹*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*; ²*Harvard Univ, Boston, MA, USA*; ³*Johns Hopkins Univ, Baltimore, MD, USA*; ⁴*Northwestern Univ, Chicago, IL, USA*; ⁵*Frontier Sci & Tech Rsr Fndn, Inc, Amherst, NY, USA*; ⁶*Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA*

11:45 148 Brain MRI Changes Associated With Poorer Cognitive Function in Treated HIV Infection

Jonathan Underwood¹; James H. Cole²; Matthan W. Caan³; David J. Sharp⁴; Davide De Francesco⁵; Robert Leech⁶; Caroline Sabin⁷; Charles B. Majoie⁸; Peter Reiss⁹; Alan Winston¹⁰; for the The Co-morbidity in Relation to Aids (COBRA) Collaboration
¹*Imperial Coll London, London, UK*; ²*Academic Med Cntr, Amsterdam, Netherlands*; ³*Univ Coll London, London, UK*; ⁴*Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands*; ⁵*Imperial Coll of Sci, Tech and Med, London, UK*

Session O-13 Oral Abstracts

Ballroom B/C

10:00 AM-12:00 PM

HCV: Curing the Patient but Not the Population

Oral Abstract Moderators

Arthur Y. Kim, *Harvard Medical School, Boston, MA, USA*
Kristen M. Marks, *Cornell University, New York, NY, USA*

10:00 149 Networks of HCV Transmissions Among Persons Who Inject Drugs: Indiana, 2015

Sumathi Ramachandran¹; Eyasu Teshale²; William Switzer³; Philip Peters⁴; Romeo R. Galang⁵; Pamela Pontones⁶; Jessica Gentry⁷; Sara J. Blosser⁸; John Ward⁹; Yury Khudyakov¹⁰; for the HIV-HCV Transmission Investigation Team
¹*CDC, Atlanta, GA, USA*; ²*Indiana State Dept of Hlth, Indianapolis, IN, USA*

10:15 150 Hepatitis B and C, Alcohol, and CD4 Drive End-Stage Liver Disease in HIV+ Adults

Keri N. Althoff¹; Amy C. Justice²; Joseph J. Eron³; Lisa Jacobson⁴; Gregory D. Kirk⁵; Marina B. Klein⁶; Vincent Lo Re⁷; Sonia Napravnik⁸; Michael J. Silverberg⁹; Richard Moore¹⁰
¹*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*; ²*Yale Univ, New Haven, CT, USA*; ³*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*; ⁴*Johns Hopkins Univ, Baltimore, MD, USA*; ⁵*McGill Univ Hlth Cntr, Montreal, QC, Canada*; ⁶*Univ of Pennsylvania, Philadelphia, PA, USA*; ⁷*Kaiser Permanente Northern California, Oakland, CA, USA*

10:30 151 Antiretroviral Therapy Reduces Intrahepatic Hepatitis C in HIV-1/HCV Coinfection

Jeffrey Quinn¹; Abraham J. Kandathil²; Jennifer Shellenberger³; Ramy El-Diwany⁴; Merve Gurakar⁵; Mark Sulkowski⁶; Ruy M. Ribeiro⁷; Alan S. Perelson⁸; David L. Thomas⁹; **Ashwin Balagopal**¹⁰
¹*Johns Hopkins Univ, Baltimore, MD, USA*; ²*Virginia Commonwealth Univ, Richmond, VA, USA*; ³*Los Alamos Natl Lab, Los Alamos, NM, USA*; ⁴*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*

10:45 152 Broadly Neutralizing Antibodies Avert HCV Reinfection or Subsequent Chronic Infection

Sabrina J. Merat¹; Richard Molenkamp²; Dorien van de Berg³; Camille Bru⁴; Sylvie M. Koekkoek⁵; Neeltje A. Kootstra⁶; Maria Prins⁷; Arjen Q. Bakker⁸; Tim Beaumont⁹; Janke Schinkel¹⁰
¹*AIMM Therapeutics, Amsterdam, Netherlands*; ²*Academic Med Cntr, Amsterdam, Netherlands*; ³*PH Service of Amsterdam, Amsterdam, Netherlands*

11:00 153 High Response Rate in HCV-Genotype 4 Patients Treated With Ravidasvir and Sofosbuvir

Gamal Esmat¹; Maissa El Raziky²; Asmaa Goma³; Tamer Elbaz⁴; Mahmoud Abouelkhair⁵; Alyaa Sabry⁶; Hadeel Gamal Eldeen⁷; Mohammed Karim⁸; Mohammed Abdel-Hamid⁹; Ola Nada¹⁰; Sherine Helmy¹¹; Hanaa Abdel-Maguid¹²; Richard Colonna¹³; Nathaniel Brown¹⁴; Eric Ruby¹⁵; Pamela Vig¹⁶; **Imam Waked**¹⁷
¹*Cairo Univ, Cairo, Egypt*; ²*Cairo Fatemeh Hosp, Cairo, Egypt*; ³*Natl Liver Inst, Shebeen El Kom, Egypt*; ⁴*Kasr Alaini Viral Hepatitis Cntr, Cairo, Egypt*; ⁵*MyLab Lab, Cairo, Egypt*; ⁶*European Egyptian Pharmaceutical Industries, Alexandria, Egypt*; ⁷*Presidio Pharmaceuticals, San Francisco, CA, USA*

11:15 154LB Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients With Acute HCV Infection

Jürgen K. Rockstroh¹; Sanjay Bhagani²; Robert H. Hyland³; Chohee Yun⁴; Wei Zhang⁵; Diana M. Brainard⁶; John G. McHutchison⁷; Patrick Ingiliz⁸; Thomas Lutz⁹; Mark Nelson⁹
¹Medizinische Univsklinik, Bonn, Germany; ²Royal Free Hosp, London, United Kingdom; ³Gilead Scis, Inc, Foster City, CA, USA; ⁴Cntr for Infectiology, Berlin, Germany; ⁵Infectiologikum, Frankfurt/Main, Frankfurt, Germany; ⁶Chelsea and Westminster Hosp NHS Fndn Trust, London, UK

Session 0-14 Oral Abstracts Ballroom A

10:00 AM-12:00 PM

Tuberculosis and Other Opportunistic Infections/Cancer Prevention: Hits and Misses

Oral Abstract Moderators

Andrew Kambugu, Infectious Diseases Institute, Kampala, Uganda

Susan E. Krown, AIDS Malignancy Consortium, New York, NY, USA

10:00 155 Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial

Alison Grant¹; Salome Charalambous²; Mpho Tlali³; Suzanne Johnson⁴; Susan Dorman⁵; Christopher Hoffmann⁶; Aaron Karat⁷; Anna Vassalli⁸; Gavin Churchyard⁹; Katherine L. Fielding¹
¹London Sch of Hygiene & Trop Med, London, UK; ²The Aurum Inst, Johannesburg, South Africa; ³Fndn for Professional Develop, Pretoria, South Africa; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

10:15 156 Acceptability of Large-Scale Household-Based TB Screening: HPTN 071 (PopART) Trial

Comfort R. Phiri¹; Sian Floyd²; Ab Schaap³; Sam Griffith⁴; Ephraim Sakala⁵; Richard Hayes⁶; Sarah J. Fidler⁷; Helen Ayles⁸; Kwame Shanaube⁹; for the HPTN071 (PopART)
¹ZAMBART, Lusaka, Zambia; ²London Sch of Hygiene & Trop Med, London, UK; ³FHI 360, Research Triangle Park, NC, USA; ⁴Imperial Coll London, London, UK

10:30 157 HIV-Associated XDR TB Is Transmitted in Households and Hospitals in South Africa

Sara C. Auld¹; James C. Brust²; Barun Mathema³; Thuli Mthiyane⁴; Nazir Ismail⁵; Pravi Moodley⁶; Darius McDaniel⁷; Salim Allana⁸; Neel Gandhi⁹; N. Sarita Shah⁹
¹Emory Univ, Atlanta, GA, USA; ²Albert Einstein Coll of Med, Bronx, NY, USA; ³Columbia Univ Mailman Sch of PH, New York, NY, USA; ⁴Univ of KwaZulu-Natal, Westville, South Africa; ⁵Natl Inst for Communicable Diseases, Johannesburg, South Africa; ⁶Univ of KwaZulu-Natal, Durban, South Africa; ⁷Emory Univ Rollins Sch of PH, Atlanta, GA, USA; ⁸Rollins Sch of PH, Emory Univ, Atlanta, GA, USA; ⁹CDC, Atlanta, GA, USA

10:45 158LB Beta-Lactams Against TB: Teaching a New Trick to an Old Dog

Andreas H. Diacon¹; Lize van der Merwe²; Marinus Barnard³; Florian Von Groote-Bidlingmaier⁴; Christoph Lange⁵; Alberto L. Garcia-Basteiro⁶; Esperança Sevens⁶; Lluís Ballellí⁷; David Barros-Aguirre⁸
¹Stellenbosch Univ, Bellville, South Africa; ²Task Applied Science, Bellville, South Africa; ³Rsr Cntr Borstel, Borstel, Germany; ⁴Barcelona Inst for Global Hlth, Barcelona, Spain; ⁵Manhiça Hlth Rsr Cntr (CISM), Manhiça, Mozambique; ⁶Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain

11:00 159 Pre-ART Cryptococcal Antigen Titer Associated With Preemptive Fluconazole Failure

Bozena M. Morawski¹; David R. Boulware²; Elizabeth Nalintya³; Agnes Kiragga⁴; Francis Kazoza⁵; Radha Rajasingham⁶; Benjamin J. Park⁷; Yukari C. Manabe⁸; Jona E. Kaplan⁹; David B. Meza⁹
¹Univ of Minnesota, Minneapolis, MN, USA; ²Infectious Diseases Inst, Kampala, Uganda; ³CDC, Atlanta, GA, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA

11:15 160 Immediate ART Initiation Reduces Risk of Infection-Related Cancer in HIV Infection

Alvaro H. Borges¹; Jacqueline Neuhaus²; Abdel Babiker³; Timothy J. Wilkin⁴; Christian Hoffmann⁵; Keith Henry⁶; Adrian Palfreeman⁷; Mamta K. Jain⁸; Sanjay Pujari⁹; Ronald T. Mitsuyasu¹⁰
¹CHIP, Rigshospet, Univ of Copenhagen, Copenhagen, Denmark; ²Univ of Minnesota, Minneapolis, MN, USA; ³Univ Coll London, London, UK; ⁴Weill Cornell Med Coll, New York, NY, USA; ⁵IPM StudyCntr, Hamburg and Univ of SchleswigHolstein, Campus Kiel, Hamburg, Germany; ⁶Hennepin County Med Cntr, Univ of Minnesota, Minneapolis, MN, USA; ⁷Med Rsr Council Clinical Trials Unit, London, UK; ⁸Univ of Texas Southwestern Med Cntr, Dallas, TX, USA; ⁹Inst of Infectious Diseases, Pune, India; ¹⁰Univ of California Los Angeles, Los Angeles, CA, USA

11:30 161 ACTG A5298: A Phase 3 Trial of the Quadrivalent HPV Vaccine in Older HIV+ Adults

Timothy J. Wilkin¹; Huichao Chen²; Michelle Cespedes³; Pawel Paczuskii⁴; Catherine Godfrey⁵; Elizabeth Chiao⁶; Amneris Lueque⁷; Jennifer Y. Webster-Cyriaque⁸; Barbara Bastow⁹; Ross Cranston⁹; for the ACTG A5298 Protocol Team
¹Weill Cornell Med Coll, New York, NY, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Icahn Sch of Med at Mount Sinai, New York, NY, USA; ⁴DAIDS, NIAID, NIH, Rockville, MD, USA; ⁵Baylor Coll of Med, Houston, TX, USA; ⁶Univ of Rochester Med Cntr, Rochester, NY, USA; ⁷Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁸Social & Scientific Systems, Inc., Silver Spring, MD, USA; ⁹Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA

11:45 162 Is Intensive Cervical Cancer Screening Justified in Immunosuppressed Women?

Michael J. Silverberg¹; Wendy Leyden²; Steven Gregorich³; Karen K. Smith-McCune⁴; Megan Huchko⁵; Miriam Kuppermann⁶; Shalini Kulasingam⁷; George F. Sawaya⁸
¹Kaiser Permanente Northern California, Oakland, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Sch of PH, Univ of Minnesota, Minneapolis, MN, USA

Session O-15 Oral Abstracts

Room 311

10:00 AM-12:00 PM

Focus on HIV Acquisition and Challenges in the Cascade

Oral Abstract Moderators

Beatriz Grinsztajn, *Instituto de Pesquisa Clínica Evandro Chagas (IPEC)/ Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil*

Timothy H. Holtz, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

163 Withdrawn

10:00 164 Isolated Seminal HIV-1 RNA Shedding in African Men With Uninfected Women Partners

Andrew Mujigira¹; Connie M. Celum²; Allan Ronald³; Nelly R. Mugo⁴; Robert W. Coombs⁵; Jared M. Baeten⁶; for the Partners PrEP Study Team

¹Univ of Washington, Seattle, WA, USA; ²Univ of Manitoba, Winnipeg, MB, Canada; ³Kenya Med Rsr Inst, Thika, Kenya

10:15 165 Exploring the Effectiveness of Traditional Circumcision Practices in Preventing HIV

Michael Pickles¹; Anne Cori²; Sian Floyd³; Helen Ayles⁴; Nulda Beyers⁵; Peter Bock⁶; Sarah J. Fidler⁷; Richard Hayes⁸; Christophe Fraser⁹; for the HPTN 071 (PopART) Study Team

¹Imperial Coll London, London, UK; ²London Sch of Hygiene & Trop Med, London, UK; ³Univ of Stellenbosch, Tygerberg, South Africa; ⁴Univ of Stellenbosch, Cape Town, South Africa

10:30 166 2013-14 Rwanda HIV Incidence Household Survey: Understanding HIV Epidemic in Rwanda

Eric Remera¹; Jean Paul Uwizihwe¹; Steve Kanters²; Augustin Mulindabigwi¹; Mmwumvaneza Mutagoma¹; Edward Mills³; Sabin nsanzimana³

¹Inst of HIV/AIDS Disease Prevention and Control, Rwanda Biomed Cntr, Kigali, Rwanda; ²Global Evaluative Scis, Vancouver, BC, Canada; ³Rwanda Biomed Cntr, Kigali, Rwanda

10:45 167 Antiretroviral Therapy and HIV Acquisition in a South African Population-Based Cohort

Catherine Oldenburg¹; Till Bärnighausen²; Frank Tanser²; Victor De Gruttola³; George R. Seage⁴; Matthew Mimiaga⁵; Kenneth H. Mayer⁶; Deenan Pillay⁷; Guy Harling¹

¹Harvard Sch of PH, Boston, MA, USA; ²Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ³Brown Univ Sch of PH, Providence, RI, USA; ⁴The Fenway Inst, Fenway Hlth, Boston, MA, USA

11:00 168LB Option B+ in Malawi: Have 4 Years of "Treat All" Shown That 90-90-90 Is Achievable?

Beth Tippett Barr¹; Andreas Jahn²; Sundeep K. Gupta³; Alice Maida⁴; Frank Chimbwandira²

¹CDC, Harare, Zimbabwe; ²Ministry of Hlth, Lilongwe, Malawi; ³CDC, Lilongwe, Malawi

11:15 169LB Measuring the Impact of Test & Treat on the HIV Cascade: The Challenge of Mobility

Joseph Larmarange¹; Collins Iwuji²; Joanna Orme-Gliemann³; Nuala McGrath⁴; Mélanie Plazy⁵; Kathy Baisley⁶; Till Bärnighausen⁷; Francois Dabis⁸; Deenan Pillay⁹; for the ANRS 12249 TasP Study Group

¹Université Paris Descartes, Paris, France; ²Africa Cntr for Population Hlth, Mtubatuba, South Africa; ³INSERM, Bordeaux, France; ⁴Univ of Southampton, Southampton, United Kingdom; ⁵London Sch of Hygiene & Trop Med, London, UK; ⁶Harvard Sch of PH, Boston, MA, USA; ⁷INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ⁸Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

11:30 169aLB HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP)

David C. Knox¹; Darrell H. Tan²; P. Richard Harrigan³; Peter L. Anderson⁴

¹Maple Leaf Med Clinic, Toronto, ON, Canada; ²St Michael's Hosp, Toronto, ON, Canada; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁴Univ of Colorado, Denver, CO, USA

11:45 169bLB Gel Applied as Anal Lube Without Applicator Provides Poor Rectal Mucosal HIV Coverage

Eugenie Shieh¹; Ethel Weld²; Edward J. Fuchs³; Karen W. Buckheit⁴; Robert W. Buckheit Jr²; Jennifer Breakey¹; Craig Hendrix¹

¹Johns Hopkins Univ, Baltimore, MD, USA; ²ImQuest Biosciences, Inc, Frederick, MD, USA

Session TD-13 Themed Discussion

Ballroom B/C

1:45 PM-2:45 PM

HIV Effects on Liver Fibrosis and Steatosis

Themed Discussion Leader

Kenneth E. Sherman, *University of Cincinnati, Cincinnati, OH, USA*

558 Poorly Controlled HIV Infection Is a Risk Factor for Liver Fibrosis in CNICS Cohort

Nina Kim¹; Robin Nance²; Stephen Van Rompaey³; Joseph A. Delaney⁴; Heidi M. Crane⁵; Katerina A. Christopoulos⁶; Wm. Christopher Mathews⁷; Richard Moore⁸; Mari M. Kitahata⁹; for the Center for AIDS Research Network of Integrated Clinical Systems

¹Univ of Washington, Seattle, WA, USA; ²Univ of Washington Sch of PH and Community Med, Seattle, WA, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴Univ of California San Diego, San Diego, CA, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA

560 Liver Fibrosis in HIV Patients: Which Factors Play a Role?

Raphael Mohr¹; Christoph Boesecke²; Carolynne Schwarze-Zander¹; Jan-Christian Wasmuth¹; Jürgen K. Rockstroh²

¹Univ Hosp Bonn, Bonn, Germany; ²Medizinische Universitätsklinik, Bonn, Germany

- 568 Alcohol Use, Hepatitis B, and Liver Fibrosis Among HIV-Infected Persons in West Africa**
Antoine Jaquet¹; Gilles Wandeler²; Marcellin Nouaman³; Didier Ekouevi⁴; Judicaël Tine⁵; Ahuatchi P. Coffie⁶; Aristophane Tanon⁷; Moussa Seydi⁸; Alain Attia⁹; Francois Dabis¹
¹INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ²Univ Hosp Bern, Bern, Switzerland; ³Prog PACCI, CHU Treichville, Abidjan, Côte d'Ivoire; ⁴INSERM U897, ISPED, Univ de Bordeaux, Abidjan, Côte d'Ivoire; ⁵CHU de Fann, Dakar, Senegal; ⁶CHU de Treichville, Abidjan, Côte d'Ivoire; ⁷CHU de Yopougon, Abidjan, Côte d'Ivoire
- 561 NASH Is Associated With a Unique Biomarker Signature in HIV-Infected Adults**
Rebecca Krakora¹; Mary McLaughlin²; Adam Rupert³; Michael Proschan⁴; Colleen Hadigan⁵; David E. Kleiner⁶; Theo Heller⁶; Joseph A. Kovacs⁷; Caryn G. Morse¹
¹NIH Clinical Cntr, Bethesda, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³NIAID, NIH, Frederick, MD, USA; ⁴NIAID, NIH, Rockville, MD, USA; ⁵NCI, Bethesda, MD, USA; ⁶NIDDK, Bethesda, MD, USA
- 553 Statin Therapy Reduces Liver Fat Measured by Computed Tomography in Patients With HIV**
Janet Lo; Michael Lu; Eli Kim; Eric Nou; Travis R. Hallett; Jakob Park; Udo Hoffmann; Steven Grinspoon
Massachusetts General Hosp, Boston, MA, USA

Session TD-14 Themed Discussion Room 302
1:45 PM-2:45 PM

Mind the Gaps: Optimizing the PMTCT Cascade

Themed Discussion Leader

Marcel Yotebieng, *Ohio State University, Columbus, OH, US*

- 789 Malawi's Option B+ 2011-2015: The Impact of Rapid ART Decentralization**
Sundeep K. Gupta¹; Andreas Jahn²; Beth Tippett Barr³; James Houston⁴; Alice Maida⁵; Jen Sabatier⁶; Crispin Musicha⁷; Frank Chimbwandira⁸
¹CDC, Lilongwe, Malawi; ²Univ of Washington, Seattle, WA, USA; ³CDC, Harare, Zimbabwe; ⁴CDC, Atlanta, GA, USA; ⁵Malawi Ministry of Hlth, Lilongwe, Malawi
- 790 Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study**
Muktar H. Aliyu¹; Meredith Blevins²; Carolyn M. Audet¹; Marcia Kalish³; Mary Lou Lindegren⁴; Usman I. Gebi⁵; Obinna Onwujekwe⁶; Bryan E. Shepherd⁷; C. William Wester⁸; Sten H. Vermund¹
¹Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ²Univ of Nigeria, Enugu, Nigeria
- 791 Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention**
Ruby N. Fayoorey¹; Duncan Chege²; Chunhui Wang³; William Reidy⁴; Zach Peters⁵; Martin W. Sirengo⁶; Masila Syengo⁶; Christin W. Barasa⁷; Mark Hawken⁸; Elaine J. Abrams¹
¹ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA; ²ICAP at Columbia Univ, Nairobi, Kenya; ³Natl AIDS and STI Control Prog, Nairobi, Kenya; ⁴ICAP at Columbia Univ, Nairobi, Kenya

- 792 Continuity of Care Among Pregnant Women Lost to Follow-up After Initiating ART**
Kate Clouse¹; Sten H. Vermund²; Mhairi Maskew³; Given Maletse⁴; Matthew P. Fox⁵
¹Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ²Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ³Boston Univ, Boston, MA, USA
- 793 Disclosure and Knowledge Are Associated With Retention in Malawi's Option B+ Program**
Risa M. Hoffman¹; Khumbo Phiri²; Julie Parent³; Jonathan F. Grotts⁴; Sara Yeatman⁵; Paul Kawale⁶; David Elashoff⁷; Judith S. Currier⁸; Alan Schooley⁹
¹Univ of California Los Angeles, Los Angeles, CA, USA; ²Partners in Hope Med Cntr, Lilongwe, Malawi; ³Univ of Colorado, Denver, CO, USA; ⁴David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA

Session TD-15 Themed Discussion Room 312
1:45 PM-2:45 PM

Pathways to Eliciting Antibody Responses

Themed Discussion Leader

Michael Seaman, *Harvard Medical School, Boston, MA, USA*

- 301 Oral PrEP Enhances Genital HIV-Neutralizing IgA in HIV-1 Exposed Seronegative Women**
 Jennifer M. Lund¹; Kristina Broiden²; Maria N. Pyra³; Katherine K. Thomas⁴; Deborah Donnell⁵; Elizabeth Irungu⁶; Timothy R. Muwonge⁶; Nelly R. Mugo⁷; Jared M. Baeten⁸; **Jairam R. Lingappa**³
¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ²Karolinska Univ, Stockholm, Sweden; ³Univ of Washington, Seattle, WA, USA; ⁴SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁵Kenya Med Rsr Inst, Thika, Kenya; ⁶Makerere Univ Coll of Hlth Scis, Kampala, Uganda
- 302 Potent Broadly Neutralising Antibody Responses in Slow-Progressing Pediatric HIV**
Emily Adland¹; Maximilian Muenchhoff²; Anna Csala³; Thumbi P. Ndungu⁴; Pieter Jooste⁵; Owen Karimanzira⁶; Carol Crowther⁷; Penny Moore⁸; Lynn Morris⁹; Philip Goulder¹
¹Univ of Oxford, Oxford, UK; ²Univ of KwaZulu-Natal, Durban, South Africa; ³Kimberley Hosp, Kimberley, South Africa; ⁴NCID, Johannesburg, South Africa
- 303 Broadly Reactive Neutralizing Activity Within the First 6 Months of HIV-1 Infection**
Amanda Fabra Garcia¹; Nuria Gonzalez²; Alberto Merino-Mansilla³; Juan Ambrosioni⁴; Anke Schultz⁵; Jose M. Gatell⁶; José Alcami⁷; José M. Miro⁸; Eloisa Yuste⁹; Victor Sanchez-Merino³
¹IDIBAPS, Barcelona, Spain; ²Inst de Salut Carlos III, Madrid, Spain; ³Inst d Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ⁴Hosp Clinic-IDIBAPS, Univ de Barcelona, Barcelona, Spain; ⁵Fraunhofer Inst for Biomed Engineering, St Ingbert, Germany; ⁶Hosp Clinic of Barcelona, Barcelona, Spain
- 317 Immunogenicity and Efficacy of ALVAC-HIV/gp120-Clade C in AluM Regimen in Macaques**
Luca Schifanelia¹; David Venzon²; Susan Barnett³; Sanjay Phogat⁴; Georgia Tomaras⁵; David Montefiori⁶; Massimiliano Bissa⁷; Veronica Galli⁸; Ruth M. Ruprecht⁹; Genevieve Franchini¹
¹NIH, Bethesda, MD, USA; ²Novartis, Cambridge, MA, USA; ³Sanofi, Swiftwater, PA, USA; ⁴Duke Univ, Durham, NC, USA; ⁵Texas Biomed Rsr Inst, San Antonio, TX, USA

318 Specific IgG Subclasses Induced in RV305, a Late Boost Vaccination of RV144 Subjects

Siriwat Akapirat¹; Sandhya Vasan²; Punnee Pitisuttithum³; Supachai Reks-Ngarm⁴; Nelson L. Michael⁵; Jean-Louis Excler⁶; Jerome H. Kim⁷; Robert O'Connell⁸; Nicos Karasavvas⁹; for the RV305 Study Group
¹Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand; ²US Military HIV Rsr Prog, APO, AP, USA; ³Mahidol Univ, Ratchathewi, Thailand; ⁴Ministry of PH, Muang Nonthaburi, Thailand; ⁵US Military HIV Rsr Prog, Bethesda, MD, USA; ⁶Henry M. Jackson Fndn for the Advancement of Military Med, Inc, Bethesda, MD, USA; ⁷Intl Vaccine Inst, Seoul, Republic of Korea

Session TD-16 Themed Discussion Room 304/306 1:45 PM-2:45 PM

Going to Scale With ART and PrEP

Themed Discussion Leader

Anne Cori, Imperial College London, London, United Kingdom

1048 Effect of Eliminating CD4 Thresholds on Number of New ART Initiators in South Africa

Jacob Bor¹; Shahira Ahmed²; Matthew P. Fox³; Sydney Rosen⁴; Frank Tanser⁵; Deenan Pillay⁶; Till Bärnighausen⁷
¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁴Harvard Sch of PH, Boston, MA, USA

1049 Optimizing Resource Allocation to Reduce HIV Incidence Across Sub-Saharan Africa

Jessica McGillen; Sarah-Jane Anderson; Timothy Hallett
Imperial Coll London, London, UK

1050 New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025

Vineet R. Prabhu, Clinton Hlth Access Initiative, Boston, MA, USA

1051 Impact of Improving HIV Care and Treatment and Initiating PrEP in the United States, 2015–2020

Emine Yaylali¹; Paul Farnham²; Evin Jacobson³; Benjamin T. Allaire⁴; Danielle L. Wagner⁵; Katherine A. Hicks⁶; Amanda A. Honeycutt⁷; Stephanie L. Sansom¹
¹CDC, Atlanta, GA, USA; ²RTI, Research Triangle Park, NC, USA; ³RTI, Waltham, MA, USA; ⁴RTI Hlth Solutions, Research Triangle Park, NC, USA

1052 PrEP Is Only Cost-Effective Among MSM in the Netherlands When Used on Demand

Brooke E. Nichols¹; Charles A. Boucher²; Marc van der Valk³; Bart J. Rijnders⁴; David A. van de Vijver¹
¹Erasmus Univ Med Cntr, Rotterdam, Netherlands; ²Academic Med Cntr, Amsterdam, Netherlands

Session TD-17 Themed Discussion 1:45 PM-2:45 PM

Ballroom A

MSM in Low- and Middle-Income Countries

Themed Discussion Leader

Adrian D. Smith, Nuffield Department of Population Health, Oxford University, Oxford, United Kingdom

921 HIV Prevalence and Risk Factors in Men Who Have Sex With Men in Bamako, Mali

Maria Lahuerta¹; Padmaja Patnaik¹; Nouhoum Telly²; Justin Knox³; Tako Ballo⁴; Adama N'diri⁵; Bouyagui Traore⁶; Seydou Doumbia⁷; Avi Hakim⁸
¹ICAP at Columbia Univ, New York, NY, USA; ²ICER Mali, Bamako, Mali; ³Cellule Sectorielle de Lutte contre le Sida, Ministère de la Sante, Bamako, Mali; ⁴CDC, Bamako, Mali; ⁵CDC, Atlanta, GA, USA

924 Online Sex-Seeking Among MSM in Nigeria: Implications for Online Intervention

Shauna Stahlman¹; Rebecca G. Nowak²; Hongjie Liu³; Trevor A. Crowell⁴; Sosthenes Ketende⁵; William A. Blattner⁶; Manhattan E. Charurat⁷; Stefan Baral⁸; for the TRUST Study Group
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Inst of Human Virology, Baltimore, MD, USA; ³Sch of PH, Univ of Maryland, College Park, MD, USA; ⁴US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA

926 Group Sex: A Cross-Sectional Online Survey Among Men Who Have Sex With Men in China

Songyuan Tang¹; Weiming Tang²; Joseph D. Tucker³; Bin Yang⁴; Ye Zhang⁵; Wei Zhang⁶; Shuijie Huang⁷; Ligang Yang⁸; Chongyi Wei⁹; Chuncheng Liu⁹; Yilu Qin¹
¹Univ of North Carolina Proj China, Guangzhou, China; ²Univ of North Carolina at Chapel Hill Inst for Global Hlth & Infectious Diseases, Chapel Hill, NC, USA; ³Guangdong Provincial Cntr for Skin Diseases and STI Control, Guangzhou, China; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵SESH Global, Guangzhou, China

927 Risk Factors for Acute and Early HIV Infection Among MSM, Bangkok, Thailand 2010–2015

Warunee Thienkrua¹; Marcel Curlin²; Eileen Dunne³; Kanokpan Pancharoen⁴; Boonyos Raengsakulrach⁵; Wannee Chonwattana⁶; Wanna Leelawiwat⁷; Philip A. Mock⁸; Anupong Chitwarakorn⁹; Timothy H. Holtz²
¹Thailand Ministry of PH, Muang Nonthaburi, Thailand; ²Oregon Hlth and Scis Univ, Portland, OR, USA; ³CDC, Atlanta, GA, USA

928 High Prevalence of HIV Among Wives of Married Men Who Have Sex With Men in India

Aylur K. Srikrishnan¹; Shruti H. Mehta²; Cecilia Tomori³; Santhanam Anand⁴; Pachamuthu Balakrishnan⁵; David Celentano⁶; Gregory M. Lucas⁷; **Sunil S. Solomon**⁸
¹YRC Cntr for AIDS Rsr and Educ, Taramani, India; ²Johns Hopkins Univ, Baltimore, MD, USA; ³YRC Cntr for AIDS Rsr and Educ, Chennai, India

Session TD-18 Themed Discussion
1:45 PM-2:45 PM

Room 311

Next Generation Sequencing for Detection of Transmitted or Linked Drug Resistance

Themed Discussion Leader

Jeffrey A. Johnson, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

487 No Evidence of Sexual Transmission of Minority HIV Drug Resistance Mutations in MSM

Antoine Chailion; Sanjay R. Mehta; Joel O. Wertheim; Ben Murrell; Susan J. Little; Douglas D. Richman; Davey M. Smith; Sara Gianella
Univ of California San Diego, San Diego, CA, USA

488 Transmitted Drug Resistance in HIV-1 Subtype C Hyperacute Infection

Urisha Singh¹; Avashna Singh¹; Marc Noguera-Julian²; Manjeetha Jaggenath³; Amber Moodley⁴; Krista Dong³; Bruce D. Walker³; Thumbi P. Ndungu⁴; Michelle Gordon⁴
¹Univ of KwaZulu-Natal, Durban, South Africa; ²IrsiCaixa Inst for AIDS Rst, Badalona, Spain; ³Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ⁴Nelson R Mandela Sch of Med, Univ of Kwazulu-Natal, Durban, South Africa

489 Integrase Inhibitors-Transmitted Drug Resistance Detected by UltraDeep Sequencing

Eve Todesco¹; Jeremy Jaffre¹; Cathia Soulié¹; Daniele Armenia²; Marc Wirlden³; Sidonie Lambert³; Christine Katlama³; Francesca Ceccherini-Silberstein³; Vincent Calvez³; Anne-Geneviève Marcelin¹
¹Sorbonne Univs, Paris, France; ²Univ of Rome Tor Vergata, Rome, Italy; ³APHP, Pitie Salpêtrière Hosp, Paris, France

490 Linkage of Rare Drug Resistance Mutations Detected by New Ultrasensitive SGS

Valerie F. Boltz¹; Junko Hattori¹; Wei Shao²; John M. Coffin³; Frank Maldarelli³; Mary F. Kearney³
¹NCI, Frederick, MD, USA; ²Leidos Biomed Rst, Inc, Frederick, MD, USA; ³Tufts Univ, Boston, MA, USA

Session S-8 Symposium
4:00 PM-6:00 PM



Ballroom B/C

Where Are the HIV Hot Spots?

Target audience: This session is directed to clinicians and scientists who are interested in understanding methods for identifying hot spots of new infection, drivers of the epidemic in vulnerable populations, and approaches to addressing these diverse epidemics.

Level of knowledge: It is assumed that participants are familiar with basic concepts of HIV epidemiology and social, cultural, and biologic contributions to HIV spread.

Objectives: At the completion of the session, participants will be able to:

- Describe new methods for identifying HIV hot spots
- Identify diverse high risk populations with high HIV incidence, including fisherfolk, young MSM, and immigrants
- Describe strategies for reducing new infections and improving outcomes in these populations

Conveners

Z. Michael Chirenje, *University of Zimbabwe, University of California San Francisco Collaborative Research Programme, Harare, Zimbabwe*



Shannon L. Hader, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

4:00 170 Location and Population: Response to the Who and Where in the HIV Epidemic

Peter Ghys, *UNAIDS, Geneva, Switzerland*



4:30 171 HIV in Fishing Communities: Prevalence, Incidence, Risk Factors, and Interventions

Zachary A. Kwena; *for the Lake Victoria Consortium for Health Research, Kenya Med Rsr Inst, Kisumu, Kenya*



5:00 172 Sex, Stigmas, and Systems: Global Issues in HIV Among Young MSM

LaRon E. Nelson, *Univ of Rochester, Rochester, NY, USA*



5:30 173 HIV and Migrants

Julia Del Amo, *Inst de Salud Carlos III, Madrid, Spain*



Session 5-9 Symposium **CME**
4:00 PM-6:00 PM

Ballroom A

#HIV-Who me? Adolescents at the Crossroads

Target audience: This session is directed to clinicians and scientists who are interested in understanding the global adolescent HIV epidemic

Level of knowledge: It is assumed that participants are familiar with basic concepts of HIV acquisition, prevention and treatment of in the adolescent age group

Objectives: At the completion of the session, participants will be able to:

- Describe the global epidemiology of HIV infection in adolescents
- Discuss the neurodevelopment of the adolescent brain and relationship to risk behaviors
- Outline innovative approaches to testing and linking adolescents with HIV care
- Describe the process and outcomes of transitioning adolescents from pediatric to adult care services

Conveners

Caroline Foster, Imperial College Healthcare NHS Trust, London, United Kingdom

Rohan Hazra, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA



4:00 174 Global Epidemiology of HIV Infection in Adolescents

Annette H. Sohn, TREAT Asia, Bangkok, Thailand



4:30 175 Blame It On the Brain

Lisa K. Simons, Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, USA



5:00 176 Finding and Engaging Adolescents With HIV in Low- and Middle-Income Countries

Rashida A. Ferrand, London Sch of Hygiene & Trop Med, London, UK



5:30 177 Thinking About the Future: Transition for Adolescents With HIV

Allison L. Agwu, Johns Hopkins Univ, Baltimore, MD, USA



Session 5-10 Symposium **CME**
4:00 PM-6:00 PM

Room 304/306

Natural Born(e) Killers

Target audience: This session is directed to clinicians and scientists who are interested in understanding role and mechanisms by which NK cells contribute to HIV prevention, treatment, and cure.

Level of knowledge: It is assumed that participants are familiar with basic immunology and cellular immune responses against virally infected cells.

Objectives: At completion of the session, participants will be able to:

- Describe the state of the field's understanding of the role of NK cells in HIV prevention and control
- Describe opportunities to exploit the antiviral activity of NK cells for cure
- Describe mechanisms for using monoclonal antibodies to direct NK cell killing of reactivated latently infected cells

Conveners

David T. Evans, University of Wisconsin–Madison, Madison, WI, USA

Silke Paust, Baylor College of Med, Houston, TX, USA



4:00 178 NK Cell-Mediated Recognition of HIV

Marcus Altfeld, Heinrich Pette Inst, Hamburg, Germany



4:30 179 Signatures of Protective NK Cell Responses

Catherine A. Blish, Stanford Univ, Stanford, CA, USA




5:00 180 Supercharging NK Cells for Cure

Jonathan Karn, Case Western Reserve Univ, Cleveland, OH, USA



5:30 181 Exposing Env: A New Strategy to Target HIV-1–Infected Cells by ADCC

Andrés Finzi, CRCHUM, Montreal, QC, Canada



Thursday, February 25, 2016 • Oral Sessions

POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in Hall A/B (poster numbers 182-756) and Hall D (poster numbers 757-1063) from 2:45 to 4:00 PM on the scheduled day.

A. Virology

- P-A1 Viral Transmission and Target Cells (Tuesday, February 23, 2016)
- P-A2 Viral Proteins: Regulation, Replication, Transcription (Wednesday, February 24, 2016)
- P-A3 Viral Proteins: Insights Into Structure (Wednesday, February 24, 2016)
- P-A4 Host Factors and Cell Response to Infection (Thursday, February 25, 2016)

B. Molecular Epidemiology and HIV/SIV Evolution

- P-B1 Detection and Spread of Genetically Diverse HIV (Tuesday, February 23, 2016)
- P-B2 Identifying Network and Transmission Pairs (Wednesday, February 24, 2016)
- P-B3 Viral Genetics: Effects on Transmission, Disease, and Reinfection (Thursday, February 25, 2016)
- P-B4 Defining the Sequence Characteristics of Transmitted Viruses (Thursday, February 25, 2016)

C. Pathogenesis: Human Studies and Animal Models

- P-C1 HIV and Intestinal Integrity (Tuesday, February 23, 2016)
- P-C2 HIV Effects on CD4+ T Cells (Tuesday, February 23, 2016)
- P-C3 Genetics and Cell Biology of HIV Infection (Tuesday, February 23, 2016)
- P-C4 Immunopathogenesis (Tuesday, February 23, 2016)
- P-C5 HIV and Microbiomes (Wednesday, February 24, 2016)
- P-C6 SIV Models of Pathogenesis (Wednesday, February 24, 2016)
- P-C7 Immune Activation and Inflammation (Wednesday, February 24, 2016)
- P-C8 Pathogenesis of Mucosal Transmission (Thursday, February 25, 2016)
- P-C9 Immune Effects of Antiretroviral Therapy (Thursday, February 25, 2016)

E. Host Immune Responses to Infection, Vaccines, and Immunotherapy

- P-E1 Antibody Responses to HIV Infection: What Drives Them and How They Affect the Virus (Tuesday, February 23, 2016)
- P-E2 Cellular Immunity: Change to Cytotoxic T Lymphocyte and NK Cells (Tuesday, February 23, 2016)
- P-E3 Evaluating HIV Vaccines: Preclinical to Clinical (Wednesday, February 24, 2016)
- P-E4 Effects of HIV on the Responses to Other Vaccines (Thursday, February 25, 2016)

F. HIV Persistence, Reservoirs, Latency, Eradication, Including Gene Therapy

- P-F1 Novel HIV Reservoirs (Tuesday, February 23, 2016)
- P-F2 HIV Reservoir: Measurement and Mechanisms of Persistence (Tuesday, February 23, 2016)
- P-F3 Tissue Reservoirs of HIV: Anatomic and Imaging Studies (Tuesday, February 23, 2016)
- P-F4 Impact of Antiretroviral Therapy on Viremic Control and Tissue Reservoirs (Wednesday, February 24, 2016)
- P-F5 Approaches to Reactivating HIV and Gene Therapy (Wednesday, February 24, 2016)
- P-F6 HIV Integration (Wednesday, February 24, 2016)
- P-F7 Stem Cells (Thursday, February 25, 2016)
- P-F8 HIV Persistence, Latency, and Reactivation (Thursday, February 25, 2016)

G. Neuropathogenesis

- P-G1 Neuroimaging: Brain Structure and Functional Response (Tuesday, February 23, 2016)
- P-G2 Virology and Basic Neuroscience (Wednesday, February 24, 2016)
- P-G3 Central Nervous System: HIV Entry, Reservoirs, and Compartmentalization (Wednesday, February 24, 2016)
- P-G4 Host and Virus Biomarkers and Immune Response (Thursday, February 25, 2016)
- P-G5 Clinical Distinctions and Therapeutic Response (Thursday, February 25, 2016)

H. Clinical Pharmacology

- P-H1 Exposure Response: Learning to Improve Safety and Efficacy (Tuesday, February 23, 2016)
- P-H2 Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions (Wednesday, February 24, 2016)
- P-H3 Pharmacogenetics (Wednesday, February 24, 2016)
- P-H4 Pharmacokinetics in Compartments (Wednesday, February 24, 2016)
- P-H5 Clinical Pharmacology of Treating Coinfections (Thursday, February 25, 2016)

I. Antiretroviral Therapy: Preclinical Studies

- P-I1 Preclinical Studies of Activity and Resistance (Thursday, February 25, 2016)

J. Antiretroviral Therapy: Randomized Clinical Trials

- P-J1 Antiretroviral Therapy: Randomized Clinical Trials (Wednesday, February 24, 2016)

L. HIV Drug Resistance

- P-L1 HIV Drug Resistance: Surveillance and Transmission (Tuesday, February 23, 2016)
- P-L2 HIV Drug Resistance: Clinical and Epidemiologic Studies (Wednesday, February 24, 2016)
- P-L3 HIV Drug Resistance in Different Drug Classes (Thursday, February 25, 2016)
- P-L4 HIV-2 Drug Resistance (Thursday, February 25, 2016)

M. HIV Diagnostics

- P-M1 HIV Diagnostics (Tuesday, February 23, 2016)
- P-M2 HIV Detection in Clinical Trials (Wednesday, February 24, 2016)
- P-M3 Detecting HCV (Thursday, February 25, 2016)

N. Hepatitis Viruses

- P-N1 HCV Staging: Stiffen Up! (Tuesday, February 23, 2016)
- P-N2 HCV Cure: Moving the Needle from the Patient to the Population (Tuesday, February 23, 2016)
- P-N3 HCV Transmission Tracking and Transmission Risks (Tuesday, February 23, 2016)
- P-N4 Progression of Liver Disease: Mediators and Moderators (Tuesday, February 23, 2016)
- P-N5 HBV Infection: Prevalence, Prevention, and Prognosticators (Wednesday, February 24, 2016)
- P-N6 HCV Infection: Therapeutic Studies and Drug Resistance (Wednesday, February 24, 2016)
- P-N7 HCV Therapeutics: Observational Experiences and “Real World” Studies (Wednesday, February 24, 2016)
- P-N8 Acute HCV Infection (Thursday, February 25, 2016)
- P-N9 Hepatitis A, D, and E (Thursday, February 25, 2016)
- P-N10 Pathogenesis of HCV Infection: Activation and Exhaustion (Thursday, February 25, 2016)
- P-N11 HCV: The Virus is Gone; The Morbidity Not So Much (Thursday, February 25, 2016)
- P-N12 HCV Mischief from Beyond the Liver (Thursday, February 25, 2016)

O. HIV-Related and Non-HIV-Related Malignancies

- P-O1 Global Burden and Mortality of Cancer in HIV (Wednesday, February 24, 2016)
- P-O2 Anal and Cervical Cancer: Treatment and Prevention (Wednesday, February 24, 2016)
- P-O3 Lymphoma and Kaposi Sarcoma (Thursday, February 25, 2016)
- P-O4 Other Cancers and Risk of Malignancies in HIV (Thursday, February 25, 2016)

P. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy

- P-P1 Stroke: Incidence and Risk Factors (Tuesday, February 23, 2016)
- P-P2 Cardiovascular Disease: Risk, Prediction, Assessment, and Management (Tuesday, February 23, 2016)
- P-P3 Atherosclerosis Pathogenesis: Role of the Immune System (Wednesday, February 24, 2016)
- P-P4 Cardiovascular Disease and Antiretroviral Therapy Effects (Wednesday, February 24, 2016)
- P-P5 Cholesterol Metabolism (Thursday, February 25, 2016)
- P-P6 NRTI Toxicities (Thursday, February 25, 2016)
- P-P7 Oxidized Lipids: Associations With Outcomes and Impact of Interventions (Thursday, February 25, 2016)
- P-P8 Smoking: More Ways It Can Harm (Thursday, February 25, 2016)
- P-P9 Noncommunicable Diseases in Low- and Middle- Income Countries (Thursday, February 25, 2016)

Q. Other Complications of HIV Infection and Antiretroviral Therapy

- P-Q1 Renal Outcomes: TAF and TDF (Tuesday, February 23, 2016)
- P-Q2 Renal and Bone Disease: Risk Factors and Biomarkers (Tuesday, February 23, 2016)
- P-Q3 Bone Disease: Sticks, Stones, and TDF (Wednesday, February 24, 2016)
- P-Q4 Metabolic Complications (Wednesday, February 24, 2016)
- P-Q5 Multimorbidity and Aging (Wednesday, February 24, 2016)
- P-Q6 Aging and Immune Effects of Antiretroviral Therapy (Thursday, February 25, 2016)
- P-Q7 Frailty and Functional Status (Thursday, February 25, 2016)
- P-Q8 Mechanisms of Pulmonary Complications (Thursday, February 25, 2016)
- P-Q9 Herpes Virus Coinfections (Thursday, February 25, 2016)

R. Tuberculosis and Other Opportunistic Infections

- P-R1 Tuberculosis: Pathogenesis Studies (Tuesday, February 23, 2016)
- P-R2 Tuberculosis Transmission (Tuesday, February 23, 2016)
- P-R3 Implementation of HIV and Tuberculosis Services (Tuesday, February 23, 2016)
- P-R4 Tuberculosis Related Outcomes and Mortality (Tuesday, February 23, 2016)
- P-R5 Diagnosis of Tuberculosis (Wednesday, February 24, 2016)
- P-R6 Tuberculosis and Antiretroviral Therapy (Wednesday, February 24, 2016)
- P-R7 Multidrug-Resistant Tuberculosis (Wednesday, February 24, 2016)
- P-R8 Tuberculosis and Pregnancy (Wednesday, February 24, 2016)
- P-R9 Cryptococcal Disease: Detection and Outcomes (Thursday, February 25, 2016)
- P-R10 Other Infectious Complications of HIV Disease (Thursday, February 25, 2016)

S. Maternal/Fetal HIV

- P-S1 HIV Acquisition and Health Outcomes During Pregnancy (Tuesday, February 23, 2016)
- P-S2 Antiretroviral Therapy Pharmacokinetics and Safety During Pregnancy and Infancy (Tuesday, February 23, 2016)
- P-S3 Partners in Crime: CMV, HIV, and MTCT (Tuesday, February 23, 2016)
- P-S4 MTCT: Regimens, Rates, and Early Infant Diagnosis (Tuesday, February 23, 2016)
- P-S5 Mind the Gaps: Optimizing the PMTCT Cascade (Wednesday, February 24, 2016)
- P-S6 Viral Dynamics and Drug Resistance During Pregnancy (Wednesday, February 24, 2016)
- P-S7 Birth Outcomes and Mortality in HIV- and ARV-Exposed Infants (Wednesday, February 24, 2016)
- P-S8 Viral and Immune Mechanisms of MTCT (Thursday, February 25, 2016)
- P-S9 Outcomes of HIV and ARV-Exposed Infants, Children, and Youth (Thursday, February 25, 2016)

T. Pediatrics and Adolescents

- P-T1 Pharmacokinetics: Efficacy and Safety of New ARVs in Children (Tuesday, February 23, 2016)
- P-T2 Getting a Handle on CNS Disease in Children and Adolescents (Tuesday, February 23, 2016)
- P-T3 Immunopathogenesis in HIV-Infected Children (Tuesday, February 23, 2016)
- P-T4 Test, Treat, and Suppress: Achieving 90-90-90 in Adolescents (Wednesday, February 24, 2016)
- P-T5 Antiretroviral Therapy and Viral Suppression in Children: Implications for Cure (Wednesday, February 24, 2016)
- P-T6 Achieving 90-90-90 in Children (Thursday, February 25, 2016)
- P-T7 HIV Drug Resistance in Children (Thursday, February 25, 2016)
- P-T8 Complications of HIV and Antiretroviral Therapy in Children (Thursday, February 25, 2016)
- P-T9 Cotreatments of Coinfections in Children (Thursday, February 25, 2016)

U. Contraception and Reproductive and Sexual Health in Women

- P-U1 Contraception and Sexual Health in Women (Thursday, February 25, 2016)

V. Prevention and Intervention Studies

- P-V1 It's Complicated: Renal Function and STIs in PrEP Users (Tuesday, February 23, 2016)
- P-V2 Topical and Systemic Preexposure Prophylaxis: New Agents, New Populations (Wednesday, February 24, 2016)
- P-V3 Predictors of PrEP Coverage and Uptake (Thursday, February 25, 2016)
- P-V4 PrEP in Primary Care: Pitfalls and Opportunities (Thursday, February 25, 2016)

W. Epidemiology

- P-W1 Populations at Risk for HIV (Tuesday, February 23, 2016)
- P-W2 Infection Status, Care, and Mortality (Tuesday, February 23, 2016)
- P-W3 Sex, Drugs, Depression, and HIV (Tuesday, February 23, 2016)
- P-W4 MSM in Low- and Middle-Income Countries (Wednesday, February 24, 2016)
- P-W5 Individuals at Risk of HIV (Thursday, February 25, 2016)

X. Implementation Science and Health Care Delivery

- P-X1 Insights from Antiretroviral Therapy Use: High-Income Settings (Tuesday, February 23, 2016)
- P-X2 Insights from Antiretroviral Therapy Use: Low-Income Settings (Tuesday, February 23, 2016)
- P-X3 HIV Testing and Prevention (Wednesday, February 24, 2016)
- P-X4 HIV Care in the Global North (Wednesday, February 24, 2016)
- P-X5 HIV Care, Financing (Wednesday, February 24, 2016)
- P-X6 HIV and Other Sexually Transmitted Infections (Thursday, February 25, 2016)
- P-X7 Access, ART Initiation, Retention, and Outcomes in the Global South (Thursday, February 25, 2016)
- P-X8 Viral Suppression (Thursday, February 25, 2016)

Y. Population and Economic Modeling

- P-Y1 Modeling: Understanding Epidemics and ART Programs (Tuesday, February 23, 2016)
- P-Y2 Going to Scale With ART and PrEP (Wednesday, February 24, 2016)
- P-Y3 Modeling the (Cost) Efficiency of Testing and Prevention (Wednesday, February 24, 2016)

POSTER LISTINGS

TUESDAY, FEBRUARY 23, 2016

Session P-A1 Poster Abstracts

2:45 PM-4:00 PM

Viral Transmission and Target Cells

Hall A/B

- 182 Identification of MDM2/HDM2 as a Positive Regulator of HIV-1 in Human Macrophages**
Yann Breton; Alexandre Deshieres; Michel Ouellet; Michel J. Tremblay
Univ Laval - Cntr de Recherche du CHU de Québec, Québec, QC, Canada
- 183 HIV-1 Induces p21-Mediated Cellular Senescence in Human Primary Macrophages**
Eva Riveira-Muñoz¹; Roger Badia¹; Maria Pujantell¹; Bonaventura Clotet²; Ester Ballana³; José A. Esté¹
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain
- 184 HIV-1 Attached to Monocytes, but Not Lymphocytes, Transmits Infection to Human Tissue**
Victor Barreto-de-Souza; Christophe Vanpouille; Leonid Margolis
Eunice Kennedy Shriver NICHHD, Bethesda, MD, USA
- 185 Essential Role for Vpr in Productive Infection of Dendritic Cells by HIV-1**
Caitlin Miller; Hisashi Akiyama; Luis Agosto; Andrew Henderson; Rahm Gummuluru
Boston Univ Sch of Med, Boston, MA, USA
- 186 Cell Membrane Binding Determines Ability of bNAb to Prevent HIV Cell-to-Cell Transfer**
Hisashi Akiyama¹; Oscar Gonzalez²; Nora G. Ramirez³; Manish Sagar²; Rahm Gummuluru¹
¹Boston Univ Sch of Med, Boston, MA, USA; ²Boston Univ, Boston, MA, USA
- 187 Enhanced Replication of Transmitted/Founder HIV-1 in Gut CD4 T Cells**
Eric L. Lee¹; Kejun Guo¹; Michael S. Harper²; Stephanie M. Dillon¹; Martin D. McCarter¹; Brad J. Barrett¹; Shilpa Iyer²; Beatrice Hahn³; Cara Wilson³; Mario L. Santiago¹
¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ²Univ of Pennsylvania, Philadelphia, PA, USA; ³Univ of Colorado Hosp, Aurora, Aurora, CO, USA
- 188 Human Th17 Cells Are Highly Permissive to Productive HIV Infection**
Aaron Christensen-Quick¹; Mark Lafferty²; Lingling Sun²; Anthony DeVico³; Alfredo Garzino-Demo²
¹Univ of California San Diego, San Diego, CA, USA; ²Inst of Human Virology, Baltimore, MD, USA
- 189 Spread of HIV-1 Is Delayed in T-Cells in the Absence of Integrin LFA-1**
 Anika Hain; Renem. Linka; Arndt Borkhardt; Dieter Häussinger;
Carsten Münk
Heinrich-Heine-Univ Düsseldorf, Düsseldorf, Germany

Session P-B1 Poster Abstracts

2:45 PM-4:00 PM

Detection and Spread of Genetically Diverse HIV

Hall A/B

- 210 Phylogenetic Analysis of HIV Full Genomes in London, UK: Initial Results From ICONIC**
Gonzalo Yebra¹; Dan Frampton²; Tiziano Gallo Cassarino²; Zisis Kozlakidis³; Paul Kellam³; Andrew Leigh Brown¹
¹Univ of Edinburgh, Edinburgh, UK; ²Univ Coll London, London, UK; ³Wellcome Trust Sanger Inst, Hinxton, UK
- 211 Comparing Three HIV-1 Subtyping Tools and a Novel Phylogenetic-Based Method**
William Switzer¹; Neeraja Saduvala²; Tianchi Zhang³; Angela L. Hernandez²; Pieter Libin³; Daniel Struck⁴; Tulio de Oliveira⁵; Anne-Mieke Vandamme⁶; Joel O. Wertheim⁷; Alexandra M. Oster¹
¹CDC, Atlanta, GA, USA; ²ICF Intl, Atlanta, GA, USA; ³Vrije Universiteit Brussel, Brussels, Belgium; ⁴Luxembourg Inst of Hlth, Luxembourg, Luxembourg; ⁵Univ of KwaZulu-Natal, Durban, South Africa; ⁶Katholieke Universiteit Leuven, Leuven, Belgium; ⁷Univ of California San Diego, San Diego, CA, USA
- 212 Identification of Rare HIV-1 Group N and HTLV-3 Strains in Rural South Cameroon**
Ana S. Vallari¹; Mary A. Rodgers¹; Vera Holzmayer¹; Julie Yamaguchi¹; Jules Kenneqne²; Bih Awazi²; Lazare Kaptue³; Dora Mbanya²; Gavin A. Cloherty⁴; Nicaise Ndembi¹
¹Abbott Lab, Abbott Park, IL, USA; ²Univ of Yaoundé, Yaoundé, Cameroon; ³Univ of Montagnes, Bangangte, Cameroon; ⁴Inst of Human Virology, Abuja, Nigeria
- 213 Complete Genomes Reveal Complex HIV-1 Diversity in the Democratic Republic of Congo**
Mary A. Rodgers¹; Ana S. Vallari¹; Barbara Harris¹; Carole McArthur²; Larry Shrestley³; Catherine Brennan¹
¹Abbott Lab, Abbott Park, IL, USA; ²Univ of Missouri-Kansas City, Kansas City, MO, USA; ³Presbyterian Church (USA), Kinshasa, Democratic Republic of Congo, Louisville, KY, USA
- 214 HIV-2 Group A in France Displayed 2 Clades With Distinct Geographical Origins**
Benoit Visseaux¹; Charlotte Charpentier¹; Mélanie Bertine¹; Amel Bessegir²; Catherine Fagard³; Florence Damond⁴; Sophie Matheron⁴; Stephane Hue⁵; Diane Descamps⁶; for the ANRS C05 HIV-2 cohort
¹INSERM UMR 1137, Paris, France; ²Univ de Bordeaux, Bordeaux, France; ³CMG-EC INSERM U897, Bordeaux, France; ⁴Hosp Bichat-Claude Bernard, Paris, France; ⁵London Sch of Hygiene & Trop Med, London, UK

Session P-C1 Poster Abstracts

2:45 PM-4:00 PM

HIV and Intestinal Integrity

Hall A/B

233 Gut Integrity, CD4 T Follicular Helper Cells, and IgA+ B Cells in GALT Following ART

John J. Zaunders¹; Gerald Mak²; Michelle Bailey²; Nabila Seddiki³; Yin Xu⁴; David Cooper²; Mark Boyd²; Anthony Kelleher²; Mark Danta⁴; Kersten K. Koelsch⁵

¹St Vincent's Hosp, Darlinghurst, Australia; ²Univ of New South Wales, Sydney, Australia; ³Universite Paris Est Creteil, Creteil, France; ⁴Kirby Inst, Sydney, Australia; ⁵Kirby Inst, Univ of New South Wales, Sydney, Australia; ⁶St Vincent's Clinical Sch, Univ of New South Wales, Sydney, Australia

234 Microbial Translocation and Inflammation Responses to Lubiprostone in HIV Infection

Gregory D. Huhn¹; Anna L. Hotton²; Andrew G. Sigman¹; Sheila M. Keating³

¹Ruth M. Rothstein CORE Cntr, Chicago, IL, USA; ²John H. Stroger Jr Hosp of Cook County, Chicago, IL, USA; ³Blood Systems Rsr Inst, San Francisco, CA, USA

235 AZO May Contribute to Recovery of Intestinal Epithelial Function in Treated HIV

Avantika Chitre; Ma Somsouk; Peter W. Hunt; Charlie C. Kim; Joseph M. McCune

Univ of California San Francisco, San Francisco, CA, USA

236 Compartment-Specific Alterations of the Intestinal ILC Pool in HIV(+) Patients

Benjamin Krämer¹; Philipp Lutz²; Felix Goeser³; Andreas Glässer⁴; Jürgen K. Rockstroh⁵; Christoph Boesecke⁶; Ulrich Spengler¹; Jacob Nattermann¹

¹Univ of Bonn, Bonn, Germany; ²Medizinische Universitätsklinik, Bonn, Germany; ³Univ Hosp Bonn, Bonn, Germany

237 IL-33/ST2 Axis as an Inflammatory and Gut Damage Marker in Primary HIV Infection

Vikram Mehraj¹; Mohammad-Ali Jenabian²; Wei Cao³; Rosalie Ponte⁴; Bertrand Lebouché⁵; Réjean Thomas⁶; Jean-Guy Baril⁷; Roger LeBlanc⁸; Cécile Tremblay⁹; Jean-Pierre Routy¹

¹Rsr Inst of the McGill Univ Hlth Cntr, Montreal, QC, Canada; ²Univ du Québec à Montréal, Montreal, QC, Canada; ³Rsr Inst of the McGill Univ Hlth Cntr, Montréal, QC, Canada; ⁴McGill Univ Hlth Cntr, Montreal, QC, Canada; ⁵Clinique Médicale l'Actuel, Montreal, QC, Canada; ⁶Clinique Médicale Quartier Latin, Montreal, QC, Canada; ⁷Clinique Médicale OPU, Montreal, QC, Canada; ⁸CRCHUM, Montreal, QC, Canada

238 Probiotics Module Th1/Th17 and IFN Response in HIV Patients on Suppressive cART

Ivan Schietroma¹; Noemi Giustini¹; Sara Serafino¹; Gabriella De Girolamo¹; Mauro Andreotti²; Carolina Scagnolari¹; Giancarlo Ceccarelli¹; Gabriella D'Ettore¹; Vincenzo Vullo¹; for the Carla Selvaggi, Giuseppe Corano, Andrea Mastrangelo, Gianfranco Fanello, Fausto Fiocca, Marileda Indinnimeo

¹Sapienza Univ of Rome, Rome, Italy; ²Inst Superiore di Sanità, Rome, Italy

239 Cenicriviroc Decreases sCD14 and LBP Levels Without Affecting Gut Permeability

Netanya S. Utay¹; Anoma Somasunderam¹; Maitreyee Nigalye¹; Will Chang²; Star Seyedkazemi²; Eric Lefebvre²

¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA; ²Tobira Therapeutics, Inc, San Francisco, CA, USA

Session P-C2 Poster Abstracts

2:45 PM-4:00 PM

HIV Effects on CD4+ T Cells

Hall A/B

240 In Vivo Evidence for a Role of Pyroptosis in HIV Pathogenesis

Gilad Doitsh¹; Stefanie Sowinski¹; Caroline Miller¹; Warner C. Greene¹; Gladstone Insts, San Francisco, CA, USA

241 Caspase Inhibition Prevents HIV Replication and Cell Death in Human Lymphoid Tissue

Elisabet Gómez-Mora¹; Elisabet Garcia¹; Peter Wienberg Ludwig²; Maria Dolores Guerrero Gilbert³; Bonaventura Clotet⁴; Julià Blanco⁵; Cecilia Cabrera⁶

¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Hosp Sant Joan de Déu, Barcelona, Spain; ³Hosp Universitari Germans Trias i Pujol, Badalona, Spain; ⁴Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain; ⁵Univ de Vic, Barcelona, Spain; ⁶IrsiCaixa Inst for AIDS Rsr, Barcelona, Spain

242 Follicular Regulatory T Cells Are Highly Permissive to HIV-1 Ex Vivo

Shannon Miller¹; Elizabeth Connick¹; Univ of Colorado, Denver, CO, USA

243 Dead Cells Tell No Tales: The Enigma of Discerning HIV-Infected Cell Death

Nathan Cummins¹; Sekar Natesampillai¹; Michele Smart¹; Scott H. Kaufmann¹; Andrew D. Badley¹; Mayo Clinic, Rochester, MN, USA

244 Multidimensional Profiling of HIV-Infected Human CD4 T Memory Stem Cells

Lara Manganaro¹; Jeffrey Johnson²; Ekta Sharma¹; Patrick Hong¹; Benhur Lee¹; Nevan Krogan²; Viviana A. Simon¹

¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of California Los Angeles, Los Angeles, CA, USA

245LB Single Cell Transcriptome Sequencing of Human Lymph Node HIV-Infected CD4 Cells

Joseph P. Casazza¹; Eli Boritz²; David Ambrozak²; Amy R. Henry¹; Sam W. Darko³; Costantinos Petrovas²; Rebecca M. Lynch¹; Gustavo Reyes Teran¹; Daniel C. Douek¹; Richard A. Koup¹

¹VRCA, NIAID, NIH, Bethesda, MD, USA; ²NIH, Bethesda, MD, USA; ³Natl Inst of Respiratory Diseases, Mexico City, Mexico

Session P-C3 Poster Abstracts

2:45 PM-4:00 PM

Genetics and Cell Biology of HIV Infection

Hall A/B

246 **BST-2, TRIM22, and RAD51 in Host Susceptibility to HIV-1 Infection and Virus Control**

Ravesh Singh¹; Vivek Naranbhai¹; Lise Jamieson²; Nigel Garrett²; Salim A. Karim³; Thumbi P. Ndungu³
¹HIV Pathogenesis Prog, Univ of Kwa-Zulu Natal, Durban, South Africa; ²CAPRISA, Univ of KwaZulu-Natal, Durban, South Africa; ³Univ of KwaZulu-Natal, Durban, South Africa

247 **6-Amino-Acid Insertion/Deletion Polymorphism in TIM1 Confers Protections Against HIV1**

Irma Saulle¹; Michela Masetti²; Mara Biasini³; Daria Trabattini²; Manuela Sironi³; Christian Brander⁴; Francesca Vichi⁵; Sergio Lo Caputo⁶; Mario Clerici⁷; Wbeimar Aguilar-Jiménez⁸
¹Univ of Milan, Brescia, Italy; ²Univ of Milan, Milan, Italy; ³Scientific Inst for Recovery and Care E. Medea, Milan, Italy; ⁴IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ⁵S. Maria Annunziata Hosp, Florence, Italy; ⁶Univ of Antioquia, Medellin, Colombia

248 **MicroRNA Profile in CD8 T Cells From HIV-Infected Individuals and Disease Progression**

Montserrat Plana¹; Lander Egaña-Gorroño¹; Alberto C. Guardo¹; Manel Enric Bargalló¹; Elisenda Vilaplana²; Tuixent Escrivà³; Iñaki Perez⁴; Josep Maria Gatell⁵; Felipe García⁶; Mireia Arnedo⁶; for the HIV Controllers Consortium of the AIDS Spanish Network
¹IDIBAPS, Barcelona, Spain; ²Univ de Vic, Barcelona, Spain; ³Fundació Clinic, Barcelona, Spain; ⁴Hosp Clinic de Barcelona, Barcelona, Spain

249 **P2X7 Purinergic Receptors Are Required for HIV-1 Infection and Inflammation**

Talia Swartz; Meagan K. O'Brien; Natasha D. Durham; Anthony M. Esposito; Nina Bhardwaj; Benjamin K. Chen
 Icahn Sch of Med at Mount Sinai, New York, NY, USA

250 **Characterization of Plasma Exosome Protein Cargo in HIV Patients on ART**

Sukrutha Chettimada; Lorenz David; Vikas Misra; Dana Gabuzda
 Dana-Farber Cancer Inst, Boston, MA, USA

251 **A Model of CD4 TCM Cell Death in HIV Infection Based on a Gene Expression Signature**

Gustavo Olvera-García¹; Tania Aguilar-García¹; Ivan Imaz-Rosshandler²; Claudia Rangel-Escareño³; Lorena Orozco³; Irma Aguilar-Delfin³; Joel Vázquez-Pérez³; Joaquín Zúñiga¹; Santiago Pérez-Partridge⁴; Enrique Espinosa¹
¹Natl Inst of Respiratory Diseases, Mexico City, Mexico; ²Natl Inst of Genomic Med, Mexico City, Mexico; ³Natl Inst of Nutrition, Mexico City, Mexico

Session P-C4 Poster Abstracts

2:45 PM-4:00 PM

Immunopathogenesis

Hall A/B

252 **IL-7 Responsiveness Is Impaired in CD4 T Cells From HIV Immune Failure Patients**

Thao Nguyen; Michael M. Lederman; Scott M. Sieg
 Case Western Reserve Univ, Cleveland, OH, USA

253 **Does Reduced HLA-I Downregulation by HIV-2 Nef Contribute to Functional Cure?**

Sophie M. Andrews¹; Chisato Yamada²; Simon Brackenridge¹; Thushan de Silva³; Tao Dong³; Sarah L. Rowland-Jones¹
¹Univ of Oxford, Oxford, UK; ²Hokkaido Univ, Sapporo, Japan; ³Univ of Sheffield, Sheffield, UK

254 **Selective Loss of T-bet and Eomes in HIV-Specific CD4+ T Cells During HIV Infection**

Marcus Buggert¹; Marianne Jansson²; Korey Demers³; Johanna Tauriainen⁴; Anders Sonnerborg⁵; Michael A. Eller⁶; Merlin L. Robb⁷; Steven G. Deeks⁸; Annika Karlsson⁹; Michael R. Betts¹
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Lund Univ, Lund, Sweden; ³Karolinska Inst, Stockholm, Sweden; ⁴US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ⁵San Francisco General Hosp, San Francisco, CA, USA

255 **Antioxidants Improve Lung Immunity and T-Cell Proliferation in Immune Non-Responders**

Sushma K. Cribbs¹; Lou Ann Brown¹; Mirko Paiardini²; Colleen Kraft³; David Rimland⁴; Jeffrey L. Lennox⁵; Vincent C. Marconi⁶; David Guidot¹
¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA

256 **The Effect of KIR-Mediated Immunity on HIV Clinical Outcome in South Africa**

Masahiko Mori¹; Ellen M. Leitman¹; Bruce D. Walker²; Thumbi P. Ndungu³; Philip Goulder¹
¹Univ of Oxford, Oxford, UK; ²Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA; ³Univ of KwaZulu-Natal, Durban, South Africa

257 **Immunomodulatory Effects of Recreational Marijuana Use in Youth Living With HIV-1**

Ashok Dinasarapu¹; **Carla Mavian**²; Alberto Riva³; Sofia Appelberg⁴; Julie Williams⁵; John Sleasman⁶; Maureen Goodenow²
¹Emory Univ, Atlanta, GA, USA; ²Univ of Florida, Gainesville, FL, USA; ³Karolinska Inst, Stockholm, Sweden; ⁴Duke Univ Sch of Med, Durham, NC, USA

258LB **T Regulatory Cell Depletion in Controller Macaques Reactivates SIV and Boosts CTLs**

Cristian Apetrei; Egidio Brocca-Cofano; Jennifer L. Stock; Benjamin B. Policchio; He Tianyu; Kevin D. Raetz; Culling Xu; Ivona Pandrea
 Univ of Pittsburgh, Pittsburgh, PA, USA

259LB **Increased Effector CD8 Lymphocyte Trafficking to Lymph Nodes Induced by hetTL-15**

George N. Pavlakis¹; Antonio Valentin¹; Cristina K. Bergamaschi¹; Dionysios K. Watson²; Costantinos Petrovas³; Xintao K. Hu⁴; James I. Mullins⁵; Barbara K. Felber⁶
¹NCI at Frederick, Frederick, MD, USA; ²NIH, Bethesda, MD, USA; ³Univ of Washington, Seattle, WA, USA; ⁴NCI, Rockville, MD, USA

Session P-E1 Poster Abstracts

2:45 PM-4:00 PM

Antibody Responses to HIV Infection: What Drives Them and How They Affect the Virus

Hall A/B

- 301 Oral PrEP Enhances Genital HIV-Neutralizing IgA in HIV-1 Exposed Seronegative Women**
Jennifer M. Lund¹; Kristina Broliden²; Maria N. Pyra³; Katherine K. Thomas⁴; Deborah Donnell⁵; Elizabeth Irungu⁶; Timothy R. Muwonge⁶; Nelly R. Mugo⁷; Jared M. Baeten⁸; **Jairam R. Lingappa¹**
¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ²Karolinska Univ, Stockholm, Sweden; ³Univ of Washington, Seattle, WA, USA; ⁴SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁵Kenya Med Rsr Inst, Thika, Kenya; ⁶Makerere Univ Coll of Hlth Scis, Kampala, Uganda
- 302 Potent Broadly Neutralising Antibody Responses in Slow-Progressing Pediatric HIV**
Emily Adland¹; Maximilian Muenchhoff²; Anna Csala³; Thumbi P. Ndungu⁴; Pieter Jooste⁵; Owen Karimanzira⁶; Carol Crowther⁷; Penny Moore⁸; Lynn Morris⁹; Philip Goulder¹⁰
¹Univ of Oxford, Oxford, UK; ²Univ of KwaZulu-Natal, Durban, South Africa; ³Kimberley Hosp, Kimberley, South Africa; ⁴NCID, Johannesburg, South Africa
- 303 Broadly Reactive Neutralizing Activity Within the First Six Months of HIV-1 Infection**
Amanda Fabra Garcia¹; Nuria Gonzalez²; Alberto Merino-Mansilla³; Juan Ambrosioni⁴; Anke Schultz⁵; Jose M. Gatell⁶; José Alcamí⁷; José M. Miro⁸; Eloisa Yuste⁹; Victor Sanchez-Merino³
¹IDIBAPS, Barcelona, Spain; ²Inst de Salud Carlos III, Madrid, Spain; ³Inst d Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ⁴Hosp Clinic-IDIBAPS, Univ de Barcelona, Barcelona, Spain; ⁵Fraunhofer Inst for Biomed Engineering, St Ingbert, Germany; ⁶Hosp Clinic of Barcelona, Barcelona, Spain
- 304 New Family of Neutralizing Antibodies in HIV Asymptomatic Long-Term Nonprogressors**
Patrice Debre¹; Vincent Vieillard²; Olivier Lucar³; Bin Su⁴; Valérie Potard⁵; Assia Samir⁶; Christiane Moog⁷; for the ANRS C015 ALT Study Ggroup
¹INSERM, Paris, France; ²INSERM U1135, Paris, France; ³INSERM UMR S-1109, Strasbourg, France; ⁴INSERM UMR-S 1136, Paris, France
- 305 WITHDRAWN**
- 306 Neutralization Differences Between CCR5 and CXCR4 Tropic Viruses in HIV-1B Infection**
Ludy Registre¹; Manish Sagar
Boston Univ, Boston, MA, USA
- 307 Humoral Immune Pressure Selects for HIV-1 CXCR4-Using Variants**
Nina Lin¹; Oscar Gonzalez²; Carlos Becerril³; Behzad Etemad⁴; Hong Lu⁵; Xueling Wu⁶; Shahin Lockman⁷; M. Essex⁸; Daniel Kuritzkes⁹; **Manish Sagar¹**
¹Boston Univ, Boston, MA, USA; ²Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ³Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Harvard Med Sch, Boston, MA, USA

308 Systematic Analysis of Glycan Heterogeneity Guides Rational Design of HIV ImmunogensWen-Han Yu; Monia Draghi; Claudia Arevalo; Peng Zhao; Douglas Lauffenburger; Lance Wells; Galit Alter
Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA**309LB Optimal Combinations of bnAbs for Prevention and Treatment of HIV-1 Clade C Infection****Michael Seaman¹**; Kshitij Wagh²; Tanmoy Bhattacharya Bhattacharya²; Carolyn Williamson³; Alex Robles⁴; Madeleine Bayne⁴; Jetta Garrity⁵; Michael Rist⁶; David Montefiori⁷; Bette Korber⁸
¹Harvard Med School, Boston, MA, USA; ²Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA; ³Univ of Cape Town and National Hlth Laboratory Service, Cape Town, South Africa; ⁴Beth Israel Deaconess Med Cntr, Boston, MA, USA; ⁵Duke Univ, Durham, NC, USA
310LB Informatics-Based Improvement of HIV-1 Neutralizing Antibody 10E8**Peter D. Kwong¹**; Young D. Kwon²; Gwo-Yu Chuang³; Baoshan Zhang⁴; Tatyana Gindin⁵; Krisha McKee⁶; Sijy O'Dell⁷; Mark Connors⁸; Lawrence Shapiro⁹; John R. Mascola¹⁰
¹Vaccine Rsr Cntr, NIAID/NIH, Bethesda, MD, USA; ²Vaccine Rsr Cntr, NIAID, NIH, Bethesda, MD, USA; ³Columbia Univ, New York, NY, USA; ⁴NIAID, NIH, Bethesda, MD, USA; ⁵VRC, NIAID, NIH, Bethesda, MD, USA
311LB Effect of Infusion of Broadly Neutralizing Antibody VRC01 on HIV Plasma ReboundTae-Wook Chun¹; Michael Sneller²; Catherine Seamon³; Jesse S. Justement⁴; Mary E. Petrone⁵; Eric Refsland⁶; Julie Ledgerwood⁷; **Katherine Clarridge¹**; Susan Moir⁸; Anthony S. Fauci⁹
¹NIAID, NIH, Bethesda, MD, USA; ²NIH, Bethesda, MD, USA; ³VRC, NIAID, NIH, Bethesda, MD, USA

Session P-E2 Poster Abstracts

2:45 PM-4:00 PM

Cellular Immunity: Change to Cytotoxic T Lymphocyte and NK Cells

Hall A/B

312 CD8 T Cells From HIV Controllers Recognize and Kill HIV+ Non-Activated CD4 T Cells**Blandine Monel¹**; Julie Boucau²; Yovana Pacheco³; Annmarie McKeon⁴; Daniel Kavanagh⁵; Sylvie Le Gall⁶; Bruce D. Walker⁷
¹Howard Hughes Med Inst/Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA; ²Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA
313 HIV-1-Specific CD8 T Cells Are Poorly Cross-Reactive During Acute Infection**Yimin Du¹**; Anju Bansal²; Jonathan Carlson³; Jesus Salazar-Gonzalez⁴; Kristin Ladell⁵; Stephanie Gras⁶; Sonya L. Heath⁷; David Price⁸; Jamie Rossjohn⁹; Paul A. Goepfert¹
¹Univ of Alabama at Birmingham, Birmingham, AL, USA; ²Microsoft Rsr, Redmond, WA, USA; ³Cardiff Univ, Cardiff, UK; ⁴Monash Univ, Clayton, Australia; ⁵NIH, Bethesda, MD, USA

314 Deleterious Effect of KIR-HLA-Associated Gag Sites on Clinical Outcome in CRF01_AE

Masahiko Mori¹; Nuanjun Wichukhinda²; Reiko Miyahara³; Archawan Rojanawiwat⁴; Panita Pathipvanich⁵; Toshiyuki Miura⁶; Michio Yasunami⁷; Koya Ariyoshi⁸; Pathom Sawanpanyalert⁹

¹Univ of Oxford, Oxford, UK; ²Ministry of PH, Nonthaburi, Thailand; ³Inst of Trop Med, Nagasaki Univ, Nagasaki, Japan; ⁴Lampang Hosp, Lampang, Thailand

315 Blockade of KIR2DL1/3 Significantly Improves the Anti-HIV-1 Activity of KIR+ NK Cells

Christian Körner¹; Camille R. Simoneau²; Mitchell E. Granoff³; Björn Corleis⁴; Eileen P. Scully⁵; Douglas S. Kwon⁶; Stephanie Jost⁷; Marcus Altfeld¹

¹Heinrich Pette Inst, Hamburg, Germany; ²Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ³Massachusetts General Hosp, Boston, MA, USA

316 IFN- α Augments NK-Mediated ADCC Lysis via VRC01 or HIV-1 Infected Subject Plasma

Costin Tomescu¹; Brian Ross²; Pablo Tebas³; Luis J. Montaner¹

¹The Wistar Inst, Philadelphia, PA, USA; ²Univ of Pennsylvania, Philadelphia, PA, USA

Session P-F1 Poster Abstracts

2:45 PM-4:00 PM

Novel HIV Reservoirs

Hall A/B

330 Persistence of HIV-Infected Alveolar Macrophages After Suppressive ART

Feiyu Hong; Heather M. Michael; Shulin M. Qin; Lawrence Kingsley; Deborah McMahon; Meghan E. Fitzpatrick; Alison Morris; John W. Mellors

Univ of Pittsburgh, Pittsburgh, PA, USA

331 Evidence of HIV Evolution in Lymphatic and Cancer Tissues in ART+ Patients

Rebecca Rose¹; Susanna L. Lamers²; David J. Nolan³; Debra L. Garcia⁴; Marco Salemi⁵; Ekaterina Maidji⁶; Cheryl Stoddart⁷; Elyse Singer⁸; **Michael S. McGrath**¹

¹Bioinformatics, LLC, Thibodaux, LA, USA; ²Emerging Pathogens Inst, Univ of Florida, Gainesville, FL, USA; ³AIDS and Cancer Specimen Resource, San Francisco, CA, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Natl Neurological AIDS Bank, Los Angeles, CA, USA

332 Role of Transitional-Memory T Cells in Productive HIV Reservoir in ULTRASTOP Patients

Chiraz Hamimi¹; Sidonie Lambert²; Ruxandra Calin³; Guislaine Carcelain⁴; Yasmine Dudoit⁵; Lambert Assoumou⁶; Vincent Calvez⁷; Dominique Costagliola⁸; Christine Katlama⁹; Brigitte Autran¹

¹INSERM, UMR-S 1135, Paris, France; ²Sorbonne Univ, Paris, France; ³APHU, Pitié-Salpêtrière Univ Hosp, Paris, France

333 Drug Activity in PrEP Breakthroughs Has a Transient Effect on SHIV DNA Reservoirs

Mian-er Cong; Chou-Pong Pau; Walid Heneine; **Gerardo Garcia-Lerma**

CDC, Atlanta, GA, USA

334 Germinal Centre T and B Cells in Lymph Node Fine-Needle Biopsies During HIV Infection

John J. Zaunders¹; William Hey-Cunningham²; Yin Xu³; Chester Pearson⁴; Michelle Bailey⁵; Brad Milner⁶; Andrew Field⁷; David Cooper⁸; Anthony Kelleher⁹; Kersten K. Koelsch¹

¹St Vincent's Hosp, Darlinghurst, Australia; ²Univ of New South Wales, Sydney, Australia; ³Kirby Inst, Sydney, Australia; ⁴Kirby Inst, Univ of New South Wales, Sydney, Australia

335 Tcm CD4 T-Cell Infection Associates With Immune Failure and HIV Persistence on ART

Vincent C. Marconi¹; Emily Ryan²; Luca Micci³; Amelie Pagliuzza⁴; Sol Aldrete⁵; Keith Delman⁶; Jacob D. Estes⁷; Nicolas Chomont⁸; Rafick Sekaly⁹; Mirko Paiardini¹

¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Yerkes Natl Primate Rsr Ctr, Emory Univ, Atlanta, GA, USA; ³Emory Univ, Atlanta, GA, USA; ⁴CRCHUM, Montreal, QC, Canada; ⁵Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA; ⁶Univ de Montréal, Montreal, QC, Canada; ⁷Case Western Reserve Univ, Cleveland, OH, USA

Session P-F2 Poster Abstracts

2:45 PM-4:00 PM

HIV Reservoir: Measurement and Mechanisms of Persistence

Hall A/B

336 Sustained HIV Release by Single Persisting CD4+ T Cells During Latency Disruption

Jason M. Hataye¹; Joseph P. Casazza²; David Ambrozak³; Eli Boritz⁴; Takuya Yamamoto⁵; Daniel C. Douek⁶; Alan S. Perelson⁷; Richard A. Koups⁸

¹NIH, Bethesda, MD, USA; ²VRC, NIAID, NIH, Bethesda, MD, USA; ³Osaka Univ, Osaka, Japan; ⁴Los Alamos Natl Lab, Los Alamos, NM, USA

337 Analysis of HIV Proviruses in Clonally Expanded Cells In Vivo

Francesco R. Simonetti¹; Jonathan Spindler²; Xiaolin Wu³; Shawn Hill⁴; Wei Shao⁵; John W. Mellors⁶; Stephen H. Hughes⁷; Mary F. Kearney⁸; Frank Maldarelli⁹; John M. Coffin¹

¹Univ of Milan, Milan, Italy; ²HIV Dynamics and Replication Prog, NCI, Frederick, MD, USA; ³Frederick Natl Lab, Frederick, MD, USA; ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA; ⁵Univ of Pittsburgh, Pittsburgh, PA, USA; ⁶NCI, Frederick, MD, USA; ⁷Tufts Univ, Boston, MA, USA

338 Viral Evolution Analysis for the Distinction of True HIV-1 Elite-Controller Patients

Maria Pernas; Concepción Casado; Isabel Olivares; Cecilio López-Galindez; for the The HIV Controllers Consortium of the AIDS Spanish Network.

Inst de Salud Carlos III, Madrid, Spain

339 Optimization of PCR Amplicons to Predict Clonality of Full-Length HIV-1 Sequences

Sarah B. Laskey¹; Katherine M. Bruner²; Robert Siliciano³

¹Johns Hopkins Univ, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Howard Hughes Med Inst, Baltimore, MD, USA

340 Clonal Expansion of Replication-Competent Proviruses Is Common in Individuals on ART

Michele D. Sobolewski¹; John K. Bui¹; Jonathan Spindler²; Andrew Musick³; Brandon Keele⁴; Wei Shao⁵; Ann Wiegand⁶; John M. Coffin⁷; Mary F. Kearney⁸; John W. Mellors⁹
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²HIV Dynamics and Replication Prog, Natl Cancer Inst, Frederick, MD, USA; ³NCI, Frederick, MD, USA; ⁴Frederick Natl Lab, Frederick, MD, USA; ⁵Leidos Biomed Rsr, Inc, Frederick, MD, USA; ⁶Tufts Univ, Boston, MA, USA

341 A Novel Assay to Quantify Replication-Competent Latent HIV-1 From rCD4+T Cells

Phalguni Gupta¹; Anwesha Sanyal¹; **Nicolas Sluis-Cremer**²; Deena Ratner³; Ming Ding⁴; Robbie B. Mailliard⁵; Charles Rinaldo⁶; Jennifer M. Zerbato⁷; Amanda Chargin⁸; Bruce K. Patterson⁹
¹Univ of Pittsburgh, Grad Sch of PH, Pittsburgh, PA, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³IncellDx, Inc, Menlo Park, CA, USA

342 Cellular HIV-1 RNA/DNA As Biomarkers of Inducible Virion Production

Anthony R. Cillo¹; Feiyu Hong¹; Angela Tsai¹; Alivelu Irrinkki²; Jasmine Kaur³; Jacob Lalezari⁴; Derek Sloan⁵; Jeffrey P. Murry⁶; John W. Mellors⁷
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Gilead Scis, Inc, Foster City, CA, USA; ³Quest Clinical Rsr, San Francisco, CA, USA

Session P-F3 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Tissue Reservoirs of HIV: Anatomic and Imaging Studies

343 FDG PET/CT Imaging of Lymph Nodes As a Measure of the HIV Reservoir in Humans

Priscilla Hsue¹; Richard Takx²; Amorina Ishai³; Irini Sereti⁴; Remi Fromentin⁵; Nicolas Chomont⁶; Sophia Hur⁷; Peter Ganz⁸; **Steven G. Deeks**⁹; Ahmed Tawakol¹⁰
¹Univ of California San Francisco, San Francisco, CA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³NIH, Bethesda, MD, USA; ⁴Univ of Montreal, Montreal, QC, Canada

344 Activation of Nasopharynx-Associated Lymphoid Tissue in HIV Infection

Danny Li¹; Richard Takx²; Amorina Ishai³; Remi Fromentin⁴; Irini Sereti⁵; Nicolas Chomont⁶; Sophia Hur⁷; Steven G. Deeks⁸; Priscilla Hsue⁹; Ahmed Tawakol¹⁰
¹Univ of California San Francisco, San Francisco, CA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³Univ of Montreal, Montreal, QC, Canada; ⁴NIH, Bethesda, MD, USA

345 HIV DNA Identified in Most Tissues of a Plasma-Negative HIV Autopsy Cohort

Susanna L. Lamers¹; Rebecca Rose²; David J. Nolan³; Debra L. Garcia⁴; Melissa Aagsalda-Garcia⁴; Bruce Shiramizu⁵; Ekaterina Maidji⁶; Cheryl Stoddart⁷; Elyse Singer⁸; Michael S. McGrath⁹
¹Bioinfoexperts, LLC, Thibodaux, LA, USA; ²Emerging Pathogens Inst, Univ of Florida, Gainesville, FL, USA; ³AIDS and Cancer Specimen Resource, San Francisco, CA, USA; ⁴Univ of Hawaii, Honolulu, HI, USA; ⁵Univ of California San Francisco, San Francisco, CA, USA; ⁶Natl Neurological AIDS Bank, Los Angeles, CA, USA

Session P-G1 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Neuroimaging: Brain Structure and Functional Response

381 Advanced MRI Predict Cognition at 1-Year Follow-up in Mildly Impaired HIV+ Patients

Cristina Graziera¹; Gaetano Perrotta²; Djalel Eddine Meskaldji³; Guillaume Bonnier⁴; Samanta Simioni⁵; Matthias Cavassini⁶; Melanie Metral⁷; Gunnar Krueger⁸; Renaud Du Pasquier⁹; for the Swiss HIV Cohort Study
¹Massachusetts General Hosp, Boston, MA, USA; ²Hosp Erasme, Univ Libre de Bruxelles, Bruxelles, Belgium; ³Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; ⁴Inst de Lavigny, Lavigny, Switzerland; ⁵Hosp Hosp Lausanne, Univ of Lausanne, Lausanne, Switzerland; ⁶CHUV, Lausanne, Switzerland; ⁷Siemens, Renens, Switzerland

382 Topographies of Cortical and Subcortical Volume Loss in HIV and Aging in the cART Era

Anika Guha¹; Matthew R. Brier²; Beau M. Ances³; Mario Ortega⁴; Elizabeth Westerhaus⁵; Brittany Nelson⁶
¹Washington Univ Sch of Med, St. Louis, MO, USA; ²Washington Univ in St. Louis, St. Louis, MO, USA

383 Meta-Analysis of Large HIV Cohort Reveals CD4 Effects on Longitudinal Brain Atrophy

Daniel Schonfeld¹; Talia M. Nir²; Christopher R. Ching³; Neda Jahanshad⁴; Jaroslav Harezlak⁵; Giovanni Schifitto⁶; Tong Zhu⁷; Ronald A. Cohen⁸; Bradford Navia⁹; Paul M. Thompson¹⁰
¹Imaging Genetics Cntr, Univ of Southern California, Marina Del Rey, CA, USA; ²Univ of California Los Angeles Sch of Med, Marina del Rey, CA, USA; ³Univ of Southern California, Los Angeles, CA, USA; ⁴Indiana Univ Fairbanks Sch of PH, Indianapolis, IN, USA; ⁵Univ of Rochester, Rochester, NY, USA; ⁶Univ of Michigan, Ann Arbor, MI, USA; ⁷Univ of Florida, Gainesville, FL, USA; ⁸Tufts Univ Sch of Med, Boston, MA, USA

384 Brain Volumetric Changes After 2 Years of ART Initiated During Acute HIV Infection

Kalpna J. Kallianpur¹; Donn Colby²; Neda Jahanshad³; James L. Fletcher⁴; Jintanat Ananworanich⁵; Katherine Clifford⁶; Khunthalee Benjapompong⁷; Collin Adams⁸; Serena S. Spudich⁹; Victor Valcour¹⁰; for the RV254/SEARCH010 Study Group
¹Univ of Hawaii, Honolulu, HI, USA; ²SEARCH, Bangkok, Thailand; ³Univ of Southern California, Los Angeles, CA, USA; ⁴Military HIV Rsr Prog, Bethesda, MD, USA; ⁵Univ of California San Francisco, San Francisco, CA, USA; ⁶Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁷Yale Univ Sch of Med, New Haven, CT, USA

385 Regionally Specific Cortical Thinning in HIV+ Patients in the cART Era

Ryan Sanford¹; Ana L. Fernandez Cruz²; Lesley K. Fellows³; Beau M. Ances⁴; Louis Collins⁵
¹McGill Univ, Montreal, QC, Canada; ²Washington Univ in St. Louis, St. Louis, MO, USA

386 NeuroHIV: A Novel High-Resolution Subcortical Shape Analysis

Christopher R. Ching¹; Talia M. Nir²; Boris A. Gutman³; Neda Jahanshad⁴; Jaroslav Harezlak⁵; Assawin Gongvatana⁶; Ronald A. Cohen⁷; Bradford Navia⁸; Paul M. Thompson⁹; for the HIV Neuroimaging Consortium

¹Univ of California Los Angeles Sch of Med, Marina del Rey, CA, USA; ²Imaging Genetics Cntr, Univ of Southern California, Marina del Rey, CA, USA; ³Imaging Genetics Cntr, Univ of Southern California, Marina del Rey, CA, USA; ⁴Univ of Southern California, Los Angeles, CA, USA; ⁵Indiana Univ Fairbanks Sch of PH, Indianapolis, IN, USA; ⁶Univ of California San Diego, San Diego, CA, USA; ⁷Univ of Florida, Gainesville, FL, USA; ⁸Tufts Univ Sch of Med, Boston, MA, USA

387 Cigarette Pack-Years May Affect Cingulate and Frontal Cortex in Chronic HIV Infection

Kalpna Kallianpur; Tracie M. Umaki; Lindsay M. Kohorn; Dominic C. Chow; Beau K. Nakamoto; Scott C. Souza; Cecilia M. Shikuma
Univ of Hawaii, Honolulu, HI, USA

388 Cardiovascular Risk Factors and the Rate of Change in Brain Structure in HIV Disease

James T. Becker¹; Mikhail Popov²; Lawrence Kingsley³; Francine Barrington⁴; Andrew J. Levine⁵; Eileen Martin⁶; Eric N. Miller⁷; Cynthia Munro⁸; Ann Ragin⁹; Ned Sacktor¹⁰; for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Univ of California Los Angeles, Los Angeles, CA, USA; ⁴Rush Univ Med Cntr, Chicago, IL, USA; ⁵Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁶Northwestern Univ, Chicago, IL, USA

389 New Method Measuring Intracranial Vessel Caliber Reveals Arterial Remodeling In HAND

Paba M. De Alwis¹; Cristah Artrip²; Winston Liu³; Bryan Smith⁴; Avindra Nath⁵; Daniel S. Reich⁶; Govind Nair⁷
¹NIH, Bethesda, MD, USA; ²Vanderbilt Univ, Nashville, TN, USA

390 Isolated Cingulate Correlates With Reduced Executive Function in HIV

Xiong Jiang¹; Many Magnus²; Chenglong Liu³; Rebecca Barasky⁴; Cuiwei Wang⁵; Michael W. Plankey⁶; Seble kassaye⁷; David J. Moore⁸; Ron Ellis⁹; Mary Young¹⁰
¹Georgetown Univ Med Cntr, Washington, DC, USA; ²George Washington Univ, Washington, DC, USA; ³Georgetown Univ, Washington, DC, USA; ⁴Univ of California San Diego, San Diego, CA, USA

391 Multifactorial Neurochemical Alterations Are Slowly Evolving Despite Viral Control

Lucette A. Cysique¹; Laurianne Juge²; Thomas M. Gates³; Kirsten Moffat⁴; Bruce J. Brew⁵; Caroline Rae⁶
¹Univ of New South Wales, Sydney, Australia; ²NeuroSci Rsr Australia (NeuRA), Randwick, Australia; ³St Vincent's Hosp, Darlinghurst, Australia

392 Effect of cART on Functional Connectivity in Cart-Naïve HIV-Infected Individuals

Yuchuan Zhuang¹; Madalina Tivarus²; Xing Qiu³; Lu Wang⁴; Emily Cosimano⁵; Alicia Tyrell⁶; Amneris Luque⁷; Mark E. Mapstone⁸; Jianhui Zhong⁹; **Giovanni Schifitto**¹
¹Univ of Rochester, Rochester, NY, USA; ²Univ of Rochester Med Cntr, Rochester, NY, USA

Session P-H1 Poster Abstracts

2:45 PM-4:00 PM

Exposure Response: Learning to Improve Safety and Efficacy

425 HIV-1 Maturation Inhibitor BMS-955176:

Pharmacokinetic and Exposure-Response Analysis

Heather Sevinsky¹; Palanikumar Ravindran²; Dirk Schuermann³; Blisse Vakkalagadda⁴; Carey Hwang⁵; Dara Hawthorne⁶; Hong Xiao⁷; Neelanjana Ray⁸; Max Lataillade⁹; Timothy Eley¹
¹Bristol-Myers Squibb, Princeton, NJ, USA; ²Charité Rsr Organisation GmbH, Berlin, Germany; ³Bristol-Myers Squibb, Wallingford, CT, USA

426 Predicting Drug Discontinuation in TDF-tolerant Patients: A Prospective PK/PG Study

Andrea Calcagno¹; Jessica Cusato²; Letizia Marinaro³; Martina Fiumano⁴; Marco Simiele⁵; Nicol Ferrara⁶; Chiara Alcantarini¹; Antonio D'Avolio⁷; Giovanni Di Perri⁸; Stefano Bonora¹
¹Univ of Torino, Torino, Italy; ²Univ of Torino, Turin, Italy

427 Random Lopinavir Concentrations Predict Resistance on Lopinavir-Based ART

Richard G. Court¹; Michelle Gordon²; Annette Stewart³; Karen Cohen⁴; Gary Maartens⁵
¹Univ of Cape Town, Cape Town, South Africa; ²Nelson R Mandela Sch of Med, Univ of Kwazulu-Natal, Durban, South Africa; ³Clinical Rsr Cntr, Univ of Cape Town, Cape Town, South Africa

428 Inflammation Investigated as a Source of Atazanavir Pharmacokinetic Variability

Charles Venuto¹; Peter W. Hunt²; Grace A. McComsey³; Gene D. Morse⁴; Susan Messing¹
¹Univ of Rochester Med Cntr, Rochester, NY, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Case Western Reserve Univ, Cleveland, OH, USA; ⁴State Univ of New York at Buffalo, Buffalo, NY, USA

429 Recommended Efavirenz Concentration for Therapeutic Drug Monitoring Is Too High

Catherine Orrell¹; **Andrzej Bienczak**²; Karen Cohen³; David R. Bangsberg⁴; Robin Wood⁵; Gary Maartens⁶; Paolo Dentì⁷
¹Univ of Cape Town, Cape Town, South Africa; ²Harvard Med Sch, Boston, MA, USA

430 Cobicistat Increases the Effects of Dabigatran on Thrombin Time in Healthy Volunteers

Kristina M. Brooks¹; Colleen Hadigan²; Lori A. Gordon³; Scott Penzak⁴; Anela Kellogg⁵; Khanh Nghiem⁶; Jay Lozier⁷; James Mikula⁸; Parag Kumar⁹
¹Clinical Pharmacokinetics Rsr Lab, Clinical Cntr, NIH, Bethesda, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³Xavier Univ of Louisiana Coll of Pharm, New Orleans, LA, USA; ⁴Univ of North Texas System Coll of Pharm, Fort Worth, TX, USA; ⁵Leidos Biomed Rsr, Inc, Bethesda, MD, USA; ⁶Clinical Cntr, NIH, Bethesda, MD, USA

431 Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With Drip Feed

Angela Colbers¹; Mieke de Hoon²; Reinout van Crevel³; Martine Kruijsen⁴; Marjolijn Duijsenberg-van Essen⁵; Evertine Abbink⁶; David M. Burger¹
¹Radboud Univ Med Cntr, Nijmegen, Netherlands; ²Elisabeth-Tweede Steden Ziekenhuis, Tilburg, Netherlands

432 Minimal Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients

José Moltó¹; Fredzzia Graterol²; Cristina Miranda¹; Ioana Bancu²; Saye Khoo³; Aliou Amara⁴; Anna Bonjoch⁵; Bonaventura Clotet¹
¹Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain; ²Hosp Universitari Germans Trias i Pujol, Badalona, Spain; ³Univ of Liverpool, Liverpool, UK

433 A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum

Stein Schalkwijk¹; Brookie M. Best²; Angela Colbers¹; Alice Stek³; Jijia Wang⁴; David Hawkins⁵; Mark Mirochnick⁶; David M. Burger⁷; for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPACT) P1026s Protocol Team, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected Pregnant Women (PANNA) Study Network
¹Radboud Univ Med Cntr, Nijmegen, Netherlands; ²Univ of California San Diego, San Diego, CA, USA; ³Univ of Southern California, Los Angeles, CA, USA; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Chelsea and Westminster Hosp NHS Fndn Trust, London, UK; ⁶Boston Univ Sch of Med, Boston, MA, USA

434 Contamination of Herbal Medicines With ARVs and Widespread Use by PLWH in Nigeria

Joshua Gini¹; Bala I. Harri²; Elkanah D. Kabilis³; Mark Stevens⁴; Paul P. Pama⁵; Aliou Amara⁶; Dilly P. Sujan⁷; Justin Chiong⁸; Saye Khoo⁹; for the Pharmacology Research Laboratories University of Liverpool
¹Univ of Liverpool, Liverpool, UK; ²Dalhatus Araf Specialist Hosp, Lafia, Nassarawa State, Lafia, Nigeria; ³Gombe State Specialist Hosp, Gombe, Nigeria; ⁴Faith Alive Fndn, Jos Plateau State, Nigeria; ⁵Fed Med Cntr Katsina, Katsina, Nigeria

435 TDF/EVG Nanoparticle Formulation: Plasma Pharmacokinetics in Humanized Mice

Christopher Destache; Subhra Mandal
 Creighton Univ, Omaha, NE, USA

436 Antiretroviral Drug Use in a Cross-sectional Population Survey in Africa: HPTN 043

Jessica M. Fogel¹; William Clarke²; Michal Kulich²; Estelle Piwowar-Manning³; Glenda Gray⁴; Linda Richter⁵; Heidi van Rooyen⁶; Thomas Coates⁷; Susan H. Eshleman⁸; for the For the HPTN 043 (NIMH Project Accept) Study Team
¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Charles Univ, Prague, Czech Republic; ³South African Med Rsr Council, Cape Town, South Africa; ⁴Univ of the Witwatersrand, Johannesburg, South Africa; ⁵Human Scis Rsr Council, Durban, South Africa; ⁶Univ of California Los Angeles, Los Angeles, CA, USA

437LB A Single Monotherapy Dose of MK-8591, a Novel NRTI, Suppresses HIV for 10 Days

Evan Friedman¹; Dirk Schuermann²; Deanne J. Rudd³; Sabrina Fox-Bosetti⁴; Sandra Zhang⁵; Martine Robberechts⁶; Andreas Hueser⁷; Daria J. Hazuda⁸; Marian Iwamoto⁹; Jay Grobler¹⁰; for the HIV Early Development Team
¹Merck & Co, Inc, Rahway, NJ, USA; ²Charité Rsr Organisation GmbH, Berlin, Germany; ³Merck & Co., Inc, Kenilworth, NJ, USA; ⁴Charité Universitätsmedizin Berlin, Germany, Rsr Hosp, Berlin, Germany; ⁵Merck & Co, Inc, West Point, PA, USA; ⁶Merck & Co, Inc, Kenilworth, NJ, USA

**Session P-L1 Poster Abstracts
2:45 PM-4:00 PM**

Hall A/B

HIV Drug Resistance: Surveillance and Transmission**477 HIV Pretreatment Drug Resistance in Mexico: A Nationally Representative WHO Survey**

Santiago Avila-Rios¹; Claudia García-Morales²; Daniela Tapia-Trejo³; Margarita Matias-Florentino⁴; Verónica Quiroz-Morales⁵; Jesús Casillas-Rodriguez⁶; Juan Sierra-Madero⁷; Eddie León⁸; Carlos Magis⁹; Gustavo Reyes Teran¹⁰; for the HIV Drug Resistance Mexican Network Group
¹Natl Inst of Respiratory Diseases, Mexico City, Mexico; ²Condesa Specialised Clinic, Mexico City, Mexico; ³Natl Inst of Med Scis and Nutrition Salvador Zubirán, Mexico City, Mexico; ⁴Natl Cntr for HIV/AIDS Prevention and Control, Mexico City, Mexico

478 The Dynamics of Drug Resistance Detected During Acute HIV Infection

Ruth M. Kanthula¹; Julie Weis²; Chris Warth³; Nelly R. Mugo⁴; Lisa Frenkel⁵; Connie M. Celum⁶; Julie M. Overbaugh⁷; Frederick Matsen⁸; Jared M. Baeten⁹; Dara Lehman¹⁰
¹Univ of Washington, Seattle, WA, USA; ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³Kenya Med Rsr Inst, Thika, Kenya; ⁴Seattle Children's Rsr Inst, Seattle, WA, USA

479LB HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP)

David C. Knox¹; Darrell H. Tan²; P. Richard Harrigan³; Peter L. Anderson⁴
¹Maple Leaf Med Clinic, Toronto, ON, Canada; ²St Michael's Hosp, Toronto, ON, Canada; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁴Univ of Colorado, Denver, CO, USA

480 Large Cluster Clinical Isolates Show Facilitated Escape From Integrase Inhibitors

Bluma G. Brenner¹; Maureen Oliveira²; Ruxandra Ilinca Ibanescu³; Olga Golubkov⁴; Bonnie A. Spira⁵; Mark A. Wainberg⁶
¹Lady Davis Inst, Montreal, QC, Canada; ²McGill Univ AIDS Cntr, Montreal, QC, Canada

481 An Informatics Approach to Predicting Rates of Transmitted HIV-1 Drug Resistance

Joseph M. Volpe¹; Dongmei Yang²; Suqin Cai³; Jay Timmerman⁴; Charles M. Walworth⁵; Jeannette M. Whitcomb⁶
¹Monogram BioScis, South San Francisco, CA, USA; ²LabCorp Informatics, Durham, NC, USA

482 Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART

Anna Maria Geretti¹; Ellen White²; Apostolos Beloukas³; Chloe Orkin⁴; Anna Tostevin⁵; Peter Tilston⁶; David Chadwick⁷; Caroline Sabin⁸; David Dunn⁹; for the HIV Drug Resistance Database and CHIC Study
¹Inst of Infection & Global Hlth, Univ of Liverpool, Liverpool, UK; ²Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ³Univ of Liverpool, Liverpool, UK; ⁴Barts Hlth NHS Trust, London, UK; ⁵Manchester Royal Infirmary, Manchester, UK; ⁶South Tees Hosp NHS Fndn Trust, Middlesbrough, UK; ⁷Univ Coll London, London, UK

- 483 Increasing Prevalence of Silent Mutations in HIV-1 Subtype B RT Which Alter Fitness**
Sushama Telwate¹; Chanson J. Brumme²; Anna C. Hearn³; Catherine F. Latham¹; Con Sonza³; P. Richard Harrigan¹; Gilda Tachedjian¹
¹Burnet Inst, Melbourne, Australia; ²BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ³Univ of Melbourne, Melbourne, Australia
- 484 No Effect of HIV-1 Subtype C on Virological Failure Rate With First-Line TDF Regimens**
Ellen White¹; Erasmus Smit²; Duncan Churchill³; Simon Collins⁴; Clare Booth⁵; Anna Tostevin¹; Caroline Sabin⁶; Deenan Pillay⁷; David Dunn¹; for the UK HIV drug resistance database and the UK Collaborative HIV cohort
¹Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ²Birmingham Heartlands Hosp, Birmingham, UK; ³Brighton and Sussex Hops NHS Trust, Brighton, UK; ⁴HIV i-Base, London, UK; ⁵Royal Free London NHS Fdn Trust, London, UK; ⁶Univ Coll London, London, UK; ⁷Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa
- 485 National Molecular Surveillance of Recently Acquired HIV Infections, Germany 2013-14**
 Andrea Hauser¹; Alexandra Hofmann¹; Kirsten Hanke¹; Viviane Bremer¹; Barbara Bartmeyer¹; Claudia Kucherer¹; **Norbert Banert**²
¹Robert Koch Inst, Berlin, Germany; ²Robert Koch-Inst, Berlin, Germany
- 486 Influence of Transmitted Drug Resistance on CD4 Decline Among ART-Naïve HIV Patients**
Anna Schultze¹; Carlo Torti²; Alessandro Cozzi-Lepri³; Anne-Mieke Vandamme⁴; Maurizio Zazzi⁵; Helen Sambatakou⁶; Andrea De Luca⁷; Anna Maria Geretti⁸; Anders Sonnenborg⁹; Giuseppe Lapadula¹⁰
¹Univ Coll London, London, UK; ²Univ Magna Graecia, Catanzaro, Italy; ³Katholieke Universiteit Leuven, Leuven, Belgium; ⁴Univ of Siena, Siena, Italy; ⁵Hippokratikon General Hosp, Univ of Athens, Athens, Greece; ⁶Inst of Infection & Global Hlth, Univ of Liverpool, Liverpool, UK; ⁷Karolinska Inst, Stockholm, Sweden; ⁸Infectious Diseases Clinic, San Gerardo Hosp, Monza, Italy
- 487 No Evidence of Sexual Transmission of Minority HIV Drug Resistance Mutations in MSM**
Antoine Chailion; Sanjay R. Mehta; Joel O. Wertheim; Ben Murrell; Susan J. Little; Douglas D. Richman; Davey M. Smith; Sara Gianella
 Univ of California San Diego, San Diego, CA, USA
- 488 Transmitted Drug Resistance in HIV-1 Subtype C Hyperacute Infection**
Urisha Singh¹; Avashna Singh¹; Marc Noguera-Julian²; Manjeetha Jaggerath³; Amber Moodley⁴; Krista Dong⁵; Bruce D. Walker⁶; Thumbi P. Ndungu⁷; Michelle Gordon⁸
¹Univ of KwaZulu-Natal, Durban, South Africa; ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ³Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ⁴Nelson R Mandela Sch of Med, Univ of Kwazulu-Natal, Durban, South Africa
- 489 Integrase Inhibitors-Transmitted Drug Resistance Detected by UltraDeep Sequencing**
Eve Todesco¹; Jeremy Jaffre¹; Cathia Soulie¹; Daniele Armenia²; Marc Wirden³; Sidonie Lambert¹; Christine Katlama¹; Francesca Ceccherini-Silberstein¹; Vincent Calvez¹; Anne-Genevieve Marcelin¹
¹Sorbonne Univs, Paris, France; ²Univ of Rome Tor Vergata, Rome, Italy; ³APHP, Pitie Salpêtrière Hosp, Paris, France
- 490 Linkage of Rare Drug Resistance Mutations Detected by New Ultrasensitive SGS**
Valerie F. Boltz¹; Junko Hattori¹; Wei Shao²; John M. Coffin³; Frank Maldarelli¹; Mary F. Kearney¹
¹NCI, Frederick, MD, USA; ²Leidos Biomed Rsr, Inc, Frederick, MD, USA; ³Tufts Univ, Boston, MA, USA
- 491LB Large-Scale Transmission and Clustering of HIV Protease Resistance in Ontario, Canada**
P. Richard Harrigan¹; Ashleigh B. Sullivan²; Jeffrey B. Joy¹; Kevin Gough³; Vanessa G. Allen⁴; Tony Mazzulli¹; Doug Sider⁵
¹BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ²Public Hlth Agency of Canada, Toronto, ON, Canada; ³St. Michael's Hosp/Univ of Toronto, Toronto, ON, Canada; ⁴Ontario Agency for Hlth Protection and Promotion, Toronto, ON, Canada; ⁵Public Hlth Ontario, Toronto, ON, Canada
- 492LB Prevalence and Incidence of Integrase Drug Resistance in BC, Canada, 2009–2015**
Katherine Lepik; Benita Yip; Marjorie A. Robbins; Conan K. Woods; Viviane D. Lima; Rachel A. McGovern; Wendy W Zhang; Rolando A. Barrios; Julio Montaner; P. Richard Harrigan
 BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 493LB Divergent ARV Resistance at Screening for ACTG A5288 Study of 3rd-Line ART in RLS**
Carole L. Wallis¹; Beatriz Grinsztejn²; Saran Vardhanabhuti³; Robert A. Salata⁴; Peter Mugenyi⁵; Catherine Godfrey⁶; Michael Hughes⁷; Ann Collier⁸; John W. Mellors⁹; for the A5288 Team
¹BARC-SA and Lancet Lab, Johannesburg, South Africa; ²Inst de Pesquisa Clinica Evandro Chagas (IPEC)/Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil; ³Statistical and Data Analysis Cntr, Harvard School of Public Hlth, Boston, MA, USA; ⁴Case Western Reserve Univ, Cleveland, OH, USA; ⁵Joint Clinical Rsr Cntr, Kampala, Uganda; ⁶DAIDS, NIAID, NIH, Rockville, MD, USA; ⁷Harvard Sch of PH, Boston, MA, USA; ⁸Univ of Washington, Seattle, WA, USA; ⁹Univ of Pittsburgh, Pittsburgh, PA, USA
- 494LB Prospective Randomized HIV Drug Resistance Testing of Kenyans Before First-Line ART**
 Michael H. Chung¹; Ingrid Beck²; Molly Levine³; Catherine Kiptiness⁴; James Munyao⁵; Rachel Silverman⁶; Christine McGrath⁷; Bhavna Chohan⁸; Samah Rafie Sakr⁹; **Lisa Frenkel**²
¹Univ of Washington, Seattle, WA, USA; ²Seattle Children's Rsr Inst, Seattle, WA, USA; ³Seattle Children's Rsr Inst, Seattle, United States; ⁴Coptic Hope Cntr, Nairobi, Kenya; ⁵Univ of Washington, Seattle, United States

Session P-M1 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HIV Diagnostics

510 Evaluation of an EIA-Based Testing Algorithm Using Dried Blood Spots From South Sudan

Idris Hakim¹; **Hetal Patel**¹; Yen Duong²; Joel Katoro³; Gregory Wani¹; Idris Farouk¹; Alex Bolo¹; Avi Hakim¹; Bharat Parekh²

¹Ministry of Hlth, Juba, South Sudan; ²CDC, Atlanta, GA, USA; ³CDC, Juba, South Sudan

511 Comparison of Cross-Sectional Incidence Assay Results From DBS and Plasma

Katherine Schlusser¹; Christopher Pilcher²; Esper G. Kallas³; Breno R. Santos⁴; Stephen G. Deeks⁵; Sheila M. Keating⁶; Shelley Facente⁷; Susan H. Eshleman⁸; Thomas C. Quinn⁹; Oliver Laeyendecker¹⁰; for the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Sao Paulo Med Sch, Sao Paulo, Brazil; ⁴Hosp Conceição, Porto Alegre, Brazil; ⁵San Francisco General Hosp, San Francisco, CA, USA; ⁶Blood Systems Rsr Inst, San Francisco, CA, USA; ⁷Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁸NIH, Bethesda, MD, USA

512 Laboratory Evaluation of the GeneXpert® HIV-1 Viral Load Assay in Zimbabwe

Zibusiso Ndlovu¹; Sekesai Mtapuri-Zinyowera²; Carol Metcalfe³; Emmanuel Farjado⁴; Kekeletso Kao⁵; Maryam Rumaney⁶; Daniel Orozco⁷; Elton Mbofana⁸; Helen Bygrave⁹
¹Médecins Sans Frontières, Harare, Zimbabwe; ²Natl Microbiology Reference Lab, Harare, Zimbabwe; ³Médecins Sans Frontières, Southern Africa Med Unit, Cape Town, South Africa; ⁴FIND, Geneva, Switzerland

513 Weakly Reactive HIV Rapid Diagnostic Test Kits Should Not Be Reported As Positive

Patrick Karugaba¹; Timothy Amukele²; Ali Elbireer³; Alice Nansamba⁴
¹Makerere Univ Johns Hopkins Univ Rsr Collab Lab, Kampala, Uganda; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

514 Extending HIV Avidity Recency Detection by Addition of p24Ag Detection

Gary Murphy¹; Anne Le Corfec²; Jamie Benson³; Jake Hall⁴; Alfredo Villarreal⁵; Karen Mintern⁶
¹PH England, London, UK; ²Bio-Rad Lab, Inc, La Coquette, France; ³Bio-Rad Lab, Inc, Hemel Hempstead, UK; ⁴Bio-Rad Lab, Inc, Benicia, CA, USA

515 Western Blot Index for Estimating Recency of HIV Infection

Mark Manak¹; Leigh . Eller²; Jennifer Malia³; Merlin L. Robb⁴; Sheila Peel⁵; for the Mark Manak, Ashley Shutt, Jennifer Malia, Leigh Anne Eller, Merlin Robb and Sheila Peel
¹Henry Jackson Fdn, Silver Spring, MD, USA; ²US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ³Walter Reed Army Inst of Rsr, Silver Spring, MD, USA

516 Low Prevalence of False Prior HIV Diagnoses in Chokwe District, Mozambique

Rob Nelson¹; Duncan MacKellar²; Ricardo Thompson³; Marcelo d. Manuel⁴; Juvencio Bonzela⁵; Didier Mugabe⁶; Chunfu Yang⁷; Bharat Parekh⁸; Daniel Shodell⁹; Edgar Monteroso⁹
¹CDC, Atlanta, GA, USA; ²Natl Inst of Hlth Mozambique, Maputo, Mozambique; ³Chokwê District Hosp, Chokwê, Mozambique; ⁴CITSC, Chokwê, Mozambique; ⁵Colorado Dept of PH and Environment, Denver, CO, USA; ⁶CDC, Maputo, Mozambique

517 HIV Incidence Assay Performance Required to Monitor Prevention Intervention Impact

Neil T. Parkin¹; Stefano Ongarello²; Jennifer Osborn³; Eduard Grebe⁴; Simon Daniel⁵; Alex Welte⁶; Christine Rousseau⁷; Reshma Kassarjee⁸; Peter Dailey⁹
¹FIND, Belmont, CA, USA; ²FIND, Geneva, Switzerland; ³SACEMA,

Stellenbosch, South Africa; ⁴Bill and Melinda Gates Fdn, Seattle, WA, USA; ⁵Univ of Cape Town and Stellenbosch Univ, Cape Town, South Africa

518 Acute Retroviral Syndrome: Useful for Guiding Testing for Acute HIV Infection?

Martin Hoeniig; Nella Green; Sanjay R. Mehta; Martha Camacho; Sara Gianella; Davey M. Smith; Susan J. Little
 Univ of California San Diego, San Diego, CA, USA

519 Comparative Sensitivity of 8 HIV Rapid Tests in HIV-Positive Patients

Heinrich Scheiblaue¹; Siri Göpel²; Tanja Westenberger¹; **Christoph Stephan**²
¹Paul-Ehrlich-Inst, Langen, Germany; ²Goethe Univ Hosp Frankfurt, Frankfurt, Germany

520 Comparison of Methods for HIV Incidence Estimation in a Cohort With Subtype C HIV

Allison R. Kirkpatrick¹; Charles Morrison²; Tsungai Chipato³; Katherine Schlusser⁴; Pai-Lien Chen⁵; Marshall Munjoma⁶; Thomas C. Quinn⁷; Susan H. Eshleman⁸; Oliver Laeyendecker⁹
¹NIAD, NIH, Baltimore, MD, USA; ²FHI 360, Durham, NC, USA; ³Univ of Zimbabwe, Harare, Zimbabwe; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Univ of California San Francisco Prog, Univ of Zimbabwe, Belgravia, Zimbabwe; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁷NIH, Bethesda, MD, USA

Session P-N1 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HCV Staging: Stiffen Up!

527 Prognostic Value of Transient Elastography and FIB-4 in HIV/HCV Coinfection

Cristina Diez¹; **Juan Berenguer**²; Rivero-Juárez Antonio³; Víctor Hontañón⁴; Leire Pérez-Latorre⁵; Francisca Cuenca⁶; Luz Martín-Carbonero⁷; Antonio Rivero⁸; José M. Bellón⁹; Juan González-García⁴
¹Hosp General Universitario Gregorio Marañón, Madrid, Spain; ²Hosp Universitario Reina Sofía, Córdoba, Spain; ³Hosp Universitario La Paz, Madrid, Spain; ⁴Inst for Hlth Rsr of La Paz Univ Hosp, Madrid, Spain

528 Variation in Liver Fibrosis Staging Using FibroTest, FIB-4, and APRI Scores

Aurielle Thomas¹; Charisse Ahmed²; Chloe Gross³; Rachel Silk⁴; Elizabeth Akoth⁵; Eleanor M. Wilson⁶; Angie Price⁷; Shyam Kottitil⁸; Henry Masuru⁹; Sarah Kattakuzhy⁹
¹NIH Clinical Cntr, Bethesda, MD, USA; ²NIH Clinical Cntr, Bethesda, MD, USA; ³Inst of Human Virology, Bethesda, MD, USA; ⁴Inst of Human Virology, Baltimore, MD, USA; ⁵Univ of Maryland Med Cntr, Baltimore, MD, USA; ⁶NIH, Bethesda, MD, USA

529 New Predictive Index Based on the Combination of Liver Stiffness and CTP

Nicolás Merchante¹; Antonio Rivero-Juárez²; Francisco Téllez²; Dolores Merino³; María José Ríos⁴; Guillermo Ojeda-Burgos⁵; Mohamed Omar Mohamed-Balghata⁶; Patricia Monje-Agudo⁷; Montserrat Pérez-Pérez⁸; Juan A. Pineda⁹; for the HEPAVIR-cirrhosis study group
¹Hosp Universitario de Valme, Sevilla, Spain; ²IMBIC, Córdoba, Spain; ³Hosp La Línea de la Concepción (AGS Campo de Gibraltar), La Línea de la Concepción, Spain; ⁴Complejo Hospario de Huelva, Huelva, Spain; ⁵Hosp Universitario Virgen de la Macarena, Seville, Spain; ⁶Hosp Universitario Virgen de la Victoria, Málaga, Spain; ⁷Complejo Hospario de Jaén, Jaén, Spain; ⁸Hosp de La Línea de la Concepción, Cádiz, Spain

- 530 Liver Stiffness Predicts Variceal Bleeding in HIV/HCV-Coinfected Patients**
Nicolás Merchante¹; Antonio Rivero-Juárez²; Francisco Téllez²; Dolores Merino³; María José Ríos⁴; Guillermo Ojeda-Burgos⁵; Mohamed Omar Mohamed-Balghata⁶; Juan Macías⁷; Antonio Rivero⁸; Juan A. Pineda⁹; for the HEPAVIR-cirrhosis study group
¹Hosp Universitario de Valme, Sevilla, Spain; ²IMIBIC, Córdoba, Spain; ³Hosp La Línea de la Concepción (AGS Campo de Gibraltar), La Línea de la Concepción, Spain; ⁴Complejo Hospario de Huelva, Huelva, Spain; ⁵Hosp Universitario Virgen de la Macarena, Sevilla, Spain; ⁶Hosp Universitario Virgen de la Victoria, Málaga, Spain; ⁷Complejo Hospario de Jaén, Jaén, Spain; ⁸Hosp Universitario Reina Sofía, Córdoba, Spain

Session P-N2 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

HCV Cure: Moving the Needle from the Patient to the Population

- 531 Hepatitis C Screening and Linkage to Care at a Comprehensive Health System**
Kassem Bourgi¹; Indira Brar²; Kimberly Baker-Genaw²
¹Henry Ford Hosp/Wayne State Univ, Troy, MI, USA; ²Henry Ford Hosp/Wayne State Univ, Detroit, MI, USA
- 532 Influence of Hepatitis C Virus Screening on Emergency Department Length of Stay**
 Douglas A. White¹; **Erik S. Anderson**²; Sarah K. Pfeil¹; Tamara Todorovich¹; Laura J. Deering¹; Tarak K. Trivedi¹
¹Highland Hosp, Alameda Hlth System, Oakland, CA, USA; ²Stanford Univ, Stanford, CA, USA
- 533 Devising a Strategy to Control the HCV Epidemic in British Columbia, Canada**
Ignacio Rozada; Julio Montaner; Mark W. Hull; Viviane D. Lima
 British Columbia Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 534 Project INSPIRE: A Comprehensive Care Coordination Program for HCV Infection**
Fabienne Laraque¹; Marie P. Bresnahan²; Mary Ford³; Payal Desai²; Eric Rude⁴; Shuchin Shukla⁴; Jeffrey Weiss⁵; Ponni Perumalswami⁶; Alain Litwin⁷; for the Project INSPIRE Implementation Team
¹New York City DHMH, Queens, NY, USA; ²New York City DHMH, Long Island City, NY, USA; ³New York City DHMH, New York City, NY, USA; ⁴New York City DHMH, Queens, NY, USA; ⁵Montefiore Med Cntr, Bronx, NY, USA; ⁶Mount Sinai Hosp, New York, NY, USA
- 535 HCV Treatment As Prevention Will Require Massive Scale-up to See Prevention Benefits**
Luis Mier-y-Teran-Romero¹; Derek A. Cummings²; David L. Thomas³; Carl Latkin⁴; John B. Wong⁴; Gregory D. Kirk⁵; Shruti H. Mehta¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Univ of Florida, Gainesville, FL, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁴Tufts Univ, Boston, MA, USA
- 536 Is HCV Elimination Possible? A Modeling Study of HIV-Positive MSM**
Sebastiaan J. Hulleigie¹; Brooke E. Nichols¹; Bart J. Rijnders²; Robert J. de Kneegt³; Jürgen K. Rockstroh⁴; Charles A. Boucher¹; David A. van de Vijver¹
¹Erasmus Univ Med Cntr, Rotterdam, Netherlands; ²Medizinische Uniklinik, Bonn, Germany

- 537 Primary Care Provider Interest in Treating HCV: A Mixed-Methods Study**
Oluwaseun Falade-Nwulia¹; Ayesha McAdams-Mahmoud¹; Risha Irvini¹; Alex Niculescu²; Kathleen Page³; Carl Latkin⁴; Monica Mix⁵; David L. Thomas⁶; Mark Sulkowski⁷; Shruti H. Mehta¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA
- 538LB High Efficacy of HCV Treatment by Primary Care Providers: The ASCEND Study**
Sarah M. Kattakuzhy¹; Chloe Gross²; Gebeyehu Teferi³; Veronica Jenkins⁴; Benjamin Emmanuel⁵; Henry Masur⁶; Shyam Kottilil⁷; for the ASCEND Investigators
¹Inst of Human Virology at Univ of Maryland, Bethesda, MD, USA; ²Inst of Human Virology, Bethesda, MD, USA; ³Unity Hlth Care, Washington, DC, USA; ⁴Family & Med Counseling Services, Washington, DC, USA; ⁵Univ of Maryland, Baltimore, MD, USA; ⁶NIH, Bethesda, MD, USA; ⁷Univ of Maryland Med Cntr, Baltimore, MD, USA
- 539LB Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV**
Mark Sulkowski¹; Preethi Krishnan²; Rakesh Tripathi³; Gretja Schnell⁴; Yan Xie⁵; Daniel Cohen⁶; Roger Trinh⁷; Nancy S. Shulman⁸; Tami Pilot-Matias⁹; Christine Collins²
¹The Johns Hopkins Univ, Baltimore, MD, USA; ²AbbVie, North Chicago, IL, USA; ³AbbVie Inc, North Chicago, IL, USA

Session P-N3 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

HCV Transmission Tracking and Transmission Risks

- 540 HCV IgG Antibody Avidity as a Biomarker to Estimate Population-Level Incidence**
Eshan U. Patel¹; Andrea L. Cox²; Shruti H. Mehta³; Denali Boon⁴; Andrew D. Redd⁵; William Osburn⁶; Gregory D. Kirk⁷; David L. Thomas⁸; Thomas C. Quinn⁹; Oliver Laeyendecker¹
¹NIH, Bethesda, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴NIAID, NIH, Bethesda, MD, USA
- 541 HCV Phylogenetic Analysis Complements HIV Contact Tracing in an HIV Outbreak Setting**
Romeo R. Galang¹; Jessica Gentry²; Sumathi Ramachandran³; Kathleen A. Backfish⁴; Sara J. Blosser⁵; Anupama Shankar⁶; Pamela Pontones⁷; William Switzer⁸; Philip Peters⁹; Yury Khudyakov¹
¹CDC, Atlanta, GA, USA; ²Indiana State Dept of Hlth, Indianapolis, IN, USA
- 542 Limited Overlap in Transmission Clusters of HIV and HCV Among MSM in the Netherlands**
Joost W. Vanhommerig¹; Daniela Bezemer²; Ard van Sighem²; Colette Smit³; Jan T. van der Meer⁴; Bart J. Rijnders⁴; Joop E. Arends⁵; Maria Prins⁶; Thijs J. van de Laar⁷; Janke Schinkel⁸; for the observational ATHENA and MOSAIC cohort studies
¹PH Service of Amsterdam, Amsterdam, Netherlands; ²Stichting HIV Monitoring, Amsterdam, Netherlands; ³Cntr of Infectious Diseases and Immunology Amsterdam, Academic Med Cntr, Amsterdam, Netherlands; ⁴Erasmus Univ Med Cntr, Rotterdam, Netherlands; ⁵Univ Med Cntr Utrecht, Utrecht, Netherlands; ⁶Sanquin Blood Supply Fdn, Amsterdam, Netherlands; ⁷Academic Med Cntr, Amsterdam, Netherlands

543 Tracing the Origin of HCV NS3 Q80K Among HIV-Infected MSM in the Netherlands

Astrid M. Newsom¹; Cynthia K. Ho²; Faydra I. Lieveeld³; Thijs J. van de Laar⁴; Jan T. van der Meer⁵; Anne M. Wensing⁶; Greet J. Boland⁷; Joop E. Arends⁸; Maria Prins⁹; Janke Schinkel⁹

¹PH Service of Amsterdam, Amsterdam, Netherlands; ²Academic Med Cntr, Amsterdam, Netherlands; ³Univ Med Cntr Utrecht, Utrecht, Netherlands; ⁴Sanquin Blood Supply Fndn, Amsterdam, Netherlands; ⁵Cntr of Infectious Diseases and Immunology Amsterdam, Academic Med Cntr, Amsterdam, Netherlands

544 Incidence of Hepatitis C Virus Infection in the HIV Outpatient Study Cohort 2000-2013

Taraz Samandari¹; Kate Buchacz²; Carl Armon³; Dana Franklin⁴; Rachel Hart⁵; Joan S. Chmiel⁶; John T. Brooks⁷; Ellen Tedaldi⁸; for the HIV Outpatient Study Investigators

¹CDC, Atlanta, GA, USA; ²Cerner Corporation, Kansas City, MO, USA; ³Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA; ⁴Temple Univ, Philadelphia, PA, USA

545 Sexual Behaviour Is Associated With Recently Acquired HCV in HIV/HCV Coinfected MSM

Marianne Martinello¹; Gregory J. Dore²; Jasmine Skurowski³; Janaki Amin⁴; Rohan I. Bopape⁵; Robert Finlayson⁶; David Baker⁷; Mark Bloch⁸; Gail V. Matthews¹

¹Kirby Inst, Univ of New South Wales, Sydney, Australia; ²The Albion Cntr, Sydney, Australia; ³Taylor Square Private Clinic, Sydney, Australia; ⁴East Sydney Doctors, Sydney, Australia; ⁵Holdsworth House Med Practice, Sydney, Australia

546 Prevalence and Factors of HCV Infection Among HIV-Negative and HIV-Positive MSM

Nathan J. Lachowsky¹; Kristine Stephenson²; Zishan Cui³; Susan Shurgold⁴; Troy Grennan⁵; Jason Wong⁶; Julio Montaner⁷; Eric A. Roth⁸; Robert S. Hogg⁹; David M. Moore¹⁰; for the Momentum Health Study

¹Univ of British Columbia, Vancouver, BC, Canada; ²Vancouver Coastal Hlth, Vancouver, BC, Canada; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁴BC Cntr for Disease Control, Vancouver, BC, Canada; ⁵Univ of Victoria, Victoria, BC, Canada; ⁶Simon Fraser Univ, Burnaby, BC, Canada

547 The Impact of Host Genes on the Risk of Acquiring Hepatitis C Virus Infection

Gaby S. Steba¹; Sylvie M. Koekkoek²; Joost W. Vanhommerig³; Kees Brinkman⁴; Jan T. van der Meer⁵; Maria Prins⁶; William A. Paxton⁷; Richard Molenkamp⁸; Janke Schinkel⁹; for the MOSAIC study group and ACS

¹Academic Med Cntr, Amsterdam, Netherlands; ²PH Service of Amsterdam, Amsterdam, Netherlands; ³OLVG Hosp, Amsterdam, Netherlands; ⁴Cntr of Infectious Diseases and Immunology Amsterdam, Academic Med Cntr, Amsterdam, Netherlands; ⁵Univ of Liverpool, Liverpool, UK

Session P-N4 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Progression of Liver Disease: Mediators and Moderators

548 Liver Disease Progression in a Community-Based Sample of HCV-Infected PWID

Javier A. Cepeda¹; David L. Thomas²; Jacque Astemborski³; Xiangrong Kong⁴; Gregory D. Kirk⁵; Shruti H. Mehta³

¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Johns Hopkins Univ, Baltimore, MD, USA

549 Protective Effect of Coffee Intake on Mortality of French HIV/HCV-Infected Patients

Patrizia Carrieri¹; Camelia Protopopescu²; Philippe Sogni³; Linda Wittkop⁴; David Zucman⁵; Francois Dabis⁶; **Bruno Spire**⁷; Dominique Salmon-Ceron⁸; for the ANRS HEPAVIH C013 Study Group

¹INSERM, Marseille, France; ²INSERM-APHP Hosp Cochin, Paris, France; ³CHU de Bordeaux, Bordeaux, France; ⁴Hosp Foch, Suresnes, France; ⁵INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ⁶INSERM UMR 912, Marseille, France

550 Statin Use and Cirrhosis Progression in an HIV/HCV Coinfected Population

Nora T. Oliver¹; Christine Hartman²; Jennifer R. Kramer³; Elizabeth Chiao¹

¹Baylor Coll of Med, Houston, TX, USA; ²Michael E. DeBakey VA Med Cntr, Houston, TX, USA

551 Statin Type and Dose Reduce the Risk of Cirrhosis and HCC in HCV Infected Patients

Tracey Simon¹; Hector Bonilla²; Raymond T. Chung³; Adeel A. Butt⁴

¹Massachusetts General Hosp, Boston, MA, USA; ²ImmunoSci Inc, Pleasanton, CA, USA; ³Harvard Med Sch, Boston, MA, USA; ⁴Hamad Hlthcare Quality Inst, Doha, Qatar

552 Assessment of Hepatic Antifibrotic Effect of Cenicriviroc in Patients With HIV

Enass Abdel-hameed; Susan D. Rouster; Kenneth E. Sherman
Univ of Cincinnati, Cincinnati, OH, USA

553 Statin Therapy Reduces Liver Fat Measured by Computed Tomography in Patients With HIV

Janet Lu; Michael Lu; Elli Kim; Eric Nou; Travis R. Hallett; Jakob Park; Udo Hoffmann; Steven Grinspoon

Massachusetts General Hosp, Boston, MA, USA

554 PETH Improves Detection of Alcohol and Associated Mortality Among HIV+/HCV+

Amy C. Justice¹; Kathleen A. McGinnis²; Janet Tate³; David A. Fiellin⁴; Vincent Lo Re⁵; Joseph Jones⁶; Judith A. Hahn⁷; Kendall J. Bryant⁸; for the VACS Project Team

¹Yale Univ, New Haven, CT, USA; ²VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA; ³VA Med Cntr, West Haven, CT, USA; ⁴VA Connecticut Hlthcare System, New Haven, CT, USA; ⁵Univ of Pennsylvania, Philadelphia, PA, USA; ⁶US Drug Testing Lab, Des Plaines, IL, USA; ⁷Univ of California San Francisco, San Francisco, CA, USA; ⁸Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

555 HLA-B18 As a Risk Factor of Progression to Severe Liver Fibrosis in HIV/HCV Patients

Mario Frías¹; Antonio Rivero-Juárez²; Francisca Cuenca³; Diego Rodríguez-Cano⁴; Juan Macías⁵; Ana Gordon⁶; Ángela Camacho⁷; Juan A. Pineda⁸; Antonio Rivero⁹

¹Instituto Maimonides de Investigación Biomédica de Córdoba, Córdoba, Spain; ²IMBIC, Córdoba, Spain; ³Hosp Universitario Reina Sofia, Córdoba, Spain; ⁴Hosp Universitario de Valme, Sevilla, Spain

556 Impact of PNPLA3 variants on the Liver Histology of 168 HIV/HCV Patients

Caterina Sagnelli¹; Marco Merli²; Caterina Uberti Foppa³; Hamid Hasson⁴; Grazia Cirillo⁵; Anna Grandone⁶; Stefania Salpietro⁷; Emanuela Messina⁸; Carmine Minichini⁹; Emanuele Miraglia Del Giudice¹⁰; Adriano Lazzarin¹¹; Nicola Coppola¹²; Evangelista Sagnelli¹³

¹Second Univ of Naples, Naples, Italy; ²Vita-Salute San Raffaele Univ, Milan, Italy; ³San Raffaele Scientific Inst, Milan, Italy; ⁴Vita-Salute Univ, San Raffaele Scientific Inst, Milan, Italy

557 The Impact of Cannabinoid Receptor2-63 Variants in Liver Biopsy of HIV/HCV Patients

Caterina Sagnelli¹; Marco Merli²; Caterina Uberti Foppa³; Hamid Hasson⁴; Giulia Bellini⁵; Carmine Minichini⁶; Stefania Salpietro⁷; Emanuela Messina⁸; Nicola Coppola⁹; Adriano Lazzarin¹⁰; Evangelista Sagnelli¹¹; Francesca Rossi¹²

¹Second Univ of Naples, Naples, Italy; ²Vita-Salute San Raffaele Univ, Milan, Italy; ³San Raffaele Scientific Inst, Milan, Italy; ⁴Vita-Salute Univ, San Raffaele Scientific Inst, Milan, Italy

558 Poorly Controlled HIV Infection Is a Risk Factor for Liver Fibrosis in CNICS Cohort

Nina Kim¹; Robin Nance²; Stephen Van Rompaey³; Joseph A. Delaney⁴; Heidi M. Crane⁵; Katerina A. Christopoulos⁶; Wm. Christopher Mathews⁷; Richard Moore⁸; Mari M. Kitahata⁹; for the Center for AIDS Research Network of Integrated Clinical Systems

¹Univ of Washington, Seattle, WA, USA; ²Univ of Washington Sch of PH and Community Med, Seattle, WA, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴Univ of California San Diego, San Diego, CA, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA

559 MiR-122 and -200a in Exosomes of ART+ HIV-1 Infected Individuals With Liver Disease

Daniel D. Murray¹; Kazuo Suzuki²; Matthew Law³; Jonel Trebicka⁴; Jacqueline Neuhaus⁵; Deborah Wentworth⁶; Michael J. Vjecha⁷; Margaret Johnson⁸; Anthony Kelleher⁹; Sean Emery¹⁰; for the INSIGHT ESPRIT and SMART Study Groups

¹Kirby Inst for Infection and Immunity in Society, Sydney, Australia; ²Kirby Inst, Univ of New South Wales, Sydney, Australia; ³Univ of New South Wales, Sydney, Australia; ⁴Univ of Bonn, Bonn, Germany; ⁵Univ of Minnesota, Minneapolis, MN, USA; ⁶VA Med Ctr, Washington, DC, USA; ⁷Royal Free London NHS Fdn Trust, London, UK

560 Liver Fibrosis in HIV Patients: Which Factors Play a Role?

Raphael Mohr¹; Christoph Boesecke²; Carolyne Schwarze-Zander³; Jan-Christian Wasmuth⁴; Jürgen K. Rockstroh⁵

¹Univ Hosp Bonn, Bonn, Germany; ²Medizinische Universitätsklinik, Bonn, Germany

561 NASH Is Associated With a Unique Biomarker Signature in HIV-Infected Adults

Rebecca Krakora¹; Mary McLaughlin²; Adam Rupert³; Michael Proschan⁴; Colleen Hadigan⁵; David E. Kleiner⁶; Theo Heller⁷; Joseph A. Kovacs⁸; Caryn G. Morse⁹

¹NIH Clinical Ctr, Bethesda, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³NIAID, NIH, Frederick, MD, USA; ⁴NIAID, NIH, Rockville, MD, USA; ⁵NCI, Bethesda, MD, USA; ⁶NIDDK, Bethesda, MD, USA

Session P-P1 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Stroke: Incidence and Risk Factors

636 Design, Implementation, and Findings of Next Generation Stroke Adjudication in HIV

Heidi M. Crane¹; Felicia Chow²; Kyra J. Becker³; Christina Marra⁴; Joseph Zunt⁵; Emily L. Ho⁶; Rizwan Kilani⁷; Robin Nance⁸; Joseph A. Delaney⁹; David Tirschwell¹⁰

¹Univ of Washington, Seattle, WA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Washington Sch of PH and Community Med, Seattle, WA, USA

637 Differences in Predictors for Ischaemic and Haemorrhagic Strokes in HIV+ Individuals

Camilla A. Hatleberg¹; David Kamara²; Lene Ryom³; Stephane de Wit⁴; Matthew Law⁵; Peter Reiss⁶; Antonella d'Arminio Monforte⁷; Jens D. Lundgren⁸; Caroline Sabin⁹; for the Data Collection on Adverse Events of Anti-HIV Drugs Study Group

¹Rigshospitet, Univ of Copenhagen, Copenhagen, Denmark; ²Univ Coll London, London, UK; ³St Pierre Univ Hosp, Brussels, Belgium; ⁴Univ of New South Wales, Sydney, Australia; ⁵Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ⁶Infectious Diseases Clinic, San Paolo Hosp, Univ of Milan, Milan, Italy

638 Persistently Increased Ischemic Stroke Risk in HIV-Infected Women

Felicia Chow¹; Susan Regan²; Sara E. Looby³; Markella V. Zanni⁴; James B. Meigs⁵; Cheryl D. Bushnell⁶; Steven K. Feske⁷; Steven Grinspoon⁸; Virginia A. Triant⁹

¹Univ of California San Francisco, San Francisco, CA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³Wake Forest Baptist Med Ctr, Winston Salem, NC, USA; ⁴Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

639 Stroke in HIV-Infected Patients in the Combination Antiretroviral Therapy Era

Juan Berenguer¹; Alejandro Alvaro-Meca²; Asuncion Diaz³; Dariela Micheloud⁴; Salvador Resino⁵

¹Hosp General Universitario Gregorio Marañón, Madrid, Spain; ²Univ Rey Juan Carlos, Alcorcón, Spain; ³Inst de Salud Carlos III, Madrid, Spain

640 Incidental Carotid Plaque in HIV Is Associated With Subsequent Cerebrovascular Events

Sumbal Janjua¹; Pedro Staziaki²; Richard Takx³; Orla Hennessy⁴; Michael Lu⁵; Markella V. Zanni⁶; Steven Grinspoon⁷; Udo Hoffmann⁸; Tomas G. Neilan⁹

¹Massachusetts General Hosp, Boston, MA, USA

Session P-P2 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Cardiovascular Disease: Risk, Prediction, Assessment, and Management

- 641 Atherosclerotic Myocardial Infarction Risk in the NA-ACCORD Compared to MESA and ARIC**
Daniel Drozd¹; Heidi M. Crane²; Susan Heckbert³; Matthew Budoff⁴; Amy C. Justice⁵; Frank J. Paella⁶; Daniel B. Klein⁷; Mari M. Kitahata⁸; Stephen J. Gange⁹; Richard Moore⁷
¹Univ of Washington, Seattle, WA, USA; ²Harbor-Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ³Yale Univ, New Haven, CT, USA; ⁴Northwestern Univ, Chicago, IL, USA; ⁵Kaiser Permanente San Leandro Med Cntr, San Leandro, CA, USA; ⁶Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁷Johns Hopkins Univ, Baltimore, MD, USA
- 642 Cardiovascular Disease Risk Model Comparison and Development in HIV-Infected Veterans**
Meredith E. Clement¹; Lawrence Park²; Ann Marie Navar³; N. L. Okeke⁴; Michael J. Pencina⁵; Pamela Douglas⁶; Susanna Naggie³
¹Duke Univ Med Cntr, Durham, NC, USA; ²Duke Clinical Rsr Inst, Durham, NC, USA; ³Duke Univ Sch of Med, Durham, NC, USA
- 643 2013 ACC/AHA Guideline Undertreats HIV-Infected Adults With Atherosclerosis**
Bernard Weigel¹; Binh An P. Phan¹; Yifei Ma¹; Rebecca Scherzer²; Danny Li¹; Sophia Hur¹; S.C. Kalapus³; Stephen G. Deeks³; Priscilla Hsue¹
¹Univ of California San Francisco, San Francisco, CA, USA; ²San Francisco General Hosp, San Francisco, CA, USA
- 644 Differences by HIV Serostatus in Coronary Artery Disease Following Stress Testing**
Matthew J. Feinstein¹; Brian Poole²; Tim S. Provias³; Frank J. Paella²; Chad Achenbach³; Donald M. Lloyd-Jones¹
¹Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ²Northwestern Univ, Chicago, IL, USA
- 645 HIV & Obesity Synergistically Increase Interleukin 6 but Not Soluble CD14 or D-dimer**
Barbara S. Taylor¹; Kaku So-Armah²; Janet Tate³; Vincent C. Marconi⁴; Roger Bedimo⁵; Adeel A. Butt⁶; Cynthia Gibert⁷; Matthew Goetz⁸; Maria Rodriguez-Barradas⁹; Matthew S. Freiberg¹⁰
¹Univ of Texas Hlth Sci Cntr San Antonio, San Antonio, TX, USA; ²Boston Univ Sch of Med, Boston, MA, USA; ³VA Med Cntr, West Haven, CT, USA; ⁴Emory Univ Sch of Med, Atlanta, GA, USA; ⁵Dallas VA Med Cntr, Dallas, TX, USA; ⁶Hamad Hlthcare Quality Inst, Doha, Qatar; ⁷VA Med Cntr, Washington, DC, USA; ⁸VA Greater Los Angeles Hlthcare System, Los Angeles, CA, USA; ⁹Michael E. DeBakey VA Med Cntr and Baylor Coll of Med, Houston, TX, USA; ¹⁰Vanderbilt Univ Sch of Med, Nashville, TN, USA
- 646 BNP Prediction of Cardiovascular Diseases in HIV+ Patients and the General Population**
Stefan Esser¹; Marina Arendt²; Till Neumann³; Lewin Eisele⁴; Raimund Erbel⁵; Karl H. Jöckel⁶; Volker Holzendorf⁷; Nico Reinsch⁸; for the HIV HEART Study Group and Heinz Nixdorf Recall Investigative Group
¹Univ Hosp Essen, Essen, Germany; ²Inst for Med Informatics, Biometry and Epi (IMIBE), Univ Hosp Essen, Essen, Germany; ³West German Heart Cntr, Univ Hosp Essen, Essen, Germany; ⁴Inst for MIMIBE, Univ Hosp Essen, Essen, Germany; ⁵Univ Leipzig, Leipzig, Germany

647 9-Year Trends in Non-Lipid Cardiovascular Disease Prevention Strategies in HIV+ Women

David B. Hanna¹; Molly Jung²; Kathryn Anastos³; Jennifer M. Cocohoba⁴; Mardge Cohen⁵; Elizabeth Golub⁶; Nancy A. Hessel⁷; Tracey E. Wilson⁸; Mary Young⁹; Robert C. Kaplan¹
¹Albert Einstein Coll of Med, Bronx, NY, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³John H. Stroger Jr. Hosp of Cook County and Rush Med Coll, Chicago, IL, USA; ⁴Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁵State Univ of New York Downstate Med Cntr, Brooklyn, NY, USA; ⁶Georgetown Univ Med Cntr, Washington, DC, USA

648 HIV Patients Have More High-risk Plaque and Cardiac Events but Less Intervention

James Nadel¹; Eoin O'Dwyer²; Sam Emmanuel³; James Otton⁴; Justyn Huang⁵; Cameron Holloway⁶
¹St Vincent's Hosp, Sydney, Australia

649 Diastolic Function Correlates With Pericardial Fat and Vascular Remodeling in HIV

Chris T. Longenecker¹; Sadeer Al Kindi²; Maya Serhal³; Bruce Kinley⁴; Danielle Labbato⁵; Grace A. McCormsey¹
¹Case Western Reserve Univ, Cleveland, OH, USA; ²Univ Hosps Case Med Cntr, Cleveland, OH, USA

650 Reduced Ovarian Reserve Relates to Cardiovascular Disease Risk in Women With HIV

Sara E. Looby¹; Kathleen Fitch²; Suman Srinivasa³; Janet Lo⁴; Danielle Rafferty⁵; Amanda Martin⁶; Judith S. Currier⁷; Steven Grinspoon⁸; **Markella V. Zanni¹**
¹Massachusetts General Hosp, Boston, MA, USA; ²David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA

Session P-Q1 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Renal Outcomes: TAF and TDF
680 Longer-Term Safety of Tenofovir Alafenamide in Renal Impairment

Frank A. Post¹; Pablo Tebas²; Amanda Clarke³; Laurent Cotte⁴; William Short⁵; Michael E. Abram⁶; Shuping Jiang⁷; Andrew Cheng⁸; Moupali Das⁹; Marshall Fordyce⁶
¹King's Coll Hosp NHS Fdn Trust, London, UK; ²Univ of Pennsylvania, Philadelphia, PA, USA; ³Brighton and Sussex Hosps NHS Trust, Brighton, UK; ⁴Hospices Civils de Lyon, Lyon, France; ⁵Perelman Sch of Med, Univ of Pennsylvania, Philadelphia, PA, USA; ⁶Gilead Scis, Inc, Foster City, CA, USA

681 Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease

David Wohl¹; Anders Thalme²; Robert Finlayson³; Shinichi Oka⁴; Thai Nguyen⁵; Susan Guo⁶; Andrew Cheng⁷; Moupali Das⁸; Marshall Fordyce⁹
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Karolinska Inst, Stockholm, Sweden; ³Taylor Square Private Clinic, Sydney, Australia; ⁴Natl Cntr for Global Hlth and Med, Tokyo, Japan; ⁵Gilead Scis, Inc, Foster City, CA, USA

682 Longer-Term Renal Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate

Bart J. Rijnders¹; Frank A. Post²; Armin Rieger³; Eugenio Teofilo⁴; David Wohl⁵; Paul E. Sax⁶; Susan Guo⁷; Andrew Cheng⁸; Moupali Das⁹; Marshall Fordyce⁹

¹Erasmus Univ Med Cntr, Rotterdam, Netherlands; ²King's Coll Hosp NHS Fdn Trust, London, UK; ³Med Univ of Vienna, Vienna, Austria; ⁴Hosp dos Capuchos, Centro Hosp par de Lisboa Central, Lisbon, Portugal; ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁶Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ⁷Gilead Scis, Inc, Foster City, CA, USA

683 Clinical Risk Factors for Severe Tenofovir (TDF) Associated Renal Tubulopathy

Lisa Hamzah¹; Sophie Jose²; Aseel Hegazi³; Angela Bailey⁴; David Chadwick⁵; Deborah Williams⁶; Margaret Johnson⁷; Rachael Jones⁸; Caroline Sabin⁹; Frank A. Post⁹

¹King's Coll London, London, UK; ²Univ Coll London, London, UK; ³St Georges' Hosp NHS Trust, London, UK; ⁴Imperial Coll Hlthcare NHS Trust, London, UK; ⁵South Tees Hosp NHS Fdn Trust, Middlesbrough, UK; ⁶Brighton and Sussex Hosps NHS Trust, Brighton, UK; ⁷Royal Free London NHS Fdn Trust, London, UK; ⁸Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ⁹King's Coll Hosp NHS Fdn Trust, London, UK

684 Short-Term Renal Impact of Tenofovir Among HIV-Infected Patients in North America

Ruibin Wang¹; Gregory M. Lucas²; Michelle Estrella³; Michael Shlipak⁴; Marianne Harris⁵; Michael A. Horberg⁶; Mari M. Kitahata⁷; Angel M. Mayor⁸; Sonia Napravnik⁹; Alison Abraham¹

¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵British Columbia Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁶Mid-Atlantic Permanente Med Group, Rockville, MD, USA; ⁷Univ of Washington, Seattle, WA, USA; ⁸Univ Central del Caribe, Bayamon, PR, USA; ⁹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

685 Associations of Tenofovir Disoproxil Fumarate With Urine Biomarkers of Kidney Damage

Vasantha Jotwani¹; Rebecca Scherzer²; Michelle Estrella³; Lisa Jacobson⁴; Mallory Witt⁵; Frank J. Palella⁶; Bernard J. Macatangay⁷; Chirag Parikh⁸; Joachim Ix⁹; Michael Shlipak¹

¹Univ of California San Francisco, San Francisco, CA, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Harbor-Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ⁵Northwestern Univ, Chicago, IL, USA; ⁶Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ⁷Yale Univ Sch of Med, New Haven, CT, USA; ⁸Univ of California San Diego, San Diego, CA, USA

Session P-Q2 Poster Abstracts 2:45 PM-4:00 PM

Hall A/B

Renal and Bone Disease: Risk Factors and Biomarkers

686 Nature of Immunosuppression and Chronic Kidney Disease Risk in HIV-Positive Persons

Lene Ryom¹; Jens D. Lundgren²; Peter Reiss³; Michael Ross³; Christoph A. Fux⁴; Philippe Morlat⁵; Eric Fontas⁶; Colette Smith⁷; Amanda Mocroft⁸; for the D:A:D Study Group

¹RigsHospet, Univ of Copenhagen, Copenhagen, Denmark; ²Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ³Mount Sinai Sch of Med, New York, NY, USA; ⁴Kantonsspital Aarau, Aarau, Switzerland; ⁵Univ of Bordeaux, Bordeaux, France; ⁶Nice Univ Hosp, Nice, France; ⁷Univ Coll London, London, UK

687 Traditional and Viral Factors Associated With Iohexol-Based GFR Slope Over 3 Years

Gregory M. Lucas¹; Mohamed G. Atta²; Katie Zook³; Allison M. McFall⁴; Shruti H. Mehta⁵; Derek M. Fine⁶; James H. Stein⁷; George J. Schwartz⁸

¹Johns Hopkins Univ, Baltimore, MD, USA; ²Univ of Wisconsin-Madison, Madison, WI, USA; ³Univ of Rochester, Rochester, NY, USA

688 The Racial Survival Paradox in HIV+ End-Stage Renal Disease (ESRD) Patients

Keri N. Althoff¹; Michelle Estrella²; Alison Abraham³; John Gill⁴; Mari M. Kitahata⁵; Michael A. Horberg⁶; Mark W. Hull⁶; Angel M. Mayor⁷; Frank J. Palella⁸; Gregory M. Lucas⁹

¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Univ of Calgary, Calgary, AB, Canada; ⁴Univ of Washington, Seattle, WA, USA; ⁵Mid-Atlantic Permanente Med Group, Rockville, MD, USA; ⁶BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁷Univ Central del Caribe, Bayamon, PR, USA; ⁸Northwestern Univ, Chicago, IL, USA; ⁹Johns Hopkins Univ, Baltimore, MD, USA

689 Activation and Senescence Markers in HIV Patients With Chronic Kidney Disease

Alexandra Ozanne¹; Frédéric-Antoin Dauchy²; Claire Rigother³; Cécile Le Scanf-Terrien⁴; Pierre Duffau⁵; Estibaliz Lazaro⁶; Charles Cazanave⁷; Sylvie Lawson-Ayari⁸; Linda Wittkop⁹; Isabelle Pellegrin²

¹Univ of Bordeaux, Bordeaux, France; ²CHU de Bordeaux, Bordeaux, France; ³CHU de Bordeaux, Bordeaux Cedex, France; ⁴INSERM, ISPED, INSERM U897, Bordeaux, France

690 Soluble CD163 Predicts Incident Chronic Lung and Kidney Disease in HIV-1 Infection

Dirte M. Kirkegaard-Klitbo¹; Niels Mejer²; Troels Bygum Knudsen³; Holger J. Møller⁴; Søren K. Moestrup⁵; Susanne D. Nielsen⁶; Gitte Kronborg⁷; Thomas Benfield⁸

¹RigsHospet, Univ of Copenhagen, Copenhagen, Denmark; ²Hvidovre Hosp, Univ of Copenhagen, Hvidovre, Denmark; ³Hillerød Hosp, Univ of Copenhagen, Hillerød, Denmark; ⁴Aarhus Univ Hosp, Aarhus Nord, Denmark

691 Use of Urine Biomarker-Derived Clusters to Predict CKD Risk and All-Cause Mortality

Rebecca Scherzer¹; Haiqun Lin²; Alison Abraham³; Heather Thiessen-Philbrook⁴; Chirag Parikh⁵; Mary Young⁶; Phyllis Tien⁷; Vasantha Jotwani⁸; Michael Shlipak⁹; for the Women's Interagency HIV Study Investigators

¹Univ of California San Francisco, San Francisco, CA, USA; ²Yale Univ Sch of PH, New Haven, CT, USA; ³Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁴Yale Univ Sch of Med, New Haven, CT, USA; ⁵Georgetown Univ Med Cntr, Washington, DC, USA

692 Differences in Urine Metabolomes With HIV Infection and Antiretroviral Drug Exposure

Andrew J. Chetwynd¹; Amanda Samarawickrama²; Alaa Abdul-Sada³; **Jaime H. Vera**⁴; Stephen G. Holt⁵; Martin Fisher⁶; Yvonne Gillece²; Elizabeth M. Hill¹

¹Univ of Sussex, Brighton, UK; ²Brighton and Sussex Hosps NHS Trust, Brighton, UK; ³Univ of Melbourne, Melbourne, Australia

693 Early Markers of Renal Dysfunction Among Cocaine Users With HIV and HCV Infection

Edana Cassol¹; Vikas Misra²; Shibani S. Mukerji³; Susan Morgello⁴; Gregory D. Kirk⁵; Shruti H. Mehta⁶; **Dana Gabuzda**²

¹Carleton Univ, Ottawa, ON, Canada; ²Dana-Farber Cancer Inst, Boston, MA, USA; ³Massachusetts General Hosp, Boston, MA, USA; ⁴Mount Sinai Sch of Med, New York, NY, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA

694 Bone Loss With Antiretroviral Therapy Is Associated With Phosphaturia

Robert Kalayjian¹; Jeffrey Albert²; Serge Cremers³; Karin Klingman⁴; Carl Fichtenbaum⁵; Joseph J. Eron⁶; Todd T. Brown⁷; Babafemi Taiwo⁸; for the AIDS Clinical Trials Group Protocol Team A5303

¹MetroHlth Med Cntr, Cleveland, OH, USA; ²Case Western Reserve Univ, Cleveland, OH, USA; ³Columbia Univ, New York, NY, USA; ⁴NIAID, NIH, Bethesda, MD, USA; ⁵Univ of Cincinnati, Cincinnati, OH, USA; ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁷Johns Hopkins Univ, Baltimore, MD, USA; ⁸Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA

695LB Immunologic Effects of Maraviroc vs Tenofovir and Associations With Bone Loss

Ellen S. Chan¹; Paria Mirmonsef²; Todd T. Brown³; Alan L. Landay⁴; Ighovwerha Ofotokun⁵; M. N. Weitzmann⁶; Jeff Martinson⁷; Jill Plants⁸; Heather J. Ribaud⁹; Babafemi Taiwo⁷

¹Harvard Univ, Boston, MA, USA; ²Rush Univ Med Cntr, Chicago, IL, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Rush Univ, Chicago, IL, USA; ⁵Emory Univ Sch of Med, Atlanta, GA, USA; ⁶Harvard Sch of PH, Boston, MA, USA; ⁷Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA

Session P-R1 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****Tuberculosis: Pathogenesis Studies****733 Baseline Sputum and Polyfunctional TB-Specific CD4+ T Cells in HIV-TB Coinfection**

David H. Canaday¹; Htin Aung²; Brigid Wilson³; Harriet Mayanja-Kizza⁴; Sophie Nalukwago⁵; Joy Baseke⁶; Michael R. Betts⁷; W. H. Boom⁸; ¹Cleveland VA Med Cntr, Cleveland, OH, USA; ²Case Western Reserve Univ, Cleveland, OH, USA; ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁴Mulago Hosp, Kampala, Uganda; ⁵Univ of Pennsylvania, Philadelphia, PA, USA

734 Neutrophil-Derived MMP-8 Activity Is Associated With Immunopathology in TB-IRIS

Naomi F. Walker¹; Katalin Wilkinson²; Graeme Meintjes³; Rene Goliath⁴; Janique Peyper⁵; Robert J. Wilkinson⁶; Jon S. Friedland⁷; Paul T. Elkington⁸

¹Imperial Coll London, London, UK; ²Francis Crick Inst Mill Hill Lab/Univ of Cape Town, Observatory, South Africa; ³Univ of Cape Town, Cape Town, South Africa; ⁴Univ of Southampton, Southampton, UK

Session P-R2 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****Tuberculosis Transmission****735 Spatiotemporal Distribution of Pediatric Tuberculosis in Central Durban, South Africa**

Gary Parker¹; Natasha Morris²; Thandi Kapwata³; Farina Karim⁴; Tilagavathy Chinappa⁵; Fernanda Maruri⁶; Mahomed-Yunus Moosa⁷; Timothy R. Sterling⁸; Yuri F. van der Heijden⁹; Alex Pym¹

¹KwaZulu-Natal Rsr Inst for TB-HIV, Durban, South Africa; ²South African Med Rsr Council, Durban, South Africa; ³eThekweni Municipality, Durban, South Africa; ⁴Vanderbilt Univ Sch of Med, Nashville, TN, USA; ⁵Univ of KwaZulu-Natal, Durban, South Africa

736 Does ART Increase Infectiousness of Smear-Positive Pulmonary Tuberculosis?

Palwasha Y. Khan¹; Katharina Kranzer²; Katherine L. Fielding³; Themba Mzembe⁴; Nimrod Mwaungulu⁵; Olivier Koole⁶; Judith Glynn²; Amelia Crampin²

¹London Sch of Hygiene & Trop Med, Cardiff, UK; ²London Sch of Hygiene & Trop Med, London, UK; ³Karonga Prevention Study, Karonga, Malawi

737 Are We Overestimating TB Transmission Among Immigrants and HIV-Positive People?

David Stucki¹; Marie Ballif²; Kathrin Zürcher³; Matthias Egger³; Sébastien Gagneux⁴; **Lukas Fenner**²

¹Swiss Trop Inst of PH, Basel, Switzerland; ²Univ of Bern, Bern, Switzerland; ³Univ Hosp Bern, Bern, Switzerland

Session P-R3 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Implementation of HIV and Tuberculosis Services

- 738 Integrated TB/HIV Services for Migrant Miners and Their Families in Lesotho**
Andrea A. Howard¹; Suzue Saito²; Koen Frederix³; Yael Hirsch-Moverman⁴; Llang B. Maama⁵; Pheleso Tau⁶; Kieran Hartsough⁷; Charles Mugizi⁸; Wafaa M. El-Sadr¹
¹ICAP at Columbia Univ, New York, NY, USA; ²Columbia Univ Mailman Sch of PH, New York, NY, USA; ³Lesotho Ministry of Hlth, Maseru, Lesotho; ⁴ICAP at Columbia Univ, Maseru, Lesotho
- 739 Diagnostic Yield of Household-Level Active Case Finding in Urban Slums in Haiti**
Vanessa R. Rivera¹; Jean W. Pape²; Serena P. Koenig³; Marc Antoine Jean Juste⁴
¹Weill Cornell Med Coll, New York, NY, USA; ²GHEKIO, Port-au-Prince, Haiti; ³Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA
- 740 Integration of HIV-TB Screening and Linkage Strengthens Community-Based HIV Care**
Ruanne V. Barnabas¹; Heidi van Rooyen²; Stephen Asimwe³; Torin Schaafsma⁴; Meighan Krows⁵; Alastair van Heerden⁶; Bosco Turyamureeba⁷; James P. Hughes⁸; Jared M. Baeten⁹; Connie M. Celum¹⁰; for the Linkages Study Team
¹Univ of Washington, Seattle, WA, USA; ²Human Scis Rsr Council, Durban, South Africa; ³Kabwohe Clinical Rsr Cntr, Bushenyi, Uganda; ⁴Human Scis Rsr Council, Msunduzi, South Africa
- 741LB WITHDRAWN**

Session P-R4 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Tuberculosis Related Outcomes and Mortality

- 742 A Clinical Prediction Rule for the Diagnosis of Tuberculosis in Seriously Ill Adults**
Rulan Griesel¹; Annemie Stewart²; Helen van der Plas³; Welile Sikhondze⁴; Molebogeng Rangaka⁵; Gary Maartens⁶; Marc Mendelson¹
¹Univ of Cape Town, Cape Town, South Africa; ²Clinical Rsr Cntr, Univ of Cape Town, Cape Town, South Africa; ³Vincent Pallotti Hosp, Cape Town, South Africa; ⁴FINI, Geneva, Switzerland; ⁵Univ Coll London, London, UK

743 High Mortality Rates in HIV-Infected TB: Suspects Who Rule Out for TB

Yukari C. Manabe¹; Rachel W. Kubiak²; Lydia Nakiyingi³; Henry Ssekitooleko⁴; Sandra Armakovitch⁵; David Hom⁶; Moses L. Joloba⁵; Jerrold Ellner⁷; Susan Dorman⁸; for the Tuberculosis Clinical Diagnostic Research Consortium
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Univ of Washington, Seattle, WA, USA; ³Infectious Diseases Inst, Makerere Univ, Kampala, Uganda; ⁴Boston Med Cntr, Boston, MA, USA; ⁵Makerere Univ, Kampala, Uganda; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

744 Mortality in HIV+ Men and Women Investigated for TB at Ethiopian Health Centers

Anton Reepalu¹; Taye T. Balcha²; Sten Skogmar¹; Nuray Güner²; Per Björkman¹
¹Lund Univ, Malmö, Sweden; ²Lund Univ, Lund, Sweden

745 Empiric TB Therapy Versus IPT in HIV-Infected Persons Initiating ART (ACTG A5274 48W)

Johnstone J. Kumwenda¹; Amita Gupta²; Xin Sung³; Miyahara Sachiko⁴; Evelyn Hogg⁵; Lynne Jones⁶; Andrew Zolopa⁷; Gregory P. Bisson⁸; Mina Hosseinipour⁸
¹Coll of Med John Hopkins Proj, Blantyre, Malawi; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Harvard Univ, Boston, MA, USA; ⁴Social & Scientific Systems, Inc, Silver Spring, MD, USA; ⁵Frontier Sci & Tech Rsr Frndn, Inc, Amherst, NY, USA; ⁶Stanford Univ, Stanford, CA, USA; ⁷Univ of Pennsylvania, Philadelphia, PA, USA; ⁸Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

746 TB Treatment Outcomes for HIV/TB Coinfected Children in Resource-Limited Countries

James G. Carlucci¹; Aaron M. Kipp²; Meredith Blevins³; Quy T. Du⁴; Lorna Renner⁴; Gary Reubenson⁵; John Salafi⁶; Marcel Yotebieng⁷; Mary Lou Lindegren⁸; April C. Pettit¹
¹Vanderbilt Univ Sch of Med, Nashville, TN, USA; ²Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ³Children's Hosp 1, Ho Chi Minh City, Vietnam; ⁴Univ of Ghana Sch of Med and Dentistry, Accra, Ghana; ⁵Rahima Moosa Mother and Child Hosp, Johannesburg, South Africa; ⁶Masaka Regional Referral Hosp, Masaka, Uganda; ⁷Ohio State Univ, Columbus, OH, USA

Session P-S1 Poster Abstracts
2:45 PM-4:00 PM

Hall D

HIV Acquisition and Health Outcomes During Pregnancy

770 No Increased Risk of HIV Incidence During Pregnancy

Chloe A. Teasdale¹; Jessica Justman²; Mary-Ann Chiasson³; Kelly Blanchard⁴; Elaine J. Abrams⁵; Heidi E. Jones⁵
¹ICAP at Columbia Univ, New York, NY, USA; ²PH Solutions, New York, NY, USA; ³Ibis Reproductive Hlth, Cambridge, MA, USA; ⁴ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA; ⁵City Univ of New York, New York, NY, USA

- 771 Effect of Pregnancy on Response to Antiretroviral Therapy Among African Women**
Athena P. Kourtis¹; Jeffrey Wiener²; Renee Heffron³; Nelly R. Mugoi⁴; Caroline King⁵; Kavita Nanda⁶; Connie M. Celum⁷; Deborah Donnell⁸; Jaiiram R. Lingappa⁹; Jared M. Baeten²
¹CDC, Atlanta, GA, USA; ²Univ of Washington, Seattle, WA, USA; ³Kenya Med Rsr Inst, Thika, Kenya; ⁴FHI 361, Chapel Hill, NC, USA; ⁵SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
- 772 Trends in Hospitalizations of Pregnant HIV-Infected Women in the USA: 2004–2011**
Alexander Ewing¹; Hema Datwani²; Lisa Flowers³; Sascha Ellington⁴; Denise Jamieson⁵; Athena P. Kourtis¹
¹CDC, Atlanta, GA, USA; ²CDC, Philadelphia, PA, USA
- 773 Cost-Effectiveness of Cotrimoxazole Among HIV+ Pregnant Women in Malarious Regions**
Sung Eun Choi; Eran Bendavid
 Stanford Univ, Stanford, CA, USA

Session P-52 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Antiretroviral Therapy Pharmacokinetics and Safety During Pregnancy and Infancy

- 774 Intracellular Atazanavir Concentrations Remain Stable During Pregnancy in HIV Women**
 Emanuele Focà¹; Andrea Calcagno²; Marco Simiele²; Elisabetta Domeneghini¹; Antonio D'Avolio¹; Maria Antonietta Forleo¹; Giovanni Di Perri¹; Eugenia Quiros Roldan³; Stefano Bonora²
¹Univ of Brescia, Brescia, Italy; ²Univ of Torino, Torino, Italy
- 775 Pharmacokinetics of Increased Dose Darunavir During Late Pregnancy and Postpartum**
Alice Stek¹; Brookie M. Best²; Edmund Capparelli³; Jiajia Wang³; David E. Shapiro⁴; Tim R. Cressley⁵; Elizabeth Smith⁶; Regis Kreitchmann⁷; Nahida Chakhtoura⁸; Mark Mirochnick⁹
¹Univ of Southern California, Los Angeles, CA, USA; ²Univ of California San Diego, San Diego, CA, USA; ³Harvard Sch of PH, Boston, MA, USA; ⁴Cntr for Biostatistics in AIDS Rsr, Harvard Sch of PH, Boston, MA, USA; ⁵Harvard Sch of PH, Boston, MA, USA; ⁶NIAID, NIH, Bethesda, MD, USA; ⁷Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil; ⁸Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁹Boston Univ Sch of Med, Boston, MA, USA

- 776 High Risk of Liver Enzyme Elevation in Pregnant Women Receiving Protease Inhibitors**
Jeanne Sibuide¹; Josiane Warszawski¹; Roland Tubiana²; Jérôme Le Chenadec³; Françoise Meier⁴; Eliane Galiba⁵; Albert Faye⁶; Stéphane Blanche⁷; Laurent Mandelbrot⁸; for the ANRS C01/CO11-EPF French Perinatal Cohort Study Group
¹CESP, INSERM U1018, Le Kremlin-Bicêtre, France; ²Sorbonne Univ, Paris, France; ³INSERM, Le Kremlin-Bicêtre, France; ⁴APHP, Hosp Louis Mourier, Colombes, France; ⁵CHU de l'Archet, Nice, France; ⁶Univ Diderot Paris 7, Sorbonne Paris-Cité, Paris, France; ⁷Hosp Necker Enfants Malades, Paris, France; ⁸Hosp Louis Mourier, Colombes, France

- 777 Pharmacokinetics of Daily Nevirapine in Neonates at High Risk of HIV Acquisition**
Tim R. Cressley¹; Baralee Punyawudho²; Saik Urien³; Gonzague Jourdain⁴; Sophie Le Coeur⁵; Nicole Ngo-Giang-Huong⁶; Pra-ornsuda Sukrakanchana⁷; Suporn Koetsawang⁸; Marc Lallemand⁹; for the PHPT-5 study team.
¹Harvard Sch of PH, Boston, MA, USA; ²Chiang Mai Univ, Chiang Mai, Thailand; ³EAU08 Univ Paris Descartes, Paris, France; ⁴IRD UMI 174-PHPT, Marseille, France; ⁵Inst d'Etudes Démographiques, Paris, Thailand; ⁶Prog for HIV Prevention and Treatment/IRD 175, Chiang Mai, Thailand; ⁷Prog for HIV Prevention and Treatment/IRD 176, Chiang Mai, Thailand; ⁸Mahidol Univ, Bangkok, Thailand; ⁹Prog for HIV Prevention and Treatment/IRD 174, Chiang Mai, Thailand

- 778 Haematological Toxicity and Neonatal Prophylaxis in Infants at High MTCT Risk**
 Elena Chiappini¹; Luminita Ene²; Luisa Galli³; Catiuscia Lisi⁴; Ruslan Mal'yuta⁵; Antoni Noguera-Julian⁶; Pablo Rojo Conejo⁷; Christoph Rudin⁸; **Claire Thorne**⁹; for the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord
¹Univ of Florence, Florence, Italy; ²Victor Babes Hosp, Bucharest, Romania; ³Perinatal Prevention of AIDS Initiative, Odessa, Ukraine; ⁴Hosp Sant Joan de Déu, Barcelona, Spain; ⁵Hosp 12 de Octubre, Madrid, Spain; ⁶Univ Children's Hosp Basel, Basel, Switzerland; ⁷Univ Coll London, London, UK

Session P-53 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Partners in Crime: CMV, HIV, and MTCT

- 779 Maternal CMV Urinary Shedding in HIV-Infected Women and Congenital CMV Infection**
Kristina Adachi¹; Jiahong Xu²; Bonnie An³; D. H. Watts⁴; Esau C. Joao⁵; Jose H. Pilotto⁶; Yvonne J. Bryson⁷; Valdilea G. Veloso⁸; Lynne M. Mofenson⁹; Karin Nielsen-Saines¹
¹Univ of California Los Angeles, Los Angeles, CA, USA; ²Westat, Inc, Rockville, MD, USA; ³David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ⁴Office of the US Global AIDS Coordinator, US Dept of State, Washington, DC, USA; ⁵Hosp Fed dos Servidores do Estado, Rio de Janeiro, Brazil; ⁶Hosp Geral de Nova Iguaçu, Rio de Janeiro, Brazil; ⁷Fiocruz, Rio de Janeiro, Brazil; ⁸Previously with NIH, Bethesda, MD, USA
- 780 TLR9 Variant Is Associated With Earlier HIV, EBV, and CMV Acquisition in Infants**
 Kristin Beima-Sofie¹; **Grace C. John-Stewart**²; Dalton Wamalwa³; Elizabeth Maleche-Obimbo⁴; Jennifer Slyker¹
¹Univ of Washington, Seattle, WA, USA; ²Univ of Nairobi, Nairobi, Kenya
- 781 HCMV Induces CCR5 Expression, Activation and HIV Infection at Feto-Maternal Interface**
Erica L. Johnson¹; Sahithi Boggavarapu²; Elan S. Johnson³; Asim Lal⁴; Parth Agrawal⁵; Rana Chakraborty⁶
¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Emory Univ, Atlanta, GA, USA

Session P-S4 Poster Abstracts
2:45 PM-4:00 PM

Hall D

MTCT: Regimens, Rates, and Early Infant Diagnosis

782 Population-Level Declines in Vertical HIV Transmission With Changing PMTCT Guidelines

Jean Maritz¹; Nei-Yuan Hsiao²; Wolfgang Preiser¹; Landon Myer²
¹Stellenbosch Univ, Cape Town, South Africa; ²Univ of Cape Town, Cape Town, South Africa

783 Introduction of Birth Testing Into the South African National Consolidated Guidelines

Ahmad Haeri Mazanderani¹; Tendesayi Kufa-Chakezha¹; Gayle Sherman²
¹NICD, Johannesburg, South Africa; ²Univ of the Witwatersrand, Johannesburg, South Africa

784 Infant Cotrimoxazole Prophylaxis Associated With Commensal Bacterial Resistance

Kathleen Powis¹; Sajini Souda²; Shahin Lockman³; Gbolahan Ajibola⁴; Kara Bennett⁵; Florence Chilisa⁶; Michael Hughes⁶; Sikhulile Moyo⁷; Joseph Makhema⁸; Roger L. Shapiro⁹
¹Massachusetts General Hosp, Boston, MA, USA; ²Univ of Botswana, Gaborone, Botswana; ³Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ⁴Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁵Bennett Statistical Consulting, Inc, Ballston Lake, NY, USA; ⁶Harvard Sch of PH, Boston, MA, USA; ⁷Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana

785 Low Uptake of Routine Infant Diagnostic Testing Following HIV PCR Testing at Birth

Jean Maritz¹; Nei-Yuan Hsiao²; Wolfgang Preiser¹; Landon Myer²
¹Stellenbosch Univ, Cape Town, South Africa; ²Univ of Cape Town, Cape Town, South Africa

786 The Value of Confirmatory Testing in Early Infant HIV Diagnosis (EID) Programs

Andrea L. Ciaranello¹; Jordan A. Francke¹; Divya Mallampati²; Rachel L. MacLean³; Martina Penazzato⁴; Taige Hou⁵; Landon Myer⁶; Elaine J. Abrams⁷; Rochelle P. Walensky⁸; Kenneth A. Freedberg⁹
¹Massachusetts General Hosp, Boston, MA, USA; ²McGaw Med Cntr of Northwestern Univ, Chicago, IL, USA; ³WHO, Geneva, Switzerland; ⁴Univ of Cape Town, Cape Town, South Africa; ⁵ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

787 Diagnostic Accuracy of Cepheid Xpert HIV-1 Qual for Early Infant Diagnosis

Sekesai Mtapuri-Zinyowera¹; Zibusiso Ndlovu²; Emmanuel Farjado³; Carol MetcalF⁴; Kekeletso Kao⁵; Maryam Rumaney⁶; Elton Mbofana⁷; Daniel Orozco⁸; Helen Bygrave⁹
¹Natl Microbiology Reference Lab, Harare, Zimbabwe; ²Médecins Sans Frontières, Harare, Zimbabwe; ³Médecins Sans Frontières, Southern Africa Med Unit, Cape Town, South Africa; ⁴FINN, Geneva, Switzerland

788 Point-of-Care p24 Infant Testing May Increase Patient Yield Despite Low Sensitivity

Bindiya Meggi¹; Nedio Mabunda¹; Adolfo Vubil¹; Osvaldo Loquilha²; Jorge I. Quevedo³; Ocean Tobaiwa⁴; Timothy Bollinger⁵; Lara Vojnov⁶; Trevor Peter⁷; Ilesh V. Jani⁸
¹Inst Nacional de Saúde de Mocambique, Maputo, Mozambique; ²Univ Eduardo Mondlane, Maputo, Mozambique; ³Clinton Hlth Access Initiative, Maputo, Mozambique; ⁴Clinton Hlth Access Initiative, Gaborone, Botswana; ⁵Inst Nacional de Saude, Maputo, Mozambique

Session P-T1 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Pharmacokinetics: Efficacy and Safety of New ARVs in Children

815 Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Edmund Capparelli¹; Kenneth Maswabi²; Steven Rossi³; Muchaneta Bhonday⁴; Sikhulile Moyo⁵; Patrick Jean-Philippe⁶; Michael Hughes⁷; Mathias Lichtenfeld⁸; Daniel Kuritzkes⁹; Roger L. Shapiro⁵
¹Univ of California San Diego, San Diego, CA, USA; ²Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁴Henry M. Jackson Fndn for the Advancement of Military Med, Inc, Rockville, MD, USA; ⁵Harvard Sch of PH, Boston, MA, USA; ⁶Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ⁷Harvard Med Sch, Boston, MA, USA

816 IMPAACT 1093: Dolutegravir in 6- to 12-Year-Old HIV-Infected Children: 48-Week Results

Andrew Wiznia¹; Carmelita Alvero²; Terry Fenton³; Kathleen George⁴; Ellen Townley⁵; Rohan Hazra⁶; Bobbie Graham⁷; Annie Buchanan⁸; Cindy Vavro⁹; Rolando Viani¹⁰; for the IMPAACT P1093 Study Group
¹Albert Einstein Coll of Med, Bronx, NY, USA; ²Harvard Sch of PH, Boston, MA, USA; ³SDAC, Harvard Sch of PH, Boston, MA, USA; ⁴IMPACT Operations, Durham, NC, USA; ⁵NIH, Rockville, MD, USA; ⁶Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁷Frontier Sci & Tech Rsr Fndn, Inc, Buffalo, NY, USA; ⁸GSK, Research Triangle Park, NC, USA; ⁹ViiV Hlthcare, Research Triangle Park, NC, USA; ¹⁰Univ of California San Diego, San Diego, CA, USA

817 Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Treatment-Naïve Adolescents

Aditya Gaur¹; Hilda Kizito²; Rana Chakraborty³; Jagmohan Batra⁴; Pope Kosalaraksa⁵; Wicham Luesomboon⁶; Yongwu Shao⁷; Devi SenGupta⁸; Martin S. Rhee⁹; Erin Quirk¹⁰
¹St. Jude Children's Rsr Hosp, Memphis, TN, USA; ²Joint Clinical Rsr Cntr, Kampala, Uganda; ³Emory Univ, Atlanta, GA, USA; ⁴Miller Children's Hosp, Long Beach, CA, USA; ⁵Khon Kaen Univ, Khon Kaen, Thailand; ⁶Queen Savang Vadhana Memorial Hosp, Chon Buri, Thailand; ⁷Gilead Scis, Inc, Foster City, CA, USA

818 Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Carlo Giaquinto¹; Muthuhadini P. Mawela²; Kulkanya Chokephaibulkit³; Annie Fang⁴; Elna van der Ryst⁵; Srinivas Rao Valluri⁶; Manoli Vourvahis⁷; Rebecca Zhang-Roper⁸; Lynn McFadyen⁹; Jayvant Heera⁸
¹Univ of Padova, Padova, Italy; ²Sefako Makgatho Hlth Scis Univ, Pretoria, South Africa; ³Siriraj Hosp, Mahidol Univ, Bangkok, Thailand; ⁴Pfizer, Inc, New York, NY, USA; ⁵Pfizer Inc, The Rsr Network, Sandwich, UK; ⁶GSK, Stockley Park, UK; ⁷Pfizer, Inc, Sandwich, UK; ⁸Pfizer, Inc, Groton, CT, USA

819 Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study

Vania Giacomet¹; Katia Maruca²; Paola Erba³; Maria Puzovio⁴; Pilar Nannini⁵; Silvia Capelli⁶; Alessandro Ambrosi⁷; Gianvincenzo Zuccotti⁸; Stefano Mora⁹
¹Luigi Sacco Hosp, Univ of Milan, Milan, Italy; ²San Raffaele Scientific Inst, Milan, Italy; ³Univ of Milan, Milan, Italy; ⁴Ospedale Buzzi, Univ of Milan, Milan, Italy

**Session P-T2 Poster Abstracts
2:45 PM-4:00 PM**

Hall D

Getting a Handle on CNS Disease in Children and Adolescents

820 HIV Encephalopathy Despite Prolonged Viral Suppression With Slow Spontaneous Recovery

Steve Innes; Barbara Laughton; Ronald van Toorn; Els Dobbels; Mark F. Cotton
 Stellenbosch Univ and Tygerberg Children's Hosp, Cape Town, South Africa

821 A Diffusion Tensor Imaging and Neurocognitive Study of HIV-Infected Children

Jacqueline Hoare¹; J.P. Fouché²; Nicole Phillips¹; John Joska¹; Robert Paul¹; Kirsten Donald¹; Kevin Thomas¹; Dan Stein¹
¹Univ of Cape Town, Cape Town, South Africa; ²Missouri Inst of Mental Hlth, St. Louis, MO, USA

822 Brain Volumes, HIV Disease Severity, and Substance Use in Perinatally Infected Youth

Paige L. Williams¹; Yanling Huo²; Shirlene D. Wang³; Kristina Uban³; Kathleen Malee⁴; Sharon L. Nichols⁵; Russell B. Van Dyke⁶; Lei Wang⁷; Elizabeth R. Sowell⁸; for the Pediatric HIV/AIDS Cohort Study (PHACS) and the Pediatric Imaging, Neurocognition, and Genetics (PING) Study
¹Harvard Sch of PH, Boston, MA, USA; ²Northwestern Univ, Chicago, IL, USA; ³Children's Hosp of Los Angeles, Los Angeles, CA, USA; ⁴Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, USA; ⁵Univ of California San Diego, San Diego, CA, USA; ⁶Tulane Univ Sch of Med, New Orleans, LA, USA; ⁷Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ⁸Keck Sch of Med at the Univ of Southern California, Los Angeles, CA, USA

823 Long-term Effects on Basal Ganglia in Youth With Perinatally Acquired HIV Infection

Christine Paula de los Angeles¹; Paige L. Williams²; Yanling Huo³; Kathleen Malee⁴; John G. Csernansky⁵; Ram Yegov⁶; Russell B. Van Dyke⁷; Elizabeth R. Sowell⁸; Lei Wang⁹; for the Pediatric HIV/AIDS Cohort Study (PHACS)
¹Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, USA; ⁴Tulane Univ Sch of Med, New Orleans, LA, USA; ⁵Keck Sch of Med at the Univ of Southern California, Los Angeles, CA, USA

Session P-T3 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Immunopathogenesis in HIV-Infected Children

824 Risk Factors for BCG IRIS in HIV-Infected infants Starting Antiretroviral Treatment

Varghese K. George¹; Elisa Nemes²; Asma Toefy³; Willem Hanekom⁴; Mark F. Cotton⁵; Charles D. Mitchell⁶; James Oleski⁷; Bonnie Zimmer⁸; Terry Fenton⁹; Savita Pahwa¹⁰; for the IMPAACT P1073
¹Univ of Miami, Miami, FL, USA; ²Univ of Cape Town, Cape Town, South Africa; ³Stellenbosch Univ and Tygerberg Children's Hosp, Cape Town, South Africa; ⁴Univ of Miami Miller Sch of Med, Miami, FL, USA; ⁵New Jersey Med Sch, Newark, NJ, USA; ⁶Frontier Sci & Tech Rsr Fndn, Inc, Amherst, MA, USA; ⁷SDAC, Harvard Sch of PH, Boston, MA, USA

825 Enhanced Inflammation and Rotavirus Vaccine Responses in Perinatal HIV-1 Infection

Priyanka Uprety¹; Jane Lindsey²; Myron Levin³; Kaitlin Rainwater-Lovett⁴; Carrie Ziemiak⁵; Susan Kaplan⁶; Micki Nelson⁷; Amanda Zadzilka⁸; Adriana Weinberg⁹; Deborah Persaud¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ⁴Merck Rsr Lab, North Wales, PA, USA; ⁵Frontier Sci & Tech Rsr Fndn, Inc, Amherst, NY, USA; ⁶Univ of Colorado, Denver, CO, USA

826 Vitamin D Supplementation Decreases Immune Activation and Exhaustion in HIV+ Youth

Allison R. Eckard¹; Ann Chahroudi²; Julia C. Rosebush³; Mary Ann O'Riordan⁴; Julie E. Daniels⁵; Monika Uribe-Leitz⁶; Bruce Kinley⁷; Danielle Labbato⁸; Vin Tangpricha⁹; Grace A. McComsey⁹
¹Med Univ of South Carolina, Charleston, SC, USA; ²Emory Univ Sch of Med, Atlanta, GA, USA; ³Case Western Reserve Univ, Cleveland, OH, USA

827 Contrasting CTL Impact in Distinct Phenotypes of Nonprogressing Pediatric HIV

Ellen M. Leitman¹; Astrid Gall²; Paul Kellam³; Jacqui Brener⁴; Azim Ansari⁵; Christina F. Thobakgale⁶; Philippa C. Matthews⁷; Philip Goulder⁸
¹Univ of Oxford, Oxford, UK; ²Wellcome Trust Sanger Inst, Hinxton, UK; ³HIV Pathogenesis Prog, Doris Duke Med Rsr Inst, Univ of KwaZulu-Natal, Durban, South Africa

828 Impact of HLA-B*81-driven Escape Mutation L188F on VRC in Pediatric Slow Progression

Ming-Han Tsai¹; Maximilian Muenchhoff²; Emily Adland³; Anna Carlqvist⁴; David Cole⁵; Andrew K. Sewell⁶; Jonathan Carlson⁷; Thumbi P. Ndungu⁸; Philip Goulder⁹; for the Professor Philip Goulder's Group
¹Univ of Oxford, Oxford, UK; ²Cardiff Univ, Cardiff, UK; ³Microsoft Rsr, Redmond, WA, USA; ⁴Univ of KwaZulu-Natal, Durban, South Africa

Session P-V1 Poster Abstracts
2:45 PM-4:00 PM

Hall D

It's Complicated: Renal Function and STIs in PrEP Users

- 866 Higher Cumulative TFV/FTC Levels in PrEP Associated With Decline in Renal Function**
Monica Gandhi¹; David V. Glidden¹; Albert Y. Liu²; Howard Hornig³; K. R. Amico⁴; Kathleen Mulligan⁵; Sybil Hosek⁶; Mauro Schechter⁷; Kenneth H. Mayer⁸; Robert Grant⁹; for the PrEP Study Team
¹Univ of California San Francisco, San Francisco, CA, USA; ²San Francisco Dept of PH, San Francisco, CA, USA; ³Univ of Michigan Sch of PH, Ann Arbor, MI, USA; ⁴John H. Stroger Jr Hosp of Cook County, Chicago, IL, USA; ⁵Projeto Praça Onze, Universidade Fed do Rio de Janeiro, Rio de Janeiro, Brazil; ⁶The Fenway Inst, Fenway Hlth, Boston, MA, USA
- 867 Changes in Renal Function Associated With TDF/FTC PrEP Use in the US Demo Project**
Albert Y. Liu¹; Eric Vittinghoff²; Peter L. Anderson³; Stephanie Cohen⁴; Susanne Doblecki-Lewis⁵; Oliver Bacon⁶; Wairimu Chege⁷; Susan P. Buchbinder⁸; Michael Kolber⁹; Richard Elion⁹; for the Demo Project Team
¹San Francisco Dept of PH, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Colorado, Denver, CO, USA; ⁴Univ of Miami, Miami, FL, USA; ⁵DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁶George Washington Univ Sch of Med, Washington, DC, USA
- 868 Rare Incidence of Proximal Tubular Dysfunction With Tenofovir-Based Chemoprophylaxis**
Kenneth K. Mugwanya¹; Jared M. Baeten²; Connie M. Celum³; Deborah Donnell⁴; Thomas Nickolas⁵; Nelly R. Mugoo⁶; Andrea Branch⁷; James K. Bairie⁸; Allan Ronald⁹; Christina Wyatt⁹; for the Partners PrEP Study Team
¹Univ of Washington, Seattle, WA, USA; ²SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³Columbia Univ, New York, NY, USA; ⁴Kenya Med Rsr Inst, Thika, Kenya; ⁵Icahn Sch of Med at Mount Sinai, New York, NY, USA; ⁶Univ of Nairobi, Nairobi, Kenya; ⁷Univ of Manitoba, Winnipeg, MB, Canada
- 869 STI Data From Community-Based PrEP Implementation Suggest Changes to CDC Guidelines**
Sarit A. Golub¹; Stephanie Pena²; Kailip Boonrai³; Nora Douglas⁴; Machel Hunt⁵; Asa Radix⁶
¹Hunter Coll and the Grad Cntr, City Univ of New York, New York, NY, USA; ²Callen-Lorde Community Hlth Cntr, New York, NY, USA; ³Hunter HIV/AIDS Rsr Team (HART), Hunter Coll, New York, NY, USA
- 870 Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project**
Stephanie Cohen¹; Eric Vittinghoff²; Susan S. Philip³; Susanne Doblecki-Lewis⁴; Oliver Bacon⁵; Wairimu Chege⁶; Richard Elion⁷; Susan P. Buchbinder⁸; Michael Kolber⁹; Albert Y. Liu⁹
¹San Francisco Dept of PH, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Miami, Miami, FL, USA; ⁴DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁵George Washington Univ Sch of Med, Washington, DC, USA

Session P-W1 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Populations at Risk for HIV

- 895 National HIV Incidence Estimates Among STI Clinic Attendees in England, UK**
Adamah Aghaizu¹; Gary Murphy²; Jennifer Tosswill¹; Daniela De Angelis³; Helen Ward⁴; Gwenda Hughes⁵; Noel O. Gill⁶; Valerie Delphech⁷
¹PH England, London, UK; ²Med Rsr Council Biostatistics Unit, Cambridge, UK; ³Imperial Coll London, London, UK
- 896 High HIV Incidence in Men Attending New York City LGBT and STD Clinics, 2009-2012**
Lucia V. Torian¹; Lisa A. Forgiore¹; William Duffy¹; Bisrom Deocharan¹; Robert Pirillo²; Orlin Trochev³; Amado Punsalang²; Anthony Muyombwe³
¹New York City Dept of Hlth, Long Island City, NY, USA; ²New York City Dept of Hlth, New York, NY, USA; ³Connecticut Dept of Hlth, Hartford, CT, USA
- 897 Longitudinal Analysis of Sexual Networks of US Black MSM in HPTN 061**
Hong Van N. Tieu¹; Beryl A. Koblin¹; Vijay Nandi¹; Pich Seekaew²; Sophia Hussen³; DeMarc A. Hickson⁴; Kenneth H. Mayer⁵; Hyman Scott⁶; Vanessa Cummings⁷; Carl Latkin⁸; for the HPTN 061 Study Team
¹New York Blood Cntr, New York, NY, USA; ²Columbia Univ Mailman Sch of PH, New York, NY, USA; ³Emory Univ, Atlanta, GA, USA; ⁴Univ of Mississippi Med Cntr, Jackson, MS, USA; ⁵The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁶Univ of California San Francisco, San Francisco, CA, USA; ⁷Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁸Johns Hopkins Univ, Baltimore, MD, USA
- 898 Does Size Really Matter? Sensitivity Analysis of Number of Seeds in an RDS Study**
Nathan J. Lachowsky¹; Henry F. Raymond²; Zishan Cui³; Paul Sereda³; Ashleigh Rich⁴; Eric A. Roth⁵; Robert S. Hogg⁶; David M. Moore⁶; for the Momentum Health Study
¹Univ of British Columbia, Vancouver, BC, Canada; ²Univ of California San Francisco, San Francisco, CA, USA; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁴Univ of Victoria, Victoria, BC, Canada; ⁵Simon Fraser Univ, Burnaby, BC, Canada; ⁶Univ of British Columbia, Vancouver, BC, Canada
- 899 Respondent-Driven Sampling: An Epidemiological Tool With Interventional Potential**
Sunil S. Solomon¹; Aylur K. Srikrishnan²; Santhanam Anand³; Allison M. McFall⁴; Pachamuthu Balakrishnan⁵; David Celentano⁶; Suresh Kumar⁷; Gregory M. Lucas⁸; Shruti H. Mehta¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²YRG Cntr for AIDS Rsr and Educ, Tararami, India; ³YRG Cntr for AIDS Rsr and Educ, Chennai, India
- 900 10 Years of HIV and STI Testing at Silom Community Clinic (SCC) in Bangkok, Thailand**
Eileen Dunne¹; Kevin Weiss²; Sarika Pattanasin³; Boonyos Raengsakulrach⁴; Warunee Thienkrua⁵; Kanokpan Pancharoen⁶; Pachara Sirivongrangson⁷; Anchalee Varangrat⁸; Chaiwat Ungsedhapand⁹; **Timothy H. Holtz**¹
¹CDC, Atlanta, GA, USA; ²Emory Univ Rollins Sch of PH, Atlanta, GA, USA; ³Thailand Ministry of PH US CDC Collab, Nonthaburi, Thailand

901 Why Are Trends in HIV Diagnoses in Sub-Saharan African Migrants in Europe Changing?

Julia Del Amo¹; Inmaculada Jarrin¹; Vicky Hernando¹; Debora Alvarez Del Arco¹; Susana Monge¹; Belen Alejos¹; Francisco Bolumar¹; Andrew Amato¹; Teymur Noori¹; Anastasia Pharris¹; for the Del Amo J, Jarrin I, Hernando V, Álvarez Del-Arco D, Monge S, Alejos S, Bolúmar F, Amato A, Noori T, Pharris A
¹*Inst de Salud Carlos III, Madrid, Spain*; ²*Univ de Alcalá, Madrid, Spain*; ³*European CDC, Stockholm, Sweden*

902 Migration, HIV Infection, and Combination HIV Prevention Access in Rakai, Uganda

Mary K. Grabowski¹; Justin Lessler¹; Jeremiah M. Bazaale²; Larry W. Chang³; Dorean Nabukalu²; Maria J. Wawer¹; Fred Nalugoda⁴; Robert Sekubugu⁵; Gertrude Nakigozi⁶; Ronald H. Gray⁴
¹*Johns Hopkins Univ, Baltimore, MD, USA*; ²*Rakai Hlth Scis Prog, Kalisizo, Uganda*; ³*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ⁴*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*; ⁵*Rakai Hlth Scis Prog, Entebbe, Uganda*; ⁶*Rakai Hlth Scis Prog, Baltimore, MD, USA*

903 HIV Epidemiology and Service Uptake Among Fisherfolk in Asembo, Western Kenya, 2015

Fredrick S. Odongo¹; Emily Zielinski-Gutierrez²; Kennedy Mutai¹; Paul Ogindo¹; George Ollilo¹; Barbara Burmen¹; Daniel Kwaro¹; Kenneth Masamaro¹; Caroline Kambona¹
¹*Kenya Med Rsr Inst, Kisumu, Kenya*; ²*US CDC, Kenya, Nairobi, Kenya*

904 Young HIV+ Adults in Botswana Less Likely to Seek Treatment or Be Virally Suppressed

Vladimir Novitsky¹; Tendani Gaolathe²; Mompoti Mmalane²; Sikhulile Moyo³; Molly Pretorius Holme¹; Kathleen Powis¹; Kathleen Wirth¹; Eric Tchetgen Tchetgen¹; Shahin Lockman¹; M. Essex¹
¹*Harvard Sch of PH, Boston, MA, USA*; ²*Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana*; ³*Massachusetts General Hosp, Boston, MA, USA*; ⁴*Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA*

905 High Risk of HIV Transmission and Acquisition Among Older South Africans

Molly S. Rosenberg¹; Xavier Gomez-Olive²; Julia K. Rohr¹; Brian Houle¹; Stephen Tollman¹; Kathleen Kahn¹; Till Bärnighausen¹
¹*Harvard Sch of PH, Boston, MA, USA*; ²*Med Rsr Council/Wits Rural PH and Health Transition Unit, Johannesburg, South Africa*; ³*Harvard Univ Sch of PH, Boston, MA, USA*; ⁴*Australian Natl Univ, Canberra, Australia*; ⁵*Univ of the Witwatersrand, Johannesburg, South Africa*

**Session P-W2 Poster Abstracts
2:45 PM-4:00 PM**

Hall D

Infection Status, Care, and Mortality

906 Factors Associated With Misreporting HIV Status Among MSM From Baltimore

Danielle German¹; Kate Shearer¹; Ju Nyeung Park¹; Colin Flynn²; Carl Latkin¹; Oliver Laeyendecker¹; Thomas C. Quinn¹; William Clarke³
¹*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*; ²*Maryland DHMH, Baltimore, MD, USA*; ³*Johns Hopkins Univ, Baltimore, MD, USA*; ⁴*NIH, Bethesda, MD, USA*; ⁵*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*

907 Validation of Self-Reported HIV Status Among Older Adults in Rural South Africa

Julia K. Rohr¹; Molly S. Rosenberg¹; Xavier Gomez-Olive²; Ryan Wagner¹; Brian Houle¹; Joshua Salomon¹; Stephen Tollman¹; Kathleen Kahn¹; Till Bärnighausen²
¹*Harvard Univ Sch of PH, Boston, MA, USA*; ²*Harvard Sch of PH, Boston, MA, USA*; ³*Med Rsr Council/Wits Rural PH and Health Transition Unit, Johannesburg, South Africa*; ⁴*Australian Natl Univ, Canberra, Australia*; ⁵*Univ of the Witwatersrand, Johannesburg, South Africa*

908 Demographics and HIV Care Among New Yorkers Living With HIV by Diagnostic Cohort

Laura Kersanske¹; Graham Harriman¹; Lucia V. Torian²; Sarah L. Braunstein¹
¹*New York City DHMH, Queens, NY, USA*; ²*New York City Dept of Hlth, Long Island City, NY, USA*

909 The Impact of HIV on Mortality in Nairobi, Kenya

Catherine N. Kiama¹; Peter W. Young²; Andrea Kim³; Joyce Wamicwe¹; Kevin M. De Cock¹; Johansen Oduor¹; Emily Rogena⁴; Julius Oyugi¹; Marie Downer²; Martin W. Sirengo⁶
¹*Ministry of Hlth, Nairobi, Kenya*; ²*CDC, Nairobi, Kenya*; ³*CDC, Atlanta, GA, USA*; ⁴*Sch of Med, Univ of Nairobi, Nairobi, Kenya*; ⁵*Cntrs for Disease Control & Prevention-Kenya, Nairobi, Kenya*; ⁶*Natl AIDS and STI Control Prog, Nairobi, Kenya*

910 Access to HIV Care in Health Districts Affected by Ebola Epidemic in Sierra Leone

Jacques D. Ndawinz¹; Kenneth Katumba²; Victor Kamara³; Wogba Kamara³; Lamin Bangura⁴; Victoria Kamara⁵; Umu N. Nabieu⁶; Etienne Guillard¹
¹*Sothlis NGO, Paris, France*; ²*Sothlis NGO, Conakry, Guinea*; ³*Natl AIDS Secretariat, Freetown, Sierra Leone*; ⁴*Natl AIDS/VIH Control Prog, Freetown, Sierra Leone*

Session P-W3 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Sex, Drugs, Depression, and HIV

911 Effect of Alcohol on All-Cause and Liver-Related Mortality Among Individuals With HIV

Chelsea Canan¹; Bryan Lau¹; Mary McCaul²; Richard Moore³; Geetanjali Chander²
¹*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*; ²*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ³*Johns Hopkins Univ, Baltimore, MD, USA*

912 Alcohol Use and Unprotected Sex in HIV-Positive Female Sex Workers in Mombasa

Darcy White¹; Kate S. Wilson¹; Linnet Masese²; George Wanje¹; Walter Jaoko¹; Kishor Mandalia³; Barbra A. Richardson¹; Jane Simoni¹; Scott McClelland¹
¹*Univ of Washington, Seattle, WA, USA*; ²*Kenya Rsr Prog at the Univ of Washington, Nairobi, Kenya*; ³*Univ of Nairobi, Nairobi, Kenya*; ⁴*Coast Province General Hosp, Mombasa, Kenya*

913 Chemsex and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men

Erica L. Pufall¹; Meaghan Kall²; Maryam Shahmanesh³; Anthony Nardone⁴; Richard Gilson⁵; Valerie Delpech⁶; Helen Ward⁷; for the Positive Voices Study Group
¹Imperial Coll London, London, UK; ²PH England, London, UK; ³Univ Coll London, London, UK

914 Testosterone Use and HIV Serostatus Among Men Who Have Sex With Men in the MACS

Sabina A. Haberlen¹; Lisa Jacobson²; Frank J. Palella³; Adrian S. Dobs⁴; Michael W. Plankey⁵; Jordan Lake⁶; Lawrence Kingsley⁷; Ron Stall⁸; Wendy S. Post⁴; Todd T. Brown⁹
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Northwestern Univ, Chicago, IL, USA; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁵Georgetown Univ Med Cntr, Washington, DC, USA; ⁶David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ⁷Univ of Pittsburgh, Pittsburgh, PA, USA; ⁸Sci Cntr for LGBT Hlth Rsr, Univ of Pittsburgh, Pittsburgh, PA, USA

915 Prevalence of Opioid Prescriptions and Risk Factors for Abuse in HIV-Infected Adults

Alejandro Pérez; Heather Bradley; Shikha Garg; Luke Shouse CDC, Atlanta, GA, USA

916 Risk Factors for HIV in an Outbreak Among Persons Who Inject Drugs, Indiana 2015

Monita Patel¹; Jesse Shields²; Michael T. Spiller³; Caitlin Conrad⁴; Jeremy Roseberry⁵; Dorothy Waterhouse⁶; Pamela Pontones⁷; Philip Peters⁸; Joan Duwve⁹; John T. Brooks¹
¹CDC, Atlanta, GA, USA; ²Clark County Hlth Dept, Jeffersonville, IN, USA; ³Indiana State Dept of Hlth, Indianapolis, IN, USA

917 Cross-Sectional vs Longitudinal HIV Incidence Estimates in People Who Inject Drugs

Andrew F. Longosz¹; Shruti H. Mehta²; Gregory D. Kirk³; Jacquie Astemborski⁴; Thomas C. Quinn⁵; Susan H. Eshleman⁶; **Oliver Laeyendecker**⁷; for the AIDS Link to Intravenous Experiences (ALIVE) cohort
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁴NIH, Bethesda, MD, USA

918 Gender-Specific Factors Related to HIV Risks Among People Who Inject Drugs in India

Bushra Sabri¹; Aylur K. Srikrishnan²; Sunil S. Solomon³; Allison M. McFall⁴; C.K. Vasudevan⁵; Santhanam Anand⁶; David Celentano⁷; Shruti H. Mehta⁸; Suresh Kumar⁹; Gregory M. Lucas¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²YRG Cntr for AIDS Rsr and Educ, Taramani, India

919 Depression and Social Isolation Mediate Effect of HIV Stigma on Women's ART Adherence

Janet M. Turan¹; Bulent Turan¹; Whitney Smith¹; Mardge Cohen²; Tracey E. Wilson³; Ada Adimora⁴; Daniel Merenstein⁵; Adebola Adedimeji⁶; Lisa R. Metsch⁷; Sheri Weiser⁸
¹Univ of Alabama at Birmingham, Birmingham, AL, USA; ²John H. Stroger Jr. Hosp of Cook County and Rush Med Coll, Chicago, IL, USA; ³State Univ of New York Downstate Med Cntr, Brooklyn, NY, USA; ⁴Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁵Georgetown Univ, Washington, DC, USA; ⁶Albert Einstein Coll of Med, Bronx, NY, USA; ⁷Columbia Univ Mailman Sch of PH, New York, NY, USA; ⁸Univ of California San Francisco, San Francisco, CA, USA

920 Depression Increases the Risk of Mortality in a Large Cohort of HIV-Infected Adults

Angela Bengtson¹; Brian W. Pence¹; Heidi M. Crane²; Katerina A. Christopoulos³; Amy D. Heine⁴; W. C. Mathew⁵; Matthew Mimiaga⁶; Richard Moore⁷; Sonia Napravnik⁸; Conall M. O'Clairigh⁹; Michael J. Mugavero⁸
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Univ of Washington, Seattle, WA, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴Univ of California San Diego, San Diego, CA, USA; ⁵Brown Univ Sch of PH, Providence, RI, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA; ⁷Massachusetts General Hosp, Boston, MA, USA; ⁸Univ of Alabama at Birmingham, Birmingham, AL, USA

Session P-X1 Poster Abstracts**Hall D****2:45 PM-4:00 PM****Insights from Antiretroviral Therapy Use: High-Income Settings****938 When to Start Antiretroviral Therapy in HIV-Positive Persons Aged Over 50 Years**

Sara Lodi; for the HIV-CAUSAL Collaboration, Harvard Sch of PH, Boston, MA, USA

939 Changes in Markers of T-Cell Senescence and Exhaustion With HIV Therapy

Theodoros Kelesidis¹; Carlee B. Moser²; James H. Stein³; Todd T. Brown⁴; Thuy T. Tran⁵; Heather J. Ribaudo⁶; Michael Dube⁷; Robert Murphy⁸; Otto Yang⁹; Judith S. Currier¹⁰; Grace A. McComsey⁷
¹David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of Wisconsin-Madison, Madison, WI, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Keck Sch of Med at the Univ of Southern California, Los Angeles, CA, USA; ⁶Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ⁷Case Western Reserve Univ, Cleveland, OH, USA

940 Should NRTIs Remain As the First-Line Therapy Choice in Resource-Limited Settings?

Viviane D. Lima¹; Mark W. Hull¹; David McVera²; P. Richard Harrigan¹; William Chau¹; Julio Montaner¹
¹BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ²Univ of British Columbia, Vancouver, BC, Canada

- 941 Lower Mortality Among Patients Starting ART From 2008 to 2010 Than Earlier in the ART Era**
Adam Trickey¹; Margaret May¹; Julia Del Amo²; Niels Obel¹; Heidi M. Crane³; Sophie Abgrall⁴; Colette Smith⁵; Suzanne Ingle¹; Jonathan Sterne⁶; for the Antiretroviral Therapy Cohort Collaboration
¹Univ of Bristol, Bristol, UK; ²Inst de Salud Carlos III, Madrid, Spain; ³Copenhagen Univ Hosp, Rigshospet, Copenhagen, Denmark; ⁴Univ of Washington, Seattle, WA, USA; ⁵Univ Hosp Antoine-Bécélère, Clamart, France; ⁶Univ Coll London, London, UK
- 942 Impact of Each Month Delay in Initiation on the Effect of 1 Year of ART on CD4 Count**
Shu Yang¹; Susan J. Little²; Davey M. Smith²; Victor De Gruttola¹; Judith Lok¹
¹Harvard Sch of PH, Boston, MA, USA; ²Univ of California San Diego, San Diego, CA, USA
- 943 Outcomes on CART in France According to Geographic Origin, Sex, and Transmission Group**
Laure-Amélie de Monteynard¹; Jacques Gilquin²; Juliette Pavié³; Jean-Luc Meynard⁴; Marie-Aude Khuong⁵; Anne Simon⁶; Aba Mahamat⁷; David Rey⁸; Dominique Costagliola⁹; Sophie Abgrall¹⁰
¹Inst Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP) UMR-S 1136, Paris, France; ²Hosp Hôtel Dieu, Paris, France; ³Hosp Européen Georges Pompidou, Paris, France; ⁴APHP, Hosp Saint Antoine, Paris, France; ⁵Hosp Delafontaine, Paris, France; ⁶La Pitié Salpêtrière Hosp, Paris, France; ⁷Cntr Hospier Andrée Rosemon, Cayenne, France; ⁸Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ⁹Sorbonne Univs, Paris, France; ¹⁰Univ Hosp Antoine-Bécélère, Clamart, France
- 944 CD4 Cell Response to First-Line cART by HIV Type in European Cohort Collaborations**
Linda Wittkop¹; Sophie Matheron²; for the COHERE in EuroCoord and ACHIEV2e study team writing committee
¹CHU de Bordeaux, Bordeaux, France; ²Hosp Bichat-Claude Bernard, Paris, France
- 945 Efficacy (Cost-Effectiveness) of EFV/FTC/TDF vs FTC/RPV/TDF in Naïve Patients**
Jose M. Gatell¹; Elisa de Lazzari²; Enrique Redondo³; Jose Mallolas⁴; Esteban Martinez⁵; Jordi Blanch⁶; Maria Martinez-Robollar⁷; Jose L. Blanco⁸; Berta Torres⁹
¹Hosp Clinic of Barcelona, Barcelona, Spain; ²Hosp Clinic de Barcelona, Barcelona, Spain; ³Gilead Scis, Inc, Madrid, Spain
- 946 Correlations of Pre-ART HIV-DNA With Outcome in First-Line Treated ART Patients**
Francesca Ceccherini-Silberstein¹; Alessandro Cozzi-Leprè²; Esther Merlini³; Giulia Marchetti⁴; Maria R. Capobianchi⁵; Andrea De Luca⁶; Nicola Gianotti⁷; Andrea Antinori⁸; Carlo Federico Perno⁹; Antonella d'Arminio Monforte¹⁰; for the ICONA Foundation
¹Univ of Rome Tor Vergata, Rome, Italy; ²Univ Coll London, London, UK; ³Univ of Milan, Milan, Italy; ⁴Clinic of Infectious Diseases, Univ of Milan, San Paolo Hosp, Milan, Italy; ⁵Inst Nazionale Malattie Infettive "L. Spallanzani", Rome, Italy; ⁶Univ of Siena, Siena, Italy; ⁷San Raffaele Scientific Inst, Milan, Italy; ⁸Univ of Rome Tor Vergata, Roma, Italy; ⁹Infectious Diseases Clinic, San Paolo Hosp, Univ of Milan, Milan, Italy
- 947 Comparable Viral Decay in Dual and Triple Dolutegravir-Based Antiretroviral Therapy**
Omar G. Sued¹; Maria I. Figueroa²; Maria J. Rolon¹; Patricia Patterson³; Danae Brown⁴; Ana M. Gun⁵; Michael Aboud⁶; Kimberley Y. Smith⁷; Pedro Cahn¹
¹Fundación Huésped, Buenos Aires, Argentina; ²Hosp Juan A. Fernández, Buenos Aires, Argentina; ³ViiV Hlthcare, Abbotsford, Australia; ⁴Centro Medico Huesped, Buenos Aires, Argentina; ⁵ViiV Hlthcare, Brentford, UK; ⁶ViiV Hlthcare, Research Triangle Park, NC, USA
- 948 Unexpectedly High Rate of Intolerance for Dolutegravir in Real-Life Setting**
 Guido van den Berk¹; Josephine Oryszczyn; Willem Blok; Narda van der Meche; Rosa Regez; Daoud Ait Moha; **Kees Brinkman**
 OLVG Hosp, Amsterdam, Netherlands
- 949 Association of Antiretroviral Use and Abnormal Uterine Bleeding in Women With HIV**
Christina Valiaveetil¹; Sheila Caddy²; Mark Yudin³; Anita Benoit⁴; Erin Ding⁵; Angela Kaida⁶; Alexandra de Pokomandy⁷; Robert S. Hogg⁸; Mona Loufy⁴
¹Univ of Toronto, Toronto, ON, Canada; ²South Hlth Campus, Calgary, AB, Canada; ³St Michael's Hosp, Toronto, ON, Canada; ⁴Women's Coll Rsr Inst, Univ of Toronto, Toronto, ON, Canada; ⁵British Columbia Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁶Simon Fraser Univ, Burnaby, BC, Canada; ⁷McGill Univ Hlth Cntr, Montréal, QC, Canada
- 950 No Selection of X4 Viruses by Maraviroc in Cell Reservoirs in R5X4 HIV Infections**
Stéphanie Raymond¹; Romain Carcenac; Florence Nicot; Nicolas Jeanne; Michelle Cazabat; Mary Requena; Lise Cuzin; Pierre Delobel; Jacques Izopet
 CHU Toulouse, Toulouse, France
- 951 Failure Rate in NRTI-Free Treatment Is Higher in 2 Compared to 3 Class Regimens**
Alexandra Scherrer¹; Jürg Böni²; Sabine Yerly³; Thomas Klimkait⁴; Vincent Aubert⁵; Matthias Cavasini⁶; Manuel Battegay⁷; Christoph Hauser⁸; Enos Bernasconi⁹; Huldrych F. Günthard¹⁰; for the Swiss HIV Cohort Study
¹Univ Hosp Zürich, Zürich, Switzerland; ²Inst of Med Virology, Swiss Natl Cntr for Retroviruses, Zürich, Switzerland; ³Geneva Univ Hosp, Geneva, Switzerland; ⁴Univ of Basel, Basel, Switzerland; ⁵Univ Hosp Lausanne, Lausanne, Switzerland; ⁶Univ Hosp Lausanne, Univ of Lausanne, Lausanne, Switzerland; ⁷Univ Hosp Basel, Basel, Switzerland; ⁸Bern Univ Hosp and Univ of Bern, Bern, Switzerland; ⁹Regional Hosp Lugano, Lugano, Switzerland; ¹⁰Univ Hosp Zurich, Zurich, Switzerland
- 952 The Impact of Medication Adherence on Virologic Failure in A5202**
Robert A. Parker¹; Dustin J. Rabideau²; Paul E. Sax³; Camlin Tierney⁴; Eric Daar⁵; Ann Collier⁶; Elena Losina⁷; Kenneth A. Freedberg¹
¹Massachusetts General Hosp, Boston, MA, USA; ²Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ³Harvard Sch of PH, Boston, MA, USA; ⁴Harbor Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ⁵Univ of Washington, Seattle, WA, USA

953 INSTI In-Class Switching on Continued Viral Suppression in the OPERA Cohort

Michael B. Wohlfeiler¹; Felix Carpio²; Phillip Lackey³; Cassidy Henegar⁴; Jennifer Fusco⁵; Michele Jonsson Funk⁶; Edward Vonesh⁶; Edwin DeJesus⁷; Gregory Fusco⁸; Anthony Mills⁹
¹AIDS Hlthcare Fndn, Los Angeles, CA, USA; ²AltaMed Hlth Services, Los Angeles, CA, USA; ³Carolinas Hlthcare System, Charlotte, NC, USA; ⁴Epididian, Inc, Durham, NC, USA; ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁶Northwestern Univ, Chicago, IL, USA; ⁷Orlando Immunology Cntr, Orlando, FL, USA; ⁸Anthony Mills, MD, Inc, Palm Springs, CA, USA

Session P-X2 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Insights from Antiretroviral Therapy Use: Low-Income Settings

954 The Validity of Self-Reported ART Use in Persons Living With HIV in Rakai, Uganda

Mary K. Grabowski¹; Joseph Kagaayi²; Ronald H. Gray³; Oliver Laeyendecker⁴; William Clarke⁵; Steven J. Reynolds⁶; Maria J. Wawer⁷; David Serwadda⁸; Thomas C. Quinn⁹; Aaron A. Tobian¹⁰
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Rakai Hlth Scis Prog, Entebbe, Uganda; ³Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁴NIH, Bethesda, MD, USA; ⁵Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁶Makerere Univ School of PH, Kampala, Uganda

955 Hospital-Based ART Delivery and Patient Outcomes: A Prospective Open Cohort in China

Chuanyi Ning¹; M. Kumi Smith²; Yufeng Hu³; Yun Lan⁴; Joseph D. Tucker¹; Weiping Cai³
¹Univ of North Carolina at Chapel Hill Inst for Global Hlth & Infectious Diseases, Chapel Hill, NC, USA; ²Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ³Guangzhou Eighth People's Hosp, Guangzhou, China

956 Virologic Failure Is Uncommon After Treatment Is Initiated During Acute HIV Infection

Trevor A. Crowell¹; Nittaya Phanuphak²; Suteeraporn Pinyakorn³; Donn Colby⁴; Somporn Tisupak⁵; Putthachard Kansomlap⁶; Naphassantant Laopraynak⁷; Robert O'Connell⁸; Merlin L. Robb⁹; Jintanat Ananworanich⁵; for the RV254/SEARCH010 Study Group
¹US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ²SEARCH, Bangkok, Thailand; ³HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁴Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand; ⁵Military HIV Rsr Prog, Bethesda, MD, USA

957 A Meta-Analysis Estimating Early Mortality ART in HIV-Positive Adults on ART in LMIC

Alana Brennan¹; Lawrence Long²; Johanna C. Useem³; Lindsay Garrison⁴; Matthew P. Fox¹
¹Boston Univ, Boston, MA, USA; ²Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ³Boston Univ Sch of PH, Boston, MA, USA

958 Response to ART and Mortality in Older HIV Patients In a Latin American Cohort

Gabriela Carriquiry¹; Mark Giganti²; Bryan E. Shepherd³; Catherine C. McGowan⁴; Eduardo Gotuzzo⁵
¹Inst de Medicina Trop Alexander von Humboldt, Lima, Peru; ²Vanderbilt Univ Sch of Med, Nashville, TN, USA; ³Vanderbilt Inst for Global Hlth, Nashville, TN, USA

959 Immunovirological Responses to HAART Between HIV-1 Group 0- and M-Infected Patients

C. Kouanfack¹; M. Vray²; A. Kfutwah³; A. Aghokeng⁴; R. Mougnotou⁵; G. Unal⁶; L. Le Foulter⁷; L. Schaeffer⁸; N. Noumsi⁹; E. Alessandri-Grati¹⁰; Eric Delaporte⁶; F. Simon¹¹; Jean-Christophe Plantier⁶; for the DynaM-0 study group
¹Hosp Central, Yaoundé, Cameroon; ²Inst Pasteur, Paris, France; ³Cntr Pasteur du Cameroun, Yaoundé, Cameroon; ⁴Inst de Recherches Medes et d'Etudes des Plantes Medicinales, Yaoundé, Cameroon; ⁵CHU de Rouen, Rouen, France; ⁶UIMI 233-RD/U1175-INSERM/Montpellier Univ, Montpellier, France; ⁷Hosp Saint Louis et Univ Paris Diderot, Paris, France; ⁸Rouen Univ Hosp, Rouen, France

960 Clinical Outcomes With Tenofovir Use in ART: Regression Discontinuity Analysis

Alana Brennan¹; Matthew P. Fox²; Mary-Ann Davies³; Kathryn Stinson⁴; Robin Wood⁵; Prozesky W. Hans⁶; Frank Tanser⁷; Geoffrey Fatti⁸; Till Bärnighausen⁹; Gilles Wandeler¹⁰; Andrew Boulle¹¹; Izukanji Sikazwe¹²; Jacob Bor¹³; Arianna Zanolini¹⁰
¹Boston Univ, Boston, MA, USA; ²Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa; ³Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa; ⁴Univ of Cape Town, Cape Town, South Africa; ⁵Univ of Stellenbosch & Tygerberg, Stellenbosch, South Africa; ⁶Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁷Kheth Impilo AIDS Free Living, Cape Town, South Africa; ⁸Harvard Sch of PH, Boston, MA, USA; ⁹Univ Hosp Bern, Bern, Switzerland; ¹⁰Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ¹¹Boston Univ Sch of PH, Boston, MA, USA

961 24-Week Results of Elvitegravir-Cobicistat-Empiricitabine-Tenofovir DF for HIV-2

Selly Ba¹; Dana N. Raugi²; Robert A. Smith³; Fatima Sall⁴; Khadim Faye⁵; Stephen E. Hawes⁶; Salif Sow⁷; Moussa Seydi⁸; **Geoffrey S. Gottlieb**⁹; for the University of Washington-Dakar HIV-2 Study Group
¹Clinique des Maladies Infectieuses, Dakar, Senegal; ²Univ of Washington, Seattle, WA, USA; ³CHU de Fann, Dakar, Senegal

962 Severe Neutropenia in HIV-Infected People on Antiretroviral Therapy in West Africa

Charline Leroi¹; Eugene Messou²; Albert Minga³; Adrien Sawadogo⁴; Joseph Drabo⁵; Moussa Maiga⁶; Marcel Zannou⁷; Moussa Seydi⁸; Francois Dabis⁹; **Antoine Jaquet**¹
¹INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ²CePReF, ACONDA, Abidjan, Côte d'Ivoire; ³Cntr Médical de Suivi de Donneurs de Sang /CNTS/PRIMO-CI, Abidjan, Côte d'Ivoire; ⁴CHU, Souro Sanou, Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso; ⁵CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; ⁶Service de Hépatito-Gastro-Entérologie, Hosp Gabriel Touré, Bamako, Mali; ⁷Cntr de Prise en Charge des Personnes Vivant Avec le VIH, CHNU, Cotonou, Benin; ⁸CHU de Fann, Dakar, Senegal

963 **Efavirenz Toxicity Manifesting As Cerebellar Ataxia: Case Series From South Africa**

Ebrahim Variava¹; Farai R. Sigauke²; Petudzai Muchichwa³; Gary Maartens⁴; **Neil Martinson⁴**
¹Klerksdorp/Tshepong Hosp, Klerksdorp, South Africa; ²Klerksdorp Tshepong Hosp Complex, Northwest Dept of Hlth, Klerksdorp, South Africa; ³Univ of Cape Town, Cape Town, South Africa; ⁴Perinatal HIV Rsr Unit, Diepkloof, South Africa

Session P-Y1 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Modeling: Understanding Epidemics and ART Programs

1042 **State-Space Models for Engagement, Retention, and Reentry in the HIV Care Cascade**

Hana Lee¹; Becky L. Genberg¹; Monicah Nyambura²; Joseph Hogan¹; Paula Braitstein³; Edwin Sang⁴
¹Brown Univ, Providence, RI, USA; ²Academic Model Providing Access to Hlthcare, Eldoret, Kenya; ³Univ of Toronto, Toronto, ON, Canada

1043 **How Far Are We From Early cART for All? A Nationwide Population-Based Study in France**

Virginie Supervie¹; Jean-Marc Lacombe²; Rosemary Dray-Spira²; **Dominique Costagliola¹**; for the FHDH-ANRS CO4 study group
¹Sorbonne Univ, Paris, France; ²INSERM U1136, Paris, France

1044 **Using Treatment As Prevention Could Eliminate the HIV Epidemic in MSM in Copenhagen**

Justin Okano¹; Danielle Robbins¹; **Laurence Palk¹**; Jan Gerstoft²; Niels Obel³; Sally Blower¹
¹Univ of California Los Angeles, Los Angeles, CA, USA; ²Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark

1045 **Estimated HIV Transmissions to Female Partners of HIV-Infected Men**

Cyprian Wejnert¹; Eli Rosenberg²; Heather Bradley¹; Gabriela Paz-Bailey³; H. Irene Hall⁴; Jacek Skarbinski¹; Jonathan Mermin¹; Jeremy Grey²
¹CDC, Atlanta, GA, USA; ²Emory Univ, Atlanta, GA, USA

1046 **Utility of the 1% HIV Prevalence Threshold in Defining Concentrated HIV Epidemics**

Michael Pickles¹; Marie-Claude Boily²; Sharmistha Mishra²
¹Imperial Coll London, London, UK; ²Univ of Toronto, Toronto, ON, Canada

1047 **The Role of Young Women in the HIV Epidemic in Benin, West Africa**

John R. Williams¹; Eugene L. Geidelberg¹; Michel Alary²; Sharmistha Mishra³; Marie-Claude Boily¹
¹Imperial Coll London, London, UK; ²Univ Laval, Québec, QC, Canada; ³Univ of Toronto, Toronto, ON, Canada

WEDNESDAY, FEBRUARY 24, 2016

Session P-A2 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Viral Proteins: Regulation, Replication, Transcription

190 **Inhibition of TCR Signaling Is Impaired in Nef Clones Derived From Elite Controllers**

Steven W. Jin¹; Tristan Markle¹; Asa Rahimi¹; Bruce D. Walker²; Zabrina Brumme¹; Mark A. Brockman¹
¹Simon Fraser Univ, Burnaby, BC, Canada; ²Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA

191 **HIV-1 Nef Dimerization Is Important for AP2 Recruitment and CD4 Downregulation**

Sherry Shu¹; Lori A. Emert-Sedlak¹; Thomas E. Smithgall
 Univ of Pittsburgh, Pittsburgh, PA, USA

192 **Quantification of HIV-1 Splicing Using a PrimerID-Tagged Deep Sequencing Assay**

Ann Emery¹; Ronald I. Swanstrom
 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

193 **Effects of Differential Cell Signaling in HIV Transcription**

Matthew J. Gagne¹; Wilson W. Wong²; Gillian M. Schiralli Lester³; Andrew Henderson¹
¹Boston Univ Sch of Med, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Univ of Rochester Med Cntr, Rochester, NY, USA

194 **High-Frequency Illegitimate Strand-Transfers Result in Defective HIV Genomes**

Xiaojun Li¹; Peihu Fan¹; Feng Gao²
¹Jilin Univ, Changchun, China; ²Human Vaccine Inst, Duke Univ Med Cntr, Durham, NC, USA

Session P-A3 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Viral Proteins: Insights Into Structure

195 **Gag-Protease-Mediated Replication Capacity Differs According to HIV-1 Subtype**

Marion W. Kiguoya¹; Jaclyn K. Mann¹; Saleha Omarjee¹; Lyle McKinnon¹; Festus M. Kiogora²; Kamini Gounder¹; Blake Ball¹; Joshua Kimani¹; Thumbi P. Ndungu¹
¹Univ of KwaZulu-Natal, Durban, South Africa; ²Univ of Nairobi, Nairobi, Kenya; ³Univ of Manitoba, Winnipeg, MB, Canada

196 **Capsid Plays a Distinct Role in HIV Infection of TCR or TLR2-Activated CD4+ T Cells**

Kimyata Valere¹; Jian Ding²; Theresa Chang¹
¹Rutgers Univ, Newark, NJ, USA; ²PH Rsr Inst, Newark, NJ, USA

197 **Consequences of p24 Gag Mutations for Capsid Stability and Viral Fitness**

Philipp Schommers¹; Gloria Martrus²; Urte Matsch¹; Tom J. Hope³; Gerd Fätkenheuer¹; Marcus Altfeld²
¹Univ of Cologne, Cologne, Germany; ²Heinrich Pette Inst, Hamburg, Germany; ³Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA

- 198 The HIV Env Signal Peptide Impacts the Glycosylation and Antigenicity of gp120**
Jason Yolitz¹; Catherine Schwing¹; Donald Van Ryk¹; Danlan Wei²; Fatima Nawaz³; Katija Jelacic³; Claudia Cicala³; Anthony S. Fauci¹; James Arthos³
¹NIAID, NIH, Bethesda, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³NIH, Bethesda, MD, USA
- 220 Increasing Role of Young MSM to HIV Epidemic Spread and Renewal**
Oliver Ratmann¹; Daniela Bezemer²; Ard van Sighem²; A. M. Pettersson³; Martin Schutten⁴; Woulfert F. Bierman⁵; Peter Reiss⁶; Christophe Fraser⁷; for the ATHENA HIV Observational Cohort
¹Imperial Coll London, London, UK; ²Stichting HIV Monitoring, Amsterdam, Netherlands; ³VU Univ Med Cntr, Amsterdam, Netherlands; ⁴Erasmus Univ Med Cntr, Rotterdam, Netherlands; ⁵Univ Med Cntr Groningen, Univ of Groningen, Groningen, Netherlands; ⁶Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands
- 221 Differences in Outbreak Size for HIV-1 Non-B Subtypes Amongst MSM in the Netherlands**
Daniela Bezemer¹; Anne Cori²; Oliver Ratmann²; Ard van Sighem¹; Peter Reiss³; Christophe Fraser²
¹Stichting HIV Monitoring, Amsterdam, Netherlands; ²Imperial Coll London, London, UK; ³Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands
- 222 Spatiotemporal Dynamics of HIV-1 Transmission in France, 1999–2014**
Antoine Chailion¹; Asma Essat²; Pierre Frange³; Francis Barin⁴; Jade GHOSN⁵; Davey M. Smith⁶; Christine Rouzioux⁶; Cécile Goujard⁷; Laurence Meyer⁸; Marie Laure Chaix⁸
¹Univ of California San Diego, San Diego, CA, USA; ²Universite Paris Sud, INSERM CESP U1018, Paris, France; ³EA7327, Univ Paris Descartes, Paris, France; ⁴Francois-Rabelais Univ, Tours, France; ⁵Hosp Hotel Dieu de Paris, Paris, France; ⁶Necker Hosp, AP-HP, Paris, France; ⁷INSERM, CESP U1018, Le Kremlin-Bicêtre, France; ⁸INSERM U941, Univ Paris Diderot, Paris, France
- 223 Potential Misclassification in Standard HIV Phylogenetic Clusters Association Studies**
Benoit Visseaux¹; Oliver Ratmann²; Christopher Monit³; David Dunn⁴; Kholoud Porter⁵; Stephane Hue⁶
¹INSERM UMR 1137, Paris, France; ²Imperial Coll London, London, UK; ³Univ Coll London, London, UK; ⁴Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ⁵Med Rsr Council, London, UK; ⁶London Sch of Hygiene & Trop Med, London, UK
- 224 Partner Services in Acute and Early HIV-Infected Adults**
Nella Green¹; Christy Anderson²; Sergei Kosakovsky Pond³; Martin Hoernig⁴; Davey M. Smith⁵; Susan Little
Univ of California San Diego, San Diego, CA, USA
- 225 Probabilistic Estimation of HIV-1 Subtype B Transmission Rates From Viral Phylogenies**
Stephane Hue¹; Roberto Murcio Villanueva²; Anna Tostevin³; Valerie Delpech⁴; Anton N. Pozniak⁵; Lynne Ashton⁶; Deenan Pillay⁷; Richard Goldstein⁸; for the UK HIV Drug Resistance Database
¹London Sch of Hygiene & Trop Med, London, UK; ²Univ Coll London, London, UK; ³Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ⁴PH England, London, UK; ⁵Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ⁶Royal Liverpool Hosp, Liverpool, UK; ⁷Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa
- 198 The HIV Env Signal Peptide Impacts the Glycosylation and Antigenicity of gp120**
Jason Yolitz¹; Catherine Schwing¹; Donald Van Ryk¹; Danlan Wei²; Fatima Nawaz³; Katija Jelacic³; Claudia Cicala³; Anthony S. Fauci¹; James Arthos³
¹NIAID, NIH, Bethesda, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³NIH, Bethesda, MD, USA
- Session P-B2 Poster Abstracts Hall A/B**
2:45 PM–4:00 PM
Identifying Network and Transmission Pairs
- 215 Infer and Characterize a Transmission Network in an Opioid-Driven HIV-1 Outbreak**
Ellsworth M. Campbell¹; Romeo R. Galang²; Walid Heneine³; William Switzer⁴; Philip Peters⁵; Michael T. Spiller⁶; Hongwei Jia⁷; Silvina Maciotra⁸; for the HIV Outbreak Investigation Team
¹Oak Ridge Inst of Sci and Educ, Decatur, GA, USA; ²CDC, Atlanta, GA, USA
- 216 HIV Phylodynamics in North Carolina: Detecting Active Clusters for Intervention**
Ann M. Dennis¹; Stephane Hue²; Joseph Sebastian³; Victoria Moblely⁴; William Miller; Joseph J. Eron
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²London Sch of Hygiene & Trop Med, London, UK; ³Lab Corporation of America, Research Triangle Park, NC, USA; ⁴North Carolina DHHS, Raleigh, NC, USA
- 217 HIV Transmission Hotspot Detection Combining Sexual and Phylogenetic Network Analysis**
Dana K. Pasquale¹; Irene A. Doherty²; Lynne A. Sampson³; Peter A. Leone⁴; Joseph Sebastian⁵; Sue L. Ledford⁶; William Miller⁷; Joseph J. Eron⁸; Ann M. Dennis
¹Univ of North Carolina at Chapel Hill Sch of Global PH, Chapel Hill, NC, USA; ²RTI, Research Triangle Park, NC, USA; ³North Carolina Division of PH, Raleigh, NC, USA; ⁴Univ of North Carolina at Chapel Hill Sch of Med, Chapel Hill, NC, USA; ⁵Lab Corporation of America, Research Triangle Park, NC, USA; ⁶Wake County Human Services, Raleigh, NC, USA; ⁷Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 218 Metamorphosis of the Montreal MSM Epidemic: Large Cluster Viruses Fuel Transmission**
Bluma G. Brenner¹; Maureen Oliveira²; Ruxandra Ilincă Ibanescu³; Olga Golubkov⁴; Isabelle Hardy⁵; Michel Roger⁶; Mark A. Wainberg³
¹Lady Davis Inst, Montreal, QC, Canada; ²Cntr Hospier Univ de Montréal, Montreal, QC, Canada; ³McGill Univ AIDS Cntr, Montreal, QC, Canada
- 219 Assessing HIV Transmission Networks in a Thai Cohort With Acute HIV Infection**
Eugène Kroon¹; Mark de Souza²; Frits van Griensven³; Donn Colby⁴; Peter P. Pham⁵; Suneer Sirivichayakul⁶; Nelson L. Michael⁷; Nittaya Phanuphak⁸; Jintanat Ananworanich⁹; Sodsai P. Tovananbutra¹⁰; for the RV254/SEARCHO10 Study Team and MHRP Viral Sequencing Core
¹SEARCH, Bangkok, Thailand; ²Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ³Military HIV Rsr Prog, Silver Spring, MD, USA; ⁴Chulalongkorn Univ, Bangkok, Thailand; ⁵US Military HIV Rsr Prog, Bethesda, MD, USA; ⁶Military HIV Rsr Prog, Bethesda, MD, USA; ⁷US Military HIV Rsr Prog, Silver Spring, MD, USA

Session P-CS Poster Abstracts
2:45 PM-4:00 PM
HIV and Microbiomes

- 260 Distinct Gut Microbiota Composition in Gay Men**
Muntsa Rocafort¹; Marc Noguera-Julian¹; Yolanda Guillen¹; Mariona Parera¹; Piotr Nowak²; Falk Hildebrand³; Roger Zeller¹; Anders Sönnnerborg³; Peer Bork⁴; Roger Paredes⁵
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²IrsiCaixa Inst for AIDS Rsr, Barcelona, Spain; ³Karolinska Inst, Stockholm, Sweden; ⁴Structural and Computational Biology, European Molecular Biology Lab, Heidelberg, Germany
- 261 Impact of HIV-Associated Changes in the Gut Microbiome on Disease Progression**
Jesús Luévano; David B. Gootenberg; Jeffrey M. Paer; Bruce D. Walker; Douglas S. Kwon
Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA
- 262 Altered Gut Microbes Enhance Mucosal CD4 T Cell Infection and Depletion Ex Vivo**
Stephanie M. Dillon¹; Eric L. Lee¹; Andrew M. Donovan¹; Kejun Guo¹; Michael S. Harper¹; Daniel N. Frank¹; Martin D. McCarter¹; Mario L. Santiago¹; Cara Wilson²
¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ²Univ of Colorado Hosp, Aurora, CO, USA
- 263 Enhancement of Microbiota in Macaques Leads to Beneficial Immune Function Modulation**
Jennifer A. Manuzak¹; Tiffany Hensley-McBain¹; Charlene Miller¹; Alexander Zevin¹; Jason M. Brenchley²; Jacob D. Estes²; Stanley Langevin³; R. Keith Reeves³; Elias Haddad⁴; Nichole Klatt⁵
¹Univ of Washington, Seattle, WA, USA; ²Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA; ³Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA; ⁴Harvard Univ, Boston, MA, USA; ⁵Drexel Univ, Philadelphia, PA, USA
- 264 Fecal Microbial Transplantation: Safety and Engraftment During Treated HIV Infection**
Ma Somsouk¹; Ivan Vujkovic-Cvijin²; Montha Pao¹; Peter W. Hunt¹; Susan V. Lynch¹; Joseph M. McCune¹
¹Univ of California San Francisco, San Francisco, CA, USA; ²NIH, Bethesda, MD, USA
- 265 Effects of HAART Treatment on the Microbiome of HIV+ Patients**
Joshua Shorestein¹; Netanya S. Utay²; Basil Siewe³; David Amstutz⁴; Rob Knight⁵
¹Univ of California San Diego, San Diego, CA, USA; ²Univ of Texas Med Branch at Galveston, Galveston, TX, USA; ³Rush Univ, Chicago, IL, USA; ⁴Univ of California Davis Med Cntr, Sacramento, CA, USA
- 266 Diet Effects on the Gut Microbiome of People Living With HIV-1**
Javier Rivera Pinto¹; Marc Noguera-Julian¹; Carla Estany¹; Muntsa Rocafort¹; Yolanda Guillen¹; Mariona Parera¹; Pep Coll¹; Bonaventura Clotet¹; Roger Paredes²; M. Luz Calle³
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain; ³IrsiCaixa Inst for AIDS Rsr, Barcelona, Spain; ⁴Univ de Vic, Barcelona, Spain

Hall A/B

- 267 Tryptophan Metabolites Are Associated to Gut Microbiota in HIV-1 Infected Patients**
 Babilonia Bargasho¹; Ujjwal Neogi¹; Lilly Schwieler¹; Göran Engberg¹; Marius Troseld¹; Anders Sönnnerborg²; **Piotr Nowak¹**
¹Karolinska Inst, Stockholm, Sweden; ²Oslo Univ Hosp, Ullevål Hosp, Oslo, Norway

Session P-C6 Poster Abstracts
2:45 PM-4:00 PM
SIV Models of Pathogenesis

Hall A/B

- 268 Chronic Semen Exposure Reduces SIVmac251 Vaginal Infection in Rhesus Macaques**
Shaheed A. Abdulhaqq¹; Melween I. Martinez²; Guobin Kang³; David Beaumont⁴; Jan Münch⁵; Georgia Tomaras⁶; Preston A. Marx⁷; Qingsheng Li⁸; Edmundo N. Kraiselburd⁹; Luis J. Montaner⁹
¹Oregon Hlth & Sci Univ, Beaverton, OR, USA; ²Caribbean Primate Rsr Cntr, San Juan, PR, USA; ³Univ of Nebraska, Lincoln, NE, USA; ⁴Duke Univ, Durham, NC, USA; ⁵Univ of Ulm, Ulm, Germany; ⁶Tulane Univ Sch of PH and Trop Med, New Orleans, LA, USA; ⁷Sch of Biological Scis and Nebraska Cntr for Virology, Univ of Nebraska, Lincoln, NE, USA; ⁸Sch of Med, Univ of Puerto Rico, San Juan, PR, USA; ⁹The Wistar Inst, Philadelphia, PA, USA
- 269 Single-Cell Expression Profiling Reveals Immune Dysfunction in Acute SIV Infection**
Sama Adnan; Premeela A. Rajakumar; James M. Billingsley; R. P. Johnson
Emory Univ, Atlanta, GA, USA
- 270 CD169 Is a Marker of Immune Activation in SIV Infection but Not Rectal Susceptibility**
Magnus Hallor¹; Meropi Aravantinou²; Rachel Singer³; Agegnehu Gettie⁴; James Blanchard⁵; Jeffrey Lifson⁶; Michael Piatak⁷; Andres Salazar⁸; Melissa Robbiani⁹; **Nina Derby¹⁰**
¹Linköping Univ, Linköping, Sweden; ²Pop Council, New York, NY, USA; ³Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ⁴Tulane Natl Primate Rsr Cntr, Covington, LA, USA; ⁵Frederick Natl Lab, Frederick, MD, USA; ⁶Oncovir, Inc, Washington, DC, USA
- 271 Adipose Tissue and HIV Infection**
Abderauf Damouche¹; Thierry Lazure²; Veronique Avettand-Fenoel³; Nicolas Huot⁴; Christine Rouzioux⁵; Jacqueline Capeau⁶; Michaela Müller-Trutwin⁷; Nathalie Dereuddre-Bosquet⁸; Roger Le Grand⁹; Olivier Lambotte⁸; Christine Bourgeois¹⁰
¹Univ Paris Sud, UMR 1184, Ivry sur seine, France; ²Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France; ³EA7327, Univ Paris Descartes, Paris, France; ⁴Inst Pasteur, Paris, France; ⁵Necker Hosp, AP-HP, Paris, France; ⁶INSERM UMR-S 938, CDR Saint-Antoine, Paris, France; ⁷Univ Paris Sud, UMR 1184, Le Kremlin-Bicêtre, Fontenay aux Roses, France; ⁸Univ Paris Sud, UMR 1184, Le Kremlin-Bicêtre, France
- 272 a4-Integrin Antibody Blocks Monocyte Traffic and Decreases SIV Pathology in DRGs**
Jessica R. Lakritz¹; Derek Thibault¹; Jake A. Robinson¹; Jennifer Campbell¹; Andrew D. Miller²; Tricia H. Burdo³
¹Boston Coll, Chestnut Hill, MA, USA; ²Cornell Univ, Ithaca, NY, USA

- 273 SIV-Associated Pathogenesis Modulation With Macrophage Targeted MGBG**
Tricia H. Burdo¹; Joshua Walker¹; Hua Xu²; Andrew D. Miller³; Michael S. McGrath⁴; Kenneth C. Williams¹
¹Boston Coll, Chestnut Hill, MA, USA; ²Pathologica LLC, San Francisco, CA, USA; ³Cornell Univ, Ithaca, NY, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA
- 274 IL-7 and Chemokines Trigger Intestinal Cell Homing in SIV-Infected Macaques**
Rosalie Ponte¹; Magali Rancez²; Suzanne Figueiredo³; Véronique Fabre-Merresman⁴; Jacques Dutrieux⁵; Bénédicte Charmeteau-De-Muylder⁶; Thomas Guilbert⁷; Rémi Cheynier⁸; Anne Couedel-Courteille⁹
¹Rsr Inst of the McGill Univ Hlth Cntr, Montréal, QC, Canada; ²CNRS, UMR8104, Paris, France; ³INSERM U1016, Paris, France; ⁴Univ Paris Diderot, Paris, France; ⁵INSERM, Paris, France; ⁶Univ Diderot Paris 7, Sorbonne Paris-Cité, Paris, France
- 275LB Apoptosis of Innate Lymphoid Cells Precedes CD4 T-Cell Death in Acute SIV Infection**
Joseph C. Mudd¹; Alexandra Ortiz²; Claire Deleage³; Kenta Matsuda⁴; Fan Wu⁵; Vanessa Hirsch⁶; R. Keith Reeves⁷; Jacob D. Estes⁸; Jason M. Brencley⁹
¹NIAD, NIH, Bethesda, MD, USA; ²Frederick National Laboratory, Leidos BioMed Rsr, Frederick, MD, USA; ³Harvard Univ, Boston, MA, USA; ⁴Frederick Natl Lab, Leidos Biomed Rsr, Frederick, MD, USA; ⁵Frederick Natl Lab for Cancer Rsr, Frederick, MD, USA
- 278 Oral Bovine Immunoglobulin Reduces Immune Activation in HIV+ Immune Nonresponders**
David Asmuth¹; Netanya S. Utay²; Ma Somsouk³; Zhong M. Ma⁴; Peter W. Hunt⁵; Surinder K. Mann⁶; Bryon M. Petschow⁷; Audrey L. Shaw⁸; Christopher J. Detzel⁹; Eric M. Weaver⁹
¹Univ of California Davis Med Cntr, Sacramento, CA, USA; ²Univ of Texas Med Branch at Galveston, Galveston, TX, USA; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴Cntr for Comparative Med, Univ of California Davis, Davis, CA, USA; ⁵Entera Hlth, Inc, Cary, NC, USA
- 279 Proteomic Profiles Associated With an Inflammaging Phenotype During HIV-1 Infection**
Stephanie M. Dillon¹; Eric L. Lee²; Brian Vestal¹; Tzu L. Phang¹; Michael G. Edwards³; Cara Wilson²
¹Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ²Univ of Colorado Hosp, Aurora, Aurora, CO, USA
- 280 Inflammasome and Th17 Activation in HIV+ Immunological Nonresponders**
Michela Masetti¹; Massimiliano Fabbiani²; Daria Trabattoni³; Antonio Muscatello⁴; Mara Biasini⁵; Nicola Squillace⁶; Irma Saille⁷; Mario Clerici⁸; Andrea Gori⁹; Alessandra Bandera⁴
¹Univ of Milan, Milan, Italy; ²Inst of Clinical Infectious Diseases, Catholic Univ of Sacred Heart, Rome, Italy; ³San Gerardo Hosp, Monza, Italy; ⁴San Gerardo General Hosp, Monza, Italy; ⁵Univ of Milan, Brescia, Italy
- 281 Derangement in Protein S and C4b Binding Protein Levels in HIV-Infected Adults**
Fatai O. Bello¹; Suleiman Akanmu²; Titilope Adeyemo³; Funmi Lesi⁴; Prosper Okonkwo⁵; Sade Ogunsonla⁶; Phyllis Kanki⁷
¹Lagos Univ Teaching Hosp, Lagos, Nigeria; ²Coll of Med, Univ of Lagos, Lagos, Nigeria; ³AIDS Prevention Initiative in Nigeria, Abuja, Nigeria; ⁴Harvard Sch of PH, Boston, MA, USA
- 282 Monocytes From Treated HIV1 Patients Release ROS Causing DNA Damage and CD4 Cell Loss**
Mehwish Younas¹; Yea Lih Lin²; Christina Psomas³; Sandrine Gimenez⁴; Pierre Portales⁵; Jacques Reynes⁶; Philippe Pasero⁷; Pierre Corbeau⁸
¹Inst of Human Genetics, Montpellier, France; ²Inst de Genetique Humaine, Montpellier, France; ³Univ Hosp Montpellier, Montpellier, France
- 283 Low ART Adherence Is Associated With Higher Inflammation Despite HIV Suppression**
Jose R. Castillo-Mancilla¹; Todd T. Brown²; Kristine M. Erlandson³; Frank J. Palella⁴; Edward M. Gardner⁵; Bernard J. Macatangay⁶; Elizabeth Breen⁷; Lisa Jacobson⁸; Peter L. Anderson⁹; Nikolas I. Wada²
¹Univ of Colorado, Denver, CO, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Northwestern Univ, Chicago, IL, USA; ⁴Denver Hlth Med Cntr, Denver, CO, USA; ⁵Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ⁶Univ of California Los Angeles, Los Angeles, CA, USA

Session P-C7 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Immune Activation and Inflammation

276 Immune Activation Profile Associated With Metabolic Syndrome in HIV-Treated Patients

Christina Psomas¹; Mehwish Younas²; Christelle Reynes³; Celine Fernandez⁴; Vincent Le Moing⁵; Claudine Barbut⁶; Nicolas Nagot⁷; Pierre Portales⁸; Jacques Reynes⁹; Pierre Corbeau⁹
¹Univ Hosp Montpellier, Montpellier, France; ²Inst of Human Genetics, Montpellier, France; ³Inst for Functional Genomics, Montpellier Univ, UMRS203, Montpellier, France; ⁴Univ Hosp Nimes, Nimes, France

277 Immune Activation, Cell Turnover, and Exhaustion in HIV+ Women With Heavy Alcohol Use

Seema N. Desai¹; Kathleen Weber²; Jane Burke-Miller³; Audrey L. French⁴; Marion Peters⁵; Mark H. Kuniholm⁶; Elizabeth Golub⁷; Kendall J. Bryant⁸; Alan L. Landay⁹; Mardge Cohen¹⁰
¹Rush Univ Med Cntr, Chicago, IL, USA; ²CORE Cntr/Cook County Hlth and Hosp System and Hektoen Inst of Med, Chicago, IL, USA; ³Hektoen Inst of Med, Chicago, IL, USA; ⁴CORE Cntr/John H. Stroger Jr Hosp of Cook County, Chicago, IL, USA; ⁵Univ of California San Francisco, San Francisco, CA, USA; ⁶Albert Einstein Coll of Med, Bronx, NY, USA; ⁷Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁸Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, USA; ⁹Rush Univ, Chicago, IL, USA; ¹⁰John H. Stroger Jr. Hosp of Cook County and Rush Med Coll, Chicago, IL, USA

Session P-E3 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Evaluating HIV Vaccines: Preclinical to Clinical

- 317 Immunogenicity and Efficacy of ALVAC-HIV/gp120-Claide C in Alum Regimen in Macaques**
Luca Schifanello¹; David Venzon²; Susan Barnett³; Sanjay Phogat⁴; Georgia Tomaras⁵; David Montefiori⁶; Massimiliano Bissa⁷; Veronica Galli⁸; Ruth M. Ruprecht⁹; Genoveffa Franchini¹
¹NIH, Bethesda, MD, USA; ²Novartis, Cambridge, MA, USA; ³Sanofi, Swiftwater, PA, USA; ⁴Duke Univ, Durham, NC, USA; ⁵Texas Biomed Rsr Inst, San Antonio, TX, USA
- 318 Specific IgG Subclasses Induced in RV305, a Late Boost Vaccination of RV144 Subjects**
Siriwat Akapirat¹; Sandhya Vasan²; Punnee Pitisuttithum³; Supachai Rerks-Ngarm⁴; Nelson L. Michael⁵; Jean-Louis Excler⁶; Jerome H. Kim⁷; Robert O'Connell⁸; Nicos Karasavvas⁹; for the RV305 Study Group
¹Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand; ²US Military HIV Rsr Prog, APO, AP, USA; ³Mahidol Univ, Ratchathewi, Thailand; ⁴Ministry of PH, Muang Nonthaburi, Thailand; ⁵US Military HIV Rsr Prog, Bethesda, MD, USA; ⁶Henry M. Jackson Fdn for the Advancement of Military Med, Inc, Bethesda, MD, USA; ⁷Intl Vaccine Inst, Seoul, Republic of Korea
- 319 Vaccine Targeting Protease Cleavage Sites Protects Cynomolgus Monkeys Against SIV**
Ma Luo¹; David Tang²; Rupert Capina³; Xin-Yong Yuan⁴; Jorge Correia-Pinto⁵
¹Natl Microbiology Lab of Canada, Winnipeg, MB, Canada; ²Univ of Santiago de Compostela, Santiago de Compostela, Spain
- 320 Shaping CTL Immunodominance With Conserved HIV Vaccines After Early Treatment (BCN01)**
Beatriz Mothe¹; Christian Manzano²; Pep Coll³; Sara Moron-Lopez⁴; Lucy Dorrell⁵; Bonaventura Clotet⁶; Javier Martinez-Picado⁷; Christian Brander⁸; Tomá Hanke⁹; for the BCN01 Study Group
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Hosp Clinic-IDIBAPS-Univ of Barcelona, Barcelona, Spain; ³Univ of Oxford, Oxford, UK; ⁴Lluita Contra la SIDA Fdn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain; ⁵The Jenner Inst, Oxford, UK
- 321 DNA/rTV/Protein Vaccination Protects Against Acquisition of SHIV162P3 Challenges**
Xuan He; Zhou Zhang; Ying Liu; Yanling Hao; Li Ren; Kunxue Hong; Yiming Shao
 Natl Cntr for AIDS/STD Control and Prevention, Chinese CDC, Beijing, China
- 322 Poly-ICL, a TLR Agonist, Is Safe and Tolerable in HIV-Infected Individuals**
Elizabeth A. Miller¹; Rachel Sabado¹; Andres Salazar²; Melissa LaMar³; Martin Markowitz; Nina Bhardwaj⁴
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Oncovir, Inc, Washington, DC, USA; ³Aaron Diamond Aids Rsr Cntr, New York, NY, USA
- 323 TLR-9 Signaling Rescues Defects in B-Cell Response in Needle-Free Immunization**
Prabhu S Arunachalam¹; Ria Mishra²; Sravan Payeli³; Deepak Selvam⁴; Richard R. Stout⁵; Udaykumar Ranga¹
¹Jawaharlal Nehru Cntr for Advanced Scientific Rsr, Bangalore, India; ²Biom Fertility and Rsr Cntr, Bangalore, India; ³Bioject Med Technologies, Inc, Tigard, OR, USA

Session P-F4 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Impact of Antiretroviral Therapy on Viremic Control and Tissue Reservoirs

- 346 Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials**
Graham C. Treasure¹; Evgenia Aga²; Ronald Bosch³; John W. Mellors⁴; Daniel Kuritzkes⁵; Rajesh T. Gandhi⁶; Michael Para⁷; Jonathan Z. Li⁸
¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of Pittsburgh, Pittsburgh, PA, USA; ⁴Harvard Med Sch, Boston, MA, USA; ⁵Massachusetts General Hosp, Boston, MA, USA; ⁶Ohio State Univ, Columbus, OH, USA
- 347 Viral and Immune Characteristics of HIV Post-Treatment Controllers in ACTG Studies**
 Behzad Etemad¹; Xiaoming Sun²; Michael M. Lederman³; Rachel Z. Gottlieb⁴; Evgenia Aga⁵; Ronald Bosch⁶; Jeffrey Jacobson⁷; Rajesh T. Gandhi⁸; Xu G. Yu⁹; **Jonathan Z. Li**¹⁰
¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA; ³Case Western Reserve Univ, Cleveland, OH, USA; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Drexel Univ Coll of Med, Philadelphia, PA, USA; ⁶Massachusetts General Hosp, Boston, MA, USA
- 348 HIV-1 in the Blood and Intestine Contributes to Viremia During Treatment Interruption**
Anni Winkelmann¹; Kirston Barton²; Bonnie Hiener³; Thomas A. Rasmussen⁴; Martin Tolstrup⁵; Wei Shao⁶; Paul W. Denton⁷; Sharon R. Lewin⁸; Ole S. Søgaard⁹; Sarah Palmer¹⁰
¹Aarhus Univ Hosp, Aarhus Nord, Denmark; ²Cntr for Virus Rsr, Westmead Millennium Inst, Westmead, Australia; ³Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia; ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA
- 349 HIV DNA Set Point Remains Elevated in Untreated vs Treated Acutely Infected Thais**
Jintanat Ananworanich¹; Nicolas Chomont²; Leigh. Eller³; Eugène Kroon⁴; Meera Bose⁵; Marty Nau⁶; Suteeraporn Pinyakorn⁷; Nelson L. Michael⁸; Nittaya Phanuphak⁹; Merlin L. Robb¹⁰; for the RV254/SEARCH010 study groups
¹Military HIV Rsr Prog, Bethesda, MD, USA; ²Univ de Montréal, Montreal, QC, Canada; ³US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ⁴SEARCH, Bangkok, Thailand; ⁵US Military HIV Rsr Prog, Bethesda, MD, USA
- 350 Impact of Long-term Antiretroviral Therapy (ART) on Cellular HIV and Inflammation**
Rajesh T. Gandhi¹; Deborah McMahon²; Ronald Bosch³; Christina Lalama⁴; Josh Cyktor⁵; Bernard J. Macatangay⁶; Charles Rinaldo⁷; Ann Collier⁸; Joseph J. Eron⁹; John W. Mellors¹⁰
¹Massachusetts General Hosp, Boston, MA, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Harvard Sch of PH, Boston, MA, USA; ⁴Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ⁵Univ of Washington, Seattle, WA, USA; ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

351 Impact of cART & Systemic Inflammation on Semen HIV-1 Reservoir in Primary Infection

Antoine Chéret¹; Julia Heitzmann²; Adeline Mèlard³; Christine Durier⁴; Ludvine David⁵; Michaëlla Muller-Trutwin⁶; Jean-Marie Chennebault⁷; Camille Lécuroux⁸; Christine Rouzioux⁹; Laurence Meyer⁶; for the ANRS 147 OPTIPRIM Team

¹Le Kremlin-Bicêtre Hosp, AP-HP, Le Kremlin-Bicêtre, France; ²INSERM SC10-US19, Villejuif, France; ³Hosp Necker, Paris, France; ⁴Inst Pasteur, Paris, France; ⁵Angers Hosp, Angers, France; ⁶INSERM U802, Le Kremlin-Bicêtre, France; ⁷Necker Hosp, AP-HP, Paris, France; ⁸INSERM, CESP U1018, Le Kremlin-Bicêtre, France

352 Predictors of Viral Control After ART Interruption in SIV-Infected Rhesus Macaques

Luka Micic¹; Emily Ryan²; Steven E. Bosinger³; Remi Fromentin³; Rafick Sekaly⁴; Nicolas Chomont⁵; Jeffrey Lifson⁶; Mirko Paiardini⁷

¹Emory Univ, Atlanta, GA, USA; ²Yerkes Natl Primate Rsr Ctr, Emory Univ, Atlanta, GA, USA; ³Univ of Montreal, Montreal, QC, Canada; ⁴Case Western Reserve Univ, Cleveland, OH, USA; ⁵Univ de Montréal, Montreal, QC, Canada; ⁶Frederick Natl Lab, Frederick, MD, USA

353 Antiretroviral Therapy in SIV Natural Hosts: Implications for AIDS Pathogenesis

Francesca Calascibetta¹; Luca Micic²; Diane Carnathan³; Benton Lawson⁴; Ann Chahroudi⁵; Jeffrey Lifson⁶; **Mirko Paiardini**⁷; Guido Silvestri⁸

¹Emory Univ, Atlanta, GA, USA; ²Emory Univ Sch of Med, Atlanta, GA, USA; ³Frederick Natl Lab, Frederick, MD, USA; ⁴Yerkes Natl Primate Rsr Ctr, Emory Univ, Atlanta, GA, USA

Session P-F5 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****Approaches to Reactivating HIV and Gene Therapy****354 Bryostatins-1 for Latent-Virus Reactivation: A Phase I, Double-Blind Clinical Trial**

Carolina Gutiérrez¹; Nadia Madrid-Elena²; Sergio Serrano-Villar³; María Jesús Pérez-Eliás⁴; María E. Martín⁵; Coral Barbas⁶; Javier Ruperez⁷; Eduardo Muñoz⁸; Trevor Castor⁹; Santiago Moreno²

¹Ramón y Cajal Hosp, IRYCIS, Madrid, Spain; ²Hosp Universitario Ramón y Cajal, Madrid, Spain; ³CEMBIO, San Pablo CEU Univ, Madrid, Spain, Madrid, Spain; ⁴Córdoba Univ, Córdoba, Spain; ⁵Aphios Corporation, Boston, MA, USA

355 Clinical Administration of Vorinostat Increases NK Cell Capacity to Produce IFN- γ

Carolina Garrido; Natalia Soriano-Sarabia; Brigitte Allard; Katherine Sholtis; Nancie M. Archin; David M. Margolis
Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

356 CCR5 Gene-Edited Cells Undergo Positive Selection in SHIV-Infected Nonhuman Primates

Christopher W. Peterson¹; Jianbin Wang²; Michael Holmes³; Patricia Polacino⁴; Shiu-Lok Hu⁵; Robert Murnane⁶; Audrey Baldessari⁷; **Hans-Peter Kiem**¹

¹Fred Hutchinson Cancer Rsr Ctr, Seattle, WA, USA; ²Sangamo BioScis, Richmond, CA, USA; ³Univ of Washington, Seattle, WA, USA; ⁴Washington Natl Primate Rsr Ctr, Seattle, WA, USA

357 Predicting Determinants of Long-Term HIV Control With Gene Therapy Strategies

Alison L. Hill¹; Lily Hu¹; Louise Hogan²; Martin A. Nowak³; Timothy J. Henrich²

¹Harvard Univ, Boston, MA, USA; ²Univ of California San Francisco, San Francisco, CA, USA

358LB T-Cell Homeostasis and CD8 Responses Predict Viral Control Post SB-728-T Treatment

Joumana Zeidan¹; Gary K. Lee²; Clarisse Benne³; Slim Fourati⁴; Shelley K. Wang⁵; Jacob Lalezari⁶; Gary Blick⁷; Geoffrey M. Nichol⁸; Dale K. Ando⁹; **Rafick Sekaly**¹

¹Case Western Reserve Univ, Cleveland, OH, USA; ²Sangamo BioSciences, Richmond, CA, USA; ³Quest Clinical Rsr, San Francisco, CA, USA; ⁴CIRCLE CARE Ctr, LLC, Norwalk, CT, USA

Session P-F6 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****HIV Integration****359 Integration Analysis of Latently Infected Cell Lines: Evidence of Ongoing Replication**

Jori Symons¹; Abha Chopra²; Eva Malantinkova³; Ward Spiegelaerde⁴; Shay Leary⁵; Don Cooper⁶; Linos Vandekerckhove⁷; Simon Mallal⁸; Sharon R. Lewin⁹; Paul U. Cameron¹

¹Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia; ²Inst for Immunology & Infectious Diseases, Murdoch Univ, Murdoch, Australia; ³Ghent Univ and Ghent Univ Hosp, Ghent, Belgium

360 HIV Integration Sites in Cellular Models of Viral Persistence

Sara Sunshine¹; Rory Kirchner²; Sami S. Amr³; Michelle Kim⁴; Alberto Bosque⁵; Robert Siliciano⁶; Vicente Planelles⁷; Oliver Hofmann⁸; Shannan Ho Sui⁹; Jonathan Z. Li¹

¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Partners HlthCare Personalized Med, Cambridge, MA, USA; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁵Univ of Utah, Salt Lake City, UT, USA; ⁶Howard Hughes Med Inst, Baltimore, MD, USA

361 Clonal Integration Site Frequency and Replication-Competent Virus in Patients on ART

Maja Kiselinova¹; Ward Spiegelaerde²; Maria J. Buzon³; Sherry McLaughlin⁴; Mathias Lichterfeld⁵; Lisa Frenkel⁶; Linos Vandekerckhove¹

¹Ghent Univ and Ghent Univ Hosp, Ghent, Belgium; ²Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ³Seattle Children's Rsr Inst, Seattle, WA, USA

362 Measurement of Integrated HIV DNA by Pulse-Field Gel Electrophoresis and ddPCR

Steven Lada; Caroline Ignacio; Douglas D. Richman; Matt F. Strain
Univ of California San Diego, San Diego, CA, USA

363 Inhibition of the IN-LEDGF/p75 Interplay by LEDGins Reduces Reactivation From Latency

Zeger Debysier¹; Lenard Vranckx²; Jonas Demeulemeester³; Annegret Boll⁴; Rik Schrijvers⁵; Eric Verdin⁶; Suha Saleh⁷; Frauke Christ⁸; Rik Gijssbers¹

¹Katholieke Universiteit Leuven, Leuven, Belgium; ²Univ of Trento, Trento, Italy; ³Gladstone Inst of Virology and Immunology, San Francisco, CA, USA

Session P-G2 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Virology and Basic Neuroscience

- 393 Productive Infection of HIV in Astrocytes via a CD4-Independent, CXCR4-Dependent Mech**
Guanhan Li¹; Caroline Anderson¹; Eugene O. Major¹; Avindra Nath²
¹NIHDS, NIH, Bethesda, MD, USA; ²NIH, Bethesda, MD, USA
- 394 A Unique In Vitro Neuropathic Phenotype of Clade D Transmitted/Founder Viruses**
Analise Gruenewald¹; Alexander J. Gill¹; George M. Shaw²; Dennis L. Kolson²
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Perelman Sch of Med, Univ of Pennsylvania, Philadelphia, PA, USA
- 395 Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons**
Sandy Hincley¹; Sean Sherman¹; Brookie M. Best²; Jeremiah Mopper²; Qing Ma³; Scott R. Letendre²; Ron Ellis²; Anne Bang¹
¹Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA, USA; ²Univ of California San Diego, San Diego, CA, USA; ³Univ at Buffalo, State Univ of New York, Buffalo, NY, USA
- 396 Chronic Low-Level HIV-1 Tat Expression Promotes a Neurodegenerative Phenotype**
Alfred Chin¹; Alex M. Dickens; Amanda L. Trout; Jackie Lovett; Joelle Dorskind; Norman Haughey
 Johns Hopkins Univ Sch of Med, Baltimore, MD, USA
- 397 Glutamine Regulates Extracellular Vesicles Release in HIV-1 Infected Macrophages**
Beiqing Wu¹; Yunlong Huang; Runze Zhao; Yuju Li; Jialin C. Zheng
 Univ of Nebraska Med Cntr, Omaha, NE, USA
- 398 HIV-1 Replication Dynamics in the CNS of TB-Coinfected Individuals**
Ikanyeng D. Seipone¹; Thumbi P. Ndungu²; Ravesh Singh¹; Vinod Patel³
¹HIV Pathogenesis Prog, Univ of Kwa-Zulu Natal, Durban, South Africa; ²Univ of KwaZulu-Natal, Durban, South Africa; ³Inkosi Albert Luthuli Hosp and the Nelson R Mandela Sch of Med, Univ of KwaZulu-Natal, Durban, South Africa
- 399 Glial Transcriptional Responses Follow HIV-1 Infection in a Humanized Mouse Brain**
Weizhe Li¹; Li E. Wu; Jaclyn Knibbe-Hollinger; Santhi Gorantla; Howard E. Gendelman; Larisa Y. Poluektova
 Univ of Nebraska Med Cntr, Omaha, NE, USA

Session P-G3 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Central Nervous System: HIV Entry, Reservoirs, and Compartmentalization

- 400 CNS Compartmentalization of HIV-1 and Sensitivity to Neutralizing Antibodies**
Karl Stefic¹; Antoine Chaillon²; Mélanie Bouvin-Pley³; Alain Moreau²; Martine Braibant²; Guillaume Gras²; Frederic Bastides²; Louis Bernard²; Francis Barin³
¹CHU de Tours, Tours, France; ²Univ of California San Diego, San Diego, CA, USA; ³François-Rabelais Univ, Tours, France, Tours, France; ⁴CHU de Tours, Tours, France
- 401 HIV Compartmentalization in the CNS Is Associated With Neurocognitive Impairment**
Natalie M. Bowman¹; Sarah B. Joseph¹; Laura P. Kincer¹; Sarah Yosief¹; Serena S. Spudich²; Joseph J. Eron¹; Richard W. Price³; Ronald I. Swanstrom¹; Kevin R. Robertson¹; for the THINC Group
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Yale Univ Sch of Med, New Haven, CT, USA; ³Univ of California San Francisco, San Francisco, CA, USA
- 402 Persistent HIV-1 in the CNS During Therapy: Evidence of a Viral Reservoir in the CNS**
Sarah B. Joseph¹; Laura P. Kincer¹; Natalie M. Bowman¹; Sarah Yosief¹; Angela Kashuba¹; Kevin R. Robertson¹; Serena S. Spudich²; Joseph J. Eron¹; Richard W. Price³; Ronald I. Swanstrom¹
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Yale Univ Sch of Med, New Haven, CT, USA; ³Univ of California San Francisco, San Francisco, CA, USA
- 403 Bone Marrow Macrophages Are a Potential Source of CNS Virus With HIV-Encephalitis**
Jaclyn C. Mallard¹; Brittany Rife²; David J. Nolan²; Graham Beck¹; Emily Papazian¹; Russell Simons¹; Tricia H. Burdo¹; Marco Salemi²; Kenneth C. Williams¹
¹Boston Coll, Chestnut Hill, MA, USA; ²Emerging Pathogens Inst, Univ of Florida, Gainesville, FL, USA
- 404 Peripheral Immune Activation Modulates HIV RNA Entry to CSF in Early Acute Infection**
Alexandra Schuetz¹; Suteeraporn Pinyakorn²; Leah Le²; Yuwadee Phuang-Ngern²; Eugène Kroon²; Linda Jagodzinski²; Thep Chalermchai¹; Victor Valcour⁴; Jintanat Ananworanich³; Serena S. Spudich¹; for the RV254/SEARCH 010 Study Group
¹US AFRIMS, Bangkok, Thailand; ²US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ³Yale Univ Sch of Med, New Haven, CT, USA; ⁴SEARCH, Bangkok, Thailand; ⁵Military HIV Rsr Prog, Bethesda, MD, USA; ⁶Univ of California San Francisco, San Francisco, CA, USA
- 405 Early CSF Viremia and CNS T-Cell Infiltrate in a Nonaccelerated SHIV Infection Model**
Sandhya Vasan¹; Piyanate Sunyakumthorn²; Matthew D. Wegner²; Eric Lombardini²; Joanna M. Hellmuth²; Jintanat Ananworanich³; Victor Valcour⁴; Robert O'Connell²; Serena S. Spudich¹; Nelson L. Michael⁶
¹US Military HIV Rsr Prog, APO, AP, USA; ²Armed Forces Rsr Inst of Med Scis, Bangkok, Thailand; ³Univ of California San Francisco, San Francisco, CA, USA; ⁴Military HIV Rsr Prog, Bethesda, MD, USA; ⁵Yale Univ Sch of Med, New Haven, CT, USA; ⁶US Military HIV Rsr Prog, Bethesda, MD, USA

406 Relative Frequency of Drug Resistance Mutations on Individual HIV-1 Genomes in HAND

Teresa Evering; Leslie St. Bernard; Jeremy Abolade; Hiroshi Mohri; Martin Markowitz
Aaron Diamond AIDS Rsr Cntr, New York, NY, USA

Session P-H2 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions

438 Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women

Nikki Mulligan¹; Brooke M. Best²; Edmund Capparelli³; Alice Stek⁴; Emily Bair⁵; Elizabeth Smith⁶; Nahida Chakhtoura⁷; Jiajia Wang⁸; Sandra Burchett⁹; Mark Mirochnick⁸
¹Univ of California San Diego, San Diego, CA, USA; ²Univ of Southern California, Los Angeles, CA, USA; ³Univ of Colorado Anschutz Med Campus, Aurora, CO, USA; ⁴NIAID, NIH, Bethesda, MD, USA; ⁵Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁶Harvard Sch of PH, Bostib, MA, USA; ⁷Children's Hosp Boston, Boston, MA, USA; ⁸Boston Univ Sch of Med, Boston, MA, USA

439 Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women

Mark Mirochnick¹; **Brookie M. Best**²; Angela Kashuba³; Craig Sykes⁴; Amanda Schauer⁵; Jiajia Wang⁶; Alice Stek⁷; Elizabeth Smith⁸; Nahida Chakhtoura⁹; Edmund Capparelli¹⁰
¹Boston Univ Sch of Med, Boston, MA, USA; ²Univ of California San Diego, San Diego, CA, USA; ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁴Harvard Sch of PH, Bostib, MA, USA; ⁵Univ of Southern California, Los Angeles, CA, USA; ⁶NIAID, NIH, Bethesda, MD, USA; ⁷Eunice Kennedy Shriver NICHD, Bethesda, MD, USA

440 Nevirapine Dosing for Treatment in the First Month of Life

Mark Mirochnick¹; Karin Nielsen-Saines²; Jose H. Pilotto³; Philippa Musoke⁴; Avinash Shetty⁵; Katherine Luzuriaga⁶; Edmund Capparelli⁷
¹Boston Univ Sch of Med, Boston, MA, USA; ²Univ of California Los Angeles, Los Angeles, CA, USA; ³Hosp Geral de Nova Iguaçu, Rio de Janeiro, Brazil; ⁴Makerere Univ, Kampala, Uganda; ⁵Wake Forest Univ, Winston Salem, NC, USA; ⁶Univ of Massachusetts Med Sch, Worcester, MA, USA; ⁷Univ of California San Diego, San Diego, CA, USA

441 Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling

Adeniyi Olagunju¹; Rajith Kumar Reddy Rajoli¹; Oluseye Bolajiji²; David J. Back¹; Saye Khoo³; Andrew Owen⁴; Marco Siccardi⁵
¹Univ of Liverpool, Liverpool, UK; ²Obafemi Awolowo Univ, Ile-Ife, Nigeria

442 Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models

Rajith Kumar Reddy Rajoli; David J. Back; Steve Rannard; Andrew Owen; Marco Siccardi
Univ of Liverpool, Liverpool, UK

Session P-H3 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Pharmacogenetics

443 Phenome-Wide Association Study (PheWAS) Using Data From ACTG Clinical Trial A5202

Anurag Verma¹; Yuki Bradford²; Shefali Verma³; Sarah Pendergrass⁴; Eric Daar⁵; Charles Venuto⁶; Gene D. Morse⁷; Paul McLaren⁸; Marylyn D. Ritchie⁹; **David W. Haas**⁷

¹The Cntr for Systems Genomics, Pennsylvania State Univ, University Park, PA, USA; ²Geisinger Hlth System, Danville, PA, USA; ³Harbor Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ⁴Univ of Rochester Med Cntr, Rochester, NY, USA; ⁵State Univ of New York at Buffalo, Buffalo, NY, USA; ⁶PH Agency of Canada, Winnipeg, MB, Canada; ⁷Vanderbilt Univ, Nashville, TN, USA

444 Effect of CYP2B6 Gene Variants on Levonorgestrel PK When Combined With EFV-Based ART

Megan Neary¹; Mohamed Lamorde²; Adeniyi Olagunju³; Kristin M. Darin⁴; Pauline Byakika-Kibwika⁵; Concepta Merry⁶; David J. Back⁷; Marco Siccardi⁸; Andrew Owen⁹; Kimberly K. Scaris¹⁰
¹Univ of Liverpool, Liverpool, UK; ²Infectious Diseases Inst, Makerere Univ, Kampala, Uganda; ³Northwestern Univ, Chicago, IL, USA; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁵Univ of Nebraska, Omaha, NE, USA

445 Transporter Genetics and TFV-DP/FTC-TP Cellular Pharmacology In Vivo

Sharon M. Seifert¹; Xinhui Chen²; Carolyn W. Clayton³; Taylor Alford⁴; Amie L. Meditz⁵; Jose R. Castillo-Mancilla⁶; Lane R. Bushman⁷; Christina Aquilante⁸; Samantha MaWhinney⁹; Peter L. Anderson¹⁰
¹Univ of Colorado Skaggs Sch of Pharm and Pharmaceutical Scis, Aurora, CO, USA; ²Univ of Colorado, Aurora, CO, USA; ³Colorado Sch of PH, Aurora, CO, USA; ⁴Beacon Cntr for Infectious Diseases, Boulder, CO, USA; ⁵Univ of Colorado, Denver, CO, USA

446 CYP2B6 Genotype Effects on Neurocognitive Impairment in HIV+ Patients on Efavirenz

Qing Ma¹; Jennifer Iudicello²; Xia Liu³; Donald Franklin⁴; Igor Grant⁵; Robert Heaton⁶; Fujie Zhang⁷; Scott R. Letendre⁸; for the CHARTER and China neuroAIDS Study Group
¹Univ at Buffalo, State Univ of New York, Buffalo, NY, USA; ²Univ of California San Diego, San Diego, CA, USA; ³China CDC, Beijing, China; ⁴Univ of California San Diego, La Jolla, CA, USA

Session P-H4 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Pharmacokinetics in Compartments

447 Multispecies ARV Distribution in Intestinal Tissue by Mass Spectrometry Imaging (MSI)

Elias P. Rosen¹; Corbin Thompson²; Craig Sykes³; Lourdes Adamson⁴; Michelle Mathews⁵; Yuri Fedoriv⁶; Paul Luciviv⁷; J. Victor Garcia⁸; Ramesh Alkkin⁹; Angela Kashuba¹⁰
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Univ of California Davis, Davis, CA, USA; ³Colorado State Univ, Fort Collins, CO, USA

448 Single-Dose Maraviroc Provides High Drug Levels in All Sites: No Gender Differences

Julie Fox¹; JuanManuel Tiraboschi; Laura J. Else²; Carolina Herrera³; Deirdre Egan⁴; Aliou Amara⁵; Akil Jackson⁶; Robin Shattock⁷; David J. Back⁸; Saye Khoo⁹; Marta Boffito¹

¹Guy's and St Thomas' NHS Fdn Trust, London, UK; ²Univ of Liverpool, Liverpool, UK; ³Imperial Coll London, London, UK; ⁴Chelsea and Westminster Hosp NHS Fdn Trust, London, UK

449 PK of FTC, TFV and 3TC in Ugandan and Nigerian Breastfeeding Mother-Infant Pairs

Cariona J. Waitt¹; Adeniyi Olagunju¹; Shadia Nakalema²; Isabella Kyohaire³; Andrew Owen⁴; Mohammed Lamorde⁵; Saye Khoo¹

¹Univ of Liverpool, Liverpool, UK; ²Infectious Diseases Inst, Makerere Univ, Kampala, Uganda

450 Multispecies Differences in Drug Transporter Expression and Localization in GI Tissue

Corbin Thompson¹; Elias P. Rosen²; Paige Charlins³; Leila Remling-Mulder⁴; Martina Kovarova⁵; Yuri Fedoriv⁶; Paul Luciw⁷; J. Victor Garcia⁸; Ramesh Akkina⁹; Angela Kashuba¹

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Colorado State Univ, Fort Collins, CO, USA; ³Univ of California Davis, Davis, CA, USA

473 Predictors of CD4 Count Recovery in the CIPRA HT-001 Trial of Early ART

Sean E. Collins¹; Michaela Calnan²; Marc Antoine Jean Juste³; Patrice Severe⁴; Rode Secours⁵; Daphne Bernard⁶; Ashita Batavia⁷; Daniel W. Fitzgerald⁸; Serena P. Koenig⁹; Jean W. Pape¹

¹Stanford Univ, Stanford, CA, USA; ²Analysis Group, Boston, MA, USA; ³GHEKIO, Port-au-Prince, Haiti; ⁴Weill Cornell Med Coll, New York, NY, USA; ⁵Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

474 Effect of Immediate ART on Risk of Severe Bacterial Infections: The START Trial

Jemma L. O'Connor¹; Fred Gordin²; **Andrew N. Phillips**³; Brian Angus⁴; David Cooper⁴; Beatrix Grinstztein⁵; Gustavo Lopardo⁶; Satyajit Das⁷; Aimee Wilkin⁸; Jens D. Lundgren⁹; for the INSIGHT START Study Group

¹Univ Coll London, London, UK; ²VA Med Cntr, Washington, DC, USA; ³John Radcliffe Hosp, Oxford, UK; ⁴Kirby Inst, Sydney, Australia; ⁵Inst de Pesquisa Clinica Evandro Chagas (IPEC)/Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil; ⁶La Fundación del Centro de Estudios Infecciológicos, Buenos Aires, Argentina; ⁷Coventry and Warwickshire NHS Partnership Trust, Coventry, UK; ⁸Wake Forest Univ, Winston Salem, NC, USA; ⁹Rigshospitalet, Univ of Copenhagen, Copenhagen, Denmark

475 Increased Quality of Life With Immediate ART Initiation: Results From the START Trial

Alan Lifson; Birgit Grund; for the INSIGHT START Quality of Life Study Group

Univ of Minnesota, Minneapolis, MN, USA

476 Gender and Racial Disparities in Initial Antiretroviral Treatment Outcome: ACTG A5257

Heather J. Ribaud¹; Raphael J. Landovitz²; Lumine H. Na³; Jeffrey L. Lennox⁴; Ighoverha Ofofokun⁵; Susan E. Cohn⁶; Daniel Kuritzkes⁶; Judith S. Currier⁷; for the ACTG A5257 Study Team

¹Harvard Sch of PH, Boston, MA, USA; ²David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ³Univ of Edinburgh, Edinburgh, UK; ⁴Emory Univ Sch of Med, Atlanta, GA, USA; ⁵Northwestern Univ, Chicago, IL, USA; ⁶Harvard Med Sch, Boston, MA, USA

Session P-1J Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Antiretroviral Therapy: Randomized Clinical Trials

470 Doravirine 100mg QD vs Efavirenz +TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results

Josep Maria Gatell¹; Francois Raffi²; Andreas Plettenberg³; Don Smith⁴; Joaquin Portilla⁵; Christian Hoffmann⁶; Keikawus Arasteh⁷; Melanie Thompson⁸; Xia Xu⁹; Hedy Tepler⁹

¹Hosp Clinic de Barcelona, Barcelona, Spain; ²Chu Hotel Dieu- Chu De Nantes, Nantes, France; ³IFI Inst for Interdisciplinary Med, Hamburg, Germany; ⁴Albion Cntr, Sydney, Australia; ⁵Univ Miguel Hernandez, Alicante, Spain; ⁶IPM StudyCntr, Hamburg and Univ of SchleswigHolstein, Campus Kiel, Hamburg, Germany; ⁷EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; ⁸AIDS Rsr Consortium of Atlanta, Atlanta, GA, USA; ⁹Merck & Co, Inc, Kenilworth, NJ, USA

471 Tolerability and Acceptability of Cabotegravir LA Injection: Results From ECLAIR Study

Miranda I. Murray¹; Martin Markowitz²; Ian Frank³; Robert Grant⁴; Kenneth H. Mayer⁵; David A. Margolis⁶; Krischan J. Hudson⁷; Britt S. Stancil⁸; Alex R. Rinehart⁹; William Spreen⁶

¹ViiV Hlthcare, Brentford, UK; ²Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ³Pereleman Sch of Med, Univ of Pennsylvania, Philadelphia, PA, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁶ViiV Hlthcare, Research Triangle Park, NC, USA; ⁷ViiV Hlthcare, Reserach triangle Park, NC, USA

472 Attachment Inhibitor Prodrug BMS-663068 in ARV-Experienced Subjects: Week 96 Analysis

Edwin DeJesus¹; Marcelo Martins²; Albrecht Stoehr³; Jaime Andrade-Villanueva⁴; Natalia Zakharova⁵; David A Stock⁶; Cyril Llamoso⁶; Samit R. Joshi⁷; George J. Hanna⁸; Max Lataillade⁹

¹Orlando Immunology Cntr, Orlando, FL, USA; ²Inst Oulton, Córdoba, Argentina; ³IFI Inst for Interdisciplinary Med, Hamburg, Germany; ⁴Hosp Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico; ⁵St Petersburg AIDS Cntr, St Petersburg, Russian Federation; ⁶Bristol-Myers Squibb, Wallingford, CT, USA; ⁷Bristol-Myers Squibb, Princeton, NJ, USA

Session P-L2 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HIV Drug Resistance: Clinical and Epidemiologic Studies

495 More Efficacious Drugs Lead to Hard Selective Sweeps in HIV Drug Resistance Evolution

Alison F. Feder¹; Soo-Yon Rhee²; Robert W. Shafer³; Dmitri A. Petrov⁴; Pleuni S. Pennings⁵

¹Stanford Univ, Stanford, CA, USA; ²San Francisco State Univ, San Francisco, CA, USA

496 Pooled Week 48 Analysis of HIV-1 Drug Resistance in E/C/F/TAF Phase 3 Studies

Michael Abram; Nicolas A. Margot; Stephanie Cox; Renee R. Ram; Danielle P. Porter; Kathryn M. Kitrinos; Marshall Fordyce; Scott McCallister; Michael Miller; Christian D. Callebaut
Gilead Scis, Inc, Foster City, CA, USA

497 HIV Drug Resistance Testing Among Patients New to HIV Care in the United States

Angela L. Hernandez¹; Eduardo Valverde²; John Weiser³; Linda Beer⁴; Yunfeng Tie⁵; **M. Cheryl Banez Ocfemia**⁶; Alexandra M. Oster¹

¹CDC, Atlanta, GA, USA; ²ICF Intl, Atlanta, GA, USA

498 Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa

Tamara Sonia Boender¹; Raph Hamers²; Pascale Ondoa³; Maureen Wellington⁴; Margaret Siwale⁵; Cissy Kityo⁶; Sulaimon Akanmu⁷; Kishor Mandalia⁸; Tobias Rinke de Wit⁹; Kim Sigaloff¹⁰; for the PanAfrican Studies to Evaluate Resistance (PASER) study group
¹Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ²Newlands Clinic, Harare, Zimbabwe; ³Lusaka Trust Hosp, Lusaka, Zambia; ⁴Joint Clinical Rsr Cntr, Kampala, Uganda; ⁵Lagos Univ Teaching Hosp, Lagos, Nigeria; ⁶Coast Province General Hosp, Mombasa, Kenya

499 Genome-Wide Association of HIV Whole Genomes Provides Insights Into Drug Resistance

Robert A. Power¹; Siva Davaniah¹; Anne Derache²; Eduan Wilkinson³; Frank Tanseer⁴; Ravindra K. Gupta⁵; Deenan Pillay⁶; Tulio de Oliveira⁴
¹Wellcome Trust Africa Cntr for Hlth and Pop Studies, Somkhele, South Africa; ²Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ³Univ Coll London, London, UK; ⁴Univ of KwaZulu-Natal, Durban, South Africa

500 Receipt and Timing of Genotypic HIV Drug Resistance Testing in the United States

Sharoda Dasgupta¹; H. Irene Hall¹; Angela L. Hernandez²; M. Cheryl Banez Ocfemia³; Neeraja Saduvala⁴; Alexandra M. Oster¹
¹CDC, Atlanta, GA, USA; ²CF Intl, Atlanta, GA, USA

501 HIV Integrase Genotypic Resistance Testing Among HIV-Infected Persons in New York

Zhenyuan Wang¹; Daniel Gordon²; Emily Walits³; Joanne Gerber⁴; Deepa Rajulu⁵; Lou Smith⁶; Bridget Anderson¹
¹New York State Dept of Hlth, Albany, NY, USA; ²Univ of Albany Sch of PH, Albany, NY, USA

502 Immunologic Criteria Are Poor Predictors of Virologic Outcomes in Nigeria

Nicaise Ndembí¹; Fati M. Ibrahim²; James Okuma³; Ahmad Aliyu¹; Samuel Peters¹; Charles Mensah¹; Alash'le Abimiku²; Clement Adebamowo³; Manhattan E. Charurat⁴; Patrick Dakum¹
¹Inst of Human Virology, Abuja, Nigeria; ²Inst of Human Virology, Univ of Maryland Sch of Med, Baltimore, MD, USA; ³Inst of Human Virology, Baltimore, MD, USA

503 Global Tenofovir Resistance Following 1st-Line Regimens for Adult HIV-1 Infection

John Gregson¹; Michelle Tang²; Nicaise Ndembí³; Raph Hamers⁴; Vincent C. Marconi⁵; Elliot Raizes⁶; Rami Kantor⁷; Robert W. Shafer⁸; **Ravindra K. Gupta**⁹; for the TenoRes Study Team
¹London Sch of Hygiene & Trop Med, London, UK; ²Stanford Univ, Stanford, CA, USA; ³Inst of Human Virology, Abuja, Nigeria; ⁴Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ⁵Emory Univ Sch of Med, Atlanta, GA, USA; ⁶CDC, Atlanta, GA, USA; ⁷Brown Univ, Providence, RI, USA; ⁸Univ Coll London, London, UK

**Session P-M2 Poster Abstracts
2:45 PM-4:00 PM**

Hall A/B

HIV Detection in Clinical Trials

521 4th Generation Rapid Tests Improve Detection of Acute Infection in MTN-003 (VOICE)

Edward Livant¹; Amy L. Opest²; Clifton W. Kelly³; Rashika Maharaj⁴; Natasha Samsunder⁵; Rosetta Lindwive Nhlangulela⁶; Patrick Karugaba⁷; Jeanne Marrazzo⁸; Z Michael Chirenje⁹; **Urvi M. Parikh**¹⁰; for the VOICE Study Team
¹Magee-Womens Hosp of the Univ of Pittsburgh Med Cntr, Pittsburgh, PA, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁴South African Med Rsr Council, Durban, South Africa; ⁵Aurum Inst for Hlth Rsr, Johannesburg, South Africa; ⁶Makerere Univ Johns Hopkins Univ Rsr Collab Lab, Kampala, Uganda; ⁷Univ of Washington, Seattle, WA, USA; ⁸Univ of Zimbabwe, Univ of California San Francisco Collaborative Rsr Prog, Harare, Zimbabwe

522 Usefulness of Rapid Tests for HIV Diagnosis in the ANRS IPERGAY PrEP Trial

Constance Delaugerre¹; Isabelle Charreau²; Nadia Mahjoub³; Eric Cua⁴; Armelle Pasquet⁵; Nolween Hall⁶; Marie Laure Chaix⁷; Guillemette Antoni⁸; Jean-Michel Molina⁹; for the IPERGAY study group
¹Hosp Saint Louis et Univ Paris Diderot, Paris, France; ²INSERM SC10-US19, Villejuif, France; ³Hosp Saint-Louis, Paris, France; ⁴Hosp de l'Archet, Paris, France; ⁵DRON Hosp, Tourcoing, France; ⁶CSiSH, Nantes, France; ⁷INSERM U941, Univ Paris Diderot, Paris, France; ⁸Hopital Saint-Louis, Paris, France

523 Use of an Automated Assay to Identify HIV Infections in a Population Survey in Africa

Estelle Piwovar-Manning¹; Shauna Wolf²; Kelsey Donohue¹; Anelet James³; Barry Kosloff⁴; Alicia Young⁵; Gert U. van Zyl⁶; Helen Ayles⁶; Richard Hayes⁶; Susan H. Eshleman¹
¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Desmond Tutu TB Cntr, Stellenbosch Univ, Cape Town, South Africa; ³ZAMBART, Lusaka, Zambia; ⁴SCHARP, Seattle, WA, USA; ⁵Stellenbosch Univ and NHLI Tygerberg Business Unit, Tygerberg, South Africa; ⁶London Sch of Hygiene & Trop Med, London, UK

524 HIV Testing in the US PrEP Demonstration Project: rEIA vs Antigen/Antibody vs RNA

Oliver Bacon¹; Eric Vittinghoff²; Stephanie Cohen³; Susanne Doblecki-Lewis⁴; Megan Coleman⁵; Susan P. Buchbinder⁶; Wairimu Chege⁷; Richard Elion⁸; Michael Kolber⁹; Albert Y. Liu¹
¹San Francisco Dept of PH, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Miami, Miami, FL, USA; ⁴Whitman-Walker Hlth, Washington, DC, USA; ⁵DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁶George Washington Univ Sch of Med, Washington, DC, USA

Session P-N5 Poster Abstracts
2:45 PM-4:00 PM

HBV Infection: Prevalence, Prevention, and Prognosticators

Hall A/B

562 Early Mortality Risk of HIV/Hepatitis B Virus Coinfected Patients Initiating ART

Mbae M. Japhet¹; Amos Ndhire²; Stanley Ndwiga³; Elisha Kirwa⁴; Ram Yogeve⁵; Robert Murphy⁶; Joseph N. Jarvis⁷
¹Consolata Hosp Mathari, Nyeri, Kenya; ²Africa Clinical Rsr Mgmt, LLC, Kisumu, Kenya; ³Gertrude's Children's Hosp, Nairobi, Kenya; ⁴Kenyatta Natl Hosp, Nairobi, Kenya; ⁵Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, USA; ⁶Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ⁷Botswana Univ of Pennsylvania Partnership, Gaborone, Botswana

563 Incidence and Risk Factors for Hepatitis B in HIV-Infected Adults in Rakai, Uganda

Emmanuel Seremba¹; Victor Ssempijja²; Sarah Kalibbala³; Ronald H. Gray⁴; Maria J. Wawer⁵; Fred Nalugoda⁶; Corey Casper⁷; Ponsiano Ocama⁸; David Serwadda⁹; Reynolds Steven⁸
¹Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ²Leidos Biomed Rsr, Inc, Frederick, MD, USA; ³Rakai Hlth Scis Prog, Rakai, Uganda; ⁴Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁵Rakai Hlth Scis Prog, Entebbe, Uganda; ⁶Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁷Makerere Univ School of PH, Kampala, Uganda; ⁸Johns Hopkins Univ, Baltimore, MD, USA

564 Long-Term Changes in Liver Fibrosis in HIV and HIV/ HBV Infected Nigerians on ART

Jennifer L. Grant¹; Oche Agbaji²; Muazu Muhammad³; Placid Ugoagwu⁴; McHenry Stephen⁵; Chloe Thio⁶; Agaba Patricia⁷; Robert Murphy⁸; Claudia Hawkins⁹
¹Northwestern Univ, Chicago, IL, USA; ²Jos Univ Teaching Hosp, Jos, Nigeria; ³AIDS Prevention Initiative in Nigeria, Ltd, Jos, Nigeria; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA

565 Changes in Viral Hepatitis Screening Practices Over Time in African HIV Clinics

Ahuatchi P. Coffie¹; Matthias Egger²; Michael Vinikoor³; Marcel Zannou⁴; Lameck Diero⁵; Akouda Patassi⁶; Ponsiano Ocama⁷; Francois Dabis⁸; Gilles Wandeler²
¹Prog PACCI, CHU Treichville, Abidjan, Côte d'Ivoire; ²Univ Hosp Bern, Bern, Switzerland; ³Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ⁴Cntr de Prise en Charge des Personnes Vivant Avec le VIH, CHNU, Cotonou, Benin; ⁵Moi Univ, Eldoret, Kenya; ⁶Univ Sylvanus Olympio, Lomé, Togo; ⁷Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁸INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France

566 Tenofovir and the Incidence of Hepatocellular Carcinoma in HIV/HBV-Coinfected Persons

Gilles Wandeler¹; David Kraus²; Peter Reiss³; Lars Peters⁴; Francois Dabis⁵; Jan Fehr⁶; Marc van der Valk⁷; Lars Gjaerde⁸; Fabrice Bonnet⁹; Andri Rauch⁹

¹Univ Hosp Bern, Bern, Switzerland; ²Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland; ³Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ⁴Copenhagen HIV Prog, Copenhagen, Denmark; ⁵INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ⁶Univ Hosp Zurich, Zurich, Switzerland; ⁷Academic Med Cntr, Amsterdam, Netherlands; ⁸Univ Hosp Bordeaux, Bordeaux, France; ⁹Bern Univ Hosp and Univ of Bern, Bern, Switzerland

567 Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections

Mohaned Shilaih¹; **Alex Marzel**²; Alexandra L. Calmy³; Katharine Darling⁴; Manuel Battegay⁵; Matthias Hoffmann⁶; Enos Bernasconi⁷; Alexandra Scherrer⁸; Huldrych F. Günthard⁹; Roger Kouyou⁹; for the Swiss HIV Cohort Study

¹Univ Hosp Zurich, Zurich, Switzerland; ²Univ Hosp Geneva, Univ of Geneva, Geneva, Switzerland; ³CHUV, Lausanne, Switzerland; ⁴Univ Hosp Basel, Basel, Switzerland; ⁵Kantonsspital St Gallen, St Gallen, Switzerland; ⁶Regional Hosp Lugano, Lugano, Switzerland; ⁷Univ Hosp Zurich, Zurich, Switzerland

568 Alcohol Use, Hepatitis B and Liver Fibrosis Among HIV-Infected Persons in West Africa

Antoine Jaquet¹; Gilles Wandeler²; Marcellin Nouaman³; Didier Ekouevi⁴; Judicaël Tine⁵; Ahuatchi P. Coffie⁶; Aristophane Tanon⁶; Moussa Seydi⁷; Alain Attia⁸; Francois Dabis¹

¹INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ²Univ Hosp Bern, Bern, Switzerland; ³Prog PACCI, CHU Treichville, Abidjan, Côte d'Ivoire; ⁴INSERM U897, ISPED, Univ de Bordeaux, Abidjan, Côte d'Ivoire; ⁵CHU de Fann, Dakar, Senegal; ⁶CHU de Treichville, Abidjan, Côte d'Ivoire; ⁷CHU de Yopougon, Abidjan, Côte d'Ivoire

569 Baseline IL-18 Level Is Associated With HBeAg Seroconversion in HIV/HBV Coinfection

Yijia Li¹; Jing Xie¹; Yang Han¹; Huanling Wang¹; Nidan Wang¹; Ting Zhu¹; Xiaojing Song¹; Yanling Li¹; Chloe Thio²; Taisheng Li¹
¹Peking Union Med Coll Hosp, Beijing, China; ²Johns Hopkins Univ, Baltimore, MD, USA

570 HBsAg Mutations Correlate With HCC, Affect HBsAg Release, and Favor Cell Proliferation

Valentina Svicher¹; Romina Salpini²; Matteo Surdo¹; Nadia Warner²; Michela Pollicita³; Francesca Ceccherini-Silberstein⁴; Massimo Andreoni⁵; Mario Angelico⁶; Stephen Locamini⁷; Carlo Federico Perno¹
¹Univ of Rome Tor Vergata, Rome, Italy; ²Victorian Infectious Diseases Reference Lab, Victoria, Australia; ³Tor Vergata Univ, Rome, Italy; ⁴Univ of Rome Tor Vergata, Roma, Italy

571 Liver Transplantation in HIV/HBV-Coinfected Patients: A Cohort Study

Christian Manzano¹; Fernando Agüero²; Miguel Montejo³; Marino Blanes⁴; Manuel Abradelo⁵; Santos del Campo⁶; Lluís Castell⁷; Antoni Rafecas⁸; Antoni Rimola⁹; José M. Miro¹⁰; for the Spanish Liver Transplantation in HIV-Infected Patients Working Group.
¹Hosp Clinic-IDIBAPS- Univ of Barcelona, Barcelona, Spain; ²Hosp Clinic de Barcelona, Barcelona, Spain; ³Hosp Universitario Cruces, Barakaldo, Spain; ⁴Hosp Universitari La Fe, Valencia, Spain; ⁵Hosp Universitario 12 de Octubre, Madrid, Spain; ⁶Hosp Ramon y Cajal, Madrid, Spain; ⁷Hosp Universitario Vall d Hebron, Barcelona, Spain; ⁸Hosp de Bellvitge-IDIBELL, Univ of Barcelona, L'Hospitalet de Llobregat, Spain; ⁹Hosp Clinic-IDIBAPS, Univ de Barcelona, Barcelona, Spain

Session P-N6 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HCV Infection: Therapeutic Studies and Drug Resistance

572 Incidence and Risk Factors of Acute Rejection in HIV+ Liver Transplant Recipients

Christian Manzano¹; Fernando Agüero²; Antoni Rafecas³; Jesús Fortún⁴; Marino Blanes⁵; Magdalena Salcedo⁶; Itxarone Bilbao⁷; Asunción Moreno⁸; Antoni Rimola⁹; José M. Miro¹⁰; for the Spanish Foundation for AIDS Research and Prevention, Liver Transplantation Investigators
¹Hosp Clinic-IDIBAPS- Univ of Barcelona, Barcelona, Spain; ²Hosp Clinic de Barcelona, Barcelona, Spain; ³Hosp de Bellvitge-IDIBELL, Univ of Barcelona, L'Hospitalet de Llobregat, Spain; ⁴Hosp Ramon y Cajal, Madrid, Spain; ⁵Hosp Universitari La Fe, Valencia, Spain; ⁶Hosp General Universitario Gregorio Marañón, Madrid, Spain; ⁷Hosp Universitario Vall d Hebron, Barcelona, Spain; ⁸Hosp Clinic-IDIBAPS, Univ de Barcelona, Barcelona, Spain

573 Retreatment of HCV/HIV-Coinfected Patients Who Failed 12 Weeks of LDV/SOF

Curtis L. Cooper¹; Susanna Naggie²; Michael S. Saag³; Jenny C. Yang⁴; Luisa M. Stamm⁵; Hadas Dvory-Sobol⁶; Philip S. Pang⁷; John G. McHutchison⁸; Douglas Dieterich⁹; Mark Sulkowski⁹
¹Ottawa Hosp - Univ of Ottawa, Ottawa, ON, Canada; ²Duke Univ Sch of Med, Durham, NC, USA; ³Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁴Gilead Scis, Inc, Foster City, CA, USA; ⁵Mount Sinai Hosp, New York, NY, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA

574 TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r+Dasabuvir+RBV for HCV/HIV Coinfection

David L. Wyles¹; Michael S. Saag²; Roger Trinh³; Jacob Lalezari⁴; Oluwatoyin Adeyemi⁵; Laveeza Bhatti⁶; Amit Khatri⁷; Yiran B. Hu⁸; Nancy S. Shulman⁹; Peter Ruane⁹
¹Univ of California San Diego, San Diego, CA, USA; ²Univ of Alabama at Birmingham, Birmingham, AL, USA; ³AbbVie Inc, North Chicago, IL, USA; ⁴Quest Clinical Rsr, San Francisco, CA, USA; ⁵Ruth M. Rothstein CORE Cntr, Chicago, IL, USA; ⁶AIDS Hlthcare Fdn, Beverly Hills, CA, USA; ⁷Peter J Ruane MD, Inc, Los Angeles, CA, USA

575 NSSA and NSSB Minor Variant Analyses in HCV/HIV Patients Failing Treatment With DCV/SOF

Dennis Hernandez¹; Saumya Pant²; Nannan Zhou³; Fiona McPhee¹
¹Bristol-Myers Squibb, Wallingford, CT, USA; ²Bristol-Myers Squibb, Princeton, NJ, USA

576 Safety and Tolerability of Elbasvir/Grazoprevir in Chronic Hepatitis C Infection

Mark S. Sulkowski¹; Geoffrey M. Dusheiko²; Michael Manns³; John M. Vierling⁴; Rajender Reddy⁵; Paul Kwo⁶; Eric Lawitz⁷; Janice Wahl⁸; Barbara Haber⁹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Royal Free Hosp Univ Coll London, London, UK; ³Medizinische Hochschule Hannover, Hannover, Germany; ⁴Baylor Coll of Med, Houston, TX, USA; ⁵Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA; ⁶Indiana Univ Sch of Med, Indianapolis, IN, USA; ⁷Texas Liver Inst, San Antonio, TX, USA; ⁸Merck & Co, Inc, Kenilworth, NJ, USA

577 HCV Resistance to Daclatasvir/Sofosbuvir Across Different Genotypes in the Real Life

Slim Fourati¹; Christophe Hezode²; Alexandre Soulier³; Lila Poiteau⁴; Marion Lavert⁵; Christophe Rodriguez⁶; Stephane Chevalier⁷; Jean-Michel Pawlotsky⁸
¹INSERM U955, Créteil, France; ²Inst Mondor de Recherche Biomédicale INSERM U955, Créteil, France

578 Polymorphisms at Codon 28 of HCV NSSA Impact NSSA Inhibitor Susceptibility

Alicia Newton; Arne Frantzell; Christos Petropoulos; Wei Huang
Monogram BioScis, South San Francisco, CA, USA

579 Genotypic and Phenotypic Characterization of Clinical HCV NSSA Drug Resistance

Wei Huang; Alicia Newton; Arne Frantzell; Jennifer Cook; Dongmei Yang; Joseph M. Volpe; Charles M. Walworth; Jeannette M. Whitcomb; Jacqueline D. Reeves; Christos Petropoulos
Monogram BioScis, South San Francisco, CA, USA

580 Resistance Associated Variants: Data From the NIAID SYNERGY Trial

Eleanor M. Wilson¹; Sarah Kattakuzhy²; Hongmei Mo³; Anuoluwapo Osinusi⁴; Henry Masur⁵; Anita Kohli⁶; Shyam Kottitil⁶
¹Inst of Human Virology, Baltimore, MD, USA; ²Inst of Human Virology, Bethesda, MD, USA; ³Gilead Scis, Inc, Foster City, CA, USA; ⁴NIH, Bethesda, MD, USA; ⁵Dignity Hlth, St. Joseph's Hosp, Phoenix, AZ, USA; ⁶Univ of Maryland Med Cntr, Baltimore, MD, USA

Session P-N7 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HCV Therapeutics: Observational Experiences and "Real-World" Studies

581 Efficacy and Safety of Sofosbuvir-Based Regimens in Clinical Practice

Adeel A. Butt¹; Peng Yan²; Obaid Shaikh³; Raymond T. Chung⁴; Kenneth E. Sherman⁵; for the ERCHIVES Study Group
¹Hamad Hlthcare Quality Inst, Doha, Qatar; ²VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA; ³Univ of Pittsburgh, Pittsburgh, PA, USA; ⁴Harvard Med Sch, Boston, MA, USA; ⁵Univ of Cincinnati, Cincinnati, OH, USA

582 Response to DAA-Based Regimens in HIV-HCV Coinfected Patients in Real Life, France

Lionel Piroth¹; Linda Wittkop²; Karine LaCombe³; Eric Rosenthal⁴; Camille Gilbert⁵; Patrizia Carrieri⁶; Francois Dabis⁷; Philippe Sogni⁸; Dominique Salmon-Ceron⁹; for the ANRS CO13 HEPAVIH Study Group
¹CHU Dijon, Dijon, France; ²CHU de Bordeaux, Bordeaux, France; ³Sorbonne Univ, Paris, France; ⁴CHU Nice, Nice, France; ⁵INSERM, Bordeaux, France; ⁶INSERM, Marseille, France; ⁷INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ⁸INSERM-APHP, Hosp Cochin, Paris, France

583 Multidisciplinary Approach for the Treatment of 1155 HCV/HIV Coinfected Patients

Isabelle Poizot-Martin¹; Albert Darque²; Isabelle Ravoux³; Amélie Ménard⁴; Catherine Dhiver⁵; Christelle Tomei⁶; Sylvie Brégeon⁷; Marc Bourrière⁸; Isabelle Portal⁹; Danielle Botta-Fridlund⁹
¹APHM Hosp Sainte-Marguerite, Marseille, France; ²Pharmacie CHU Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France; ³Inst Hospo Universitaire Méditerranée Infection, Marseille, France; ⁴Hosp St Joseph, Marseille, France; ⁵CHU Timone, AP-HM, Marseille, France

584 Directly Acting Agents Against HCV Results From the German Hepatitis C Cohort (GECCO)

Stefan Christensen¹; Stefan Mauss²; Dietrich Huetpepe³; Thomas Lutz⁴; Knud Schewe⁵; Jürgen K. Rockstroh⁶; Axel Baumgarten⁷; Karl Georg Simon⁸; Heiner Busch⁹; Patrick Ingiliz⁷
¹Cntr for Interdisciplinary Med, Muenster, Germany; ²Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany; ³Practice for Gastroenterology Herne, Herne, Germany; ⁴Infektiologikum, Frankfurt/Main, Frankfurt, Germany; ⁵CH Hamburg, Hamburg, Germany; ⁶Medizinische Univklinik, Bonn, Germany; ⁷Med Cntr for Infectious Diseases, Berlin, Germany; ⁸Practice for Gastroenterology Leverkusen, Leverkusen, Germany

585 High HCV Cure Rates for Drug Users Treated With DAAs at an Urban Primary Care Clinic

Brianna Norton¹; Julia Fleming²; Meredith Steinman³; Kim Yu⁴; Joseph Deluca⁵; Chinazo O. Cunningham⁶; Alain Litwin⁷
Montefiore Med Cntr, Bronx, NY, USA

586 Impact of Liver Stiffness on Response to DAA-Based HCV Therapy In Cirrhotic Patients

Karin Neukam¹; Antonio Rivero-Juárez²; Luis E Morano-Amado³; Rafael Granados⁴; Antoni o Collado⁵; Dolores Merino⁶; M^o José Blanco Rodríguez⁷; Sergio Reus-Bañuls⁸; Juan A. Pineda⁹; for the Grupo de Estudio de Hepatitis Virica, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC; Grupo de Estudio de Hepatitis Virica, Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR; RIS-HEP07
¹Valme Univ Hosp, Seville, Spain; ²IMIBIC, Córdoba, Spain; ³Hosp Universitario Alvaro Cunqueiro, Vigo, Spain; ⁴Hosp Universitario de Gran Canaria Doctor Negrin, Las Palmas, Spain; ⁵Hosp Universitario Torrecárdenas, Almería, Spain; ⁶Complejo Hospario de Huelva, Huelva, Spain; ⁷Hosp Jerez de la Frontera (AGS Norte de Cádiz), Jerez de la Frontera, Spain; ⁸Hosp General Universitario de Alicante, Alicante, Spain; ⁹Hosp Universitario de Valme, Sevilla, Spain

587 Success of Direct-Acting Antivirals for Hepatitis C in an Indigent Population

Christina Yek¹; Carolina De La Flor¹; Amit Singal¹; Mamta K. Jain²; Ting-Yi Chen³; Cindy L. Zoellner⁴; Christian Mayorga⁵; Lisa Casey⁶
¹Univ of Texas Southwestern, Dallas, TX, USA; ²Univ of Texas Southwestern Med Cntr, Dallas, TX, USA

588 Ledipasvir/Sofosbuvir Failures in the Real World: What Patients Are at Risk?

Dost Sarpel¹; Alyson Harty¹; Donald Gardenier¹; Ponn Perumalswami²; Michael P. Mullen³; Ira M. Jacobson⁴; Andrea Branch⁵; Douglas Dieterich⁶
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Mount Sinai Hosp, New York, NY, USA; ³Mount Sinai Beth Israel, New York, NY, USA

589 Dolutegravir and Outcome of HCV Therapy With Direct-Acting Antiviral Agents

Stefan Mauss¹; Patrick Ingiliz²; Dietrich Huetpepe³; Thomas Lutz⁴; Karl Georg Simon⁵; Knud Schewe⁶; Christoph Boesecke⁷; Guenther Schmutz⁸; Axel Baumgarten⁹; Stefan Christensen⁸
¹Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany; ²Med Cntr for Infectious Diseases, Berlin, Germany; ³Practice for Gastroenterology Herne, Herne, Germany; ⁴Infektiologikum, Frankfurt/Main, Frankfurt, Germany; ⁵Practice for Gastroenterology Leverkusen, Leverkusen, Germany; ⁶CH Hamburg, Hamburg, Germany; ⁷Univ Hosp Bonn, Bonn, Germany; ⁸Cntr for Interdisciplinary Med, Muenster, Germany

Session P-01 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Global Burden and Mortality of Cancer in HIV

613 Risk of Cancer in HIV-Positive Adults on ART in South Africa: A Record Linkage Study

Mazvita M. Sengayi¹; Adrian Spoerri²; Matthias Egger³; Janet Giddy⁴; Mhairi Maskew⁵; Elvira Singh⁶; Julia Bohlius⁷; for the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA)
¹Nati Cancer Registry, NHLS, Johannesburg, South Africa; ²Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland; ³Univ Hosp Bern, Bern, Switzerland; ⁴McCord Hosp, Durban, South Africa; ⁵Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa

614 No Difference in Stage at Cancer Diagnosis by AIDS Status Among HIV-Infected Adults

Surbhi Grover¹; Heidi M. Crane²; John Gill³; James J. Goedert⁴; Mari M. Kitahata⁵; Richard Moore⁶; Sonia Napravnik⁷; Anita Rachlis⁸; Michael J. Silverberg⁹; Keri N. Althoff¹⁰
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Univ of Washington, Seattle, WA, USA; ³Univ of Calgary, Calgary, AB, Canada; ⁴NIH, Bethesda, MD, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA; ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁷Sunnybrook Rsr Inst, Sunnybrook Hlth Scis Cntr, Toronto, ON, Canada; ⁸Kaiser Permanente Northern California, Oakland, CA, USA; ⁹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA

- 615 Cancer Versus Tuberculosis Mortality Among HIV-Infected Individuals in Botswana**
Scott Dryden-Peterson¹; Gita Suneja²; Heluf Medhin³; Memory Bvochora-Nsingo⁴; Mukendi K. Kayembe⁵; Neo Tapela⁶; Shahin Lockman¹
¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Univ of Utah Sch of Med, Salt Lake City, UT, USA; ³Botswana Ministry of Hlth, Gaborone, Botswana; ⁴Gaborone Private Hosp, Gaborone, Botswana; ⁵Natl Hlth Lab, Gaborone, Botswana
- 616 Excess Mortality Rates Among HIV-Infected Cancer Patients in the United States**
Anna Coghill¹; Ruth Pfeiffer; Meredith Shiels; Eric Engels
 NC, Rockville, MD, USA
- 617 Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy**
Eliane Rohner¹; Lukas Büttikofer²; Mhairi Maskew³; Yi-Ming A. Chen⁴; Ruth Friedman⁵; Gypsamber DSouza⁶; Matthias Egger⁷; Julia Bohlius⁸; for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
¹Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland; ²Univ of Bern, Bern, Switzerland; ³Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ⁴Kaohsiung Med Univ, Kaohsiung, Taiwan; ⁵Inst Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil; ⁶Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁷Univ Hosp Bern, Bern, Switzerland
- 618 Risk of Kaposi Sarcoma in HIV-Positive Adults on ART: A Global Analysis**
Eliane Rohner¹; Julia Bohlius²; Lukas Büttikofer³; Mhairi Maskew⁴; Yi-Ming A. Chen⁵; Valeria Fink⁶; Chad Achenbach⁷; Matthias Egger⁸; for the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
¹Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland; ²Univ of Bern, Bern, Switzerland; ³Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ⁴Kaohsiung Med Univ, Kaohsiung, Taiwan; ⁵Fundación Huésped, Buenos Aires, Argentina; ⁶Northwestern Univ, Chicago, IL, USA; ⁷Univ Hosp Bern, Bern, Switzerland
- 619 Kaposi Sarcoma Risk in Children on ART From Africa, Europe, and Asia**
Eliane Rohner; Julia Bohlius; for the on behalf of the International Epidemiologic Databases to Evaluate AIDS Southern Africa, the Collaboration of Observational HIV Epidemiological Research in Europe in EuroCoord, and the TREAT Asia Pediatric HIV Observational Database
 Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland
- 621 Randomized Trial Comparing HIV-1 Cervical Shedding After Cryotherapy Versus LEEP**
Sharon A. Greene¹; Christine J. McGrath²; Dara Lehman³; T. T. Trinh⁴; Nelly Yatchi⁵; Barbra A. Richardson⁶; Grace C. John-Stewart⁷; Hugo De Vuyst⁸; Nelly R. Mugoz⁹; Michael H. Chung¹⁰
¹Univ of Washington, Seattle, WA, USA; ²Univ of Texas Med Branch at Galveston, Galveston, TX, USA; ³Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁴Intl Agency for Rsr on Cancer, Lyon, France; ⁵Kenya Med Rsr Inst, Thika, Kenya
- 622 Decline in Annual Pap Testing Among HIV-Positive Women in Ontario, Canada**
Ann N. Burchell¹; Claire Kendall²; Stephanie Cheng³; Tony Antoniou⁴; Ahmed M. Bayoumi⁵; Rick Glazier⁶; Aisha Lofters⁷; Janet M. Raboud⁸; Mark Yudin⁹; Mona Loutfy⁹
¹St Michael's Hosp, Toronto, ON, Canada; ²Univ of Ottawa, Ottawa, ON, Canada; ³Inst for Clinical Evaluative Scis, Toronto, ON, Canada; ⁴Dalla Lana Sch of PH, Toronto, ON, Canada; ⁵Women's Coll Rsr Inst, Univ of Toronto, Toronto, ON, Canada
- 623 Feasibility of Post-Partum Testing for HR-HPV Among HIV-Positive and -Negative Women**
 Erin Dressel¹; Gabriela DelBianco²; Gilhen Rodriguez³; James R. Murphy⁴; Gloria P. Heresi⁵; **Laura J. Benjamins**⁶
¹Univ of Texas Hlth Sci Cntr at Houston, Houston, TX, USA; ²Univ of Texas Med Sch at Houston, Houston, TX, USA; ³The Univ of Texas Med Sch at Houston, Houston, TX, USA
- 624 Role of p16 Testing in Cervical Cancer Screening Among HIV-Infected Women**
Christine J. McGrath¹; Rochelle L. Garcia²; Hugo De Vuyst³; Ritesh Pannani⁴; Barbra A. Richardson⁵; Grace C. John-Stewart⁶; Evans Nyongesa-Malava⁷; Samah Sakr⁸; Nelly R. Mugoz⁹; Michael H. Chung¹⁰
¹Univ of Texas Med Branch at Galveston, Galveston, TX, USA; ²Univ of Washington, Seattle, WA, USA; ³Intl Agency for Rsr on Cancer, Lyon, France; ⁴Kenya Med Rsr Inst, Nairobi, Kenya; ⁵Kenya Rsr Prog at the Univ of Washington, Nairobi, Kenya; ⁶Coptic Hosp, Nairobi, Kenya; ⁷Kenya Med Rsr Inst, Thika, Kenya
- 625 High Prevalence of HR-HPV Infection in HIV-Infected Women From Tanzania**
 Tessa Lennemann¹; Ruby Mcharo²; Asli Bauer³; Liset Torres⁴; Mkunde Chachage⁵; Nice Mwinuka⁶; Leonard Maboko⁷; John France⁸; Christof Geldmacher⁹; **Arne Kroidl**¹⁰
¹Natl Inst for Med Rsr Mbeya Med Rsr Cntr, Mbeya, Tanzania; ²Mbeya Referral Hosp, Mbeya, Tanzania; ³Univ of Munich, Munich, Germany; ⁴Univ of Munich, Munich, Germany
- 626 HPV Type Distribution in HIV-Infected Persons With Anal HSIL and Impact on Recurrence**
Michael Gaisa¹; Keith M. Sigel²; Stephen Goldstone³; Matthew Silverstein⁴; Iain MacLeod⁵
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Harvard Sch of PH, Boston, MA, USA

Session P-02 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Anal and Cervical Cancer: Treatment and Prevention

620 Long-Term Complications of Radiotherapy For Anal Cancer in HIV

Leela Chockalingam; Michael Gaisa; Matthew Silverstein; Keith M. Sigel
 Icahn Sch of Med at Mount Sinai, New York, NY, USA

- 627 Multiple HPV Genotypes As a Risk Factor for High Grade AIN in HIV-1 Infected Males**
Cristina Rovelli¹; Andrea Poli²; Massimo Cernuschi³; Andrea Marco Tamburini⁴; Sara Racca⁵; Laura Galli⁶; Giuseppe Tambussi⁷; Antonella Castagna⁸; Adriano Lazzarin⁹; Silvia Nozza³
¹Università Vita-Salute San Raffaele, Milano, Italy; ²Università Vita-Salute San Raffaele, Milan, Italy; ³San Raffaele Scientific Inst, Milan, Italy; ⁴Vita-Salute Univ, San Raffaele Scientific Inst, Milan, Italy
- 628 Prevalence of HPV-Related Lesions in an Urban Cohort of HIV-Positive Men in Germany**
 Wolfgang Fuchs¹; Ulrike Wieland²; Adriane Skaletz-Rorowski³; Jochen Swoboda⁴; Alexander Kreuter⁵; Claudia Michalik⁶; Anja Potthoff⁷; **Norbert H. Brockmeyer**⁸; for the Competence Network for HIV/AIDS
¹Clinic for Dermatology, Ruhr-Universität Bochum, Germany, Bochum, Germany; ²Natl Reference Cntr for Papilloma- and Polyomaviruses, Univ of Cologne, Cologne, Germany; ³Competence Network for HIV/AIDS, Ruhr-Universität, Bochum, Germany; ⁴Inst of Cytology, Bonn, Germany; ⁵Helios St. Elisabeth Hosp Oberhausen, Oberhausen, Germany; ⁶KompNet HIV/AIDS, Bochum, Germany; ⁷Fachklinikum Borkum, Borkum, Germany

Session P-P3 Poster Abstracts **Hall A/B**
2:45 PM-4:00 PM
Atherosclerosis Pathogenesis: Role of the Immune System

- 651 Correlates and Longitudinal Implications of FGF23 Levels in HIV-Positive Individuals**
Mohamed G. Atta¹; Michelle Estrella²; Derek M. Fine³; Katie Zook⁴; Jose Manuel Monroy Trujillo⁵; James H. Stein⁶; Gregory M. Lucas⁷
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Univ of Wisconsin-Madison, Madison, WI, USA
- 652 Nonclassical Monocyte, MCP-1 Predict Subclinical Atherosclerosis Progression in HIV**
Dominic C. Chow¹; Lishomwa C. Ndhlovu²; Lindsay M. Kohorn³; Guangxiang Zhang⁴; Howard N. Hodis⁵; Matthew Budoff⁶; Yanjie Li⁷; Sheila M. Keating⁸; Philip J. Norris⁹; Cecilia M. Shikuma¹⁰
¹Univ of Hawaii, Honolulu, HI, USA; ²Univ of Southern California, Los Angeles, CA, USA; ³Harbor-Univ of California Los Angeles Med Cntr, Torrance, CA, USA; ⁴Blood Systems Rsr Inst, San Francisco, CA, USA
- 653 Association of T Cell and Macrophage Activation With Vascular Health in HIV**
Heather Grome; Louise Barnett; Cindy Hager; Timothy R. Sterling; Spyros A. Kalams; John R. Koethe
 Vanderbilt Univ Sch of Med, Nashville, TN, USA
- 654 Effect of T-Cell Activation and Inflammation on Endothelial Dysfunction in HIV**
Arjun Sinha; Yifei Ma; Rebecca Scherzer; Danny Li; Steven G. Deeks; Peter Ganz; Priscilla Hsue
 Univ of California San Francisco, San Francisco, CA, USA

- 655 CCR5+CD8+ T-Cell Levels Are Associated With Cardiovascular Events in Patients on cART**
Laura Tarancón¹; Rebeca S. de Pablo²; Isaac Rosado³; Beatriz Dominguez⁴; Miguel Genebat⁵; María José Polaino⁶; Mohammed Rafii-El-Idrissi Benhnia⁷; Yolanda M. Pacheco⁸; Manuel Leal⁹; Ezequiel Ruiz-Mateos⁴
¹BioMed Inst of Sevilla, Sevilla, Spain; ²BioMed Inst of Sevilla, Sevilla, Spain; ³Inst of BioMed of Sevilla (IBIS), Seville, Spain; ⁴BioMed Inst of Sevilla, Seville, Spain; ⁵BioMed Inst of Sevilla, Sevilla, Spain
- 656 Soluble TWEAK May Predict Carotid Atherosclerosis in Treated HIV Infection**
Sahera Dirajjal-Fargo¹; Abdus Sattar²; Manjusha Kulkarni³; Nicholas T. Funderburg⁴; Grace A. McComsey⁵
¹Case Western Reserve Univ, Cleveland, OH, USA; ²Case Western Reserve Univ Sch of Med, Cleveland, OH, USA; ³Ohio State Univ, Columbus, OH, USA
- 657 Diet, Gut Integrity Markers, and Cardiovascular Disease Risk in HIV+ Adults**
Allison R. Weibel¹; Abdus Sattar²; Nicholas T. Funderburg³; Bruce Kinley⁴; Chris T. Longenecker⁵; Danielle Labbato⁶; Morgan Boucher⁷; Grace A. McComsey⁸
¹Case Western Reserve Univ, Cleveland, OH, USA; ²Case Western Reserve Univ Sch of Med, Cleveland, OH, USA; ³Ohio State Univ, Columbus, OH, USA

Session P-P4 Poster Abstracts **Hall A/B**
2:45 PM-4:00 PM
Cardiovascular Disease and Antiretroviral Therapy Effects

- 658 Does Pulse-Wave Velocity Normalize With Increasing Time on ART? Evidence From CHER**
Steve Innes¹; Mark F. Cotton²; Kennedy Otwombe³; Philip G. Herbst⁴; Barbara Laughton⁵; Richard Haubrich⁶; Sara H. Browne⁷
¹Stellenbosch Univ and Tygerberg Children's Hosp, Cape Town, South Africa; ²Univ of the Witwatersrand, Johannesburg, South Africa; ³Stellenbosch Univ and Tygerberg Academic Hosp, Cape Town, South Africa; ⁴Univ of California San Diego, San Diego, CA, USA
- 659 Changes in CVD Risk Factors With Early and Deferred ART in the START Trial**
Jason V. Baker¹; Shweta Sharma²; for the The INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
¹Hennepin County Med Cntr, Univ of Minnesota, Minneapolis, MN, USA; ²Univ of Minnesota, Minneapolis, MN, USA
- 660 Cardiovascular Biomarkers After Switch to ABC/DTG/3TC: The STRIIVING Study**
Jordan Lake¹; Judith S. Currier²; Justin Kotloff³; Clare Brennan⁴; Catherine Granier⁵; Mark Shafer⁶; Martin Gartland⁷; Brian Wynne⁸; Michael Aboud⁹
¹David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ²Viiiv Hlthcare, Research Triangle Park, NC, USA; ³CSC, Middlesex, UK; ⁴Viiiv Hlthcare, Collegeville, PA, USA; ⁵Viiiv Hlthcare, Brentford, UK

661 Abacavir (ABC) Use and Risk of Recurrent Myocardial Infarction (MI)

Caroline Sabin¹; Lene Ryom²; Ole Kirk³; Antonella d'Arminio Monforte⁴; Christian Pradier⁵; Rainer Weber⁶; Andrew N. Phillips⁷; Francois Dabis⁸; Jens D. Lundgren⁹; for the D:A:D Study Group
¹Univ Coll London, London, UK; ²Rigshospitalet, Univ of Copenhagen, Copenhagen, Denmark; ³Infectious Diseases Clinic, San Paolo Hosp, Univ of Milan, Milan, Italy; ⁴Nice Univ Hosp, Nice, France; ⁵Univ Hosp Zurich, Zurich, Switzerland; ⁶INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France

662 Cardiovascular Risk Profile of Abacavir and Tenofovir Independent of HIV Infection

Michael Emerson¹; Erica Smyth²; Mark Nelson³
¹Imperial Coll London, London, UK; ²Chelsea and Westminster Hosp NHS Fdn Trust, London, UK

663 Abacavir Induces Platelet-Endothelium Interactions Through Endothelial P2X7 Receptors

Cesar Rios-Navarro¹; Samuel Orden¹; Victor Collado-Diaz²; Maria Angeles Martinez-Cuesta³; Juan V. Esplugaes⁴; **Angeles Alvarez**¹
¹Univ of Valencia, Valencia, Spain; ²Univ de Valencia, Valencia, Spain

Session P-Q3 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****Bone Disease: Sticks, Stones, and TDF****696 TDF and Quantitative Ultrasound Bone Density in African Patients on Second-Line ART**

Firmin N. Kabore¹; Sabrina Eymard-Duvernay²; Amandine Cournil³; Jacques Zoungrana⁴; Assane Diouf⁵; Arsène Héma⁶; Laura Ciaffri⁷; Eric Delaporte⁸
¹CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso; ²INSERM, Montpellier, France; ³UMI 233-IRD/U1175-INSERM/Montpellier Univ, Montpellier, France; ⁴CHU Sourô Sanou, Bobo-Dioullasso, Burkina Faso; ⁵Cheikh Anta Diop Univ, Dakar, Senegal; ⁶IRD, Site ANRS Cameroun, Yaoundé, Cameroon

697 Bone-Mineral Density After Switching to ATV/r+3TC: A Substudy of the AtLaS-M Trial

Alessandro D'Avino¹; Andrea De Luca²; Anna Pia Lassandro³; Nicoletta Ciccarelli⁴; Francesca Lombardi⁵; Massimo Giuliani⁶; Adriano Lazzarin⁷; Massimiliano Fabbiani⁸; Simona Di Giambenedetto⁹; Roberto Cauda⁹
¹Inst of Clinical Infectious Diseases - Università Cattolica del Sacro Cuore, Rome, Italy; ²Univ of Siena, Siena, Italy; ³Catholic Univ, Rome, Italy; ⁴Inst of Clinical Infectious Diseases, Catholic Univ of Sacred Heart, Rome, Italy; ⁵San Gallicano Dermatological Inst, IRCCS, Rome, Italy; ⁶Vita-Salute Univ, San Raffaele Scientific Inst, Milan, Italy

698 Osteoporosis and Fractures in HIV-Infected Adults: Who Is Afraid of the Lumbar Spine?

Linda A. Battalora¹; Kate Buchacz²; Carl Armon³; John Hammer⁴; Joan S. Chmiel⁵; John R. Spear⁶; John T. Brooks⁷; Benjamin Young⁸; Edgar T. Overton⁹; for the HIV Outpatient Study (HOPS) and SUN Study Investigators
¹Colorado Sch of Mines, Golden, CO, USA; ²CDC, Atlanta, GA, USA; ³Cerner Corporation, Kansas City, MO, USA; ⁴Denver Infectious Disease Consultants, Denver, CO, USA; ⁵Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA; ⁶International Association of Providers of AIDS Care, Washington, DC, USA; ⁷Univ of Alabama at Birmingham, Birmingham, AL, USA

699 Fractures Occur at a Younger Age in HIV+ Men in the Multicenter AIDS Cohort Study

Anda R. Gonciulea¹; Ruibin Wang²; Kerri N. Althoff³; Frank J. Palella⁴; Jordan Lake⁵; Lawrence Kingsley⁶; Todd T. Brown⁶
¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ³Northwestern Univ, Chicago, IL, USA; ⁴David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ⁵Univ of Pittsburgh, Pittsburgh, PA, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA

700 Racial Differences in Bioavailable Vitamin D With Supplementation: ACTG A5280

Michael T. Yin¹; Ellen S. Chan²; Todd T. Brown³; Pablo Tebas⁴; Grace A. McComsey⁵; Kathy Melbourne⁶; Royce Hardin⁷; Heather J. Ribaud⁸; Edgar T. Overton⁹; for the ACTG 5280 Study Team
¹Columbia Univ Med Cntr, New York, NY, USA; ²Harvard Univ, Boston, MA, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Univ of Pennsylvania, Philadelphia, PA, USA; ⁵Case Western Reserve Univ, Cleveland, OH, USA; ⁶Gilead Scis, Inc, Foster City, CA, USA; ⁷Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁸Harvard Sch of PH, Boston, MA, USA; ⁹Univ of Alabama at Birmingham, Birmingham, AL, USA

Session P-Q4 Poster Abstracts**Hall A/B****2:45 PM-4:00 PM****Metabolic Complications****701 Blood Microbiome in Treatment-Naïve HIV-1-Infected Persons Developing Hyperglycemia Under ART**

Jacques Amar¹; Mathilde Ghislain²; Corinne Vigouroux³; Jacqueline Capeau⁴; Cecile Goujard⁵; Beverley Balkau⁶; Jean Philippe Bastard⁷; Laurence Meyer⁸; **Pierre Delobel**¹
¹INSERM 1048, Toulouse, France; ²INSERM, UMR-S 1018, Paris, France; ³Sorbonne Univs, Paris, France; ⁴INSERM UMR-S 938, CDR Saint-Antoine, Paris, France; ⁵INSERM, UMR-S 1018, CESP, Paris, France; ⁶INSERM, CESP U1018, Le Kremlin-Bicêtre, France; ⁷CHU Toulouse, Toulouse, France

702 WITHDRAWN**703 Incidence and Risk Factors for Overweight and Obesity After Initiation of ART**

Alexander Kintu¹; Enju Liu²; Till Bärnighausen³; Donna Spiegelman⁴; Wafaie W. Fawzi⁵; for the Alex Kintu, Enju Liu, Till Baernighausen, Donna Spiegelman, Wafaie Fawzi
¹Harvard Sch of PH, Boston, MA, USA; ²Harvard T.H. Chan Sch of PH, Boston, MA, USA; ³Harvard University, Boston, MA, USA

704 Measurement of Abdominal Fat Changes in HIV-Infected Individuals Initiating Therapy

Priya Bhagwat¹; Ighowherha Ofotokun²; Grace A. McComsey³; Todd T. Brown⁴; Carlee B. Moser⁵; Heather J. Ribaud⁶; Catherine A. Sugar⁷; Judith S. Currier⁸
¹Univ of California Los Angeles Sch of PH, Los Angeles, CA, USA; ²Emory Univ Sch of Med, Atlanta, GA, USA; ³Case Western Reserve Univ, Cleveland, OH, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Harvard Sch of PH, Boston, MA, USA; ⁶David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA

705 Metabolic Alterations and Physical Function in Older HIV-Infected Adults

Mehri McKellar; James Bain; Olga Ilkayeva; Michael Muehlbauer; Thomas O'Connell; Robert Stevens; Miriam Morey; Carl Pieper; William Kraus; Kim Huffman
Duke Univ, Durham, NC, USA

706 Superior Glucose Tolerance and Metabolite Profiles in Women vs Men on Long-Term ART

John R. Koethe¹; Cathy Jenkins²; Chris Petucci³; Jeffrey Culver³; Bryan E. Shepherd⁴; Spyros A. Kalamis⁵; Timothy R. Sterling¹
¹*Vanderbilt Univ Sch of Med, Nashville, TN, USA*; ²*Vanderbilt Univ, Nashville, TN, USA*; ³*Sanford Burnham Prebys Metabolomics Core at the Southeast Cntr for Integrated Metabolomics, Gainesville, FL, USA*; ⁴*Vanderbilt Inst for Global Hlth, Nashville, TN, USA*

707 Reduced Dicer and Brown Adipose Tissue (BAT) Gene Expression in HIV Lipodystrophy

Martin Torriani¹; **Suman Srinivasa**²; Kathleen Fitch³; Thomas Thomou⁴; Kimberly Wong⁵; Eva Petrow⁶; Aaron M. Cypess⁷; Steven Grinspoon¹
¹*Massachusetts General Hosp, Boston, MA, USA*; ²*Joslin Diabetes Cntr, Boston, MA, USA*; ³*NIDDK, NIH, Bethesda, MD, USA*

**Session P-Q5 Poster Abstracts
2:45 PM-4:00 PM**

Hall A/B

Multimorbidity and Aging

708 Hospitalizations With AIDS and Chronic End-Organ Conditions in HIV Outpatient Study

Kate Buchacz¹; Linda A. Battalora²; Carl Armon³; Rachel Hart⁴; John T. Brooks⁵; for the the HIV Outpatient Study
¹*CDC, Atlanta, GA, USA*; ²*Colorado Sch of Mines, Golden, CO, USA*; ³*Cerner Corporation, Kansas City, MO, USA*

709 Ageing With HIV: Emerging Importance of Chronic Comorbidities in Patients Over 75

Clotilde Allavena¹; **Camille Bernaud**¹; Sylvie Lariven²; Marc-Antoine Valantin³; Tristan Ferry⁴; Lise Cuzin⁵; Alissa Naqvi⁶; Matthieu Hanf⁷; André Cabié⁸; for the DatAIDS Study Group
¹*CHU Nantes Univ Hosp, Nantes, France*; ²*Hosp Bichat-Claude Bernard, Paris, France*; ³*Pitié Salpêtrière Hosp, Paris, France*; ⁴*Hosp de la Croix-Rousse, Lyon, France*; ⁵*CHU Toulouse, Toulouse, France*; ⁶*CHU Nice, Nice, France*; ⁷*CHU Fort de France, Fort de France, France*

710 Incremental Association Between CD4:CD8 Ratio and Incidence of Non-AIDS Events

Padraig McGettrick¹; Willard Tinago²; Aoife Lacey³; Alan Macken²; Ailbhe Ni Fhlathartaigh⁴; Sadhbh Tennant⁵; John Lambert⁶; Gerard Sheehan⁷; Patrick Mallon⁸
¹*HIV Molecular Rsr Group, UCD Sch of Med, Univ Coll Dublin, Dublin 7, Ireland*; ²*Univ Coll Dublin, Dublin, Ireland*; ³*Mater Misericordiae Univ Hosp, Dublin, Ireland*

711 Impact of Monocyte Metabolism on Serious Non-AIDS Events in HIV+ Individuals

Riya Palchaudhuri¹; Joshua Anzinger²; Jhingling Zhou³; David Anderson⁴; Joseph M. McCune⁵; Suzanne M. Crowe⁶; Clovis Palmer¹
¹*Burnet Inst, Melbourne, Australia*; ²*Univ of West Indies, Kingston, Jamaica*; ³*Univ of California San Francisco, San Francisco, CA, USA*

712 IGF-1 Levels Predict Advanced Aging in HIV/HCV Coinfected Persons

Jeffrey Quinn¹; Jacque Astemborski²; Gregory D. Kirk³; Shruti H. Mehta⁴; David L. Thomas⁵; Ashwin Balagopal¹
¹*Johns Hopkins Univ, Baltimore, MD, USA*; ²*Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA*; ³*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*

713 HLA-B57.01 Promotes Significantly Better Periodontal Health in HIV-Positive Patients

Gundolf Schuettfort¹; Kyu Hyun Park²; Christoph Stephan³; Timo Wolf⁴; Annette Haberl⁵; Eva Herrmann⁶; Hans-Reinhard Brodt⁷; Philipp de Leuw¹
¹*Univ Hosp Frankfurt, Frankfurt am Main, Germany*; ²*Dental Office, Schöner Mund Oberursel, Oberursel, Germany*; ³*Goethe Univ Hosp Frankfurt, Frankfurt, Germany*; ⁴*JW Goethe Univ of Frankfurt, Frankfurt, Germany*

714 Association of Depressive Symptoms With Biomarkers in Veterans With and Without HIV

Jessica R. White¹; Kaku So-Armah²; Jesse Stewart³; Samir Gupta⁴; Adeel A. Butt⁵; Cynthia Gibert⁶; Maria Rodriguez-Barradas⁷; Roger Bedimo⁸; Amy C. Justice⁹; Matthew S. Freiberg¹⁰
¹*Maricopa County Dept of PH, Phoenix, AZ, USA*; ²*Boston Univ Sch of Med, Boston, MA, USA*; ³*Indiana Univ Purdue Univ Indianapolis, Indianapolis, IN, USA*; ⁴*Indiana Univ Sch of Med, Indianapolis, IN, USA*; ⁵*Hamad Hlthcare Quality Inst, Doha, Qatar*; ⁶*VA Med Cntr, Washington, DC, USA*; ⁷*Michael E. DeBakey VA Med Cntr and Baylor Coll of Med, Houston, TX, USA*; ⁸*Dallas VA Med Cntr, Dallas, TX, USA*; ⁹*Yale Univ, New Haven, CT, USA*; ¹⁰*Vanderbilt Univ Sch of Med, Nashville, TN, USA*

**Session P-R5 Poster Abstracts
2:45 PM-4:00 PM**

Hall A/B

Diagnosis of Tuberculosis

747 Urine LAM Testing in Advanced HIV-Infected Adults in a Trial of Empiric TB Therapy

Gregory P. Bisson¹; Amita Gupta²; Sachiko Miyahara³; Xin Sung⁴; Jing Bao⁵; Carrie L. Fry⁶; Yukari C. Manabe⁷; Johnstone J. Kumwenda⁸; Mina Hosseinipour⁹; for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team
¹*Univ of Pennsylvania, Philadelphia, PA, USA*; ²*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ³*Harvard Univ, Boston, MA, USA*; ⁴*NIADA, NIH, Bethesda, MD, USA*; ⁵*Frontier Sci & Tech Rsr Fndn, Inc, Amherst, NY, USA*; ⁶*Johns Hopkins Univ, Baltimore, MD, USA*; ⁷*Coll of Med John Hopkins Prof, Blantyre, Malawi*; ⁸*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

748 Stool Xpert MTB/RIF and Urine LAM for Diagnosing TB in HIV-infected Kenyan Children

Patricia B. Pavlinac¹; Lisa M. Cranmer²; Irene N. Njuguna³; Vincent O. Otieno⁴; Elizabeth Maleche-Obimbo⁵; John Gatimu⁶; Julius Oyugi⁷; Judd L. Walson⁸; Dalton Wamalwa⁹; Grace C. John-Stewart¹
¹*Univ of Washington, Seattle, WA, USA*; ²*Emory Univ Sch of Med, Atlanta, GA, USA*; ³*Univ of Nairobi, Nairobi, Kenya*; ⁴*Becton, Dickinson and Company, Nairobi, Kenya*; ⁵*Sch of Med, Univ of Nairobi, Nairobi, Kenya*

749 High Sensitivity of Abbott RealTime MTB and MTB RIF/INH Resistance Assays

Carole L. Wallis¹; Neeshan Ramdin¹; Raquel V. Viana¹; Ning Tang²; Hong Wang³; Modiehi Rakgokong⁴; Joshua Koster⁴; Gregor Leckie⁵; Ebrahim Variava⁶; Neil Martinson⁶

¹BARC-SA and Lancet Lab, Johannesburg, South Africa; ²Abbott Molecular, Des Plaines, IL, USA; ³Perinatal HIV Rsr Unit, Johannesburg, South Africa; ⁴Klerksdorp/Tshepong Hosp, Klerksdorp, South Africa; ⁵Perinatal HIV Rsr Unit, Diepkloof, South Africa

750 Diagnostic Yield of TB Testing for Patients Who Present for HIV Testing in Haiti

Vanessa R. Rivera¹; Diessy Decome²; Marc Antoine Jean Juste²; Patrice Severe²; Colette Guiteau Moise²

¹Weill Cornell Med Coll, New York, NY, USA; ²GHESKIO, Port-au-Prince, Haiti

Session P-R6 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Tuberculosis and Antiretroviral Therapy

751 Association of Tuberculosis With CD4 Recovery and HIV RNA Decline on ART in Europe

Hansjakob Furrer, for the The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Bern Univ Hosp and Univ of Bern, Bern, Switzerland

752 High TB Risk in HIV-Positive Patients on Second-Line Antiretrovirals in Pune, India

Vidya Mave¹; Dileep Kadam¹; Sonali Salvi¹; Anita Basavaraj¹; Ajay Chandanwale¹; Samir Joshi¹; Nikhil Gupta²; Robert Bollinger²; Amita Gupta³

¹BJ Med Coll, Pune, India; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

753 TB Outcomes With ATV/r and Two Rifamycin-Containing TB Regimens In HIV/TB in India

Jeffrey D. Jenks¹; Constance A. Benson¹; Nagalingeswaran Kumarasamy²; Ezhilarasi Chandrasekaran²; Pradeep Ambrose²; Tokugha Yepthomi³; Chitra Devaraj³; Poongulali Selvamuthu³

¹Univ of California San Diego, San Diego, CA, USA; ²YRG Cntr for AIDS Rsr and Educ, Chennai, India

Session P-R7 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Multidrug-Resistant Tuberculosis

754 Incorporation of Bedaquiline in the South African National TB Programme

Norbret Ndjeka, for the Bedaquiline Implementers of the South African National TB Programme
Natl Dept of Hlth, Pretoria, South Africa

755 Treatment Outcomes for HIV/MDR-TB Coinfection in the Era of Antiretroviral Therapy

Sanghyuk S. Shin¹; Chawangwa Modongo²; Nicola Zetola³

¹Univ of California Los Angeles Sch of PH, Los Angeles, CA, USA; ²Botswana Univ of Pennsylvania Partnership, Gaborone, Botswana; ³Univ of Pennsylvania, Philadelphia, PA, USA

756 Hearing Loss and Laboratory Adverse Events in Patients With MDR TB and HIV on ART

James C. Brust¹; N. Sarita Shah²; Salim Allana³; Thuli Mthiyane⁴; Koleka Mlisana⁵; Pravi Moodley⁶; Iqbal Master⁶; Yuming Ning⁷; Neel Gandhi⁸

¹Albert Einstein Coll of Med, Bronx, NY, USA; ²CDC, Atlanta, GA, USA; ³Rollins Sch of PH, Emory Univ, Atlanta, GA, USA; ⁴Univ of KwaZulu-Natal, Westville, South Africa; ⁵Univ of KwaZulu-Natal, Durban, South Africa; ⁶King Dinuzuu Hosp Complex, Durban, South Africa; ⁷Montefiore Med Cntr, Bronx, NY, USA; ⁸Emory Univ Rollins Sch of PH, Atlanta, GA, USA

Session P-R8 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Tuberculosis and Pregnancy

757 Burden of Tuberculosis in HIV+ Pregnant & Postpartum Women in Cape Town, South Africa

Jasanthia Odayar¹; Molebogeng Rangaka²; Allison Zerbe³; Greg Petro³; Tamsin Phillips⁴; James McIntyre⁴; Elaine J. Abrams⁵; Landon Myer¹

¹Univ of Cape Town, Cape Town, South Africa; ²Univ Coll London, London, UK; ³CAP at Columbia Univ, New York, NY, USA; ⁴Anova Hlth Inst, Johannesburg, South Africa; ⁵CAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

758 Pregnancy Intensifies the IFN-gamma Suppression of HIV in TB-Infected Indian Women

Jyoti S. Mathad¹; Ramesh Bhosale²; Usha Balasubramanian³; Prasad Deshpande²; Savita Kanade²; Vidya Mave⁴; Amita Gupta⁴

¹Weill Cornell Med Coll, New York, NY, USA; ²Byramjee Jeejeebhoy Med Coll, Pune, India; ³BJ Med Coll, Pune, India; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

Session P-S5 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Mind the Gaps: Optimizing the PMTCT Cascade

789 Malawi's Option B+ 2011–2015: The Impact of Rapid ART Decentralization

Sundeep K. Gupta¹; Andreas Jahn²; Beth Tippett Barr³; James Houston⁴; Alice Maida⁵; Jen Sabatier⁶; Crispin Musicha⁷; Frank Chimbwandira⁸

¹CDC, Lilongwe, Malawi; ²Univ of Washington, Seattle, WA, USA; ³CDC, Harare, Zimbabwe; ⁴CDC, Atlanta, GA, USA; ⁵Malawi Ministry of Hlth, Lilongwe, Malawi

790 Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study

Muktar H. Aliyu¹; Meridith Blevins¹; Carolyn M. Audet¹; Marcia Kalish¹; Mary Lou Lindgren¹; Usman I. Gebi¹; Obinna Onwujiakwe²; Bryan E. Shepherd³; C. William Wester³; Sten H. Vermund⁴

¹Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ²Univ of Nigeria, Enugu, Nigeria

791 Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention

Ruby N. Fayerose¹; Duncan Chege²; Chunhui Wang¹; William Reidy¹; Zach Peters¹; Martin W. Sirengo³; Masila Syengo²; Christin W. Barasa⁴; Mark Hawken⁵; Elaine J. Abrams¹

¹ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA; ²ICAP at Columbia Univ, Nairobi, Kenya; ³Natl AIDS and STI Control Prog, Nairobi, Kenya; ⁴ICAP at Columbia Univ, Nairobi, Kenya

792 Continuity of Care Among Pregnant Women Lost to Follow-up After Initiating ART

Kate Clouse¹; Sten H. Vermund¹; Mhairi Maskew²; Given Maletse²; Matthew P. Fox³

¹Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ²Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ³Boston Univ, Boston, MA, USA

793 Disclosure and Knowledge Are Associated With Retention in Malawi's Option B+ Program

Risa M. Hoffman¹; Khumbo Phiri²; Julie Parent³; Jonathan F. Grotts⁴; Sara Yeatman⁵; Paul Kawale⁶; David Elashoff⁷; Judith S. Currier⁸; Alan Schooley²

¹Univ of California Los Angeles, Los Angeles, CA, USA; ²Partners in Hope Med Cntr, Lilongwe, Malawi; ³Univ of Colorado, Denver, CO, USA; ⁴David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA

**Session P-56 Poster Abstracts
2:45 PM-4:00 PM**

Hall D

Viral Dynamics and Drug Resistance During Pregnancy

794 Initiating cART in Pregnancy: Impact on HIV RNA Decay

Jasmini Alagaratnam¹; Sarah Chitty²; Anemiek DeRuiter³; Fionnuala Finnerty⁴; Rebecca Marcus⁵; Achyuta V. Nori⁶; Liat Sarner⁷; Rimi Shah⁸; Graham Taylor¹; for the London HIV Perinatal Research Group (LHPRG)

¹St Mary's Hosp, Imperial Coll NHS Trust, London, UK; ²Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ³Guys and St Thomas' NHS Fdn Trust, London, UK; ⁴Brighton and Sussex Hosps NHS Trust, Brighton, UK; ⁵Royal London Hosp, London, UK; ⁶Royal Free Hosp, London, UK

795 Viraemic Episodes Occur Frequently in Postpartum South African Women on ART

Landon Myer¹; Lorn Dunning¹; Nei-Yuan Hsiao¹; Tamsin Phillips¹; Allison Zerbe²; James McIntyre³; Elaine J. Abrams⁴

¹Univ of Cape Town, Cape Town, South Africa; ²ICAP at Columbia Univ, New York, NY, USA; ³Anova Hlth Inst, Johannesburg, South Africa; ⁴ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

796 Viral Suppression and Retention 2–5 Years After ART Initiation in Pregnancy in Uganda

Catherine A. Koss¹; Paul Natureeba²; Dalsone Kwarisiima²; Mike Ogena²; Tamara Clark¹; Deborah Cohan¹; Peter Olwoch²; Edwin Charlebois¹; Moses R. Kamya³; Diane V. Havlir¹

¹Univ of California San Francisco, San Francisco, CA, USA; ²Makerere Univ of California San Francisco Rsr Collab, Kampala, Uganda; ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda

797 HIV Resistance in Pregnant Women With Detectable HIV-1 RNA at Delivery in Mozambique

Maria Ruperez¹; Marc Noguera-Julian²; Raquel González¹; Rocío Bellido¹; Anifa Vala¹; Cristina Rodriguez²; Esperança Sevens¹; Eusebio Macete¹; Roger Paredes¹; Clara Menéndez¹

¹Barcelona Inst for Global Hlth, Barcelona, Spain; ²IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ³Manhiça Hlth Rsr Cntr (CISM), Manhiça, Mozambique

Session P-57 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Birth Outcomes and Mortality in HIV- and ARV-Exposed Infants

798 Maternal Vitamin D Deficiency Is Associated With Preterm Birth in HIV-Infected Women

Jennifer Jao¹; Laura Freimanis²; Marissa Mussi-Pinhata³; Rachel Cohen⁴; Jacqueline P. Monteiro⁵; Maria Letícia S. Cruz¹; Andrea Branch⁶; Rhoda S. Sperling⁷; George K. Siberry⁸; for the National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI)

¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Westat, Inc., Rockville, MD, USA; ³Univ of Sao Paulo, Sao Paulo, Brazil; ⁴Hosp Fed dos Servidores do Estado, Rio de Janeiro, Brazil; ⁵Eunice Kennedy Shriver NICHD, Bethesda, MD, USA

799 Timing of ART Initiation in Pregnancy and Birth Outcomes in South African Women

Thokozile Malaba¹; Tamsin Phillips²; Greg Petro³; Kirsty Brittain¹; Allison Zerbe⁴; Agnes Ronan⁵; James McIntyre⁶; Elaine J. Abrams⁷; Landon Myer¹

¹Univ of Cape Town, Cape Town, South Africa; ²ICAP at Columbia Univ, New York, NY, USA; ³Anova Hlth Inst, Johannesburg, South Africa; ⁴ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

800 Higher Mortality in HIV-Exposed/Uninfected vs HIV-Unexposed Infants, Botswana

Gbolahan Ajibola¹; Gloria Mayondi¹; Jean Leidner²; Haruna Jibril³; Joseph Makhema⁴; Mompoti Mmalane⁵; Modiegi Diseko⁶; Roger L. Shapiro⁷; Betsy Kammerer⁸; Shahin Lockman⁸

¹Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ²Goodtables Consulting, Oklahoma, OK, USA; ³Ministry of Hlth, Gaborone, Botswana; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Boston Children's Hosp, Harvard Med Sch, Boston, MA, USA; ⁶Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

801LB Cotrimoxazole and Reduced Infectious Morbidity in HIV-Exposed Uninfected Infants

Nicole L. Davis¹; Jeffrey Wiener²; Sascha Ellington³; Charles Chasela³; Dumbani Kayira⁴; Michael Hudgens⁵; Charles van der Horst⁶; Denise Jamieson⁷; Athena P. Kourtis⁸

¹US Cntrs for Disease Control and Prevention, Atlanta, GA, USA; ²CDC, Atlanta, GA, USA; ³Univ of the Witwatersrand, Johannesburg, South Africa; ⁴Univ of North Carolina Project Malawi, Lilongwe, Malawi; ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

- 802 HIV-Exposed Children Account for More Than Half of 24-Month Mortality in Botswana**
Rebecca Zash¹; Jean Leidner²; Sajini Souda³; Kelebogile Binda⁴; Heather J. Ribaudo⁵; Sikhulile Moyo⁶; Kathleen Powis⁷; Joseph Makhema⁸; Shahin Lockman⁹; Roger L. Shapiro⁹
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA; ²Goodtables Consulting, Oklahoma, OK, USA; ³Univ of Botswana, Gaborone, Botswana; ⁴Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁵Harvard Sch of PH, Boston, MA, USA; ⁶Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁷Massachusetts General Hosp, Boston, MA, USA; ⁸Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA
- 803 Mortality Risk Associated With Preterm and SGA Stratified by Maternal HIV Status**
Ayesha Sania¹; Emily Smith²; Wafaie W. Fawzi²
¹CAP, Columbia Univ Mailman Sch of PH, New York, NY, USA; ²Harvard Sch of PH, Boston, MA, USA
- 804 HBV and HCV Infections in HIV-Infected Pregnant Women: Obstetrical Outcomes**
Valerie Benhamou¹; Roland Tubiana²; Sophie Matheron³; Pierre Sellier⁴; Laurent Mandelbrot⁵; Jérôme Le Chenadec⁶; Emmanuelle Marel⁷; Babak Khoshnood⁸; Josiane Warszawski⁹; for the ANRS CO1/CO11 – EPF French Perinatal Cohort Study Group
¹INSERM 1153, PARIS, France; ²Sorbonne Univs, Paris, France; ³Hosp Bichat-Claude Bernard, Paris, France; ⁴Groupe Hospier Saint-Louis, Lariboisiere, Fernand Widal, AP-HP, Paris, France; ⁵Hosp Louis Mourier, Colombes, France; ⁶INSERM, Le Kremlin-Bicêtre, France; ⁷CESP, INSERM U1018, Le Kremlin Bicêtre, France; ⁸INSERM 1154, Paris, France
- 805 Maternal ART and Hospitalization or Death Among HIV-Exposed Uninfected Infants**
Scott Dryden-Peterson¹; Tatiana Ramos²; Roger L. Shapiro³; Shahin Lockman¹
¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³Harvard Sch of PH, Boston, MA, USA
- 830 Weak HIV Antibody Responses in Perinatally Infected Young Adults**
Allison R. Kirkpatrick¹; Aylin Unsal²; Joel N. Blankson³; Richard Moore⁴; Thomas C. Quinn⁵; Colleen Hadigan⁶; Oliver Laeyendecker⁷
¹NIH, Baltimore, MD, USA; ²NIH, Bethesda, MD, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵NIH, Bethesda, MD, USA
- 831 Incidence of Virologic Rebound in Perinatally HIV-Infected Adolescents on Stable ART**
Tavitiya Sudjaritruk¹; Linda Aupibul¹; Saramony Sarun²; Thoa P. Le³; Torsak Bunupuradah⁴; Rawiwan Hansudewechakul⁵; Pagakrong Lumbiganon⁷; Kulkanya Chokeyhaibulkit⁸; Azar Karimnia⁹; for the TREAT Asia Pediatric HIV Observational Database (TApHOD)
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Rsr Inst for Hlth Scis Chiang Mai Univ, Chiang Mai, Thailand; ³Univ of Hlth Scis Cambodia, Phnom Penh, Cambodia; ⁴Children's Hosp 1, Ho Chi Minh City, Vietnam; ⁵HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁶Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand; ⁷Srinagarind Hosp, Khon Kaen Univ, Khon Kaen, Thailand; ⁸Siriraj Hosp, Mahidol Univ, Bangkok, Thailand; ⁹Kirby Inst, Sydney, Australia
- 832 Longitudinal Virologic Suppression Among a Cohort of Behaviorally HIV-Infected Youth**
Sarah Wood¹; Elizabeth D. Lowenthal²; Susan S. Lee³; Nadia Dowshen³
¹Univ of Pennsylvania Perelman Sch of Med, Philadelphia, PA, USA; ²Children's Hosp of Philadelphia, Philadelphia, PA, USA; ³Univ of Pennsylvania, Philadelphia, PA, USA
- 833 Psychological Reactance Is a Novel Risk Factor for Adolescent HIV Treatment Failure**
Elizabeth D. Lowenthal¹; Tafireyi Marukutira²; Jennifer Chapman³; Ontibele Tshumbe⁴; Mogomotsi Matshaba⁵; Gabriel Anabwani⁶; Robert Gross⁵
¹Univ of Pennsylvania Perelman Sch of Med, Philadelphia, PA, USA; ²Botswana-Baylor Children's Clinical Cntr of Excellence, Gaborone, Botswana; ³Children's Hosp of Philadelphia, Philadelphia, PA, USA
- 834 Economic Evaluation of a Novel Adherence Strategy in Perinatally HIV-Infected Youth**
Naomi Lin¹; Jolene Skordis-Worrall¹; Sarah J. Fidler²; Caroline Foster³
¹Univ Coll London, London, UK; ²Imperial Coll London, London, UK; ³Imperial Coll Healthcare NHS Trust, London, UK
- 835 Clinical Outcomes in Adults With Perinatal HIV After Transfer From Pediatric Care**
Rebecca L. Hope¹; Ali Judd²; Caroline Foster³; Katia Prime⁴; Pat Tookey⁵; Eva Jungmann⁶; Russell Viner⁷
¹IDEO.org, Oakland, CA, USA; ²Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ³Imperial Coll Hlthcare NHS Trust, London, UK; ⁴St George's & Queen Mary's Hosp, London, UK; ⁵Univ Coll London, London, UK; ⁶Mortimer Market Cntr, London, UK

Session P-T4 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Test, Treat, and Suppress: Achieving 90-90-90 in Adolescents

829 Increasing Adolescent HIV Testing With a Hybrid Mobile Strategy in Uganda and Kenya

Kevin Kadete¹; Theodore D. Ruel²; Elizabeth Bukusi³; Tamara Clark⁴; Edwin Charlebois⁵; Maya Petersen⁶; Moses R. Kamya⁷; Diane V. Havlir⁸; Gabriel Chamie⁹; for the Sustainable East Africa Research in Community Health

¹Kenya Med Rsr Inst, Kisumu, Kenya; ²Univ of California San Francisco, San Francisco, CA, USA; ³Cntr for Microbiology Rsr, Kenya Med Rsr Inst, Kisumu, Kenya; ⁴Univ of California Berkeley, Berkeley, CA, USA; ⁵Makerere Univ Coll of Hlth Scis, Kampala, Uganda

Session P-T5 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Antiretroviral Therapy and Viral Suppression in Children: Implications for Cure

- 836 Strong IFN-g Responses and Limited HIV Reservoirs in Adolescent Virologic Controllers**
Jason Brophy¹; Fatima Kakkar²; Hinatae Dieumegard³; Amelie Pagliuzza⁴; Ari Bitnun⁵; Lindy Samson¹; Stanley Read⁶; Nicolas Chomont⁷; Hugo Soudeyns⁸; for the EPIC4 Study Group
¹Children's Hosp of Eastern Ontario, Ottawa, ON, Canada; ²Univ de Montréal, Montréal, QC, Canada; ³CHU Sainte-Justine, Montréal, QC, Canada; ⁴CRCHUM, Montreal, QC, Canada; ⁵Hosp for Sick Children, Univ of Toronto, Toronto, ON, Canada; ⁶Univ de Montréal, Montreal, QC, Canada; ⁷CHU Sainte-Justine, Montreal, QC, Canada
- 837 Kinetics of Cell-Associated HIV DNA During Viral Suppression in HIV-Infected Children**
Matias Moragas; Debora Mecikovsky; Solange Arazi Caillaud; Paula Aulicino; Rosa Bologna; Luisa Sen; Andrea Mangano
 Hosp de Pediatría SAMIC Prof Dr Juan P. Garrahan, Buenos Aires, Argentina
- 838 HIV-1 DNA Dynamics Over a Decade or More of Viral Suppression in Perinatal Infection**
Priyanka Uprety¹; Kunjal Patel²; Brad Karalius³; Kaitlin Rainwater-Lovett⁴; Carrie Ziemiak⁵; Ya Chen⁶; Suzanne Siminski⁷; Russell B. Van Dyke⁸; George R. Seage⁹; Deborah Persaud¹
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Frontier Sci & Tech Rsr Fndn, Inc, Amherst, NY, USA; ⁴Tulane Univ Sch of Med, New Orleans, LA, USA
- 839 Value of Ultrasensitive HIV Assay in Infants With Negative Routine Laboratory Results**
Arjen J. Stam¹; Denise van Hout²; Sibyl P. Geelen¹; Annelies Riezebos-Briman³; Joop Schellekens⁴; E. H. Schölvinc⁵; Kiki Tesselaaar⁶; Tom F. Wolfs⁷; Monique Nijhuis⁸; Anne M. Wensing¹
¹Univ Med Ctr Utrecht, Utrecht, Netherlands; ²Univ Med Ctr Groningen, Groningen, Netherlands; ³CERTE, Groningen, Netherlands
- 840 HIV Antibodies and Reservoir Size in Perinatally Infected Children on HAART**
 Josephine Brice¹; Fatoumata Tiguem Telly²; Maxime Grudé³; Anne Derache⁴; Deenan Pillay⁵; Francis Barin⁶; Vincent Calvez⁷; Maryam Sylla⁸; Almostapha Maiga⁹; **Anne-Geneviève Marcelin**¹
¹UMR-S 1136 Pierre Louis Inst of Epi and PH, Paris, France; ²SEREF0, Univ of Scis Techniques and Technologies of Bamako, Bamako, Mali; ³Sorbonne Univ, Paris, France; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁵François-Rabelais Univ, Tours, France, Tours, France; ⁶CHU Gabriel Toure, Bamako, Mali; ⁷SEREF0, Univ of Scis Techniques and Technologies of Bamako, Bamako, Mali

Session P-V2 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Topical and Systemic Preexposure Prophylaxis: New Agents, New Populations

- 871 Phase I Trial to Assess Safety, PK, and PD of Film and Gel Formulations of Tenofvir**
Katherine E. Bunge¹; Charlene S. Dezzutti¹; Craig Hendrix²; Mark A. Marzinke³; Hans Spiegel⁴; Bernard Moncla⁴; Jill Schwartz⁵; Leslie Meyn⁶; Lisa Rohan⁷; Sharon L. Hillier⁸
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³DAIDS, NIAID, NIH, Rockville, MD, USA; ⁴Magee-Womens Hosp of the Univ of Pittsburgh Med Ctr, Pittsburgh, PA, USA; ⁵CONRAD, Arlington, VA, USA
- 872 Safety and Pharmacokinetics of Dapivirine Vaginal Rings in Postmenopausal US Women**
Beatrice A. Chen¹; Craig Hoesley²; Robert A. Salata³; Jingyang Zhang⁴; Lydia E. Soto-Torres⁵; Annalene Nel⁶; Sherri Johnson⁷; Charlene S. Dezzutti⁸; Mark A. Marzinke⁹; for the MTN-024/IPM 031 Protocol Team for the Microbicide Trials Network
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Univ of Alabama at Birmingham, Birmingham, AL, USA; ³Case Western Reserve Univ, Cleveland, OH, USA; ⁴SCHARP, Seattle, WA, USA; ⁵NIAID, NIH, Bethesda, MD, USA; ⁶Intl Partnership for Microbicides, Paarl, South Africa; ⁷FHI 360, Washington DC, DC, USA; ⁸Johns Hopkins Univ, Baltimore, MD, USA
- 873 Adherence and Acceptability of a Dapivirine Vaginal Ring in Postmenopausal US Women**
Ariane van der Straten¹; Nicole Laborde²; Helen Cheng³; Craig Hoesley⁴; Robert A. Salata⁵; Sherri Johnson⁶; Annalene Nel⁷; Lydia E. Soto-Torres⁸; Beatrice A. Chen⁹; for the MTN-024/IPM 031 Protocol Team for the Microbicide Trials Network
¹RTI, San Francisco, CA, USA; ²Univ of Alabama at Birmingham, Birmingham, AL, USA; ³Case Western Reserve Univ, Cleveland, OH, USA; ⁴FHI 360, Washington DC, DC, USA; ⁵Intl Partnership for Microbicides, Paarl, South Africa; ⁶NIAID, NIH, Bethesda, MD, USA; ⁷Univ of Pittsburgh, Pittsburgh, PA, USA
- 874 Distinct Pharmacodynamic Activity of Rilpivirine in Mucosal Explant Tissue**
Charlene S. Dezzutti¹; Laura J. Else²; Sarah E. Yandura³; Cory Shelter⁴; Julie Russo⁵; David J. Back⁶; Ian McGowan⁴
¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Univ of Liverpool, Liverpool, UK; ³Magee-Womens Hosp of the Univ of Pittsburgh Med Ctr, Pittsburgh, PA, USA; ⁴Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA
- 875 A First-in-Human Trial of PC-1005 (MIV-150 and Zinc Acetate in a Carrageenan Gel)**
Barbara A. Friedland¹; Craig Hoesley²; Marlena Gehret Plagianos³; Shimin Zhang⁴; Elena Hoskin⁵; Mochine Alami⁶; Natalia Teleshova⁷; Thomas Zydowsky⁸; José Fernández-Romero⁹; George Creasy¹
¹Pop Council, New York, NY, USA; ²Univ of Alabama at Birmingham, Birmingham, AL, USA
- 876 CVLs From Women Vaginally Dosed With PC-1005 Inhibit Mucosal HIV-1 and HSV-2 Ex Vivo**
Guillermo Villegas¹; Shimin Zhang²; Olga Mizenina³; Kyle Kleinbeck⁴; Michael Cooney⁵; Craig Hoesley⁶; George Creasy⁷; José Fernández-Romero⁸; Thomas Zydowsky⁹; Natalia Teleshova¹
¹Pop Council, New York, NY, USA; ²Univ of Alabama at Birmingham, Birmingham, AL, USA

- 877 Transport of Drug and Virus in FRTs of Macaques Treated With a TDF Intravaginal Ring**
Adina K. Ott¹; Katarina K. Halavaty¹; Jonathan Su¹; Danijela Maric¹; Samuel Sung¹; Mark A. Marzinke²; Tom J. Hope¹; Patrick Kiser¹
¹Northwestern Univ, Chicago, IL, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA
- 878 Impact of STI on Pharmacokinetics of Topical Tenofovir in Macaques**
Natalia Makarova¹; Rachael Aubert¹; Angela Holder¹; Chuong Dinh¹; Tara Henning¹; Ellen Kersh¹; Janet Nicholl¹; Walid Heneine¹; Charles Dobard¹
CDC, Atlanta, GA, USA
- 879 A Long-Acting Biodegradable Subcutaneous Implant for Tenofovir HIV PrEP**
Erica B. Schlesinger¹; Daniel Johengen¹; Ellen Leucke²; Stephanie Swarner³; Phillip Durham⁴; Leah Johnson⁵; Ginger Rothrock²; Ian McGowan⁴; Ariane van der Straten⁶; Tejal Desai¹
¹Univ of California San Francisco, San Francisco, CA, USA; ²RTI, San Francisco, CA, USA; ³RTI, Research Triangle Park, NC, USA; ⁴Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA
- 880 Assessing Formulations of Tenofovir 1% Gel in HIV Seronegative Adults via RNA-Seq**
Mark Cameron¹; Aarthi Talla¹; Peter Wilkinson¹; John Pyles¹; Rafick Sekaly¹; Ian McGowan²
¹Case Western Reserve Univ, Cleveland, OH, USA; ²Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA
- 881 Understanding Pain and Anxiety Experienced Around Long-Acting Injectable PrEP**
Kathrine Meyers¹; Kristina Rodriguez²; Martin Markowitz³; Sarit A. Golub²
¹Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ²Hunter Coll and the Grad Cntr, City Univ of New York, New York, NY, USA
- 882LB WITHDRAWN**
- 922 Stigma, Access to Care, and HIV Among Men Who Sell Sex in Nigeria**
Trevor A. Crowell¹; Babjide Keshinro²; Stefan Baral³; Sheree R. Schwartz⁴; Rebecca G. Nowak⁵; Sylvia Adebajo⁶; William A. Blattner⁴; Manhattan E. Charurat⁷; Julie Ake⁸; for the TRUST/RV368 Study Group
¹US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ²Walter Reed Prog – Nigeria, Abuja, Nigeria; ³Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁴Inst of Human Virology, Baltimore, MD, USA; ⁵Pop Council Nigeria, Abuja, Nigeria
- 923 Incidence of STIs Among MSM Engaged in Treatment as Prevention in Nigeria**
Rebecca G. Nowak¹; Trevor A. Crowell²; Stefan Baral³; Teclair Ndomb⁴; Babjide Keshinro⁵; Sheila Peel⁶; Charlotte Gaydos⁷; Julie Ake⁸; William A. Blattner⁹; Manhattan E. Charurat¹⁰
¹Inst of Human Virology, Baltimore, MD, USA; ²US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ³Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁴Inst of Human Virology, Abuja, Nigeria; ⁵Walter Reed Prog – Nigeria, Abuja, Nigeria; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA
- 924 Online Sex-Seeking Among MSM in Nigeria: Implications for Online Intervention**
Shauna Stahlman¹; Rebecca G. Nowak²; Hongjie Liu³; Trevor A. Crowell⁴; Sosthenes Ketende⁵; William A. Blattner⁶; Manhattan E. Charurat⁷; Stefan Baral⁸; for the TRUST Study Group
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Inst of Human Virology, Baltimore, MD, USA; ³Sch of PH, Univ of Maryland, College Park, MD, USA; ⁴US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA
- 925 Stigma and Openness about Sexual Identity Among MSM: A Latent Class Analysis**
Shauna Stahlman¹; Claire Holland²; Sosthenes Ketende³; Lynn Van Lith⁴; Duncan Kochelani⁵; Zandile Mnisi⁶; Bhekis Sithole⁷; Libet Maloney⁸; Stefan Baral⁹
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ Cntr for Communication Progs, Baltimore, MD, USA; ³Swaziland Ministry of Hlth, Mbabane, Swaziland; ⁴Hlth Communication Capacity Collaborative Proj, Mbabane, Swaziland
- 926 Group Sex: A Cross-Sectional Online Survey Among Men Who Have Sex With Men in China**
Songyuan Tang¹; Weiming Tang²; Joseph D. Tucker³; Bin Yang⁴; Ye Zhang⁵; Wei Zhang⁶; Shujie Huang⁷; Ligang Yang⁸; Chongyi Wei⁹; Chuncheng Liu⁹; Yilu Qin¹
¹Univ of North Carolina Proj China, Guangzhou, China; ²Univ of North Carolina at Chapel Hill Inst for Global Hlth & Infectious Diseases, Chapel Hill, NC, USA; ³Guangdong Provincial Cntr for Skin Diseases and STI Control, Guangzhou, China; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵SESH Global, Guangzhou, China

Session P-W4 Poster Abstracts

Hall D

2:45 PM-4:00 PM

MSM in Low- and Middle-Income Countries

921 HIV Prevalence and Risk Factors in Men Who Have Sex With Men in Bamako, Mali

Maria Lahuerta¹; Padmaja Patnaik²; Nouhoum Telly³; Justin Knox⁴; Tako Ballo⁵; Adama N'dir⁶; Bouyagui Traore⁷; Seydou Doumbia⁸; Avi Hakim⁹

¹ICAP at Columbia Univ, New York, NY, USA; ²ICER Mali, Bamako, Mali; ³Cellule Sectorielle de Lutte contre le Sida, Ministère de la Santé, Bamako, Mali; ⁴CDC, Bamako, Mali; ⁵CDC, Atlanta, GA, USA

927 Risk Factors for Acute and Early HIV Infection Among MSM, Bangkok, Thailand 2010–2015

Warunee Thienkrua¹; Marcel Curlin¹; Eileen Dunne²; Kanokpan Pancharoen¹; Boonyos Raengsakulrach¹; Wannee Chonwattana¹; Wanna Leelawiwat¹; Philip A. Mock¹; Anupong Chitwarakorn¹; **Timothy H. Holtz³**
¹Thailand Ministry of PH US CDC Collab, Nonthaburi, Thailand; ²Oregon Hlth and Scis Univ, Portland, OR, USA; ³CDC, Atlanta, GA, USA

928 High Prevalence of HIV Among Wives of Married Men Who Have Sex With Men in India

Aylur K. Srikrishnan¹; Shruti H. Mehta²; Cecilia Tomori²; Santhanam Anand¹; Pachamuthu Balakrishnan²; David Celentano²; Gregory M. Lucas²; **Sunil S. Solomon²**
¹YRG Cntr for AIDS Rsr and Educ, Taramani, India; ²Johns Hopkins Univ, Baltimore, MD, USA; ³YRG Cntr for AIDS Rsr and Educ, Chennai, India

Session P-X3 Poster Abstracts

Hall D

2:45 PM-4:00 PM

HIV Testing and Prevention

964 Effective Disease Intervention Is Key Component to Acute HIV Detection

JoAnn D. Kuruc¹; Sarah Willili¹; Nicole Dzialowy²; Jason Maxwell²; John Barnhart²; Victoria Mobley²; Cynthia Gay²; Erika Samoff²
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²North Carolina Division of PH, Raleigh, NC, USA; ³North Carolina DHHS, Raleigh, NC, USA

965 Late HIV Diagnosis and Missed Opportunities for HIV Testing in South Carolina

Sharon Weissman¹; Kristina Kintziger²; Helmut Albrecht¹; Terri Stephens³; Babatunde Edun¹; Wayne Duffus¹
¹Univ of South Carolina, Columbia, SC, USA; ²Dept of Med, Georgia Regents Univ, Augusta, GA, USA; ³South Carolina Dept of Hlth and Environmental Control, Columbia, SC, USA

966 Missed Opportunities for HIV Testing During Routine Doctor Visits, BRFSS, 2011-2013

Michelle Van Handel¹; Patricia Dietz
 CDC, Atlanta, GA, USA

967 Setting a Benchmark for HIV Testing at Visits to US Physician Offices

Karen Hoover¹; Charles Rose¹; Philip Peters
 CDC, Atlanta, GA, USA

968 Implementation of a Rapid HIV Testing Program in Psychiatric Inpatient Wards

Maryann J. Popiel¹; Vikram Duvvi¹; Albert Turkieh¹; Ethan Cowan¹; Yvette Calderon¹; Anuj Rao¹; **Jennifer Zahn¹**; Uttara Gadde¹; Stephanie Haimowitz¹; Jason Leider
 Jacobi Med Cntr, Bronx, NY, USA

969 Tailoring Mass Media MSM HIV Test Interventions to Reach High-Risk Men

Ngai Sze Wong¹; Weiming Tang²; Larry Han³; John Best⁴; Ye Zhang⁵; Shujie Huang⁶; Bin Yang⁷; Lai Sze Tso⁸; Chongyi Wei⁹; Joseph D. Tucker⁸
¹South China-UNCI STI Rsr Training Cntr, Guangzhou, China; ²Univ of North Carolina Proj China, Guangzhou, China; ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Guangdong Provincial Cntr for Skin Diseases and STI Control, Guangzhou, China; ⁶Univ of North Carolina at Chapel Hill Inst for Global Hlth & Infectious Diseases, Chapel Hill, NC, USA

970 Feasibility of a Social-Entrepreneurship Model to Promote HIV Self-Testing Among MSM

Fei Zhong¹; **Weiming Tang²**; Weibin Cheng¹; Peng Lin³; Qiongmiao Wu⁴; Yanshan Cai¹; Lili Fan¹; Yuteng Zhao¹; Xi Chen¹; Joseph D. Tucker⁵; Gang Meng¹; Huifang Xu¹
¹Guangzhou Cntr for Disease Control and Prevention, Guangzhou, China; ²Univ of North Carolina Proj China, Guangzhou, China; ³Guangdong CDC, Guangzhou, China; ⁴Univ of North Carolina at Chapel Hill Inst for Global Hlth & Infectious Diseases, Chapel Hill, NC, USA

971 HIV Self-Testing in the Seattle Transgender Community: A Mixed-Methods Evaluation

Julia E. Hood¹; Elizabeth W. Forsyth²; Jillian Neary³; Susan Buskin⁴; Mathew R. Golden⁵; David A. Katz²
¹PH, Seattle & King County, Seattle, WA, USA; ²Evergreen State Coll, Seattle, WA, USA; ³Univ of Washington, Seattle, WA, USA; ⁴Seattle King County PH, Seattle, WA, USA; ⁵Univ of Washington Sch of Med, Seattle, WA, USA

972 MSM and TG Accessing HIV VCT in Bangkok: Spatial Characteristics, 2005-2015

Kevin Weiss¹; Sarika Pattanasin²; Wipas Wimonasate³; Jirawat Suksamosorn⁴; Prin Visavakum⁵; Wichuda Sukwicha⁶; Samart Karuchit⁷; Chaiwat Ungsedhapand⁸; Eileen Dunne⁹; Timothy H. Holtz²
¹Emory Univ Rollins Sch of PH, Atlanta, GA, USA; ²Thailand Ministry of PH US CDC Collab, Nonthaburi, Thailand; ³CDC, Atlanta, GA, USA

973 Effect of Secondary Distribution of HIV Self-Tests on Women's Sexual Decision-Making

Harsha Thirumurthy¹; Samuel H. Masters²; Sue N. Mavedzenge³; Eunice Omanga⁴; Kawango Agot⁵
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²RTI, San Francisco, CA, USA; ³Impact Rsr and Develop Org, Kisumu, Kenya

974 Awareness of HIV Status: the Disclosure Gap in Rural Africa

Elisa López Varela¹; **Laura de la Fuente Soro¹**; Orvalho J. Augusto²; Charfudin Saccoor³; Ariel Nhacolo³; Esmeralda Karajeane³; Paula M. Vaz³; Denise Naniche¹
¹Barcelona Inst for Global Hlth, Barcelona, Spain; ²Centro de Investigação da Manhiça (CISM), Maputo, Mozambique; ³Fundação Ariel Glaser, Maputo, Mozambique

- 975 Home-Based HIV Testing and New HIV Diagnoses in Chókhwè District, Mozambique**
Isabelle Casavant¹; Duncan MacKellar²; Ricardo Thompson³; Robert Nelson⁴; Juvenio Bonzela⁵; Bertur Alfance⁶; Stanley Wei⁷; Daniel Shodell⁸; Judite Cardoso⁹; Nely Honwana¹
¹CDC, Maputo, Mozambique; ²CDC, Atlanta, GA, USA; ³Natl Inst of Hlth Mozambique, Maputo, Mozambique; ⁴CITS, Chókhwè, Mozambique; ⁵Provincial Directorate of PH, Xaixai, Mozambique; ⁶Colorado Dept of PH and Environment, Denver, CO, USA; ⁷Jhpiego, Maputo, Mozambique
- 976 Increased Linkage to HIV Care After Clinic vs Community Testing in Rural Mozambique**
Elisa López Varela¹; Laura de la Fuente Sorol²; Orvalho J. Augusto³; Charfudin Sacoor⁴; Ariel Nhacolo⁵; Esmeralda Karajeane⁶; Paula M. Vaz⁷; Denise Nanihe¹
¹Barcelona Inst for Global Hlth, Barcelona, Spain; ²Centro de Investigação da Manhiça (CISM), Maputo, Mozambique; ³Fundação Ariel Glaser, Maputo, Mozambique
- 977 Effect of SMS, Phone Call, and In-Person Reminders on Repeat HIV Test Uptake in Kenya**
Peter M. Mugo¹; Elizabeth W. Wahome²; Evanson Gichuru³; Grace Mwashigadi⁴; Alexander N. Thiong'o⁵; Henrike A. Prins⁶; Tobias Rinke de Wit⁷; Susan M. Graham⁸; Edward J. Sanders¹
¹Kenya Med Rsr Inst, Kilifi, Kenya; ²Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ³Univ of Washington, Seattle, WA, USA
- 978 Effective, High-Yield HIV Testing for Partners of Newly Diagnosed Persons in Tanzania**
Marya Plotkin¹; Catherine Kahabuka²; Mbaraka Amuni³; Mustafa Njozi⁴; Werner Maokola⁵; Erick Mlangwa⁶; Mary Drake⁷; Kelly Curran⁸; Charlene Brown⁹; Vincent Wong⁷
¹Jhpiego, Chapel Hill, NC, USA; ²Kahabuka Consulting, Dar es Salaam, Tanzania; ³Jhpiego, Dar es Salaam, Tanzania; ⁴Natl AIDS Control Prog, Dar es Salaam, Tanzania; ⁵US Agency for Intl Develop-Tanzania, Dar es Salaam, Tanzania; ⁶Jhpiego, Baltimore, MD, USA; ⁷US Agency for Intl Develop, Washington, DC, USA
- 979 94% Population HIV Testing Coverage With Repeat Hybrid Mobile Testing in East Africa**
Gabriel Chamie¹; Jane Kabami²; Emmanuel Ssemmondo³; Tamara Clark⁴; Elizabeth Bukusi⁵; Maya Petersen⁶; Moses R. Kanya⁷; Diane V. Havlir⁸; Edwin Charlebois⁹; for the Sustainable East Africa Research for Community Health (SEARCH) team
¹Univ of California San Francisco, San Francisco, CA, USA; ²Makerere Univ- Univ of California Rsr Collab, Kampala, Uganda; ³Cntr for Microbiology Rsr, Kenya Med Rsr Inst, Kisumu, Kenya; ⁴Univ of California Berkeley, Berkeley, CA, USA; ⁵Makerere Univ Coll of Hlth Scis, KAMPALA, Uganda
- 980 Does a Male CHiP Increase Uptake of HIV Testing by Men Lessons From HPTN071 Study**
Mwelwa M. Phiri¹; Kwame Shanaube²; Sian Floyd³; Ephraim Sakala⁴; Stable Besa⁵; Sam Griffith⁶; Helen Ayles⁷; for the HPTN 071/PopART Team
¹ZAMBART, Lusaka, Zambia; ²London Sch of Hygiene & Trop Med, London, UK; ³FHI 360, Research Triangle Park, NC, USA
- 981 Uptake of HIV Testing in the HPTN 071 (PopART) Trial in Zambia**
Kwame Shanaube¹; Joseph M. Chaila²; Sian Floyd³; Ab Schaap⁴; Sam Griffith⁵; Richard Hayes⁶; Sarah J. Fidler⁷; Helen Ayles⁸; for the HPTN071/PopART
¹ZAMBART, Lusaka, Zambia; ²London Sch of Hygiene & Trop Med, London, UK; ³FHI 360, Research Triangle Park, NC, USA; ⁴Imperial Coll London, London, UK
- 982 HIV Testing and ART Coverage Before a UTT Intervention: Findings in HPTN 071 (PopART)**
Helen Ayles¹; Sian Floyd²; Nomtha Mandla³; Alicia Young⁴; Deborah Donnell⁵; Nkatya Kasese⁶; Ayana Moore⁶; Nulda Beyers⁷; Sarah J. Fidler⁸; Richard Hayes¹
¹London Sch of Hygiene & Trop Med, London, UK; ²Univ of Stellenbosch, Cape Town, South Africa; ³SCHARP, Seattle, WA, USA; ⁴SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁵ZAMBART, Lusaka, Zambia; ⁶Family Hlth Intl, Durham, NC, USA; ⁷Univ of Stellenbosch, Tygerberg, South Africa; ⁸Imperial Coll London, London, UK
- 983 HIV Testing and Linkage to Care in the Botswana Combination Prevention Project**
Pamela J. Bachanas¹; Mary G. Alwano²; Stephanie K. Behell³; John Wen⁴; Winnie Sento⁵; Jan S. Moore⁶; Molly Pretorius Holme⁷; Tendani Gaolethe⁸; Refelwetse Lebelonyane⁹; Lisa A. Mills²
¹CDC, Atlanta, GA, USA; ²CDC, Gaborone, Botswana; ³Tebelopele Counseling and Testing Cntr, Gaborone, Botswana; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁶Ministry of Hlth, Gaborone, Botswana
- 984 Cross-Sectional HIV Incidence at Scale-up of ART in 24 Rural Communities in Botswana**
Sikhulile Moyo¹; Coretah Boleo²; Terence Mohammed³; Lucy Mupfumi⁴; Simani Gaseitsiwe⁵; Rosemary Musonda⁶; Erik van Widenfelt⁷; Joseph Makhema⁸; M. Essex⁹; Vladimir Novitsky²
¹Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ²Harvard Sch of PH, Boston, MA, USA
- 985 Local Social Network Features Predict HIV Testing Uptake in a Rural Ugandan Community**
Wenjng Zheng¹; Laura Balzer²; Lillian Brown³; Norton Sang⁴; Tamara Clark⁵; Edwin Charlebois⁶; Moses R. Kanya⁷; Diane V. Havlir⁸; Maya Petersen⁹; for the SEARCH Collaboration
¹Univ of California San Francisco, San Francisco, CA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Kenya Med Rsr Inst, Nairobi, Kenya; ⁴Makerere Univ Coll of Hlth Scis, KAMPALA, Uganda; ⁵Univ of California Berkeley, Berkeley, CA, USA
- 986 Combination HIV Prevention and HIV Incidence in a Ugandan Hotspot Fishing Community**
Joseph Kagaayi¹; Mary K. Grabowski²; Gertrude Nakigozi³; Godfrey Kigozi⁴; Fred Nalugoda⁵; Robert Sekubugu⁶; Ronald H. Gray⁷; David Serwadda⁸; Maria J. Wawer⁹; Larry W. Chang¹
¹Rakai Hlth Scis Prog, Entebbe, Uganda; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Rakai Hlth Scis Prog, Baltimore, MD, USA; ⁴Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁵Makerere Univ School of PH, Kampala, Uganda; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

- 987 Genital Inflammation and HIV Shedding Post-Male Circumcision in Rakai, Uganda**
Eshan U. Patel¹; Mary K. Grabowski²; Godfrey Kigozi³; Ronald H. Gray⁴; Andrew D. Redd⁵; Allison R. Kirkpatrick⁶; David Serwadda⁷; Maria J. Wawer⁸; Thomas C. Quinn⁹; Aaron A. Tobian⁷
¹NIH, Bethesda, MD, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Rakai Hlth Scis Prog, Entebbe, Uganda; ⁴Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁵NIAID, NIH, Bethesda, MD, USA; ⁶Makerere Univ School of PH, Kampala, Uganda; ⁷Johns Hopkins Univ Sch of Med, Baltimore, MD, USA
- 988 Home-Based HIV Counseling and Testing Using Index Patients in Lesotho**
 Abby L. DiCarlo¹; Allison Zerbe²; Zach Peters³; Koen Frederix⁴; Joanne E. Mantell⁵; Robert Remien⁶; **Wafaa M. El-Sadr**¹
¹ICAP at Columbia Univ, New York, NY, USA; ²ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA; ³HIV Cntr for Clinical and Behavioral Studies, Columbia Univ and New York State Psychiatric Inst, New York, NY, USA

Session P-X4 Poster Abstracts
2:45 PM-4:00 PM

Hall D

HIV Care in the Global North

- 989 Prevention for HIV-Infected Persons in HPTN 065: Room for Improvement**
Wafaa M. El-Sadr¹; Ann Kurth²; Jennifer H. Farrior³; Kate Buchacz⁴; Brett Hanscom⁵; Laura McKinstry⁶; Richard Elion⁷; Viraj Patel⁸; Deborah Donnell⁹; Bernard Branson⁸
¹ICAP at Columbia Univ, New York, NY, USA; ²New York Univ, New York, NY, USA; ³FHI 360, Durham, NC, USA; ⁴CDC, Atlanta, GA, USA; ⁵SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁶George Washington Univ Sch of Med, Washington, DC, USA; ⁷Montefiore Med Cntr, Bronx, NY, USA; ⁸Scientific Affairs, Atlanta, GA, USA
- 990 Increased Levels of HIV Baseline Drug Resistance Testing & Early Treatment Initiation**
Hong-Ha M. Truong¹; Sharon Pipkin²; Robert Grant³; Teri Liegler⁴; Susan Scheer⁵
¹Univ of California San Francisco, San Francisco, CA, USA; ²San Francisco Dept of PH, San Francisco, CA, USA
- 991 HIV Prevalence and Care in the New York State Department of Corrections**
Lou Smith¹; Brenda L. Moncur²; Bridget Anderson³; James Tesoriero³; Carl J. Koenigsmann⁴; Heidi Reukauf⁵; Deepa Rajulu⁶; Daniel A. O'Connell¹
¹New York State Dept of Hlth, Albany, NY, USA; ²Hlth Rsr, Inc, Albany, NY, USA; ³New York State Dept of Hlth, AIDS Inst, Albany, NY, USA; ⁴Dept of Corrections and Community Supervision, Albany, NY, USA
- 992 Frequency and Duration of Churn Among Persons Living With HIV in Washington, DC**
Maggie Dorr¹; Amanda Castel²; Kerri Dorsey³; Adam Allston³
¹George Washington Univ, Washington, DC, USA; ²George Washington Univ Milken Inst Sch of PH, Washington, DC, USA; ³District of Columbia Dept of Hlth, HIV/AIDS, Hepatitis, STD, and TB Administration, Washington, DC, USA

- 993 UCARE4LIFE: Mobile Texting to Improve HIV Care Continuum Outcomes for Minority Youth**
Carrie Jeffries¹; Polly Ross²; Sabrina Matoff-Stepp³; Renata Thompson⁴; Jennie L. Harris⁵; Jennifer D. Uhrig⁶; Laura Cheever⁷
¹US DHHS, Rockville, MD, USA; ²RTI, Research Triangle Park, NC, USA
- 994 Missed Opportunities: Adapting the HIV Care Continuum to Reduce HIV-Related Deaths**
Sarah Braunstein¹; Rebekkah Robbins²; Demetre C. Daskalakis³
 New York City DHMH, Queens, NY, USA
- 995 A Novel Practical Spatial Analysis of HIV Care Outcomes, Metro Atlanta, 2012-2014**
Neela D. Goswami¹; Jeffrey McMichael²; Deepali Rane³; Jane Kelly⁴; Julie Clennon⁵; Carlos del Rio⁶; Travis Sanchez⁷
¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Georgia Dept of PH, Atlanta, GA, USA; ³Emory Univ, Atlanta, GA, USA
- 996 Factors Associated With Retention and Engagement in HIV Care (the REACH Survey)**
Alison R. Howarth¹; Fiona Burns²; Caroline Sabin³; Vanessa Apea³
¹Univ Coll London, London, UK; ²Barts Hlth NHS Trust, London, UK
- 997 Computer-Based Prevention Counseling for HIV-Infected Persons (HPTN 065)**
Ann Kurth¹; Jennifer H. Farrior²; Brett Hanscom³; Laura McKinstry⁴; Jill Stanton⁵; Allison Zerbe⁶; Richard Elion⁷; Jason Leider⁸; Bernard Branson⁹; Wafaa M. El-Sadr⁴
¹New York Univ, New York, NY, USA; ²FHI 360, Durham, NC, USA; ³SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁴ICAP at Columbia Univ, New York, NY, USA; ⁵George Washington Univ Sch of Med, Washington, DC, USA; ⁶Jacobi Med Cntr, Bronx, NY, USA; ⁷Scientific Affairs, Atlanta, GA, USA
- 998 The Swedish HIV Treatment Cascade**
Magnus Gisslén¹; Veronica Svedhem²; Lena Lindborg³; Leo Flamholz⁴; Hans Norrgren⁵; Suzanne Wendahl⁶; Anders Sönnnerborg⁷
¹Univ of Gothenburg, Gothenburg, Sweden; ²Karolinska Inst, Stockholm, Sweden; ³Venhalsan, Sodersjukhuset, Stockholm, Sweden; ⁴Skåne Univ Hosp, Malmö, Sweden; ⁵Lund Univ, Lund, Sweden; ⁶Luleå Hosp, Luleå, Sweden

Session P-X5 Poster Abstracts
2:45 PM-4:00 PM

Hall D

HIV Care, Financing

- 999 Antiretroviral Treatment Among Commercially Insured Persons With HIV in the United States**
Kashif Iqbal¹; Ya-Lin A. Huang²; Philip Peters³; Karen Hoover⁴
 CDC, Atlanta, GA, USA
- 1000 Increases in Health Insurance Coverage Among MSM 20 US Cities, 2008–2014**
 Laura A. Cooley¹; Brooke Hoots²; Cyprian Wejnert³; Rashunda Lewis⁴; **Gabriela Paz-Bailey**⁵; for the NHBS Study Group
 CDC, Atlanta, GA, USA

1001 Reliance on Ryan White Coverage for Provider Visits Following the Affordable Care Act

Stephen A. Berry¹; John Fleishman²; Baligh R. Yehia³; Richard Moore⁴; Allison L. Agwu⁵; Wm. Christopher Mathews⁶; Todd Korthis⁷; Ank E. Nijhawan⁸; Kelly A. Gebol⁹; for the HIV Research Network
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Agency for Hlthcare Rsr and Quality, Rockville, MD, USA; ³Univ of Pennsylvania, Philadelphia, PA, USA; ⁴Univ of California San Diego, San Diego, CA, USA; ⁵Oregon Hlth & Sci Univ, Portland, OR, USA; ⁶Univ of Texas Southwestern Med Cntr, Dallas, TX, USA

1002 Receipt of Ryan White Care Services Is Associated With Improved Long-Term Outcomes

Tanner Nassau; Melissa Miller; Coleman Terrell; Sebastian Branca; Kathleen Brady
 Philadelphia Dept of PH, Philadelphia, PA, USA

1003 The Causal Impact of ART Initiation on Household Food Security

Bryan N. Patenaude¹; Natsayi Chimbindi²; Deenan Pillay³; Till Bärnighausen⁴
¹Harvard Sch of PH, Boston, MA, USA; ²Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

Session P-Y2 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Going to Scale With ART and PrEP

1048 Effect of Eliminating CD4 Thresholds on Number of New ART Initiators in South Africa

Jacob Bor¹; Shahira Ahmed²; Matthew P. Fox³; Sydney Rosen²; Frank Tanser⁴; Deenan Pillay⁵; Till Bärnighausen⁶
¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁴Harvard Sch of PH, Boston, MA, USA

1049 Optimizing Resource Allocation to Reduce HIV Incidence Across Sub-Saharan Africa

Jessica McGillen; Sarah-Jane Anderson; Timothy Hallett
 Imperial Coll London, London, UK

1050 New ARVs Could Represent Over USD 3 Billion in Cost Savings Through 2025

Vineet R. Prabhu, Clinton Hlth Access Initiative, Boston, MA, USA

1051 Impact of Improving HIV Care and Treatment and Initiating PrEP in the United States, 2015-2020

Emine Yaylali¹; Paul Farnham²; Evin Jacobson³; Benjamin T. Allaire²; Danielle L. Wagner⁴; Katherine A. Hicks⁵; Amanda A. Honeycutt²; Stephanie L. Sansom¹
¹CDC, Atlanta, GA, USA; ²RTI, Research Triangle Park, NC, USA; ³RTI, Waltham, MA, USA; ⁴RTI Hlth Solutions, Research Triangle Park, NC, USA

1052 PrEP Is Only Cost-Effective Among MSM in the Netherlands When Used on Demand

Brooke E. Nichols¹; Charles A. Boucher¹; Marc van der Valk²; Bart J. Rijnders³; David A. van de Vijver¹
¹Erasmus Univ Med Cntr, Rotterdam, Netherlands; ²Academic Med Cntr, Amsterdam, Netherlands

Session P-Y3 Poster Abstracts

2:45 PM-4:00 PM

Hall D

Modeling the (Cost) Efficiency of Testing and Prevention

1053 Linkage of UK HIV and Tuberculosis Data Using Probabilistic and Deterministic Methods

Joanne R. Winter¹; Valerie Delpech²; Peter Kirwan³; Helen R. Stagg⁴; Srividhya Venugopalan⁵; Andrew Skingsley⁶; Maeve K. Lalor⁷; H. L. Thomas⁸; Ibrahim R. Abubakar¹
¹Univ Coll London, London, UK; ²PH England, London, UK

1054 Optimal Rollout of "Treatment As Prevention" in Africa: Efficiency Versus Equity

Brian J. Coburn; Justin Okano; Sally Blower
 Univ of California Los Angeles, Los Angeles, CA, USA

1055 Modeled Effectiveness of Nondaily PrEP Based on Sex Coverage Data From HPTN067 ADAPT

Dobromir T. Dimitrov¹; Kate M. Mitchell¹; James P. Hughes²; Deborah Donnell³; Linda-Gail Bekker⁴; Robert Grant⁵; Marie-Claude Boily⁶
¹Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ²Imperial Coll London, London, UK; ³Univ of Washington, Seattle, WA, USA; ⁴Desmond Tutu HIV Cntr, Cape Town, South Africa; ⁵Univ of California San Francisco, San Francisco, CA, USA

1056 Scale-up of Antiretroviral Therapy and Preexposure Prophylaxis in Swaziland

Eugene T. Richardson¹; Futhi Dennis²; Nokwazi Mathabela³; Khanya Mabuza⁴; Allen Waligo⁵; Eren Bandavid⁶; Sabina Alistar⁷; Marelize Gorgens⁸; Francois Venter⁴
¹Stanford Univ, Stanford, CA, USA; ²Natl Emergency Response Council on HIV and AIDS (NERCHA), Mbabane, Swaziland; ³The World Bank, Washington, DC, USA; ⁴Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa

1057 Dapivirine Vaginal Ring Preexposure Prophylaxis for HIV Prevention in South Africa

Robert Glaubius¹; Kerri J. Penrose²; Greg Hood³; Urvi M. Parikh²; **Ume Abbas⁴**
¹Cleveland Clinic, Cleveland, OH, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Pittsburgh Supercomputing Cntr, Pittsburgh, PA, USA; ⁴Baylor Coll of Med, Houston, TX, USA

1058 Cost-Effectiveness of the Intravaginal Dapivirine Ring: A Modeling Analysis

Jennifer Smith¹; Kate Harris²; Geoff Garnett²; Lut Van Damme²; Timothy Hallett¹
¹Imperial Coll London, London, UK; ²Bill and Melinda Gates Fndn, Seattle, WA, USA

1059 Determinants of Economic Efficiency in HIV Prevention: Evidence From ORPHEA Kenya

Omar Galarraga¹; Richard Wamai²; Sandra G. Sosa-Rubi³; Mercy Mugo⁴; David Contreras⁵; Sergio Bautista-Arredondo⁶; Helen Nyakundi⁷; Joseph Wang'Ombe⁴
¹Brown Univ Sch of PH, Providence, RI, USA; ²Northeastern Univ, Boston, MA, USA; ³INSP, Cuernavaca, Mexico; ⁴Univ of Nairobi, Nairobi, Kenya

- 1060 Global Variation in the Impact of Male Circumcision in Preventing HIV Among MSM**
Liilith K. Whittles¹; Kate M. Mitchell¹; Romain Silhol¹; Dobromir T. Dimitrov²; Marie-Claude Boily¹
¹Imperial Coll London, London, UK; ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA
- 1061 What Does Community HIV Testing Really Cost in South Africa?**
 Guillermo Martínez Pérez¹; Aline Aurore Niyibizi²; Jessie Kurkunar³; Amir Shroufi⁴; Sarah Jane Steele⁵; **Gilles Van Cutsem³**
¹Médecins Sans Frontières, South Africa & Lesotho, Eshowe, South Africa; ²Médecins Sans Frontières, Roma, Lesotho; ³Médecins Sans Frontières, Cape Town, South Africa; ⁴Médecins Sans Frontières, South Africa & Lesotho, Cape Town, South Africa
- 1062 Costs of Hybrid Mobile Multi-Disease Testing With High HIV Test Coverage, East Africa**
Wei Chang¹; Gabriel Chamie²; Harsha Thirumurthy³; Tamara Clark⁴; Edwin Charlebois⁵; Maya Petersen⁶; Moses R. Kamya⁷; Diane V. Havlir⁸; James G. Kahn⁹; for the Sustainable East Africa Research for Community Health (SEARCH) Collaboration
¹Univ of California San Francisco, San Francisco, CA, USA; ²Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ³Univ of California Berkeley, Berkeley, CA, USA; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda
- 1063 Targeting Serodiscordant Couples Within Home HIV Testing Campaigns: A Modeling Study**
Sarah T. Roberts¹; Aditya S. Khanna²; Ruanne V. Barnabas³; Steven M. Goodreau⁴; Jared M. Baeten⁵; Connie M. Celum⁶; Susan L. Cassels⁷
¹Univ of Washington, Seattle, WA, USA; ²Univ of Chicago, Chicago, IL, USA; ³Univ of California Santa Barbara, Santa Barbara, CA, USA

THURSDAY, FEBRUARY 25, 2016

Session P-A4 Poster Abstracts **Hall A/B**

2:45 PM-4:00 PM

Host Factors and Cell Response to Infection

- 199 Transcriptional Regulation of the APOBEC3 Repertoire Through the CBFβ/RUNX Axis**
Brett D. Anderson¹; Reuben S. Harris²
¹Univ of Minnesota, Minneapolis, MN, USA; ²Howard Hughes Med Inst, Minneapolis, MN, USA
- 200 Is Endogenous APOBEC3H an HIV-1 Transmission Barrier?**
Jiayi Wang¹; Allison M. Landl¹; Brian J. Hoium¹; Eric W. Refsland¹; Elizabeth M. Luengas²; Romel D. Mackelprang³; William L. Brown⁴; Michael Emerman⁵; Jairam R. Lingappa⁶; Reuben S. Harris⁴
¹Univ of Minnesota, Minneapolis, MN, USA; ²Univ of Washington, Seattle, WA, USA; ³Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁴Howard Hughes Med Inst, Minneapolis, MN, USA
- 201 Characterization of Novel Human APOBEC3A Variants**
Matthew Hernandez¹; Lara Manganaro²; Marcel Ooms³; Lubbertus C. Mulder⁴; Veronica Iannucci⁵; Marsha Dillon-White⁶; Sandra N. Terry⁷; Ekta Sharma⁸; Viviana A. Simon⁹
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA

- 202 CBFβ Protects HIV-1 Vif From MDM2-Mediated Degradation**
Yusuke Matsui¹; Keisuke Shindo²; Kayoko Nagata³; Noriyoshi Yoshinaga⁴; Kotaro Shirakawa⁵; Masayuki Kobayashi⁶; Akifumi Takaori-Kondo⁷
 Kyoto Univ, Kyoto, Japan
- 203 MARCH8 Restricts HIV-1 Infection by Reducing Envelope Incorporation Into Virions**
Kenzo Tokunaga¹; Takuya Tada¹; Yanzhao Zhang¹; Takayoshi Koyama¹; Minoru Tobiome¹; Yasuko Tsunetsugu-Yokota¹; Shoji Yamaoka¹; Hideaki Fujita¹
¹Natl Inst of Infectious Diseases, Tokyo, Japan; ²Tokyo Med and Dental Univ, Tokyo, Japan; ³Nagasaki Intl Univ, Nagasaki, Japan
- 204 Sirtuins Modulate HIV Integration and Replication: New Cellular Anti-HIV Targets**
Michelino Di Rosa¹; Ilaria Gnemmi²; Beatrice Riva³; Ubaldina Galli⁴; Armando Genazzani⁵; Pier Luigi Canonico⁶; Marilia R. Pinzone⁷; Fabrizio Condorelli⁸; Giuseppe Nunnari¹
¹Univ of Catania, Catania, Italy; ²Sch of Pharm, Univ of Piemonte Orientale A. Avogadro, Novara, Italy
- 205 SAMHD1 Phosphorylation Affects dNTPase Activity and HIV-1 Replication Capacity**
Roger Badia¹; Eva Riveira-Muñoz²; Maria Pujantell³; Javier Torres-Torronteras⁴; Bonaventura Clotet⁵; Luis Menéndez-Arias⁶; Ramón Martí⁷; Ester Ballana⁸; José A. Esté⁹
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Vall d Hebron Inst de Recerca, Barcelona, Spain; ³Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain; ⁴Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas UAM), Madrid, Spain
- 206 Novel Mutant HIV-1 Strains With Greater Resistance to Cytomologue Macaque TRIMCyp**
Tahmina Sultana¹; Emi E. Nakayama²; Satoshi E. Tobita³; Yohei Seki⁴; Akatsuki Saito⁵; Masako Nomaguchi⁶; Akio Adachi⁷; Hirofumi Akari⁸; Tatsuo E. Shioda¹
¹Rsr Inst for Microbial Diseases, Osaka Univ, Suita, Japan; ²Osaka Univ, Suita, Japan; ³Kyoto Univ, Kyoto, Japan; ⁴Inst for Virus Rsr, Kyoto Univ, Kyoto, Japan; ⁵Inst of Hlth BioScis, The Univ of Tokushima Grad Sch, Tokushima, Japan
- 207 The G1/S Specific Cyclin D2 Acts As a Viral Restriction Factor in Primary Macrophages**
Ester Ballana¹; Roger Badia²; Maria Pujantell³; Eva Riveira-Muñoz⁴; José A. Esté⁵; Bonaventura Clotet⁶
¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Lluita Contra la SIDA Fndn, Germans Trias i Pujol Univ Hosp, Barcelona, Spain
- 208 Characterizing Dynamics of Proteo-Transcriptomic Response to HIV-1 Infection**
Monica Golumbeanu¹; Pejman Mohammadi²; Sébastien Desfarges³; Céline Hernandez⁴; Manfred Quadroni⁵; Amalio Telenti⁶; Niko Beerenwinkel⁷; Angela Guffi⁸
¹ETH Zürich, Basel, Switzerland; ²New York Genome Cntr, New York, NY, USA; ³Inst of Microbiology, Lausanne Univ Hosp and Univ of Lausanne, Lausanne, Switzerland; ⁴Inst de Biologie de l'Ecole Normale Supérieure, Paris, France; ⁵Univ of Lausanne, Lausanne, Switzerland; ⁶Univ of California San Diego, San Diego, CA, USA

209LB Kinesin-1 and Nup358 Cooperatively Mediate the Nuclear Import of HIV During Infection

Edward Campbell; Adarsh Dharan; Sarah Talley
Loyola Univ Chicago, Maywood, IL, USA

Session P-B3 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Viral Genetics: Effects on Transmission, Disease, and Reinfection

226 HIV-1 Subtypes: 5 LTR-Leader Sequence Variants and Late HIV Seroconversion

Ma Luo¹; Raghavan Sampathkumar²; Ian MacArthur³; Joel Scott-Herridge⁴; Paul Sandstrom⁵; Joshua Kimani⁶; Francis Plummer¹
¹Natl Microbiology Lab of Canada, Winnipeg, MB, Canada; ²Univ of Manitoba, Winnipeg, MB, Canada; ³Univ of Nairobi, Nairobi, Kenya

227 HIV-1 Stop Codon Usage and Its Clinical Impacts in Rural Ugandan Patients

Guinevere Q. Lee¹; Viviane D. Lima²; Wendy Zhang³; Yap Boum³; Simone H. Kigozi⁴; A. Rain Mocello⁴; Peter W. Hunt⁴; Jeffrey N. Martin⁴; David R. Bangsberg⁵; P. Richard Harrigan²
¹Massachusetts General Hosp, Boston, MA, USA; ²BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ³Mbarara Univ of Sci and Tech, Mbarara, Uganda; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Harvard Med Sch, Boston, MA, USA

228 Intrahost Viral Competition and Archiving Dynamics in HIV-1 Superinfection

Antoine Chailion; Davey M. Smith; Susan J. Little; Gemma Caballero; Douglas D. Richman; Gabriel Wagner
Univ of California San Diego, San Diego, CA, USA

229 Spatiotemporal Dynamics of Drug Resistance Evolution and Persistence of RT-SHIV

Alison F. Feder¹; Christopher Kline²; Shiu-Lok Hu³; Brandon Keele⁴; Dmitri A. Petrov¹; Pleuni S. Pennings²; Zandrea Ambrose⁵
¹Stanford Univ, Stanford, CA, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Univ of Washington, Seattle, WA, USA; ⁴Frederick Natl Lab, Frederick, MD, USA; ⁵San Francisco State Univ, San Francisco, CA, USA

Session P-B4 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Defining the Sequence Characteristics of Transmitted Viruses

230 Limited Evidence for a Bias Toward Consensus Residues Upon HIV-1 Transmission

Morgane Rolland¹; Julie Ake²; Merlin L. Robb²; Nelson L. Michael¹
¹US Military HIV Rsr Prog, Silver Spring, MD, USA; ²US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ³US Military HIV Rsr Prog, Bethesda, MD, USA

231 Mode of Sexual Transmission Can Exert an Impact on Shaping the HIV-1 Founder Virus

Damien C. Tully¹; Colin B. Ogilvie¹; Rebecca E. Batorsky¹; Eric S. Rosenberg¹; Kenneth H. Mayer¹; Heiko Jessen¹; Sergei Kosakovsky Pond¹; Marcus Altfeld²; Jonathan Carlson³; Todd M. Allen¹
¹Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ²Massachusetts General Hosp, Boston, MA, USA; ³The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁴HIV Clinic Praxis Jessen, Berlin, Germany; ⁵Univ of California San Diego, San Diego, CA, USA; ⁶Heinrich Pette Inst, Hamburg, Germany; ⁷Microsoft Rsr, Redmond, WA, USA

232 Characterizing the Multiplicity of HIV Founder Variants During Sexual Transmission

Antoine Chailion¹; Sara Gianella¹; Susan J. Little¹; Christy Anderson¹; Gemma Caballero¹; Francis Barin¹; Sergei Kosakovsky Pond¹; Douglas D. Richman¹; Davey M. Smith¹; Sanjay R. Mehta¹
¹Univ of California San Diego, San Diego, CA, USA; ²François-Rabelais Univ, Tours, France

Session P-C8 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Pathogenesis of Mucosal Transmission

284 Progesterone (P4) Indirectly Increases Susceptibility to HIV Within Genital Mucosa

Jason Neidelman¹; Joseph Chen²; Nargis Kohgadari¹; Janis A. Müller³; Jeremy W. Martin¹; Jan Münch³; Ruth M. Greenblatt¹; Linda Giudice¹; Warner C. Greene¹; Nadia R. Roan²
¹Gladstone Insts, San Francisco, CA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Ulm, Ulm, Germany

285 Seminal Plasma Induces Inflammation and Enhances HIV-1 Infection in Cervical Explants

Andrea Introini¹; Annelie Tjernlund¹; Stéphanie Boström¹; Bo Hejdeman¹; Anna Gibbs¹; Frideborg Bradley¹; Kristina Brolden³
¹Karolinska Inst, Stockholm, Sweden; ²Södersjukhuset, Stockholm, Sweden; ³Karolinska Univ, Stockholm, Sweden

286 The Effect of Condomless Receptive Anal Intercourse on the Rectal Mucosa in MSM

Colleen F. Kelley¹; Jing Yang¹; Gregory Tharp¹; Kirk A. Easley²; Mark Mulligan¹; Patrick Sullivan¹; Steven E. Bosinger³; Rama Amara³; for the Emory Center for AIDS Research
¹Emory Univ, Atlanta, GA, USA; ²Emory Univ Rollins Sch of PH, Atlanta, GA, USA; ³Yerkes Natl Primate Rsr Cntr, Emory Univ, Atlanta, GA, USA

287 Reduced Peripheral a4B7+ CD4+ T Cells Correlate With Mucosal CD4+ T Cell Loss in AHI

Alexandra Schuetz¹; Chayada Sajaweerawan¹; Nittaya Phanuphak²; Rungsun Rerknimitz³; Nonpen Tantivayakul¹; Nitiya Chomchey²; Merlin L. Robb⁴; Robin Dewar⁵; Mark de Souza²; Jintanat Ananvoranich⁶; for the RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups
¹US AFRRMS, Bangkok, Thailand; ²SEARCH, Bangkok, Thailand; ³Chulalongkorn Univ, Bangkok, Thailand; ⁴US Military HIV Rsr Prog, Walter Reed Army Inst of Rsr, Silver Spring, MD, USA; ⁵Frederick Cancer Rsr and Develop Cntr, Frederick, MD, USA; ⁶Military HIV Rsr Prog, Bethesda, MD, USA

- 288 HIV Infections in Novel CD1a Cells From Human Vaginal Mucosa**
Victor Pena-Cruz¹; Luis Agosto²; Hisashi Akiyama²; Jean-Robert Larrieux²; Rahm Gummuluru²; Manish Sagari¹
¹Boston Univ, Boston, MA, USA; ²Boston Univ Sch of Med, Boston, MA, USA; ³Boston Med Cntr, Boston, MA, USA
- 289 Influx of Th1 Cells in the Gut Mucosa Impairs the Homing of Th17 Cells Under cART**
Claire Loiseau¹; Mary Requena²; Michelle Cazabat²; Nicolas Carrere²; Bertrand Suc²; Bruno Marchou²; Jacques Izopet²; Pierre Delobel²
¹INSERM 1043, Toulouse, France; ²CHU Toulouse, Toulouse, France
- 290 Reduced Rectal HIV RNA After Peg-IFN- α 2b Added to ART Together With ART Interruption**
 Emmanouil Papasavvas¹; Guobin Kang²; **Livio Azzoni**³; Faten Aberra³; Pablo Tebas³; Karam Mounzer⁴; Jay R. Kostman⁵; Douglas D. Richman⁶; Qingsheng Li⁷; Luis J. Montaner¹
¹The Wistar Inst, Philadelphia, PA, USA; ²Univ of Nebraska, Lincoln, NE, USA; ³Univ of Pennsylvania, Philadelphia, PA, USA; ⁴Jonathan Lax Immune Disorders Treatment Cntr, Philadelphia, PA, USA; ⁵John Bell Hlth Cntr, Philadelphia, PA, USA; ⁶Univ of California San Diego, San Diego, CA, USA; ⁷Sch of Biological Scis and Nebraska Cntr for Virology, Univ of Nebraska, Lincoln, NE, USA
- 291 Effect of Acute HIV Infection on CD4/CD8 Normalization After ART Initiation**
Thibaut Davy; Sonia Napravnik; Anna Cope; JoAnn D. Kuruc; Cynthia Gay; Joseph J. Eron
 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 292 Acute HIV Treatment Reverses CD8 T Cell Activation, Exhaustion, and Apoptosis**
 Jessica Eagar¹; Sarah D. Sterrett¹; Nilesh Amatya²; Anju Bansal²; Steffanie Sabbaj²; Katharine J. Bar²; **Sonya L. Heath**¹
¹Univ of Alabama at Birmingham, Birmingham, AL, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁴Univ of Pennsylvania, Philadelphia, PA, USA
- 293 Inflammatory Biomarker Changes After Antiretroviral Treatment (ART) Initiation**
Konstantia Angelidou¹; Peter W. Hunt²; Alan Tenorio³; Alan L. Landay⁴; Cara Wilson⁵; Benigno Rodriguez⁶; Stephen G. Deeks⁷; Ronald Bosch⁸; Michael M. Lederman⁹
¹Harvard Sch of PH, Boston, MA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³GSK, Research Triangle Park, NC, USA; ⁴Rush Univ, Chicago, IL, USA; ⁵Univ of Colorado Hosp, Aurora, CO, USA; ⁶Case Western Reserve Univ Sch of Med, Cleveland, OH, USA; ⁷San Francisco General Hosp, San Francisco, CA, USA; ⁸Case Western Reserve Univ, Cleveland, OH, USA
- 294 Increased Innate Function Following HIV-1 Suppression Is Linked to Epigenetic Changes**
Eileen P. Scully¹; Ainsley Lockhart²; Wilfredo Garcia-Beltran³; Christine D. Palmer⁴; Chelsey Musante⁵; Eric S. Rosenberg⁶; Todd M. Allen⁷; J. Judy Chang⁸; Ronald Bosch⁹; Marcus Altfield⁹
¹Massachusetts General Hosp, Boston, MA, USA; ²Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ³Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Heinrich Pette Inst, Hamburg, Germany
- 295 Inhibition of P2X7 Enhances T-Cell Potential of CD34 in HIV+ c-ART Nonresponders**
Inna Menkova-Garnier¹; Clarisse Benne¹; Hakim Hocini²; Pascaline Tisserand³; Constance Delaunay⁴; Emile Foucat⁴; Laure Bourdery⁴; Yves Lévy¹; Jean-Daniel Lelièvre¹
¹Inst Mondor de Recherche Biomédicale INSERM U955, Univ Paris Est Créteil, Créteil, France; ²Inst Mondor de Recherche Biomédicale INSERM U955, Vaccin Rsr Inst (VRI), Créteil, France; ³Hosp Saint Louis et Univ Paris Diderot, Paris, France; ⁴Univ Paris Est-Créteil, Créteil, France
- 296 Maraviroc and Immune Recovery in Advanced AIDS (CD4 <100)**
Pablo F. Belaunzaran-Zamudio¹; Livio Azzoni²; Juan Sierra-Madero³; Yanick Caro-Vega⁴; Iriñi Sereti⁵; David H. Canaday⁶; Brian Claggett⁷; Benigno Rodriguez⁸; Ian M. Sanne⁹; Michael M. Lederman⁹
¹Inst Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; ²The Wistar Inst, Philadelphia, PA, USA; ³NIH, Bethesda, MD, USA; ⁴Cleveland VA Med Cntr, Cleveland, OH, USA; ⁵Case Western Reserve Univ, Cleveland, OH, USA; ⁶Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa
- 297 Transcriptomic Signature of Atorvastatin Response Among ART-Treated Adults in Africa**
Damalie Nakanjako¹; Khader Ghemim²; Isaac Ssinabulya³; Rose M. Nabantanzi⁴; Lois Bayigga⁴; Agnes Kiragga⁴; Harriet Mayanja-Kizza⁵; Moses R. Kanya; Andrew Kambugu⁶; Pontiano Kaleebu⁷; Alison M. Elliott⁸; Rafick Sekaly⁹
¹Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ²Case Western Reserve Univ, Cleveland, OH, USA; ³Coll of Hlth Scis, Makerere Univ, Kampala, Uganda; ⁴Infectious Diseases Inst, Kampala, Uganda; ⁵Med Rsr Council/Uganda Virus Rsr Inst Uganda Rsr Unit on AIDS, Entebbe, Uganda; ⁶Med Researh Council/Uganda Virus Rsr Inst, Entebbe, Uganda; ⁷Case Western Reserve Univ, Cleveland, OH, USA
- 298 ACE-Inhibitors to Decrease Lymphoid Fibrosis and the Size of the Latent Reservoir**
Leslie R. Cockerham¹; Ma Somsouk²; Sunil K. Joshi³; Sharon R. Lewin⁴; Steven A. Yukl⁵; Ajantha Rhodes⁶; Elizabeth Sinclair⁷; Marc Hellerstein⁸; Stephen G. Deeks⁹; Hiroyu Hatano⁹
¹Med Coll of Wisconsin, Milwaukee, WI, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³San Francisco VA Med Cntr, San Francisco, CA, USA; ⁴Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia; ⁵Univ of Melbourne, Melbourne, Australia; ⁶Univ of California Berkeley, Berkeley, CA, USA; ⁷San Francisco General Hosp, San Francisco, CA, USA

Session P-C9 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Immune Effects of Antiretroviral Therapy

299 Distinctive Dynamics of Phenotypic Cellular Restoration in IRIS

Pablo F. Belauzarán-Zamudio¹; Livio Azzoni²; David H. Canaday³; Yanink Caro-Vega⁴; Brian Claggett⁵; Benigno Rodriguez⁶; Juan Sierra-Madero⁷; Ian M. Sanne⁸; Irini Sereti⁹; Michael M. Lederman¹⁰

¹*Inst Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico*; ²*The Wistar Inst, Philadelphia, PA, USA*; ³*Cleveland VA Med Ctr, Cleveland, OH, USA*; ⁴*Case Western Reserve Univ, Cleveland, OH, USA*; ⁵*Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa*; ⁶*NIH, Bethesda, MD, USA*

300LB Only T-Cell Responses to Nef/Tat/Rev Correlate With Infected Cell Frequencies on ART

Allison Thomas¹; John W. Mellors²; Rajesh Gandhi³; Deborah McMahon⁴; Joseph Eron⁵; Ronald Bosch⁶; Christina Lalama⁷; Joshua Cytkor⁸; Bruce D. Walker⁹; **Brad Jones**¹

¹*George Washington Univ, Washington, DC, USA*; ²*Univ of Pittsburgh, Pittsburgh, PA, USA*; ³*Massachusetts General Hosp, Boston, MA, USA*; ⁴*Univ of North Carolina, Chapel Hill, NC, USA*; ⁵*Harvard Univ, Boston, MA, USA*; ⁶*Harvard Sch of PH, Boston, MA, USA*; ⁷*Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA*

Session P-E4 Poster Abstracts 2:45 PM-4:00 PM

Hall A/B

Effects of HIV on the Responses to Other Vaccines

324 Distinct B-cell Gene Signatures Define Ability to Respond to H1N1 Vaccine in HIV+ Children

Nicola Cotugno¹; Lesley De Armas²; Suresh Pallikkuth³; Alberto Cagliga⁴; Stefano Rinaldi⁵; Paolo Rossi⁶; Paolo Palma⁷; Savita Pahwa⁸
¹*Bambino Gesù Children's Hosp, Univ of Rome Tor Vergata, Rome, Italy*; ²*Miller Sch of Med, Univ of Miami, Miami, FL, USA*; ³*Bambino Gesù Children's Hosp, Rome, Italy*; ⁴*Univ of Miami Miller Sch of Med, Miami, FL, USA*

325 NextGen Sequencing Defines Response to H1N1 Vaccination in HIV-Infected Individuals

Li Yin¹; Carina Rodriguez²; Jiqiang Yao³; Kaifen Chang⁴; Manju Karki⁵; Fahong Yu⁶; John Sleasman⁷; Maureen Goodenow¹
¹*Univ of Florida, Gainesville, FL, USA*; ²*Univ of South Florida, Tampa, FL, USA*; ³*Moffitt Cancer Ctr, Tampa, FL, USA*; ⁴*Duke Univ Sch of Med, Durham, NC, USA*

326 CD4/CD8 Ratio and K/T Ratio Predict Yellow Fever Vaccine Response in HIV+ Patients

Vivian I. Avelino-Silva¹; Karina T. Miyaji²; Marcos S. Freire³; Ana M. Sartori⁴; Peter W. Hunt⁵; Huang Yong⁶; Ester C. Sabino⁷; Dayane A. Costa⁸; Juliana Z. Dias⁹; Esper G. Kallas¹
¹*Univ of Sao Paulo Med Sch, Sao Paulo, Brazil*; ²*Fundação Oswaldo Cruz, Rio de Janeiro, Brazil*; ³*Univ of California San Francisco, San Francisco, CA, USA*

327 Steady State and Post-Vaccination TFH Dynamics in HIV Patients Treated With cART

Eirini Moysi¹; Louis Edward Gonzalez²; Lesley De Armas³; Joseph P. Casazza⁴; Varghese K. George⁵; Rajendra Pahwa⁶; Suresh Pallikkuth⁷; Richard A. Koup⁸; Constantinos Petrovas⁹; Savita Pahwa²
¹*NIH, Bethesda, MD, USA*; ²*Univ of Miami, Miller Sch of Med, Miami, FL, USA*; ³*Miller Sch of Med, Univ of Miami, Miami, FL, USA*; ⁴*VRC, NIAID, NIH, Bethesda, MD, USA*; ⁵*Univ of Miami, Miami, FL, USA*

328 WITHDRAWN

329 Impaired Responses to Vaccine in HCV Infection Are Related to Baseline Inflammation

Carey L. Shive¹; Chelsey Judge²; Robert Kalayjian³; Melissa Osborn⁴; Kenneth E. Sherman⁵; Carl Fichtenbaum⁶; Daniel Popkin⁷; Scott M. Sieg⁸; Benigno Rodriguez⁹; Donald Anthony¹⁰
¹*Cleveland VA Med Ctr, Cleveland, OH, USA*; ²*Case Western Reserve Univ, Cleveland, OH, USA*; ³*MetroHlth Med Ctr, Cleveland, OH, USA*; ⁴*Univ of Cincinnati, Cincinnati, OH, USA*; ⁵*Case Western Reserve Univ Sch of Med, Cleveland, OH, USA*

Session P-F7 Poster Abstracts 2:45 PM-4:00 PM

Hall A/B

Stem Cells

364 Treatment of HIV and AML by Allogeneic CCR5-d32 Blood Stem Cell Transplantation

Guido Kobbe¹; Rolf Kaiser²; Elena Knops³; Nadine Luebke⁴; Gabor A. Dunay⁵; Johannes Fischer⁶; Falk Huettig⁷; Rainer Haas⁸; Dieter Haeussinger⁹; **Bjoern-Erik O. Jensen**¹
¹*Duesseldorf Univ Hosp, Heinrich-Heine Univ Duesseldorf, Duesseldorf, Germany*; ²*Inst of Virology, Univ of Cologne, Cologne, Germany*; ³*Univ Clinic of Cologne, Cologne, Germany*; ⁴*Inst for Virology, Heinrich-Heine-Univ, Univ Hosp, Duesseldorf, Germany*; ⁵*Heinrich Pette Inst, Hamburg, Germany*; ⁶*Inst of Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine Univ Duesseldorf, Duesseldorf, Germany*

365 HIV-1 Viral Rebound Following Allogeneic Hematopoietic Stem-Cell Transplantation

Kersten K. Koelsch¹; John J. Zaunders²; Angie Pinto³; Kazuo Suzuki⁴; Sarah C. Saxon⁵; Bonnie Hiener⁶; Sarah Palmer⁷; Sam T. Milliken⁸; Anthony Kelleher⁹; David Cooper¹⁰; for the Sydney HIV SCT Study Group
¹*Kirby Inst, Univ of New South Wales, Sydney, Australia*; ²*St Vincent's Hosp, Darlinghurst, Australia*; ³*St Vincent's Hosp, Sydney, Australia*; ⁴*Ctr for Virus Rsr, Westmead Millennium Inst, Westmead, Australia*; ⁵*Univ of New South Wales, Sydney, Australia*; ⁶*Kirby Inst, Sydney, Australia*

366 A Tale of Two Stem-Cell Transplantations in HIV+ Patients: Clues to Eradicate HIV

Maria Salgado¹; Mi Kwon²; Monique Nijhuis³; Jan van Lunzen⁴; Julià Blanco⁵; Julian Schulze zur Wiesch⁶; Gero Hutter⁷; Anne M. Wensing⁸; Jose Luis Diez⁹; Javier Martinez-Picado¹⁰; for the EpiStem Consortium ¹IrsiCaixa Inst for AIDS Rsr, Badalona, Spain; ²Hosp General Universitario Gregorio Marañón, Madrid, Spain; ³Univ Med Ctr Utrecht, Utrecht, Netherlands; ⁴Univ Med Cntr Hamburg-Eppendorf, Hamburg, Germany; ⁵Univ de Vic, Barcelona, Spain; ⁶Cellex, Dresden, Germany

367 Ex Vivo Determination of Stem-Cell Transplantation Graft-Versus-HIV Reservoir Effects

Louise Hogan¹; Kristen S. Hobbs²; Emily Hanhauser¹; Christine D. Palmer³; Marisol Romero-Tejeda⁴; Yvonne P. Robles⁵; Stephanie Jost⁶; Daniel Kuritzkes⁷; Jerome Ritz⁸; Timothy J. Henrich¹ ¹Univ of California San Francisco, San Francisco, CA, USA; ²Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; ³Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ⁴Harvard Med Sch, Boston, MA, USA; ⁵Dana-Farber Cancer Inst, Boston, MA, USA

Session P-F8 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HIV Persistence, Latency, and Reactivation

368 WITHDRAWN

369 Differential Effect of Selenium on HIV Replication and Reactivation in Primary Cells

Christina Gavegnano¹; Raymond F. Schinazi²; Sally Yuan²; Deanna Kulp³; Nicolas Durier⁴; Ariana Santos¹ ¹Emory Univ Sch of Med, Atlanta, GA, USA; ²Janssen Pharmaceuticals, Springhouse, PA, USA; ³Southern Rsr Inst, Frederick, MD, USA; ⁴TREAT Asia/amfAR, Bangkok, Thailand

370 Kinetics of HIV-1 Latency Reversal Measured by a New Flow-Based Technique

Gloria Martrus; Annika Niehrs; Anne Rechten; Marcus Altfeld *Heinrich Pette Inst, Hamburg, Germany*

371 Reactivation of Latent HIV-1 in J-Lat T Cells by Type I Interferon Agonists

Melanie Alvarado¹; Mark A. Alday²; Priscilla Natcher³; Vanessa Muhlenbruch⁴; Audrey M. Rutz⁵; Jonathan C. Rupp⁶; Benjamin R. Harrison⁷; Faye D. Schilkey⁸; Viviana A. Simon⁹; Eric M. Bortz¹⁰ ¹Univ of Alaska Anchorage, Anchorage, AK, USA; ²Natl Cntr for Genome Resources, Santa Fe, NM, USA; ³Icahn Sch of Med at Mount Sinai, New York, NY, USA

372 CSF1R Antagonists Sensitize HIV-Infected Macrophages to Death

Francesc Cunyat; Jennifer N. Rainho; Mario Stevenson *Univ of Miami, Miami, FL, USA*

373 Effect of HIV-1 Nef on MHC-I After Latency Reversal in Primary CD4 T Cells

Thomas Vollbrecht; John Guatelli *Univ of California San Diego, San Diego, CA, USA*

374 Effect of Primary CD8 T Cells on Romidepsin and Bryostatatin-Treated CD4 T Cells

Victoria Walker-Sperling; Joel N. Blankson *Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*

375 Dendritic Cell T-Cell Culture Facilitates HIV Latency in Proliferating CD4+ T Cells

Nitasha A. Kumar¹; Renee M. van der Sluis²; Talia Mota³; Sharon R. Lewin⁴; Paul U. Cameron³ ¹Emory Univ, Atlanta, GA, USA; ²The Peter Doherty Inst, Univ of Melbourne, Melbourne, Australia; ³Doherty Inst for Infection and Immunity, Univ of Melbourne, Melbourne, Australia

376 Role of Dendritic Cell Polarization in the Induction of HIV-1 Latency Reversal

Robbie B. Mailliard¹; Charles Rinaldo²; Jan R. Kristoff³; Margaret Carlson⁴; Jennifer M. Zerbato⁵; Nicolas Sluis-Cremer⁶; Phalguni Gupta³ ¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Univ of Pittsburgh, Grad Sch of PH, Pittsburgh, PA, USA

377 Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent HIV-1

Jennifer Zerbato; Deborah McMahon; Michele D. Sobolewski; John W. Mellors; Nicolas Sluis-Cremer *Univ of Pittsburgh, Pittsburgh, PA, USA*

378 Follicular Tregs Reduce HIV Replication and Reactivation From Latency Ex Vivo

Brodie Miles; Elizabeth Connick *Univ of Colorado, Denver, CO, USA*

379 A Subset of Infectious Proviruses Persist and Expand Following Activation Ex Vivo

John K. Bui¹; Elias Halvas²; Elizabeth Fyne³; Michele D. Sobolewski¹; Dianna Koontz²; Mary F. Kearney⁴; Wei Shao⁵; Feiyu Hong⁶; John W. Mellors¹ ¹Univ of Pittsburgh, Pittsburgh, PA, USA; ²Univ of Pittsburgh Sch of Med, Pittsburgh, PA, USA; ³NCI, Frederick, MD, USA; ⁴Leidos Biomed Rsr, Inc, Frederick, MD, USA

380 Transcription of Novel HIV-1 RNA Species in the Setting of Undetectable Virus

Hiroimi Imamichi¹; Robin Dewar²; Joseph A. Adelsberger³; Catherine A. Rehm⁴; Catherine Seamon⁵; Gregg Roby⁶; Alice Pau⁷; H. Clifford Lane⁸ ¹NIAID, NIH, Frederick, MD, USA; ²Frederick Cancer Rsr and Develop Cntr, Frederick, MD, USA; ³Leidos Biomed Rsr, Inc, Frederick, MD, USA; ⁴NIAID, NIH, Bethesda, MD, USA; ⁵NIAID, NIH, Rockville, MD, USA

Session P-G4 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Host and Virus Biomarkers and Immune Response

- 407 Dual Role of Activated and HIV-Specific CD8 T Cells in CSF During Acute HIV Infection**
Lydie Trautmann¹; Cari Kessing²; Eugène Kroon³; Donn Colby⁴; Shelly Krebs⁵; Napapon Sailasuta⁶; Jintana Intana⁷; Victor Valcour⁸; Jintanat Ananworanich⁹; Serena S. Spudich¹⁰; for the SEARCH 010/011/013 Study Groups
¹Military HIV Rsr Prog, Silver Spring, MD, USA; ²The Scripps Rsr Inst, Jupiter, FL, USA; ³SEARCH, Bangkok, Thailand; ⁴Military HIV Rsr Prog, Bethesda, MD, USA; ⁵Univ of Hawaii, Honolulu, HI, USA; ⁶Univ of California San Francisco, San Francisco, CA, USA; ⁷Yale Univ Sch of Med, New Haven, CT, USA
- 408 CD4/CD8 Ratio Decline and Risk of Neurocognitive Deterioration**
Matteo Vassallo¹; Roxane Fabre²; Jacques Durant³; Christine Lebrun-Frenay⁴; Brigitte Dunais⁵; Muriel Laffon⁶; Francine DeSalvador⁷; Jacqueline Cottalorda⁸; Michel Tichioni⁹; Pierre Dellamonica¹⁰; Christian Pradier¹¹
¹Cntr Hospier de Cannes, Cannes, France; ²Nice Univ Hosp, Nice, France; ³CHU de Nice, Nice, France
- 409 Novel CSF Biomarker Associations With HIV-Associated Neurocognitive Disorder (HAND)**
Asha R. Kallianpur¹; Haley Gittleman²; Scott R. Letendre³; Ron Ellis⁴; Jill Barnholtz-Sloan⁵; William Bush⁶; Robert Heaton⁷; David Samuels⁸; Todd Hulgian⁹; for the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Study Group
¹Cleveland Clinic Lerner Rsr Inst, Cleveland, OH, USA; ²Case Western Reserve Univ, Cleveland, OH, USA; ³Univ of California San Diego, San Diego, CA, USA; ⁴Case Western Reserve Univ Sch of Med, Cleveland, OH, USA; ⁵Univ of California San Diego, La Jolla, CA, USA; ⁶Vanderbilt Univ Sch of Med, Nashville, TN, USA; ⁷Vanderbilt Univ, Nashville, TN, USA
- 410 (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV Infection**
Martin Hoenigl¹; Michelli Faria de Oliveira²; Josué Pérez-Santiago³; Malcolm Finkelman⁴; Yonglong Zhang⁵; Sheldon R. Morris⁶; Ron Ellis⁷; Sara Gianella⁸
¹Univ of California San Diego, San Diego, CA, USA; ²Rsr Lab, Associates of Cape Cod, Inc, Falmouth, MA, USA
- 411 Use of Mass Cytometry to Study Cellular Subsets in CSF and Blood in ART-Treated HIV**
Shang-Lin Chung¹; Diane Trotta²; Leah Le³; Laurie Andrews⁴; Jennifer Chiarella⁵; Khadir Raddassi⁶; Serena S. Spudich⁷; Brinda Emu⁸
¹Yale Univ Sch of Med, New Haven, CT, USA; ²Yale Univ Sch of Med, New Haven, CT, USA
- 412 CNS Drug Distribution and CSF Inflammation During Suppressive Antiretroviral Therapy**
Albert Anderson¹; Jennifer Iudicello²; Asha R. Kallianpur³; Karen Tolentino⁴; Ron Ellis⁵; Igor Grant⁶; Todd Hulgian⁷; **Scott R. Letendre**⁸; for the CHARTER Group
¹Emory Univ, Atlanta, GA, USA; ²Univ of California San Diego, San Diego, CA, USA; ³Cleveland Clinic Lerner Rsr Inst, Cleveland, OH, USA; ⁴Univ of California San Diego, La Jolla, CA, USA; ⁵Vanderbilt Univ, Nashville, TN, USA

413 Role of HCV Coinfection on CSF Biomarkers in HIV Patients

Andrea Antinori¹; Valentina Fedele²; Carmela Pinnetti³; Patrizia Lorenzini⁴; Stefania Carta⁵; Veronica Bordini⁶; Federico Martini⁷; Francesca Ceccherini-Silberstein⁸; Adriana Ammassari⁹; Carlo Federico Perno¹⁰
¹Inst Nazionale Malattie Infettive "L. Spallanzani", Rome, Italy; ²Univ of Rome Tor Vergata, Rome, Italy

414 Psychiatric Symptoms Are Common in Acute HIV and Correlate With Disease Biomarkers

Joanna M. Hellmuth¹; Chun-Zi Peng²; Victor Valcour³; Donn Colby⁴; Ponpen Tantivayakul⁵; Shelly Krebs⁶; Praphan Phanuphak⁷; Serena S. Spudich⁸; Robert Paul⁹; for the RV254/SEARCH 010 Study Group
¹Univ of California San Francisco, San Francisco, CA, USA; ²Missouri Inst for Mental Hlth, St. Louis, MO, USA; ³SEARCH, Bangkok, Thailand; ⁴Military HIV Rsr Prog, Bethesda, MD, USA; ⁵Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁶Yale Univ Sch of Med, New Haven, CT, USA

Session P-G5 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Clinical Distinctions and Therapeutic Response

415 Neurologic Signs and Symptoms Frequently Manifest in Acute HIV Infection

Joanna M. Hellmuth¹; James L. Fletcher²; Victor Valcour³; Eugène Kroon⁴; Jintanat Ananworanich⁵; Linda Jagodzinski⁶; Duangthai Suttichom⁷; Nittaya Phanuphak⁸; Serena S. Spudich⁹; for the SEARCH 010/RV254 Study Group
¹Univ of California San Francisco, San Francisco, CA, USA; ²SEARCH, Bangkok, Thailand; ³Military HIV Rsr Prog, Bethesda, MD, USA; ⁴Yale Univ Sch of Med, New Haven, CT, USA

416 Male/Female Differences in Cognitive Function in HIV+ Individuals

Pauline Maki¹; Leah Rubin²; Gayle Springer³; Ned Sacktor⁴; Eric N. Miller⁵; Victor Valcour⁶; Mary Young⁷; James T. Becker⁸; Eric C. Seaberg⁹; Eileen Martin¹⁰; for the Neurocognitive Working Groups of the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study
¹Univ of Illinois at Chicago, Chicago, IL, USA; ²Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁴Univ of California Los Angeles, Los Angeles, CA, USA; ⁵Univ of California San Francisco, San Francisco, CA, USA; ⁶Georgetown Univ Med Cntr, Washington, DC, USA; ⁷Univ of Pittsburgh, Pittsburgh, PA, USA; ⁸Rush Univ Med Cntr, Chicago, IL, USA

417 CNS Safety of Simplification to ATV/r+3TC in Virologically Suppressed HIV+ Patients

Nicoletta Ciccarelli¹; Massimiliano Fabbiani²; Eugenia Quiros Roldan³; Manuela Colafigli⁴; Antonella Castagna⁵; Roberta Gagliardini⁶; Andrea De Luca⁷; Simona Di Giambenedetto⁸; Roberto Cauda⁹; for the ATLAS-M Study Group
¹Catholic Univ, Rome, Italy; ²Inst of Clinical Infectious Diseases, Catholic Univ of Sacred Heart, Rome, Italy; ³Univ of Brescia, Brescia, Italy; ⁴San Gallicano Dermatological Inst, IRCCS, Rome, Italy; ⁵San Raffaele Scientific Inst, Milan, Italy; ⁶Univ of Siena, Siena, Italy

418 Neurocognitive Improvement With NRTI-Sparing Treatment in Acute HIV Infection

Cynthia Gay¹; Sarah Willits¹; JoAnn D. Kuruc¹; Kara S. McGee²; Angela Kashuba³; Mehri S. McKellar³; Charles B. Hicks³; Joseph J. Eron¹; David M. Margolis¹; Kevin R. Robertson¹

¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Duke Univ, Durham, NC, USA; ³Univ of California San Diego, San Diego, CA, USA

419 HIV Associated Neurocognitive Impairment: A Randomized Controlled Trial of Lithium

Eric H. DeCloedt¹; Carla S. Freeman²; Maia S. Lesosky²; Gary Maartens²; John Joska²

¹Stellenbosch Univ, Tygerberg, South Africa; ²Univ of Cape Town, Cape Town, South Africa

420 Week48 Cognitive Improvement in HAND After Switch to HAART Based on CHARTER Score +3

Gilles Force¹; Valerie Hahn²; Helene Defferriere²; Natacha Darchy⁴; Jacques Ropers⁵; Philippe Aegerter⁶; Constance Delaugerre⁶; Gilles Peytavin¹; Pierre De Truchis³

¹Hosp Franco-Britannique, Levallois-Perret, France; ²Cntr Hospier Sainte-Anne, Paris, France; ³Hosp Raymond Poincaré, APHP, Garches, France; ⁴Inst Hospier Franco-Britannique, Levallois-Perret, France; ⁵Hosp Ambroise Paré, APHP, Boulogne, France; ⁶Hosp Saint Louis et Univ Paris Diderot, Paris, France; ⁷IAME, INSERM UMR 1137, Univ Paris 7 UF 301, Paris, France

421 Statin or ACE/ARB Effects on Neurocognitive Function of HIV-Infected Adults

Kristine M. Erlandson¹; Douglas Kitch²; C. William Wester³; Robert Kalayjian⁴; Edgar T. Overton⁵; Jose R. Castillo-Mancilla⁶; Susan L. Koletar⁷; Constance A. Benson⁸; Kevin R. Robertson⁹; Judith Lok²

¹Univ of Colorado, Denver, CO, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Vanderbilt Inst for Global Hlth, Nashville, TN, USA; ⁴MetroHlth Med Cntr, Cleveland, OH, USA; ⁵Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁶Ohio State Univ, Columbus, OH, USA; ⁷Univ of California San Diego, San Diego, CA, USA; ⁸Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

422 Liver Fibrosis Linked to Cognition in HIV and HCV: The Women's Interagency HIV Study

Victor Valcour¹; Leah Rubin²; Mary Obasi³; Pauline Maki⁴; Mary Young⁵; Wendy Mack⁶; Mardge Cohen⁷; Ada Adimora⁸; Phyllis Tien¹; for the Women's Interagency HIV Study Protocol Team

¹Univ of California San Francisco, San Francisco, CA, USA; ²Univ of Illinois at Chicago, Chicago, IL, USA; ³Georgetown Univ Med Cntr, Washington, DC, USA; ⁴Univ of Southern California, Los Angeles, CA, USA; ⁵John H. Stroger Jr. Hosp of Cook County and Rush Med Coll, Chicago, IL, USA; ⁶Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA

423LB A Randomised Controlled Trial of Maraviroc-Intensified bPI ART on Cognitive Function

Alan Winston¹; George Bouliotis²; Ranjababu Kulaseregaram¹; Amanda Clarke³; Frank A. Post⁴; Mark Nelson⁵; Laura Burgess⁶; Borja Mora-Peris⁷; Steve Taylor⁸; Deborah Ashby⁹

¹Imperial Coll of Sci, Tech and Med, London, UK; ²Imperial College London, United Kingdom; ³St. Thomas' Hosp, London, United Kingdom; ⁴Brighton and Sussex Hosps NHS Trust, Brighton, UK; ⁵King's Coll Hosp NHS Fdn Trust, London, UK; ⁶Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ⁷Birmingham Heartlands Hosp, Birmingham, United Kingdom

424LB Neurocognitive Safety After 96-WKS on ATV/r+3TC: Results of the Randomized SALT Trial

Ignacio Perez-Valero¹; Juan Pasquau²; Rafael Rubio³; Antonio Rivero⁴; Jesús Santos⁵; Jose Sanz⁶; Ana Mariño⁷; Herminia Esteban⁸; Jose Antonio Perez-Molina⁹; for the SALT Study Group

¹Hosp Universitario La Paz, Madrid, Spain; ²Hosp Virgen de las Nieves, Complejo Hospario Universitario Granada, Granada, Spain; ³Hosp Universitario Doce de Octubre, Madrid, Spain; ⁴Hosp Universitario Reina Sofia, Córdoba, Spain; ⁵Hosp Universitario Virgen de la Victoria, Malaga, Spain; ⁶Hosp Universitario Principe de Asturias, Madrid, Spain; ⁷Hosp Arquitecto Marañón, Ferrol, Spain; ⁸Fundación SEIMC-GESIDA, Madrid, Spain; ⁹Hosp Universitario Ramón y Cajal, Madrid, Spain

Session P-H5 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Clinical Pharmacology of Treating Coinfections

451 Antiretroviral Use and Implications for DAA Therapy in HIV/HCV Coinfection

Marianne Martinello¹; Gregory J. Dore²; Jasmine Skurowski¹; Rohan I. Bopage³; Robert Finlayson⁴; David Baker⁵; Mark Bloch⁶; Gail V. Matthews¹

¹Kirby Inst, Univ of New South Wales, Sydney, Australia; ²The Albion Cntr, Sydney, Australia; ³Taylor Square Private Clinic, Sydney, Australia; ⁴East Sydney Doctors, Sydney, Australia; ⁵Holdsworth House Med Practice, Sydney, Australia

452 Real-Life Renal Safety of Boosted TDF in HIV/HCV Patients on SOF/LDV

M.J. Vivancos-Gallego; A. Moreno; María Jesús Pérez-Elias; A. Díaz de Santiago; Carmen Quereda-Rodríguez; J.L. Casado; Sara Bañón; M. Sánchez-Conde; M.L. Mateos; Santiago Moreno
Hosp Universitario Ramón y Cajal, Madrid, Spain

453 Interactions Between ABT-493 Plus ABT-530 Combination and Rilpivirine or Raltegravir

Matthew P. Kosloski¹; Sandeep Dutta¹; Bifeng Ding¹; Stanley Wang¹; Jens Kort²; Wei Liu²; **Rajneet K. Oberoi**¹

¹AbbVie Inc, North Chicago, IL, USA; ²AbbVie Inc, Redwood City, CA, USA

454 Pharmacokinetics of Dolutegravir and Rilpivirine in Combination With SMV and SOF

Marco Merli¹; Laura Galli²; Letizia Marinoaro³; Alexandra Ariaud⁴; Emanuela Messina⁴; Caterina Uberti Foppa⁴; Antonella Castagna⁴; Adriano Lazzarin⁴; Stefano Bonora⁴; Hamid Hasson⁴

¹Vita-Salute San Raffaele Univ, Milan, Italy; ²San Raffaele Scientific Inst, Milan, Italy; ³Univ of Turin, Turin, Italy; ⁴Vita-Salute Univ, San Raffaele Scientific Inst, Milan, Italy

455 Effect of Direct Acting Antivirals on the Pharmacokinetics of Calcineurin Inhibitors

Thibaut Gelé¹; Aurélie Barrail-Tran²; Audrey Coilly³; Claire Laforest⁴; Rodolph Anty⁵; Georges-Philipp Pageaux⁶; Jean-Charles Duclos-Vallée⁷; **Anne-Marie Taburet**¹; for the ANRS CO23 CUPILT study team
¹Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France; ²Hosp Bicêtre, Kremlin Bicêtre, France; ³Hosp Paul Brousse, Villejuif, France; ⁴Hosp Pontchaillou, Rennes, France; ⁵Hosp Nice, Nice, France; ⁶Hosp Montpellier, Montpellier, France

456 Multiple-Dose Treatment With Rifabutin Reduces the Exposure of Doravirine

Sauzanne Khalilieh¹; Kelly Yee¹; Rosa Sanchez¹; Rachael Liu¹; Li Fan¹; Maureen Martell¹; Radu Pop²; Heather Jordan³; Marian Iwamoto¹
¹Merck & Co, Inc, Kenilworth, NJ, USA; ²Pharma Medica Rsr, Inc, Mississauga, ON, Canada; ³Pharma Medica Rsr, Inc, St. Charles, MO, USA

457 Pharmacokinetics of Anti-TB Drugs in HIV-Infected and -Uninfected Children With TB

Agibothu Kupparam Hemanth Kumar¹; Geetha Ramachandran¹; T. Kannan¹; P.K. Bhavani¹; S. Ramesh Kumar¹; N. Ravichandran¹; S. Kalpana¹; G. N. Sanjeeva¹; Dipti Agarwal¹; Soumya Swaminathan¹
¹Natl Inst for Rsr in Tuberculosis, Chennai, India; ²Government Hosp of Thoracic Med, Chennai, India; ³Inst of Child Hlth, Chennai, India; ⁴Indira Gandhi Inst of Child Hlth, Bengaluru, India; ⁵Sarajini Naidu Med Coll, Agra, India

458 Optimal Use of Efavirenz in HIV+/TB+ Coinfected Children Aged 3 to 24 months

Carolyn Moore¹; Pearl Samson²; Edmund Capparelli³; Mutsawashe Bwakura-Dangarembizi⁴; Patrick Jean-Philippe⁵; Nahida Chakhtoura⁶; Alex Benns⁷; Bonnie Zimmer⁸; Chivon McMullen-Jackson⁹; Ellen G. Chadwick⁹
¹Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ²Harvard Sch of PH, Boston, MA, USA; ³Univ of California San Diego, San Diego, CA, USA; ⁴Univ of Zimbabwe, Harare, Zimbabwe; ⁵Henry M. Jackson Fndn for the Advancement of Military Med, Inc, Rockville, MD, USA; ⁶Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁷Frontier Sci & Tech Rsr Fndn, Inc, Amherst, MA, USA; ⁸Baylor Coll of Med, Houston, TX, USA; ⁹Northwestern Univ, Chicago, IL, USA

459 Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro

Owain Roberts; David J. Back; Saye Khoo; Andrew Owen; Marco Siccardi
Univ of Liverpool, Liverpool, UK

460 HIV-1 Attachment Inhibitor Prodrug BMS-663068: PK Assessment With Rosuvastatin

Ishani Landry; Blisse Vakkalagadda; Susan Lubin; Michael Hesney; Jian Wang; Frank LaCreta; Timothy Eley
Bristol-Myers Squibb, Princeton, NJ, USA

461LB Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment-Naïve Patients

Didier Scherrer¹; Jean-Marc Steens²; Supparatpinyo Kuanchai³; Ratanasuwani Winai⁴; Kiat Rungrungham⁵; Regine Rouzier⁶; Jamal Tazi⁷; Paul Gineste⁸; Hartmut Ehrlich⁹; Robert Murphy¹⁰
¹ABIVAX, Montpellier, France; ²ABIVAX, Paris, France; ³Rsr Inst for Hlth Sciences, Chiang Mai Univ, Chiang Mai, Thailand; ⁴Sriraj Hosp, Bangkok, Thailand; ⁵HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁶Cap Rsr, Phoenix, Mauritius; ⁷Univ of Montpellier, Montpellier, France; ⁸ABIVAX SA, Paris, France; ⁹Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA

Session P-11 Poster Abstracts 2:45 PM-4:00 PM

Hall A/B

Preclinical Studies of Activity and Resistance

462 A Quantitative Model of ART Efficacy Explains the Clinical Success of Dolutegravir

Sarah B. Laskey¹; Robert Siliciano²
¹Johns Hopkins Univ, Baltimore, MD, USA; ²Howard Hughes Med Inst, Baltimore, MD, USA

463 HIV-1 Transcription Inhibition by New p300 Inhibitors

Kotaro Shirakawa¹; Melanie Ott²; Eric Verdin²
¹Kyoto Univ, Kyoto, Japan; ²Gladstone Inst of Virology and Immunology, San Francisco, CA, USA

464 Maturation Inhibitor BMS-955176: Activity Against PI-Resistant Clinical Isolates

Neelanjana Ray¹; Tianbo Li²; Tricia Protack²; Zeyu Lin²; Petronella M. van Ham³; Carey Hwang³; Mark Krystal³; Monique Nijhuis³; Max Lataillade³; Ira B. Dicker²
¹Bristol-Myers Squibb, Princeton, NJ, USA; ²Bristol-Myers Squibb, Wallingford, CT, USA; ³Univ Med Cntr Utrecht, Utrecht, Netherlands

465 Resistance Pathways for Potent and Broadly Active HIV-1 Maturation Inhibitors

Emiko Urano¹; Sherimay D. Ablan¹; Justin A. Kaplan¹; Nishani Kuruppu¹; David E. Martin²; Theodore J. Nitz²; Carl T. Wild²; Eric O. Freed¹
¹NCI, Frederick, MD, USA; ²DFH Pharma, Inc, Gaithersburg, MD, USA

466 Maturation Inhibitor BMS-955176: Integrated Model of Polymorphic Antiviral Responses

Zeyu Lin; Joseph Cantone; Hao Lu; Beata Nowicka-Sans; Tricia Protack; Dieter Drexler; Mark Cockett; Mark Krystal; Alicia Regueiro-Ren; Ira Dicker
Bristol-Myers Squibb, Wallingford, CT, USA

467 Reduction of SIV-Mediated Immune Activation by p38 MAPK In Vivo Inhibition

Omkar Chaudhary¹; Vivek Narayan¹; Ronald Veazey²; Anna Aldovini¹
¹Boston Children's Hosp, Harvard Med Sch, Boston, MA, USA; ²Tulane Natl Primate Rsr Cntr, Covington, LA, USA

468 PBMC From Patients on Chronic Treatment With Dasatinib Are Resistant to HIV Infection

Mayte Coiras¹; Mercedes Bermejo¹; Javier Garcia-Perez¹; Benjamin Descours²; Juan Ambrosioni¹; Nuria Climent¹; Monsef Benkirane¹; José M. Miño³; Montserrat Plana⁴; José Alcamí¹
¹Inst de Salud Carlos III, Madrid, Spain; ²Inst de Genetique Humaine, Montpellier, France; ³Hosp Clinic-IDIBAPS, Univ de Barcelona, Barcelona, Spain; ⁴IDIBAPS, Barcelona, Spain

469LB Efficacy of an Engineered Bispecific Anti-HIV Antibody in Humanized Mice

Anastasia Lanzi¹; Yaoming Huang¹; Jian Yu¹; Chasity D. Andrews¹; Xin Yao¹; Lily Tsai¹; Mili R. Gajjar¹; Michael Seaman¹; Neal N. Padte¹; David D. Ho¹
¹Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ²Harvard Med School, Boston, MA, USA

Session P-L3 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

HIV Drug Resistance in Different Drug Classes

- 504 Incompatibility of HIV-1 Resistance to Both Cenicriviroc and Neutralizing Antibodies**
Takeo Kuwata¹; Ikumi Enomoto¹; Masanori Baba²; Shuzo Matsushita¹
¹Kumamoto Univ, Kumamoto, Japan; ²Kagoshima Univ, Kagoshima, Japan
- 505 Molecular Dynamics of the CD4-Mimetic Resistant HIV-1 Gp120 by MD Simulation**
Shigeyoshi Harada¹; Masaru Yokoyama²; Shuzo Matsushita³; Hironori Sato⁴; Tetsuro Matano¹; Kazuhisa Yoshimura¹
¹Natl Inst of Infectious Diseases, Shinjuku, Japan; ²Natl Inst of Infectious Diseases, Musashimurayama, Japan; ³Kumamoto Univ, Kumamoto, Japan
- 506 Suppress NNRTI-Resistant Mutants by Doravirine at Clinically Relevant Concentrations**
Ming-Tain Lai; Nancy Sachs; MeiZhen Feng; Min Xu; Jay Grobler; Wade Blair; Mike Miller; Daria J. Hazuda
 Merck & Co, Inc, West Point, PA, USA
- 507 The Effect of E157Q in HIV-1 Integrase on R263K-Mediated Dolutegravir Resistance**
Kaitlin Anstett¹; Vincent Cutillassi²; Robert Fusco¹; Thibault Mesplede²; Bonnie A. Spira³; Mark A. Wainberg³
¹McGill Univ, Montreal, QC, Canada; ²McGill Univ AIDS Cntr, Montreal, QC, Canada

Session P-L4 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

HIV-2 Drug Resistance

- 508 Drug Resistance Mutations in HIV-2 Patients Failing Raltegravir and Dolutegravir**
Silvia Requena¹; Carmen de Mendoza²; Teresa Cabezas³; Rosa García⁴; Maria Jose Amengual⁵; Ana Belen Lozano⁶; Juan Manuel Fernandez⁷; Vicente Soriano⁸; Ana Treviño⁹; for the Spanish HIV-2 Study Group
¹Puerta de Hierro Rsr Inst, Majadahonda, Spain; ²La Paz Univ Hosp, Madrid, Spain; ³Hosp de Poniente, Almería, Spain; ⁴Hosp Universitario Fundación Jiménez Díaz, Madrid, Spain; ⁵Corporación Sanitaria Parc Taulí, Barcelona, Spain; ⁶Hosp La Paz, Madrid, Spain; ⁷Hosp Universitario Puerta de Hierro de Madrid, Madrid, Spain
- 509 Prevalence of Minority Resistant Variants in HIV-2 Naïve Patients: ANRS C05 Cohort**
 Alexandre Storto¹; Benoit Visseaux²; Gilles Collin³; Catherine Fagard⁴; Marine Naudin⁵; Florence Diamond⁶; Marie-Aude Khuong⁷; Sophie Matheron⁸; Diane Descamps⁹; **Charlotte Charpentier**²
¹Hosp Bichat-Claude Bernard, Paris, France; ²INSERM UMR 1137, Paris, France; ³CMG-EC de l'INSERM U897, Bordeaux, France; ⁴Hosp Delafontaine, Paris, France; ⁵Hosp Bichat-Claude Bernard, Paris, France

Session P-M3 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Detecting HCV

- 525 Comparison of 4 HCV Viral Load Assays at High Viral Load**
 Robert Ehret¹; Marcel Schütze¹; Andrew Moritz²; Hauke Walter²; Gunnar Schallasta³; Annemarie Berger⁴; **Martin J. Obermeier**¹
¹Med Cntr for Infectious Diseases, Berlin, Germany; ²Medizinisches Infektiologiezentrum Berlin, Berlin, Germany; ³Prof Gisela Enders & Kollegen MVZ GbR, Stuttgart, Germany; ⁴Inst of Virology, Univ of Frankfurt, Frankfurt, Germany
- 526 HCV Ag Core's Screening Performance in Mono-Infected, HIV- and HBV-Coinfected Patients**
Léa Duchesne¹; Richard Njouom²; Frédéric L. Lissock²; Ghislaine Flore Tamko-Mella²; Alexandre Soulier³; Stephane Chevaliez²; Karine LaCombe⁴; Nicolas Rouveau⁵; Lila Poiteau⁶; Sandrine Rallier⁶
¹INSERM, UMR-S 1136, Paris, France; ²Inst Pasteur of Cameroon, Yaounde, Cameroon; ³INSERM U955, Créteil, France; ⁴Sorbonne Univs, Paris, France; ⁵Natl Agency of Rsr on AIDS and Viral Hepatitis, Paris, France; ⁶Natl Reference Cntr for Viral Hepatitis B, C and Delta, Hosp Henri Mondor, Univ Paris-Est, Créteil, France

Session P-N8 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Acute HCV Infection

- 590 Incidence/Deaths Related to Acute Hepatitis C in Spain: Impact of HIV/HCV Coinfection**
 Alejandro Alvaro-Meca¹; Asuncion Diaz²; Marta Sánchez-Carrillo³; Sonia Vázquez-Morón⁴; Salvador Resino⁵; **Verónica Briz**²
¹Univ Rey Juan Carlos, Alcorcón, Spain; ²Inst de Salud Carlos III, Madrid, Spain

Session P-N9 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Hepatitis A, D, and E

- 591 Hepatitis A Virus Vaccination and Immunity Among at Risk HIV-Infected Adults**
Nicholas P. DeGroot¹; Christine Mattson¹; Yunfeng Tie²; John T. Brooks³; Shikha Garg⁴
¹CDC, Atlanta, GA, USA; ²ICF Intl, Atlanta, GA, USA
- 592 Antiretroviral Therapy and Hepatitis Delta Replication in HIV-Coinfected Patients**
Charles Béguelin¹; Darius Moradpour²; Roland Sahli³; Huldrych F. Günthard⁴; Manuel Battegay⁵; Alexandra L. Calmy⁶; Enos Bernasconi⁷; Andri Rauch⁸; Gilles Wandeler⁹; for the Swiss HIV Cohort Study
¹Bern Univ Hosp and Univ of Bern, Bern, Switzerland; ²CHU Vaudois, Univ of Lausanne, Lausanne, Switzerland; ³Inst of Microbiology, CHU Vaudois, Univ of Lausanne, Lausanne, Switzerland; ⁴Univ Hosp Zurich, Zurich, Switzerland; ⁵Univ Hosp Basel, Basel, Switzerland; ⁶Univ Hosp Geneva, Univ of Geneva, Geneva, Switzerland; ⁷Regional Hosp Lugano, Lugano, Switzerland; ⁸Univ Hosp Bern, Bern, Switzerland

593 Acute and Chronic Hepatitis E Virus Infection in HIV-Infected United States Women

Mark H. Kuniholm¹; Edgar Ong²; Boris M. Hogema³; Marco Koppelman⁴; Kathryn Anastos⁵; Marion Peters⁶; Eric C. Seaberg⁷; Chloe Thio⁸; Kenrad E. Nelson⁹; Jeffrey Linnen⁷

¹Albert Einstein Coll of Med, Bronx, NY, USA; ²Hologic, Inc., San Diego, CA, USA; ³Sanguin Rsr and Diagnostics, Amsterdam, Netherlands; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁶Johns Hopkins Univ, Baltimore, MD, USA; ⁷Hologic, Inc, San Diego, CA, USA

594 High Prevalence of Anti-HEV IgG Is Not Associated With HIV Infection in Rakai, Uganda

Denali Boon¹; Andrew D. Redd²; Oliver Laeyendecker³; Ponsiano Ocama⁴; Steven J. Reynolds⁵; Ronald H. Gray⁶; Robert H. Purcell⁷; Thomas C. Quinn⁸; Lara Stabinski⁹; for the Rakai Health Sciences Program

¹Johns Hopkins Univ, Baltimore, MD, USA; ²NIAID, NIH, Bethesda, MD, USA; ³NIH, Bethesda, MD, USA; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁵Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁷Office of the US Global AIDS Coordinator, US Dept of State, Washington, DC, USA

Session P-N10 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Pathogenesis of HCV Infection: Activation and Exhaustion

595 Oxylipin Metabolites As Markers of Inflammation and Liver Disease in HCV Infection

Susanna Naggie¹; Eric G. Meissner²; Lisa St. Johns-Williams³; Will Thompson⁴; Derek Cyr⁵; Joseph Lucas⁶; Arthur Moseley⁷; Shyam Kottilli⁸; Keyur Patel⁹

¹Duke Univ Sch of Med, Durham, NC, USA; ²Med Univ of South Carolina, Charleston, SC, USA; ³Duke Univ, Durham, NC, USA; ⁴Univ of Maryland Med Cntr, Baltimore, MD, USA; ⁵Duke Clinical Rsr Inst, Durham, NC, USA

596 WITHDRAWN

597 Understanding the Relative Contributions of IDU and HCV on Systemic Immune Activation

Martin Markowitz¹; Sherry Deren²; Charles Cleland³; Melissa LaMar; Evelyn Silva⁴; Pedro Batista⁵; Leslie St. Bernard⁶; Natanya Gettie⁷; Haekyung Lee⁸; Saurabh Mehandru⁹

¹Aaron Diamond AIDS Rsr Cntr, New York, NY, USA; ²Cntr for Drug Use and HIV Rsr, New York Univ Coll of Nursing, New York, NY, USA; ³BOOMHlth, Bronx, NY, USA; ⁴Icahn Sch of Med at Mount Sinai, New York, NY, USA

598 Mucosal-Associated Invariant T (MAIT) Cells in HIV/HCV Coinfection

Maddalena Cerrone¹; Esther Merlini²; Bonnie van Wilgenburg³; Leo Swadling⁴; Camilla Tincati⁵; Stefania Cannizzo⁶; Anna De Bona⁷; Antonella d'Arminio Monforte⁸; Paul Klenerman⁹; Giulia Marchetti⁴

¹Univ of Milan, Milan, Italy; ²Univ of Oxford, Oxford, UK; ³Infectious Diseases Clinic, San Paolo Hosp, Univ of Milan, Milan, Italy; ⁴Clinic of Infectious Diseases, Univ of Milan, San Paolo Hosp, Milan, Italy

599 Hepatic & Peripheral Responses to 2 Different DAA Regimens in HIV/HCV Coinfection

Louisa C. Howard¹; Anita Kohli²; Julia Purdy³; Elana S. Rosenthal⁴; Shikha Shrivastava⁵; Bhawna Poonia⁶; Henry Masur⁷; Shyam Kottilli⁸; Eleanor M. Wilson⁹

¹NIH, Bethesda, MD, USA; ²Dignity Hlth, St. Joseph's Hosp, Phoenix, AZ, USA; ³The Inst of Human Virology, Univ of Maryland, Baltimore, MD, USA; ⁴Univ of Maryland Med Cntr, Baltimore, MD, USA; ⁵Inst of Human Virology, Baltimore, MD, USA

600 Intrahepatic Immune Composition Changes Markedly With Interferon-Free HCV Treatment

Cody Orr¹; Johannes Aartun²; Henry Masur³; Shyam Kottilli⁴; **Eric G. Meissner**⁵

¹Med Univ of South Carolina, Charleston, SC, USA; ²NIH, Bethesda, MD, USA; ³Univ of Maryland Med Cntr, Baltimore, MD, USA

601 GWAS of Relapse in HIV-1/HCV Coinfected Patients Treated With LDV/SOF in ION-4

Sarah E. Kleinstein¹; Patrick R. Shea²; Luisa M. Stamm³; Jenny C. Yang⁴; Philip S. Pang⁵; Mani Subramanian⁶; John G. McHutchison⁷; Mark Sulkowski⁸; David V. Goldstein⁹; Susanna Naggie⁴

¹Columbia Univ, New York, NY, USA; ²Gilead Scis, Inc, Foster City, CA, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Duke Univ Sch of Med, Durham, NC, USA

602 Pacbio Sequencing of the HCV Envelope: From Early Acute to Chronic Infection

Cynthia K. Ho¹; Jayna Raghwani²; Sylvie M. Koekoek³; Richard Liang⁴; Menno D. de Jong⁵; Oliver Pybus⁶; Richard Molenkamp⁷; **Janke Schinkel**⁸

¹Academic Med Cntr, Amsterdam, Netherlands; ²Univ of Oxford, Oxford, UK; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada

Session P-N11 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

HCV: The Virus Is Gone; The Morbidity Not So Much

603 Frequency and Predictors of Liver Function Impairment in Cirrhotic Patients Treated With DAAs

Karin Neukam¹; Rafael Granados²; Luis E Morano-Amado³; Manuel Márquez⁴; Francisco Téllez⁵; María José Ríos⁶; José Hernández-Quero⁷; Edward R. Cachay⁸; Juan A. Pineda⁹; for the Grupo de Estudio de Hepatitis Virica, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC; Grupo de Estudio de Hepatitis Virica, Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR; RIS-HEP07

¹Valme Univ Hosp, Seville, Spain; ²Hosp Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain; ³Hosp Universitario Alvaro Cunqueiro, Vigo, Spain; ⁴Hosp Universitario Virgen de la Victoria, Málaga, Spain; ⁵Hosp La Línea de la Concepción (AGS Campo de Gibraltar), La Línea de la Concepción, Spain; ⁶Hosp Universitario Virgen de la Macarena, Seville, Spain; ⁷Hosp Universitario San Cecilio, Granada, Spain; ⁸Univ of California San Diego, San Diego, CA, USA; ⁹Hosp Universitario de Valme, Sevilla, Spain

604 Liver Cancer After Hep C Cure: Less Cirrhosis and Less Liver Fat Than Expected

Andrea Branch; Chiara Rocha; M. I. Fiel; Erin Doyle; Nicholas Goosens; Yujin Hoshida; Thomas Schiano; Myron Schwartz
Ichahn Sch of Med at Mount Sinai, New York, NY, USA

605 Residual Risk of Disease Progression After Hepatitis C Cure in HIV-HCV Patients

Dominique Salmon-Ceron¹; Camille Gilbert²; Philippe Sogni¹; Francois Dabis³; Julie Bottero⁴; Patrick Mialhes⁵; Lionel Piroth⁶; Firouze Bani-Sadr⁷; Linda Wittkop⁸; for the the ANRS C013 Hepaviv Study Group
¹INSERM-APHP, Hosp Cochin, Paris, France; ²INSERM, Bordeaux, France; ³INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France; ⁴Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France; ⁵CHU Lyon, Lyon, France; ⁶CHU Dijon, Dijon, France; ⁷CHU Reims, Reims, France; ⁸CHU de Bordeaux, Bordeaux, France

606 Hepatitis C Genotype 6 Is Associated With Progression of Liver Fibrosis in HIV Patients

Anchalee Avihingsanon¹; Suparat Khemmark²; Tanakorn Apornpong³; Sivaporn Kukanok⁴; Vorapot Sapsirisiravat⁵; Salyavit Chittmittrapap²; Stephen J. Kerr¹; Sombat Treeprasertsuk²; Pisit Tankijvanich²; Kiat Ruxrungham²; for the HCV Study Team
¹HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ²Chulalongkorn Univ, Bangkok, Thailand

607 Impact of Occult HBV Infection in HCC Presentation in HCV-Related Cirrhosis

Nicola Coppola¹; Valentina Lodice²; Mario Starace¹; Carmine Minichini¹; Nunzia Farella¹; Lorenzo Onorato¹; Giulia Liorre¹; Evangelista Sagnelli¹; Giorgio De Stefano²
¹Second Univ of Naples, Naples, Italy; ²AORN dei Colli, P.O. Cotugno, Naples, Italy

Session P-N12 Poster Abstracts Hall A/B
2:45 PM-4:00 PM

HCV Mischieff From Beyond the Liver

608 CB2-63 RR Variant Is Associated With Immune-Mediated Disorders in HCV Patients

Nicola Coppola; Rosa Zampino; Giulia Bellini; Maria Stanzone; Nicolina Capoluongo; Margherita Macera; Luigi E. Adinolfi; Emanuele Miraglia Del Giudice; Evangelista Sagnelli; Francesca Rossi
Second Univ of Naples, Naples, Italy

609 Prevalence and Risk Factors of Low Muscle Mass in HIV/ Viral Hepatitis Coinfection

Charitha Gowda¹; Todd T. Brown²; Charlene Compher¹; Kimberly A. Ford¹; Jay R. Kostman³; Pamela A. Shaw⁴; Phyllis Tien⁵; Vincent Lo Re¹
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³John Bell Hlth Cntr, Philadelphia, PA, USA; ⁴Univ of Pennsylvania, Philadelphia, PA, USA; ⁵Univ of California San Francisco, San Francisco, CA, USA

610 Rapid Improving of Glycemic Control in HCV Patients Treated With IFN-Free Regimens

Paolo Pavone; Tiziana Tieghi; Gabriella D'Etorre; Miriam Lichtner; Raffaella Morocco; Ivano Mezzaroma; Giulia Passavanti; Claudio M. Mastroianni; Vincenzo Vullo
Sapienza Univ of Rome, Rome, Italy

611 Eradication of HCV and Extrahepatic Comorbidities in HIV/HCV Coinfection

Juan Berenguer¹; Miguel A. Von Wichmann²; José López-Aldeguer³; María J. Galindo⁴; Josep Mallolas⁵; Manel Crespo⁶; María J. Tellez⁷; José M. Bellón⁸; Juan González-García⁹; for the GeSIDA 3603 Study Group
¹Hosp General Universitario Gregorio Marañón, Madrid, Spain; ²Hosp Universitario Donostia, San Sebastián, Spain; ³Hosp Universitari i Politècnic La Fe, Valencia, Spain; ⁴Hosp Clínico Universitario de Valencia, Valencia, Spain; ⁵Hosp Clinic de Barcelona, Barcelona, Spain; ⁶Hosp Universitari Vall d Hebron, Barcelona, Spain; ⁷Hosp Clinico San Carlos, Madrid, Spain; ⁸Inst for Hlth Rsr of La Paz Univ Hosp, Madrid, Spain

612 Hepatitis C and the Risk of Non-Liver-Related Morbidity and Mortality in HIV+ Persons

Helen Kovari¹; Rainer Weber²; Alexandra L. Calmy³; Matthias Cavassini⁴; Marcel Stoeckle⁵; Patrick Schmid⁶; Enos Bernasconi⁷; Andri Rauch⁸; Bruno Ledergerber⁹; for the Swiss HIV Cohort Study
¹Univ Hosp Zurich, Zurich, Switzerland; ²Univ Hosp Geneva, Univ of Geneva, Geneva, Switzerland; ³Univ Hosp Lausanne, Univ of Lausanne, Lausanne, Switzerland; ⁴Univ Hosp Basel, Basel, Switzerland; ⁵Cantonal Hosp, St Gall, Switzerland, St Gall, Switzerland; ⁶Regional Hosp Lugano, Lugano, Switzerland; ⁷Bern Univ Hosp and Univ of Bern, Bern, Switzerland

Session P-03 Poster Abstracts Hall A/B

2:45 PM-4:00 PM
Lymphoma and Kaposi Sarcoma

629 APOBEC3 Boosters Kill Primary Effusion Lymphoma and Other Cancer Cell Lines

Chisu Song¹; Gary Schiltz²; Meejeon Roh³; Isabelle Clerc¹; Neha Malik¹; Hannah Hudson¹; Kiwon Nam¹; **Richard T. D'Aquila**¹
¹Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ²Northwestern Univ, Chicago, IL, USA

630 Risk Factors for Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL) in Europe

Leah Shepherd¹; Alvaro H. Borges²; Johannes Bogner³; Andrzej Horban⁴; Elena Kuzovatova⁵; Manuel Bategay⁶; Marcelo Lasso⁷; Jens D. Lundgren⁸; Amanda Mcoffret¹; for the EuroSIDA in EuroCOORD
¹Univ Coll London, London, UK; ²CHIP Rigshospitalet, Univ of Copenhagen, Copenhagen, Denmark; ³Medizinische Poliklinik, Munich, Germany; ⁴Hosp for Infectious Diseases in Warsaw, Med Univ of Warsaw, Warsaw, Poland; ⁵Academician Blokhina Nizhny Novgorod Rsr Inst of Epi and Microbiology, Novgorod, Russian Federation; ⁶Univ Hosp Basel, Basel, Switzerland; ⁷Hosp J.M. Ramos Mejia, Buenos Aires, Argentina; ⁸Rigshospitet, Univ of Copenhagen, Copenhagen, Denmark

631 Kaposi Sarcoma Survival in Adults: The South African Antiretroviral Treatment Era

Mazvita M. Sengayi¹; Danuta M. Kielkowski¹; Matthias Egger²; Lydia Dreoosi³; Julia Bohlius⁴
¹Natl Cancer Registry, NHLS, Johannesburg, South Africa; ²Univ Hosp Bern, Bern, Switzerland; ³Univ of Pretoria and Steve Biko Academic Hosp, Pretoria, South Africa; ⁴Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland

Session P-04 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Other Cancers and Risk of Malignancies in HIV

632 HIV Testing, Status, and Treatment Among Patients at the Uganda Cancer Institute

Matine Ghadrshenas¹; Rachel A. Bender Ignacio¹; Daniel H. Low¹; Warren T. Phipps²; Jackson Orem³; Ann Duerr²; Corey Casper²
¹Univ of Washington, Seattle, WA, USA; ²Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³Uganda Cancer Inst, Kampala, Uganda

633 Low CD4/CD8 Ratio As a Predictor of Cancer Risk in HIV-Infected Persons

Keith M. Sigel¹; Brinda Emu²; Lesley Park³; Kristina Crothers⁴; Cynthia Gibert⁵; Matthew Goetz⁶; Sheldon Brown⁷; Maria Rodriguez-Barradas⁸; Janet Tate⁹; Robert Dubrow¹⁰
¹Icahn Sch of Med at Mount Sinai, New York, NY, USA; ²Yale Univ Sch of Med, New Haven, CT, USA; ³Stanford Univ, Stanford, CA, USA; ⁴Univ of Washington Sch of Med, Seattle, WA, USA; ⁵VA Med Cntr, Washington, DC, USA; ⁶VA Greater Los Angeles Hlthcare System, Los Angeles, CA, USA; ⁷James J. Peters VA Med Cntr, Bronx, NY, USA; ⁸Michael E. DeBakey VA Med Cntr and Baylor Coll of Med, Houston, TX, USA; ⁹VA Med Cntr, West Haven, CT, USA; ¹⁰Yale Univ Sch of PH, New Haven, CT, USA

634 Real-Life Experience With Sofafenib for the Treatment of HCC in HIV-Infected Patients

Nicolás Merchante¹; Esperanza Merino²; Boris Revollo³; Francisco Rodríguez-Arondo⁴; Marcial Delgado-Fernández; José López-Aldeguer⁵; Francisco Téllez²; María J. Galindo⁶; Koldo Aguirrebengoa⁷; Juan A. Pineda⁸; for the Grupo de Estudio de Hepatitis Viricas de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; GEHEP-SEIMC
¹Hosp Universitario de Valme, Sevilla, Spain; ²Hosp General Universitario de Alicante, Alicante, Spain; ³Hosp German Trias i Pujol, Badalona, Spain; ⁴Hosp Universitario de Donostia, San Sebastián, Spain; ⁵Hosp Regional de Málaga, Málaga, Spain; ⁶Hosp Universitari i Politècnic La Fe, Valencia, Spain; ⁷Hosp La Línea de la Concepción (AGS Campo de Gibraltar), La Línea de la Concepción, Spain; ⁸Hosp Clínico Universitario de Valencia, Valencia, Spain; ⁹Hosp de Cruces, Baracaldo, Spain

635 Decreased *Helicobacter pylori* Prevalence in HIV-Infected Subjects

Christian Schulz¹; Michael Selgrad²; Peter Malfertheiner¹
¹Univ of Magdeburg, Magdeburg, Germany; ²Univ of Regensburg, Regensburg, Germany

Session P-P5 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

Cholesterol Metabolism

664 Cholesterol Efflux in Newly Diagnosed HIV and Effects of Antiretroviral Therapy

Mabel Toribio¹; Markella V. Zanni¹; Gregory Robbins¹; Amanda Martin¹; Tricia H. Burdo²; Min Hi Park³; Meghan Feldpausch³; Kathy Melbourne³; Michael Fitzgerald¹; Steven K. Grinspoon¹
¹Massachusetts General Hosp, Boston, MA, USA; ²Boston Coll, Chestnut Hill, MA, USA; ³Gilead Scis, Inc, Foster City, CA, USA

665 Dysregulated Monocyte Cholesterol Metabolism Gene Expression With ART Initiation

Jane A. O'Halloran¹; Robert T. Maughan¹; Eoin R. Feeney¹; John Lambert²; Gerard Sheehan³; Graeme Moyle¹; Anton N. Pozniak¹; Peter Reiss⁴; Patrick Mallon¹
¹Univ Coll Dublin, Dublin, Ireland; ²Mater Misericordiae Univ Hosp, Dublin, Ireland; ³Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ⁴Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands

Session P-P6 Poster Abstracts
2:45 PM-4:00 PM

Hall A/B

NRTI Toxicities

666 Metabolic Profiles After Switch From Failing First-Line ART in the Second-Line Study

Mark Boyd¹; Amanda H. Yao¹; Cecilia Moore¹; David Cooper²; for the SECOND-LINE Study Group
¹Kirby Inst, Univ of New South Wales, Sydney, Australia; ²Kirby Inst, Sydney, Australia

667 Variation in EraP Influences Risk for HLA-B*57:01 Positive Abacavir Hypersensitivity

Rebecca Pavlos¹; Kaija Strautins¹; Ian James¹; Simon Mallal¹; Alec Redwood²; **Elizabeth J. Phillips²**
¹Inst for Immunology & Infectious Diseases, Murdoch Univ, Murdoch, Australia; ²Vanderbilt Univ Sch of Med, Nashville, TN, USA

668 AZT/NNRTI Induce Greater Adipose Tissue Mitochondrial Toxicity Than AZT/PI

Robert T. Maughan¹; Elena Alvarez²; Anthony Kelleher²; David Cooper³; Andrew Carr³; Patrick Mallon¹; for the HAMAO01 Study Investigators
¹Univ Coll Dublin, Dublin, Ireland; ²Univ of New South Wales, Sydney, Australia; ³Kirby Inst, Sydney, Australia; ⁴St Vincent's Hosp, Sydney, Sydney, Australia

669 Regulation of Telomerase Activity in PBMCs Exposed to Antiretroviral Drugs

Natalia C. Stella Ascariz¹; Rocío Montejano¹; Laura Pintado²; Susana Monge³; José I. Bernardino⁴; Ignacio Pérez-Valero⁵; María L. Montes¹; Jesús Mingorance¹; Rosario Perona⁶; Jose R. Arribas¹
¹Inst for Hlth Rsr of La Paz Univ Hosp, Madrid, Spain; ²Inst de Investigaciones Biomédicas, Madrid, Spain; ³Univ de Alcalá, Madrid, Spain

670 Risk Factors of Short Telomere Length and Decreased Mitochondrial DNA in HIV Patients

Rumi Minami¹; Soichiro Takahama¹; Yu Kaku¹; Masahiro Yamamoto
Natl Hosp Org, Kyushu Med Cntr, Fukuoka, Japan

Session P-P7 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Oxidized Lipids: Associations With Outcomes and Impact of Interventions

- 671 CRP, D-dimer, and Oxidized LDL Predict Myocardial Infarction in Treated HIV Infection**
Peter W. Hunt¹; Heidi M. Crane²; Daniel Drozd³; Michelle Floris-Moore⁴; Richard Moore⁵; Mari M. Kitahata⁶; Michael S. Saag⁷; Michael M. Lederman⁸; Jeffrey N. Martin⁹; for the CFAR Network of Integrated Clinical Systems (CNICS)
¹Univ of California San Francisco, San Francisco, CA, USA; ²Univ of Washington, Seattle, WA, USA; ³Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁴Johns Hopkins Univ, Baltimore, MD, USA; ⁵Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁶Case Western Reserve Univ, Cleveland, OH, USA
- 672 Lack of Associations of Oxidized Lipoproteins With Atherosclerosis in HIV: ACTG A5260**
Theodoros Kelesidis¹; Thuy T. Tran²; Todd T. Brown³; Carlee B. Moser⁴; Heather J. Ribaud⁵; Michael Dube⁶; Robert Murphy⁷; Otto Yang⁸; Grace A. McCormey⁹; James H. Stein¹⁰; Judith S. Currier¹¹
¹David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Keck Sch of Med at the Univ of Southern California, Los Angeles, CA, USA; ⁵Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ⁶Case Western Reserve Univ, Cleveland, OH, USA; ⁷Univ of Wisconsin-Madison, Madison, WI, USA
- 673 Statin Effects on oxLDL in Relationship to Plaque and Arterial Inflammation in HIV**
Eric Nou¹; Michael Lu; Sara E. Looby; Kathleen Fitch; Elli Kim; Hang Lee; Udo Hoffmann; Steven Grinspoon; Janet Lo
Massachusetts General Hosp, Boston, MA, USA

Session P-P8 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Smoking: More Ways It Can Harm

- 674 The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status**
Corryllyn O. Hileman¹; Chris T. Longenecker²; Danielle Labbato³; Bruce Kinley⁴; Grace A. McCormey⁵
¹MetroHlth Med Cntr, Cleveland, OH, USA; ²Case Western Reserve Univ, Cleveland, OH, USA
- 675 Coronary Artery Calcification on Chest Computed Tomography in HIV-Infected Smokers**
Alain Makinson¹; Sabrina Eymard-Duvernay²; Iskander Bouassida³; François Raffi⁴; Sophie Abgrall⁵; Pierre Tattevin⁶; Vincent Le Moing⁷; Jacques Reynes⁸; Sébastien Bommart⁹; for the ANRS EP48 HIV CHEST Study Team
¹Univ Hosp Montpellier, Montpellier, France; ²INSERM, Montpellier, France; ³Univ Hosp Nantes, Nantes, France; ⁴Univ Hosp Antoine-Béclère, Clamart, France; ⁵Pontchaillou Univ Hosp, Rennes, France

Session P-P9 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Noncommunicable Diseases in Low- and Middle-Income Countries

- 676 Incidence and Predictors of Hypertension Among HIV Patients in Rural Tanzania**
Eduardo Rodriguez-Arbol¹; Kim Mwamelo²; Aneth Y. Kalinjuma³; Hansjakob Furrer⁴; Christoph Hatz⁵; Marcel Tanner⁶; Manuel Battegay⁷; Emilio Letang⁸; for the KIULARCO Study Group
¹Virgen del Rocío Univ Hosp, Seville, Spain; ²Ifakara Hlth Inst, Ifakara, Tanzania; ³Ifakara Hlth Inst, Morogoro, Tanzania; ⁴Bern Univ Hosp and Univ of Bem, Bem, Switzerland; ⁵Swiss Trop Inst of PH, Basel, Switzerland; ⁶Univ Hosp Basel, Basel, Switzerland
- 677 Population-Level Decline in BMI and Blood Pressure Following Mass HIV Treatment**
Pascal Geldsetzer¹; Andrea B. Feigl²; Frank Tanser³; Dickman Gareta⁴; Deenan Pillay⁵; Till Barnighausen⁶
¹Harvard Sch of PH, Boston, MA, USA; ²Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa
- 678 HIV Infection, ART Use, and Access to Care for NCDs in Agincourt, South Africa**
Jennifer Manne-Goehler¹; Livia Montana²; Xavier Gomez-Olive³; Alisha Wade⁴; Stephen Tollman⁵; Thomas A. Gaziano⁶; Till Barnighausen⁷
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Med Rsr Council/Wits Rural PH and Health Transition Unit, Johannesburg, South Africa; ⁴Univ of the Witwatersrand, Johannesburg, South Africa; ⁵Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA
- 679 The Burden of NCDs Among the HIV-Infected Population in Agincourt, South Africa**
Jennifer Manne-Goehler¹; Livia Montana²; Xavier Gomez-Olive³; Alisha Wade⁴; Stephen Tollman⁵; Till Barnighausen⁶; Thomas A. Gaziano⁷
¹Beth Israel Deaconess Med Cntr, Boston, MA, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Med Rsr Council/Wits Rural PH and Health Transition Unit, Johannesburg, South Africa; ⁴Univ of the Witwatersrand, Johannesburg, South Africa; ⁵Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA

Session P-Q6 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM

Aging and Immune Effects of Antiretroviral Therapy

- 715 Higher Plasma Cell-Free DNA Levels Are Associated With Younger Age and HIV Infection**
Omar Arshad¹; Izabelle Gadawski²; Beheroze Sattha³; **Hélène Côté⁴**; for the Canadian Institutes of Health Research Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA cohort)
Univ of British Columbia, Vancouver, BC, Canada

716 Peak HIV Viral Load Is Associated With Increased Blood Mitochondrial DNA Mutations

Adam S. Ziada¹; Jarek Ignas-Menzies¹; Meng Ying Lu¹; Beheroze Sattha¹; Sara Saberi¹; P. Richard Harrigan¹; **Hélène Côté**²; for the Canadian Institute of Health Research Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
¹Univ of British Columbia, Vancouver, BC, Canada; ²BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada

717 Equivalent Decline in Inflammation Markers With Tenofovir Alafenamide and Tenofovir DF

Grace A. McComsey¹; Nicholas T. Funderburg²; Manjusha Kulkarni²; Hui C. Liu²; Yafeng Zhang²; Jason Dinosa²; Andrew Cheng³; Scott McCallister⁴; Marshall Fordyce⁵; Mouपाल Das⁶
¹Case Western Reserve Univ, Cleveland, OH, USA; ²Ohio State Univ, Columbus, OH, USA; ³Gilead Scis, Inc, Foster City, CA, USA

718 Similar Inflammatory Marker Levels With LPV/r+3TC Versus LPV/r+2NRTIs at 48 Weeks

Darrell H. Tan¹; Maria I. Figueroa²; Mari J. Rolon²; Omar G. Sued²; Janet M. Raboud³; Leah Szadkowski³; Rupert Kaul³; Mark W. Hull⁴; Sharon L. Walmsley⁵; Pedro Cahn⁶
¹St Michael's Hosp, Toronto, ON, Canada; ²Fundación Huésped, Buenos Aires, Argentina; ³Dalla Lana Sch of PH, Toronto, ON, Canada; ⁴Univ Hlth Network, Toronto, ON, Canada; ⁵Univ of Toronto, Toronto, ON, Canada; ⁶BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada

Session P-Q7 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Frailty and Functional Status

719 Frailty Is Associated With NNRTI-Based Initial ART and Modifiable Risks in ACTG 5322

Kristine M. Erlandson¹; Kunling Wu²; Susan L. Koletar²; Robert Kalayjian²; Babafemi Taiwo²; Frank J. Palella²; Katherin Tassiopoulos²
¹Univ of Colorado, Denver, CO, USA; ²Harvard Sch of PH, Boston, MA, USA; ³Ohio State Univ, Columbus, OH, USA; ⁴MetroHlth Med Cntr, Cleveland, OH, USA; ⁵Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA; ⁶Northwestern Univ, Chicago, IL, USA

720 Prevalence of Falls Among Older Women in the Women's Interagency HIV Study

Anjali Sharma¹; Donald R. Hoover²; Qiuju Shi²; Susan Holman³; Michael W. Plankey⁴; Amber L. Wheeler⁵; Kathleen Weber⁶; Elizabeth Golub⁷; Marcia K. Holstad⁸; Michael T. Yin¹⁰
¹Albert Einstein Coll of Med, Bronx, NY, USA; ²Rutgers Univ, Piscataway, NJ, USA; ³New York Med Coll, Valhalla, NY, USA; ⁴State Univ of New York Downstate Med Cntr, Brooklyn, NY, USA; ⁵Georgetown Univ Med Cntr, Washington, DC, USA; ⁶Univ of California San Francisco, San Francisco, CA, USA; ⁷CORE Cntr/Cook County Hlth and Hosp System and Hektoen Inst of Med, Chicago, IL, USA; ⁸Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ⁹Emory Univ, Atlanta, GA, USA; ¹⁰Columbia Univ Med Cntr, New York, NY, USA

721 Factors Associated With Limitations in Daily Activity Among Older HIV+ Adults

Kristine M. Erlandson¹; Kunling Wu²; Robert Kalayjian²; Susan L. Koletar²; Babafemi Taiwo²; Frank J. Palella²; Katherin Tassiopoulos²
¹Univ of Colorado, Denver, CO, USA; ²Harvard Sch of PH, Boston, MA, USA; ³MetroHlth Med Cntr, Cleveland, OH, USA; ⁴Ohio State Univ, Columbus, OH, USA; ⁵Feinberg Sch of Med, Northwestern Univ, Chicago, IL, USA; ⁶Northwestern Univ, Chicago, IL, USA

722 Fitness Characteristics of United States Air Force Members With HIV Infection

Asha R. De¹; Xiaoho Xu²; James White³; Thankam Sunil²; Jason Okulicz³
¹San Antonio Military Med Cntr, Fort Sam Houston, TX, USA; ²Univ of Texas San Antonio, San Antonio, TX, USA; ³San Antonio Military Med Cntr, San Antonio, TX, USA

723 Frailty in HIV-Infected Patients Is Associated With Increased Insulin Resistance

Dominic Chow; Lindsay M. Kohorn; Tanawan Riangwiwat; Scott C. Souza; Kalpana J. Kallianpur; Beau K. Nakamoto; Lishomwa C. Ndhlovu; Cecilia M. Shikuma
¹Univ of Hawaii, Honolulu, HI, USA

Session P-Q8 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Mechanisms of Pulmonary Complications

724 HIV gp120 in the Lungs of HAART-Treated Individuals Impairs Pulmonary Immunity

Paul J. Collini¹; Martin Bewley¹; Julia M. Greig²; Christine Bowman²; David H. Dockrell¹
¹Univ of Sheffield, Sheffield, UK; ²Sheffield Teaching Hosps, Sheffield, UK

725 The Host Response to the HIV Airway Epithelial Cell Microbiome

Janice Leung¹; Marc Sze²; Stella Xu¹; Emily Vucic²; Wan Lam²; Stephen Lam²; Corey Nislow¹; Julio Montaner¹; Don Sin¹; S. F. Paul Man¹
¹Univ of British Columbia, Vancouver, BC, Canada; ²Univ of Michigan, Ann Arbor, MI, USA; ³BC Cancer Rsr Cntr, Vancouver, BC, Canada; ⁴BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada

Session P-Q9 Poster Abstracts

2:45 PM-4:00 PM

Hall A/B

Herpes Virus Coinfections

726 Immunological Signaling During HSV-2 and CMV Vaginal Reactivation at ART Initiation

Andrew D. Redd¹; Eshan U. Patel¹; Allison R. Kirkpatrick²; Aaron A. Tobian¹; Sara Gianella¹; Sarah Kalibbala¹; Thomas C. Quinn³; David Serwadda⁴; Steven J. Reynolds⁵; Martha Nason¹
¹NIAID, NIH, Bethesda, MD, USA; ²NIH, Bethesda, MD, USA; ³NIAID, NIH, Baltimore, MD, USA; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁵Univ of California San Diego, San Diego, CA, USA; ⁶Rakai Hlth Scis Prog, Rakai, Uganda; ⁷Makerere Univ School of PH, Kampala, Uganda

- 727 Longitudinal Viral Dynamics in Semen of HIV+ Men Before and After Early ART**
Sheldon R. Morris; Davey M. Smith; Milenka Vargas; Susan J. Little; Sara Gianella
Univ of California San Diego, San Diego, CA, USA
- 728 HSV-2 Acquisition Among HIV-1 Infected Adults With Tenofovir-Based ART in ACTG 5175**
Connie M. Celum¹; Ting Hong¹; Anne Cent¹; Rhoda Morrow¹; Jared M. Baeten¹; Nagalingeswaran Kumarasamy²; Beatriz Grinsztejn³; Mina Hossainpour⁴; Thomas B. Campbell⁵; for the ACTG 5175 team
¹*Univ of Washington, Seattle, WA, USA*; ²*YRG Cntr for AIDS Rsr and Educ, Chennai, India*; ³*Inst de Pesquisa Clinica Evandro Chagas (IPEC)/ Fundaçao Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil*; ⁴*Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA*; ⁵*Univ of Colorado, Denver, CO, USA*
- 729 CMV Status Is Associated With CD4/CD8 Restoration in Primary HIV-Infected Patients**
Patrick Mialhes¹; Christophe Malcus²; Pierre Pradat³; Isabelle Delfour⁴; Julien Saison⁵; Jean-Claude Tardy⁶; Isabelle Cohen-Codar⁷; Christian Chidiac⁸; Guillaume Monneret⁹; Tristan Ferry⁹
¹*CHU Lyon, Lyon, France*; ²*CHU de Lyon, Lyon, France*; ³*Hopital de la Croix Rousse, Lyon, France*; ⁴*AbbVie, Inc, Rungis, France*
- 730 CD4+ T Cell Dysfunction During Early HIV Infection Might Trigger CMV Shedding**
Jennifer M. Dan¹; Marta Massanella²; Davey M. Smith¹; Milenka Vargas¹; Rachel Schrier¹; Susan J. Little¹; Sara Gianella¹
¹*Univ of California San Diego, San Diego, CA, USA*; ²*CRCHUM, Montreal, QC, Canada*
- 731 High Anti-CMV IgG Levels Predict HIV Disease Progression**
Eshan U. Patel¹; Sara Gianella²; Kevin Newell³; Aaron A. Tobian⁴; Allison R. Kirkpatrick⁵; Mary K. Grabowski⁶; David Serwadda⁷; Thomas C. Quinn⁸; Andrew D. Redd⁹; Steven J. Reynolds¹⁰
¹*NIH, Bethesda, MD, USA*; ²*Univ of California San Diego, San Diego, CA, USA*; ³*Rsr Data and Communication Technologies, Inc, Garrett Park, MD, USA*; ⁴*Johns Hopkins Univ Sch of Med, Baltimore, MD, USA*; ⁵*NIAID, NIH, Baltimore, MD, USA*; ⁶*Johns Hopkins Univ, Baltimore, MD, USA*; ⁷*Makerere Univ School of PH, Kampala, Uganda*; ⁸*NIAID, NIH, Bethesda, MD, USA*
- 732 CX3CR1+ CD8 T Cells Are Promoted by CMV Coinfection in Treated HIV Infection**
Michael L. Freeman¹; Joseph C. Mudd²; Souheil-Antoine Younes¹; Soumya Panigrahi¹; Michael M. Lederman¹
¹*Case Western Reserve Univ, Cleveland, OH, USA*; ²*NIAID, NIH, Bethesda, MD, USA*

Session P-R9 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Cryptococcal Disease: Detection and Outcomes

- 759 Evaluation of Provider-Initiated Cryptococcal Antigen Screening, South Africa**
Nicky Longley¹; Snigdha Vallabhaneeni²; Mariette Smith³; Rachel Smith⁴; Meg Osler⁵; Nicola Kelly⁶; Anna Cross⁷; Andrew Bouille⁸; Graeme Meintjes⁹; Nelesh Govender⁹
¹*St George's Univ of London, London, UK*; ²*CDC, Atlanta, GA, USA*; ³*Univ of Cape Town, Cape Town, South Africa*; ⁴*Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa*; ⁵*Natl Inst of Communicable Diseases, Johannesburg, South Africa*
- 760 Maximizing Detection and Improving Outcomes of Cryptococcosis in Rural Tanzania**
Diana Faini¹; Aneth V. Kalinjuma²; Julie Neborak³; Alexa King⁴; Dorcas Mnzava⁵; Tracy Glass⁶; Hansjakob Furrer⁷; Christoph Hatz⁸; David R. Boulware⁹; Emilio Letang⁴
¹*Ifakara Hlth Inst, Dar es Salaam, Tanzania*; ²*Ifakara Hlth Inst, Morogoro, Tanzania*; ³*Univ of Minnesota, Minneapolis, MN, USA*; ⁴*Swiss Trop Inst of PH, Basel, Switzerland*; ⁵*Bern Univ Hosp and Univ of Bern, Bern, Switzerland*
- 761 Neurocognitive Function in HIV-Infected Persons With Cryptococcal Antigenemia**
Martha P. Montgomery¹; Noeline Nakasujja²; Bozena M. Morawski³; Radha Rajasingham⁴; Elizabeth Nalintya⁵; Renee Donahue Carlson⁶; Jonathan E. Kaplan⁷; Andrew Kambugu⁸; David B. Meya⁹; David R. Boulware¹⁰; for the COAT and ORCAS Trial Teams
¹*Univ of Minnesota, Minneapolis, MN, USA*; ²*Makerere Univ Coll of Hlth Scis, Kampala, Uganda*; ³*Infectious Diseases Inst, Kampala, Uganda*; ⁴*Emory Univ Sch of Med, Atlanta, GA, USA*; ⁵*CDC, Atlanta, GA, USA*
- 762 Immunologic Discrimination of Cryptococcal IRIS From Culture-Positive Relapse**
David R. Boulware¹; Joshua R. Rhein²; Edward N. Janoff³; Abdu Musubire⁴; Andrew Kambugu⁵; Paul Bohjanen⁶; David B. Meya⁷; for the COAT Trial Team
¹*Univ of Minnesota, Minneapolis, MN, USA*; ²*Univ of Colorado, Denver, CO, USA*; ³*Infectious Diseases Inst, Kampala, Uganda*
- 763 Acute Kidney Injury and Urine Biomarkers in HIV-Associated Cryptococcal Meningitis**
Charlotte Schutz¹; David R. Boulware²; Katherine Huppler Hullsiek³; Joshua R. Rhein⁴; Kabanda Taseera⁵; Conrad Muzora⁶; David B. Meya⁷; Friedrich Thienemann⁸; Maximilian von Hohenberg⁹; Graeme Meintjes¹⁰; for the COAT Trial Team
¹*Univ of Cape Town, Cape Town, South Africa*; ²*Univ of Minnesota, Minneapolis, MN, USA*; ³*Mbarara Univ of Sci and Tech, Mbarara, Uganda*; ⁴*Infectious Diseases Inst, Kampala, Uganda*

Session P-R10 Poster Abstracts

2:45 PM-4:00 PM

Hall D

Other Infectious Complications of HIV Disease

764 Pulmonary Aspergillosis May Be Common in AIDS With Smear Negative Tuberculosis

Iain D. Page¹; William Worodria²; Alfred Andama²; Irene Ayakaka²; Lucian Davis³; Laurence Huang³; Malcolm Richardson¹; David W. Denning¹

¹Univ of Manchester, Manchester, UK; ²Mulago Hosp, Kampala, Uganda; ³Univ of California San Francisco, San Francisco, CA, USA

765 Safety of Stopping Primary *T. gondii* Prophylaxis With Suppressed Viremia and CD4>100

Jose Miro¹; Anna Esteve²; Hansjakob Furrer³; for the Opportunistic Infection Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

¹Hosp Clinic of Barcelona, Barcelona, Spain; ²CEIISCAT, Badalona, Spain; ³Bern Univ Hosp and Univ of Bern, Bern, Switzerland

766 WITHDRAWN**767 The Cerebrospinal Fluid TPPA for Neurosyphilis Diagnosis**

Christina Marra; Lauren Tantalio; Sharon Sahi; Shelia Dunaway
Univ of Washington, Seattle, WA, USA

768 Invasive Pneumococcal Disease Among HIV-Infected Individuals in Toronto, Canada

Nisha Andany¹; Sharon L. Walmsley²; Allison McGeer³; for the Toronto Invasive Bacterial Diseases Network

¹Univ of Toronto, Toronto, ON, Canada; ²Univ Hlth Network, Toronto, ON, Canada; ³Mount Sinai Hosp, Toronto, ON, Canada

769 Aetiology and Outcome of Community-Acquired Pneumonia in HIV-Infected Malawian Adults

Stephen J. Aston¹; Antonia Ho²; Hannah Jary³; Dean Everett³; Henry Mwandumba³; Robert S. Heyderman⁴; Mulinda Nyirenda⁵; Stephen Gordon⁶

¹Liverpool Sch of Trop Med, Liverpool, UK; ²Univ of Liverpool, Liverpool, UK; ³Malawi Liverpool Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi; ⁴Univ Coll London, London, UK; ⁵Queen Elizabeth Central Hosp, Blantyre, Malawi; ⁶Malawi Liverpool Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi

Session P-S8 Poster Abstracts

2:45 PM-4:00 PM

Hall D

Viral and Immune Mechanisms of MTCT

806 Recombination Elevates HIV-1 Evolution Following Mother-to-Child Transmission

Mohan Somasundaran¹; Keri Sanborn¹; Katherine Luzuriaga¹; Thomas Leitner²

¹Univ of Massachusetts Med Sch, Worcester, MA, USA; ²Los Alamos Natl Lab, Los Alamos, NM, USA

807 Infant CD4+ T Cells Have a Distinct Immunophenotype by Single Cell Analysis

Pamela Lincez; Fan Li; Kyle J. Nakamura; David Lee; Nicole H. Tobin; Grace M. Aldrovandi
Children's Hosp of Los Angeles, Los Angeles, CA, USA

Session P-S9 Poster Abstracts

2:45 PM-4:00 PM

Hall D

Outcomes of HIV and ARV-Exposed Infants, Children, and Youth

808 Duration of Tenofovir Exposure In Utero and Linear Growth in the First Year of Life

Stanzi M. le Roux¹; Jennifer Jao²; Kirsty Brittain³; Tamsin Phillips³; Agnes Ronan³; Olawaseun A. Olatunbosun³; Allison Zerbe⁴; Elaine J. Abrams⁵; Landon Myer⁶

¹Sch of PH & Family Med, Univ of Cape Town, Cape Town, South Africa; ²Icahn Sch of Med at Mount Sinai, New York, NY, USA; ³Univ of Cape Town, Cape Town, South Africa; ⁴ICAP at Columbia Univ, New York, NY, USA; ⁵ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

809 Severe Respiratory Infections in HIV-Exposed Uninfected Infants: Serologic Analysis

Adriana Weinberg¹; Marissa Mussi-Pinhata²; Qilu Yu³; Rachel Cohen⁴; Volia Almeida⁵; Fabiana Amaral⁵; Laura Freimanis⁵; Jennifer S. Read⁶; George K. Siberry⁷; for the NISDI, LILAC and CIRAI study teams

¹Univ of Colorado, Denver, CO, USA; ²Univ of Sao Paulo, Sao Paulo, Brazil; ³Westat, Inc., Rockville, MD, USA; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Eunice Kennedy Shriver NICHD, Bethesda, MD, USA

810 Similar HIV Protection From ZDV vs NVP Prophylaxis in Formula-Fed Infants in Botswana

Kathleen Powis¹; Shahin Lockman²; Gbolahan Ajibola³; Kara Bennett⁴; Jean Leidner⁵; Michael Hughes⁶; Sikhulile Moyo⁷; Erik van Widenfelt⁸; Joseph Makhema⁹; Roger L. Shapiro⁹

¹Massachusetts General Hosp, Boston, MA, USA; ²Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ³Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; ⁴Bennett Statistical Consulting, Inc., Ballston Lake, NY, USA; ⁵Goodtables Consulting, Oklahoma, OK, USA; ⁶Harvard Sch of PH, Boston, MA, USA

811 Risk of Cancer in Children Exposed to Didanosine in Utero

Mira Heyhel¹; Stéphanie Goujon²; Roland Tubiana³; Catherine Dollfus⁴; Albert Faye⁵; Laurent Mandelbrot⁶; Jacqueline Clavel⁷; Josiane Warszawski⁸; Stéphane Blanche⁹; for the ANRS C01/C011-EPF French Perinatal Cohort Study Group

¹CESP, INSERM U1018, Le Kremlin-Bicêtre, France; ²INSERM, UMR 1153, Villejuif, France; ³Sorbonne Univs, Paris, France; ⁴Hosp Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁵Univ Diderot Paris 7, Sorbonne Paris-Cité, Paris, France; ⁶Hosp Louis Mourier, Colombes, France; ⁷Hosp Necker Enfants Malades, Paris, France

812 Elevated Mitochondrial DNA Content in HIV-Exposed Uninfected Children With Autism

Matthew Budd¹; Lindy Samson²; Jennifer Bowes³; Kristina Calli⁴; Suzanne Lewis⁵; Hélène Côté⁶; Jason Brophy⁷; for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
¹Univ of British Columbia, Vancouver, BC, Canada; ²Children's Hosp of Eastern Ontario, Ottawa, ON, Canada

813 ARV Risk for Speech and Language Impairments in HEU Children at 3 and 5 Years

Mabel L. Rice¹; Jonathan S. Russell²; Toni Frederick³; Murli Purswani⁴; Paige L. Williams⁵; George K. Siberry⁶; Sean M. Redmond⁷; Howard J. Hoffman⁸; Tzy-Jyun Yao⁹; for the Pediatric HIV/AIDS Cohort Study (PHACS)
¹Univ of Kansas, Lawrence, KS, USA; ²Harvard Univ, Boston, MA, USA; ³Univ of Southern California, Los Angeles, CA, USA; ⁴Albert Einstein Coll of Med, Bronx, NY, USA; ⁵Harvard Sch of PH, Boston, MA, USA; ⁶Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁷Univ of Utah, Salt Lake City, UT, USA; ⁸Natl Inst on Deafness and Other Communication Disorders, Bethesda, MD, USA

814 Longitudinal Evaluation of Language Impairment in Perinatally HIV Exposed Adolescents

Sean M. Redmond¹; Tzy-Jyun Yao²; Jonathan S. Russell³; Mabel L. Rice⁴; Howard J. Hoffman⁵; George K. Siberry⁶; Paige L. Williams⁷; for the Pediatric HIV/AIDS Cohort Study (PHACS) team.
¹Univ of Utah, Salt Lake City, UT, USA; ²Harvard Univ, Boston, MA, USA; ³Univ of Kansas, Lawrence, KS, USA; ⁴Natl Inst on Deafness and Other Communication Disorders, Bethesda, MD, USA; ⁵Eunice Kennedy Shriver NICHD, Bethesda, MD, USA; ⁶Harvard Sch of PH, Boston, MA, USA

Session P-T6 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Achieving 90-90-90 in Children

841 Hybrid HIV Testing Strategy Achieves High Coverage of Rural East African Children

James Ayieko¹; Gabriel Chamie²; Craig R. Cohen³; Tamara Clark⁴; Edwin Charlebois⁵; Maya Petersen⁶; Moses R. Kamya⁷; Diane V. Havlir⁸; Theodore D. Ruel⁹
¹Kenya Med Rsr Inst, Kisumu, Kenya; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of California Berkeley, Berkeley, CA, USA; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda

842 Outcomes of the Test and Treat Policy for HIV-Infected Children and Adolescents

Rita Atugonza; Jacqueline B. Kanywa; Vincent Tukei; Adeodata Kekitiinwa
Baylor Coll of Med Children's Frndn Uganda, Kampala, Uganda

843 48-week Outcomes of African Children Starting ART at CD4 >500 With Streamlined Care

Florence Mwangwa¹; Diane V. Havlir²; Vivek Jain³; Dathan Byonanebye⁴; Dalsone Kwarisima⁵; Tamara Clark⁶; Edwin Charlebois⁷; Maya Petersen⁸; Moses R. Kamya; Theodore D. Ruel⁹
¹Infectious Diseases Rsr Collab, Kampala, Uganda; ²Univ of California San Francisco, San Francisco, CA, USA; ³Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ⁴Makerere Univ-Univ of California San Francisco Rsr Collab, Kampala, Uganda; ⁵Univ of California Berkeley, Berkeley, CA, USA

844 Family Clinic Day RCT in Uganda: Child Antiretroviral Therapy Retention and Adherence

Justin C. Graves¹; Christine J. Schellack²; Margaret L. Prust³; Esther Mirembe⁴; Marta A. Prescott⁵; Betty Mirembe⁶; Ivan Lukabwye⁷; Barbara Asire⁸; Peter Elyanu⁹; Sarah Moberley¹⁰
¹Clinton Hlth Access Initiative, Boston, MA, USA; ²Clinton Hlth Access Initiative, Kampala, Uganda; ³Uganda Ministry of Hlth, Kampala, Uganda; ⁴Clinton Hlth Access Initiative, Melbourne, Australia

845 12-Month Treatment Outcomes Amongst HIV-Positive Orphans and Nonorphans

Cheryl J. Hendrickson¹; Alana Brennan²; Denise Evans³; Ian M. Sanne⁴; Sharon Patz⁵; Sanlie Untiedt⁶; Jean Bassett⁷; Matthew P. Fox²
¹Hlth Economics and Epi Rsr Office, Johannesburg, South Africa; ²Boston Univ, Boston, MA, USA; ³Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ⁴Alexandra Clinic, Alexandra, South Africa; ⁵Witkoppen Hlth And Welfare Cntr, Johannesburg, South Africa

846 An Audit of Weight-Based Antiretroviral Therapy Dosing in Children

Subathira Dakshina¹; Lavanya Raman²; Rashida A. Ferrand³; Palwasha Y. Khan⁴; Katharina Kranzer⁵; Hilda Mujuru⁶
¹Barts Hlth NHS Trust, London, UK; ²Southend Univ Hosp, Westcliff on Sea, UK; ³London Sch of Hygiene & Trop Med, London, UK; ⁴London Sch of Hygiene & Trop Med, Cardiff, UK; ⁵Univ of Zimbabwe, Harare, Zimbabwe

Session P-T7 Poster Abstracts

Hall D

2:45 PM-4:00 PM

HIV Drug Resistance in Children

847 Persistence of HIV Drug Resistance in Children Exposed to Nevirapine Prophylaxis

Ruth M. Kanthula¹; Ingrid Beck²; Gisela Van Dyk³; Rachel Silverman⁴; Scott Olson⁵; Christen Salyer⁶; Sharon Cassol⁷; Theresa Roussouw⁸; Lisa Frenkel⁹
¹Univ of Washington, Seattle, WA, USA; ²Seattle Children's Rsr Inst, Seattle, WA, USA; ³Univ of Pretoria, Pretoria, South Africa

848 Independent lineages of HIV-1 Multidrug Resistance in Children Failing Early ART

Camille M. Lange¹; Stephane Hue²; Avy Violari³; Mark F. Cotton⁴; Diana Gibb⁵; Deenan Pillay⁶; Ravindra K. Gupta⁷
¹NIH, Bethesda, MD, USA; ²London Sch of Hygiene & Trop Med, London, UK; ³Univ of the Witwatersrand, Johannesburg, South Africa; ⁴Stellenbosch Univ and Tygerberg Children's Hosp, Cape Town, South Africa; ⁵Med Rsr Council Clinical Trials Unit, London, UK; ⁶Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁷Univ Coll London, London, UK

849 Transmitted Drug Resistance and First-Line ART Treatment Outcomes in Ugandan Children

Cissy Kityo¹; Ragna S. Boerma²; Kim Sigaloff³; Elizabeth Kaudha⁴; Job Calis⁵; Victor Musiime⁶; Tamara Sonia Boender⁷; Henry Mugerwa⁸; Tobias Rinke de Wit⁹; Peter Mugenyi¹⁰
¹Joint Clinical Rsr Cntr, Kampala, Uganda; ²Amsterdam Inst for Global Hlth and Develop, Amsterdam, Netherlands; ³Academic Med Cntr, Amsterdam, Netherlands; ⁴Makerere Univ Coll of Hlth Scis, Kampala, Uganda

850 Drug Resistance Compromises Second-Line ART in Mozambican Children Failing First-Line

Paula M. Vaz¹; William C. Buck²; Dulce A. Bila³; Nilesh Bhatt³; Kebba Jobarteh¹; Loide Cossa²; Charity Alfredo²; James Houston³; Amina Sousa²; Chunfu Yang⁴

¹Fundação Ariel Glaser, Maputo, Mozambique; ²CDC, Maputo, Mozambique; ³Inst Nacional de Saúde, Maputo, Mozambique; ⁴CDC, Atlanta, GA, USA

Session P-T8 Poster Abstracts**Hall D****2:45 PM-4:00 PM****Complications of HIV and Antiretroviral Therapy in Children****851 Dysregulated Epigenome in Perinatally HIV-Infected Children on ART**

Stephanie Shiau¹; Stephen M. Arpadi¹; Renate Strehlau²; Avy Violaris²; Shuang Wang³; Faezah Patel²; Marc Foca²; Ashraf Coovadia²; Elaine J. Abrams²; Louise Kuhn²; for the CHANGES Study Team

¹Columbia Univ Med Cntr, New York, NY, USA; ²Univ of the Witwatersrand, Johannesburg, South Africa; ³Columbia Univ, New York, NY, USA; ⁴ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA

852 Timing of Pubertal Onset in Perinatally Infected South African Adolescents on ART

Landon Myer¹; James Nuttall¹; Helena Rabie²; Kirsty Brittain¹; Lisa Frigati³; Paul Roux³; Diane Gray³; Linda-Gail Bekker³; Heather J. Zar³; for the Cape Town Adolescent Antiretroviral Cohort

¹Univ of Cape Town, Cape Town, South Africa; ²Stellenbosch Univ, Cape Town, South Africa; ³Groote Schuur Hosp, Cape Town, South Africa; ⁴Desmond Tutu HIV Cntr, Cape Town, South Africa

853 Left Heart Abnormalities in HIV-Infected Children in Harare, Zimbabwe

Edith D. Majonga¹; Jon O. Odland²; Rashida A. Ferrand³; Katharina Kranzer³; Grace McHugh³; John Metcalfe⁴; Tsitsi Bandason¹; Hilda Mujuru²; Juan P. Kaski⁵

¹Biomed Rsr and Training Inst, Harare, Zimbabwe; ²The Arctic Univ of Norway, Tromsø, Norway; ³London Sch of Hygiene & Trop Med, London, UK; ⁴Univ of California San Francisco, San Francisco, CA, USA; ⁵Univ of Zimbabwe, Harare, Zimbabwe; ⁶Great Ormond Street Hosp & UCL Inst of Cardiovascular Sci, London, UK

854 Cardiovascular Disease Biomarkers in Perinatally HIV-Infected Adolescents on ART

Liesl Zuhlke¹; Kirsty Brittain¹; Linda-Gail Bekker²; Helena Rabie²; James Nuttall¹; Brian Eley³; Paul Roux³; **Landon Myer**³; Heather J. Zar³; for the Cape Town Adolescent Antiretroviral Cohort

¹Univ of Cape Town, Cape Town, South Africa; ²Desmond Tutu HIV Cntr, Cape Town, South Africa; ³Stellenbosch Univ, Cape Town, South Africa; ⁴Groote Schuur Hosp, Cape Town, South Africa

855 Lipotrophy/Lipohypertrophy Outcomes After ART Switch in Children in the UK/Ireland

Steve Innes¹; Justin Harvey²; Jeannie Collins³; Mark F. Cotton¹; Ali Judd¹

¹Stellenbosch Univ and Tygerberg Children's Hosp, Cape Town, South Africa; ²Stellenbosch Univ, Cape Town, South Africa; ³Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK

856 Patterns of Systemic Hypertension Among Adults With Perinatally Acquired HIV

Patrick A. Ryscavage; Thomas Macharia; Lino R. Trinidad; Susan Lovelace; Vicki Tepper; Robert R. Redfield

Univ of Maryland Sch of Med, Baltimore, MD, USA

857 Prevalence of Persistent Renal Dysfunction in Perinatal Thai HIV Adolescents

Tanit Phupitakphol¹; Torsak Bunupuradah¹; Jiratchaya Sophonphan¹; Wasana Prasitsuebsai¹; Supavorn Anugulruengkitt²; Watsamon Jantarabenjakul¹; Bunruan Sopa¹; Kiat Ruxrungtham¹; Ankanee Chanakul¹; Thanyawee Puthanakit²; for the HIV-NATO15 cohort

¹HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ²Chulalongkorn Univ, Bangkok, Thailand

Session P-T9 Poster Abstracts**Hall D****2:45 PM-4:00 PM****Cotreatments of Coinfections in Children****858 Early Weight and Height Changes in Asian Children Using Cotrimoxazole With ART**

David C. Boettiger¹; Dina Muktiarti²; Truong Huu Khanh³;

Suneeta Saghayam⁴; Torsak Bunupuradah⁵; Ly Penh Sun⁶; Raviwan Hansudewechakul⁷; Lam Van Nguyen⁸; Azar Kariminia⁹; for the TREAT Asia Pediatric HIV Observational Database group

¹Univ of New South Wales, Sydney, Australia; ²Cipto Mangunkusumo General Hosp, Jakarta, Indonesia; ³Children's Hosp 1, Ho Chi Minh City, Vietnam; ⁴YRG Cntr for AIDS Rsr and Educ, Chennai, India; ⁵HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁶Natl Cntr for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia; ⁷Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand; ⁸Natl Hosp of Ped, Hanoi, Vietnam; ⁹Kirby Inst, Sydney, Australia

859 Effects of Vitamin D Supplementation on BMD and Bone Markers in HIV+ Youth

Allison R. Eckard¹; Ann Chahroudi²; Julia C. Rosebush²; Mary Ann O'Riordan³; Julie E. Daniels³; Monika Uribe-Leitz²; Bruce Kinley²; Danielle Labbato³; Vin Tangpricha³; Grace A. McCormsey⁴

¹Med Univ of South Carolina, Charleston, SC, USA; ²Emory Univ Sch of Med, Atlanta, GA, USA; ³Case Western Reserve Univ, Cleveland, OH, USA

860 Seroprevalence of Hepatitis B Among HIV-Infected Children and Adolescents in Asia

Linda Aurbibil¹; Azar Kariminia²; Vibol Ung³; Moy Siew Fong³; Oanh Ngoc Le³; Raviwan Hansudewechakul⁴; Torsak Bunupuradah⁵; Nia Kurniati⁶; Pagakrong Lumbiganon⁷; **Tavitiya Sudjaritruk**¹⁰; for the TREAT Asia Pediatric HIV Observational Database (TAPOD)

¹Rsr Inst for Hlth Scis Chiang Mai Univ, Chiang Mai, Thailand; ²Kirby Inst, Sydney, Australia; ³Univ of Hlth Scis Cambodia, Phnom Penh, Cambodia; ⁴Hosp Likas, Kota Kinabalu, Malaysia; ⁵Worldwide Orphans Fndn, Ho Chi Minh City, Vietnam; ⁶Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand; ⁷HIV-NAT, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand; ⁸Cipto Mangunkusumo General Hosp, Jakarta, Indonesia; ⁹Srinagarind Hosp, Khon Kaen Univ, Khon Kaen, Thailand; ¹⁰Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA

Session P-U1 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Contraception and Sexual Health in Women
861 Correlates of Injectable Contraceptive Discontinuation Following HIV-1 Seroconversion

Margaret R. Caplan¹; Jennie L. McKeeney²; Raphael J. Landovitz³; Thesla Palanee-Phillips⁴; Gonasagrie Nair⁵; Felix Mhlanga⁶; Jennifer E. Balkus⁶; Sharon A. Riddler⁷; Pamina Gorbach⁸

¹David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA; ²Rollins Sch of PH, Emory Univ, Atlanta, GA, USA; ³Wits Reproductive Hlth and HIV Inst, Johannesburg, South Africa; ⁴Univ of KwaZulu-Natal, Durban, South Africa; ⁵Univ of Zimbabwe, Univ of California San Francisco Collaborative Rsr Prog, Harare, Zimbabwe; ⁶Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁷Univ of Pittsburgh, Pittsburgh, PA, USA; ⁸Univ of California Los Angeles Sch of PH, Los Angeles, CA, USA

862 Correlation Between Cotherapy of Efavirenz-Based ART and Pregnancy Among Women

Stephen Okoboi; Eunice Ajambo; Irene Bagala; Ronald Oceng; Sophie Nantume; Robinah Acham; Bernard Etkuot
TASO-Uganda, Kampala, Uganda

863 Is Menopause Associated With Unprotected Sex in High-Risk HIV-Positive Kenyan Women?

Marielle S. Goyette¹; Kate S. Wilson¹; Ruth Deya¹; Linnet Masese²; Juma Shafi³; Barbra A. Richardson⁴; Kishor Mandaliya⁴; Walter Jaoko⁴; Scott McClelland¹

¹Univ of Washington, Seattle, WA, USA; ²Kenya Rsr Prog at the Univ of Washington, Nairobi, Kenya; ³Univ of Nairobi, Nairobi, Kenya; ⁴Coast Province General Hosp, Mombasa, Kenya

864 Fertility Desire, Unprotected Sex, and Viral Load in HIV-Positive FSWs in Kenya

Kate S. Wilson¹; Linnet Masese²; Lucy Adala³; Juma Shafi³; Barbra A. Richardson⁴; Jane Simoni⁴; Kishor Mandaliya⁴; Walter Jaoko⁴; Scott McClelland¹

¹Univ of Washington, Seattle, WA, USA; ²Kenya Rsr Prog at the Univ of Washington, Nairobi, Kenya; ³Univ of Nairobi, Nairobi, Kenya; ⁴Coast Province General Hosp, Mombasa, Kenya

865 Inaccurate Reporting of Condom Use Among Women Using Injectable Contraception

Renee Heffron¹; Urvi M. Parikh²; Kerri J. Penrose³; Nelly R. Mugoz³; Deborah Donnell⁴; Connie M. Celum¹; John W. Mellors⁵; Jared M. Baeten¹

¹Univ of Washington, Seattle, WA, USA; ²Univ of Pittsburgh, Pittsburgh, PA, USA; ³Kenya Med Rsr Inst, Thika, Kenya; ⁴SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA

Session P-V3 Poster Abstracts
2:45 PM-4:00 PM

Hall D

Predictors of PrEP Coverage and Uptake
883LB HPTN 073: PrEP Uptake and Use by Black Men Who Have Sex With Men in 3 US Cities

Darrell P. Wheeler¹; Sheldon Fields²; LaRon E. Nelson³; Leo Wilton⁴; Lisa Hightow-Weidman⁵; Steven Shoptaw⁶; Many Magnus⁷; Geetha Beauchamp⁸; Phaedrea Watkins⁹; Kenneth H. Mayer¹⁰

¹State Univ of New York at Albany, Albany, NY, USA; ²Charles R. Drew Univ of Med and Sci, Los Angeles, CA, USA; ³Univ of Rochester, Rochester, NY, USA; ⁴State Univ of New York at Binghamton, Binghamton, NY, USA; ⁵Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁶David Geffen School of Medicine at Univ of California Los Angeles, Los Angeles, CA, USA; ⁷George Washington Univ, Washington, DC, USA; ⁸Statistical Cntr for HIV/AIDS Rsr & Prevention, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁹FHI 361, Durham, NC, USA; ¹⁰The Fenway Inst, Fenway Hlth, Boston, MA, USA

884 HPTN 067/ADAPT: Predictors of Coverage of Sex Events in PrEP Regimens, Thai MSM-TGW

Timothy H. Holtz¹; Anupong Chitwarakorn²; James P. Hughes³; Marcel Curlin⁴; Anchalee Varangrat⁵; K. R. Amico⁶; Teeraparp Watanatanyaporn⁷; Maoji Li⁸; Philip A. Mock⁹; Robert Grant⁸

¹CDC, Atlanta, GA, USA; ²Ministry of PH, Muang Nonthaburi, Thailand; ³Univ of Washington, Seattle, WA, USA; ⁴Oregon Hlth and Scis Univ, Portland, OR, USA; ⁵Thailand Ministry of PH US CDC Collab, Nonthaburi, Thailand; ⁶Univ of Michigan Sch of PH, Ann Arbor, MI, USA; ⁷Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁸Univ of California San Francisco, San Francisco, CA, USA

885 HPTN 067-ADAPT: Factors Associated With PrEP Coverage Among New York City MSM and TGW

Sharon Mannheimer¹; Yael Hirsch-Moverman²; Julie Franks³; Avelino Loquere⁴; James P. Hughes⁵; Maoji Li⁶; Vanessa Elharrar⁷; Michael J. Storratt⁸; Robert Grant⁹; for the HPTN 067/ADAPT Harlem Study Team

¹Harlem Hosp, New York, NY, USA; ²Columbia Univ Mailman Sch of PH, New York, NY, USA; ³Univ of Washington, Seattle, WA, USA; ⁴Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ⁵DAIDS, NIAID, NIH, Bethesda, MD, USA; ⁶NIMH, NIH, Bethesda, MD, USA; ⁷Univ of California San Francisco, San Francisco, CA, USA

886 On Demand PrEP With Oral TDF-FTC in the Open-Label Phase of the ANRS IPERGAY Trial

Jean-Michel Molina¹; Isabelle Charreau²; Bruno Spire³; Laurent Cotte⁴; Gilles Pialoux⁵; Catherine Capitant⁶; Cécile Tremblay⁶; Daniela Rojas Castro⁷; Laurence Meyer⁸; for the ANRS IPERGAY Study Group
¹Hopital Saint-Louis, Paris, France; ²INSERM SC10-US19, Villejuif, France; ³INSERM UMR 912, Marseille, France; ⁴Hospices Civils de Lyon, Lyon, France; ⁵Tenon Hosp, Paris, France; ⁶CRCHUM, Montreal, QC, Canada; ⁷AIDES, Mission Recherche Innovation Evaluation, Pantin, France; ⁸INSERM, CESP U1018, Le Kremlin-Bicêtre, France

887 PrEP and Condom Use in High Risk MSM in the ANRS IPERGAY Trial

Luis Sagaon Teyssier¹; Marie Suzan-Monti²; Daniela Rojas Castro²; Nolween Hall³; Catherine Capitant⁴; Christian Chidiac⁵; Cécile Tremblay⁶; Bruno Spire⁷; Jean-Michel Molina⁸; for the ANRS IPERGAY Study Group

¹UMR912 SESSTIM, Marseille, France; ²AIDES, Mission Recherche Innovation Evaluation, Pantin, France; ³CISIH, Nantes, France; ⁴INSERM SC10-US19, Villejuif, France; ⁵Hosp de la Croix-Rousse, Lyon, France; ⁶CRCHUM, Montreal, QC, Canada; ⁷INSERM UMR 912, Marseille, France; ⁸Hopital Saint-Louis, Paris, France

888 Increasing PrEP Use Among Men Who Have Sex With Men, New York City, 2013-2015

Kathleen K. Scanlin¹; Paul M. Salcuni²; Zoe R. Edelstein³; Demetre C. Daskalakis⁴; Nana P. Mensah⁵; Benjamin Tsou⁶; Julie Myers⁴
¹New York City DHMH, Brooklyn, NY, USA; ²New York City DHMH, Long Island City, NY, USA; ³New York City DHMH, Queens, NY, USA; ⁴New York City DHMH, Long Island City, NY, USA

889 Awareness and Use of PrEP Appear to Be Increasing Among Internet Samples of US MSM

Kevin P. Delaney¹; Travis Sanchez²; Kristina Bowles³; Emeka Oraka⁴; Elizabeth DiNenno⁵; Patrick Sullivan⁶
¹CDC, Atlanta, GA, USA; ²Emory Univ, Atlanta, GA, USA; ³ICF Intl, Atlanta, GA, USA

Session P-V4 Poster Abstracts**Hall D****2:45 PM-4:00 PM****PrEP in Primary Care: Pitfalls and Opportunities****890 Increasing HIV Suppression, PrEP Use, and STDs in Boston MSM Accessing Primary Care**

Kenneth H. Mayer¹; Ken Levine²; Kevin M. Maloney³; Shayne Zaslowsky⁴; Douglas S. Krakower⁵; Chris Grasso⁶; Betsey H. John⁷; Dawn Fukuda⁸; Kevin Cranston⁹; Stephen H. Boswell⁹

¹The Fenway Inst, Fenway Hlth, Boston, MA, USA; ²Beth Israel Deaconess Med Cntr, Boston, MA, USA; ³Fenway Hlth, Boston, MA, USA; ⁴Massachusetts Dept of PH, Boston, MA, USA

891 Missed Opportunities to Prescribe PrEP by Primary Care Physicians in Saint Louis

Rupa Patel¹; Philip Chan²; Amy Nunn³; Katherine Goodenberger⁴; Kenneth H. Mayer⁵; Leandro Mena⁶; Enola K. Proctor⁷; William Powderly⁸

¹Washington Univ in St. Louis, St. Louis, MO, USA; ²Brown Univ, Providence, RI, USA; ³The Fenway Inst, Fenway Hlth, Boston, MA, USA; ⁴Univ of Mississippi, Jackson, MS, USA

892 Early Adopters and Incident PrEP Prescribing in a Detailing Campaign, 2014-2015

Zoe R. Edelstein¹; Paul M. Salcuni²; Arjee Restar³; Julie Myers⁴; Benjamin Tsou⁵; Demetre C. Daskalakis⁶

¹New York City DHMH, Queens, NY, USA; ²New York City DHMH, Long Island City, NY, USA; ³New York City DHMH, Long Island City, NY, USA

893 Correlates of Uptake of HIV Prevention Interventions Among Black MSM in DC, 2013-2014

Matthew E. Levy¹; Christopher Watson²; Madhu Balachandran³; Irene Kuo⁴; Leo Wilton⁵; Russell Brewer⁶; Sheldon Fields⁷; James Peterson⁸; Manya Magnus⁹

¹George Washington Univ Milken Inst Sch of PH, Washington, DC, USA; ²George Washington Univ, Washington, DC, USA; ³State Univ of New York at Binghamton, Binghamton, NY, USA; ⁴Louisiana PH Inst, New Orleans, LA, USA; ⁵Charles R. Drew Univ of Med and Sci, Los Angeles, CA, USA

894 HIV Preexposure Prophylaxis: Adherence and Discontinuation in Clinical Practice

Julia L. Marcus¹; Leo B. Hurley²; C. Bradley Hare³; Dong Phuong Nguyen⁴; Tony Phengrasamy⁵; Michael J. Silverberg⁶; Jonathan E. Volk⁷

¹Kaiser Permanente Northern California, Oakland, CA, USA; ²Kaiser Permanente Northern California, San Francisco, CA, USA

Session P-W5 Poster Abstracts**Hall D****2:45 PM-4:00 PM****Individuals at Risk of HIV****929 Subsequent HIV Disease Risk Following Syphilis Diagnosis in a Southern MSM Population**

David Sweat; Sulaiman Aizezi

Shelby County Hlth Dept, Memphis, TN, USA

930 Behavioral Differences Between Young and Older Black Men Who Have Sex With Men

Teresa Finlayson; William L. Jeffries; Kristen Hess; Alexandra Balaji; Gabriela Paz-Bailey; for the NHBS Study Group

CDC, Atlanta, GA, USA

931 Association Between Family Environment and HIV-Related Risk Behavior Among Young MSM

Alexandra Balaji¹; Gabriela Paz-Bailey²; Lina Nerlander³; Cyprian Wejnert⁴; Justin Smith⁵; Michael Newcomb⁶; Brian Mustanski⁷; Kathleen Brady⁸; Sarah L. Braunstein⁹; Teresa Finlayson¹

¹CDC, Atlanta, GA, USA; ²Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ³Philadelphia Dept of PH, Philadelphia, PA, USA; ⁴New York City DHMH, Queens, NY, USA

932 STIs and Predictive Sexual Risk Behaviors Among HIV+ Military Cohort Members

Grace E. Macalino¹; Morgan Byrne²; Anuradha Ganesan³; Robert Deiss⁴; Jason Okulicz⁵; Tahaniyat Lalani⁶; Brian Agan⁷

¹Infectious Disease Clinical Rsr Prog, Rockville, MD, USA; ²Uniformed Services Univ of the Hlth Scis, Bethesda, MD, USA; ³Infectious Disease Clinical Rsr Prog, San Diego, CA, USA; ⁴San Antonio Military Med Cntr, San Antonio, TX, USA

933 Intentional HIV Seroadaptive Behavior Patterns Among Seattle MSM, 2008-2014

Sara N. Glick¹; Richard Burt²; Christine Khosropour³; Hanne Thiede³

¹Univ of Washington, Seattle, WA, USA; ²PH, Seattle & King County, Seattle, WA, USA; ³PH, Seattle & King County (retired), Seattle, WA, USA

934 Determinants of HIV Transmission Risk Among HIV-Infected Persons Engaged in Care

Charitha Gowda¹; Dagan Coppock²; Cristina E. Brickman³; Pamela A. Shaw⁴; Robert Gross⁵
¹Univ of Pennsylvania, Philadelphia, PA, USA; ²Univ of California San Francisco, San Francisco, CA, USA; ³Univ of Pennsylvania Perelman Sch of Med, Philadelphia, PA, USA

935 Food Insecurity Is Associated With HIV Serostatus and Sexually Transmitted Infections

Kartika Palar¹; Barbara Laraia²; Alexander C. Tsai¹; Mallory Johnson¹; Sheri Weiser¹
¹Univ of California San Francisco, San Francisco, CA, USA; ²Univ of California Berkeley, Berkeley, CA, USA; ³Massachusetts General Hosp, Boston, MA, USA

936 Impact of Male Partners and Schooling on HIV Risk Among South African Girls: HPTN 068

Audrey Pettifor¹; Jing Wang²; Amanda Selin¹; James P. Hughes³; Catherine MacPhail⁴; Xavier Gomez-Olive⁵; Ryan Wagner⁶; Estelle Piwowar-Manning⁷; Kathleen Kahn⁸
¹Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA; ³Univ of Washington, Seattle, WA, USA; ⁴Univ of New England, Armidale, Australia; ⁵Med Rsr Council/Wits Rural PH and Health Transition Unit, Johannesburg, South Africa; ⁶Johns Hopkins Univ Sch of Med, Baltimore, MD, USA

937 Correlates of HIV in Large Population Surveys: A Comprehensive HIV Association Study

Eran Bendavid¹; Chirag Patel²; Jay Bhattacharya¹
¹Stanford Univ, Stanford, CA, USA; ²Harvard Univ, Boston, MA, USA

Session P-X6 Poster Abstracts

Hall D

2:45 PM-4:00 PM

HIV and Other Sexually Transmitted Infections

1004 Increased STD Testing Among HIV-Infected Adults in Care United States, 2009–2013

Christine Mattson; Christopher Johnson; Heather Bradley; Linda Beer; Roy L. Shouse
CDC, Atlanta, GA, USA

1005 Increased Gonorrhea and Chlamydia Case Detection in a Multisite US HIV Cohort

Julia Goldberg Raifman¹; Anne K. Monroe²; Kelly A. Gebo³; Khalil Ghanem⁴; Allison L. Agwu⁵; Todd Korthuis⁶; Wm. Christopher Matthews⁶; Aditya Gaur⁷; Stephen A. Berry⁸; for the HIV Research Network
¹Johns Hopkins Bloomberg Sch of PH, Baltimore, MD, USA; ²Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ³Johns Hopkins Univ, Baltimore, MD, USA; ⁴Johns Hopkins Bayview Med Cntr, Baltimore, MD, USA; ⁵Oregon Hlth & Sci Univ, Portland, OR, USA; ⁶Univ of California San Diego, San Diego, CA, USA; ⁷St Jude Children's Rsr Hosp, Memphis, TN, USA

1006 Gonorrhea and Chlamydia Testing in US HIV-Infected Men Who Have Sex With Men

Monita Patel¹; Shikha Garg¹; John T. Brooks²; Yunfeng Tie³; Heather Bradley¹
¹CDC, Atlanta, GA, USA; ²ICF Intl, Atlanta, GA, USA

1007 Incident Syphilis, Gonorrhea, and Chlamydia Infection Among a Cohort of MSM

Nathan J. Lachowsky¹; **Kristine Stephenson**²; Zishan Cui³; Susan Shurgold⁴; Ashleigh Rich⁵; Troy Grennan⁶; Jason Wong⁷; Eric A. Roth⁸; Robert S. Hogg⁹; David M. Moore¹⁰; for the Momentum Health Study
¹Univ of British Columbia, Vancouver, BC, Canada; ²Vancouver Coastal Hlth, Vancouver, BC, Canada; ³BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada; ⁴BC Cntr for Disease Control, Vancouver, BC, Canada; ⁵Univ of Victoria, Victoria, BC, Canada; ⁶Simon Fraser Univ, Burnaby, BC, Canada; ⁷Univ of British Columbia, Vancouver, BC, Canada

1008 The Importance of Linkage and Engagement of Care in Post HIV STI Acquisition

Kerri Dorsey¹; Amanda Castel¹; Adam Allston²
¹George Washington Univ Milken Inst Sch of PH, Washington, DC, USA; ²District of Columbia Dept of Hlth, HIV/AIDS, Hepatitis, STD, and TB Administration, Washington, DC, USA

1009 Evidence of HIV Care Following STD Clinic Visits by Out-of-Care HIV-Positive persons

Olga Tymieczky¹; Kelly Jamison²; Preeti Pathela³; Sarah L. Braunstein⁴; Julia Schillinger⁵; **Denis Nash**¹
¹Sch of PH, City Univ of New York, New York, NY, USA; ²New York City DHMH, Long Island City, NY, USA; ³New York City DHMH, Queens, NY, USA

Session P-X7 Poster Abstracts

Hall D

2:45 PM-4:00 PM

Access, ART Initiation, Retention, and Outcomes in the Global South

1010 Successful Implementation of Extended ART Initiation Criteria in Rural South Africa

Sarah Jane Steele¹; Amir Shroufi²; Guillermo Martínez Pérez²; Carol Metcalfe³; Tsion Solom³; Gemma Arellano³; Aline Aurore Niyibizi⁴; Tom Ellman⁵; Gilles Van Cutsem⁶
¹Médecins Sans Frontières, South Africa & Lesotho, Cape Town, South Africa; ²Médecins Sans Frontières, Cape Town, South Africa; ³Médecins Sans Frontières, South Africa & Lesotho, Eshowe, South Africa; ⁴Médecins Sans Frontières, Southern Africa Med Unit, Cape Town, South Africa; ⁵Médecins Sans Frontières, Roma, Lesotho

1011 The Real-World Impact of CD4-Eligibility Criteria on Retention in HIV Care

Jacob Bor¹; Matthew P. Fox²; Sydney Rosen³; Atheendar Venkataramani⁴; Frank Tanser⁵; Deenan Pillay⁶; Till Bärnighausen⁵
¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Massachusetts General Hosp, Boston, MA, USA; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁵Harvard Sch of PH, Boston, MA, USA

1012 Do ART Eligibility Expansions Crowd Out the Sickest? Evidence From South Africa

Sheryl A. Kluber¹; Matthew P. Fox²; Michael LaValley³; Till Bärnighausen⁴; Deenan Pillay⁵; Jacob Bor¹
¹Boston Univ Sch of PH, Boston, MA, USA; ²Boston Univ, Boston, MA, USA; ³Harvard Sch of PH, Boston, MA, USA; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

- 1013 Imputing Clinical Records From Routine Laboratory Data: Date of ART Initiation**
Mhairi Maskew¹; Jacob Bor²; Cheryl J. Hendrickson³; William B. MacLeod⁴; Till Bärnighausen⁵; Deenan Pillay⁶; Ian M. Sanne⁷; Sergio Carmona⁸; Wendy Stevens⁹; Matthew P. Fox⁹
¹Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ²Boston Univ Sch of PH, Boston, MA, USA; ³Hlth Economics and Epi Rsr Office, Johannesburg, South Africa; ⁴Harvard Sch of PH, Boston, MA, USA; ⁵Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa; ⁶Natl Hlth Lab Service/Wits Univ, Johannesburg, South Africa; ⁷Univ of the Witwatersrand, Johannesburg, South Africa; ⁸Boston Univ, Boston, MA, USA
- 1014 Prospective Multisite Cohort Study of Pre-ART Losses and ART Refusal in South Africa**
Ingrid T. Katz¹; Janan Dietrich²; Laura M. Bogart³; Dominick Leone⁴; Ingrid Courtney⁵; Gugu Tshabalala⁶; Garrett M. Fitzmaurice⁷; Glenda Gray⁸; Catherine Orrell⁹; David R. Bangsberg⁹
¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA; ²Perinatal HIV Rsr Unit, Soweto, South Africa; ³Boston Children's Hosp, Harvard Med Sch, Boston, MA, USA; ⁴Ragon Inst of MGH, MIT, and Harvard, Cambridge, MA, USA; ⁵Desmond Tutu HIV Fdn, Cape Town, South Africa; ⁶South African Med Rsr Council, Cape Town, South Africa; ⁷Univ of Cape Town, Cape Town, South Africa; ⁸Harvard Med Sch, Boston, MA, USA
- 1015 6-Year Retention and Immunological Response to ART by Gender: leDEA West Africa**
Thierry Tiendrebeogo¹; Juan Burgos-Soto²; Eugene Messou³; Aristophane Tanon⁴; Vivian Kwaghuge⁵; Marcel Zannou⁶; Albert Minga⁶; Nathalie De Rekenoire⁷; Francois Dabis⁸; Renaud Bequet⁹
¹INSERM U897, Bordeaux, France; ²CePReF, ACONDA, Abidjan, Côte d'Ivoire; ³CHU de Treichville, Abidjan, Côte d'Ivoire; ⁴Univ of Abuja Teaching Hosp, Abuja, Nigeria; ⁵Cntr de Prise en Charge des Personnes Vivant Avec le VIH, CHNU, Cotonou, Benin; ⁶Cntr Médical de Suivi de Donneurs de Sang /CNTS/PRIMO-CI, Abidjan, Côte d'Ivoire; ⁷INSERM U897, ISPED, Univ de Bordeaux, Bordeaux, France
- 1016 Barriers to Care and 1-Year Mortality in Newly Diagnosed HIV+ Persons in South Africa**
Ingrid V. Bassett¹; Sharon M. Coleman²; Janet Giddy³; Laura M. Bogart⁴; Christine E. Chaisson⁵; Douglas Ross⁶; Tessa Govender⁷; Rochelle P. Walensky⁸; Kenneth A. Freedberg⁹; Elena Losina⁸
¹Massachusetts General Hosp, Boston, MA, USA; ²Boston Univ Sch of PH, Boston, MA, USA; ³McCord Hosp, Durban, South Africa; ⁴Boston Children's Hosp, Harvard Med Sch, Boston, MA, USA; ⁵Midlands Med Cntr, Pietermaritzburg, South Africa; ⁶Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA
- 1017 Retention of Clinically Stable ART Patients in a Rapid Model of Care in Haiti**
Colette Guiteau Moise¹; Clovy Bellot²; Kelly A. Hennessey³; Vanessa R. Rivera⁴; Patrice Severe⁵; Darley Aubin⁶; Fabienne Homeus⁷; Alex Saint-Vil⁸; Serena P. Koenig⁹; Jean W. Pape¹⁰
¹GHESKIO, Port-au-Prince, Haiti; ²Analysis Group, Boston, MA, USA; ³Weill Cornell Med Coll, New York, NY, USA; ⁴Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, USA
- 1018 Evaluating Appointment Patterns to Improve Sustainability of HIV Treatment in Zambia**
Monika Roy¹; Charles Holmes²; Izukanji Sikazwe³; Thea Savory⁴; Mwanza Mwanza⁵; Carolyn Moore⁶; Kafula Mulenga⁷; Nancy L. Czaicki⁸; Nancy Padian⁹; Elvin H. Geng¹⁰
¹Univ of California San Francisco, San Francisco, CA, USA; ²Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ³Univ of California Berkeley, Berkeley, CA, USA
- 1019 Identifying Hotspots of Poor Adherence Among Patients on ART in Zambia**
Nancy L. Czaicki¹; Charles Holmes²; Izukanji Sikazwe³; Paul Somwe⁴; Monika Roy⁵; Thea Savory⁶; Mwanza Mwanza⁷; David V. Glidden⁸; Nancy Padian⁹; Elvin H. Geng¹⁰
¹Univ of California Berkeley, Berkeley, CA, USA; ²Cntr for Infectious Disease Rsr in Zambia, Lusaka, Zambia; ³Univ of California San Francisco, San Francisco, CA, USA
- 1020 Late ART Initiation and 12-Month Mortality After ART Initiation in Sub-Saharan Africa**
Quynh T. Vo¹; Olga Tymczyk²; Batya Elul³; Wafaa M. El-Sadr⁴; Yingfeng Wu⁵; Laurence Ahoua⁶; Sarah Kulkarni⁶; Susie Hoffman⁷; Denis Nash⁸
¹ICAP at Columbia Univ, Boston, MA, USA; ²Sch of PH, City Univ of New York, New York, NY, USA; ³Columbia Univ, New York, NY, USA; ⁴ICAP at Columbia Univ, New York, NY, USA; ⁵ICAP at Columbia Univ, Maputo, Mozambique; ⁶City Univ of New York, New York, NY, USA
- 1021 Declining Mortality in Patients on ART Lost to Follow-up in Sub-Saharan Africa**
Anne Mooser¹; Kathrin Zürcher²; Denis Nash³; Olga Tymczyk⁴; Margaret Couvillon⁵; **Matthias Egger**⁶; for the leDEA and MESH Consortia
¹Univ of Bern, Bern, Switzerland; ²Sch of PH, City Univ of New York, New York, NY, USA
- 1022 Lost to Found: The Silent Transfer of Antiretroviral Therapy Patients in South Africa**
Claudine M. Hennessey¹; Andrew Boulele²; Kathryn Stinson³; Mariette Smith⁴
¹Univ of Cape Town, Cape Town, South Africa; ²Cntr for Infectious Disease Epi and Rsr, Cape Town, South Africa
- 1023 Countries With Lower HIV Prevalence Have Lower ARV Coverage: UNAIDS 2015 Database**
Andrew M. Hill¹; Anton N. Pozniak²; Thomas Dauncey³; Jacob Levi⁴; Katherine Heath⁵; Shaffiq Essajee⁶; Carmen Perez Elias⁷
¹Liverpool Univ, Liverpool, UK; ²Chelsea and Westminster Hosp NHS Fdn Trust, London, UK; ³Imperial Coll London, London, UK; ⁴Univ of Oxford, Oxford, UK; ⁵WHO, Geneva, Switzerland; ⁶UNITAID, Geneva, Switzerland

Session P-X8 Poster Abstracts
2:45 PM-4:00 PM
Viral Suppression

Hall D

1024 Feasibility of the Third 90-90-90 Target: Viral Load Coverage and Outcomes in Rwanda

Muhayimpundu Ribakare¹; Jean d'Amour Ndahimana¹; Byiringiro Rusisiro¹; Gad Niyibizi¹; Jean Paul Uwizhiwe²; Catherine Kirik³; Sabin Nsanziimana¹

¹Rwanda Biomed Cntr, Kigali, Rwanda; ²Inst of HIV/AIDS Disease Prevention and Control, Rwanda Biomed Cntr, Kigali, Rwanda; ³Partners In Hlth, Kigali, Rwanda

1025 ART Coverage and Viral Load in Tanzania: Bukoba Combination Prevention Baseline Study

Sarah E. Porter¹; Duncan MacKellar¹; Rachel Weber²; Haruka Maruyama³; Sherri Pals³; Gretchen Antelman⁴; Oscar Ernest⁵; Robert Josiah⁶; Jessica Justman⁷

¹CDC, Atlanta, GA, USA; ²CTS Global, Inc, Assigned to US CDC, Dar es Salaam, Tanzania; ³ICAP at Columbia Univ, Dar es Salaam, Tanzania; ⁴Elizabeth Glaser Pediatric AIDS Fndn, Dar es Salaam, Tanzania; ⁵ICAP at Columbia Univ, Bukoba, Tanzania; ⁶Natl AIDS Control Prog, Dar es Salaam, Tanzania; ⁷ICAP at Columbia Univ, New York, NY, USA

1026 Heterogeneity in Local Population Viremia Despite >50% Suppression in East Africa

Vivek Jain¹; Dathan Byonanebye²; Teri Liegler¹; Dalsone Kwarisima³; Norton Sang⁴; Edwin Charlebois⁵; Maya Petersen⁶; Moses R. Kamya⁷; Diane V. Havlir¹; for the SEARCH Collaboration

¹Univ of California San Francisco, San Francisco, CA, USA; ²Makerere Univ Coll of Hlth Scis, Kampala, Uganda; ³Makerere Univ-Univ of California San Francisco Rsr Collab, Kampala, Uganda; ⁴Kenya Med Rsr Inst, Nairobi, Kenya; ⁵Univ of California Berkeley, Berkeley, CA, USA

1027 High Rate of Viral Suppression in Late Mortality on First-Line ART in Uganda/Zimbabwe

David I. Dolling¹; Pontiano Kaleebu²; Peter Nkurunziza³; Moira Spyer⁴; Charles Gilks⁵; Deenan Pillay⁶; Ruth Goodall⁷; for the DART Virology Group

¹Med Rsr Council Clinical Trials Unit at Univ Coll London, London, UK; ²Med Rsr Council/Uganda Virus Rsr Inst Uganda Rsr Unit on AIDS, Entebbe, Uganda; ³Sch of Pop Hlth, Univ of Queensland, Herston, Australia; ⁴Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

1028 Measuring Viral Load Suppression in South Africa Using a Novel, National Database

William B. MacLeod¹; Jacob Bor²; Nicole Fraser³; Zara Shubber³; Ian M. Sanne⁴; Wendy Stevens⁵; Tshepo Molapo⁶; Mokgadi Phokojoe⁷; Yogan Pillay⁸; Sergio Carmona⁶

¹Boston Univ Sch of PH, Boston, MA, USA; ²The World Bank, Washington, DC, USA; ³Univ of the Witwatersrand, Wits Hlth Consortium, Johannesburg, South Africa; ⁴Univ of the Witwatersrand, Johannesburg, South Africa; ⁵Natl Dept of Hlth, Pretoria, South Africa; ⁶Natl Hlth Lab Service/Wits Univ, Johannesburg, South Africa

1029 Comparing Adherence Methods: Which Best Predicts Virological and Resistance Outcome?

Catherine Orrell¹; Karen Cohen²; Rory Leisegang³; David R. Bangsberg⁴; Gary Maartens⁵; Robin Wood¹

¹Univ of Cape Town, Cape Town, South Africa; ²Harvard Med Sch, Boston, MA, USA

1030 Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa

Dami A. Collier¹; Kathy Baisley²; Dickman Garetta³; Deenan Pillay³; Ravindra K. Gupta⁴

¹Univ Coll London, London, UK; ²London Sch of Hygiene & Trop Med, London, UK; ³Africa Cntr for Hlth and Pop Studies, Mtubatuba, South Africa

1031 Outcomes of Patients Enrolled in ART Adherence Clubs After Viral Resuppression

Joseph T. Sharp¹; Lynne Wilkinson²; Vivian Cox³; Carol Cragg⁴; Gilles Van Cutsem⁵; Anna Grimsrud⁶

¹Univ of Cape Town, Cape Town, South Africa; ²Médecins Sans Frontières, Khayelitsha, South Africa; ³Western Cape Dept of Hlth, Cape Town, South Africa; ⁴Médecins Sans Frontières, Cape Town, South Africa; ⁵IAS, Cape Town, South Africa

1032 Substance Use Is a Major Barrier to Viral Suppression Among Key Populations in India

Sunil S. Solomon¹; Gregory M. Lucas²; Aylur K. Srikrishnan³; Allison M. McFall⁴; David Celentano⁵; Shanmugam Saravanan⁶; Suresh Kumar⁷; **Shruti H. Mehta¹**

¹Johns Hopkins Univ, Baltimore, MD, USA; ²YRG Cntr for AIDS Rsr and Educ, Tararami, India; ³YRG Cntr for AIDS Rsr and Educ, Chennai, India

1033 Durable Viral Suppression Among HIV-Diagnosed Persons United States, 2012–2013

Nicole Crepaz¹; Tian Tang²; Gary Marks³; Michael J. Mugavero⁴; Lorena Espinoza⁵; H. Irene Hall⁶

¹CDC, Atlanta, GA, USA; ²ICF Intl, Atlanta, GA, USA; ³Univ of Alabama at Birmingham, Birmingham, AL, USA

1034 Changes in Viral Load Across US Clinics Over Time

Jane Simoni¹; Robin Nance²; Joseph A. Delaney³; Ira B. Wilson⁴; Frances Aunon⁵; Steven A. Safren⁶; Michael J. Mugavero⁷; Kenneth H. Mayer⁸; Mari M. Kitahata⁹; **Heidi M. Crane¹**

¹Univ of Washington, Seattle, WA, USA; ²Univ of Washington Sch of PH and Community Med, Seattle, WA, USA; ³Brown Univ Sch of PH, Providence, RI, USA; ⁴Massachusetts General Hosp, Boston, MA, USA; ⁵Univ of Alabama at Birmingham, Birmingham, AL, USA; ⁶The Fenway Inst, Fenway Hlth, Boston, MA, USA

1035 Differences in HIV Viral Suppression by Frequency and Type of Healthcare Visits

Michael A. Horberg¹; Jackie Blank²; Kevin B. Rubenstein³; Leo B. Hurley⁴; Julia L. Marcus⁵; Daniel B. Klein⁶; Peter M. Kadleck⁷; Michael J. Silverberg⁸

¹Mid-Atlantic Permanente Med Group, Rockville, MD, USA; ²Kaiser Permanente Northern California, Oakland, CA, USA; ³Kaiser Permanente San Leandro Med Cntr, San Leandro, CA, USA; ⁴Mid-Atlantic Permanente Med Group, Washington, DC, USA

1036 Community Viral Load: Measure Validation and Public Health Utility

Kathryn M. Leifheit¹; Christina Schumacher²; Patrick Chaulk³; Carolyn Nganga-Good⁴; Jacky M. Jennings⁵

¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²Baltimore City Hlth Dept, Baltimore, MD, USA

1037 HIV Viral Suppression Among Adults Diagnosed With Depression in the United States

Runa Gokhale; Heather Bradley; Shikha Garg; Roy L. Shouse
CDC, Atlanta, GA, USA

1038 Clinician and Patient Attitudes Toward Financial Incentives for HIV Care (HPTN 065)

Jennifer H. Farrior¹; Allison Zerbe²; Ann Kurth³; Brett Hanscom⁴; Laura McKinstry⁵; Barry Zingman⁶; Fred Gordin⁶; Deborah Donnell⁴; Bernard Branson⁷; Wafaa M. El-Sadr²
¹*FHI 360, Durham, NC, USA*; ²*ICAP at Columbia Univ, New York, NY, USA*; ³*New York Univ, New York, NY, USA*; ⁴*SCHARP, Fred Hutchinson Cancer Rsr Cntr, Seattle, WA, USA*; ⁵*Montefiore Med Cntr, Bronx, NY, USA*; ⁶*VA Med Cntr, Washington, DC, USA*; ⁷*Scientific Affairs, Atlanta, GA, USA*

1039 A Commitment Contract for Virologic Suppression in Poorly Adherent HIV+ Individuals

Marcela Alsan¹; John Beshears²; Minh Nguyen³; James Choi²; Wendy Armstrong³; Bridget Madrian²; Carlos del Rio⁴; David Laibson²; Vincent C. Marconi⁴
¹*Stanford Univ, Stanford, CA, USA*; ²*Harvard Univ, Boston, MA, USA*; ³*Emory Univ, Atlanta, GA, USA*; ⁴*Emory Univ Sch of Med, Atlanta, GA, USA*

1040 Quantifying Viral Load Distribution in a Clinic Population Using the Lorenz Curve

Katerina Christopoulos; Wendy Hartogenesis; David V. Glidden; Christopher Pilcher; Monica Gandhi; Elvin H. Geng
Univ of California San Francisco, San Francisco, CA, USA

1041 Recent Increases in Virologic Suppression Among HIV-Positive MSM in Vancouver, Canada

David M. Moore¹; Zishan Cui²; Nathan J. Lachowsky¹; Henry F. Raymond³; Eric A. Roth⁴; Ashleigh Rich²; Paul Sereda²; David Hall¹; Julio Montaner⁵; Willi McFarland²; Robert S. Hogg⁶
¹*Univ of British Columbia, Vancouver, BC, Canada*; ²*BC Cntr for Excellence in HIV/AIDS, Vancouver, BC, Canada*; ³*Univ of California San Francisco, San Francisco, CA, USA*; ⁴*Univ of Victoria, Victoria, BC, Canada*; ⁵*Vancouver Coastal Hlth, Vancouver, BC, Canada*; ⁶*Simon Fraser Univ, Burnaby, BC, Canada*

DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL CONCERNS

Disclosure information is presented generally as submitted by the corresponding presenting abstract author or invited speaker. The authors and speakers below provided all relevant disclosures of financial relationships with commercial entities for themselves and their spouses or partners, as well as funding provided to their institutions.

Abram, Michael

Self: Employee and stockholder, Gilead Sciences

Allavena, Clotilde

Self: Travel grants or honoraria from Mylan, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD, and ViiV Healthcare

Altfeld, Marcus

Self: Speaker honorarium from MSD, Bristol-Myers Squibb, Janssen & Janssen, and Gilead

Althoff, Keri

Self: Medical Advisory Board for Gilead Sciences

Ananworanich, Jintanat

Self: Advisory boards for ViiV Healthcare and Merck

Anderson, Peter

Self: Contract work and study drug donation from Gilead Sciences

Asmuth, David

Self: Grant and travel funds support from Entera Health

Bernardino, Jose

Self: Personal fees from Bristol-Myers Squibb, Gilead Sciences, ViiV healthcare, MSD, and Janssen

Berry, Stephen

Self: Advisor for Bristol-Myers Squibb

Bisson, Gregory

Self: Endpoint adjudicator for a post-marketing surveillance study for Pfizer; consultant for Celgene

Boettiger, David

Self: Funding from Gilead Australia

Boyd, Mark

Self: Research funding from AbbVie, Merck, and Gilead; honoraria for service on HIV advisory boards from Merck, Gilead, and ViiV Healthcare; honoraria for educational presentations from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim

Brinkman, Kees

Self: Advisory boards for AbbVie, ViiV Healthcare, Gilead, Janssen, and Bristol-Myers Squibb

Brockmeyer, Norbert

Self: Congress sponsorship and research funding from Gilead, MSD, Sanofi Pasteur, ViiV Healthcare, and GSK

Brophy, Jason

Self: Educational Grant from AbbVie

Butt, Adeel

Institution: Grants funding from AbbVie and Gilead

Calcagno, Andrea

Self: Research grants from Gilead and Bristol-Myers Squibb; speaker's honoraria from AbbVie, Bristol-Myers Squibb, Gilead, MSD, Janssen-Cilag, and ViiV

Chang, Larry

Self: Advisor, stockholder, entitled to royalties, emocha Mobile Health

Charpentier, Charlotte

Honorarium from MSD, Gilead, ViiV, Bristol-Myers Squibb, and Janssen

Chen, Beatrice

Institution: Research funding from Bayer, Medicines 360, and Agile Therapeutics

Chockalingam, Leela

Self: Advisor, Gilead Sciences

Christensen, Stefan

Self: Consulting or speaker grant from AbbVie, Bristol-Myers Squibb, Gilead, Hexal, Janssen-Cilag, MSD, Reckitt-Benckiser, ViiV Healthcare

Cohen, Stephanie

Self: Study drug and drug-level testing from Gilead

Connick, Elizabeth

Self: DSMB for a study partially funded by Sangamo Biosciences

Cooper, Curtis

Self: Advisor and research funding from Gilead and AbbVie; advisor for Merck

Costagliola, Dominique

Self: Travel grants, honoraria, and study grants from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme-Chibret, and ViiV Healthcare

Cranston, Ross

Spouse or Partner: Consultant for Novical Life Sciences and ABIVAX; research grants from Janssen R&D and ViiV Healthcare

Cysique, Lucette

Self: Research support from MSD, AbbVie
Institution: Research support from AbbVie

D'Aquila, Richard

Self: Honoraria from Janssen Scientific Affairs, Janssen Therapeutics, and Clinical Care Options

DeJesus, Edwin

Self: Advisory board and speaker fees from Janssen and Gilead Science

Derby, Nina

Institution: Received Poly-ICLC from Oncovir

Dicker, Ira

Self: Employee of Bristol-Myers Squibb

Dolling, David

Institution: Research support from GlaxoSmithKline, Gilead Sciences, and Boehringer Ingelheim

Eckard, Allison

Self: Advisor and speaker for Gilead Sciences
Institution: Research funding from GlaxoSmithKline, Cubist Pharmaceuticals, and Bristol-Myers Squibb

Eley, Timothy

Self: Employee and shareholder of Bristol-Myers Squibb

Institution: Bristol-Myers Squibb owned the rights to BMS66068 when this study was conducted

Erlanson, Kristine

Self: Research funding from Gilead Sciences

Eron, Joseph

Self: Consultant to Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare
Institution: Research grants from Janssen, Gilead Sciences, ViiV Healthcare, and AbbVie

Fidler, Sarah

Self: Research funding from GSK and MSD

Gallant, Joel

Self: Consulting and advisory boards: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co, and ViiV Healthcare
Institution: Grant funding from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co, and Sangamo

Garrett, Katy

Institution: Research grant from Gilead Sciences

Gatell, Jose Maria

Self: Honoraria for lectures from AbbVie, Janssen, Gilead, ViiV, and Bristol-Myers Squibb
Institution: Grant funding from MSD, AbbVie, Janssen, Gilead, ViiV, and Bristol-Myers Squibb

Gaur, Aditya

Self: Study investigator on clinical trials sponsored by Gilead Sciences

Giaquinto, Carlo

Self: Advisor to ViiV, Merck, Gilead, speaker travel from ViiV Healthcare
Institution: Grants from ViiV Healthcare, Gilead, Bristol-Myers Squibb, and Johnson and Johnson

Gisslén, Magnus

Self: Research grants from Abbott/AbbVie, Baxter, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec; honoraria as speaker and/or scientific advisor from Abbott/AbbVie, Bioinvent, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, Merck, Pfizer, Roche, and Tibotec

Golub, Sarit

Self: Study drug from Gilead

Gottlieb, Geoffrey

Self: Research support from Gilead Sciences, Alere, and Abbott Molecular Diagnostics

Grant, Alison

Self: Validation panels from Alere

Grant, Robert

Self: Study medication from Gilead Sciences

Grobler, Jay

Disclosure will be provided prior to the presentation

Hamzah, Lisa

Self: Funding to attend conferences from Gilead Sciences and honoraria from Janssen-Cilag

Harrigan, P. Richard

Self: Grants from, advisor to, or speaker for events sponsored by Pfizer, GlaxoSmithKline, Abbott, Merck, Tobira Therapeutics, Virco, and Quest Diagnostics; consultant for ViiV Healthcare, Tobira Therapeutics, Selah Genomics, and Quest Diagnostics; stockholder in Merck, Illumina, Gilead, and EKF Diagnostics; funding support from CIHR/GSK Research Chair in Clinical Virology
Institution: Contracts to perform drug-resistance testing for Merck, ViiV, and Janssen

Harris, Reuben

Self: Cofounder of ApoGen Biotechnologies

Heath, Sonya

Self: Advisor for and grant from Merck
Institution: Research award from Merck

Hernandez, Dennis

Self: Employee of Bristol-Myers Squibb

Hoeningl, Martin

Self: Speaker honorarium from Merck
Institution: Funding from Gilead

Hsue, Priscilla

Self: Honoraria from Gilead, Merck, and Bristol-Myers Squibb

Huang, Wei

Self: Employee of Monogram Biosciences

Huhn, Gregory

Self: Consultant for Gilead Sciences and ViiV; therapeutic advisor for Practice Point Communications

Hunt, Peter

Self: Consultant for Merck, Gilead, and ViiV

Jain, Vivek

Institution: Grant support from Gilead Sciences

Jensen, Bjoern-Erik

Self: Board membership ViiV (past); payment for lectures from ViiV, Janssen-Cilag, Boehringer Ingelheim, Gilead, AbbVie, and Bristol-Myers Squibb (past)

Kalayjian, Robert

Self: Community advisory board, Sensor-Kinesis Corporation

Kattakuzhy, Sarah

Institution: Research grant from Gilead

Khalilieh, Sauzanne

Self: Employee of Merck Sharp & Dohme; may hold stock or stock options

Institution: Research funding from Merck & Co

Kiser, Jennifer

Spouse or Partner: Speaker for Astellas

Institution: Research grant from Janssen

Knox, David

Self: Honoraria from ViiV Healthcare and Gilead Sciences

Institution: Funding from Gilead Sciences

Kouanfack, Charles

Self: Board member for Bristol-Myers Squibb

Krystal, Mark

Self: Employee of Bristol-Myers Squibb

La Rosa, Alberto

Self: Employment at Janssen Peru

LaCombe, Karine

Self: Advisor for Bristol-Myers Squibb, Gilead, MSD, AbbVie, and Janssen

Institution: Research grant from Gilead and Janssen

Landovitz, Raphael

Self: Consulting fees, travel, and drug supply from Gilead Sciences

Letendre, Scott

Self: Advisory board: ViiV Healthcare and Merck & Co

Institution: Research funds from Gilead Sciences and ViiV Healthcare

Lingappa, Jairam

Self: Scientific advisory board, Prosetta Antivirals

Liu, Albert

Self: Study drug and drug level testing provided by Gilead Sciences

Longley, Nicky

Self: Speaker honoraria from Pfizer and MSD, development of educational materials for TerraNova, consultant for Fujifilm Pharmaceuticals
Spouse or Partner: Yes

Institution: St George's University of London, investigator-initiated research grant (Pfizer)

Luetkemeyer, Anne

Self: Advisor for and travel support from Bristol-Myers Squibb and Gilead

Institution: Research grant support from AbbVie, Bristol-Myers Squibb, Gilead, Merck, and Pfizer

Mallon, Patrick

Self: Honoraria, travel, and/or consultancy from Gilead Sciences, Bristol-Myers Squibb, ViiV Healthcare, Merck Sharpe & Dohme, and Janssen-Cilag

Marcus, Julia

Self: Research grant support from Merck

Margolis, David

Self: Employee of ViiV Healthcare; stockholder in GSK

Martus, Gloria

Self: Grant award from Gilead

Mauss, Stefan

Self: Scientific boards, review panels, and board membership for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Roche, and ViiV; speaker's bureau for AbbVie, Bristol-Myers Squibb, Gilead, Roche, and Janssen; Consultant for AbbVie, Bristol-Myers Squibb

Mayer, Kenneth

Self: Research grants from Gilead Sciences and ViiV

McComsey, Grace

Self: Employee, advisor to Gilead, ViiV, Bristol-Myers Squibb, and ICON

Institution: Grant support from Gilead, ViiV, Bristol-Myers Squibb, and AstraZeneca

McGowan, Ian

Self: Advisor, Abivax and Novicoll Life Sciences

Institution: Research grant from Janssen R&D

Meissner, Eric

Institution: Support from Gilead Sciences

Merat, Sabrina

Self: Employee of AIMM Therapeutics
Institution: AIMM Therapeutics is a joint venture of IMMPACT and the Academic Medical Center at the University of Amsterdam

Mirochnick, Mark

Self: Consultant for Merck; DSMB member, Merck and ViiV

Mogalian, Erik

Self: Employee of Gilead Sciences

Molina, Jean-Michel

Self: Advisory board for Gilead, Merck, ViiV, Janssen, and Bristol-Myers Squibb; grants from Merck and Gilead

Murray, Miranda

Self: Employee of ViiV Healthcare

Naggie, Susanna

Self: Advisor for Gilead, AbbVie, Bristol-Myers Squibb, Janssen, Vertex, and Merck

Institution: Research grants from Gilead, AbbVie, Bristol-Myers Squibb, Janssen, Vertex, and Merck

Newton, Alicia

Self: Consultant for Monogram Biosciences

Obermeier, Martin

Institution: Research grant from Hologic

Oberoi, Rajneet**Self:** Employee and stockholder, AbbVie**Spouse or Partner:** Employee and stockholder, AbbVie**Patel, Rupa****Self:** Advisor, Gilead Advisory Meeting for PrEP**Perez-Valero, Ignacio****Self:** Lecture payments from Gilead Sciences SA, Bristol-Myers Squibb SA, Janssen-Cilag SA, and Viiv Laboratories**Phillips, Andrew****Self:** Honoraria (Gilead Sciences, AbbVie), consultant (GlaxoSmithKline)**Pickett, James****Institution:** Grants from Gilead**Post, Frank****Self:** Support from Gilead Sciences; personal fees from Gilead Sciences, Viiv, AbbVie, MSD, and Janssen; grants from Viiv and Gilead**Ray, Neelanjana****Self:** Employee of Bristol-Myers Squibb**Rijnders, Bart****Self:** Research grants, board memberships, consultancy, lecture payment, and travel reimbursement from Gilead, MSD, Bristol-Myers Squibb, and Janssen-Cilag**Robertson, Kevin****Self:** Consultant for GSK**Rockstroh, Jürgen****Self:** Honoraria for consulting or speaking from Abbott, AbbVie, Bionor, Bristol-Myers Squibb, Cipla, Gilead Sciences, Janssen, Merck, and Viiv**Rodgers, Mary****Self:** Employee and shareholder of Abbott Laboratories**Spouse or Partner:** Shareholder of Abbott Laboratories**Sabin, Caroline****Self:** Advisor, Gilead Sciences, Viiv Healthcare, Janssen-Cilag, Bristol-Myers Squibb**Scherzer, Rebecca****Self:** Honorarium from Merck**Schinkel, Janke****Self:** Financial support from Janssen-Cilag and Gilead**Schuetfort, Gundolf****Self:** Travel and speaker grants from Gilead Sciences, Viiv Healthcare, Janssen, MSD, and Bristol-Myers Squibb**Scully, Eileen****Spouse or Partner:** CEO of emocha medical software platform**Sevinsky, Heather****Self:** Employee and shareholder of Bristol-Myers Squibb**Sigel, Keith****Self:** Paid consultant to Gilead Sciences**Silverberg, Michael****Institution:** Research grants from Pfizer and Merck**Spire, Bruno****Institution:** Research support from Abbott France, GlaxoSmithKline, Roche, and Schering Plough**Steens, Jean-Marc****Self:** Stockholder in GlaxoSmithKline and ABIVAX; chief medical officer at ABIVAX**Stephan, Christoph****Self:** Travel and speaker grants from Gilead Sciences, AbbVie, Viiv Healthcare, Janssen, MSD, and Bristol-Myers Squibb**Sued, Omar****Self:** Honorarium and travel grants from Glaxo and AbbVie**Institution:** Research grant from Viiv; support from Merck and Richmond Argentina**Sulkowski, Mark****Self:** Fees from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Tobira; consultant/advisory board member for AbbVie, Achillion, Cocystal, Bristol-Myers Squibb, Gilead, and Janssen**Institution:** Research grants from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, and Gilead**Sullivan, Patrick****Self:** Grant from Gilead Sciences**Tan, Darrell****Institution:** Research grants from Gilead and Viiv; honoraria from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Viiv**Thio, Chloe****Institution:** Investigator initiated research grant from Gilead Sciences**Thorne, Claire****Self:** Grant from AbbVie**Tieu, Hong Van****Self:** Research grant from Merck**Trkola, Alexandra****Spouse or Partner:** DSMB member for Merck; advisor to Gilead, Boehringer Ingelheim, and Janssen; research grants from Gilead, Merck, Viiv, Roche, and Janssen**Utay, Netanya****Self:** Scientific adviser for Tobira Therapeutics**Vallari, Ana****Self:** Employee and shareholder of Abbott Laboratories**Spouse or Partner:** Shareholder of Abbott Laboratories**van Sighem, Ard****Institution:** Travel grants from Gilead Sciences; speaker honoraria from Janssen, Bristol-Myers Squibb, and Viiv Healthcare**Vera, Jaime****Self:** Lecture honoraria from Merck and Janssen-Cilag; sponsorship to attend scientific conferences from Janssen-Cilag, Gilead Sciences, AbbVie, and MSD**Verna, Elizabeth****Self:** Grant support from Merck and Sanofi**Volpe, Joseph****Self:** Employee of Monogram Biosciences**Waked, Imam****Self:** Speaker, investigator, and/or consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Hoffmann-La Roche, Janssen, Merck, Onxeo, and Pharco**Weinberg, Adriana****Spouse or Partner:** Patent royalties from Merck
Institution: Patent royalties from Merck**Weitz, David****Self:** Cofounder of several companies that use drop-based microfluidics**Whitney, James****Self:** Consultant for Bristol-Myers Squibb
Institution: Research grant from Gilead**Wilkin, Timothy****Institution:** Research support from Gilead and Bristol-Myers Squibb**Spouse or Partner:** Employee of Johnson & Johnson**Winston, Alan****Institution:** Research grant from Viiv Healthcare**Wittkop, Linda****Self:** Board member for Bristol-Myers Squibb**Wohl, David****Self:** Advisor to Gilead Sciences and Janssen
Institution: Funding from Gilead Sciences and Merck**Wyles, David****Self:** Grant/research support from AbbVie, Bristol-Myers Squibb, Gilead, Merck, and Tacere Therapeutics; consultant/advisor for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck**Yin, Michael****Self:** Consultant for Gilead

DISCLOSURE INFORMATION

The following have no relevant financial relationships to disclose. Any updates will be reflected in the mobile app.

Abbas, Ume	Becker, James	Carriquiry, Gabriela	Czaicki, Nancy	Falade-Nwulia, Oluwaseun
Abdel-hameed, Enass	Béguelin, Charles	Carroll, Michael	Dakshina, Subathira	Fallah, Mosoka
Abdel-Mohsen, Mohamed	Belaunzarán-Zamudio, Pablo	Cartwright, Emily	Damouche, Abderaouf Dan, Jennifer	Faria de Oliveira, Michelli Farquhar, Carey
Abdulhaqq, Shaheed	Bello, Fatai	Casavant, Isabelle	Dasgupta, Sharoda	Farrior, Jennifer
Abrams, Elaine	Bendavid, Eran	Casazza, Joseph	Davey, Richard	Fayorsey, Ruby
Adachi, Kristina	Bengtson, Angela	Castillo-Mancilla, Jose	D'Avino, Alessandro	Feder, Alison
Adland, Emily	Benhammou, Valerie	Ceccherini-Silberstein, Francesca	Davis, Nicole	Feinstein, Matthew
Adnan, Sama	Benito, Jose	Celum, Connie	Davy, Thibaut	Ferrand, Rashida
Aghaizu, Adamma	Benjamins, Laura	Cepeda, Javier	De, Asha	Finlayson, Teresa
Agwu, Allison	Berenguer, Juan	Cerrone, Maddalena	De Alwis, Paba	Finzi, Andrés
Ajibola, Gbolahan	Berry, Stephen	Chaillon, Antoine	de la Fuente Soro, Laura	Floyd, Sian
Akpirat, Siriwat	Best, Brookie	Chamie, Gabriel	de los Angeles, Christine	Fogel, Jessica
Akiyama, Hisashi	Bezemer, Daniela	Chan, Ellen	Paul, Ellen	Folkword, Joy
Alagaratnam, Jasmini	Bhagwat, Priya	Chang, Wei	de Monteynard, Laure-Amélie	Force, Gilles
Aliyu, Muktar	Bibollet-Ruche, Frederic	Charpentier, Charlotte	Debre, Patrice	Fourati, Slim
Alsan, Marcela	Bieniczak, Andrzej	Chaudhary, Omkar	Debyser, Zeger	Fox, Julie
Alteri, Claudia	Blish, Catherine	Chéret, Antoine	Declodet, Eric	Freeman, Michael
Alvarado, Melanie	Boender, Tamara Sonia	Cherutich, Peter	DeGroot, Nicholas	Frenkel, Lisa
Alvarez, Angeles	Bolay, Fatorma	Chettimada, Sukrutha	Del Amo, Julia	Frias, Mario
Alvarez, Xavier	Boltz, Valerie	Chin, Alfred	Delaney, Kevin	Friedland, Barbara
Ances, Beau	Bonito, Andrea	Ching, Christopher	DeLaugerre, Constance	Friedland, Gerald
Andany, Nisha	Boon, Denali	Chitre, Avantika	Delobel, Pierre	Friedman, Evan
Anderson, Brett	Bor, Jacob	Chiu, Calvin	Dennis, Ann	Furrer, Hansjakob
Anderson, Erik	Borges, Alvaro	Choi, Sung Eun	Desai, Seema	Gabuzda, Dana
Andrews, Chasity	Boulware, David	Chow, Dominic	Destache, Christopher	Gagne, Matthew
Andrews, Sophie	Bourgi, Kassem	Chow, Felicia	Dezutti, Charlene	Gaisa, Michael
Angelidou, Konstantia	Bowman, Natalie	Christ, Frauke	Di Rosa, Michelino	Galang, Romeo
Anstett, Kaitlin	Bradley, Heather	Christensen-Quick, Aaron	Diaz, Andreas	Galarraga, Omar
Antinori, Andrea	Branch, Andrea	Christopoulos, Katerina	Dillon, Stephanie	Gandhi, Monica
Apetrei, Cristian	Braunstein, Sarah	Chung, Shang-Lin	Dimitrov, Dobromir	Gandhi, Rajesh
Arpadi, Stephen	Brennan, Alana	Ciaranello, Andrea	Dirajlal-Fargo, Sahera	Gaolathe, Tendani
Aston, Stephen	Brenner, Bluma	Ciccirelli, Nicoletta	Dorsey, Kerri	Garcia-Lerma, Gerardo
Atta, Mohamed	Breton, Yann	Cillo, Anthony	Droz, Daniel	Garrido, Carolina
Atugonza, Rita	Briz, Verónica	Clarridge, Katherine	Doitsh, Gilad	Gavegnano, Christina
Auld, Sara	Brooks, John	Clement, Meredith	Dorr, Maggie	Gay, Cynthia
Avelino-Silva, Vivian	Brooks, Kristina	Clouse, Kate	Dorsey, Kerri	Geldsetzer, Pascal
Avihingsanon, Anchalee	Bruner, Katherine	Cockerham, Leslie	Dryden-Peterson, Scott	Geng, Elvin
Avila-Rios, Santiago	Brust, James	Coffie, Ahuatchi	Du, Yimin	George, Varghese
Ayieko, James	Buchacz, Kate	Coghill, Anna	Duchesne, Léa	Geretti, Anna Maria
Ayles, Helen	Budd, Matthew	Coiras, Mayte	Ericsen, Adam	Geman, Danielle
Azzoni, Livio	Buggert, Marcus	Colbers, Angela	Esser, Stefan	Ghadshenas, Matine
Bachanas, Pamela	Bui, John	Collier, Dami	Edelstein, Zoe	Ghys, Peter
Bacon, Oliver	Bunge, Katherine	Collini, Paul	Egger, Matthias	Giacomet, Vania
Badia, Roger	Burchell, Ann	Collins, Sean	El-Diwany, Ramy	Gianella, Sara
Baeten, Jared	Burdo, Tricia	Coppola, Nicola	El-Sadr, Wafaa	Giaquinto, Carlo
Baker, Jason	Burgener, Adam	Côté, Héléne	Emerson, Michael	Gini, Joshua
Balagopal, Ashwin	Calascibetta, Francesca	Cotugno, Nicola	Emery, Ann	Glick, Sara
Balaji, Alexandra	Cameron, Mark	Court, Richard	Ericesen, Adam	Gokhale, Runa
Ballana, Ester	Campbell, Edward	Crane, Heidi	Esser, Stefan	Goldberg Raifman, Julia
Banga, Riddhima	Campbell, Ellsworth	Crepaz, Nicole	Estas, Jacob	Golumbeanu, Monica
Bannert, Norbert	Canada, David	Cressey, Tim	Eted, Jean-François	Gómez-Mora, Elisabet
Bar, Katharine	Canan, Chelsea	Cribbs, Sushma	Euler, Zelda	Gonculea, Anda
Barnabas, Ruanne	Cannon, Paula	Crowe, Suzanne	Eving, Teresa	Gopalan, Narendran
Barreto-de-Souza, Victor	Caplan, Margaret	Crowell, Trevor	Ewing, Alexander	Gossez, Morgane
Bassett, Ingrid	Capparelli, Edmund	Cummins, Nathan	Fabra Garcia, Amanda	Goswami, Neela
Batista, Facundo	Carlucci, James	Cunyat, Francesc	Faimi, Diana	Gowda, Charitha

Goyette, Marielle	Janjua, Sumbal	Lange, Camille	Maskew, Mhairi	Ndawinz, Jacques
Grabowski, Mary	Jao, Jennifer	Lanzi, Anastasia	Mathad, Jyoti	Ndembu, Nicaise
Grant, Jennifer	Japhet, Mbae	Laraque, Fabienne	Matsui, Yusuke	Ndjeka, Norbert
Granziera, Cristina	Jaquet, Antoine	Larmarange, Joseph	Mattson, Christine	Ndlovu, Zibusiso
Graves, Justin	Jeffries, Carrie	Laskey, Sarah	Maughan, Robert	Neary, Megan
Greene, Sharon	Jenks, Jeffrey	le Roux, Stanzi	Mave, Vidya	Nel, Annalene
Griesel, Rulan	Jiang, Xiong	Lee, Eric	Mavian, Carla	Nelson, LaRon
Griffith, Linda	Jin, Steven	Lee, Guinevere	Mayer, Kenneth	Nelson, Rob
Grimsrud, Anna	Johnson, Erica	Lee, Hana	McCormack, Sheena	Neukam, Karin
Grobler, Jay	Johnson, Leah	Leifheit, Kathryn	McGettrick, Padraig	Newsom, Astrid
Grome, Heather	John-Stewart, Grace	Leitman, Ellen	McGillen, Jessica	Nguyen, Thao
Gruenewald, Analise	Jones, Brad	Lepik, Katherine	McGowan, Ian	Nichols, Brooke
Guha, Anika	Joseph, Sarah	Leung, Janice	McGrath, Christine	Ning, Chuanyi
Guiteau Moise, Colette	Jotwani, Vasantha	Levy, Matthew	McGrath, Michael	Njuguna, Irene
Gulick, Roy	Justice, Amy	Li, Danny	McKellar, Mehri	Norton, Brianna
Gupta, Ravindra	Kabore, Firmin	Li, Guanhan	Meggi, Bindiya	Nou, Eric
Gupta, Sundeeep	Kadede, Kevin	Li, Jonathan	Mehra, Vikram	Novikova, Mariia
Gutiérrez, Carolina	Kajubi, Richard	Li, Weizhe	Mehta, Sanjay	Novitsky, Vladimir
Haas, David	Kallianpur, Asha	Li, Xiang	Mehta, Shruti	Nowak, Piotr
Haberlen, Sabina	Kallianpur, Kalpana	Li, Xiaojun	Mendoza, Daniel	Nowak, Rebecca
Haeri Mazanderani, Ahmad	Kanthula, Ruth	Li, Yijia	Menkova-Garnier, Inna	O'Brien, Meagan
Hamimi, Chiraz	Karn, Jonathan	Lifson, Alan	Merchante, Nicolás	O'Brien, Sean
Hanna, David	Karugaba, Patrick	Lima, Viviane	Merli, Marco	Ocfemia, M. Cheryl Banez
Harada, Shigeyoshi	Katz, Ingrid	Lin, Naomi	Metsch, Lisa	O'Connor, Gemma
Hare, C. Bradley	Kearney, Mary	Lincez, Pamela	Meyers, Kathrine	Odayer, Jasantha
Hataye, Jason	Kelesidis, Theodoros	Little, Susan	Miaihles, Patrick	Odongo, Fredrick
Hatleberg, Camilla	Kelley, Colleen	Lo, Janet	Micci, Luca	Ofofokun, Ighowwerra
He, Xuan	Kersanske, Laura	Lodi, Sara	Mier-y-Teran-Romero, Luis	O'Halloran, Jane
Heffron, Renee	Khan, Palwasha	Loiseau, Claire	Miles, Brodie	Okano, Justin
Hellmuth, Joanna	Kiama, Catherine	Longenecker, Chris	Miller, Caitlin	Okoboi, Stephen
Hemanth Kumar, Agibothu	Kiguoya, Marion	López Varela, Elisa	Miller, Elizabeth	Olagunju, Adeniyi
Kupparam	Kim, Nina	Lowenthal, Elizabeth	Miller, Shannon	Oldenburg, Catherine
Hendrickson, Cheryl	Kintu, Alexander	Lucas, Gregory	Mimami, Rumi	Oliver, Nora
Hennessey, Claudine	Kirkegaard-Klitbo, Ditte	Luévano, Jesús	Miro, Jose	Olney, Jack
Henrich, Timothy	Kirkpatrick, Allison	Luo, Ma	Mohr, Raphael	Olvera-García, Gustavo
Hernandez, Matthew	Kiselinova, Maja	Ma, Qing	Moltó, José	Orrell, Catherine
Hess, Kristen	Kityo, Cissy	Macalino, Grace	Monel, Blandine	Ott, Adina
Hileman, Corri Lynn	Kleinstein, Sarah	MacBrayne, Christine	Montgomery, Martha	Ozanne, Alexandra
Hill, Alison	Klubberg, Sheryl	Mackelprang, Romel	Moore, Carolyn	Page, Iain
Hill, Andrew	Koelsch, Kersten	MacLeod, William	Moore, David	Palar, Kartika
Hinckley, Sandy	Koethe, John	Mailliard, Robbie	Moragas, Matias	Palchoudhuri, Riya
Hleyhel, Mira	Kong, Xiangrong	Majonga, Edith	Morawski, Bozena	Palesch, David
Hoare, Jacqueline	Körner, Christian	Makarova, Natalia	Mori, Masahiko	Palk, Laurence
Hoffman, Risa	Koss, Catherine	Maki, Pauline	Morris, Martina	Parikh, Urvi
Hoffmann, Christopher	Kourtis, Athena	Makinson, Alain	Mothe, Beatriz	Parker, Gary
Hogan, Louise	Kovari, Helen	Malaba, Thokozile	Moyo, Sikhulile	Parker, Robert
Holtz, Timothy	Krakora, Rebecca	Mallard, Jacyln	Moyi, Eirini	Parkin, Neil
Hong, Feiyu	Kroidl, Arne	Manabe, Yukari	Mudd, Joseph	Pasquale, Dana
Hood, Julia	Kumar, Nitasha	Manak, Mark	Mugglin, Catrina	Patel, Eshan
Hoots, Brooke	Kumwenda, Johnstone	Manganaro, Lara	Mugo, Peter	Patel, Hetal
Hoover, Karen	Kuniholm, Mark	Manne-Goehler, Jennifer	Mugwanya, Kenneth	Patel, Monita
Hope, Rebecca	Kurth, Ann	Mannheimer, Sharon	Mujigira, Andrew	Patenaude, Bryan
Horberg, Michael	Kuruc, JoAnn	Manuzak, Jennifer	Mukerji, Shibani	Pavlakis, George
Howard, Andrea	Kuwata, Takeo	Manzardo, Christian	Mulligan, Nikki	Pavlinac, Patricia
Howard, Louisa	Kwarisiima, Dalsone	Märkelin, Anne-Geneviève	Münk, Carsten	Pavone, Paolo
Howarth, Alison	Kwena, Zachary	Marconi, Vincent	Murnane, Pamela	Pena-Cruz, Victor
Hue, Stephane	Kwong, Peter	Maritz, Jean	Murphy, Gary	Pérez, Alejandro
Hughes, Stephen	Lachowsky, Nathan	Markowitz, Martin	Murray, Daniel	Pernas, Maria
Hullegie, Sebastiaan	Lada, Steven	Marra, Christina	Mwangwa, Florence	Peterson, Christopher
Hurley, James	Laeyendecker, Oliver	Martinello, Marianne	Myer, Landon	Petrovas, Costantinos
Imamichi, Hiromi	Lahuerta, Maria	Martin-Gayo, Enrique	Mylvaganam, Geetha	Pettifor, Audrey
Innes, Steve	Lai, Ming-Tain	Martinson, Neil	Nadel, James	Phillips, Elizabeth
Introuini, Andrea	Lake, Jordan	Marzel, Alex	Nassau, Denis	Phiri, Comfort
Iqbal, Kashif	Lakritz, Jessica	Mascola, John	Nassau, Tanner	Phiri, Mwelwa
Jahn, Andreas	Lamers, Susanna	Masetti, Michela	Nattermann, Jacob	Phupitakphol, Tanit

Pickles, Michael
 Piwowar-Manning, Estelle
 Pizzato, Massimo
 Plana, Montserrat
 Plotkin, Marya
 Poizot-Martín, Isabelle
 Ponte, Rosalie
 Porter, Sarah
 Poteat, Tonia
 Power, Robert
 Powis, Kathleen
 Prabhu, Vineet
 Psomas, Christina
 Pufall, Erica
 Pushpakom, Sudeep
 Quinn, Jeffrey
 Rajoli, Rajith Kumar Reddy
 Ramachandran, Sumathi
 Raymond, Stéphanie
 Redd, Andrew
 Redmond, Sean
 Reepalu, Anton
 Registre, Ludy
 Remera, Eric
 Requena, Silvia
 Ribakare, Muhayimpundu
 Ribaldo, Heather
 Rice, Mabel
 Richardson, Eugene
 Riveira-Muñoz, Eva
 Rivera, Vanessa
 Rivera Pinto, Javier
 Roan, Nadia
 Roberts, Owain
 Roberts, Sarah
 Rocafort, Muntasa
 Rodríguez-Arbolí, Eduardo
 Rohner, Eliane
 Rohr, Julia
 Rolland, Morgane
 Romero, Fabio
 Rosen, Elias
 Rosen, Sydney
 Rosenberg, Molly
 Rovelli, Cristina
 Roy, Monika
 Rozada, Ignacio
 Rubin, Eric
 Ruperez, Maria
 Ryom, Lene
 Ryscavage, Patrick
 S Arunachalam, Prabhu
 Sabri, Bushra
 Sacktor, Ned
 Sagaon Teyssier, Luis
 Sagar, Manish
 Sagnelli, Caterina
 Salantes, Brenda
 Salgado, Maria
 Salmon-Ceron, Dominique
 Samandari, Taraz
 Samuels, David
 Sanford, Ryan
 Sania, Ayesha
 Santiago, Mario
 Sarpel, Dost
 Saule, Irma
 Scanlin, Kathleen
 Schalkwijk, Stein
 Scherrer, Alexandra
 Schietroma, Ivan
 Schifanella, Luca
 Schifitto, Giovanni
 Schlusser, Katherine
 Schommers, Philipp
 Schonfeld, Daniel
 Schuetz, Alexandra
 Schulze, Anna
 Schulz, Christian
 Schutz, Charlotte
 Seaman, Michael
 Seifert, Sharon
 Seipone, Ikanyeng
 Sekaly, Rafick
 Sengayi, Mazvita
 Seremba, Emmanuel
 Severe, Karine
 Shanaube, Kwame
 Shapiro, Roger
 Sharma, Anjali
 Sharp, Joseph
 Shepherd, Leah
 Shiau, Stephanie
 Shieh, Eugenie
 Shin, Sanghyuk
 Shirakawa, Kotaro
 Shive, Carey
 Shoreinstein, Joshua
 Shu, Sherry
 Siberry, George
 Sibiude, Jeanne
 Simon, Tracey
 Simonetti, Francesco
 Simonich, Cassandra
 Simons, Lisa
 Singh, Ravesh
 Singh, Urisha
 Sinha, Arjun
 Sips, Magdalena
 Sissoko, Daouda
 Sluis-Cremer, Nicolas
 Smith, Jennifer
 Smith, Lou
 Sobolewski, Michele
 Søgaard, Ole
 Sohn, Annette
 Solomon, Sunil
 Somasundaran, Mohan
 Somsouk, Ma
 Stahlman, Shauna
 Stam, Arjen
 Steba, Gaby
 Steele, Sarah Jane
 Stéfic, Karl
 Stek, Alice
 Stella Ascariz, Natalia
 Stephenson, Kristine
 Stucki, David
 Sudjaritruk, Tavitiya
 Sultana, Tahmina
 Summers, Michael
 Sunshine, Sara
 Svicher, Valentina
 Swartz, Talia
 Sweat, David
 Switzer, William
 Symons, Jori
 Taburet, Anne-Marie
 Tang, Songyuan
 Tang, Weiming
 Tarancón, Laura
 Taylor, Barbara
 Teasdale, Chloe
 Telwatte, Sushama
 Thienkrua, Warunee
 Thio, Chloe
 Thirumurthy, Harsha
 Thomas, Aurielle
 Thompson, Corbin
 Tiendrebeogo, Thierry
 Tippett Barr, Beth
 Todesco, Eve
 Tokunaga, Kenzo
 Tomescu, Costin
 Torian, Lucia
 Torriani, Martin
 Tovanabutra, Sodsai
 Trautmann, Lydie
 Treasure, Graham
 Trickey, Adam
 Truong, Hong-Ha
 Tsai, Ming-Han
 Tully, Damien
 Turan, Janet
 Underwood, Jonathan
 Uprety, Priyanka
 Urano, Emiko
 Valcour, Victor
 Valere, Kimyata
 Valiaveittil, Christina
 Van Cutsem, Gilles
 van der Straten, Ariane
 Van Handel, Michelle
 Vanhommerig, Joost
 Vasan, Sandhya
 Vassallo, Matteo
 Vaz, Paula
 Venuto, Charles
 Verna, Elizabeth
 Villegas, Guillermo
 Visseaux, Benoit
 Vivancos-Gallego, M.J.
 Vo, Quynh
 Vollbrecht, Thomas
 Wagner, Gabriel
 Waitt, Catriona
 Walker, Bruce
 Walker, Naomi
 Walker-Sperling, Victoria
 Wallis, Carole
 Wandeler, Gilles
 Wang, Jiayi
 Wang, Ruibin
 Wang, Zhengyan
 Webel, Allison
 Weigel, Bernard
 Weiss, Kevin
 Weissman, Sharon
 Weinert, Cyprian
 Wetzel, Katherine
 Wheeler, Darrell
 White, Darcy
 White, Jessica
 Whittles, Lolith
 Wilkinson, Thomas
 Williams, John
 Williams, Paige
 Wilson, Eleanor
 Wilson, Kate
 Winckelmann, Anni
 Winter, Joanne
 Wittkop, Linda
 Wiznia, Andrew
 Wohlfelder, Michael
 Wong, Ngai Sze
 Wood, Sarah
 Worobey, Michael
 Wu, Beiqing
 Wu, Yuanfei
 Yang, Shu
 Yaylali, Emine
 Yebra, Gonzalo
 Yek, Christina
 Yin, Li
 Yolitz, Jason
 Younas, Mehwish
 Yu, Wen-Han
 Yukl, Steven
 Zahn, Jennifer
 Zanni, Markella
 Zash, Rebecca
 Zauanders, John
 Zerbato, Jennifer
 Zheng, Wenjing

INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that noted women or women's issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

TUESDAY, FEBRUARY 23, 2016

- 33 Breast Milk and In Utero HIV-1 Transmission Select for Unique Envelope Signatures**, Thomas A. Wilkinson, Children's Hosp of Los Angeles, Los Angeles, CA, USA, et al. (Oral Abstracts Session O-3)
- 36 Impact of Maternal Tenofovir Use on HIV-Exposed Newborn Bone Mineral**, George K. Siberry, Eunice Kennedy Shriver NICHD, Bethesda, MD, USA, et al. (Oral Abstracts Session O-3)
- 49 Male Partner Home HIV Testing vs Clinic Invitation in Pregnancy: A Randomized Trial**, Carey Farquhar, Univ of Washington, Seattle, WA, USA, et al. (Oral Abstracts Session O-5)
- 301 Oral PrEP Enhances Genital HIV-Neutralizing IgA in HIV-1 Exposed Seronegative Women**, Jairam R. Lingappa, Univ of Washington, Seattle, WA, USA, et al. (Poster Abstracts Session P-E1)
- 438 Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women**, Nikki Mulligan, Univ of California San Diego, San Diego, CA, USA, et al. (Themed Discussion Session TD-1)
- 439 Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women**, Mark Mirochnick, Boston Univ Sch of Med, Boston, MA, USA, et al. (Themed Discussion Session TD-1)
- 638 Persistently Increased Ischemic Stroke Risk in HIV-Infected Women**, Virginia A. Triant, Massachusetts General Hosp, Boston, MA, USA, et al. (Poster Abstracts Session P-P1)
- 647 9-Year Trends in Non-Lipid Cardiovascular Disease Prevention Strategies in HIV+ Women**, David B. Hanna, Albert Einstein Coll of Med, Bronx, NY, USA, et al. (Poster Abstracts Session P-P2)
- 650 Reduced Ovarian Reserve Relates to Cardiovascular Disease Risk in Women With HIV**, Markella V. Zanni, Massachusetts General Hosp, Boston, MA, USA, et al. (Poster Abstracts Session P-P2)
- 770 No Increased Risk of HIV Incidence During Pregnancy**, Chloe A. Teasdale, ICAP at Columbia Univ, New York, NY, USA, et al. (Poster Abstracts Session P-S1)
- 771 Effect of Pregnancy on Response to Antiretroviral Therapy Among African Women**, Athena P. Kourtis, CDC, Atlanta, GA, USA, et al. (Poster Abstracts Session P-S1)
- 772 Trends in Hospitalizations of Pregnant HIV-Infected Women in the USA: 2004–2011**, Alexander Ewing, CDC, Atlanta, GA, USA, et al. (Poster Abstracts Session P-S1)
- 773 Cost-Effectiveness of Cotrimoxazole Among HIV+ Pregnant Women in Malarious Regions**, Sung Eun Choi, Stanford Univ, Stanford, CA, USA, et al. (Poster Abstracts Session P-S1)
- 774 Intracellular Atazanavir Concentrations Remain Stable During Pregnancy in HIV Women**, Andrea Bonito, Univ of Brescia, Brescia, Italy, et al. (Poster Abstracts Session P-S2)
- 775 Pharmacokinetics of Increased Dose Darunavir During Late Pregnancy and Postpartum**, Alice Stek, Univ of Southern California, Los Angeles, CA, USA, et al. (Poster Abstracts Session P-S2)
- 776 High Risk of Liver Enzyme Elevation in Pregnant Women Receiving Protease Inhibitors**, Jeanne Sibude, CESP, INSERM U1018, Le Kremlin-Bicêtre, France, et al. (Poster Abstracts Session P-S2)
- 779 Maternal CMV Urinary Shedding in HIV-Infected Women and Congenital CMV Infection**, Kristina Adachi, Univ of California Los Angeles, Los Angeles, CA, USA, et al. (Poster Abstracts Session P-S3)
- 823 Long-term Effects on Basal Ganglia in Youth With Perinatally Acquired HIV Infection**, Christine Paula de los Angeles, Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA, et al. (Poster Abstracts Session P-T2)
- 828 Impact of HLA-B*81-driven Escape Mutation L188F on VRC in Pediatric Slow Progression**, Ming-Han Tsai, Univ of Oxford, Oxford, UK, et al. (Poster Abstracts Session P-T3)
- 904 Young HIV+ Adults in Botswana Less Likely to Seek Treatment or Be Virally Suppressed**, Vladimir Novitsky, Harvard Sch of PH, Boston, MA, USA, et al. (Poster Abstracts Session P-W1)
- 919 Depression and Social Isolation Mediate Effect of HIV Stigma on Women's ART Adherence**, Janet M. Turan, Univ of Alabama at Birmingham, Birmingham, AL, USA, et al. (Poster Abstracts Session P-W3)
- 949 Association of Antiretroviral Use and Abnormal Uterine Bleeding in Women With HIV**, Christina Valiaveetil, Univ of Toronto, Toronto, ON, Canada, et al. (Poster Abstracts Session P-X1)
- 1047 The Role of Young Women in the HIV Epidemic in Benin, West Africa**, John R. Williams, Imperial Coll London, London, UK, et al. (Poster Abstracts Session P-Y1)

WEDNESDAY, FEBRUARY 24, 2016

- 101 EFV Reduced PK of Piperazine for Malaria Prevention in HIV+ Ugandan Pregnant Women**, Richard Kajubi, Makerere Univ, Kampala, Uganda, et al. (Oral Abstracts Session O-8)
- 102LB Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF**, Katy L Garrett, Univ of North Carolina at Chapel Hill, Chapel Hill, USA, et al. (Oral Abstracts Session O-8)
- 1058 Cost-Effectiveness of the Intravaginal Dapivirine Ring: A Modeling Analysis**, Jennifer Smith, Imperial Coll London, London, UK, et al. (Poster Abstracts Session P-Y3)
- 109LB A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women**, Jared M. Baeten, Univ of Washington, Seattle, WA, USA, et al. (Oral Abstracts Session O-9)

- 110LBSafety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women**, Annalene Nel, Intl Partnership for Microbicides, Paarl, South Africa, et al. (Oral Abstracts Session O-9)
- 277 Immune Activation, Cell Turnover, and Exhaustion in HIV+ Women With Heavy Alcohol Use**, Seema N. Desai, Rush Univ Med Cntr, Chicago, IL, USA, et al. (Poster Abstracts Session P-C7)
- 438 Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women**, Nikki Mulligan, Univ of California San Diego, San Diego, CA, USA, et al. (Poster Abstracts Session P-H2)
- 439 Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women**, Mark Mirochnick, Boston Univ Sch of Med, Boston, MA, USA, et al. (Poster Abstracts Session P-H2)
- 444 Effect of CYP2B6 Gene Variants on Levonorgestrel PK When Combined With EFV-Based ART**, Megan Neary, Univ of Liverpool, Liverpool, UK, et al. (Poster Abstracts Session P-H3)
- 448 Single-Dose Maraviroc Provides High Drug Levels in All Sites; No Gender Differences**, Julie Fox, Guys and St Thomas' NHS Fndn Trust, London, UK, et al. (Poster Abstracts Session P-H4)
- 449 PK of FTC, TDF and 3TC in Ugandan and Nigerian Breastfeeding Mother-Infant Pairs**, Catriona J. Waitt, Univ of Liverpool, Liverpool, UK, et al. (Poster Abstracts Session P-H4)
- 617 Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy**, Eliane Rohner, Inst of Social and Preventive Med, Univ of Bern, Bern, Switzerland, et al. (Poster Abstracts Session P-01)
- 621 Randomized Trial Comparing HIV-1 Cervical Shedding After Cryotherapy Versus LEEP**, Sharon A. Greene, Univ of Washington, Seattle, WA, USA, et al. (Poster Abstracts Session P-02)
- 622 Decline in Annual Pap Testing Among HIV-Positive Women in Ontario, Canada**, Ann N. Burchell, St Michael's Hosp, Toronto, ON, Canada, et al. (Poster Abstracts Session P-02)
- 623 Feasibility of Post-Partum Testing for HR-HPV Among HIV-Positive and -Negative Women**, Laura J. Benjamins, The Univ of Texas Med Sch at Houston, Houston, TX, USA, et al. (Poster Abstracts Session P-02)
- 624 Role of p16 Testing in Cervical Cancer Screening Among HIV-Infected Women**, Christine J. McGrath, Univ of Texas Med Branch at Galveston, Galveston, TX, USA, et al. (Poster Abstracts Session P-02)
- 625 High Prevalence of HR-HPV Infection in HIV-Infected Women From Tanzania**, Arne Kroidl, Univ of Munich, Munich, Germany, et al. (Poster Abstracts Session P-02)
- 638 Persistently Increased Ischemic Stroke Risk in HIV-Infected Women**, Virginia A. Triant, Massachusetts General Hosp, Boston, MA, USA, et al. (Themed Discussion Session TD-7)
- 706 Superior Glucose Tolerance and Metabolite Profiles in Women vs Men on Long-Term ART**, John R. Koethe, Vanderbilt Univ Sch of Med, Nashville, TN, USA, et al. (Poster Abstracts Session P-Q4)
- 757 Burden of Tuberculosis in HIV+ Pregnant & Postpartum Women in Cape Town, South Africa**, Landon Myer, Univ of Cape Town, Cape Town, South Africa, et al. (Poster Abstracts Session P-R8)
- 758 Pregnancy Intensifies the IFN- γ Suppression of HIV in TB-Infected Indian Women**, Jyoti S. Mathad, Weill Cornell Med Coll, New York, NY, USA, et al. (Poster Abstracts Session P-R8)
- 790 Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study**, Muktar H. Aliyu, Vanderbilt Inst for Global Hlth, Nashville, TN, USA, et al. (Poster Abstracts Session P-S5)
- 791 Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention**, Ruby N. Faylorsey, ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA, et al. (Poster Abstracts Session P-S5)
- 792 Continuity of Care Among Pregnant Women Lost to Follow-up After Initiating ART**, Kate Clouse, Vanderbilt Inst for Global Hlth, Nashville, TN, USA, et al. (Poster Abstracts Session P-S5)
- 793 Disclosure and Knowledge Are Associated With Retention in Malawi's Option B+ Program**, Risa M. Hoffman, Univ of California Los Angeles, Los Angeles, CA, USA, et al. (Poster Abstracts Session P-S5)
- 794 Initiating cART in Pregnancy: Impact on HIV RNA Decay**, Jasmini Alagaratnam, St Mary's Hosp, Imperial Coll NHS Trust, London, UK, et al. (Poster Abstracts Session P-S6)
- 795 Viramaic Episodes Occur Frequently in Postpartum South African Women on ART**, Landon Myer, Univ of Cape Town, Cape Town, South Africa, et al. (Poster Abstracts Session P-S6)
- 796 Viral Suppression and Retention 2–5 Years After ART Initiation in Pregnancy in Uganda**, Catherine A. Koss, Univ of California San Francisco, San Francisco, CA, USA, et al. (Poster Abstracts Session P-S6)
- 797 HIV Resistance in Pregnant Women With Detectable HIV-1 RNA at Delivery in Mozambique**, Maria Ruperez, Barcelona Inst for Global Hlth, Barcelona, Spain, et al. (Poster Abstracts Session P-S6)
- 798 Maternal Vitamin D Deficiency Is Associated With Preterm Birth in HIV-Infected Women**, Jennifer Jao, Icahn Sch of Med at Mount Sinai, New York, NY, USA, et al. (Poster Abstracts Session P-S7)
- 799 Timing of ART Initiation in Pregnancy and Birth Outcomes in South African Women**, Landon Myer, Univ of Cape Town, Cape Town, South Africa, et al. (Poster Abstracts Session P-S7)
- 803 Mortality Risk Associated With Preterm and SGA Stratified by Maternal HIV Status**, Ayesha Sania, ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA, et al. (Poster Abstracts Session P-S7)
- 804 HBV and HCV Infections in HIV-Infected Pregnant Women: Obstetrical Outcomes**, Valerie Benhammou, INSERM 1153, PARIS, France, et al. (Poster Abstracts Session P-S7)
- 833 Psychological Reactance Is a Novel Risk Factor for Adolescent HIV Treatment Failure**, Elizabeth D. Lowenthal, Univ of Pennsylvania Perelman Sch of Med, Philadelphia, PA, USA, et al. (Poster Abstracts Session P-T4)
- 871 Phase I Trial to Assess Safety, PK, and PD of Film and Gel Formulations of Tenofovir**, Katherine E. Bunge, Univ of Pittsburgh, Pittsburgh, PA, USA, et al. (Poster Abstracts Session P-V2)
- 872 Safety and Pharmacokinetics of Dapivirine Vaginal Rings in Postmenopausal US Women**, Beatrice A. Chen, Univ of Pittsburgh, Pittsburgh, PA, USA, et al. (Poster Abstracts Session P-V2)
- 873 Adherence and Acceptability of a Dapivirine Vaginal Ring in Postmenopausal US Women**, Ariane van der Straten, RTI, San Francisco, CA, USA, et al. (Poster Abstracts Session P-V2)
- 875 A First-in-Human Trial of PC-1005 (MIV-150 and Zinc Acetate in a Carrageenan Gel)**, Barbara A. Friedland, Pop Council, New York, NY, USA, et al. (Poster Abstracts Session P-V2)

- 876 CVLs From Women Vaginally Dosed With PC-1005 Inhibit Mucosal HIV-1 and HSV-2 Ex Vivo**, Guillermo Villegas, Pop Council, New York, NY, USA, et al. (Poster Abstracts Session P-V2)
- 973 Effect of Secondary Distribution of HIV Self-Tests on Women's Sexual Decision-Making**, Harsha Thirumurthy, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, et al. (Poster Abstracts Session P-X3)

THURSDAY, FEBRUARY 25, 2016

- 168LB Option B+ in Malawi: Have 4 Years of "Treat All" Shown That 90-90-90 Is Achievable?**, Beth Tippet Barr, CDC, Harare, Zimbabwe, et al. (Oral Abstracts Session O-15)
- 285 Seminal Plasma Induces Inflammation and Enhances HIV-1 Infection in Cervical Explants**, Andrea Introini, Karolinska Inst, Stockholm, Sweden, et al. (Poster Abstracts Session P-C8)
- 162 Is Intensive Cervical Cancer Screening Justified in Immunosuppressed Women?**, Michael J. Silverberg, Kaiser Permanente Northern California, Oakland, CA, USA, et al. (Oral Abstracts Session O-14)
- 301 Oral PrEP Enhances Genital HIV-Neutralizing IgA in HIV-1 Exposed Seronegative Women**, Jairam R. Lingappa, Univ of Washington, Seattle, WA, USA, et al. (Themed Discussion Session TD-15)
- 422 Liver Fibrosis Linked to Cognition in HIV and HCV: The Women's Interagency HIV Study**, Victor Valcour, Univ of California San Francisco, San Francisco, CA, USA, et al. (Poster Abstracts Session P-G5)
- 720 Prevalence of Falls Among Older Women in the Women's Interagency HIV Study**, Anjali Sharma, Albert Einstein Coll of Med, Bronx, NY, USA, et al. (Poster Abstracts Session P-Q7)
- 726 Immunological Signaling During HSV-2 and CMV Vaginal Reactivation at ART Initiation**, Andrew D. Redd, NIAID, NIH, Bethesda, MD, USA, et al. (Poster Abstracts Session P-Q9)
- 789 Malawi's Option B+ 2011-2015: The Impact of Rapid ART Decentralization**, Sundeep K. Gupta, CDC, Lilongwe, Malawi, et al. (Themed Discussion Session TD-14)
- 790 Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study**, Muktar H Aliyu, Vanderbilt Inst for Global Hlth, Nashville, TN, USA, et al. (Themed Discussion Session TD-14)
- 791 Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention**, Ruby N. Faylorsey, ICAP, Columbia Univ Mailman Sch of PH, New York, NY, USA, et al. (Themed Discussion Session TD-14)
- 792 Continuity of Care Among Pregnant Women Lost to Follow-up After Initiating ART**, Kate Clouse, Vanderbilt Inst for Global Hlth, Nashville, TN, USA, et al. (Themed Discussion Session TD-14)
- 793 Disclosure and Knowledge Are Associated With Retention in Malawi's Option B+ Program**, Risa M. Hoffman, Univ of California Los Angeles, Los Angeles, CA, USA, et al. (Themed Discussion Session TD-14)
- 861 Correlates of Injectable Contraceptive Discontinuation Following HIV-1 Seroconversion**, Margaret R. Caplan, David Geffen Sch of Med at Univ of California Los Angeles, Los Angeles, CA, USA, et al. (Poster Abstracts Session P-U1)
- 862 Correlation Between Cotherapy of Efavirenz-Based ART and Pregnancy Among Women**, Stephen Okoboi, TASO-Uganda, Kampala, Uganda, et al. (Poster Abstracts Session P-U1)
- 863 Is Menopause Associated With Unprotected Sex in High-Risk HIV-Positive Kenyan Women?**, Marielle S. Goyette, Univ of Washington, Seattle, WA, USA, et al. (Poster Abstracts Session P-U1)
- 864 Fertility Desire, Unprotected Sex, and Viral Load in HIV-Positive FSWs in Kenya**, Kate S. Wilson, Univ of Washington, Seattle, WA, USA, et al. (Poster Abstracts Session P-U1)
- 865 Inaccurate Reporting of Condom Use Among Women Using Injectable Contraception**, Renee Heffron, Univ of Washington, Seattle, WA, USA, et al. (Poster Abstracts Session P-U1)

AUTHOR INDEX

Bold numbers indicate a presenting author role for that abstract. Any updates will be reflected in the mobile app.

—A—

- Aamer, Hadeqa: 88
 Aartun, Johannes: 600
 Abbas, Ume: **1057**
 Abbink, Evertine: 431
 Abdel-hameed, Enass: **552**
 Abdel-Hamid, Mohammed: 153
 Abdel-Maguid, Hanaa: 153
 Abdel-Mohsen, Mohamed: **81**
 Abdul-Sada, Alaa: 692
 Abdulhaqq, Shaheed A.: **268**
 Abdullah, Fareed: 115
 Aberg, Judith: 44LB
 Aberra, Faten: 290
 Abgrall, Sophie: 675, 941, 943
 Abimiku, Alash'le: 502
 Ablan, Sherimay D.: 465
 Abolade, Jeremy: 406
 Aboud, Michael: 660, 947
 Abouelkhair, Mahmoud: 153
 Abradelo, Manuel: 571
 Abraham, Alison: 684, 688, 691
 Abram, Michael E.: **496**, 680
 Abrams, Elaine J.: **34**, 39, 757, 770, 786, 791, 795, 799, 808, 851
 Abubakar, Ibrahim R.: 1053
 Acham, Robinah: 862
 Achenbach, Chad: 618, 644
 Adachi, Akio: 206
 Adachi, Kristina: **779**
 Adala, Lucy: 864
 Adams, Collin: 384
 Adamson, Lourdes: 447
 Adebajo, Sylvia: 922
 Adebamowo, Clement: 502
 Adedimeji, Adebola: 919
 Adelsberger, Joseph A.: 380
 Adeyemi, Oluwatoyin: 574
 Adeyemo, Titilope: 281
 Adimora, Ada: 422, 919
 Adinolfi, Luigi E.: 608
 Adland, Emily: **302**, 828
 Adnan, Sama S.: **269**
 Aegerter, Philippe: 420
 Aga, Evgenia: 346, 347
 Agan, Brian: 932
 Agarwal, Dipti: 457
 Agbaji, Oche: 564
 Aghaizu, Adamma: **895**
 Aghokeng, A.: 959
 Agosto, Luis: 185, 288
 Agot, Kawango: 973
 Agrawal, Parth: 781
 Agsalda-Garcia, Melissa: 345
 Aguero, Fernando: 571, 572
 Aguilar-Delfin, Irma: 251
 Aguilar-Garcia, Tania: 251
 Aguilar-Jiménez, Wbeimar: 247
 Aguirrengoa, Koldo: 634
 Agwu, Allison L.: **177**, 1001, 1005
 Ahmed, Charisse: 528
 Ahmed, Rafi: 93LB
 Ahmed, Shahira: 1048
 Ahoua, Laurence: 1020
 Ait Moha, Daoud: 948
 Aizezi, Sulaiman: 929
 Ajambo, Eunice: 862
 Ajibola, Gbolahan: 37, 784, **800**, 810
 Akanmu, Sulaimon: 498
 Akanmu, Suleiman: 281
 Akapirat, Siriwat: **318**
 Akari, Hirofumi: 206
 Ake, Julie: 230, 922, 923
 Akiyama, Hisashi: 185, **186**, 288
 Akkina, Ramesh: 447, 450
 Akoth, Elizabeth: 528
 Al Kindi, Sadeer: 649
 Alagaratnam, Jasmini: **794**
 Alami, Mohcine: 875
 Alary, Michel: 1047
 Albert, Jeffrey: 694
 Albrecht, Helmut: 965
 Alcamí, José: 303, 468
 Alcantarini, Chiara: 426
 Alday, Mark A.: 371
 Aldovini, Anna: 467
 Aldrete, Susi: 335
 Aldrovandi, Grace M.: 33, 807
 Alejos, Belen: 901
 Alessandri-Gradt, E.: 959
 Alfaca, Bertur: 975, 975
 Alford, Taylor: 445
 Alfredo, Charity: 850
 Alistar, Sabina: 1056
 Aliyu, Ahmad: 502
 Aliyu, Mukhtar H.: **790**
 Allaire, Benjamin T.: 1051
 Allana, Salim: 157, 756
 Allard, Brigitte: 355
 Allavena, Clotilde: 709
 Allen, Mary: 90
 Allen, Todd M.: 231, 294
 Allen, Vanessa G.: 491LB
 Allston, Adam: 992, 1008
 Almeida, Volia: 809
 Alsan, Marcela: **1039**
 Alter, Galit: 91, 305, 308
 Alteri, Claudia: **18LB**
 Altfeld, Marcus: **178**, 197, 231, 294, 315, 370
 Althoff, Keri N.: **150**, **614**, **688**, 699
 Alvarado, Melanie: **371**
 Alvarez, Angeles: **663**
 Alvarez, Elena: 668
 Alvarez, Xavier: **141**
 Alvarez Del Arco, Debora: 901
 Alvaro-Meca, Alejandro: 590, 639
 Alvero, Carmelita: 816
 Alwano, Mary G.: 983
 Amanyire, Gideon: 112
 Amar, Jacques: 701
 Amara, Aliou: 432, 434, 448
 Amara, Rama: 93LB, 286
 Amaral, Fabiana: 809
 Amato, Andrew: 901
 Amatya, Nilesh: 292
 Ambrose, Pradeep: 753
 Ambrose, Zandrea: 229
 Ambrosi, Alessandro: 819
 Ambrosioni, Juan: 303, 468
 Ambrozak, David: 94, 245LB, 336
 Amengual, Maria Jose: 508
 Amico, K. R.: 103, 866, 884
 Amin, Janaki: 545
 Ammassari, Adriana: 413
 Amr, Sami S.: 360
 Amukele, Timothy: 513
 Amuri, Mbaraka: 978
 Anabwani, Gabriel: 833
 Anand, Santhanam: 899, 918, 928
 Ananworanich, Jintanat: 219, 287, **349**, 384, 404, 405, 407, 415, 956
 Anastos, Kathryn: 593, 647
 Ances, Beau M.: **61**, 382, 385
 Andama, Alfred: 764
 Andany, Nisha: **768**
 Anderson, Albert: 412
 Anderson, Brett D.: **199**
 Anderson, Bridget: 501, 991
 Anderson, Caroline: 393
 Anderson, Christy: 224, 232
 Anderson, David: 711
 Anderson, Erik S.: **532**
 Anderson, Peter L.: **96**, 283, 445, 169aLB, 867
 Anderson, Sarah-Jane: 1049
 Ando, Dale K.: 358LB
 Andrade, Adriana: 104
 Andrade-Villanueva, Jaime: 472
 Andrei, Massimo: 570
 Andreotti, Mauro: 238
 Andrews, Chasity D.: **105**, 469LB
 Andrews, Laurie: 411
 Andrews, Sarah F.: 94
 Andrews, Sophie M.: **253**
 Angelico, Mario: 570
 Angelidou, Konstantia: **293**
 Anglade, Stravinsky B.:
 Anglaret, Xavier: 75LB
 Angus, Brian: 474
 Ank, Bonnie: 779
 Ankrom, Wendy: 98
 Ansari, Azim: 827
 Anstett, Kaitlin: **507**
 Antelman, Gretchen: 1025
 Anthony, Donald: 329
 Antinori, Andrea: , 946
 Antoni, Guillemette: 522
 Antonio, Rivero-Juárez: 527
 Antoniou, Tony: 622

- Anty, Rodolph: 455
 Anugulruengkitt, Supavorn: 87
 Anzinger, Joshua: 711
 Apea, Vanessa: 996
 Apetrei, Cristian: **258LB**
 Apornpong, Tanakorn: 606
 Appelberg, Sofia: 257
 Aquilante, Christina: 445
 Arasteh, Keikawus: 470
 Aravantinou, Meropi: 270
 Arazi Caillaud, Solange: 837
 Archin, Nancie M.: 355
 Arellano, Gemma: 1010
 Arends, Joop E.: 542, 543
 Arendt, Marina: 646
 Arevalo, Claudia: 308
 Ariaudo, Alexandra: 454
 Ariyoshi, Koya: 314
 Armakovitch, Sandra: 743
 Armenia, Daniele: 489
 Armon, Carl: 544, 698, 708
 Armstrong, Wendy: 1039
 Arnedo, Mireia: 248
 Arpadi, Stephen M.: **40**, 851
 Arribas, Jose R.: 45, 669
 Arshad, Omair: 715
 Arthos, James: 198
 Artrip, Cristah: 389
 Ásbjörnsdóttir, Kristjana H.: 50
 Ashby, Deborah: 423LB
 Ashton, Lynne: 225
 Aasiimwe, Stephen: 740
 Asila, Victor: 49
 Asire, Barbara: 844
 Asmuth, David: 265, **278**
 Assoumou, Lambert: 332
 Astemborski, Jacquie: 548, 712, 917
 Aston, Stephen J.: **769**
 Atta, Mohamed G.: **651**, 687
 Attia, Alain: 568
 Atugonza, Rita: **842**
 Aubert, Rachael: 878
 Aubert, Vincent: 951
 Aubin, Darley: 1017
 Audet, Carolyn M.: 790
 Augusto, Orvalho J.: 974, 976
 Auld, Sara C.: **157**
 Aulicino, Paula: 837
 Aung, Htin: 733
 Aunon, Frances: 1034
 Aurrpibul, Linda: 831, 860
 Autran, Brigitte: 332
 Avelino-Silva, Vivian I.: **326**
- Avettand-Fenoel, Veronique: 271
 Avhingsanon, Anchalee: **606**
 Avila-Rios, Santiago: **477**
 Awazi, Bih: 212
 Aweeka, Francesca: 101
 Ayakaka, Irene: 764
 Ayieko, James: 116, **841**
 Ayles, Helen: 114, **120**, 156, 165, 523, 980, 981, 982
 Azzoni, Livio: **290**, 296, 299
- B-**
- Ba, Selly: 961
 Baba, Masanori: 504
 Babiker, Abdel: 45, 87, 160
 Babusis, Darius: 107
 Bachanas, Pamela J.: **983**
 Back, David J.: 441, 442, 444, 448, 459, 874
 Backfish, Kathleen A.: 541
 Bacon, Oliver: **524**, 867, 870
 Badia, Roger: 183, **205**, 207
 Badley, Andrew D.: 243
 Baeten, Jared M.: 17, **109LB**, 164, 301, 478, 728, 740, 771, 865, 868, 1063
 Bagala, Irene: 862
 Bailer, Robert: 90
 Bailey, Angela: 683
 Bailey, Justin R.: 135
 Bailey, Michelle: 233, 334
 Bain, James: 705
 Baisley, Kathy: 169LB, 1030
 Baker, David: 451, 545
 Baker, Jason V.: **41**, **659**
 Baker-Genaw, Kimberly: 531
 Bakker, Arjen Q.: 152
 Bakshi, Rahul: 104
 Balachandran, Madhu: 893
 Balagopal, Ashwin: 135, **151**, 712
 Balaji, Alexandra: 930, **931**
 Balakrishnan, Pachamuthu: 899, 928
 Balasubramaniam, Muthukumar: 137
 Balasubramanian, Usha: 758
 Balcha, Taye T.: 744
 Baldessari, Audrey: 356
 Bale, Michael: 85
 Balestra, Emanuela: 18LB
 Balkau, Beverley: 701
 Balkus, Jennifer E.: 861
 Ball, Blake: 195
- Ballana, Ester: 183, 205, **207**
 Ballell, Lluís: 158LB
 Ballif, Marie: 737
 Ballo, Tako: 921
 Balzer, Laura: 985
 Bamshad, Michael J.: 17
 Bancu, Ioana: 432
 Bandason, Tsitsi: 853
 Bandera, Alessandra: 18LB, 280
 Bang, Anne: 395
 Banga, Riddhima: **82**
 Bangsberg, David R.: 227, 429, 1014, 1029
 Bangura, Lamin: 910
 Bani-Sadr, Firouzé: 605
 Bannert, Norbert: **485**
 Bañón, Sara: 452
 Bansal, Anju: 292, 313
 Bao, Jing: 747
 Bar, Katharine J.: **32LB**, 92, 292
 Baral, Stefan: 922, 923, 924, 925
 Barasa, Christotin W.: 791
 Barasky, Rebecca: 390
 Barbas, Coral: 354
 Barbuat, Claudine: 276
 Bardsley, Mark: 32LB
 Bargalló, Manel Enric: 248
 Baril, Jean-Guy: 237
 Barin, Francis: 222, 232, 400, 840
 Barnabas, Ruanne V.: 49, **740**, 1063
 Barnard, Marinus: 158LB
 Barnes, Tiffany L.: 95LB
 Barnett, Louise: 653
 Barnett, Susan: 317
 Barnhart, John: 964
 Barnholtz-Sloan, Jill: 409
 Bärnighausen, Till: 167, 169LB, 677, 678, 679, 703, 905, 907, 960, 1003, 1011, 1012, 1013, 1048
 Barqasho, Babilonia: 267
 Barr, Emily: 438
 Barrail-Tran, Aurélie: 455
 Barreto-de-Souza, Victor: **184**
 Barrett, Brad J.: 187
 Barrett, Stephanie E.: 98
 Barrie, Mohamed B.: 72LB
 Barrington, Francine: 388
 Barrios, Rolando A.: 492LB
 Barros-Aguirre, David: 158LB
 Barry, Moomie: 73LB
 Bartmeyer, Barbara: 485
- Barton, Kirston: 348
 Basavaraj, Anita: 752
 Baseke, Joy: 733
 Bassett, Ingrid V.: **1016**
 Bassett, Jean: 845
 Bastard, Jean Philippe: 701
 Bastides, Frederic: 400
 Bastow, Barbara: 161
 Batavia, Ashita: 473
 Batista, Facundo: **127**
 Batista, Pedro: 597
 Batorsky, Rebecca E.: 231
 Batra, Jagmohan: 817
 Battalora, Linda A.: **698**, 708
 Battegay, Manuel: 567, 592, 630, 676, 951
 Bauer, Asli: 625
 Baumgarten, Axel: 584, 589
 Bautista-Arredondo, Sergio: 1059
 Bayigga, Lois: 297
 Bayne, Madeleine: 309LB
 Bayoumi, Ahmed M.: 622
 Bazaaie, Jeremiah M.: 902
 Beauchamp, Geetha: 883LB
 Beaumont, David: 268
 Beaumont, Tim: 152
 Beavogui, Abdoul H.: 75LB
 Becerril, Carlos: 307
 Beck, Graham: 403
 Beck, Ingrid: 494LB, 847
 Becker, James T.: **388**, 416
 Becker, Kyra J.: 636
 Beccuet, Renaud: 1015
 Bedimo, Roger: 645, 714
 Beer, Linda: 53, 497, 1004
 Beerenwinkel, Niko: 208
 Béguelin, Charles: **592**
 Behel, Stephanie K.: 983
 Beima-Sofie, Kristin: 780
 Bekker, Linda-Gail: 48LB, 110LB, 852, 854, 1005
 Belaunzarán-Zamudio, Pablo F.: **296**, **299**
 Bellido, Rocio: 797
 Bellini, Giulia: 557, 608
 Bello, Fatai O.: **281**
 Bellón, José M.: 527, 611
 Bellot, Clovy: 1017
 Beloukas, Apostolos: 482
 Bendavid, Eran: 117, 773, **937**, 1056
 Bender Ignacio, Rachel A.: 632
 Benfield, Thomas: 690

- Bengtson, Angela: **920**
 Benhammou, Valerie: **804**
 Benhnia, Mohammed Rafii-El-Idrissi: 655
 Benito, Jose M.: **596**
 Benjamins, Laura J.: **623**
 Benjapornpong, Khunthalee: 384
 Benki-Nugent, Sarah: 38
 Benkirane, Monsef: 468
 Benne, Clarisse: 295, 358LB
 Bennett, Kara: 37, 784, 810
 Benns, Alex: 458
 Benoit, Anita: 949
 Benson, Constance A.: 421, 753
 Benson, Jamie: 514
 Berenguer, Juan: **527, 611, 639**
 Bergamaschi, Cristina K.: 259LB
 Berger, Annemarie: 525
 Berger, Jeffrey S.: 44LB
 Bermejo, Mercedes: 468
 Bernard, Daphne: 473
 Bernard, Louis: 400
 Bernardino, Jose I.: **45, 669**
 Bernasconi, Enos: 567, 592, 612, 951
 Bernaud, Camille: 709
 Berry, Stephen A.: **1001**, 1005
 Bershteyn, Anna: 117

 Bertine, Mélanie: 214
 Bertoli, Ada: 18LB
 Berzins, Baiba: 147
 Besa, Stable: 980
 Beshears, John: 1039
 Bess, Julian W.: 138
 Besseghir, Amel: 214
 Best, Brookie M.: 395, 433, 438, **439, 775**
 Best, John: 969
 Betts, Michael R.: 24, 254, 733
 Bewley, Martin: 724
 Beyers, Nulda: 165, 982
 Bezemer, Daniela: 220, **221**, 542
 Bhagani, Sanjay: 154LB
 Bhagwat, Priya: **704**
 Bhardwaj, Nina: 249, 322
 Bhatt, Niles: 850
 Bhattacharya, Jay: 937
 Bhattacharya, Tanmoy
 Bhattacharya: 309LB
 Bhatti, Laveeza: 574
 Bhavani, P.K.: 457
 Bhondai, Muchaneta: 815

 Bhosale, Ramesh: 758
 Biasin, Mara: 247, 280
 Bibollet-Ruche, Frederic: **133**
 Bienczak, Andrzej: **429**
 Bierman, Wouler F.: 220
 Bila, Dulce A.: 850
 Bilbao, Itxarone: 572
 Billingsley, James M.: 269
 Binda, Kelebogile: 802
 Bishopric, George A.: 55
 Bissa, Massimiliano: 317
 Bisson, Gregory P.: **745, 747**
 Bitnun, Ari: 836
 Björkman, Per: 744
 Blair, Christopher: 35LB
 Blair, Wade: 506
 Blanch, Jordi: 945
 Blanchard, James: 270
 Blanchard, Kelly: 770
 Blanche, Stéphane: 776, 811
 Blanco, Jose L.: 945
 Blanco, Juliá: 241, 366
 Blanco Rodríguez, M^a José: 586
 Blanes, Marino: 571, 572
 Blank, Jackie: 1035
 Blankson, Joel N.: 135, 374, 830
 Blattner, William A.: 922, 923, 924
 Blevins, Meridith: 746, 790
 Blick, Gary: 358LB
 Blish, Catherine A.: **179**
 Bloch, Mark: 451, 545
 Blok, Willem: 948
 Blokken, Jolien: 139
 Blosser, Sara J.: 149, 541
 Blower, Sally: 1044, 1054
 Bock, Peter: 114, 165
 Boender, Tamara Sonia: **498**, 849
 Boerma, Ragna S.: 849
 Boesecke, Christoph: 236, 560, 589
 Boettiger, David C.: **858**
 Boffito, Marta: 448
 Bogart, Laura M.: 1014, 1016
 Boggavarapu, Sahithi: 781
 Bogner, Johannes: 630
 Bohjanen, Paul: 762, 762
 Bohlius, Julia: 613, 617, 618, 619, 631
 Boily, Marie-Claude: 1046, 1047, 1055, 1060
 Bolaji, Oluseye: 441
 Boland, Greet J.: 543

 Bolay, Fatorma: **76LB**
 Boleo, Coretha: 984
 Boll, Annegret: 363
 Bollinger, Robert: 752
 Bollinger, Timothy: 788
 Bolo, Alex: 510
 Bologna, Rosa: 837
 Boltz, Valerie F.: **490**
 Bolumar, Francisco: 901
 Bommart, Sébastien: 675
 Böni, Jürg: 951
 Bonilla, Hector: 551
 Bonito, Andrea: **774**
 Bonjoch, Anna: 432
 Bonnet, Fabrice: 566
 Bonnier, Guillaume: 381
 Bonora, Stefano: 426, 454, 774
 Bonzela, Juvencio: 516, 975
 Boom, W. H.: 733
 Boon, Denali: 540, **594**
 Boonraj, Kailip: 869
 Booth, Clare: 484
 Bopage, Rohan I.: 451, 545
 Bor, Jacob: 960, **1011**, 1012, 1013, 1028, **1048**
 Bordoni, Veronica: 413
 Borges, Alvaro H.: **46, 160, 630**
 Boritz, Eli: 245LB, 336
 Bork, Peer: 260
 Borkhardt, Arndt: 189
 Borremans, Maarten: 110LB
 Borrenberghs, Doortje: 139
 Borrow, Persephone: 133
 Bortz, Eric M.: 371
 Bosch, Ronald: 25, 43, 293, 294, 300LB, 346, 347, 350
 Bose, Meera: 349
 Bosinger, Steven E.: 20, 22, 286, 352
 Bosque, Alberto: 360
 Boström, Stéphanie: 285
 Boswell, Stephen H.: 890
 Botta-Fridlund, Danielle: 583
 Bottero, Julie: 605
 Bouassida, Iskander: 675
 Boucau, Julie: 312
 Boucher, Charles A.: 536, 1052
 Boucher, Morgan: 657
 Bouliotis, George: 423LB
 Boule, Andrew: 117, 759, 960, 1022
 Boulware, David R.: 159, 760, 761, **762**, 763
 Boum, Yap: 227

 Bourdery, Laure: 295
 Bourgeois, Christine: 271
 Bourgi, Kassem: **531**
 Bourlière, Marc: 583
 Bouvin-Pley, Mélanie: 400
 Bowes, Jennifer: 812
 Bowles, Kristina: 889
 Bowman, Christine: 724
 Bowman, Natalie M.: **401**, 402
 Boyd, Mark: 233, **666**
 Brackenridge, Simon: 253
 Bradford, Yuki: 443
 Bradley, Frیدهborg: 285
 Bradley, Heather: **53**, 915, 1004, 1006, 1037, 1045
 Brady, Kathleen: 931, 1002
 Braibant, Martine: 400
 Brainard, Diana M.: 99, 154LB
 Braitstein, Paula: 51, 1042
 Branca, Sebastian: 1002
 Branch, Andrea: 588, **604**, 798, 868
 Brander, Christian: 247, 320
 Branson, Bernard: 989, 997, 1038
 Brar, Indira: 531
 Braun, Dominique L.: 89LB
 Braunstein, Sarah L.: 908, 931, **994**, 1009
 Breakey, Jennifer: 169bLB
 Breen, Elizabeth: 283
 Brégigeon, Sylvie: 583
 Bremer, Viviane: 485
 Brencley, Jason M.: 21, 94, 263, 275LB
 Brener, Jacqui: 827
 Brennan, Alana: 845, **957, 960**
 Brennan, Catherine: 213
 Brennan, Clare: 660
 Brenner, Bluma G.: **218, 480**
 Bresnahan, Marie P.: 534
 Breton, Yann: **182**
 Brew, Bruce J.: 391
 Brewer, Russell: 893
 Brice, Josephine: 840
 Brinkman, Cristina E.: 934
 Brier, Matthew R.: 382
 Brinkman, Kees: 547, **948**
 Brinson, Cynthia: 29
 Brittain, Kirsty: 799, 808, 852, 854
 Briz, Verónica: **590**
 Brocca-Cofano, Egidio: 258LB
 Brockman, Mark A.: 190

- Brockmeyer, Norbert H.: **628**
 Brodt, Hans-Reinhard: 713
 Broliden, Kristina: 285, 301
 Brooks, John T.: **132**, 544, 591, 698, 708, 916, 1006
 Brooks, Kristina M.: **430**
 Brophy, Jason: 812, **836**
 Brouckaert, Peter: 97
 Brown, Charlene: 918
 Brown, Danae: 947
 Brown, Elizabeth R.: 109LB
 Brown, Lillian: 985
 Brown, Lou Ann: 255
 Brown, Nathaniel: 153
 Brown, Sheldon: 633
 Brown, Todd T.: 144, 147, 283, 609, 672, 694, 695LB, 699, 700, 704, 914, 939
 Brown, William L.: 200
 Browne, Sara H.: 658
 Browning, Renee: 36
 Bru, Camille: 152
 Brumme, Chanson J.: 483
 Brumme, Zabrina: 190
 Bruner, Katherine M.: **83**, 339
 Brust, James C.: 157, **756**
 Bryant, Kendall J.: 277, 554
 Bryson, Yvonne J.: 779
 Buchacz, Kate: 544, 698, **708**, 989
 Buchanan, Annie: 816
 Buchbinder, Susan P.: 524, 867, 870
 Buck, William C.: 850
 Buckheit, Karen W.: 169bLB
 Buckheit Jr, Robert W.: 169bLB
 Buckingham, Kati: 17
 Budd, Matthew: **812**
 Budoff, Matthew: 641, 652
 Buggert, Marcus: **254**
 Bui, John K.: 340, **379**
 Bukusi, Elizabeth: 829, 979
 Bunge, Katherine E.: **871**
 Bunupuradah, Torsak: 831, 857, 858, 860
 Burchell, Ann N.: **622**
 Burchett, Sandra: 438
 Burdo, Tricia H.: 272, **273**, 403, 664
 Burgener, Adam: **6**
 Burger, David M.: 431, 433
 Burgess, Laura: 423LB
 Burgos-Soto, Juan: 1015, 1015
 Burke-Miller, Jane: 277
 Burmen, Barbara: 903
 Burns, Fiona: 996
 Burt, Richard: 933
 Burwitz, Benjamin J.: 21
 Busch, Heiner: 584
 Bush, William: 409
 Bushman, Lane R.: 445
 Bushnell, Cheryl D.: 638
 Buskin, Susan: 971
 Bütikofer, Lukas: 617, 618
 Butt, Adeel A.: 551, **581**, 645, 714
 Buzon, Maria J.: 361
 Bvochora-Nsingo, Memory: 615
 Bwakura-Dangarembizi, Mutsawashe: 458
 Byakika-Kibwika, Pauline: 444
 Bygrave, Helen: 512, 787
 Bygum Knudsen, Troels: 690
 Byonanebye, Dathan: 116, 843, 1026
 Byrne, Morgan: 932
- C—
- Caan, Matthan W.: 148
 Caballero, Gemma: 228, 232
 Cabello, Alfonso: 596
 Cabezas, Teresa: 508
 Cabié, André: 709
 Cabrera, Cecilia: 241
 Cachay, Edward R.: 603
 Caddy, Sheila: 949
 Caggigi, Alberto: 324
 Cahn, Pedro: 718, 947
 Cai, Suqin: 481
 Cai, Weiping: 955
 Cai, Yanshan: 970
 Calascibetta, Francesca: 353
 Calcagno, Andrea: **63**, **426**, 774
 Calderon, Yvette: 968
 Calin, Ruxandra: 332
 Calis, Job: 849
 Calle, M. Luz: 266
 Callebaut, Christian D.: 496
 Calli, Kristina: 812
 Calmy, Alexandra L.: 567, 592, 612
 Calnan, Michaela: 473
 Calvez, Vincent: 332, 489, 840
 Camacho, Ángela: 555
 Camacho, Martha: 518
 Cameron, Mark: **880**
 Cameron, Paul U.: 359, 375
 Campbell, Edward M.: **209LB**
 Campbell, Ellsworth M.: **215**
 Campbell, Jennifer: 272
 Campbell, Thomas B.: 728
 Canaday, David H.: 296, 299, **733**
 Canan, Chelsea: **911**
 Cannizzo, Stefania: 598
 Cannon, Paula M.: **78**
 Canonico, Pier Luigi: 204
 Cantone, Joseph: 466
 Cao, Wei: 237
 Capeau, Jacqueline: 271, 701
 Capelli, Silvia: 819
 Capina, Rupert: 319
 Capitant, Catherine: 886, 887
 Caplan, Margaret R.: **861**
 Capobianchi, Maria R.: 946
 Capoluongo, Nicolina: 608
 Capparelli, Edmund: 32LB, 438, 439, 440, 458, 775, **815**
 Carballo-Diéguez, Alex: 108LB
 Carcelain, Guislaine: 332
 Carcenac, Romain: 950
 Cardoso, Judite: 975
 Carlqvist, Anna: 828
 Carlson, Jonathan: 231, 313, 828
 Carlson, Margaret: 376
 Carlucci, James G.: **746**
 Carmona, Sergio: 1013, 1028
 Carnathan, Diane: 359
 Caro-Vega, Yanink: 296, 299
 Carpio, Felix: 953
 Carr, Andrew: 668
 Carrere, Nicolas: 289
 Carrieri, Patrizia: 549, 582
 Carriquiry, Gabriela: **958**
 Carroll, Michael C.: **128**
 Carroll, Miles W.: 75LB
 Carta, Stefania: 413
 Cartwright, Emily K.: **22**
 Casado, Concepción: 338
 Casado, J.L.: 452
 Casavant, Isabelle: **975**
 Casazza, Joseph P.: **245LB**, 327, 336
 Casey, Lisa: 587
 Casillas-Rodríguez, Jesús: 477
 Casper, Corey: 563, 632
 Cassels, Susan L.: 1063
 Cassol, Edana: 693
 Cassol, Sharon: 847
 Castagna, Antonella: 417, 454, 627
 Castel, Amanda: 992, 1008
 Castells, Lluís: 571
 Castillo-Mancilla, Jose R.: **283**, 421, 445
 Castor, Trevor: 354
 Cauda, Roberto: 417, 697
 Cavassini, Matthias: 82, 381, 612, 951
 Cazabat, Michelle: 289, 950
 Cazanave, Charles: 689
 Ceccarelli, Giancarlo: 238
 Ceccherini-Silberstein, Francesca: 18LB, 413, 489, 570, **946**
 Celentano, David: 899, 918, 928, 1032
 Celum, Connie M.: 17, 164, 478, **728**, 740, 771, 865, 868, 1063
 Cent, Anne: 728
 Cepeda, Javier A.: **548**
 Cernuschi, Massimo: 627
 Cerqueira, Fernanda: 91
 Cerrone, Maddalena: **598**
 Cespedes, Michelle: 161
 Chachage, Mkunde: 625
 Chadwick, David: 482, 683
 Chadwick, Ellen G.: 458
 Chahroudi, Ann: 22, 353, 826, 859
 Chaila, Joseph M.: 981
 Chaillon, Antoine: 143, **222**, 228, 232, 400, **487**
 Chaisson, Christine E.: 1016
 Chaix, Marie Laure: 222, 522
 Chakhtoura, Nahida: 438, 439, 458, 775
 Chakraborty, Rana: 781, 817
 Chalermchai, Thep: 404
 Chamie, Gabriel: 829, 841, **979**, 1062
 Chan, Ellen S.: 147, **695LB**, 700
 Chan, Philip: 891
 Chanakul, Ankanee: 857
 Chandanwale, Ajay: 752
 Chander, Geetanjali: 911
 Chandrasekaran, Ezhilarasi: 753
 Chang, J. Judy: 294
 Chang, Kaifen: 325
 Chang, Larry W.: 902, **986**
 Chang, Theresa: 196
 Chang, Wei: **1062**
 Chang, Will: 239
 Chao, Chun: 54

- Chapman, Jennifer: 833
 Charalambous, Salome: 113LB, 155
 Chargin, Amanda: 341
 Chariyalertsak, Suwat: 48LB
 Charlebois, Edwin: 796, 829, 841, 843, 979, 985, 1026, 1062
 Charlins, Paige: 450
 Charmeteau-De-Muylder, Bénédicte: 274
 Charpentier, Charlotte: 214, **509**
 Charreau, Isabelle: 522, 886
 Charurat, Manhattan E.: 502, 922, 923, 924
 Chasela, Charles: 801LB
 Chattergoon, Michael: 135
 Chouk, William: 940
 Chaudhary, Omkar: **467**
 Chauk, Patrick: 1036
 Chavez, Leonard: 81
 Cheever, Laura: 993
 Chege, Duncan: 791
 Chege, Wairimu: 524, 867, 870
 Chen, Beatrice A.: **872**, 873
 Chen, Benjamin K.: 249
 Chen, Huichao: 161
 Chen, Joseph: 284
 Chen, Pai-Lien: 520
 Chen, Ting-Yi: 587
 Chen, Xi: 970
 Chen, Xinhui: 99, 445
 Chen, Ya: 838
 Chen, Yi-Ming A.: 617, 618
 Chen, Ying: 103
 Cheng, Andrew: 29, 680, 681, 682, 717
 Cheng, Helen: 873
 Cheng, Stephanie: 622
 Cheng, Weibin: 970
 Chennebault, Jean-Marie: 351
 Chéret, Antoine: **351**
 Chertova, Elena N.: 138
 Cherutich, Peter: **50**
 Chettimada, Sukrutha U.: **250**
 Chetwynd, Andrew J.: 692
 Chevaliez, Stephane: 526, 577
 Chew, Glen M.: 81
 Cheynier, Rémi: 274
 Chiao, Elizabeth: 161, 550
 Chiappini, Elena: 778
 Chiarella, Jennifer: 411
 Chiasson, Mary-Ann: 770
 Chidiac, Christian: 729, 887
 Chilisa, Florence: 784
 Chimbindi, Natsayi: 1003
 Chimbwandira, Frank: 118, 168LB, 789
 Chin, Alfred C.: **396**
 Chinappa, Tilagavathy: 735
 Ching, Christopher R.: 383, **386**
 Chiong, Justin: 434
 Chipato, Tsungai: 520
 Chirenje, Z Michael: 521
 Chitre, Avantika S.: **235**
 Chittmitrapap, Salyavit: 606
 Chitty, Sarah: 794
 Chitwarakorn, Anupong: 884, 927
 Chiu, Calvin: **115**
 Chmiel, Joan S.: 544, 698
 Chockingam, Leela D.: **620**
 Chohan, Bhavna: 494LB
 Choi, James: 1039
 Choi, Sung Eun: **773**
 Choephaibulkit, Kulkanya: 818, 831, 1120
 Chomchey, Nitiya: 287
 Chomont, Nicolas: 335, 343, 344, 349, 352, 836
 Chong, Jessica: 17
 Chonwattana, Wannee: 927
 Chopra, Abha: 359
 Chow, Dominic C.: 387, **652**, **723**
 Chow, Felicia: **43**, 636, **638**
 Christ, Frauke: 139, 363
 Christensen, Stefan: **584**, 589
 Christensen-Quick, Aaron: **188**
 Christopoulos, Katerina A.: 558, 920, **1040**
 Chuang, Gwo-Yu: 310LB
 Chun, Tae-Wook: 311LB
 Chung, Michael H.: 494LB, 621, 624
 Chung, Raymond T.: 99, 551, 581
 Chung, Shang-Lin: **411**
 Churchill, Duncan: 484
 Churchyard, Gavin: 113LB, 155
 Ciaffi, Laura: 696
 Giananello, Andrea L.: **786**
 Cicala, Claudia: 198
 Ciccarelli, Nicoletta: **417**, 697
 Cihlar, Tomas: 95LB
 Cillo, Anthony R.: 85, **342**
 Cirillo, Grazia: 556
 Ciuffi, Angela: 208
 Clagget, Brian: 296, 299
 Clark, Tamara: 796, 829, 841, 843, 979, 985, 1062
 Clarke, Amanda: 423LB, 680
 Clarke, William: 436, 906, 954
 Clarridge, Katherine: **311LB**
 Clavel, Jacqueline: 811
 Clayton, Carolyn W.: 445
 Cleland, Charles: 597
 Clement, Meredith E.: **642**
 Clennon, Julie: 995
 Clerc, Isabelle: 629
 Clerici, Mario: 247, 280
 Clifford, Katherine: 384
 Climent, Nuria: 468
 Cloherty, Gavin A.: 212
 Clotet, Bonaventura: 183, 205, 207, 241, 266, 320, 432
 Clouse, Kate: **792**, **792**
 Coates, Thomas: 436
 Coburn, Brian J.: 1054
 Cockerham, Leslie R.: **298**
 Cockett, Mark: 97, 466
 Cocohoba, Jennifer M.: 647
 Coffie, Ahuatchi P.: **565**, 568
 Coffin, John M.: 85, 337, 340, 490
 Coghill, Anna E.: **616**
 Cohan, Deborah: 796
 Cohen, Craig R.: 841
 Cohen, Daniel: 539LB
 Cohen, Mardge: 277, 422, 647, 919
 Cohen, Rachel: 798, 809
 Cohen, Ronald A.: 383, 386
 Cohen, Stephanie: 524, 867, **870**
 Cohen-Codar, Isabelle: 729
 Cohn, Susan E.: 55, 476
 Cohen, Karen: 427, 429, 1029
 Coilly, Audrey: 455
 Coiras, Mayte: **468**
 Colafigli, Manuela: 417
 Colbers, Angela: **431**, 433
 Colby, Donn: 219, 384, 407, 414, 956
 Cole, David: 828
 Cole, James H.: 148
 Cole, Michael: 19
 Coleman, Megan: 524
 Coleman, Sharon M.: 1016
 Coll, Pep: 266, 320
 Collado, Antonio: 586
 Collado-Diaz, Victor: 663
 Collier, Ann: 30, 350, 493LB, 952
 Collier, Dami A.: **1030**
 Collin, Gilles: 509
 Collini, Paul J.: **724**
 Collins, Christine: 539LB
 Collins, Jeannie: 855
 Collins, Louis: 385
 Collins, Sean E.: **473**
 Collins, Simon: 484
 Collman, Ronald: 24
 Colonna, Richard: 153
 Compfer, Charlene: 609
 Condorelli, Fabrizio: 204
 Cong, Mian-er: 333
 Connick, Elizabeth: 23, **130**, 242, 378
 Connors, Mark: 310LB
 Conrad, Caitlin: 916
 Contreras, David: 1059
 Cook, Jennifer: 579
 Cooley, Laura A.: 1000
 Coombs, Robert W.: 164
 Cooney, Michael: 876
 Cooper, Curtis L.: **573**
 Cooper, David: 233, 334, 365, 474, 666, 668
 Cooper, Don: 359
 Coovadia, Ashraf: 39, 40, 851
 Cope, Anne: 291
 Coppock, Dagan: 934
 Coppola, Nicola: 556, 557, **607**, **608**
 Corbeau, Pierre: 276, 282
 Cori, Anne: 165, 221
 Corleis, Björn: 315
 Corpataux, Jean-Marc: 82
 Correia-Pinto, Jorge: 319
 Cosimano, Emily: 392
 Cossa, Loide: 850
 Costa, Dayane A.: 326
 Costagliola, Dominique: 332, 943, **1043**
 Côté, Hélène: **715**, **716**, 812
 Cottalorda, Jacqueline: 408
 Cotte, Laurent: 680, 886
 Cotton, Mark F.: 658, 820, 824, 848, 855
 Cottrell, Mackenzie L.: 102LB
 Cotugno, Nicola: **324**
 Couedel-Courteille, Anne: 274
 Courmil, Amandine: 696
 Court, Richard G.: **427**
 Courtney, Ingrid: 1014
 Couvillon, Margaret: 1021
 Cowan, Ethan: 968
 Cox, Andrea L.: 540

- Cox, Stephanie: 496
 Cox, Vivian: 1031
 Cozzi-Lepri, Alessandro: 486, 946
 Cragg, Carol: 1031
 Crampin, Amelia: 736
 Crane, Heidi M.: **42**, 558, 614, **636**, 641, 671, 920, 941, **1034**
 Cranmer, Lisa M.: 38, 748
 Cranston, Kevin: 890
 Cranston, Ross: 104, **108LB**, 161
 Creasy, George: 875, 876
 Cremers, Serge: 694
 Crepez, Nicole: **1033**
 Crespo, Manel: 611
 Cressey, Tim R.: 775, **777**
 Cribbs, Sushma K.: **255**
 Cross, Anna: 759
 Crothers, Kristina: 633
 Crowe, Suzanne M.: **125**, 711
 Crowell, Trevor A.: **922**, 923, 924, **956**
 Crowther, Carol: 302
 Cruz, Maria Leticia S.: 798
 Csala, Anna: 302
 Csernansky, John G.: 823
 Cua, Eric: 522
 Cuenca, Francisca: 527, 555
 Cui, Zishan: 546, 898, 1007, 1041
 Culver, Jeffrey: 706
 Cummings, Derek A.: 535
 Cummings, Vanessa: 897
 Cummins, Nathan W.: **243**
 Cunningham, Chinazo O.: 585
 Cunyat, Francesc: **372**
 Curlin, Marcel: 884, 927
 Curran, Kelly: 978
 Currier, Judith S.: 55, 476, 650, 660, 672, 704, 793, 939
 Cusato, Jessica: 426
 Cutillas, Vincent: 507
 Cuzin, Lise: 709, 950
 Cyktor, Josh: 350
 Cypess, Aaron M.: 707
 Cyr, Derek: 595
 Cysique, Lucette A.: **391**
 Cytko, Joshua: 300LB
 Czaicki, Nancy L.: 1018, **1019**
- D—
 D'Aquila, Richard T.: **629**
 d'Arminio Monforte, Antonella: 598, 637, 661, 946
 D'Avino, Alessandro: **697**
 D'Avolio, Antonio: 426, 774
 D'Ettoire, Gabriella: 238, 610
 Daar, Eric: 29, 443, 952
 Dabis, Francois: 169LB, 549, 565, 566, 568, 582, 605, 661, 962, 1015
 Dailey, Peter: 517
 Dakshina, Subathira: **846**
 Dakum, Patrick: 502
 Diamond, Florence: 214, 509
 Damouche, Abderaouf: **271**
 Dan, Jennifer M.: **730**
 Danesh, Ali: 81
 Daniel, Simon: 517
 Daniels, Julie E.: 826, 859
 Danta, Mark: 233
 Darchy, Natacha: 420
 Darin, Kristin M.: 444
 Darko, Sam W.: 245LB
 Darling, Katharine: 567
 Darque, Albert: 583
 Das, Moupali: 27, 680, 681, 682, 717
 Das, Satyajit: 474
 Dasgupta, Sharoda: **500**
 Daskalakis, Demetre C.: 888, 892, 994
 Datwani, Hema: 772
 Dauchy, Frédéric-Antoin: 689
 Dauncey, Thomas: 1023
 Davaniah, Siva: 499
 Davey, Richard T.: **77LB**
 David, Lorenz: 145, 250
 David, Ludivine: 351
 Davies, Mary-Ann: 960
 Davis, Jonathan: 97
 Davis, Lucian: 764
 Davis, Nicole L.: **801LB**
 Davy, Thibaut: **291**
 De, Asha R.: **722**
 De Alwis, Paba M.: **389**
 De Angelis, Daniela: 895
 De Armas, Lesley: 324, 327
 De Bona, Anna: 598
 De Cock, Kevin M.: 909
 De Francesco, Davide: 148
 De Girolamo, Gabriella: 238
 De Gruttola, Victor: 167, 942
 de Hoon, Mieke: 431
 de Jong, Menno D.: 602
 de Knegt, Robert J.: 536
 De La Flor, Carolina: 587
- de la Fuente Soro, Laura: **974**, 976
 de Lazzari, Elisa: 945
 de Leuw, Philipp: 713
 de los Angeles, Christine Paula: **823**
 De Luca, Andrea: 417, 486, 697, 946
 de Mendoza, Carmen: 508
 de Monteynard, Laure-Amélie: **943**
 de Oliveira, Tulio: 211, 499
 de Pablo, Rebeca S.: 655
 de Pokomandy, Alexandra: 699
 De Rekeneire, Nathalie: 1015
 de Silva, Thushan: 253
 de Souza, Mark: 219, 287
 De Stefano, Giorgio: 607
 De Truchis, Pierre: 420
 De Vuyst, Hugo: 621, 624
 De Wit, Flore: 139
 de Wit, Stephanie: 637
 Debre, Patrice: **304**
 Debyser, Zeger: **139**, **363**
 Decker, Timothy: 133
 Decloedt, Eric H.: **419**
 Decome, Diessy: 750
 Deeks, Steven G.: 81, 83, 254, 293, 298, **343**, 344, 511, 643, 654
 Deering, Laura J.: 532
 Defferriere, Helene: 420
 DeGroot, Nicholas P.: **591**
 Deiss, Robert: 932
 DeJesus, Edwin: 29, **472**, 953
 Del Amo, Julia: **173**, **901**, 941
 del Campo, Santos: 571
 Del Prete, Gregory Q.: 84, 138
 del Rio, Carlos: 27, 995, 1039
 Delaney, Joseph A.: 42, 558, 636, 1034
 Delaney, Kevin P.: **889**
 Delaporte, Eric: 73LB, 696, 959
 Delaunoy, Constance: 295, 420, **522**
 DelBianco, Gabriela: 623
 Deleage, Claire: 275LB
 Delfour, Isabelle: 729
 Delgado-Fernández, Marcial: 634
 Dellamonica, Pierre: 408
 Delman, Keith: 335
 Delobel, Pierre: 289, **701**, 950
 Delpech, Valerie: 225, 895,
- 913, 1053
 Deluca, Joseph: 585
 Demers, Corey: 254
 Demeulemeester, Jonas: 363
 Deng, Xutao: 81
 Denning, David W.: 764
 Dennis, Ann M.: **216**, **217**
 Dennis, Futhi: 1056
 Denti, Paolo: 429
 Denton, Paul W.: 348
 Deocharan, Bisrom: 896
 Derache, Anne: 499, 840
 Derby, Nina: **270**
 Deren, Sherry: 597
 Dereuddre-Bosquet, Nathalie: 271
- DeRuijter, Annemiek: 794
 Desai, Payal: 534
 Desai, Seema N.: **277**
 Desai, Tejal: 879
 DeSalvador, Francine: 408
 Descamps, Diane: 214, 509
 Descours, Benjamin: 468
 Desfarges, Sébastien: 208
 Deshieri, Alexandre: 182
 Deshpande, Prasad: 758
 Destache, Christopher J.: **435**
 Detzel, Christopher J.: 278
 Devaraj, Chitra: 753
 DeVico, Anthony: 188
 Devlin, Brid: 110LB
 Dewar, Robin: 287, 380
 Deya, Ruth: 863
 Deyoungs, Frank: 107
 Dezzutti, Charlene S.: 871, 872, **874**
 Dharan, Adarsh: 209LB
 Dhiver, Catherine: 583
 Di Giambenedetto, Simona: 417, 697
 Di Perri, Giovanni: 426, 774
 Di Rosa, Michelino: **204**
 Diacon, Andreas H.: **158LB**
 Dias, Juliana Z.: 326
 Diaz, Asuncion: 590, 639
 Diaz de Santiago, A.: 452
 DiCarlo, Abby L.: 988
 Dickens, Alex M.: 396
 Dicker, Ira B.: 464, **466**
 Diero, Lameck: 565
 Dieterich, Douglas: 573, 588
 Dietrich, Janan: 1014

- Dietz, Patricia: 966
 Dieumegard, Hinatea: 836
 Díez, Cristina: 527
 Díez, José Luis: 366
 Dillon, Stephanie M.: 134, 187, **262, 279**
 Dillon-White, Marsha: 201
 Dimitrov, Dobromir T.: **1055**, 1060
 DiNapoli, Sarah R.: 21
 Dinasarapu, Ashok: 257
 DiNenno, Elizabeth: 889
 Ding, Bifeng: 453
 Ding, Erin: 949
 Ding, Jian: 196
 Ding, Ming: 341
 Dinh, Chuong: 878
 Dinoso, Jason: 717
 Diouf, Assane: 696
 Dirajlal-Fargo, Sahara: **666**
 Dirix, Lieve: 139
 Diseko, Modiegi: 800
 Dittmer, Ulf: 134
 Dobard, Charles: 878
 Dobbels, Els: 820
 Doblecki-Lewis, Susanne: 524, 867, 870
 Dobs, Adrian S.: 914
 Dockrell, David H.: 724
 Doherty, Irene A.: 217
 Doitsh, Gilad: **240**
 Dollfus, Catherine: 811
 Dolling, David I.: **1027, 1027**
 Domeneghini, Elisabetta: 774
 Dominguez, Beatriz: 655
 Donahue Carlson, Renee: 761
 Donald, Kirsten: 821
 Dong, Krista: 488
 Dong, Tao: 253
 Donnell, Deborah: 301, 771, 865, 868, 982, 989, 1038, 1055
 Donohue, Kelsey: 523
 Donovan, Andrew M.: 262
 Dore, Gregory J.: 451, 545
 Dorey, David: 311B
 Dorman, Susan: 155, 743
 Dorr, Maggie: **992**
 Dorrell, Lucy: 320
 Dorsey, Grant: 101
 Dorsey, Kerri: 992, **1008**
 Dorskind, Joelle: 396
 Douek, Daniel C.: 245LB, 336
 Douglas, Nora: 869
 Douglas, Pamela: 642
 Doumbia, Seydou: 921
 Dowdy, David: 113LB
 Downer, Marie: 909
 Dowshen, Nadia: 832
 Doyle, Erin: 604
 Drabo, Joseph: 962
 Draghi, Monia: 308
 Drake, Mary: 978
 Dray-Spira, Rosemary: 1043
 Dreosti, Lydia: 631
 Dressel, Erin: 623
 Drexler, Dieter: 466
 Drozd, Daniel: 42, **641**, 671
 Dryden-Peterson, Scott: **615**, **805**
 DSouza, Gypsamber: 617
 Du, Quy T.: 746
 Du, Yimin: **313**
 Du Pasquier, Renaud: 381
 Dube, Michael: 672, 939
 Dubrow, Robert: 633
 Duchesne, Léa: **526**
 Duclos-Vallée, Jean-Charles: 455
 Dudoit, Yasmine: 332
 Duerr, Ann: 632
 Duffau, Pierre: 689
 Duffus, Wayne: 965
 Duffy, William: 896
 Dugast, Anne Sophie: 91
 Duisenberg-van Essenberg, Marjolijn: 431
 Dunais, Brigitte: 408
 Dunaway, Shelia: 767
 Dunay, Gabor A.: 364
 Dunbar, Matt: 50
 Dunn, David: 223, 482, 484
 Dunne, Eileen: **900**, 927, 972
 Dunning, Lorn: 795
 Duong, Yen: 510
 Duprez, Daniel: 41
 Duraffour, Sophie: 75LB
 Durant, Jacques: 408
 Durham, Natasha D.: 249
 Durham, Phillip: 879
 Durier, Christine: 351
 Durier, Nicolas: 369
 Dusheiko, Geoffrey M.: 576
 Dutrieux, Jacques: 274
 Dutta, Anupriya: 145
 Dutta, Sandeep: 453
 Duvedi, Vikram: 968
 Duwve, Joan: 916
 Dvory-Sobol, Hadas: 573
 Dzialowy, Nicole: 964
 —E—
 Eagar, Jessica: 292
 Easley, Kirk A.: 22, 47, 286
 Eaton, Jeffrey W.: 51, **117**
 Ebner, Hanna: 89LB
 Eckard, Allison R.: **826, 859**
 Edelstein, Zoe R.: 888, **892**
 Edun, Babatunde: 965
 Edwards, Michael G.: 279
 Egan, Deidre: 448
 Egaña-Gorroño, Lander: 248
 Egger, Matthias: 118, 565, 613, 617, 618, 631, 737, **1021**
 Ehret, Robert: 525
 Ehrlich, Hartmut: 461LB
 Eisele, Lewin: 646
 Ekouevi, Didier: 568, 568
 El Raziky, Maissa: 153
 El-Diwany, Ramy: **135**, 151
 El-Sadr, Wafaa M.: 738, **988**, **989**, 997, 1020, 1038
 Elashoff, David: 793
 Elbaz, Tamer: 153
 Elbireer, Ali: 513
 Eley, Brian: 854
 Eley, Timothy: 425, 460
 Elharrar, Vanessa: 885
 Elion, Richard: 524, 867, 870, 989, 997
 Elkington, Paul T.: 734
 Eller, Leigh.: 349, 515
 Eller, Michael A.: 254
 Ellington, Sascha: 772, 801LB
 Elliott, Alison M.: 297
 Ellis, Ron: 43, 143, 144, 390, 395, 409, 410, 412
 Ellman, Tom: 1010
 Ellner, Jerrold: 743
 Else, Laura J.: 448, 874
 Elul, Batya: 1020
 Elyanu, Peter: 844
 Emerman, Michael: 200
 Emerson, Michael: **662**
 Emert-Sedlak, Lori A.: 191
 Emery, Ann L.: **192**
 Emery, Sean: 559
 Emmanuel, Benjamin: 538LB
 Emmanuel, Sam: 648
 Emond, Mary: 17
 Emu, Brinda: 142, 411, 633
 Ene, Luminita: 778
 Engberg, Göran: 267
 Engels, Eric: 616, 616
 Enomoto, Ikumi: 504
 Erba, Paola: 819, 819
 Erbel, Raimund: 646
 Ericson, Adam J.: **21**
 Erlandson, Kristine M.: 283, **421**, **719, 721**
 Ernest, Oscar: 1025
 Eron, Joseph J.: **16, 25**, 31LB, 147, 150, 216, 217, 291, 300LB, 350, 401, 402, 418, 694
 Escribá, Tuixent: 248
 Eshleman, Susan H.: 436, 511, 520, 523, 917
 Esmat, Gamal: **65**, 153
 Espinosa, Enrique: 251
 Espinoza, Lorena: 1033
 Eस्पलугues, Juan V.: 663
 Esposito, Anthony M.: 249
 Essajee, Shaffiq: 1023
 Essat, Asma: 222
 Esser, Stefan: **646**
 Essex, M.: 37, 111, 307, 904, 984
 Estany, Carla: 266
 Esté, José A.: 183, 205, 207
 Esteban, Herminia: 424LB
 Estes, Jacob D.: 22, **129**, 263, 275LB, 335
 Esteve, Anna: 765
 Estill, Janne: 118
 Estrella, Michelle: 651, 684, 685, 688
 Etard, Jean-François: **731B**
 Etemad, Behzad: 307, 347
 Etukoit, Bernard: 862
 Euler, Zelda: **305**
 Eva Malantinkova, Eva: 359
 Evans, Denise: 845
 Everett, Dean: 769
 Evering, Teresa H.: **406**
 Ewing, Alexander: **772**
 Excler, Jean-Louis: 318
 Eymard-Duvernay, Sabrina: 675, 696
 —F—
 Fabbiani, Massimiliano: 280, 417, 697
 Fabra García, Amanda: **303**
 Fabre, Roxane: 408
 Fabre-Mersseman, Véronique: 274

- Facente, Shelley: 511
 Fagard, Catherine: 214, 509
 Faini, Diana: **760, 760**
 Falade-Nwulia, Oluwaseun:
 12, 537
 Fallah, Mosoka: **74LB**
 Fan, Li: 456
 Fan, Lili: 970
 Fan, Peihu: 194
 Fang, Annie: 818, 1120
 Farella, Nunzia: 607
 Faria de Oliveira, Michelli:
 143, 410
 Farjado, Emmanuel: 512, 787
 Farmer, Paul: 72LB
 Farnham, Paul: 1051
 Farouk, Idris: 510
 Farquhar, Carey: **49, 50**
 Farrior, Jennifer H.: 989, 997,
 1038
 Fätkenheuer, Gerd: 197
 Fatti, Geoffrey: 960
 Fauci, Anthony S.: 198, 311LB
 Fawzi, Wafaie W.: 703, 803
 Faye, Albert: 776, 811
 Faye, Khadim: 961
 Fayorsey, Ruby N.: **791**
 Feaster, Daniel J.: 27
 Fedele, Valentina: 413
 Feder, Alison F.: **229, 495**
 Fedoriw, Yuri: 447, 450
 Feehey, Eoin R.: 665
 Fehr, Jan: 566
 Feigl, Andrea B.: 677
 Feinstein, Matthew J.: **42, 644**
 Felber, Barbara K.: 259LB
 Feldpausch, Meghan: 664
 Fellows, Lesley K.: 385
 Feng, MeiZhen: 506
 Fenner, Lukas: 737
 Fenton, Terry: 816, 824
 Fernandez, Celine: 276
 Fernandez, Juan Manuel: 508
 Fernandez Cruz, Ana L.: 385
 Fernández-Romero, José:
 875, 876
 Ferrand, Rashida A.: **176,**
 846, 853
 Ferrando-Martinez, Sara: 94
 Ferrara, Micol: 426
 Ferris, Andrea: 84
 Ferry, Tristan: 709, 729
 Feske, Steven K.: 638
 Fichtenbaum, Carl: 329, 694
 Fidler, Sarah J.: 87, **114,** 156,
 165, 834, 981, 982
 Fiel, M. I.: 604
 Field, Andrew: 334
 Fielding, Katherine L.: 113LB,
 155, 736
 Fields, Sheldon: 883LB, 893
 Fiellin, David A.: 554
 Figueiredo, Suzanne: 274
 Figueroa, Maria I.: 718, 947
 Fillgrove, Kerry L.: 98
 Fine, Derek M.: 651, 687
 Fink, Valeria: 618
 Finkelman, Malcolm: 410
 Finlayson, Robert: 451, 545, 681
 Finlayson, Teresa: **930,** 931
 Finnerty, Fionnuala: 794
 Finzi, Andrés: **181**
 Fischer, Johannes: 364
 Fisher, Martin: 692
 Fitch, Kathleen: 650, 673, 707
 Fitzgerald, Daniel W.: 473,
 Fitzgerald, Michael: 664
 Fitzmaurice, Garrett M.: 1014
 Fitzpatrick, Meghan E.: 330
 Fiumano, Martina: 426
 Flamholz, Leo: 998
 Fleishman, John: 1001
 Fleming, Julia: 585
 Fletcher, James L.: 384, 415
 Florence, Eric: 46
 Floris-Moore, Michelle: 671
 Flowers, Lisa: 772
 Floyd, Sian: 114, 156, 165, 980,
 981, **982**
 Flynn, Colin: 906
 Focà, Emanuele: 774
 Foca, Marc: 851
 Fogel, Jessica M.: **436**
 Folkvord, Joy M.: **23**
 Fong, Moy Siew: 860
 Fontas, Eric: 686
 Force, Gilles: **420**
 Ford, Mary: 534
 Ford, Susan L.: 106
 Forde, Kimberly A.: 609
 Fordyce, Marshall: 496, 680,
 681, 682, 717
 Forgione, Lisa A.: 896
 Forleo, Maria Antonietta: 774
 Forsyth, Elizabeth W.: 971
 Fortún, Jesús: 572
 Foster, Antonia: 47
 Foster, Caroline: 834, 835
 Foucat, Emile: 295
 Fouche, J.P.: 821
 Fourati, Slim: 358LB
 Fourati, Slim: **577**
 Fowler, Mary G.: 36
 Fox, Julie: **448**
 Fox, Matthew P.: 28, 792, 845,
 957, 960, 1011, 1012, 1013,
 1048
 Fox-Bosetti, Sabrina: 437LB
 Frampton, Dan: 210
 France, John: 625
 Franchini, Genoveffa: 317
 Francke, Jordan A.: 786
 Frange, Pierre: 222
 Frank, Daniel N.: 262
 Frank, Ian: 106, 471
 Franklin, Dana: 544
 Franklin, Donald: 446
 Franks, Julie: 885
 Frantzell, Arne: 578, 579
 Fraser, Christoph: 165, 220, 221
 Fraser, Nicole: 1028
 Frater, John: 87
 Frederick, Toni: 813
 Frederix, Koen: 738, 988
 Freed, Eric O.: 137, 465
 Freedberg, Kenneth A.: 786,
 952, 1016
 Freeman, Carla S.: 419
 Freeman, Gordon J.: 93LB
 Freeman, Michael L.: **732**
 Freiberg, Matthew S.: 645, 714
 Freimanis, Laura: 798, 809
 Freire, Marcos S.: 326
 French, Audrey L.: 277
 Frenkel, Lisa: 361, 478, **494LB,**
 847
 Frías, Mario: **555**
 Friedland, Barbara A.: **875**
 Friedland, Gerald H.: **14**
 Friedland, Jon S.: 734
 Friedman, Evan: 98, **437LB**
 Friedman, Ruth: 617
 Friedrich, Thomas C.: 21
 Frigati, Lisa: 852
 Fromentin, Remi: 343, 344, 352
 Fry, Carrie L.: 747
 Fuchs, Edward J.: 169bLB
 Fuchs, Wolfgang: 628
 Fujita, Hideaki: 203
 Fukuda, Dawn: 890
 Funderburg, Nicholas T.: 44LB,
 656, 657, 717
 Furrer, Hansjakob: 676, **751,**
 760, 765
 Fusco, Gregory: 953
 Fusco, Jennifer: 953
 Fusco, Robert: 507
 Fu, Christoph A.: 686
 Fyne, Elizabeth: 379, 379
- G—
- Gabuzda, Dana: 145, 250, **693**
 Gachuhi, Averie: 34
 Gadabu, Oliver: 118
 Gadawski, Izabelle: 715
 Gadde, Uttara: 968
 Gagliardini, Roberta: 417
 Gagne, Matthew J.: **193**
 Gagneux, Sébastien: 737
 Gaisa, Michael: 620, **626**
 Gajjar, Mili R.: 469LB
 Galang, Romeo R.: 149, 215,
 541
 Galarraga, Omar: **1059**
 Galiba, Eliane: 776
 Galindo, Maria J.: 611, 634
 Gall, Astrid: 827
 Gallant, Joel: **29**
 Galli, Laura: 454, 627
 Galli, Luisa: 778
 Galli, Ubaldina: 204
 Galli, Veronica: 317
 Gallo Cassarino, Tiziano: 210
 Gamal Eldeen, Hadeel: 153
 Gandhi, Monica: **866,** 1040
 Gandhi, Neel: 157, 756
 Gandhi, Rajesh: 300LB, 346,
 347, **350**
 Ganesan, Anuradha: 932
 Gange, Stephen J.: 641
 Ganz, Peter: 343, 654
 Gao, Feng: 194
 Gaolathe, Tendani: **111,** 904
 Gaolethe, Tendani: 983
 Garcia, Debra L.: 331, 345
 Garcia, Elisabet: 241
 García, Felipe: 248
 Garcia, J. Victor: 447, 450
 Garcia, Rochelle L.: 624
 García, Rosa: 508, 596
 García-Basteiro, Alberto L.:
 158LB
 Garcia-Beltran, Wilfredo: 294
 García-Lerma, Gerardo: **107,**
 333
 García-Morales, Claudia: 477

- García-Perez, Javier: 468
 García-Samaniego, Javier: 596
 Gardener, Donald: 588
 Gardner, Edward M.: 283
 Garet, Dickman: 677, 1030
 Gara, Shikha: 591, 915, 1006, 1037
 Gargalianos-Kakolyris, Panagiotis: 46
 Garnett, Geoff: 1058
 Garrett, Katy L.: **102LB**
 Garrett, Nigel: 246
 Garrido, Carolina: **355**
 Garrison, Lindsay: 957
 Garrity, Jetta: 309LB
 Gartland, Martin: 660
 Garzino-Demo, Alfredo: 188
 Gaseitsiwe, Simani: 984
 Gatell, Jose M.: 303, 248, **470, 945**
 Gates, Thomas M.: 391
 Gatimu, John: 748
 Gaur, Aditya: **817, 1005**
 Gavegnano, Christina: **369**
 Gay, Cynthia: 25, 102LB, 291, **418, 964**
 Gaydos, Charlotte: 923
 Gaziano, Thomas A.: 678, 679
 Gebi, Usman I.: 790
 Gebo, Kelly A.: 1001, 1005
 Geelen, Sibyl P.: 839
 Gehret Plagianos, Marlena: 875
 Geidelberg, Eugene L.: 1047
 Geldmacher, Christof: 625
 Geldsetzer, Pascal: **677**
 Gelé, Thibaut: 455
 Geleziunas, Romas: 95LB
 Genazzani, Armando: 204
 Genberg, Becky L.: 1042
 Gendelman, Howard E.: 399
 Genebat, Miguel: 655
 Geng, Elvin H.: **112, 121, 1018, 1019, 1040**
 Gentry, Jessica: 149, 541
 George, Kathleen: 36, 816
 George, Varghese K.: 327, **824**
 Gerber, Joanne: 501
 Geretti, Anna Maria: **482, 486**
 German, Danielle: **906**
 Gerstoft, Jan: 1044
 Gettie, Agegnehu: 105, 270
 Gettie, Natanya: 597
 Ghadrshenas, Matine: **632**
 Ghanem, Khalil: 1005
 Ghislain, Mathilde: 701
 Gheim, Khader: 297
 GHOSN, Jade: 222
 Ghys, Peter: **170**
 Giacomet, Vania: **819**
 Gianella, Sara: 143, 232, 410, 487, 518, 726, **727, 730, 731**
 Gianotti, Nicola: 946
 Giaquinto, Carlo: **818, 1120**
 Gibb, Diana: 848
 Gibbert, Kathrin: 134
 Gibbs, Anna: 285
 Gibbs, Richard: 20
 Gibert, Cynthia: 633, 645, 714
 Gichuru, Evanson: 977
 Giddy, Janet: 613, 1016
 Giganti, Mark: 958
 Gijsbers, Rik: 363
 Gilbert, Camille: 582, 605
 Gilks, Charles: 1027
 Gill, Alexander J.: 394
 Gill, John: 614, 688
 Gill, Noel O.: 895
 Gillece, Yvonne: 692
 Gilquin, Jacques: 943
 Gilson, Richard: 913
 Gimenez, Sandrine: 282
 Gindin, Tatyana: 310LB
 Gindy, Marian: 98
 Ginsteste, Paul: 461LB
 Gini, Joshua: **434**
 Ginindza, Sibuse: 113LB
 Gisslén, Magnus: **60, 998**
 Gittleman, Haley: 409
 Giudice, Linda: 284
 Giuliani, Massimo: 697
 Giustini, Noemi: 238
 Gjaerde, Lars: 566
 Glass, Tracy: 760
 Glässner, Andreas: 236
 Glaubius, Robert: 1057
 Glazier, Rick: 622
 Glick, Sara N.: **933**
 Glidden, David V.: 48LB, 112, 866, 1019, 1040
 Glynn, Judith: 736
 Gnemmi, Ilaria: 204
 Gobillot, Theodore: 88
 Godfrey, Catherine: 161, 493LB
 Goedert, James J.: 614
 Goepfert, Paul A.: 313
 Goeser, Felix: 236
 Goetz, Matthew: 633, 645
 Gokhale, Runa H.: **1037**
 Goldberg Raifman, Julia: **1005**
 Golden, Mathew R.: 50, 971
 Goldstein, David V.: 601
 Goldstein, Richard: 225
 Goldstone, Stephen: 626
 Goliath, Rene: 734
 Golub, Elizabeth: 277, 647, 720
 Golub, Sarit A.: **869, 881**
 Golubkov, Olga: 218, 480
 Golumbeanu, Monica: **208**
 Gomaa, Asmaa: 153
 Gómez-Mora, Elisabet: **241**
 Gomez-Olive, Xavier: 678, 679, 905, 907, 936
 Gonciulea, Anda R.: **699**
 Gone, Molly Ann: 49
 Gongvatana, Assawin: 386
 Gonzalez, Louis Edward: 327
 Gonzalez, Nuria: 303
 Gonzalez, Oscar: 186, 307
 González, Raquel: 797
 González-García, Juan: 31LB, 527, 611
 Goodall, Ruth: 1027
 Gooden, Lauren: 27
 Goodenberger, Katherine: 891
 Goodenow, Maureen: 257, 325
 Goodreau, Steven M.: 1063
 Goosens, Nicholas: 604
 Goosenberg, David B.: 261
 Göpel, Siri: 519
 Gorantla, Santhi: 399
 Gorbach, Pamina: 861
 Gordin, Fred: 474, 1038
 Gordon, Ana: 555
 Gordon, Daniel: 501
 Gordon, Lori A.: 430
 Gordon, Michelle: 427, 488
 Gordon, Stephen: 769
 Gorgens, Marelize: 1056
 Gorgolas, Miguel: 596
 Gori, Andrea: 18LB, 280
 Gossez, Morgane: **87**
 Goswami, Neela D.: **995**
 Gottlieb, Geoffrey S.: **961**
 Gottlieb, Rachel Z.: 347
 Gottlinger, Heinrich G.: 136
 Gotuzzo, Eduardo: 958
 Gough, Kevin: 491LB
 Goujard, Cécile: 222, 701
 Goujon, Stéphanie: 811
 Goulder, Philip: 256, 302, 827, 828
 Gounder, Kamini: 195
 Govender, Nelesh: 759
 Govender, Tessa: 1016
 Gowda, Charitha: **609, 934**
 Goyette, Marielle S.: **863**
 Grabowski, Mary K.: 731, **902, 954, 986, 987**
 Graham, Barney: 32LB, 90
 Graham, Bobbie: 816
 Graham, Susan M.: 977
 Granade, Timothy: 140
 Granados, Rafael: 586, 603
 Grandone, Anna: 556
 Granier, Catherine: 660
 Granoff, Mitchell E.: 315
 Grant, Alison: **155**
 Grant, Igor: 412, 446
 Grant, Jennifer L.: **564**
 Grant, Robert: **48LB, 106, 471, 866, 884, 885, 990, 1055**
 Granziere, Cristina: **381**
 Gras, Guillaume: 400
 Gras, Stephanie: 313
 Grasso, Chris: 890
 Graterol, Fredzia: 432
 Graves, Justin C.: **844**
 Gray, Diane: 852
 Gray, Glenda: 436, 1014
 Gray, Ronald H.: 563, 594, 902, 954, 986, 987
 Grebe, Eduard: 517
 Green, Nella: 224, 518
 Greenblatt, Ruth M.: 284
 Greene, Justin M.: 21
 Greene, Sharon A.: **621**
 Greene, Warner C.: 240, 284
 Gregorich, Steven: 162
 Gregson, John: 503
 Greig, Julia M.: 724
 Grennan, Troy: 546, 1007
 Gres, Anna T.: 137
 Grey, Jeremy: 1045
 Griesel, Rulan: **742**
 Griffith, Linda: **8**
 Griffith, Sam: 156, 980, 981
 Griffith, Sandy: 31LB
 Grimsrud, Anna: **122, 1031**
 Grinspoon, Steven: 553, 638, 640, 650, 664, 673, 707
 Grinsztejn, Beatriz: 474, 493LB, 728
 Grobler, Jay: **98, 437LB, 506**
 Grome, Heather N.: **653**
 Gross, Chloe: 528, 538LB

- Gross, Robert: 833, 934
 Grotts, Jonathan F.: 793, 793
 Grover, Surbhi: 614
 Grudé, Maxime: 840
 Gruenewald, Analise: **394**
 Grund, Birgit: 475
 Grunenberg, Nicole: 90
 Guanira, Juan: 48LB
 Guardo, Alberto C.: 248
 Guatelli, John: 373
 Guedj, Jeremie: 75LB
 Guerrero Gilabert, Maria
 Dolores: 241
 Guha, Anika: **382**
 Guidot, David: 255
 Guilbert, Thomas: 274
 Guillard, Etienne: 910
 Guillen, Yolanda: 260, 266
 Guiteau Moise, Colette: 750,
 1017
 Gulick, Roy: **103**, 104
 Gummuluru, Rahm: 185, 186,
 288
 Gun, Ana M.: 947
 Güner, Nuray: 744
 Günthard, Huldrych F.: 89LB,
 567, 592, 951
 Gunther, Stephan: 75LB
 Guo, Kejun: 134, 187, 262
 Guo, Susan: 681, 682
 Guo, Yan: 144
 Gupta, Amita: 745, 747, 752,
 758
 Gupta, Phalguni: 341, 376
 Gupta, Ravindra K.: 499, **503**,
 848, 1030
 Gupta, Samir: 714
 Gupta, Sundeeep K.: 35LB,
 168LB, **789**
 Gupte, Nikhil: 752
 Gurakar, Merve: 151
 Guthrie, Teresa: 115
 Gutiérrez, Carolina: **354**
 Gutman, Boris A.: 386
- H—
 Haas, Andreas: 118
 Haas, David W.: **443**
 Haas, Rainer: 364
 Haber, Barbara: 576
 Haberl, Annette: 713
 Haberlen, Sabina A.: **914**
 Haddad, Elias: 263, 263
 Hadigan, Colleen: 430, 561, 830
- Haeri Mazanderani, Ahmad: **783**
 Haessinger, Dieter: 364
 Hager, Cindy: 653
 Hahn, Beatrice: 133, 187
 Hahn, Judith A.: 554
 Hahn, Valerie: 420
 Haimowitz, Stephanie: 968
 Hain, Anika: 189
 Hakim, Avi: 510, 921
 Hakim, Idris: 510
 Halavaty, Katarina K.: 877
 Hall, David: 1041
 Hall, H. Irene: 52, 500, 1033,
 1045
 Hall, Jake: 514
 Hall, Nolween: 522, 887
 Hallett, Timothy: 51, 117, 1049,
 1058
 Hallett, Travis R.: 553
 Hallor, Magnus: 270
 Halvas, Elias: 379
 Hamers, Raph: 498, 503
 Hamid, Hasson: 556
 Hamimi, Chiraz: **332**
 Hammer, John: 698
 Hammer, Scott M.: **1**
 Hamzah, Lisa: **683**
 Han, Larry: 969
 Han, Yang: 569
 Hanekom, Willem: 824
 Hanf, Matthieu: 709
 Hanhauser, Emily: 86, 367
 Hanke, Kirsten: 485
 Hanke, Tomá: 320
 Hanna, David B.: **647**
 Hanna, George J.: 472
 Hans, Prozesky W.: 960
 Hanscom, Brett: 989, 997, 1038
 Hansudewechakul, Rawiwan:
 831, 858, 860
 Hao, Yanling: 321
 Harada, Shigeyoshi: **505**
 Hardin, Royce: 700
 Hardy, Isabelle: 218
 Hare, C. Bradley: **68**, 894
 Harezlak, Jaroslaw: 383, 386
 Harling, Guy: 167
 Harper, Michael S.: 134, 187, 262
 Harri, Bala I.: 434
 Harrigan, P. Richard: 227,
 169aLB, 483, **491LB**, 492LB,
 716, 940
 Harriman, Graham: 908
 Harris, Barbara: 213
- Harris, Jennie L.: 993
 Harris, Kate: 1058
 Harris, Marianne: 684
 Harris, Reuben S.: **59**, 199, 200
 Harrison, Benjamin R.: 371
 Harrison, Linda J.: 30, 32LB
 Hart, Rachel: 544, 708
 Hartman, Christine: 550
 Hartogensis, Wendy: 1040
 Hartsough, Kieran: 738
 Harty, Alyson: 588
 Harvey, Justin: 855
 Hasenkrug, Kim J.: 134
 Hasson, Hamid: 454, 557
 Hatano, Hiroyu: 298
 Hataye, Jason M.: 25, **336**
 Hatleberg, Camilla I.: **637**
 Hattori, Junko: 490
 Hatz, Christoph: 676, 760
 Haubrich, Richard: 658
 Haughey, Norman: 146, 396
 Hauser, Andrea: 485
 Hauser, Christoph: 951
 Häussinger, Dieter: 189
 Havliir, Diane V.: 101, 112, 116,
 796, 829, 841, 843, 979, 985,
 1026, 1062
 Hawes, Stephen E.: 961
 Hawken, Mark: 791
 Hawkins, Claudia: 594
 Hawkins, David: 433
 Hawthorne, Dara: 425
 Hayes, Richard: 114, 156, 165,
 523, 981, 982
 Hazra, Rohan: 816
 Hazuda, Daria J.: 98, 437LB, 506
 He, Xuan: **321**
 Hearsps, Anna C.: 483
 Heath, Katherine: 1023
 Heath, Laura M.: 33
 Heath, Sonya L.: **292**, 313
 Heaton, Robert: 409, 446
 Heckbert, Susan: 42, 641
 Heera, Jayvant: 818, 1120
 Heffron, Renee: 771, **865**
 Hegazi, Aseel: 683
 Heine, Amy D.: 920
 Heitzmann, Julia: 351
 Hejdeman, Bo: 285
 Heller, Theo: 561
 Hellerstein, Marc: 298
 Hellmuth, Joanna M.: 405,
 414, 415
 Helmy, Sherine: 153
- Héma, Arsène: 696
 Hemanth Kumar, Agibothu
 Kupparam: **457**
 Henderson, Andrew: 185, 193
 Hendrickson, Cheryl J.: **845**,
 1013
 Hendrix, Craig: 871, 169bLB
 Hendrix, Jelle: 139
 Henegar, Cassidy: 953
 Heneine, Walid: 107, 140, 215,
 333, 878
 Hennessey, Claudine M.: **1022**
 Hennessey, Kelly A.: 1017
 Hennessy, Orla: 640
 Henning, Tara: 878
 Henrich, Timothy J.: **86**, 357, 367
 Henry, Amy R.: 245LB
 Henry, Keith: 160
 Hensley-McBain, Tiffany: 263
 Herbst, Philip G.: 658
 Heresi, Gloria P.: 623
 Hernandez, Angela L.: 211,
 497, 500
 Hernandez, Céline: 208
 Hernandez, Dennis: **575**
 Hernandez, Matthew M.: **201**
 Hernández-Quero, José: 603
 Hernando, Vicky: 901
 Herrera, Carolina: 448
 Herrmann, Eva: 713
 Hesney, Michael: 460
 Hess, Kristen: **52**, 930
 Hesselgesser, Joseph: 95LB
 Hessel, Nancy A.: 647
 Hey-Cunningham, William: 334
 Heyderman, Robert S.: 769
 Hezode, Christophe: 577
 Hicks, Charles B.: 418
 Hicks, Katherine A.: 1051
 Hicks, Sakeenah: 93LB
 Hickson, DeMarc A.: 897
 Hiener, Bonnie: 348, 365
 Hightow-Weidman, Lisa: 883LB
 Hijdra, Rosanne M.:
 Hildebrand, Falk: 260
 Hileman, Corriynn O.: **674**
 Hill, Alison L.: **357**
 Hill, Andrew M.: **1023**
 Hill, Elizabeth M.: 692
 Hill, Shawn: 337
 Hillier, Sharon L.: 109LB, 871
 Hinkley, Sandy: **395**
 Hirsch, Vanessa: 275LB
 Hirsch-Moverman, Yael: 738,

- 885
Hleyhel, Mira: **811**
Hlophe, Thabo: 34
Ho, Antonia: 769
Ho, Cynthia K.: 543, 543, 602
Ho, David D.: 105, 469LB
Ho, Emily L.: 636, 636
Ho Sui, Shannan: 360
Hoare, Jacqueline: **821**
Hobbs, Kristen S.: 86, 367
Hocini, Hakim: 295
Hodis, Howard N.: 652
Hoensigl, Martin: 224, **410, 518**
Hoesley, Craig: 872, 873, 875, 876
Hoffman, Howard J.: 813, 814
Hoffman, Risa M.: **793, 793**
Hoffman, Susie: 1020
Hoffmann, Christian: 160, 470
Hoffmann, Christopher: **113LB**, 155
Hoffmann, Matthias: 567
Hoffmann, Udo: 553, 640, 673
Hofkens, Johan: 139
Hofmann, Alexandra: 485
Hoffmann, Oliver: 360
Hogan, Joseph: 51, 1042
Hogan, Louise: 86, 357, **367**
Hogema, Boris M.: 593
Hogg, Evelyn: 745
Hogg, Robert S.: 546, 898, 949, 1007, 1041
Hoh, Rebecca: 81
Houim, Brian J.: 200
Holder, Angela: 878
Hollabaugh, Kimberly M.: 99
Holland, Claire: 925
Holloway, Cameron: 648
Holman, Alexander: 145
Holman, Susan: 720
Holmes, Charles: 1018, 1019
Holmes, Michael: 356
Holstad, Marcia K.: 720
Holt, Stephen G.: 692
Holtz, Timothy H.: **884, 900**, 927, 972
Holzendorf, Volker: 646
Holzmayer, Vera: 212
Hom, David: 743
Homeus, Fabienne: 1017
Honeycutt, Amanda A.: 1051
Hong, Feiyu: 85, **330**, 342, 379
Hong, Kunxue: 321
Hong, Patrick: 244
Hong, Ting: 728
Hong, Zhi: 105
Hontañón, Víctor: 527
Honwana, Nely: 975
Hood, Greg: 1057
Hood, Julia E.: **971**
Hoots, Brooke: **1000**
Hoover, Donald R.: 720
Hoover, Karen: **967**, 999
Hope, Rebecca L.: **835**
Hope, Tom J.: 197, 877
Horban, Andrzej: 630
Horberg, Michael A.: 54, 684, 688, **1035**
Hornig, Howard: 866
Hosek, Sybil: 866
Hoshida, Yujin: 604
Hoskin, Elena: 875
Hosseinpour, Mina: 30, 728, 745, 747
Hotton, Anna L.: 234
Hou, Taige: 786
Hou, Xuanlin: 17
Houle, Brian: 905, 907
Houston, James: 789, 850
Howard, Andrea A.: **738**
Howard, Louisa C.: **599**
Howarth, Alison R.: **996**
Hoxie, James A.: 32LB
Hoy, Jennifer: 46
Hsiao, Nei-Yuan: 782, 785, 795
Hsue, Priscilla: **343**, 344, 643, 654
Hu, Lily: 357
Hu, Shiu-Lok: 229, 356
Hu, Xiaohong: 52
Hu, Xintao K.: 259LB
Hu, Yiran B.: 574
Hu, Yufeng: 955
Huang, Justyn: 648
Huang, Laurence: 764
Huang, Liusheng: 101
Huang, Ping: 53
Huang, Shuijie: 926, 969
Huang, Wei: 578, **579**
Huang, Ya-Lin A.: 999
Huang, Yaoxing: 469LB
Huang, Yunda: 90
Huang, Yunlong: 397
Huber, Michael: 89LB
Huchko, Megan: 162
Hudgens, Michael: 801LB
Hudson, Hannah: 629
Hudson, Krischan J.: 106, 471
Hue, Stephane: 214, 216, 223, **225**, 848
Hueppe, Dietrich: 584, 589
Hueser, Andreas: 437LB
Huettig, Falk: 364
Huffman, Kim: 705
Hughes, Gwenda: 895
Hughes, James P.: 740, 884, 885, 936, 1055
Hughes, Michael: 37, 99, 493LB, 784, 810, 815
Hughes, Stephen H.: **84**, 337
Huhn, Gregory D.: **234**
Hulgan, Todd: 144, 409, 412
Hull, Mark W.: 533, 688, 718, 940
Hullegie, Sebastiaan J.: **536**
Hunt, Machel: 869, 869
Hunt, Peter W.: 44LB, 227, 235, 264, 278, 293, 326, 428, **671**
Huo, Yanling: 822, 823
Huot, Nicolas: 271
Huppler Hullsiek, Katherine: 41, 763
Hur, Sophia: 343, 344, 643
Hural, John: 90
Hurley, James H.: **58**
Hurley, Leo B.: 894, 1035
Hurst, Jacob: 87
Hussen, Sophia: 897
Hutter, Gero: 366
Hwang, Carey: 25, 425, 464
Hyland, Robert H.: 154LB
Højen, Jesper: 26LB
—|—
Iannucci, Veronica: 201
Ibanescu, Ruxandra Ilinca: 218, 480
Ibrahim, Fati M.: 502
Ignacio, Caroline: 362
Ignas-Menzies, Jarek: 716
Ilkayeva, Olga: 705
Imamichi, Hiromi: **380**
Imaz-Rosshandler, Ivan: 251
Ingiliz, Patrick: 154LB
Ingiliz, Patrick: 584, 589
Ingle, Suzanne: 941
Innes, Steve: **658, 820, 855**
Intana, Jintana: 407
Introini, Andrea: **285**
Iodice, Valentina: 607
Iordanskiy, Sergey: 368
Iqbal, Kashif: **999**
Ireland, Terra M.: 138
Irrinki, Alivelu: 342
Irungu, Elizabeth: 301
Irvin, Risha: 537
Ishai, Amorina: 343, 344
Ismail, Nazir: 157
Iudicello, Jennifer: 412, 446
Iwamoto, Marian: 98, 437LB, 456
Iwuji, Collins: 169LB
Ix, Joachim: 685
Iyer, Shilpa: 133, 187
Izopet, Jacques: 289, 950
—J—
Jackson, Akil: 448
Jacobson, Cindy: 108LB
Jacobson, Evin: 1051
Jacobson, Ira M.: 588
Jacobson, Jeffrey: 347
Jacobson, Lisa: 150, 283, 685, 914
Jaffe, Harold W.: 140
Jaffre, Jeremy: 489
Jagannathan, Pransana: 101
Jaggernath, Manjeetha: 488
Jagodzinski, Linda: 404, 415
Jahanshad, Neda: 383, 384, 386
Jahn, Andreas: 35LB, **119**, 168LB
Jahn, Andreas: 789
Jain, Mamta K.: 27, 160, 587
Jain, Vivek: 116, 843, **1026**
James, Anet: 523
James, Ian: 667
Jamieson, Denise: 772, 801LB
Jamieson, Lise: 246
Jamison, Kelly: 1009
Janez, Tomazic: 46
Jani, Ilesh V.: 788
Janjua, Sumbal A.: **640**
Janoff, Edward N.: 762
Jansson, Marianne: 254
Jantarabenjakul, Watsamon: 857
Jao, Jennifer: **798**, 808
Jaoko, Walter: 863, 864, 912
Japhet, Mbae M.: **562**
Jaquet, Antoine: **568, 962**
Jarrin, Inmaculada: 901
Jarvis, Joseph N.: 562
Jary, Hannah: 769
Jean Juste, Marc Antoine: 473, 739, 750
Jean-Philippe, Patrick: 458, 815
Jeanne, Nicolas: 950

- Jeffries, Carrie: **993**
 Jeffries, William L.: 930
 Jelicic, Katija: 198
 Jenabian, Mohammad-Ali: 237
 Jenkins, Cathy: 706
 Jenkins, Veronica: 538LB
 Jenks, Jeffrey D.: **753**
 Jennings, Jacky M.: 1036
 Jensen, Joern-Erik O.: **364**
 Jessen, Heiko: 231
 Jia, Hongwei: 215
 Jiang, Shuping: 680
 Jiang, Xiong: **390**
 Jibril, Haruna: 800
 Jin, Steven W.: **190**
 Joao, Esau C.: 779
 Jobarteh, Kebba: 850
 Jöckel, Karl H.: 646
 Johengen, Daniel: 879
 John, Betsey H.: 890
 John-Stewart, Grace C.: 38, 621, 624, 748, **780**
 Johnson, Christopher: 1004
 Johnson, Elan S.: 781
 Johnson, Erica L.: **781**
 Johnson, Jeffrey: 244
 Johnson, Leah: **879**
 Johnson, Leigh F.: 115
 Johnson, Mallory: 935
 Johnson, Margaret: 559, 683
 Johnson, R. P.: 269
 Johnson, Sherri: 108LB, 872, 873
 Johnson, Suzanne: 155
 Joloba, Moses L.: 743
 Jones, Brad: **300LB**
 Jones, Heidi E.: 770
 Jones, James H.: 72LB
 Jones, Joseph: 554
 Jones, Lynne: 745
 Jones, Rachael: 683
 Jonsson Funk, Michele: 953
 Jooste, Pieter: 302
 Jordan, Heather: 456
 Jose, Sophie: 683
- Joseph, Sarah B.: 401, **402**
 Joshi, Samir: 752
 Joshi, Samit R.: 472
 Joshi, Sunil K.: 80, 298
 Josiah, Robert: 1025
 Joska, John: 419, 821
 Jost, Stephanie: 315, 367
 Jotwani, Vasantha: **685**, 691
 Jourdain, Gonzague: 777
- Joy, Jeffrey B.: 491LB
 Judd, Ali: 835, 855
 Judge, Chelsey: 329
 Juge, Laurianne: 391
 Jung, Molly: 647
 Jungmann, Eva: 835
 Justement, Jesse S.: 311LB
 Justice, Amy C.: 150, **554**, 641, 714
 Justman, Jessica: 770, 1025
- K—
- Kabami, Jane: 979
 Kabilis, Elkanah D.: 434
 Kabore, Firmin N.: **696**
 Kadam, Dileep: 752
 Kadede, Kevin: **829**
 Kadelka, Claus: 89LB
 Kadlecik, Peter M.: 1035
 Kagaayi, Joseph: 954, 986
 Kahabuka, Catherine: 978
 Kahn, James G.: 1062
 Kahn, Kathleen: 905, 907, 936
 Kaida, Angela: 949
 Kairie, James K.: 868
 Kaiser, Philipp: 80
 Kaiser, Rolf: 364
 Kajubi, Richard: **101**
 Kakkar, Fatima: 836
 Kaku, Yu: 670
 Kakuru, Abel: 101
 Kalams, Spyros A.: 653, 706
 Kalapus, S.C.: 643
 Kalayjian, Robert: 329, 421, **694**, 719, 721
 Kaleebu, Pontiano: 87, 297, 1027
 Kalibbala, Sarah: 563, 726
 Kalinjuma, Aneth V.: 676, 760
 Kalish, Marcia: 790
 Kalkwarf, Heidi J.: 36
 Kall, Meaghan: 913
 Kallas, Esper G.: 326, 511
 Kalliampur, Asha R.: 144, **409**, 412
 Kalliampur, Kalpana J.: **384**, **387**, 723
 Kalpana, S.: 457
 Kamara, David: 637, 637
 Kamara, Victor: 910
 Kamara, Victoria: 910
 Kamara, Wogba: 910
 Kambona, Caroline: 903
 Kambuğu, Andrew: 297, 761, 762
- Kammerer, Betsy: 800
 Kampiire, Leatitia: 112
 Kamyra, Moses R.: 101, 112, 116, 297, 796, 829, 841, 843, 979, 985, 1026, 1062
 Kanade, Savita: 758
 Kandathil, Abraham J.: 151
 Kang, Guobin: 268, 290
 Kankasa, Chipepo: 33
 Kanki, Phyllis: 281
 Kannan, T.: 457
 Kansomplap, Putthachard: 956
 Kanters, Steve: 166
 Kanthula, Ruth M.: **478**, **847**
 Kantor, Rami: 503
 Kanywa, Jacqueline B.: 842
 Kao, Kekeleto: 512, 787
 Kapiga, Saidi: 110LB
 Kaplan, Jona E.: 159, 761
 Kaplan, Justin A.: 465
 Kaplan, Robert C.: 647
 Kaplan, Susan: 825
 Kaptue, Lazare: 212
 Kapwata, Thandi: 735
 Karajeanes, Esmeralda: 974, 976
 Karalius, Brad: 838
 Karasavvas, Nicos: 318
 Karat, Aaron: 155
 Karim, Farina: 735
 Karim, Mohammed: 153
 Karim, Salim A.: 246
 Karimanzira, Owen: 302
 Karimonia, Azar: 831, 858, 860
 Karki, Manju: 325
 Karku, Sahr: 72LB
 Karlsson, Annika: 254
 Karn, Jonathan: **180**
 Karuchit, Samart: 972
 Karugaba, Patrick: **513**, 521
 Kasese, Nkatya: 982
 Kashanchi, Fatah: 368
 Kashuba, Angela: 102LB, 402, 418, 439, 447, 450
 Kaski, Juan P.: 853
 Kassanjee, Reshma: 517
 kassaye, Seble: 390
 Katlama, Christine: 332, 489
 Katoro, Joel: 510
 Kattakuzhy, Sarah: 528, **538LB**, 580
 Katumba, Kenneth: 910
 Katuramu, Richard: 112
 Katz, David A.: 717
- Katz, Ingrid T.: **1014**
 Kaudha, Elizabeth: 849
 Kaufman, Jonathan J.: 40
 Kaufmann, Scott H.: 243
 Kaul, Rupert: 718
 Kaur, Jasmine: 342
 Kavanagh, Daniel: 312
 Kawale, Paul: 793
 Kayembe, Mukendi K.: 615
 Kayira, Dumbani: 801LB
 Kazer, Sam W.: 19
 Kazooza, Francis: 159
 Kearney, Mary F.: **85**, 337, 340, 379, 490
 Keating, Sheila M.: 81, 234, 511, 652
 Keele, Brandon: 84, 138, 229, 340
 Keiser, Olivia: 118
 Kekitiinwa, Adeodata: 842
 Kelesidis, Theodoros: **672**, **939**
 Kellam, Paul: 210, 827
 Kelleher, Anthony: 233, 334, 365, 559, 668
 Kelley, Colleen F.: **286**
 Kellogg, Anela: 430
 Kelly, Clifton W.: 521
 Kelly, J. Daniel: 72LB
 Kelly, Jane: 995
 Kelly, Nicola: 759
 Kendall, Claire: 622
 Kenmegne, Jules: 212
 Kerr, Stephen J.: 606
 Kersanske, Laura: **908**
 Kersh, Ellen: 878
 Keshinro, Babjide: 922, 923
 Kessing, Cari: 407
 Ketende, Sosthenes: 924, 925
 Kfutwah, A.: 959
 Khalilieh, Sauzanne: **456**
 Khan, Palwasha Y.: **736**, 846
 Khanh, Truong Huu: 858
 Khanna, Aditya S.: 1063
 Khatri, Amit: 574
 Khemmark, Suparat: 606
 Khoo, Saye: 432, 434, 441, 448, 449, 459
 Khoshnood, Babak: 804
 Khosropour, Christine: 933
 Khudyakov, Yury: 149, 541
 Khuong, Marie-Aude: 509, 943
 Kiama, Catherine N.: **909**
 Kielkowski, Danuta M.: 631
 Kiem, Hans-Peter: 356

- Kigozi, Godfrey: 163, 986, 987
 Kigozi, Simone H.: 227
 Kiguoya, Marion W.: **195**
 Kilani, Ritwan: 636
 Kim, Aandrea: 909
 Kim, Charlie C.: 235
 Kim, Elli: 553, 673
 Kim, Jerome H.: 318
 Kim, Michelle: 360
 Kim, Nicholas: 80
 Kim, Nina: **558**
 Kim, Peggy: 80
 Kim, Peter S.: 30
 Kimaiyo, Sylvester: 51
 Kimani, Joshua: 195, 226
 Kincer, Laura P.: 401, 402
 King, Alexa: 760
 King, Caroline: 771
 Kingsley, Lawrence: 330, 388, 699, 914
 Kinley, Bruce: 649, 657, 674, 826, 859
 Kintu, Alexander: **703**
 Kintziger, Kristina: 965
 Kinuthia, John: 49
 Kiogora, Festus M.: 195
 Kipp, Aaron M.: 746
 Kiptiness, Catherine: 494LB
 Kiragga, Agnes: 159, 297
 Kirby, Karen A.: 137
 Kirchner, Rory: 360
 Kirk, Catherine: 1024
 Kirk, Gregory D.: 150, 535, 540, 548, 693, 712, 917
 Kirk, Ole: 661
 Kirkegaard-Klitbo, Ditte M.: **690**
 Kirkpatrick, Allison R.: **520**, 726, 731, **830**, 987
 Kirwa, Elisha: 562
 Kirwan, Peter: 1053
 Kiselinova, Maja: **361**
 Kiser, Jennifer: 3, 99
 Kiser, Patrick: 877
 Kitahata, Mari M.: 42, 558, 614, 641, 671, 684, 688, 1034
 Kitch, Douglas: 44LB, 421
 Kitrinis, Kathryn M.: 496
 Kityo, Cissy: 498, **849**
 Kiwango, Eva: 115
 Kizito, Hilda: 817
 Klatt, Nichole: 263
 Klein, Daniel B.: 54, 641, 1035
 Klein, Daniel J.: 117
 Klein, Marina B.: 150
 Kleinbeck, Kyle: 876
 Kleiner, David E.: 561
 Kleinstein, Sarah E.: **601**
 Klenerman, Paul: 598
 Klimkait, Thomas: 951
 Kline, Christopher: 229
 Klingman, Karin: 44LB, 694
 Kluberg, Sheryl A.: **1012**
 Knezevic, Andrea: 47
 Knibbe-Hollinger, Jaclyn: 399
 Knight, Rob: 265
 Knobell, Hernando: 45
 Knops, Elena: 364
 Knox, David C.: **169aLB**
 Knox, Justin: 921
 Kobayashi, Masayuki: 202
 Kobbe, Guido: 364
 Koblin, Beryl A.: 140, 897
 Kochelani, Duncan: 925
 Koekkoek, Sylvie M.: 152, 547, 602
 Koelsch, Kersten K.: 233, 334, **365**
 Koenig, Serena P.: 473, 739, 1017
 Koenigsmann, Carl J.: 991
 Koethe, John R.: 653, **706**
 Koetsawang, Suporn: 777
 Kohgadai, Nargis: 284
 Kohli, Anita: 580, 599
 Kohorn, Lindsay M.: 387, 652, 723
 Kolb, Kellie E.: 19
 Kolber, Michael: 524, 867, 870
 Koletar, Susan L.: 421, 719, 721
 Kolie, Jacques: 75LB
 Kolson, Dennis L.: 394
 Kong, Xiangrong: 548
 Koole, Olivier: 736
 Koontz, Dianna: 379
 Kootstra, Neeltje A.: 152
 Koppelman, Marco: 593
 Korber, Bette: 309LB
 Körner, Christian: **315**
 Kort, Jens: 453
 Korthis, Todd: 1001, 1005
 Kosakovsky Pond, Sergei: 224, 231, 232
 Kosalaraksa, Pope: 817
 Kosloff, Barry: 523
 Kosloski, Matthew P.: 453
 Koss, Catherine A.: **796**
 Kostera, Joshua: 749
 Kostman, Jay R.: 290, 609
 Koteff, Justin: 660
 Kottlil, Shyam: 528, 538LB, 580, 595, 599, 600
 Kouanfack, C.: **959**
 Koup, Richard A.: 25, 32LB, 90, 94, 245LB, 327, 336
 Kourtis, Athena P.: **771**, 772, 801LB
 Kouyos, Roger: 89LB, 567
 Kovacs, Joseph A.: 561
 Kovari, Helen: **612**
 Kovarova, Martina: 450
 Koyama, Takayoshi: 203
 Kozlakidis, Zisis: 210
 Kraft, Colleen: 255
 Kraiselburd, Edmundo N.: 268
 Krakora, Rebecca: **561**
 Krakower, Douglas S.: 890
 Krakowiak, Daisy: 49
 Krämer, Benjamin: 236
 Kramer, Jennifer R.: 550
 Kranzer, Katharina: 736, 846, 853
 Kraus, David: 566
 Kraus, William: 705
 Krebs, Shelly: 407, 414
 Kreitchmann, Regis: 775
 Kreuter, Alexander: 628
 Krishnan, Preethi: 539LB
 Kristoff, Jan R.: 376
 Krogan, Nevan: 244
 Kroidl, Arne: **625**
 Kronborg, Gitte: 690
 Kroon, Eugène: 219, 349, 404, 407, 415
 Krows, Meighan: 740
 Krueger, Gunnar: 381
 Kruijssen, Martine: 431
 Krykbaeva, Marina: 91
 Krystal, Mark: 97, 464, 466
 Kuanchai, Supparatpinyo: 461LB
 Kubeka, Griffiths: 113LB
 Kubiak, Rachel W.: 743
 Kucherer, Claudia: 485
 Kudchodkar, Sagar: 137
 Kufa-Chakezha, Tendesayi: 783
 Kuhn, Louise: 33, 39, 40, 851
 Kukanok, Sivaporn: 606
 Kulasegaram, Ranjababu: 423LB
 Kulasingam, Shalini: 162
 Kulich, Michal: 436
 Kulkarni, Manjusha: 656, 717
 Kulkarni, Sarah: 1020
 Kulpa, Deanna: 369
 Kumar, Nitasha A.: **375**
 Kumar, Parag: 430
 Kumar, Suresh: 899, 918, 1032
 Kumarasamy, Nagalingeswaran: 30, 728, 753
 Kumwenda, Johnstone J.: **745**, 747
 Kuniholm, Mark H.: 277, **593**
 Kunjara Na Ayudhya, Ratiya: 108LB
 Kuo, Irene: 893
 Kuppermann, Miriam: 162
 Kuritzkes, Daniel: 86, 307, 346, 367, 476, 815
 Kurkunar, Jessie: 1061
 Kurniati, Nia: 860
 Kurth, Ann: 989, **997**, 1038
 Kuruc, JoAnn D.: 291, 418, **964**
 Kuruppu, Nishani: 465
 Kuwata, Takeo: **504**
 Kuzovatova, Elena: 630
 Kwaghue, Vivian: 1015
 Kwarisiima, Dalsone: **116**, 796, 843, 1026
 Kwaro, Daniel: 903
 Kwena, Zachary A.: **171**
 Kwo, Paul: 576
 Kwon, Douglas S.: 261, 315
 Kwon, Mi: 366
 Kwon, Young D.: 310LB
 Kwong, Peter D.: **310LB**
 Kyohaire, Isabella: 449
 — — —
 La Rosa, Alberto M.: **30**
 Labbato, Danielle: 649, 657, 674, 826, 859
 Laborde, Nicole: 873
 LaCasce, Ann S.: 86
 Lacey, Aofie: 710
 Lachowsky, Nathan J.: **546**, **898**, 1007, 1041
 Lackey, Philip: 953
 Lackner, Andrew: 141
 Lacombe, Jean-Marc: 1043
 LaCombe, Karine: **10**, **66**, 526, 582
 LaCreta, Frank: 460
 Lada, Steven M.: **362**
 Ladell, Kristin: 313
 Laeyendecker, Oliver: 511, 520, 540, 594, 830, 906, **917**, 954
 Lafferty, Mark: 188
 Laffon, Muriel: 408

- Laforest, Claire: 455
 Lahiri, Cecile D.: 47
 Lahuerta, Maria: **921**
 Lai, Ming-Tain: 98, **506**
 Laibson, David: 1039
 Lake, Jordan: **660**, 699, 914
 Lakritz, Jessica R.: **272**
 Lal, Asim: 781
 Lalama, Christina: 300LB, 350
 Lalani, Tahaniyat: 932
 Lalezari, Jacob: 342, 358LB, 574
 Lallemand, Marc: 777
 Lalor, Maeve K.: 1053
 Lam, Stephen: 725
 Lam, Wan: 725
 Lama, Javier: 108LB
 LaMar, Melissa: 322, 597
 Lambert, John: 665, 710
 Lambert, Sidonie: 332, 489
 Lambotte, Olivier: 271
 Lamers, Susanna L.: 331, **345**
 Lamorde, Mohammed: 444, 449
 Lampiris, Harry: 80
 Lan, Yun: 955
 Land, Allison M.: 200
 Landay, Alan L.: 277, 293, 695LB
 Landovitz, Raphael J.: **55**, 103, 104, 476, 861
 Landry, Ishani: **460**
 Lane, H. Clifford: 380
 Lange, Camille M.: **848**
 Lange, Christoph: 158LB
 Langevin, Stanley: 263
 Langwenya, Nontokoza: 34
 Lansky, Amy: 52
 Lanzi, Anastasia: **469LB**
 Laopranyak, Naphassantan: 956
 Lapadula, Giuseppe: 486
 Laraia, Barbara: 935
 Laraque, Fabienne: **534**
 Lariven, Sylvie: 709
 Larmarange, Joseph: **169LB**
 Larrieux, Jean-Robert: 288
 Laskey, Sarah B.: 83, **339**, **462**
 Lassandro, Anna Pia: 697
 Lataillade, Max: 425, 464, 472
 Latham, Catherine F.: 483
 Latkin, Carl: 535, 537, 897, 906
 Lau, Bryan: 911
 Lauck, Michael: 21
 Lauffenburger, Douglas: 308
 Laughton, Barbara: 658, 820
 LaValley, Michael: 1012
 Lavert, Marion: 577
 Law, Matthew: 559, 637
 Lawitz, Eric: 576
 Lawson, Benton: 93LB, 353
 Lawson-Ayayi, Sylvie: 689
 Lazare, Estibaliz: 689
 Lazzaro, Thierry: 271
 Lazzarin, Adriano: 454, 556, 557, 627, 697
 Le, Leah: 404, 411
 Le, Oanh Ngoc: 860
 Le, Thoà P.: 831
 Le Chenadec, Jérôme: 776, 804
 Le Coeur, Sophie: 777
 Le Corfec, Anne: 514
 Le Foulter, L.: 959
 Le Gall, Sylvie: 312
 Le Grand, Roger: 271
 Le Moing, Vincent: 276, 675
 le Roux, Stanzi M.: **808**
 Le Scanf-Terrien, Cécile: 689
 Leadabrand, Kaitlyn S.: 86
 Leal, Manuel: 655
 Leary, Shay: 359
 Lebelonyane, Refeletswe: 111, 983
 LeBlanc, Roger: 237
 Lebouché, Bertrand: 237
 Lebrun-Frenay, Christine: 408
 Leckie, Gregor: 749
 Lécuroux, Camille: 351
 Ledergerber, Bruno: 612
 Lederman, Michael M.: 252, 293, 296, 299, 347, 671, 732
 Ledford, Sue L.: 217
 Ledgerwood, Julie: 90, 311LB
 Lee, Anthony: 147
 Lee, Benhur: 33, 244
 Lee, David: 807
 Lee, Eric L.: 134, **187**, 262, 279
 Lee, Gary K.: 358LB
 Lee, Guinevere Q.: **227**
 Lee, Haekyung: 597
 Lee, Hana: **1042**
 Lee, Hang: 673
 Lee, Susan S.: 832
 Leech, Robert: 148
 Leelawiwat, Wanna: 927
 Lefebvre, Eric: 239
 Lehman, Dara: 478, 621
 Leider, Jason: 968, 997
 Leidner, Jean: 800, 802, 810
 Leifheit, Kathryn M.: **1036**
 Leigh Brown, Andrew: 210
 Leisegang, Rory: 1029
 Leitman, Ellen M.: 256, **827**
 Leitner, Thomas: 806
 Lelièvre, Jean-Daniel: 295
 Lennemann, Tessa: 625
 Lennox, Jeffrey L.: 47, 55, 255, 476
 León, Eddie: 477
 Leone, Dominick: 1014
 Leone, Peter A.: 217
 Lepik, Katherine J.: **492LB**
 Leroi, Charline: 962
 Leroy, Sandrine: 73LB
 Lesi, Funmi: 281
 Lesosky, Maia S.: 419
 Lessler, Justin: 902
 Letang, Emilio: 676, 760
 Letendre, Scott R.: 143, 144, 395, 409, **412**, 446
 Leth, Steffen: 26LB
 Leucke, Ellen: 879
 Leung, Janice: **725**
 Levi, Jacob: 1023
 Levin, Myron: 825
 Levine, Andrew J.: 388
 Levine, Ken: 890
 Levine, Molly: 494LB
 Levy, Matthew E.: **893**
 Lévy, Yves: 295
 Lewin, Sharon R.: 298, 348, 359, 375
 Lewis, Rashunda: 1000
 Lewis, Suzanne: 812
 Leyden, Wendy: 54, 162
 Li, Danny: **344**, 643, 654
 Li, Fan: 807
 Li, Fangyong: 142
 Li, Guanhan: **393**
 Li, Jonathan Z.: 346, **347**, 360
 Li, Maoji: 884, 885
 Li, Peilin: 80
 Li, Qingsheng: 268, 290
 Li, Shengbin: 23
 Li, Taisheng: 569
 Li, Tianbo: 464
 Li, Weizhe: **399**
 Li, Xiang: **142**
 Li, Xiaojun: **194**
 Li, Yanjie: 652
 Li, Yanling: 569
 Li, Yijia: **569**
 Li, Yingying: 133
 Li, Yuju: 397
 Li, Zhufang: 97
 Liang, Richard: 602
 Libin, Pieter: 211
 Lichterfeld, Mathias: 361, 815
 Lichtner, Miriam: 610
 Liegler, Teri: 990, 1026
 Lieveld, Faydra I.: 543
 Lifson, Alan: **475**
 Lifson, Jeffrey: 84, 138, 270, 352, 353
 Lim, So-Yon: 95LB
 Lima, Viviane D.: 227, 492LB, 533, **940**
 Lin, Haiqun: 691
 Lin, Naomi: **834**
 Lin, Nina: 307
 Lin, Peng: 970
 Lin, Yea Lih: 282
 Lin, Zeyu: 464, 466
 Linas, Benjamin P.: 43
 Lincez, Pamela J.: **807**
 Lindborg, Lena: 998
 Lindegren, Mary Lou: 746, 790
 Lindsey, Jane: 825
 Ling, John: 100
 Lingappa, Jairam R.: 17, 200, **301**, 771
 Linka, Rene m.: 189
 Linnen, Jeffrey: 593
 Liorre, Giulia: 607
 Lisi, Catiuscia: 778
 Lissock, Frédéric L.: 526
 Little, Susan J.: 143, **224**, 228, 232, 487, 518, 727, 730, 942
 Litwin, Alain: 534, 585
 Liu, Albert Y.: 48LB, 524, 866, **867**, 870
 Liu, Chenglong: 390
 Liu, Chungheng: 926
 Liu, Enju: 703
 Liu, Hongbing: 80
 Liu, Hongjie: 924
 Liu, Hui C.: 717
 Liu, Rachael: 456
 Liu, Wei: 453
 Liu, Winston: 389
 Liu, Xia: 446
 Liu, Ying: 321
 Liu, Yue: 20
 Livant, Edward: 521
 Llamoso, Cyril: 472
 Lloyd-Jones, Donald M.: 644
 Lo, Janet: **553**, 650, 673
 Lo Caputo, Sergio: 247

- Lo Re, Vincent: 150, 554, 609
 Locarnini, Stephen: 570
 Locascio, Joseph: 145
 Lockhart, Ainsley: 294
 Lockman, Shahin: 37, 111, 307,
 615, 784, 800, 802, 805,
 810, 904
 Lodi, Sara: **938**
 Lofters, Aisha: 622
 Loiseau, Claire: **289**
 Lok, Judith: 421, 942
 Lombardi, Francesca: 697
 Lombardini, Eric: 405
 Long, Lawrence: 28, 957
 Longenecker, Chris T.: **649**,
 657, 674
 Longley, Nicky: **759**
 Longos, Andrew F.: 917
 Looby, Sara E.: 638, 650, 673
 Lopardo, Gustavo: 474
 López Varela, Elisa: 974, **976**
 López-Aldeguer, José: 611, 634
 López-Galindez, Cecilio: 338
 Loquere, Avelino: 885
 Loquilha, Osvaldo: 788
 Lorenzini, Patrizia: 413
 Losina, Elena: 952, 1016
 Losso, Marcelo: 630
 Loutfy, Mona: 622, 949
 Lovelace, Susan: 856
 Lovett, Jackie: 396
 Low, Daniel H.: 632
 Lowenthal, Elizabeth D.: 832,
833
 Lozano, Ana Belen: 508
 Lozier, Jay: 430
 Lu, Hao: 466
 Lu, Hong: 307
 Lu, Meng Ying: 716
 Lu, Michael: 553, 640, 673
 Lubin, Susan: 460
 Lucar, Olivier: 304
 Lucas, Gregory M.: 651, 684,
687, 688, 899, 918, 928, 1032
 Lucas, Joseph: 595
 Luciw, Paul: 447, 450
 Luebke, Nadine: 364
 Luengas, Elizabeth M.: 200
 Luesomboon, Wicham: 817
 Luetkemeyer, Anne F.: **9**
 Luévano, Jesús M.: **261**
 Lukabwe, Ivan: 844
 Lumbiganon, Pagakrong:
 831, 860
- Lund, Jennifer M.: 301, 301
 Lundgren, Jens D.: 46, 474, 630,
 637, 661, 686
 Luo, Ma: **226**, **319**
 Luque, Amneris: 161, 392
 Lutalo, Tom: 163
 Lutz, Philipp: 236
 Lutz, Thomas: 154LB, 584, 589
 Luzuriaga, Katherine: 440, 806
 Lynch, Rebecca M.: 245LB
 Lynch, Susan V.: 264
- M—
- Ma, Qing: 395, **446**
 Ma, Yifei: 643, 654
 Ma, Zhong M.: 278
 Maama, Llang B.: 738
 Maartens, Gary: 419, 427, 429,
 742, 963, 1029
 Maboko, Leonard: 625
- Mabunda, Nedio: 788
 Mabuto, Tonderai: 113LB
 Mabuza, Khanya: 1056
 Macalino, Grace E.: **932**
 MacArthur, Ian: 226
 Macatangay, Bernard J.: 283,
 350, 685
 MacBrayne, Christine E.: **99**
 Macera, Margherita: 608
 Macete, Eusebio: 797
 Macharia, Thomas: 856
 Macías, Juan: 530, 555
 Mack, Wendy: 422
 MacKellar, Duncan: 516, 975,
 1025
 Mackelprang, Romel D.: **17**, 200
 Macken, Alan: 710
 MacLean, Rachel L.: 786
 MacLeod, Iain: 626
 MacLeod, William B.: 1013,
1028
 MacPhail, Catherine: 936
 Madrian, Bridget: 1039
 Madrid-Elena, Nadia: 354
 Magis, Carlos: 477
 Magnus, Many: 390, 883LB,
 893
 Mahamat, Aba: 943
 Mahan, Alison: 305
 Maharaj, Rashika: 521
 Mahjoub, Nadia: 522
 Maida, Alice: 168LB, 789
 Maidji, Ekaterina: 331, 345
- Maiga, Almoustapha: 840
 Maiga, Moussa: 962
 Mailliard, Robbie B.: 341, **376**
 Majid, Rana: 702
 Majoie, Charles B.: 148
 Majonga, Edith D.: **853**
 Major, Eugene O.: 393
 Mak, Gerald: 233
 Makarova, Natalia: **878**
 Makhema, Joseph: 37, 111, 784,
 800, 802, 810, 984
 Maki, Pauline: **416**, 422
 Makinson, Alain: **675**
 Malaba, Thokozile: **799**
 Malcus, Christophe: 729
 Maldarelli, Frank: 337, 490
 Maleche-Obimbo, Elizabeth: 38,
 748, 780
 Malee, Kathleen: 822, 823
 Malette, Given: 28, 792
 Malfetheriner, Peter: 635
 Malia, Jennifer: 515
 Malik, Neha: 629
 Mallal, Simon: 359, 667
 Mallampati, Divya: 786
 Mallard, Jaclyn C.: **403**
 Mallolas, Jose: 945
 Mallolas, Josep: 611
 Mallon, Patrick: **126**, 665,
 668, 710
 Maloney, Kevin M.: 890
 Maloney, Libet: 925
 Malvy, Denis: 75LB
 Malyuta, Ruslan: 778
 Man, S. F. Paul: 725
 Manabe, Yukari C.: 159, **743**,
 747
 Manak, Mark: **515**
 Mandal, Subhra: 435
 Mandaliya, Kishor: 498, 863,
 864, 912
 Mandelbrot, Laurent: 776,
 804, 811
 Mandla, Nomtha: 982
 Mandler, Raul: 27
 Manganaro, Lara: 201, **244**
 Mangano, Andrea: 837
 Mann, Jaclyn K.: 195
 Mann, Surinder K.: 278
 Manne-Goehler, Jennifer:
678, **679**
 Mannheim, Sharon: **885**
 Manns, Michael: 576
 Mantell, Joanne E.: 988, 988
- Manuel, Marcelo d.: 516
 Manuzak, Jennifer A.: **263**
 Manzardo, Christian: 320,
571, **572**
 Maokola, Werner: 978
 Mapstone, Mark E.: 392
 Marcelin, Anne-Geneviève:
 489, **840**
 Marchetti, Giulia: 598, 946
 Marchou, Bruno: 289
 Marconi, Vincent C.: 255, 335,
 503, 645, 1039
 Marcus, Julia L.: **54**, **894**, 1035
 Marcus, Rebecca: 794
 Marel, Emannelle: 804
 Margolis, David A.: **31LB**,
 106, 471
 Margolis, David M.: 355, 418
 Margolis, Leonid: 184
 Margot, Nicolas A.: 496
 Maric, Danijela: 877
 Marinaro, Letizia: 426, 454
 Mariño, Ana: 424LB
 Maritz, Jean: **782**, **785**
 Mark, Jennifer: 49
 Markle, Tristan: 190
 Markowitz, Martin: 105, **106**,
 322, 406, 471, **597**, 881
 Marks, Gary: 1033
 Marocco, Raffaella: 610
 Márquez, Manuel: 603
 Marr, Caroline: 36
 Marra, Christina: 636, **767**
 Marrazzo, Jeanne: 521
 Martell, Maureen: 456
 Martí, Ramón: 205
 Martin, Amanda: 650, 664
 Martin, David E.: 465
 Martin, Eileen: 388, 416
 Martin, Jeffrey N.: 227, 671
 Martin, Jeremy W.: 284
 Martín, María E.: 354
 Martín-Carbonero, Luz: 527
 Martín-Gayo, Enrique: **19**
 Martinello, Marianne: **451**, **545**
 Martinez, Esteban: 945
 Martinez, Melween I.: 268
 Martínez Pérez, Guillermo:
 1010, 1061
 Martínez-Cuesta, María Ángeles:
 663
 Martínez-Picado, Javier: 320,
 366
 Martínez-Rebollar, Maria: 945

- Martini, Federico: 413
 Martins, Marcelo: 472
 Martinson, Jeff: 695LB
 Martinson, Neil: 749, **963**
 Martrus, Gloria: 197, **370**
 Maruca, Katia: 819
 Marukutira, Tafireyi: 833
 Maruri, Fernanda: 735
 Maruyama, Haruka: 1025
 Marx, Preston A.: 268
 Marzel, Alex: **567**
 Marzinke, Mark A.: 103, 108LB, 871, 872, 877
 Masamaro, Kenneth: 903
 Masciotra, Silvina: 215
 Mascola, John R.: **15**, 94, 310LB
 Masepe, Linnet: 863, 864, 912
 Masetti, Michela: 247, **280**
 Maskew, Mhairi: 28, 613, 617, 618, 792, **1013**
 Mason, Stephen W.: 25
 Massanella, Marta: 730
 Massud, Ivana: 107
 Master, Iqbal: 756
 Masters, Samuel H.: 973
 Mastroianni, Claudio M.: 610
 Masur, Henry: 528, 538LB, 580, 599, 600
 Maswabi, Kenneth: 815
 Matano, Tetsuro: 505
 Mateos, M.L.: 452
 Mathabela, Nokwazi: 1056
 Mathad, Jyoti S.: **758**
 Mathema, Barun: 157
 Matheron, Sophie: 214, 509, 804, 944
 Matheson, Tim: 27
 Mathew, W. C.: 920
 Mathews, Michelle: 447
 Mathews, Wm. Christopher: 558, 1001, 1005
 Mathias, Anita: 100
 Matías-Florentino, Margarita: 477
 Matoff-Stepp, Sabrina: 993
 Matschl, Urte: 197
 Matsen, Frederick: 478
 Matshaba, Mogomotsi: 833
 Matsuda, Kenta: 275LB
 Matsui, Yusuke: **202**
 Matsushita, Shuzo: 504, 505
 Matthews, Gail V.: 451, 545
 Matthews, Philippa C.: 827
 Mattson, Christine: 53, 591,
- 1004**
- Maughan, Robert T.: 665, **668**
 Mauss, Stefan: 584, **589**
 Mave, Vidya: **752**, 758
 Mavedzenge, Sue N.: 973
 Mavian, Carla: **257**
 Mawela, Muthuhadini P.: 818, 1120
 MaWhinney, Samantha: 445
 Maxwell, Jason: 964
 May, Margaret: 941
 Mayanja-Kizza, Harriet: 297, 733
 Mayer, Kenneth H.: **90**, 103, 104, 106, 167, 231, 471, 866, 883LB, **890**, 891, 897, 1034
 Mayondi, Gloria: 800
 Mayor, Angel M.: 684, 688
 Mayorga, Christian: 587
 Mazzulli, Tony: 491LB
 Mbanya, Dora: 212
 Mbofana, Elton: 512, 787
 McAdams-Mahmoud, Ayesha: 537
 McArthur, Carole: 213
 McArthur, Justin: 146
 McCallister, Scott: 102LB, 496, 717
 McCarter, Martin D.: 134, 187, 262
 McCaul, Mary: 911
 McCauley, Marybeth: 103
 McClelland, Scott: 863, 864, 912
 McComsey, Grace A.: **123**, 428, 649, 656, 657, 672, 674, 700, 704, **717**, 826, 859, 939
 McCormack, Sheena: **69**
 McCune, Joseph M.: 235, 264, 711
 McDaniel, Darius: 157
 McDermott, Adrian B.: 94
 McDonagh, Thomas: 97
 McFadyen, Lynn: 818, 1120
 McFall, Allison M.: 687, 899, 918, 1032
 McFarland, Willi: 1041
 McGee, Kara S.: 418
 McGeer, Allison: 768
 McGettrick, Padraig: **710**
 McGillen, Jessica B.: **1049**
 McGinnis, Kathleen A.: 554
 McGovern, Rachel A.: 492LB
 McGowan, Catherine C.: 958
 McGowan, Ian: **71**, **104**, 108LB, 109LB, 874, 879, 880
- McGrath, Christine: 494LB
 McGrath, Christine J.: 621, **624**
 McGrath, Michael S.: 273, **331**, 345
 McGrath, Nuala: 169LB
 Mcharo, Ruby: 625
 McHugh, Grace: 853
 McHutchison, John G.: 154LB, 573, 601
 McIntyre, James: 757, 795, 799
 McKay, Richard A.: 140
 McKee, Krishna: 310LB
 McKellar, Mehri S.: 418, **705**
 McKenney, Jennie L.: 861
 McKeon, Annmarie: 312
 McKinnon, Lyle: 195
 McKinstry, Laura: 989, 997, 1038
 McLaren, Paul: 443
 McLaughlin, Mary: 561
 McLaughlin, Sherry: 361
 McMahan, Vanessa: 48LB
 McMahan, Deborah: 300LB, 330, 350, 377
 McMahan, Don: 40
 McMichael, Jeffrey: 995
 McMullen-Jackson, Chivon: 458
 McNally, John: 100
 McNicholl, Janet: 878
 McPhee, Fiona: 575
 McRobie, Ellen: 51
 McVera, David: 940
 Mecikovsky, Debora: 837
 Medhin, Heluf: 615
 Meditz, Amie L.: 445
 Meggi, Bindiya: **788**
 Mehandru, Saurabh: 597
 Mehraj, Vikram: **237**
 Mehta, Sanjay R.: 144, **232**, 487, 518
 Mehta, Shruti H.: 535, 537, 540, 548, 687, 693, 712, 899, 917, 918, 928, **1032**
 Meier, Françoise: 776
 Meigs, James B.: 638
 Meintjes, Graeme: 734, 759, 763
 Meissner, Eric G.: 595, **600**
 Mejer, Niels: 690
 Mélard, Aline: 351
 Melbourne, Kathy: 664, 700
 Mellors, John W.: 25, 30, 85, 300LB, 330, 337, 340, 342, 346, 350, 377, 379, 493LB, 865
 Mena, Leandro: 891
- Ménard, Amélie: 583
 Mendelson, Marc: 742
 Mendoza, Daniel: **328**
 Menéndez, Clara: 797
 Menéndez-Arias, Luis: 205
 Meng, Gang: 970
 Menkova-Garnier, Inna: **295**
 Mensah, Charles: 502
 Mensah, Nana P.: 888
 Merat, Sabrina J.: **152**
 Merchante, Nicolás: **529**, **530**, **634**
 Merenstein, Daniel: 919
 Merino, Dolores: 529, 530, 586
 Merino, Esperanza: 634
 Merino-Mansilla, Alberto: 303
 Merli, Marco: **454**, 556, 557
 Merat, Esther: 598, 946
 Mermin, Jonathan: 52, 1045
 Merry, Concepta: 444
 Meskaldji, Djalel Eddine: 381
 Mesman, Annelies W.: 72LB
 Mesplede, Thibault: 507
 Messer, Michael: 32LB
 Messina, Emanuela: 454, 556, 557
 Messing, Susan: 428
 Messou, Eugene: 962, 1015
 Metcalf, Carol: 512, 787, 1010
 Metcalfe, John: 853
 Metral, Melanie: 381
 Metsch, Lisa R.: **27**, 919
 Meya, David B.: 159, 761, 762, 763
 Meyer, Laurence: 222, 351, 701, 886
 Meyer-Rath, Gesine: 115
 Meyers, Kathrine: **881**
 Meyn, Leslie: 871
 Meynard, Jean-Luc: 943
 Mezzaroma, Ivano: 610
 Mhlanga, Felix: 861
 Miallhes, Patrick: 605, **729**
 Micci, Luca: 335, **352**, 353
 Michael, Heather M.: 330
 Michael, Nelson L.: 219, 230, 318, 349, 405
 Michalik, Claudia: 628
 Micheloud, Daniela: 639
 Midkiff, Cecily: 141
 Mier-y-Teran-Romero, Luis: **535**
 Mikula, James: 430
 Miles, Brodie: **378**
 Miller, Andrew D.: 272, 273

- Miller, Caitlin M.: **185**
 Miller, Caroline: 240
 Miller, Charlene: 263
 Miller, Elizabeth A.: **322**
 Miller, Eric N.: 388, 416
 Miller, Melissa: 1002
 Miller, Michael: 95LB, 107, 496
 Miller, Mike: 506
 Miller, Shannon M.: **242**
 Miller, William: 216, 217
 Milliken, Sam T.: 365
 Mills, Anthony: 953
 Mills, Edward: 166
 Mills, Lisa A.: 111, 983
 Milner, Brad: 334
 Mimiaga, Matthew: 167, 920
 Minami, Rumi: **670**
 Minga, Albert: 962, 1015
 Mingorance, Jesús: 669
 Minichini, Carmine: 556, 557, 607
 Mintern, Karen: 514
 Miraglia Del Giudice, Emanuele: 556, 608
 Miranda, Cristina: 432
 Mirembé, Betty: 844
 Mirembé, Esther: 844
 Mirmonsef, Paria: 695LB
 Miro, José M.: 303, 303, 468, 571, 572, **765**
 Mirochnick, Mark: 433, 438, **439, 440, 775**
 Mishra, Ria: 323
 Mishra, Sharmistha: 1046, 1047
 Misra, Vikas: 145, 250, 693
 Mitchell, Charles D.: 824
 Mitchell, James: 107
 Mitchell, Kate M.: 1055, 1060
 Mitsuyasu, Ronald T.: 160
 Miura, Toshiyuki: 314
 Mix, Monica: 537
 Miyahara, Reiko: 314
 Miyahara, Sachiko: 147, 747
 Miyaji, Karina T.: 326
 Mizenina, Olga: 876
 Mlanga, Erick: 978
 Mlisana, Koleka: 756
 Mmalane, Mompoti: 800, 904
 Mnisi, Zandile: 925
 Mnzava, Dorcas: 760
 Mo, Hongmei: 580
 Moberley, Sarah: 844
 Mobley, Victoria: 216, 964
 Mocello, A. Rain: 227
 Mock, Philip A.: 884, 927
 Mocreft, Amanda: 45, 46, 630, 686
 Modongo, Chawangwa: 755
 Moestrup, Søren K.: 690
 Mofenson, Lynne M.: 779
 Moffat, Kirsten: 391
 Mogalian, Erik: **100**
 Mohammadi, Pejman: 208
 Mohammed, Terence: 984
 Mohns, Mariel S.: 21
 Mohr, Raphael: **560**
 Mohri, Hiroshi: 406
 Moir, Susan: 311LB
 Molapo, Tshepo: 1028
 Molenkamp, Richard: 152, 547, 602
 Molina, Jean-Michel: 45, 522, **886, 887**
 Moltó, José: **432**
 Momper, Jeremiah: 395
 Moncla, Bernard: 871
 Moncur, Brenda L.: 991
 Monel, Blandine: **312**
 Monge, Susana: 669, 901
 Mongwenyana, Constance: 28
 Monit, Christopher: 223
 Monje-Agudo, Patricia: 529
 Monneret, Guillaume: 729
 Monroe, Anne K.: 1005
 Monroy Trujillo, Jose Manuel: 651
 Montana, Livia: 678, 679
 Montaner, Julio: 492LB, 533, 546, 725, 940, 1041
 Montaner, Luis J.: 268, 290, 316
 Montefiori, David: 309LB, 317
 Monteiro, Jacqueline P.: 798
 Montejano, Rocío: 669
 Montejo, Miguel: 571
 Monteroso, Edgar: 516
 Montes, Maria L.: 669
 Montgomery, Martha P.: **761**
 Moodley, Amber: 488
 Moodley, Pravi: 157, 756
 Moog, Christiane: 304
 Moore, Ayana: 982
 Moore, Carolyn: **458**, 1018
 Moore, Cecilia: 666
 Moore, David J.: 390
 Moore, David M.: 546, 898, 1007, **1041**
 Moore, Jan S.: 983
 Moore, Penny: 302
 Moore, Richard: 42, 150, 558, 614, 641, 671, 830, 911, 920, 1001
 Moosa, Mahomed-Yunus: 735
 Mooser, Anne: 1021
 Mora, Stefano: 819
 Mora-Peris, Borja: 423LB
 Moradpour, Darius: 592
 Moragas, Matias: **837**
 Morano-Amado, Luis E.: 586, 603
 Morawski, Bozena M.: **159, 761**
 Moreau, Alain: 400
 Moreno, A.: 452
 Moreno, Asunción: 572
 Moreno, Santiago: 354, 452
 Morey, Miriam: 705
 Morey, Tristan:
 Morgello, Susan: 693
 Mori, Masahiko: **256, 314**
 Moritz, Andrew: 525
 Morlat, Philippe: 686
 Moron-Lopez, Sara: 320
 Morris, Alison: 330
 Morris, Lynn: 302
 Morris, Martina: **5**
 Morris, Natasha: 735
 Morris, Sheldon R.: 143, 410, 727
 Morrison, Charles: 520
 Morrow, Rhoda: 728
 Morse, Caryn G.: 561
 Morse, Gene D.: 428, 443
 Moseley, Arthur: 595
 Moser, Carlee B.: 672, 704, 939
 Mota, Talia: 375
 Mothe, Beatriz: **320**
 Mougnotou, R.: 959
 Mounzer, Karam: 290
 Moxley, Richard: 146
 Moyle, Graeme: 665
 Moyo, Sikhulile: 37, 111, 784, 802, 810, 815, 904, **984**
 Moysi, Eirini: **327**
 Msellati, Philippe: 73LB
 Msukwa, Malango: 118
 Mtapuri-Zinyowera, Sekesai: 512, 787
 Mthethwa-Hleta, Simangele: 34
 Mthiyane, Thuli: 157, 756
 Muchichwa, Petudzai: 963
 Mudd, Joseph C.: **275LB, 732**
 Muehlbauer, Michael: 705
 Muenchhoff, Maximilian: 302, 828
 Mugabe, Didier: 516
 Mugavero, Michael J.: 920, 1033, 1034
 Mugerwa, Henry: 849
 Mugglin, Catrina A.: **118**
 Mugizi, Charles: 738
 Mugo, Mercy: 1059
 Mugo, Nelly R.: 17, 164, 301, 478, 621, 624, 771, 865, 868
 Mugo, Peter M.: **977**
 Mugwanya, Kenneth K.: **868**
 Mugenyi, Peter: 493LB, 849
 Muhammad, Muazu: 564
 Muhlenbruch, Vanessa: 371
 Mujugira, Andrew: **164**
 Mujuru, Hilda: 846, 853
 Mukerji, Shibani S.: **145, 693**
 Muktiarti, Dina: 858
 Mulder, Lubbertus C.: 201
 Mulenga, Kafula: 1018, 1018
 Mulindabigwi, Augustin: 166
 Mullen, Michael P.: 588
 Müller, Janis A.: 284
 Müller-Trutwin, Michaela: 271, 351
 Mulligan, Kathleen: 48LB, 866
 Mulligan, Mark: 286
 Mulligan, Nikki: **438**
 Mullins, James I.: 33, 259LB
 Münch, Jan: 268, 284
 Munjoma, Marshall: 520
 Münk, Carsten: **189**
 Muñoz, Eduardo: 354
 Muñoz, Saray: 596
 Munro, Cynthia: 146, 388
 Munyao, James: 494LB
 Mupfumi, Lucy: 984
 Murcio Villanueva, Roberto: 225
 Murnane, Pamela: **39**
 Murnane, Robert: 356
 Murphy, Gary: **514, 895**
 Murphy, James R.: 623
 Murphy, Robert: 461LB, 562, 564, 672, 939
 Murray, Alexandra: 83
 Murray, Daniel D.: **559**
 Murray, Megan: 72LB
 Murray, Miranda I.: **471**
 Murrell, Ben: 487
 Murry, Jeffrey P.: 342
 Musante, Chelsey: 294
 Muscatello, Antonio: 280
 Musicha, Crispin: 789
 Musick, Andrew: 85, 340

- Musiime, Victor: 849
 Musoke, Philippa: 440
 Musonda, Rosemary: 984
 Mussi-Pinhata, Marissa: 798, 809
 Mustanski, Brian: 931
 Musubire, Abdu: 762
 Mutagoma, Mwumvaneza: 166
 Mutai, Kennedy: 903
 Mutschler, James P.: 21
 Muwonge, Timothy R.: 301
 Muyombwe, Anthony: 896
 Muzny, Donna: 20
 Muzooru, Conrad: 763
 Mwamelo, Kim: 676
 Mwandumba, Henry: 769
 Mwangwa, Florence: 116, **843**
 Mwanza, Mwanza: 1018, 1019
 Mwashigadi, Grace: 977
 Mwaungulu, Nimrod: 736
 Mwebaza, Norah: 101
 Mwinuka, Nice: 625
 Myer, Landon: 34, 757, 782, 785, 786, **795**, 799, 808, **852**, **854**
 Myers, Julie: 888, 892
 Mylvaganam, Geetha: **93LB**
 Mzembe, Themba: 736
 Møller, Holger J.: 690
 Mørk, Alejandra: 26LB
- N—
 N'dir, Adama: 921
 Na, Lumine H.: 476
 Nabantanzi, Rose M.: 297
 Nabieu, Umu N.: 910
 Nabukalu, Dorean: 902
 Nada, Ola: 153
 Nadel, James: **648**
 Nagata, Kayoko: 202
 Naggie, Susanna: 99, 573, **595**, 601, 642
 Nagot, Nicolas: 276
 Nair, Gonasagrie: 861
 Nair, Govind: 389
 Nakalema, Shadia: 449
 Nakamoto, Beau K.: 387, 723
 Nakamura, Kyle J.: 33, 807
 Nakanjako, Damalie: **297**
 Nakasujja, Noeline: 761
 Nakayama, Emi E.: 206
 Nakigozi, Gertrude: 163, 902, 986
 Nakiyingi, Lydia: 743
 Nalintya, Elizabeth: 159, 761
- Nalugoda, Fred: 163, 563, 902, 986
 Nalukwago, Sophie: 733
 Nam, Kiwon: 629
 Namusoby, Jennifer: 112
 Nance, Robin: 42, 558, 636, 1034
 Nanda, Kavita: 771
 Nandi, Vijay: 897
 Naniche, Denise: 974, 976
 Nannini, Pilar: 819
 Nansamba, Alice: 513
 Nantume, Sophie: 862
 Napravnik, Sonia: 150, 291, 614, 684, 920
 Naqvi, Alissa: 709
 Naranbhai, Vivek: 246
 Narayan, Vivek: 467
 Nardone, Anthony: 913
 Nash, Denis: **1009**, 1020, 1021
 Nason, Martha: 726
 Nassau, Tanner B.: **1002**
 Natcher, Priscilla: 371
 Natesampillai, Sekar: 243
 Nath, Avindra: 146, 389, 393
 Nattermann, Jacob: **236**
 Natureeba, Paul: 796
 Nau, Marty: 349
 Naudin, Marine: 509
 Navar, Ann Marie: 642
 Navia, Bradford: 383, 386
 Nawaz, Fatima: 198
 Ndahimana, Jean d'Amour: 1024
 Ndawinz, Jacques D.: **910**
 Ndebelo, Nicaise: 212, **502**, 503
 Ndhere, Amos: 562
 Ndhlovu, Lishomwa C.: 81, 652, 723
 Ndjeka, Norbert: **754**
 Ndlovu, Zibusiso: **512**, **787**
 Ndomb, Teclair: 923
 Nduati, Ruth: 88
 Ndungu, Thumbi P.: 195, 246, 256, 302, 398, 488, 828
 Ndwiga, Stanley: 562
 Neary, Jillian: 971
 Neary, Moberg: **444**
 Neborak, Julie: 760
 Nega, Melon: 93LB
 Neidleman, Jason: 284
 Neilan, Tomas G.: 640
 Nel, Annalene: 109LB, **110LB**, 872, 873
 Nelson, Brittany: 382
 Nelson, Kenrad E.: 593
- Nelson, LaRon E.: **172**, 883LB
 Nelson, Mark: 154LB, 423LB, 662
 Nelson, Micki: 825
 Nelson, Rob: **516**
 Nelson, Robert: 975
 Nemes, Elisa: 824
 Neogi, Ujjwal: 267
 Nerlander, Lina: 931
 Neuhaus, Jacqueline: 160, 559
 Neukam, Karin: **586**, **603**
 Neumann, Till: 646
 Newcomb, Michael: 931
 Newell, Kevin: 731
 Newsom, Astrid M.: **543**
 Newton, Alicia: **578**, 579
 Nganga-Good, Carolyn: 1036
 Nghiem, Khanh: 430
 Ngo-Giang-Huong, Nicole: 777
 Nguyen, Dong Phuong: 894
 Nguyen, Lam Van: 858
 Nguyen, Minh: 1039
 Nguyen, Thai: 681
 Nguyen, Thao P.: **252**
 Nguyen, Thi Huyen Tram: 75LB
 Nhalo, Ariel: 974, 976
 Nhlangulela, Rosetta Lindiwe: 521
 Ni Fhlathearthaigh, Ailbhe: 710
 Nichol, Geoffrey M.: 358LB
 Nichols, Brooke E.: 536, **1052**
 Nichols, Sharon L.: 822
 Nickolas, Thomas: 868
 Nicot, Florence: 950
 Niculescu, Alex: 537
 Niehrs, Annika: 370
 Nielsen, Susanne D.: 690
 Nielsen-Saines, Karin: 440, 779
 Nigalye, Maitreyee: 239
 Nijhawan, Ank E.: 1001
 Nijhuis, Monique: 366, 464, 839
 Nikiforov, Alexiy: 104
 Ning, Chuanyi: **955**
 Ning, Yuming: 756
 Nir, Talia M.: 383, 386
 Nislow, Corey: 725
 Nissen, Sara: 26LB
 Nitz, Theodore J.: 465
 Niyibizi, Aline Aurore: 1010, 1061
 Niyibizi, Gad: 1024
 Njouom, Richard: 526
 Njozi, Mustafa: 978
 Njuguna, Irene N.: **38**, 748
 Nkurunziza, Peter: 1027
- Noguera-Julian, Antoni: 778
 Noguera-Julian, Marc: 260, 266, 488, 797
 Nolan, David J.: 331, 345, 403
 Nomaguchi, Masako: 206
 Noori, Teymur: 901
 Nori, Achyuta V.: 794
 Norrgren, Hans: 998
 Norris, Philip J.: 652
 Norton, Brianna L.: **585**
 Nou, Eric: 553, **673**
 Nouaman, Marcellin: 568
 Noumsi, N.: 959
 Novikova, Mariia: **137**
 Novitsky, Vladimir: **904**, 984
 Nowak, Martin A.: 357
 Nowak, Piotr: 260, **267**
 Nowak, Rebecca G.: 922, **923**, 924
 Nowicka-Sans, Beata: 466
 Nozza, Silvia: 627
 nsanzimana, Sabina: 166, 1024
 Nunn, Amy: 891
 Nunnari, Giuseppe: 204
 Nuttall, James: 852, 854
 Nuwagaba-Biribonwoha, Harriet: 34
 Nyakundi, Helen: 1059
 Nyambura, Monica: 51, 1042
 Nyirenda, Mulinda: 769
 Nyongesa-Malava, Evans: 624
 Nyoni, Cynthia: 28
- O—
 O'Brien, Meagan K.: **44LB**, 249
 O'Brien, Sean P.: **138**
 O'Cleirigh, Conall M.: 920
 O'Connell, Daniel A.: 991
 O'Connell, Robert: 318, 405, 956
 O'Connell, Thomas: 705
 O'Connor, David H.: 21
 O'Connor, Jemma L.: **474**
 O'Dwyer, Eoin: 648
 O'Halloran, Jane A.: **665**
 O'Riordan, Mary Ann: 826, 859
 Obasi, Gary: 422
 Obel, Niels: 941, 1044
 Obermeier, Martin J.: **525**
 Oberoi, Rajneet K.: **453**
 Ocama, Ponsiano: 563, 565, 594
 Oceng, Ronald: 862
 Ocfemia, M. Cheryl Banez: **497**, 500
 Odayar, Jasantha: **757**

- Odland, Jon O.: 853
 Odongo, Fredrick S.: **903**
 Oduor, Johansen: 909
 Ofotokun, Ighowherha: **47, 55,**
 476, 695LB, 704
 Ogena, Mike: 796
 Ogilvie, Colin B.: 231
 Ogindo, Paul: 903
 Ogunsola, Sade: 281
 Ojeda-Burgos, Guillermo:
 529, 530
 Oka, Shinichi: 681
 Okano, Justin: 1044, **1054**
 Okeke, N. L.: 642
 Okello, Velephi: 34
 Okinyi, Helen M.: 38
 Okoboi, Stephen: **862**
 Okonkwo, Prosper: 281
 Okulicz, Jason: 722, 932
 Okuma, James: 502
 Olagunju, Adeniyi: **441, 444,**
 449
 Olatunbosun, Olawaseun A.: 808
 Oldenburg, Catherine: **167**
 Oleski, James: 824
 Olilo, George: 903
 Olivares, Isabel: 338
 oliveira, Maureen: 218, 480
 Oliver, Nora T.: **550**
 Olney, Jack J.: **51, 117**
 Olson, Scott: 847
 Olvera-García, Gustavo: **251**
 Olwoch, Peter: 796
 Omanga, Eunice: 973
 Omar Mohamed-Balghata,
 Mohamed: 529, 530
 Omarjee, Saleha: 195
 Ondoa, Pascale: 498
 Ong, Edgar: 593
 Ongarello, Stefano: 517
 Onorato, Lorenzo: 607
 Onwujekwe, Obinna: 790
 Ooms, Marcel: 201
 Opest, Amy L.: 521
 Oraka, Emeka: 889
 Orden, Samuel: 663
 Orem, Jackson: 632
 Orkin, Chloe: 482
 Orne-Gliemann, Joanna: 169LB
 Orozco, Daniel: 512, 787
 Orozco, Lorena: 251
 Orr, Cody: 600
 Orrell, Catherine: 429, 1014,
 1029
- Ortega, Mario: 382
 Ortiz, Alexandra: 275LB
 Oryszczyn, Josephine: 948
 Osborn, Jennifer: 517
 Osborn, Melissa: 329
 Osburn, William: 540
 Osinus, Anuoluwapo: 100, 580
 Osler, Meg: 759
 Osoti, Alfred: 49
 Oster, Alexandra M.: 211,
 497, 500
 Østergaard, Lars: 26LB
 Osuna, Christa E.: 95LB
 Otieno, Felix A.: 50
 Otieno, Vincent O.: 38, 748
 Ott, Adina K.: **877**
 Ott, Melanie: 463
 Otton, James: 648
 Otwombe, Kennedy: 658
 Ouellet, Michel: 182
 Ouyang, Zhengyu: 19
 Overbaugh, Julie M.: 88, 478
 Overton, Edgar T.: 32LB, 421,
 698, 700
 Owaraganise, Asiphah: 116
 Owen, Andrew: 441, 442, 444,
 449, 459
 Oyugi, Julius: 748, 909
 Ozanne, Alexandra: **689**
 O'Dell, Sijy: 310LB
- P—**
- Pacheco, Yolanda M.: 655
 Pacheco, Yovana: 312
 Paczusi, Pawel: 161
 Padian, Nancy: 1018, 1019
 Padte, Neal N.: 469LB
 Paer, Jeffrey M.: 261
 Page, Iain D.: **764**
 Page, Kathleen: 537
 Pageaux, Georges-Philipp: 455
 Pagliuza, Amelie: 335, 836
 Pahwa, Rajendra: 327
 Pahwa, Savita: 324, 327, 824
 Paiardini, Mirko: 22, 24, 255,
 335, 352, 353
 Palanee-Phillips, Tesla: 109LB,
 861
 Palar, Kartika: **935**
 Palchauthuri, Riya: **711**
 Palella, Frank J.: 283, 641, 644,
 685, 688, 699, 719, 721, 914
 Palesch, David J.: **20**
 Palfreeman, Adrian: 160
- Palk, Laurence: **1044**
 Pallikkuth, Suresh: 324, 327
 Palma, Paolo: 324
 Palmer, Christine D.: 86, 294, 367
 Palmer, Clovis: 711
 Palmer, Sarah: 348, 365
 Pals, Sherri: 1025
 Pama, Paul P.: 434
 Pamnani, Ritesh: 624
 Pancharoen, Kanokpan: 900,
 927
 Pandrea, Ivona: 258LB
 Pang, Philip S.: 573, 601
 Panigrahi, Soumya: 732
 Pant, Saumya: 575
 Pantaleo, Giuseppe: 82
 Pao, Montha: 264, 264
 Papasavvas, Emmanouil: 290
 Papazian, Emily: 403
 Pape, Jean W.: 473, 739,
 1017
 Para, Michael: 346
 Paredes, Roger: 260, 266, 797
 Parekh, Bharat: 510, 516
 Parent, Julie: 793
 Parera, Marionna: 260, 266
 Parikh, Chirag: 685, 691
 Parikh, Urvi M.: **521, 865, 1057**
 Park, Benjamin J.: 159
 Park, Jakob: 553
 Park, Ju Nyeung: 906
 Park, Kyu Hyun: 713
 Park, Lawrence: 642
 Park, Lesley: 633
 Park, Min Hi: 664
 Parker, Gary: **735**
 Parker, Robert A.: **952**
 Parkin, Neil T.: **517**
 Pasero, Philippe: 282
 Pasquale, Dana K.: **217**
 Pasquau, Juan: 424LB
 Pasquet, Armelle: 522
 Passavanti, Giulia: 610
 Patassi, Akouda: 565
 Patel, Chirag: 937
 Patel, Eshan U.: **540, 726,**
 731, 987
 Patel, Faezeh: 39, 40, 851
 Patel, Hetal: **510**
 Patel, Keyur: 595
 Patel, Kunjal: 838
 Patel, Monita: **916, 1006**
 Patel, Rupa: **891**
 Patel, Vinod: 398
- Patel, Viraj: 989
 Patenaude, Bryan N.: **1003**
 Pathela, Preeti: 1009
 Pathipvanich, Panita: 314
 Patnaik, Padmaja: 921, 921
 Patricia, Agaba: 564
 Pattanasin, Sarika: 900, 972
 Patterson, Bruce K.: 341
 Patterson, Patricia: 947
 Patz, Sharon: 845
 Pau, Alice: 380
 Pau, Chou-Pong: 333
 Paul, Robert: 414, 821
 Pavie, Juliette: 624
 Pavlakis, George N.: **259LB**
 Pavlinac, Patricia B.: **748**
 Pavlos, Rebecca: 667
 Pavone, Paolo: **610**
 Pawlotsky, Jean-Michel: 577
 Paxton, William A.: 547
 Payeli, Sravan: 323
 Paz-Bailey, Gabriela: 930, 931,
 1000, 1045
 Pearson, Chester: 334
 Peel, Sheila: 515, 923
 Peery, Anne: 102LB
 Pegu, Amarendra: 94
 Pellegrin, Isabelle: 689
 Pena, Stephanie: 869
 Pena-Cruz, Victor: **288**
 Penazzato, Martina: 786
 Pence, Brian W.: 920
 Pencina, Michael J.: 642
 Pendergrass, Sarah: 443
 Peng, Chun-Zi: 414
 Pennings, Pleuni S.: 229, 495
 Penrose, Kerri J.: 865, 1057
 Penugonda, Sudhir: 145
 Penzak, Scott: 430
 Perelson, Alan S.: 151, 336
 Pérez, Alejandro: **915**
 Perez, Ináki: 248
 Perez Elias, Carmen: 1023
 Pérez-Elias, María Jesús: 354,
 452
 Pérez-Latorre, Leire: 527
 Perez-Molina, Jose Antonio:
 424LB
 Pérez-Patrigeon, Santiago: 251
 Pérez-Pérez, Montserrat: 529
 Pérez-Santiago, Josué: 410
 Perez-Valero, Ignacio: **424LB**
 Pérez-Valero, Ignacio: 669
 Pernas, Maria: **338**

- Perno, Carlo Federico: 18LB, 413, 570, 946
 Perona, Rosario: 669
 Perreau, Matthieu: 82
 Perrotta, Gaetano: 381
 Persaud, Deborah: 825, 838
 Perumalswami, Ponni: 534, 588
 Peter, Trevor: 788
 Peters, Lars: 566
 Peters, Marion: 277, 593
 Peters, Philip: 149, 215, 541, 916, 967, 999
 Peters, Samuel: 502
 Peters, Zach: 791, 988
 Petersen, Maya: 116, 829, 841, 843, 979, 985, 1026, 1062
 Peterson, Christopher W.: 356
 Peterson, James: 893
 Peterson, Julia: 142
 Petro, Greg: 757, 799
 Petrone, Mary E.: 311LB
 Petropoulos, Christos: 578, 579
 Petrov, Dmitri A.: 229, 495
 Petrovas, Costantinos: **94**, 245LB, 259LB, 327
 Petrow, Eva: 707
 Petschow, Bryon M.: 278
 Pettersson, A. M.: 220
 Pettifor, Audrey: **936**
 Pettit, April C.: 746
 Petucci, Chris: 706
 Peyper, Janique: 734
 Peytavin, Gilles: 420
 Pfeiffer, Ruth: 616
 Pfeil, Sarah K.: 532
 Pham, Peter P.: 219
 Phan, Binh An P.: 643
 Phang, Tzu L.: 279
 Phanuphak, Nittaya: 219, 287, 349, 415, 956
 Phanuphak, Praphan: 414
 Pharris, Anastasia: 901
 Phengrasamy, Tony: 894
 Phillip, Susan S.: 870
 Phillips, Andrew N.: 117, **474**, 661
 Phillips, Elizabeth J.: **667**
 Phillips, Nicole: 821
 Phillips, Tamsin: 757, 795, 799, 808
 Phipps, Warren T.: 632
 Phiri, Comfort R.: **156**
 Phiri, Happy: 35LB
 Phiri, Khumbo: 793
 Phiri, Mwelwa M.: **980**
 Phogat, Sanjay: 317
 Phokojoe, Mokgadi: 1028
 Phuang-Ngern, Yuwadee: 404
 Phupitakphol, Tanit: **857**
 Pialoux, Gilles: 886
 Piatak, Michael: 270
 Pickett, James: **70**
 Pickles, Michael: **165, 1046**
 Pieper, Carl: 705
 Pilcher, Christopher: 511, 1040
 Pillai, Satish: 81
 Pillay, Deenan: 167, 169LB, 225, 484, 499, 677, 840, 848, 1003, 1011, 1012, 1013, 1027, 1030, 1048
 Pillay, Yogan: 115, 1028
 Pilot-Matias, Tami: 539LB
 Pilotto, Jose H.: 440, 779
 Pineda, Juan A.: 529, 530, 555, 586, 603, 634
 Pinnetti, Carmela: 413
 Pintado, Laura: 669
 Pinto, Angie: 365
 Pinyakorn, Suteeraporn: 349, 404, 956
 Pinzone, Marilia R.: 204
 Piper, Jeanna: 108LB
 Pipkin, Sharon: 990
 Pirillo, Robert: 896
 Pirmohamed, Munir: 702
 Piroth, Lionel: 582, 605
 Pitisuttithum, Punnee: 318
 Piwowar-Manning, Estelle: 436, **523, 936**
 Pizzato, Massimo: **57**
 Plana, Montserrat: **248**, 468
 Planelles, Vicente: 360
 Plankey, Michael W.: 390, 720, 914
 Plantier, Jean-Christophe: 959
 Plants, Jill: 695LB
 Plazy, Mélanie: 169LB
 Plettenberg, Andreas: 470
 Plotkin, Marya: **978**
 Plummer, Andrew: 29
 Plummer, Francis: 226
 Poiteau, Lila: 526, 577
 Poizat-Martin, Isabelle: **583**
 Polacino, Patricia: 356
 Polaino, Maria José: 655
 Poli, Andrea: 627
 Policicchio, Benjamin B.: 258LB
 Pollack, Ross: 83
 Pollicita, Michela: 570
 Poluektova, Larisa Y.: 399
 Ponte, Rosalie: 237, **274**
 Pontones, Pamela: 149, 541, 916
 Poole, Brian: 644
 Poon, Amanda: 105
 Poonia, Bhawna: 599
 Pop, Radu: 456
 Popiel, Maryann J.: 968
 Popkin, Daniel: 329
 Popov, Mikhail: 388
 Portal, Isabelle: 583
 Portales, Pierre: 276, 282
 Porter, Danielle P.: 496
 Porter, Kholoud: 87, 223
 Porter, Sarah E.: **1025**
 Portilla, Joaquin: 470
 Post, Frank A.: 423LB, **680**, 682, 683
 Post, Wendy S.: 914
 Potard, Valérie: 304
 Poteat, Tonia C.: **79**
 Potthoff, Anja: 628
 Powderly, William: 891
 Power, Robert A.: **499**
 Powis, Kathleen: 37, **784**, 802, **810**, 904
 Pozniak, Anton N.: 225, 665, 1023
 Prabhu, Vineet R.: **1050**
 Pradat, Pierre: 729
 Pradier, Christian: 408, 661
 Prasitsuebsai, Wasana: 857
 Preiser, Wolfgang: 782, 785
 Prescott, Marta R.: 844
 Pretorius Holme, Molly: 111, 904, 983
 Price, Angie: 528
 Price, David: 313
 Price, Richard W.: 142, 401, 402
 Prime, Katia: 835
 Prince, Heather M.: 102LB
 Prins, Henrieke A.: 977
 Prins, Maria: 152, 542, 543, 547
 Procopio, Francesco: 82
 Proctor, Enola K.: 891
 Proschan, Michael: 561
 Protack, Tricia: 464, 466
 Protopopescu, Camelia: 549
 Provias, Tim S.: 644
 Prust, Margaret L.: 844
 Psomas, Christina: **276**, 282
 Pufall, Erica L.: **913**
 Pujantell, Maria: 183, 205, 207
 Pujari, Sanjay: 160
 Punsalang, Amado: 896
 Punyawudho, Baralee: 777
 Purcell, Robert H.: 594
 Purdy, Julia: 599
 Purswani, Murl: 813
 Pushpakom, Sudeep P.: **702**
 Puthanakit, Thanayawe: 857
 Puzzovio, Maria: 819
 Pybus, Oliver: 602
 Pyles, John: 880
 Pym, Alex: 735
 Pyra, Maria N.: 301
- Q—**
 Qin, Shulin M.: 330
 Qin, Yilu: 926, 926
 Qiu, Xing: 392
 Quadroni, Manfredo: 208
 Quereda-Rodriguez, Carmen: 452
 Quesenberry, Charles P.: 54
 Quevedo, Jorge I.: 788
 Quinn, Jeffrey: 151, **712**
 Quinn, Thomas C.: 511, 520, 540, 594, 726, 731, 830, 906, 917, 954, 987
 Quirk, Erin: 817
 Quiros Roldan, Eugenia: 417, 774
 Quiroz-Morales, Verónica: 477
 Quiwa, Komba: 72LB
- R—**
 Rabideau, Dustin J.: 952
 Rabie, Helena: 852, 854
 Raboud, Janet M.: 622, 718
 Racca, Sara: 627
 Rachlis, Anita: 614
 Raddassi, Khadir: 411
 Radix, Asa: 869
 Rae, Caroline: 391
 Raehtz, Kevin D.: 258LB
 Raengsakulrach, Boonyos: 900, 927
 Rafeecas, Antoni: 571, 572
 Rafferty, Danielle: 650
 Raffi, Francois: 29, 45, 470, 675
 Rafie Sakr, Samah: 494LB
 Raghwani, Jayna: 602
 Ragin, Ann: 388
 Rahimi, Asa: 190
 Rainho, Jennifer N.: 372

- Rainwater, Stephanie: 88
 Rainwater-Lovett, Kaitlin: 825, 838
 Raizes, Elliot: 503
 Rajakumar, Premeela A.: 269
 Rajasingham, Radha: 159, 761
 Rajoli, Rajith Kumar Reddy: 441, **442**
 Rajulu, Deepa: 501, 991
 Rakasz, Eva: 23
 Rakgokong, Modiehi: 749
 Rallier, Sandrine: 526
 Rallon, Norma: 596
 Ram, Renee R.: 496
 Ramachandran, Geetha: 457
 Ramachandran, Sumathi: **149**, 541
 Raman, Lavanya: 846
 Ramdin, Neeshan: 749
 Ramesh Kumar, S.: 457
 Ramirez, Nora G.: 186
 Ramjee, Gita: 87
 Ramos, Tatiana: 805
 Ramteke, Sarah: 39
 Rancez, Magali: 274
 Rane, Deepali: 995
 Ranga, Udaykumar: 323
 Rangaka, Molebogeng: 742, 757
 Rangel-Escareño, Claudia: 251
 Rannard, Steve: 442, 442
 Rao, Anuj: 968
 Rasmussen, Thomas: 26LB
 Rasmussen, Thomas A.: 348
 Ratmann, Oliver: 220, 221, 223
 Ratner, Deena: 341
 Rauch, Andri: 566, 592, 612
 Raugi, Dana N.: 961
 Ravaux, Isabelle: 583
 Raveendran, Muthuswamy: 20
 Ravichandran, N.: 457
 Ravindran, Palanikumar: 425
 Ray, Adrian: 107
 Ray, Neelanjana: 425, **464**
 Ray, Stuart C.: 135
 Raymond, Henry F.: 898, 1041
 Raymond, Stéphanie: **950**
 Read, Jennifer S.: 809
 Read, Stanley: 836
 Reachtien, Anne: 370
 Redd, Andrew D.: 540, 594, **726**, 731, 987
 Reddy, Rajender: 576
 Redfield, Robert R.: 856
 Redmond, Sean M.: 813, **814**
 Redondo, Enrique: 945
 Redwood, Alec: 667
 Reepalu, Anton: **744**
 Rees, Helen: 87
 Reeves, Jacqueline D.: 579
 Reeves, R. Keith: 263, 275LB
 Refsland, Eric W.: 200
 Refsland, Eric: 311LB
 Regan, Susan: 638
 Regez, Rosa: 948
 Registre, Ludy: **306**
 Regueiro-Ren, Alicia: 466
 Rehm, Catherine A.: 380
 Reich, Daniel S.: 389
 Reidy, William: 791
 Reinsch, Nico: 646
 Reiss, Peter: 148, 220, 221, 566, 637, 665, 686
 Remera, Eric: **166**
 Remien, Robert: 988
 Remling-Mulder, Leila: 450
 Ren, Li: 321
 Renner, Lorna: 746
 Requena, Mary: 289, 950
 Requena, Silvia: **508**
 Rerknimitr, Rungsun: 287
 Rerks-Ngarm, Supachai: 318
 Resino, Salvador: 590, 639
 Restar, Arjee: 892
 Reubenson, Gary: 746
 Reukauf, Heidi: 991
 Reus-Bañuls, Sergio: 586
 Revollo, Boris: 634
 Rey, David: 943
 Reyes Teran, Gustavo: 245LB, 477
 Reynes, Christelle: 276
 Reynes, Jacques: 45, 276, 282, 675
 Reynolds, Steven J.: 163, 594, 726, 731, 954
 Rhee, Martin S.: 29, 817
 Rhee, Soo-Yon: 495
 Rhein, Joshua R.: 762, 763
 Rhodes, Ajantha: 298
 Rianguiwat, Tanawan: 723
 Ribakare, Muhayimpundu: **1024**
 Ribaldo, Heather J.: 55, **476**, 672, 695LB, 700, 704, 802, 939
 Ribeiro, Ruy M.: 151
 Rice, Andrew: 80
 Rice, Mabel L.: **813**, 814
 Rich, Ashleigh: 898, 1007, 1041
 Richardson, Barbra A.: 50, 108LB, 621, 624, 863, 864, 912
 Richardson, Eugene T.: **72LB**, **1056**
 Richardson, Malcolm: 764
 Richardson, Paul: 103
 Richman, Douglas D.: 83, 228, 232, 290, 362, 487
 Richter, Linda: 436
 Riddler, Sharon A.: 861
 Rieger, Armin: 682
 Riezebos-Brilman, Annelies: 839
 Rife, Brittany: 403
 Rigother, Claire: 689
 Rijnders, Bart J.: 536, 542, **682**, 1052
 Rimland, David: 255
 Rimola, Anton: 571, 572
 Rinaldi, Stefano: 324
 Rinaldo, Charles: 341, 350, 376
 Rinehart, Alex R.: 106, 471
 Rinke de Wit, Tobias: 498, 849, 977
 Ríos, María José: 529, 530, 603
 Ríos-Navarro, Cesar: 663
 Rist, Michael: 309LB
 Ritchie, Marylyn D.: 443
 Ritz, Jerome: 367
 Ritz, Justin: 25
 Riva, Alberto: 257
 Riva, Beatrice: 204
 Riveira-Muñoz, Eva: **183**, 205, 207
 Rivera, Vanessa R.: **739**, **750**, 1017
 Rivera Pinto, Javier: **266**
 Rivero, Antonio: 424LB, 527, 530, 555
 Rivero-Juárez, Antonio: 529, 530, 555, 586
 Roa, Jhoanna C.: 99
 Roan, Nadia R.: **284**
 Robb, Merlin L.: 230, 254, 287, 349, 515, 956
 Robberechts, Martine: 437LB
 Robbiani, Melissa: 270
 Robbins, Danielle: 1044
 Robbins, Gregory: 664
 Robbins, Marjorie A.: 492LB
 Robbins, Rebekkah: 994
 Roberts, Emily: 24
 Roberts, Owain: **459**
 Roberts, Sarah T.: **1063**
 Robertson, Kevin R.: **147**, 401, 402, 418, 421
 Robinson, Jake A.: 272
 Robles, Alex: 309LB
 Robles, Yvonne P.: 86, 367
 Roby, Gregg: 380, 380
 Rocafort, Muntsa: **260**, 266
 Rocha, Chiara: 604
 Rocha, Susana: 139
 Rockstroh, Jürjen K.: **154LB**, 236, 536, 560, 584
 Rodgers, Mary A.: 212, **213**
 Rodriguez, Allan: 27
 Rodriguez, Benigno: 293, 296, 299, 329
 Rodriguez, Carina: 325
 Rodriguez, Christophe: 577
 Rodríguez, Cristina: 797
 Rodriguez, Gilhen: 623
 Rodriguez, Kristina: 881
 Rodríguez-Arbolf, Eduardo: **676**
 Rodríguez-Arrondo, Francisco: 634
 Rodríguez-Barradas, María: 633, 645, 714
 Rodríguez-Cano, Diego: 555
 Rogena, Emily: 909
 Roger, Michel: 218
 Rogers, Jeffrey: 20
 Roh, Meejeon: 629
 Rohan, Lisa: 871
 Rohner, Eliane: **617**, **618**, **619**
 Rohr, Julia K.: 905, **907**
 Rojanawiwat, Archawin: 314
 Rojas Castro, Daniela: 886, 887
 Rojo Conejo, Pablo: 778
 Rolland, Morgane: **230**
 Rolon, Maria J.: 718, 947
 Romero, Fabio: **368**
 Romero-Tejada, Marisol: 367
 Ronald, Allan: 164, 868
 Ronan, Agnes: 799, 808
 Rooney, James: 102LB, 107
 Ropers, Jacques: 420
 Rosado, Isaac: 655
 Rose, Charles: 967
 Rose, Rebecca: 331, 345
 Roseberry, Jeremy: 916
 Rosebush, Julia C.: 826, 859
 Rosen, Elias P.: **447**, 450
 Rosen, Sydney: **28**, 1011, 1048
 Rosenberg, Eli: 1045

- Rosenberg, Eric S.: 231, 294
 Rosenberg, Molly S.: **905**, 907
 Rosenberg, Zeda: 109LB, 110LB
 Rosenthal, Elana S.: 599
 Rosenthal, Eric: 582
 Rosenthal, Philip: 101
 Roser, James D.: 138
 Ross, Brian: 316
 Ross, Douglas: 1016, 1016
 Ross, Michael: 686
 Ross, Polly: 993
 Rossi, Francesca: 557, 608
 Rossi, Paolo: 324
 Rossi, Steven: 815, 815
 Rossjohn, Jamie: 313
 Rossouw, Theresa: 847
 Roth, Eric A.: 546, 898, 1007, 1041
 Rothrock, Ginger: 879
 Rousseau, Christine: 517
 Rouster, Susan D.: 552
 Routy, Jean-Pierre: 237
 Rouveau, Nicolas: 526
 Roux, Paul: 852, 854
 Rouzier, Regine: 461LB
 Rouzioux, Christine: 222, 271, 351
 Rovelli, Cristina: **627**
 Rowland-Jones, Sarah L.: 253
 Roy, Monika: **1018**, 1019
 Rozada, Ignacio: **533**
 Ruane, Peter: 29, 574
 Rubenstein, Kevin B.: 1035
 Rubin, Eric J.: **131**
 Rubin, Leah: 416, 422
 Rubio, Rafael: 424LB
 Ruby, Eric: 153
 Rudd, Deanne J.: 437LB
 Rude, Eric: 534
 Rudin, Christoph: 778
 Ruel, Theodore D.: 829, 841, 843
 Ruiz-Mateos, Ezequiel: 655
 Rumaney, Maryam: 512, 787
 Ruperez, Javier: 354
 Ruperez, Maria: **797**
 Rupert, Adam: 561
 Rupp, Jonathan C.: 371
 Ruprecht, Ruth M.: 317, 317
 Rusert, Peter: 89LB
 Rusin, David: 147
 Ruisiro, Byiringiro: 1024
 Russell, Jonathan S.: 813, 814
 Russell, Ronnie: 133
 Russell-Lodrigue, Kasi: 105
- Russo, Julie: 874
 Rutherford, George: 72LB
 Rutz, Audrey M.: 371
 Ruxrngtham, Kiat: 461LB, 606, 857
 Ryan, Emily: 335, 352
 Ryom, Lene: 637, 661, **686**
 Ryscavage, Patrick A.: **856**
- S—
 S Arunachalam, Prabhu: **323**
 Saag, Michael: 42, 573, 574, 671
 Sabado, Rachel: 322
 Sabapathy, Kaplana: 114
 Sabatier, Jen: 789
 Sabbaj, Steffanie: 292
 Saberi, Sara: 716
 Sabin, Caroline: 148, 482, 484, 637, **661**, 683, 996
 Sabino, Ester C.: 326
 Sabri, Bushra: **918**
 Sabry, Alyaa: 153
 Sacha, Jonah B.: 21
 Sachiko, Miyahara: 745
 Sachs, Nancy: 506
 Sacktor, Ned: **146**, 388, 416
 Sacoor, Charfudin: 974, 976
 Saduvala, Neeraja: 211, 500
 Safren, Steven A.: 1034
 Sagaon Teyssier, Luis: **887**
 Sagar, Manish: 186, 288, 306, **307**
 Saghayam, Suneeta: 858
 Sagnelli, Caterina: **556**, **557**
 Sagnelli, Evangelista: 556, 607, 608
 Sahabo, Ruben: 34
 Sahi, Sharon: 767
 Sahli, Roland: 592
 Sailasuta, Napapon: 407
 Saint-Vil, Alix: 1017
 Saison, Julien: 729
 Saito, Akatsuki: 206
 Saito, Suzue: 738
 Sajjaweerawan, Chayada: 287
 Sajwani, Karim: 100
 Sakala, Ephraim: 156, 980
 Sakr, Samah: 624
 Salantes, Brenda: **92**
 Salata, Robert A.: 493LB, 872, 873
 Salazar, Andres: 270, 322
 Salazar-Gonzalez, Jesus: 313
 Salcedo, Magdalena: 572
- Salcuni, Paul M.: 888, 892
 Saleh, Suha: 363
 Salemi, Marco: 331, 403
 Salgado, Maria: **366**
 Saliou Sow, Mamadou: 73LB
 Sall, Fatima: 961
 Salmon-Ceron, Dominique: 549, 582, **605**
 Salomon, Joshua: 907
 Salpietro, Stefania: 556, 557
 Salpini, Romina: 570
 Salvi, Sonali: 752
 Salyer, Christen: 847
 Samandari, Taraz: **544**
 Samarawickrama, Amanda: 692
 Sambai, Betsy: 50
 Sambatakou, Helen: 486
 Samoff, Erica: 964
 Sampathkumar, Raghavan: 226
 Sampson, Lynne A.: 217
 Samri, Assia: 304
 Samson, Lindy: 812, 836
 Samson, Pearl: 458
 Samsunder, Natasha: 521
 Samuels, David: **144**, 409
 Sanborn, Kerri: 806
 Sanchez, Rosa: 456
 Sanchez, Travis: 889, 995
 Sánchez-Carrillo, Marta: 590
 Sánchez-Conde, M.: 452
 Sanchez-Merino, Victor: 303
 Sanders, Eduard J.: 977
 Sandstrom, Paul: 226
 Sanford, Ryan: **385**
 Sang, Edwin: 51, 1042
 Sang, Norton: 985, 1026
 Sania, Ayesha: **803**
 Sanisetty, Srisowmya: 95LB
 Sanjeeva, G. N.: 457
 Sanne, Ian M.: 28, 296, 299, 845, 1013, 1028
 Sansom, Stephanie L.: 1051
 Santiago, Mario L.: **134**, 187, 262
 Santos, Ariana: 369
 Santos, Breno R.: 511
 Santos, Jesús: 424LB
 Sanyal, Anvesha: 341
 Sanz, Jose: 424LB
 Sapsirisavat, Vorapot: 606
 Sarafianos, Stefan G.: 137
 Saravanan, Shanmugam: 1032
 Sarner, Liat: 794
 Sarpel, Dost: **588**
- Sartori, Ana M.: 326
 Sarun, Saramony: 831
 Sasson, Sarah C.: 365
 Sato, Hironori: 505
 Sattar, Abdus: 656, 657
 Satttha, Beheroze: 715, 716
 Saulle, Irma: **247**, 280
 Savane, Ibrahimia: 73LB
 Savory, Thea: 1018, 1019
 Sawadogo, Adrien: 962
 Sawanpanyalert, Pathom: 314
 Sawaya, George F.: 162
 Sax, Paul E.: 682, 952
 Scagnolari, Carolina: 238
 Scanlin, Kathleen K.: **888**
 Scarlatti, Gabriella: 18LB
 Scarsi, Kimberly K.: 444
 Schaafsma, Torin: 740
 Schaap, Ab: 114, 156, 981
 Schaeffer, L.: 959
 Schalasta, Gunnar: 525
 Schalkwijk, Stein: **433**
 Schanz, Merle: 89LB
 Schauer, Amanda: 102LB, 439
 Schechter, Mauro: 48LB, 866
 Scheer, Susan: 990
 Scheiblaue, Heinrich: 519
 Scheinfeld, Benjamin: 92
 Schellack, Christine J.: 844
 Schellekens, Joop: 839
 Scherrer, Alexandra: 567, **951**
 Scherrer, Didier: 461LB
 Scherzer, Rebecca: 643, 654, 685, **691**
 Schewe, Knud: 584, 589
 Schiano, Thomas: 604
 Schietroma, Ivan: **238**
 Schifanella, Luca: **317**
 Schifitto, Giovanni: 383, **392**
 Schilkey, Faye D.: 371
 Schillinger, Julia: 1009
 Schiltz, Gary: 629
 Schinazi, Raymond F.: 369
 Schinkel, Janke: 152, 542, 543, 547, **602**
 Schiralli Lester, Gillian M.: 193
 Schleimann, Mariane: 26LB
 Schlesinger, Erica B.: 879
 Schlusser, Katherine: **511**, 520
 Schmid, Patrick: 612
 Schmitz, Joern E.: 22
 Schmutz, Guenther: 589
 Schnell, Greta: 539LB

- Schölvinck, E. H.: 839
 Schommers, Philipp: **197**
 Schonfeld, Daniel: **383**
 Schooley, Alan: 793
 Schouten, Erik: 35LB
 Schrier, Rachel: 730
 Schrijvers, Rik: 363
 Schuermann, Dirk: 425, 437LB
 Schuettfort, Gundolf: **713**
 Schuetz, Alexandra: **287, 404**
 Schultz, Anke: 303
 Schultze, Anna: **486**
 Schulz, Christian: **635**
 Schulze zur Wiesch, Julian: 366
 Schumacher, Christina: 1036
 Schutten, Martin: 220
 Schutz, Charlotte: **763**
 Schütze, Marcel: 525
 Schwartz, George J.: 687
 Schwartz, Jill: 871
 Schwartz, Katie: 109LB
 Schwartz, Myron: 604
 Schwartz, Sheree R.: 922
 Schwarze-Zander, Carolynne: 560
 Schwieler, Lilly: 267
 Schwing, Catherine: 198
 Scott, Hymen: 897
 Scott-Herridge, Joel: 226
 Scully, Eileen P.: 86, **294**, 315
 Seaberg, Eric C.: 416, 593
 Seage, George R.: 167, 838
 Seaman, Michael: **309LB**, 469LB
 Seamon, Catherine: 311LB, 380
 Seaton, Kelly: 90
 Sebastian, Joseph: 216, 217
 Secours, Rode: 473
 Seddiki, Nabila: 233
 Sedlacek, Dalibor: 46
 Seekaew, Pich: 897
 Seifert, Sharon M.: **445**
 Seipone, Ikanyeng D.: **398**
 Sekaly, Rafick: 297, 335, 352, **358LB**, 880
 Seki, Yohei: 206
 Sekubugu, Robert: 902, 986
 Selgrad, Michael: 635
 Selin, Amanda: 936
 Sellier, Pierre: 804
 Selvam, Deepak: 323
 Selvamuthu, Poongulali: 753
 Semitala, Fred Collins: 112
 Semrau, Katherine: 33
 Sen, Luisa: 837
 Sengayi, Mazvita M.: **613, 631**
 SenGupta, Devi: 817
 Sento, Winnie: 983
 Serafino, Sara: 238
 Sereda, Paul: 898, 1041
 Seremba, Emmanuel: **563**
 Sereti, Irini: 296, 299, 343, 344
 Serhal, Maya: 649
 Serrano-Villar, Sergio: 354
 Serwadda, David: 163, 563, 726, 731, 954, 986, 987
 Sevene, Esperança: 158LB, 797
 Severe, Patrice: 473, 750, 1017
 Sevinsky, Heather: **425**
 Sewell, Andrew K.: 828
 Seydi, Moussa: 568, 961, 962
 Seyedkazemi, Star: 239
 Shafer, Mark: 660
 Shafer, Robert W.: 495, 503
 Shafi, Juma: 863, 864
 Shah, N. Sarita: 157, 756
 Shah, Rimi: 794
 Shahmanesh, Maryam: 913
 Shaikh, Obaid: 581
 Shalek, Alex K.: 19
 Shanaube, Kwame: 114, 156, 980, **981**
 Shankar, Anupama: 541
 Shao, Wei: 85, 337, 340, 348, 379, 490
 Shao, Yiming: 321
 Shao, Yongwu: 817
 Shapiro, David E.: 775
 Shapiro, Lawrence: 310LB
 Shapiro, Roger L.: **37**, 784, 800, 802, 805, 810, 815
 Sharma, Anjali: **720**
 Sharma, Ekta: 201, 244
 Sharma, Monisha: 49
 Sharma, Shweta: 659
 Sharp, David J.: 148
 Sharp, Joseph T.: **1031**
 Shattock, Robin: 448
 Shaw, Audrey L.: 278
 Shaw, Christiana M.: 133
 Shaw, George M.: 133, 394
 Shaw, Pamela A.: 609, 934
 Shea, Patrick R.: 601
 Shearer, Kate: 906
 Sheehan, Gerard: 665, 710
 Shellenberger, Jennifer: 151
 Shelter, Cory: 874
 Shen, Gong: 100
 Shepherd, Bryan E.: 706, 790, 958
 Shepherd, John A.: 36
 Shepherd, Leah: **630**
 Sherman, Gayle: 783
 Sherman, Kenneth E.: 329, 552, 581
 Sherman, Sean: 395
 Sheth, Anandi N.: 47
 Shetty, Avinash: 440
 Shi, Qiuhu: 720
 Shiau, Stephanie: 39, 40, **851**
 Shieh, Eugene: **169bLB**
 Shields, Jesse: 916
 Shiels, Meredith: 616
 Shikuma, Cecilia M.: 387, 652, 723
 Shilaih, Mohamed: 567
 Shin, Sanghyuk S.: **755**
 Shindo, Keisuke: 202
 Shioda, Tatsuo E.: 206
 Shirakawa, Kotaro: 202, **463**
 Shiramizu, Bruce: 345
 Shive, Carey L.: **329**
 Shlipak, Michael: 684, 685, 691
 Shodell, Daniel: 516, 975
 Sholtis, Katherine: 355
 Shoptaw, Steven: 883LB
 Shorestein, Joshua: **265**
 Short, William: 680
 Shouse, Luke: 915
 Shouse, Roy L.: 53, 1004, 1037
 Shrivastava, Shikha: 599
 Shroufi, Amir: 1010, 1061
 Shu, Sherry T.: **191**
 Shubber, Zara: 1028
 Shukla, Shuchin: 534
 Shulman, Nancy S.: 539LB, 574
 Shurgold, Susan: 546, 1007
 Siberry, George K.: **36**, 798, 809, 813, 814
 Sibiude, Jeanne: **776**
 Siccardi, Marco: 441, 442, 444, 459
 Sider, Doug: 491LB
 Sieg, Scott M.: 252, 329
 Sierra-Madero, Juan: 296, 299, 477
 Siewe, Basil: 265
 Sigaloff, Kim: 498, 849
 Sigauke, Farai R.: 963
 Sigel, Keith M.: 620, 626, **633**
 Sigman, Andrew G.: 234
 Sikazwe, Izukanji: 960, 1018, 1019
 Sikhondze, Welile: 742
 Silhol, Romain: 1060
 Siliciano, Janet: 83
 Siliciano, Robert: 83, 135, 339, 360, 462
 Silk, Rachel: 528
 Silva, Evelyn: 597
 Silverberg, Michael J.: 54, 150, **162**, 614, 894, 1035
 Silverman, Rachel: 494LB
 Silverman, Rachel: 847
 Silverstein, Matthew: 620, 626
 Silvestri, Guido: 20, 22, 24, 353
 Simele, Marco: 426, 774
 Siminski, Suzanne: 838
 Simioni, Samanta: 381
 Simon, Anne: 943
 Simon, F.: 959
 Simon, Karl Georg: 584, 589
 Simon, Tracey: **551**
 Simon, Viviana A.: 201, 244, 371
 Simoneau, Camille R.: 315
 Simonetti, Francesco R.: **337**
 Simoni, Jane: 864, 912, 1034
 Simonich, Cassandra: **88**
 Simons, Lisa K.: **175**
 Simons, Russell: 403
 Sin, Don: 725
 Sinclair, Elizabeth: 142, 298
 Singal, Amit: 587
 Singer, Elyse: 331, 345
 Singer, Rachel: 270
 Singh, Avashna: 488
 Singh, Elvira: 613
 Singh, Ravesh: **246**, 398
 Singh, Urisha: **488**
 Sinha, Arjun: **654**
 Sips, Magdalena: **91**
 Sirengo, Martin W.: 791, 909
 Sirivichayakul, Sunee: 219
 Sirivongrangson, Pachara: 900
 Sironi, Manuela: 247
 Sissoko, Daouda: **75LB**
 Sithole, Bhekie: 925
 Siwale, Margaret: 498
 Skaletz-Rorowski, Adriana: 628
 Skarbinski, Jacek: 1045
 Skingsley, Andrew: 1053
 Skinner, Pamela: 23
 Skogmar, Sten: 744
 Skolasky, Richard L.: 146

- Skordis-Worrall, Jolene: 834
 Skurowski, Jasmine: 451, 545
 Slaymaker, Emma: 117
 Sleasman, John: 257, 325
 Sloan, Derek: 342
 Sluis-Cremer, Nicolas: **341**,
 376, 377
 Slyker, Jennifer: 780
 Smart, Michele: 243
 Smit, Colette: 542
 Smit, Erasmus: 484
 Smith, Andrew G.: 133
 Smith, Bryan: 389
 Smith, Colette: 686, 941
 Smith, Davey M.: 143, 222,
 224, 228, 232, 487, 518, 727,
 730, 942
 Smith, Don: 470
 Smith, Elizabeth: 438, 439, 775
 Smith, Emily: 803
 Smith, Jennifer: **1058**
 Smith, Justin: 931
 Smith, Kimberley Y.: 311B, 947
 Smith, Lou: 501, **991**
 Smith, M. Kumi: 955
 Smith, Mariette: 759, 1022
 Smith, Rachel: 759
 Smith, Robert A.: 961
 Smith, Whitney: 919
 Smith-McCune, Karen K.: 162
 Smithgall, Thomas E.: 191
 Smyth, Erica: 662
 Sneller, Michael: 3111B
 So-Armah, Kaku: 645, 714
 Soars, Matt: 97
 Sobolewski, Michele D.: **340**,
 377, 379
 Sogni, Philippe: 549, 582, 605
 Soheilian, Ferri: 137
 Sohn, Annette H.: **174**
 Soliman, Mary: 83
 Solom, Tsion: 1010
 Solomon, Sunil S.: **899**, 918,
928, 1032
 Somasundaran, Mohan: **806**
 Somasunderam, Anoma: 239
 Sommerfelt, Maja: 261B
 Somsouk, Ma: 235, **264**, 278,
 298
 Somwe, Paul: 1019
 Song, Chisu: 629
 Song, Xiaojing: 569
 Sönnerrborg, Anders: 254, 260,
 267, 486, 998
 Sonza, Con: 483
 Sopa, Bunruan: 857
 Sophonphan, Jiratchaya: 857
 Soria, Alessandro: 181B
 Soriano, Vicente: 508
 Soriano-Sarabia, Natalia: 355
 Sosa-Rubi, Sandra G.: 1059
 Soto-Torres, Lydia E.: 1091B,
 872, 873
 Souda, Sajini: 784, 802
 Soudeyns, Hugo: 836
 Soulié, Cathia: 489
 Soulier, Alexandre: 526, 577
 Sousa, Amina: 850
 Souza, Scott C.: 387, 723
 Sow, Salif: 961
 Sowell, Elizabeth R.: 822, 823
 Sowinski, Stefanie: 240
 Spear, John R.: 698
 Spengler, Ulrich: 236
 Sperling, Rhoda S.: 798
 Spiegel, Hans: 871
 Spiegelaerde, Ward: 359, 361
 Spiegelman, Donna: 703
 Spiller, Michael T.: 215, 916
 Spindler, Jonathan: 85, 337, 340
 Spira, Bonnie A.: 480, 507
 Spire, Bruno: **549**, 886, 887
 Spoerri, Adrian: 613
 Spreen, William: 311B, 105,
 106, 471
 Springer, Gayle: 416
 Spudich, Serena S.: 142, 384,
 401, 402, 404, 405, 407, 411,
 414, 415
 Spyer, Moira: 1027
 Squillace, Nicola: 280
 Srikrishnan, Aylur K.: 899, 918,
 928, 1032
 Srinivasa, Suman: 650, 707
 Ssali, John: 746
 Ssekasanvu, Joseph: 163
 Ssekitooleko, Henry: 743
 Ssemmondo, Emmanuel: 979
 Ssempijja, Victor: 563
 Ssinabulya, Isaac: 297
 St. Bernard, Leslie: 105, 406, 597
 St. Johns-Williams, Lisa: 595
 Stabinski, Lara: 594
 Stagg, Helen R.: 1053
 Stahlman, Shauna: **924**, **925**
 Stall, Ron: 914
 Stam, Arjen J.: **839**
 Stamm, Luisa M.: 100, 573, 601
 Stancil, Britt S.: 106, 471
 Stanton, Jill: 997
 Stanzione, Maria: 608
 Starace, Mario: 607
 Staziaki, Pedro: 640
 Steba, Gaby S.: **547**
 Steele, Sarah Jane: **1010**, 1061
 Steens, Jean-Marc: **461LB**
 Stefic, Karl: **400**
 Stein, Dan: 821
 Stein, James H.: 441B, 651, 672,
 687, 939
 Steiner, Joseph: 146
 Steinman, Meredith: 585
 Stek, Alice: 433, 438, 439, **775**
 Stella Ascariz, Natalia C.: **669**
 Stellbrink, Hans-Jürgen:
 311B, 46
 Stephan, Christoph: **519**, 713
 Stephen, McHenry: 564
 Stephens, Terri: 965
 Stephenson, Kristine: 546, **1007**
 Sterling, Timothy R.: 653,
 706, 735
 Stern, Joshua: 38
 Sterne, Jonathan: 941
 Sterrett, Sarah D.: 292
 Steven, Reynolds: 563
 Stevens, Mark: 434
 Stevens, Robert: 705
 Stevens, Wendy: 1013, 1028
 Stevenson, Mario: 372
 Stewart, Annemie: 427, 742
 Stewart, Jesse: 714
 Shreshley, Larry: 213
 Stinson, Kathryn: 960, 1022
 Stirratt, Michael J.: 885
 Stitzer, Maxine L.: 27
 Stock, David A: 472
 Stock, Jennifer L.: 258LB
 Stoddart, Cheryl: 331, 345
 Stoeckle, Marcel: 612
 Stoehr, Albrecht: 472
 Storto, Alexandre: 509
 Stout, Richard R.: 323
 Strain, Matt F.: 83, 143, 362
 Stranix-Chibanda, Lynda: 36
 Strautins, Kaija: 667
 Strehlau, Renate: 39, 40, 851
 Struck, Daniel: 211
 Stucki, David: **737**
 Su, Bin: 304
 Su, Jonathan: 877
 Subramanian, Mani: 601
 Suc, Bertrand: 289
 Sudjaritruk, Tavitaya: **831**, **860**
 Sued, Omar G.: 718, **947**
 Sugar, Catherine A.: 704
 Sujan, Dilly P.: 434
 Sukrakanchana, Pra-ornsuda:
 777
 Suksamosorn, Jirawat: 972
 Sukwicha, Wichuda: 972
 Sulkowski, Mark: 151, **539LB**,
 573, 537, **576**, 601
 Sullivan, Ashleigh B.: 491LB
 Sullivan, Patrick: **4**, 286, 889
 Sultana, Tahmina: **206**
 Summers, Michael F.: **56**
 Sumner, Tom: 115
 Sun, Lingling: 188
 Sun, Ly Penh: 858
 Sun, Xiaoming: 347
 Sun, Yongnian: 97
 Suneja, Gita: 615
 Stephenson, Kristine: 546, **1007**
 Sung, Xin: 745, 747
 Sung, Samuel: 877
 Sunil, Thankam: 722
 Sunshine, Sara: **360**
 Sunyakumthorn, Piyanate: 405
 Supervie, Virginia: 1043
 Surdo, Matteo: 570
 Suttichom, Duanghathai: 415
 Suzan-Monti, Marie: 887
 Suzuki, Kazuo: 365, 559
 Svedhem, Veronica: 998
 Svicher, Valentina: **570**
 Swadling, Leo: 598
 Swaminathan, Soumya: 457,
 Swannstrom, Ronald I.: **62**, 192,
 401, 402
 Swarner, Stephanie: 879
 Swartz, Talia: **249**
 Sweat, David: **929**
 Switzer, William: 149, **211**,
 215, 541
 Swoboda, Jochen: 628
 Syengo, Masila: 791
 Sykes, Craig: 1021B, 439, 447
 Sylla, Maryam: 840
 Symons, Jori: **359**
 Szadkowski, Leah: 718
 Sze, Marc: 725
 Sogaard, Ole S.: **261B**, 348

—T—

- Taburet, Anne-Marie: **455**
 Tachedjian, Gilda: 483
 Tada, Takuya: 203
 Taiwo, Babafemi: 30, 147, 694, 695LB, 719, 721
 Takahama, Soichiro: 670
 Takaori-Kondo, Akifumi: 202
 Takx, Richard: 343, 344, 640
 Talla, Aarthi: 880
 Talley, Sarah: 209LB
 Tamburini, Andrea Marco: 627
 Tambussi, Giuseppe: 627
 Tamko-Mella, Ghislaine Flore: 526
 Tan, Darrell H.: 479LB, **169aLB**
 Tang, David: 319
 Tang, Michelle: 503
 Tang, Ning: 749
 Tang, Songyuan: **926**
 Tang, Tian: 1033
 Tang, Weiming: 926, 969, **970**
 Tangpricha, Vin: 826, 859
 Tankijvanich, Pisit: 606
 Tanner, Marcel: 676
 Tanon, Aristophane: 568, 568, 1015
 Tanser, Frank: 167, 499, 677, 960, 1011, 1048
 Tantalo, Lauren: 767
 Tantivayakul, Ponpen: 287, 414
 Tapela, Neo: 615
 Tapia, Ken: 38
 Tapia-Trejo, Daniela: 477
 Tarancón, Laura: **655**
 Tardy, Jean-Claude: 729
 Taseera, Kabanda: 763
 Tassiopoulos, Katherin: 719, 721
 Tate, Janet: 554, 633, 645
 Tattevin, Pierre: 675
 Tau, Pheletso: 738
 Tauriainen, Johanna: 254
 Taverner, Bernard: 73LB
 Tawakol, Ahmed: 343, 344
 Taylor, Barbara S.: **645**
 Taylor, Graham: 794
 Taylor, Steve: 423LB
 Tazi, Jamal: 461LB
 Tchetgen Tchetgen, Eric: 111, 904
 Teasdale, Chloe A.: **770**
 Tebas, Pablo: 32LB, 44LB, 290, 316, 680, 700
 Tedaldi, Ellen: 544
 Teferi, Gebeyehu: 538LB
 Telenti, Amalio: 208
 Teleshova, Natalia: 875, 876
 Téllez, Francisco: 529, 530, 603, 634
 Tellez, María J.: 611
 Telly, Fatoumata Tiguem: 480
 Telly, Nouhoum: 921
 Telwatte, Sushama: **483**
 Tennant, Sadhbh: 710
 Tenorio, Alan: 293
 Tenthani, Lyson: 118
 Teofilo, Eugenio: 682
 Tepper, Vicki: 856
 Tepler, Hedy: 470
 Terrell, Coleman: 1002
 Terry, Sandra N.: 201
 Teshale, Eyasu: 149
 Tesoriero, James: 991
 Tesselaar, Kiki: 839
 Thalme, Anders: 681
 Tharp, Gregory: 20, 286
 Thibault, Derek: 272
 Thiede, Hanne: 933
 Thienemann, Friedrich: 763
 Thienkrua, Warunee: 900, **927**
 Thiessen-Philbrook, Heather: 691
 Thindwa, Deus: 35LB
 Thio, Chloe: **67**, 564, 569, 593
 Thiong'o, Alexander N.: 977
 Thirumurthy, Harsha: **973**, 1062
 Thobakgale, Christina F.: 827
 Thomas, Allison: 300LB
 Thomas, Aurielle: **528**
 Thomas, David L.: 135, 151, 535, 537, 540, 548, 712
 Thomas, H. L.: 1053
 Thomas, Katherine K.: 301
 Thomas, Kevin: 821
 Thomas, Melissa: 23
 Thomas, Réjean: 237
 Thomou, Thomas: 707
 Thompson, Corbin: 447, **450**
 Thompson, Melanie: 470
 Thompson, Paul M.: 383, 386
 Thompson, Renata: 993
 Thompson, Ricardo: 516, 975
 Thompson, Will: 595
 Thorne, Claire: **778**
 Tianyu, He: 258LB
 Ticchioni, Michel: 408
 Tie, Yunfeng: 497, 591, 1006
 Tieghi, Tiziana: 610
 Tien, Phyllis: 422, 609, 691
 Tiendrebeogo, Thierry: **1015**
 Tierney, Camlin: 36, 952
 Tieu, Hong Van N.: **897**
 Tilston, Peter: 482
 Timmerman, Jay: 481
 Tinago, Willard: 710
 Tincati, Camilla: 598
 Tine, Judicaël: 568
 Tippett Barr, Beth: **351B**, **168LB**, 789
 Tipsuk, Somporn: 956
 Tiraboschi, JuanManuel: 448
 Tirschwell, David: 636
 Tisserand, Pascaline: 295
 Titanji, Kehmia: 47
 Tivarus, Madalina: 392
 Tjernlund, Annelie: 285
 Tlali, Mpho: 155
 Tobaiwa, Ocean: 788
 Tobian, Aaron A.: 726, 731, 954, 987
 Tobin, Nicole H.: 807
 Tobita, Satoshi E.: 206
 Tobiume, Minoru: 203
 Todesco, Eve: **489**
 Todorovich, Tamara: 532
 Toefy, Asma: 824
 Tokunaga, Kenzo: **203**
 Tolazzi, Monica: 18LB
 Tolentino, Karen: 412
 Tollman, Stephen: 678, 679, 905, 907
 Tolstrup, Martin: 26LB, 348
 Tomaras, Georgia: 268, 317
 Tomei, Christelle: 583
 Tomescu, Costin: **316**
 Tomori, Cecilia: 928
 Tookey, Pat: 835
 Torian, Lucia V.: **896**, 908
 Toribio, Mabel: **664**
 Torres, Berta: 945
 Torres, Liset: 625
 Torres-Torronteras, Javier: 205
 Torriani, Martin: **707**
 Torti, Carlo: 486
 Tosswill, Jennifer: 895
 Tostevin, Anna: 225, 482, 484
 Toure, Abdoulaye I.: 73LB
 Tovananubatra, Sodsai P.: **219**
 Towner, William J.: 54
 Townley, Ellen: 816
 Trabattoni, Daria: 247, 280
 Tran, Thuy T.: 55, 672, 939
 Traore, Bouyagui: 921
 Trautmann, Lydie: **407**
 Treasure, Graham C.: **346**
 Trebicka, Jonel: 559
 Treeprasertsuk, Sombat: 606
 Tremblay, Cécile: 237, 886, 887
 Tremblay, Michel J.: 182
 Tressler, Randall L.: 25
 Treviño, Ana: 508
 Triant, Virginia A.: 638
 Trickey, Adam: **941**
 Trinh, Roger: 539LB, 574
 Trinh, T. T.: 621
 Trinidad, Lino R.: 856
 Tripathi, Rakesh: 539LB
 Trivedi, Tarak K.: 532
 Trkola, Alexandra: **891B**
 Trosev, Orlin: 896
 Troseid, Marius: 267
 Trotta, Diane: 411
 Trout, Amanda L.: 396
 Truong, Hong-Ha M.: **990**
 Tsai, Alexander C.: 935
 Tsai, Angela: 342
 Tsai, Lily: 469LB
 Tsai, Ming-Han: **828**
 Tshabalala, Gugu: 1014
 Tshume, Ontibile: 833
 Tso, Lai Sze: 969
 Tsoi, Benjamin: 888, 892
 Tsunetsugu-Yokota, Yasuko: 203
 Tubiana, Roland: 776, 804, 811
 Tucker, Joseph D.: 926, 955, 969, 970
 Tukei, Vincent: 842
 Tully, Damien C.: **231**
 Turan, Bulent: 919
 Turan, Janet M.: **919**
 Turkieh, Albert: 968
 Turyamureeba, Bosco: 740
 Tymejczyk, Olga: 1009, 1020, 1021
 Tyrell, Alicia: 392

—U—

- Uban, Kristina: 822
 Uberti Foppa, Caterina: 454, 556, 557
 Ugoagwu, Placid: 564
 Uhrig, Jennifer D.: 993
 Ukpong, Morenike: **2**
 Umaki, Tracie M.: 387
 Unal, G.: 959
 Underwood, Jonathan: **148**

- Ung, Vibol: 860
 Ungsedhapand, Chaiwat: 900, 972
 Unsal, Aylin: 830
 Untiedt, Sanlie: 845
 Uprety, Priyanka: **825, 838**
 Urano, Emiko: **465**
 Uribe-Leitz, Monika: 826, 859
 Urien, Saik: 777
 Usami, Yoshiko: 136
 Useem, Johanna C.: 957
 Utay, Netanya S.: **239**, 265, 278
 Uzizhiwe, Jean Paul: 166, 1024
 Uzdavinieni, Vilma: 46
- V—
 Vakkalagadda, Blisse: 425, 460
 Vala, Anifa: 797
 Valantin, Marc-Antoine: 709
 Valcour, Victor: 384, 404, 405, 407, 414, 415, 416, **422**
 Valentin, Antonio: 259LB
 Valere, Kimyata: **196**
 Valiaveetil, Christina: **949**
 Vallabhaneni, Snigdha: 759
 Vallari, Ana S.: **212**, 213
 Valluri, Srinivas Rao: 818, 1120
 Valverde, Eduardo: 497
 van Crevel, Reinout: 431
 Van Cutsem, Gilles: 1010, 1031, **1061**
 Van Damme, Lut: 1058
 van de Berg, Dorien: 152
 van de Laar, Thijs J.: 542, 543
 van de Vijver, David A.: 536, 1052
 van den Berk, Guido: 948
 van der Heijden, Yuri F.: 735
 van der Horst, Charles: 801LB
 van der Meche, Narda: 948
 van der Meer, Jan T.: 542, 543, 547
 van der Merwe, Lize: 158LB
 van der Ryst, Helen: 742
 van der Rys, Elna: 818, 1120
 van der Sluis, Renee M.: 375
 van der Straten, Ariane: **873**, 879
 van der Valk, Marc: 566, 1052
 Van Dyk, Gisela: 847
 Van Dyke, Russell B.: 822, 823, 838
 van Griensven, Frits: 219
 van Ham, Petronella M.: 464
 Van Handel, Michelle M.: **966**
 van Heerden, Alastair: 740
 van Hout, Denise: 839
 Van Lith, Lynn: 925
 van Lunzen, Jan: 366
 van Oosterhout, Joep: 351B, 118
 Van Rompaey, Stephen: 558
 van Rooyen, Heidi: 436, 740
 Van Ryk, Donald: 198
 van Sighem, Ard: **220**, 221, 542
 van Toorn, Ronald: 820
 van Widenfelt, Erik: 810, 984
 van Wilgenburg, Bonnie: 598
 van Zyl, Gert U.: 523
 Vandamme, Anne-Mieke: 211, 486
 Vandekerckhove, Linos: 359, 361
 Vanderford, Thomas H.: 22
 Vanhommerig, Joost W.: **542**, 547
 Vanpouille, Christophe: 184
 Varangrat, Anchalee: 884, 900
 Vardhanabhuti, Saran: 493LB
 Vargas, Milenka: 727, 730
 Variava, Ebrahim: 749, 963
 Vasan, Sandhya: 318, **405**
 Vassall, Anna: 155
 Vassallo, Matteo: **408**
 Vasudevan, C.K.: 918
 Vavro, Cindy: 816
 Vaz, Paula M.: **850**, 974, 976
 Vázquez-Morón, Sonia: 590
 Vázquez-Pérez, Joel: 251
 Veazey, Ronald: 467
 Veloso, Valdilea G.: 48LB, 779
 Velu, Vijayakumar: 93LB
 Venkataramani, Atheendar: 1011
 Venter, Francois: 1056
 Venugopalan, Srividhya: 1053
 Venuto, Charles: **428**, 443
 Venzon, David: 317
 Vera, Jaime H.: **692**
 Verdin, Eric: 363, 463
 Verma, Anurag: 443
 Verma, Shefali: 443
 Vermund, Sten H.: 790, 792
 Verna, Elizabeth C.: **11**, **124**
 Vestal, Brian: 279
 Viana, Raquel V.: 749
 Viani, Rolando: 816
 Vichi, Francesca: 247
 Vieillard, Vincent: 304
 Vierling, John M.: 576
 Vig, Pamela: 153
 Vigouroux, Corinne: 701
 Vilaplana, Elisenda: 248
 Villarreal, Alfredo: 514
 Villegas, Guillermo: **876**
 Viner, Russell: 835
 Vinikoor, Michael: 565
 Violari, Avy: 848, 851
 Visavakum, Prin: 972
 Visseaux, Benoit: **214**, **223**, 509
 Vittinghoff, Eric: 524, 867, 870
 Vivancos-Gallego, M.J.: **452**
 Vjecha, Michael J.: 559
 Vo, Quynh T.: **1020**
 Vojnov, Lara: 788
 Volk, Jonathan E.: 894
 Vollbrecht, Thomas: **373**
 Volpe, Joseph M.: **481**, 579
 Von Groote-Bidlingmaier, Florian: 158LB
 von Hohenberg, Maximilian: 763
 von Lettow, Monique: 35LB
 Von Wichmann, Miguel A.: 611
 Vonesh, Edward: 953
 Vourvahis, Manoli: 818, 1120
 Vranckx, Lenard: 363
 Vray, M.: 959
 Vubil, Adolfo: 788
 Vucic, Emily: 725
 Vujkovic-Cvijin, Ivan: 264
 Vullo, Vincenzo: 238, 610
 Vunnavva, Aswani: 47
- W—
 Wada, Nikolas I.: 283
 Wade, Alisha: 678, 679
 Wagh, Kshitij: 309LB
 Wagner, Danielle L.: 1051
 Wagner, Gabriel A.: **228**
 Wagner, Ryan: 907, 936
 Wahl, Janice: 576
 Wahome, Elizabeth W.: 977
 Wainberg, Mark A.: 218, 480, 507
 Waitt, Catriona J.: **449**
 Waked, Imam: **64**, **153**
 Walensky, Rochelle P.: 786, 1016
 Waligo, Allen: 1056
 Walits, Emily: 501
 Walker, Bruce D.: **13**, 19, 190, 256, 261, 300LB, 312, 488
 Walker, Joshua: 273
 Walker, Naomi F.: **734**
 Walker-Sperling, Victoria E.: **374**
 Wallenta, Jeanna: 112
 Wallet, Cedrick: 45
 Wallis, Carole L.: 30, **493LB**, **749**
 Walmsley, Sharon L.: 718, 768
 Watson, Judd L.: 748
 Walter, Hauke: 525
 Walworth, Charles M.: 481, 579
 Wamai, Richard: 1059
 Wamalwa, Dalton: 38, 748, 780
 Wamicwac, Joyce: 909
 Wamuti, Beatrice: 50
 Wandeler, Gilles: 565, **566**, 568, 592, 960
 wang, Chunhui: 791
 Wang, Cuiwei: 390
 Wang, Hong: 749
 Wang, Huanling: 569
 Wang, Jijia: 433, 438, 439, 775
 Wang, Jian: 460
 Wang, Jianbin: 356
 Wang, Jiayi: **200**
 Wang, Junjie: 936
 Wang, Lei: 822, 823
 Wang, Lu: 392
 Wang, Nidan: 569
 Wang, Ruibin: **684**, 699
 Wang, Shelley K.: 358LB
 Wang, Shirlene D.: 822
 Wang, Shuang: 851
 Wang, Stanley: 453
 Wang, Zhengyan: **501**
 Wang'Ombe, Joseph: 1059
 Wani, Gregory: 510
 Wanje, George: 912
 Ward, Helen: 895, 913
 Ward, John: 149
 Warner, Nadia: 570
 Warszawski, Josiane: 776, 804, 811
 Warth, Chris: 478
 Wasmuth, Jan-Christian: 560
 Watanatanyaporn, Teeraparp: 884
 Waterhouse, Dorothy: 916
 Watkins, Phaedra: 883LB
 Watson, Christopher: 893
 Watson, Dionysios K.: 259LB
 Watts, D. H.: 779
 Watts, Thomas D.: 140
 Wawer, Maria J.: 163, 563, 902, 954, 986, 987
 Weaver, Eric M.: 278
 Webb, Nicholas E.: 33
 Webel, Allison R.: **657**

- Weber, Kathleen: 277, 720
 Weber, Rachel: 1025
 Weber, Rainer: 612, 661
 Webster-Cyriaque, Jennifer Y.: 161
 Wegner, Matthew D.: 405
 Wei, Chongyi: 926, 969
 Wei, Danlan: 198
 Wei, Stanley: 975
 Weigel, Bernard: **643**
 Weinberg, Adriana: **809**, 825
 Weis, Julie: 478
 Weiser, John: 497
 Weiser, Sheri: 919, 935
 Weiss, Jeffrey: 534
 Weiss, Kevin: 900, **972**
 Weissman, Sharon: **965**
 Weitz, David A.: **7**
 Weitzmann, M. N.: 47, 695LB
 Wejnert, Cyprian: 931, 1000, **1045**
 Weld, Ethel: 169bLB
 Wellington, Maureen: 498
 Wells, Lance: 308
 Welte, Alex: 517
 Wen, John: 983
 Wendahl, Suzanne: 998
 Wensel, David: 97
 Wensing, Anne M.: 366, 543, 839
 Wentworth, Deborah: 559
 Wertheim, Joel O.: 211, 487
 Westenberger, Tanja: 519
 Wester, C. William: 421, 790
 Westerhaus, Elizabeth: 382
 Wetzel, Katherine: **24**
 Wheelan, Sarah J.: 135
 Wheeler, Amber L.: 720
 Wheeler, Darrell P.: **883LB**
 Whitcomb, Jeannette M.: 481, 579
 White, Darcy: **912**
 White, Douglas A.: 532
 White, Ellen: 482, **484**
 White, James: 722
 White, Jessica R.: **714**
 Whitney, James B.: **95LB**
 Whittles, Lilit K.: **1060**
 Wichukchinda, Nuanjun: 314
 Wiegand, Ann: 340
 Wieland, Ulrike: 628
 Wienberg Ludwig, Peter: 241
 Wiener, Jeffrey: 771, 801LB
 Wild, Carl T.: 465
 Wilkin, Aimee: 474
 Wilkin, Timothy J.: 103, 104, 160, **161**
 Wilkinson, Eduan: 499
 Wilkinson, Katalin: 734
 Wilkinson, Lynne: 1031
 Wilkinson, Peter: 880
 Wilkinson, Robert J.: 734
 Wilkinson, Thomas A.: **33**
 Williams, Deborah: 683
 Williams, John R.: **1047**
 Williams, Julie: 257
 Williams, Katherine: 88
 Williams, Kenneth C.: 141, 273, 403
 Williams, Paige L.: 813, 814, **822**, 823
 Williams, Peter: 31LB
 Williamson, Carolyn: 309LB
 Willils, Sarah: 418, 964
 Wilson, Brigid: 733
 Wilson, Cara: 134, 187, 262, 279, 293
 Wilson, Eleanor M.: 528, **580**, 599
 Wilson, Ira B.: 1034
 Wilson, Kate S.: 863, **864**, 912
 Wilson, Michael R.: 43
 Wilson, Tracey E.: 647, 919
 Wilton, Leo: 883LB, 893
 Wimonsate, Wipas: 972
 Winai, Ratanasuwann: 461LB
 Winckelmann, Anni: **348**
 Winston, Alan: 148, **423LB**
 Winter, Joanne R.: **1053**
 Wirden, Marc: 489
 Wirth, Kathleen: 111, 904
 Witt, Mallory: 685
 Wittkop, Linda: 549, **582**, 605, 689, **944**
 Wiznia, Andrew: **816**
 Wohl, David: **681**, 682
 Wohlfleiler, Michael B.: **953**
 Wolf, Shauna: 523
 Wolf, Timo: 713
 Wolfs, Tom F.: 839
 Wolinsky, Steven: 145
 Wong, Jason: 546, 1007
 Wong, John B.: 535
 Wong, Joseph K.: 80
 Wong, Kimberly: 707
 Wong, Ngai Sze: **969**
 Wong, Vincent: 978
 Wong, Wilson W.: 193
 Wood, Robin: 429, 960, 1029
 Wood, Sandra L.: 98
 Wood, Sarah: **832**
 Woods, Conan K.: 492LB
 Worley, Kim C.: 20
 Worobey, Michael: **140**
 Worodria, William: 764
 Wu, Beiqing: **397**
 Wu, Fan: 275LB
 Wu, Kunling: 43, 719, 721
 Wu, Li E.: 399
 Wu, Qiongmiao: 970
 Wu, Xiaolin: 84, 337
 Wu, Xueling: 307
 Wu, Yingfeng: 1020
 Wu, Yuanfei: **136**
 Wyatt, Christina: 868
 Wyles, David: **574**
 Wyman Engen, Nicole: 41
 Wynne, Brian: 660
—X—
 Xiao, Hong: 425
 Xie, Jing: 569
 Xie, Yan: 539LB
 Xu, Cuiling: 258LB
 Xu, Hua: 273
 Xu, Huifang: 970
 Xu, Jiahong: 779
 Xu, Lanfang: 54
 xu, Min: 506
 Xu, Stella: 725
 Xu, Xia: 470
 Xu, Xiaoho: 722
 Xu, Yin: 233, 334
—Y—
 Yamada, Chisato: 253
 Yamaguchi, Julie: 212
 Yamamoto, Masahiro: 670
 Yamamoto, Takuya: 336
 Yamaoka, Shoji: 203
 Yan, Mingjin: 29
 Yan, Peng: 581
 Yandura, Sarah E.: 874
 Yang, Bin: 926, 969
 Yang, Blia: 114
 Yang, Chunfu: 516, 850
 Yang, Dongmei: 481, 579
 Yang, Jenny C.: 573, 601
 Yang, Jing: 286
 Yang, Ligang: 926
 Yang, Otto: 672, 939
 Yang, Shu: **942**
 Yao, Amanda H.: 666
 Yao, Jiqiang: 325
 Yao, Tzy-Jyun: 813, 814
 Yao, Xin: 469LB
 Yasunami, Michio: 314
 Yatchi, Nelly: 621
 Yaylali, Emine: **1051**
 Yazdanpanah, Yazdan: 31LB
 Yeatman, Sara: 793
 Yebrá, Gonzalo: **210**
 Yee, Kelly: 456
 Yehia, Baligh R.: 1001
 Yek, Christina: **587**
 Yephthomi, Tokugha: 753
 Yerly, Sabine: 951
 Yi, Anji: 142
 Yi, Yanjie: 24
 Yin, Li: **325**
 Yin, Michael T.: 40, **700**, 720
 Yin, Peng: 702
 Yip, Benita: 492LB
 Yogeve, Ram: 562, 823
 Yokoyama, Masaru: 505
 Yoltz, Jason: **198**
 Yong, Huang: 326
 Yosef, Nir: 19
 Yoshimura, Kazuhisa: 505
 Yoshinaga, Noriyoshi: 202
 Yosief, Sarah: 401, 402
 Yotebieng, Marcel: 746
 Younas, Mehwish: 276, **282**
 Younes, Souheil-Antoine: 732
 Young, Alicia: 103, 104, 523, 982
 Young, Benjamin: 698
 Young, Mary: 390, 416, 422, 647, 691
 Young, Peter W.: 909
 Young, Rebekah: 42
 Yu, Fahong: 325
 Yu, Jian: 469LB
 Yu, Kim: 585
 Yu, Qilu: 809
 Yu, Wen-Han: **308**
 Yu, Xu G.: 19, 347
 Yuan, Sally: 369
 Yuan, Xin-Yong: 319
 Yudin, Mark: 622, 949
 Yuki, Steven A.: **80**, 298
 Yun, Chohee: 154LB
 Yuste, Eloisa: 303

-Z-

- Zadzilka, Amanda: 825
 Zahn, Jennifer: **968**
 Zakharova, Natalia: 472
 Zampino, Rosa: 608
 Zanni, Markella V.: 638, 640, **650**, 664
 Zannou, Marcel: 565, 962, 1015
 Zanolini, Arianna: 960
 Zapata, Juan: 368
 Zar, Heather J.: 852, 854
 Zash, Rebecca: **802**
 Zaslow, Shayne: 890
 Zaunders, John J.: **233**, **334**, 365
 Zazzi, Maurizio: 486
 Zeidan, Joumana: 358LB
 Zeller, Georg: 260
 Zerbato, Jennifer M.: 341, 376, **377**
 Zerbe, Allison: 34, 757, 795, 799, 808, 988, 997, 1038
 Zetola, Nicola: 755
 Zevin, Alexander: 263, 263
 Zhang, Baoshan: 310LB
 Zhang, Fujie: 446
 Zhang, Guangxiang: 652
 Zhang, Jingyang: 872
 Zhang, Sandra: 437LB
 Zhang, Sharon: 97
 Zhang, Shimin: 875, 876
 Zhang, Tianchi: 211
 Zhang, Wei: 154LB
 Zhang, Wei: 926, 926
 Zhang, Wendy: 227, 492LB
 Zhang, Yafeng: 717
 Zhang, Yanzhao: 203
 Zhang, Ye: 926, 969
 Zhang, Yonglong: 410
 Zhang, Zhou: 321
 Zhang-Roper, Rebecca: 818, 1120
 Zhao, Peng: 308
 Zhao, Runze: 397
 Zhao, Yuteng: 970
 Zheng, Jialin C.: 397
 Zheng, Lu: 30
 Zheng, Wenjing: **985**
 Zhong, Fei: 970
 Zhong, Jianhui: 392
 Zhou, Jhingling: 711
 Zhou, Nannan: 575
 Zhu, Ting: 569
 Zhu, Tong: 383
 Zhuang, Yuchuan: 392
 Ziada, Adam S.: 716
 Zielinski-Gutierrez, Emily: 903
 Ziemniak, Carrie: 825, 838
 Zimmer, Bonnie: 458, 824
 Zingman, Barry: 1038
 Zoellner, Cindy L.: 587
 Zolopa, Andrew: 745
 Zook, Katie: 651, 687
 Zoungrana, Jacques: 696
 Zuccotti, Gianvincenzo: 819
 Zucman, David: 549
 Zuhlke, Lies: 854
 Zúñiga, Joaquín: 251
 Zunt, Joseph: 636
 Zürcher, Kathrin: 737, 1021
 Zvonar, Ivan: 305
 Zwierski, Sheryl: 37
 Zydowsky, Thomas: 875, 876

KEYWORD INDEX

- 12-week use - 44LB, 153, 816, 932
 2-LTR circles - 196, 211, 362, 745
 2B4 - 161, 211
 3TC - 281
 4E10 epitope - 305, 976
 4th-generation immunoassay - 521, 523, 964
- A-**
- A20/TNFAIP3 - 235
 Abacavir - 660, 661, 663
 ABC-3TC - 297, 952
 Abnormal uterine bleeding - 949
 Abstracts - 478
 ACA - 967, 1001
 Acceptability - 156, 873, 883LB, 970, 1014
 Access to care - 120, 122, 537, 587, 678, 902, 967, 968, 972, 1014, 1042, 1043
 Acquired drug resistance - 229, 281, 305, 478, 495, 741LB
 Acquired immunodeficiency syndrome - 296, 302
 Actigraphy - 305
 Activation - 251, 290, 291, 302, 653, 826
 Acute - 291
 Acute Hepatitis C - 99, 154LB, 297, 536, 581, 590, 602
 Acute HIV Infection - 13, 21, 87, 133, 188, 187, 219, 269, 287, 320, 349, 384, 404, 407, 414, 415, 418, 518, 521, 524, 727, 942, 927, 956, 964
 Acute kidney injury - 763
 Acute rejection - 572
 Acute Retroviral Syndrome - 518
 Acute SIV - 23, 274, 275LB
 Adaptor protein 2 (AP2) - 191
 Adherence - 96, 99, 283, 476, 793, 795, 844, 873, 894, 919, 1029, 1034, 1039, 1055
 Adherence to ART - 864, 940, 1019, 1022
 Adipose tissue - 123, 271, 668, 702, 707
 Adolescent and young people - 172, 174, 175, 176, 177, 442, 817, 822, 823, 829, 831, 833, 834, 835, 836, 845, 852, 854, 931, 936
 Adults - 17, 55, 349, 419, 565, 640, 915, 940, 948
 Adverse events - 667, 702, 855, 948
- Africa - 28, 75LB, 109LB, 112, 113LB, 118, 120, 167, 212, 227, 419, 436, 564, 565, 624, 625, 676, 696, 771, 801LB, 833, 840, 843, 849, 901, 912, 937, 961, 977, 983, 985, 1019, 1021, 1022, 1042, 1063
 African American - 52, 538LB, 883LB, 929
 Age - 118, 220
 Age specific estimates - 904
 Aging - 145, 183, 279, 382, 396, 421, 646, 669, 670, 705, 709, 712, 715, 716, 719, 720, 721, 905, 938
 AIDS - 265, 554, 614
 AIDS Dementia Complex - 422
 AIDS-related malignancy - 616
 Albuminuria - 651
 Alcohol - 150, 257, 277, 554, 568, 822, 911, 912
 Algorithm - 510, 521
 Alpha 4 beta 7 - 287
 ALVAC/AIDSAX - 317
 Amphotericin B deoxycholate - 763
 Anal cancer - 620, 628, 626, 633
 Anal HPV subtyping - 626
 Anal HSIL - 626
 Anal intercourse - 887, 882LB
 Anal swabs - 628
 Analytic treatment interruption (ATI) - 32LB, 92, 346, 347
 Anatomical site - 331, 345
 Anthropometric - 852
 Anti-calcineurin immunosuppressive drugs - 162, 455
 Anti-PD-L1 - 25
 Antibodies - 15, 311LB, 504, 840
 Antibody Neutralization - 15
 Antibody response - 92, 318, 323, 830
 Antibody-dependent cell-mediated cytotoxicity (ADCC) - 180, 181
 Antigen/antibody assays - 521
 Antiretroviral - 63, 71, 702, 961, 999, 1023
 Antiretroviral agents - 32LB
 Antiretroviral drug - 16, 97, 395, 436, 461LB, 466, 505, 506, 662, 696
 Antiretroviral drug transporters - 450
 Antiretroviral failure - 833, 850, 940, 1031
 Antiretroviral pharmacokinetics - 63, 433, 439, 440, 442, 443, 449, 453, 454, 774
- Antiretroviral Therapy (ART) - 16, 22, 41, 53, 87, 112, 118, 119, 121, 122, 126, 147, 151, 155, 160, 164, 167, 229, 252, 257, 265, 280, 290, 293, 330, 350, 384, 406, 418, 429, 434, 443, 445, 446, 462, 465, 473, 474, 475, 480, 491LB, 496, 512, 559, 561, 566, 567, 592, 613, 617, 618, 619, 621, 646, 660, 672, 677, 678, 679, 680, 692, 703, 707, 709, 728, 729, 734, 736, 751, 755, 761, 805, 812, 838, 844, 851, 853, 906, 910, 923, 930, 939, 940, 941, 944, 949, 954, 956, 957, 958, 989, 1003, 1020
- Adherence - 27, 834, 1031
 - Care evaluation - 35LB, 1028
 - Cascade - 119, 1014
 - Coverage - 111, 163, 904, 954, 1023, 1025
 - Initiation - 28, 38, 665, 1010, 1012, 1014
 - Intensification - 950
 - Naïve - 821
 - Outcomes - 39, 122, 744, 771, 796, 813, 821, 845, 849, 943, 951, 1022, 1029, 1032
 - Patients - 85, 860
 - Program monitoring - 119, 1013, 1041
 - Scale-up - 122, 789, 860, 1012, 1023, 1041, 1056
 - Switch - 953
 - Atorvastatin adjunct therapy, Africa - 297
- Antiretroviral tissue penetration - 447, 450, 874
 Antiretroviral treatment - 55, 458, 552, 697, 788, 794, 800, 824, 840, 1017
 Antituberculosis treatment - 155, 158LB 180, 458, 734, 741LB, 746, 753
 Antiviral activity - 247, 464, 874
 Antiviral Factor - 203
 Antiviral therapy - 466
 Anxiety - 414
 APOBEC3 - 59, 199, 201, 629
 APOBEC3F - 59
 APOBEC3G/F - 81, 83, 629
 APOBEC3H - 200
 APOE - 145
 Apoptosis - 243
 Appointment reminders - 977
 Archival HIV-1 - 140
 Asia - 314, 349, 569, 831, 858
 Aspergillosis - 764
 Aspirin - 44LB
 Assay - 83
 Association study - 937

- Astrocyte - 393
 Asymptomatic infection - 72LB
 Atazanavir/ritonavir - 417, 428, 692, 753, 774
 Atherosclerosis - 640, 654, 656, 658, 673
 Atorvastatin - 551
 Atripla - 706, 945
 Attrition - 118
 Awareness - 974
- B-**
- B cell responses - 127, 324
 B cells - 127
 B-type Natriuretic Peptide (BNP) - 646
 Bacterial functions - 474
 Bacterial translocation - 187, 239
 Balance - 895
 Barriers to care - 1016, 1042
 Basal ganglia - 823
 BCG - 824
 Behavioral - 55, 917, 931, 934, 969, 993
 Big data - 4
 Bimolecular fluorescence complementation (BiFC) - 191
 Biodegradable implant - 879
 Bioenergetics - 144
 Bioinformatics - 260, 481, 950
 Biomarker - 276, 342, 410, 540, 660, 671, 685, 691, 715, 865, 939
 Birth outcomes - 799
 Birth PCR - 783, 785
 Bispecific antibodies - 94
 Bispecific antibodies - 469LB
 Black MSM - 893, 897, 930
 Blimp-1 - 153
 Blood pressure - 677
 BMS-626529 - 460, 472
 BMS-663068 - 460, 472
 BMS-955176 - 425, 464, 466
 Body composition - 40, 722
 Body mass index - 677
 Bone - 36, 40, 46, 47, 699, 819
 - Renal safety - 808
 - Disease - 46, 126, 694, 698
 - Marrow - 365
 - Marrow monocytes/macrophages - 403
 - Mineral density (BMD) - 48LB, 695LB, 696, 698, 859
 - turnover markers - 47, 126, 694, 859
- Boosted - 452
 Botswana - 37, 111, 784, 802, 805, 810, 904, 984
 Brain - 175, 822
 Brain structure - 384, 386, 387, 388, 389
 Breakthrough HIV Infection - 479LB
 Breastfeeding and breast milk - 441, 449, 828
 Broadly neutralizing antibodies - 32LB, 89LB, 90, 186, 302, 309LB 303, 311LB
 Bryostatins-1 - 354
 BST-2/Tetherin - 181, 246
 Burden of disease - 52, 679
 Bystander pathogenesis - 243
- C-**
- Cabotegravir - 31LB, 71, 105, 106, 881
 Canada - 622
 Cancer - 86, 160, 162, 331, 613, 620, 622, 629, 811
 - Risk - 604, 615
 - Stage - 614
 - Survival - 614, 615, 616
- Cannabinoid receptor 2 - 557
 Capsid - 196, 197
 Cardiac abnormalities - 853
 Cardiometabolic health - 722
 Cardiovascular - 41, 646, 659, 660, 671
 Cardiovascular disease - 43, 636, 638, 640, 642, 644, 646, 648, 650, 653, 655, 658, 662, 664, 665, 673, 675, 676, 687, 854 -
 - Risk factors - 636, 637, 642, 644, 646, 647, 659, 661, 662, 666, 675, 704, 711, 715, 722, 914
- Cardiovascular markers - 657
 Care retention - 993, 1002, 1042
 CARE+ - 997
 Care-delivery model - 68, 534
 Carotid intima-media thickness - 643, 651, 656, 672, 674
 cART - 160, 295, 382, 569, 831
 Cascade of care - 28, 120, 1042, 1043, 1051
- Case-control study - 293, 640, 824
 Caspase-1 - 241
 Caspase-3/7 - 241
 Causal inference methods - 942
 Cause of death - 941
 Cause-specific mortality - 911, 941
 CBF β - 199, 202
 CCR5 - 78, 296, 306, 357, 358LB, 552, 781
 CCR5 expression - 242, 655
 CCR6 - 188
 CD1a - 288
 CD34+ hematopoietic stem cells - 295
 CD4 T cell - 58, 186, 244, 254, 271, 334, 369, 946
 - Count - 304, 386, 486, 942
 - Death - 187, 241, 243
 - Depletion - 188, 262
 - Nadir - 386
 - Receptor - 191, 193
 - Reconstitution - 233, 252
 - Recovery - 234, 295, 335, 473, 751
 - Response - 944 CD4 CD8
 - Ratio - 278, 291, 326, 408, 633, 710, 729
- CD8 T cell - 248, 269, 274, 312, 313, 407, 732, 827
 CD8 T cell suppression - 22, 374
 CD9 - 250
 CDK - 207
 Cell activation - 244, 653
 Cell associated HIV DNA - 85, 300LB, 330, 349
 Cell associated HIV RNA - 85, 245LB, 330
 Cell cycle - 183, 207, 251
 Cell death - 251, 295, 372
 Cell traffic brain macrophages - 141
 Cell-free mtDNA - 715
 Cell-to-cell infection - 393
 Cell-to-cell transmission - 184, 186
 Cellular factors/Cytokines - 244
 Cellular model - 360
 Cenicriviroc - 239
 Central fat - 704
 Central memory T cells - 251, 335
- Central nervous system (CNS) - 60, 63, 142, 144, 388, 392, 395, 398, 400, 405, 412
 Cerebrospinal fluid (CSF) - 404, 405, 407, 411, 412, 413, 446, 767
 Cerebrovascular - 43, 640
 Cervical cancer - 162, 615, 617, 621, 625
 Cervical cancer screening - 162, 623, 624, 625
 CHARTER score - 420
 Chemokine - 254, 274
 Chemokine receptor - 239
 Chemsex - 913
 Children - 302, 442, 619, 840, 841, 842, 843, 850, 1023
 - Child mortality - 802
 - Childhood tuberculosis - 746, 748
- China - 969, 970
 Chlamydia - 922, 1005
 Chlamydia trachomatis - 1004, 1006
- Cholesterol - 145, 643, 659
 Chronic Hepatitis B - 564, 568, 569
 Chronic Hepatitis C - 10, 66, 151, 528, 529, 530, 531, 538LB, 548, 574, 581, 583, 587, 604
 Chronic HIV infection - 245LB, 387, 396, 403, 528, 654, 673, 708
 Chronic Inflammation - 240, 271, 654
 Chronic kidney disease - 686, 687, 691
 Chronic lung disease - 724, 725
 Churn - 992
 Circulating recombinant form (CRF) - 213
 Circumcision - 165, 987
 Cirrhosis - 124, 422, 527, 550, 551, 574, 603, 610
 Clade C - 317
 Clinical management - 177
 Clinical monitoring - 1005
 Clinical outcomes - 53, 256, 345, 587, 611, 960
 Clinical parameters - 227
 Clinical pharmacology - 445, 449, 453, 777, 815

- Clinical prediction rule - 742
 Clinical trial - 25, 26LB, 354, 436, 443, 494LB, 681, 700, 741LB, 816, 817, 873
 Clonal expansion - 84, 85, 337, 339, 340, 361
 Clonal HIV populations - 339, 361
 Cluster Randomized Trial - 50, 155, 219, 691, 985
 CMV - 779, 780
 Coagulation - 430, 714
 Cobicistat - 430, 459
 Cocaine - 693
 Codon-pair bias - 227
 Coffee - 549
 Cognition - 422
 Cognitive impairment - 144, 387, 421, 721
 Cognitive performance - 148, 822
 Cohort - 283, 860
 Cohort study - 54, 227, 350, 421, 582, 584, 605, 698, 715, 943, 948
 Coinfection - 526, 528, 583, 596, 755
 Combination ART - 728
 Community based - 70, 538LB, 983, 985
 Community viral load - 1025, 1036
 Community-Acquired Pneumonia - 769
 Community-based HIV testing and counseling - 111, 740, 972, 975, 976, 983, 1059, 1061, 1062
 Community-based intervention - 120, 436, 980
 Comorbidity - 126, 612, 637, 690, 709, 713
 Comorbidity - 801LB
 Compartmentalization - 143, 398, 400, 402, 406
 Computer counseling intervention - 997
 Computer simulation model - 336
 Condoms - 863, 887, 1041
 Continuum of care - 738, 994, 1002
 Controllers - 261, 338
 Copy Number Variation - 201
 Coreceptor switch - 306, 307
 Coronary artery disease - 644, 648, 675
 Coronary artery plaque - 648
 Correlates of protection - 179
 Cortical Thickness - 385
 Cost - 1050, 1059, 1061, 1062
 Cost model - 115
 Cost-effectiveness - 115, 536, 773, 945, 1052, 1056, 1058
 Cotrimoxazole - 37, 773, 784, 801LB, 858
 Couples - 49
 CRF01_AE - 314
 CRF02_AG - 222
 Cross-reactivity - 313
 Cross-sectional incidence testing - 511, 517, 520, 540, 976, 984
 Cross-sectional study - 715, 1025
 Crushing - 431
 Cryptococcal antigenemia - 159, 759, 760, 761
 Cryptococcal meningitis - 159, 759, 760, 762, 763
 Cryptococcosis - 760, 762
 Cryptococcus titers - 159
 CSF biomarkers - 413
 Cure - 342
 CVD - 664
 CX3CR1 - 732
 CXCR4 - 306, 393
 Cycling of Engagement - 1042
 Cynomolgus monkey - 206, 319
 CYP2B6 - 458
 Cytokines - 259LB, 762
 Cytomegalovirus (CMV) - 729, 730, 731, 732
 Cytotoxic T lymphocytes (CTL) - 13, 23, 94, 130, 259LB, 269, 300LB, 320, 374
- D-**
 D-dimer - 645
 DAA-based therapy - 589
 Daclatasvir - 575, 577
 Dapivirine - 872, 873, 1057, 1058
 Dapivirine Vaginal Ring - 110LB
 Darunavir - 459, 574, 692, 775
 Dasatinib - 468
 Data linkage - 1053
 DBS - 511
 DC-SIGN - 547
 ddPCR - 362
 De novo immunogen design - 308
 Decentralization - 789
 Deep sequencing - 231
 Defective provirus - 83
 Democratic Republic of Congo - 213
 Dendritic cells - 19, 128, 185, 186, 270, 288, 328
 Depression - 414, 714, 919, 920, 1037
 Developmental pharmacology - 440
 Diabetes - 610
 Diabetes mellitus - 647, 706
 Diagnosis - 767
 Diagnostic accuracy studies - 787
 Didanosine - 811
 Diet - 266, 657
 Diffuse tensor imaging - 821
 Direct transmission - 184, 220
 Direct-acting antiviral (DAA) - 97, 455, 583, 585, 587, 600, 610
 Directly-active-antiretroviral - 599
 Disability - 721
 Disclosure - 906, 974
 Discontinuation - 765
 Disparities - 721, 902, 990, 994, 1033
 Disparity - 52
 Diversity - 86, 179, 212, 331
 DNA damage - 282, 629
 DNA vaccine - 259LB
 Dolutegravir - 432, 438, 462, 508, 589, 660, 816, 947, 948, 953
 Dolutegravir resistance - 480, 507
 Dolutegravir resistance - 492LB
 Doravirine - 456, 470, 506
 Dorsal root ganglia - 272
 Drip feed - 431
 Droplet digital PCR - 7
 Drug - 363
 • Combinations - 454, 462
 • Discovery - 505
 • Distribution - 412
 • Interactions (DTG) - 10, 100, 430, 453, 455, 456, 459, 589, 1050
 • Resistance - 16, 477, 498, 504, 543, 756, 847, 850
 • Resistance mutations - 210, 406, 462, 465, 480, 483, 487, 488, 499, 505, 507
 • Resistance surveillance - 492LB
 • Resistance testing - 976
 • Use - 149, 913, 915, 1041
 Drug-resistant tuberculosis - 157, 754, 755
 Dual Therapy - 424LB
 DXA - 817
 Dyslipidemia - 665, 854
- E-**
 E/C/F/TAF - 496, 817
 Early
 • Antiretroviral Therapy - 320, 473, 659, 843, 990
 • ART start - 143, 291, 352, 942
 • Diagnosis - 522, 675, 829
 • HIV infection - 927
 • HIV infection - 35LB
 • Infant Antiretroviral Therapy - 658, 786
 • Infant diagnosis - 782, 785, 786, 787, 788
 • Infection - 84
 • Mortality - 155, 747, 957
 • Treatment - 1043
 East Africa - 773, 979, 1062
 Ebola - 72LB, 73LB, 74LB, 75LB, 76LB, 77LB, 910
 Echocardiography - 649, 853
 Economic evaluation - 834

Efavirenz - 429, 433, 441, 444, 446, 458, 470, 862, 945, 963
 EfDA - 98
 Effectiveness - 121, 1055
 Effector/memory - 254, 299
 Efficacy - 469LB, 495, 810, 818, 1120
 Efficacy and safety - 472
 Efficiency - 945
 EFV - 40, 101
 EFV400 - 1050
 eGFR - 693, 857
 Electronic adherence monitoring - 1029
 Elimination - 1044
 ELISA 4th generation - 522
 Elite controller - 19, 190
 Elvitegravir - 431, 480
 Emergency department - 532
 Emtricitabine - 104, 107, 449, 866
 End-stage liver disease - 11, 150
 End-stage renal disease - 688
 Endothelial dysfunction - 653, 654
 Endothelium - 663
 Engagement in care - 996, 1008, 1009
 Entry inhibition - 97, 505
 Env - 398, 505
 Envelope - 33, 303, 307, 398, 505, 602
 Eomes - 254
 Epidemic classification - 1046
 Epidemiology - 51, 52, 64, 174, 216, 526, 536, 541, 583, 590, 616, 624, 736, 890, 905, 915, 974, 1036, 1060
 Epigenetics - 294, 463, 725, 851
 Epithelial cells - 235, 725
 Epitope - 152, 303, 313
 Epstein-Barr virus - 630, 780
 Eradication - 25, 353
 ERAP - 667
 ERCHIVES - 581
 ESRD - 432
 Europe - 486, 630, 1044
 EWAS - 851
 Ex vivo - 245LB, 285
 Executive function - 390
 Exercise - 719
 Exhaustion - 269, 596, 826
 Exosomes - 250, 559
 Explant - 874
 Exposure-Response - 425
 Extended Duration - 98
 Extracellular Vesicles - 397

-F-
 Falls - 720
 False-positive diagnoses - 516, 786

False-recent rate - 540
 Family environment - 931
 FDG-PET/CT - 343, 344
 Female reproductive tract - 268, 284, 285
 Female sex workers - 226, 912, 973, 1047, 1059
 Fertility desire - 864
 Feasibility - 970
 Fetal - 36
 FGF-23 - 651
 FibroScan - 606
 Fibrosis - 273, 298, 528, 551
 Financial incentives - 1038
 First-line ART failure - 476, 482
 Fisherfolk - 903, 954, 986
 Fixed-dose combination - 963
 Flagellin - 239
 Flow cytometry - 253, 411
 Fluconazole prophylaxis - 159, 760, 761
 Food insecurity - 935
 Fracture - 46, 698, 699
 Frailty - 709, 719, 723
 Functionality - 720
 Fungal infection - 764
 Fusion inhibitors - 97

-G-

Gag - 137, 195, 197, 314, 465
 Galectin-9 - 81
 Gastric cancer - 635
 Gastrointestinal - 236
 GBV-C - 326
 Gender - 416, 744, 918
 Gender Disparities - 416, 476, 531, 1015
 Gene editing - 78
 Gene editing - 358LB
 Gene expression - 251, 324, 880
 Gene therapy - 78, 356, 357
 Genetic diversity - 226, 959
 Genetic polymorphism - 247
 Genetic polymorphisms - 444, 445
 Genetic variant - 149, 780
 Genetics - 17
 Genital - 284
 Genital tract of women - 102LB
 Genital tract sampling - 439, 987
 Genome - 20
 Genome-wide association - 499
 Genomics - 737
 Genotype - 525
 Geographic differences - 214
 Geographic origin - 943
 Germinal center - 233, 334
 GHESKIO - 750, 1017

Global - 174, 1060
 Global Hepatitis Outbreak and Surveillance Technology (GHOST) - 149
 Glucose metabolism - 711
 Glutaminase - 397
 Glycosylation - 81
 Gonorrhea - 922, 1005
 gp120 - 181, 724
 gp160 trimer - 138
 gp41 motif - 304
 Group sex - 926
 Growth - 852, 858
 Guidelines - 643, 832, 869
 Guinea - 75LB
 Gut associated lymphoid tissue (GALT) - 233, 238, 348, 450
 Gut homing - 274, 289
 Gut immunology - 187, 235, 237, 262
 Gut microbiome - 261, 262, 657
 Gut microbiota - 21, 260, 266
 GWAS - 601

-H-

HAART - 589, 707, 724, 959, 1039
 Hair concentrations - 866
 Haiti - 473,
 HAND - 144, 146, 388, 389, 406, 420
 Harm reduction - 533
 HAV/HBV responsiveness - 329
 HBsAg - 570
 Health care providers - 892, 966
 Health district - 910
 Helicobacter pylori - 635
 Heme oxygenase-1 - 394
 Hemodialysis - 432
 Hepatitis - 124, 591
 Hepatitis B Virus (HBV) - 150, 562, 563, 566, 567, 571, 607, 804
 Hepatitis B Virus (HBV)-HIV co-infection - 567
 Hepatitis C virus (HCV) - 11, 64, 149, 150, 329, 525, 526, 527, 532, 533, 534, 535, 537, 539LB, 540, 542, 543, 544, 546, 549, 551, 554, 556, 557, 575, 577, 578, 579, 595, 597, 600, 606, 607, 608, 611, 639, 693, 804

- Continuum of care - 587
- Genotype 6 - 606
- HIV coinfection - 9, 100, 329, 413, 527, 541, 545, 550, 556, 559, 573, 574, 575, 582, 584, 605, 610
- Incidence - 64, 544, 546
- Inhibitors - 525
- NS5A - 578, 579

- RAWs - 539LB, 578, 579
- Sequence - 541
- Testing - 525, 976
- Treatment - 10, 11, 12, 153, 536, 580, 581, 582, 588, 598, 600, 611
- Hepatitis D - 592
- Hepatitis E virus - 593, 594
- Hepatocellular carcinoma - 551, 566, 604, 634
- Herpes simplex virus - 935
- Heterogeneity - 1049
- Heterosexual - 231
- Heterosexual women - 1045
- HEV seroprevalence - 594
- High screening viral load - 952
- High-Env HIV - 138
- High-grade anal intraepithelial neoplasia - 161, 627
- High-risk - 986, 1031
- Highly exposed seronegative - 268
- Histone acetyltransferase - 463
- Histone deacetylase inhibitor - 348
- Histopathology - 272, 345
- HIV - 50, 51, 70, 115, 116, 139, 166, 181, 196, 226, 235, 246, 261, 267, 343, 344, 365, 382, 389, 393, 427, 437LB, 474, 491LB, 511, 549, 553, 554, 562, 572, 617, 618, 619, 623, 690, 714, 720, 772, 775, 823, 841, 863, 898, 918, 928, 957, 958, 960, 999, 1015
- Adherence - 835, 952
- Associated neurocognitive disorders (HAND) - 60, 146, 381, 389, 390, 392, 398, 399, 403, 412, 417, 419, 424LB, 821
- Associated neurocognitive impairment - 382, 410
- Associated non-AIDS - 710
- Asymptomatic Long-Term Non-Progressors - 304
- Care - 761, 849, 908, 991, 996, 1033
- Care cascade - 51, 117, 169LB, 899, 1011
- Care continuum - 113LB, 992, 1043
- Clinician survey - 1038
- Coinfection - 546, 590, 591, 565, 743
- Comorbidity - 632
- Control - 312
- Cure - 94, 363, 364, 376
- Diagnosis - 513, 514, 523, 39, 901
- Disease progression - 195, 248, 302, 731
- DNA - 143, 350, 362, 946
- DNA decay - 837, 838
- DNA reservoir - 351, 364, 365, 839, 950
- Drug resistance - 481, 482, 485, 487, 494LB, 496, 502
- Drug resistance testing - 500, 501, 990
- Encephalopathy of childhood - 820
- Epidemic - 222, 1047
- Exposed infants - 36, 782, 784, 808, 810
- Exposed uninfected - 17, 247, 802
- Exposed uninfected children - 800, 813, 814
- Fitness - 230
- Glycan heterogeneity - 308
- Immunology - 13, 236, 244, 298, 939
- Immunology and vaccine responses - 309LB, 313, 327
- Incidence - 511, 514, 517, 830, 886, 895, 901, 917, 936, 965, 984
- Infected Adolescent - 175, 852
- Infected adults - 436, 672, 698, 947, 981
- Infected CD4, NK cells - 26LB, 135, 178, 341
- Infected children and adolescents - 802, 814, 821, 857
- Infected men who have sex with men - 222, 351, 542, 591, 627, 922, 923
- Infected patients - 276, 282, 437LB, 97, 552, 563, 696
- Infected population - 591, 622, 982, 1026
- Infection - 171, 177, 267, 271, 470, 500, 571, 637, 648, 669, 804, 861, 991
- Inflammation, immune activation - 135, 269, 297, 380, 411, 674, 781
- Interventions - 171, 834, 893, 1044
- Latency - 193, 354, 355, 360, 362, 363, 369, 370, 373, 375, 377
- LTR - 226, 337
- Malignancies - 615, 632
- Mortality - 909, 994
- MTCT - 779, 781, 791
- National program - 35LB, 168LB
- Neurocognitive disorder - 408, 409
- Pathogenesis - 89LB, 209LB, 298, 397, 598
- Patient survey - 1038
- Persistence - 298, 337, 345, 348, 374
- Positive children - 38, 820, 824, 837, 848, 858, 860
- Positive unaware - 224
- Positive women - 609, 622, 771, 775, 791, 792
- Prevalence - 983
- Prevention - 68, 69, 165, 172, 469LB, 517, 524, 872, 881, 884, 888, 891, 892, 893, 902, 936, 973, 1000, 1049, 1058
- Production - 137
- Proviral transcription - 193, 380
- Provirus - 83, 139, 380
- Recent (early) infection - 224, 303
- Recombination - 18LB
- Replication control - 135, 352
- Reservoir - 259LB, 271, 336, 350, 352, 298, 300LB, 334, 343, 348, 370, 377, 417, 450
- Restriction and host factors - 135
- Risk - 770, 829, 918, 929, 931, 935, 937
- RNA - 192, 290, 904, 946
- RNA suppression - 234, 687, 1026
- Self-testing - 970, 971, 973
- Seroconversion - 917
- Serodiscordant couples - 988, 1026
- Shedding - 621, 987
- Status - 644, 903, 906, 907, 981, 991
- Subtype - 89LB, 195, 226
- Superinfection - 228
- Surveillance - 485, 516, 909, 990
- Surveillance data - 217, 915, 1033, 1036, 1053
- Susceptibility - 17, 165, 182
- Testing and counselling - 113LB, 120, 176, 510, 513, 516, 524, 829, 901, 903, 909, 965, 966, 967, 973, 978, 979, 982, 988
- Transmission - 17, 133, 230, 232, 268, 284, 285, 286, 864, 903, 926, 1036, 1045, 1049
- Transmission clusters - 216, 217
- Transmission networks - 5
- Treatment - 469LB
- Treatment as prevention - 1007
- Unexposed uninfected - 692, 800
- Vaccine - 259LB, 376
- Vaccine Trial - 318
- Viral evolution - 192, 806
- Viral load - 512, 794, 822, 991, 1033, 1034, 1036
- HIV-Tuberculosis coinfection - 615, 740, 741LB, 733, 1016
- HIV/CMV coinfection - 730, 732, 781
- HIV/HAV coinfection - 591
- HIV/STD coinfection - 1008, 1009
- HIV-1 - 18LB, 31LB, 137, 185, 192, 199, 200, 202, 205, 223, 303, 311LB, 325, 367, 464, 498, 776, 811, 999
- Assembly and maturation - 137
- Attachment inhibitor - 460, 472, 480
- Cell-associated RNA - 300LB, 380
- Diversity - 213
- Eradication - 95LB, 366, 372
- Evolution - 338, 495
- Group N - 212
- Infection inhibition - 247
- Infection phenotypes - 260
- Inhibition - 463

- Integration - 360
 - Latency – 261B, 180, 341, 359, 371, 374, 376
 - Mouse model - 399, 447
 - Neutralization - 311LB
 - Persistence - 81, 95LB, 255, 300LB, 330, 379, 380, 402
 - Prevention - 109LB
 - Prevention Microbicides - 110LB
 - Reactivation kinetics – 32LB, 369, 370
 - Reservoir - 182, 468
 - RNA – 164, 437LB
 - Single-copy assay - 25
 - Specific t cells - 19, 25
 - Subtype c - 520, 904
 - Subtypes - 210, 485
 - Subtyping - 211
 - Transmission – 18LB, 351, 487
 - Vaccine - 19, 195, 317
 - Viral load - 864, 1035
 - HIV-2 - 214, 253, 508, 509, 944, 961
 - HLA - 713
 - HLA alleles - 555
 - HLA class I - 253, 256, 314, 315, 667, 827
 - HLA-associated polymorphisms - 828
 - HLA-B57.01 - 197, 667, 713
 - Home testing and counseling - 49, 51, 980, 981, 988, 1063
 - Hormonal contraception - 6, 284, 862
 - Hospitalizations – 38, 590, 708, 772
 - Host factors - 182, 189, 248, 284, 371
 - Host genetics - 20, 201, 547, 601
 - Host restriction factors - 134, 201, 205, 207
 - Host-pathogen interaction - 59, 189, 205
 - Host-pathogen interaction - 209LB
 - Host-virus interactions - 139, 189, 208
 - Hotspots – 72LB, 1019
 - HPV - 623, 625, 626, 627, 628
 - HSCs - 78
 - HSIL - 625
 - HSP70 - 250
 - HSV-2 - 728
 - HTLV-3 - 212
 - Human herpesviruses - 727
 - Human immunodeficiency virus - 686, 785, 968
 - Human papillomavirus - 161, 628
 - Humanized mice - 469LB
 - Humans - 242
 - Humoral response - 325
 - Hyperacute infection - 488
 - Hypertension - 637, 647, 676, 856
- |—**
- IFN - 19, 238
 - IFN-g - 355, 730
 - IgG - 593
 - IgG Subclasses - 318
 - IL-18 - 569
 - IL-33 - 237
 - IL-6 - 278
 - IL-7 - 252
 - Illumina MiSeq - 360
 - Imaging - 61, 447
 - Immigrant - 173
 - Immune - 236
 - Activation - 21, 44LB, 142, 237, 238, 264, 270, 276, 277, 278, 280, 282, 326, 404, 408, 467, 597, 599, 656, 689, 717, 729, 731, 825
 - Exhaustion - 277, 939
 - Reconstitution - 280, 294
 - Reconstitution inflammatory syndrome (IRIS) - 299, 726, 734, 762, 824
 - Recovery - 562
 - Response – 89LB, 179, 248, 731
 - Restoration – 278
 - Senescence - 689
 - Immunodeficiency - 686
 - Immunodiscordant individuals - 335
 - Immunoglobulin A - 233
 - Immunohistochemistry - 405
 - Immunologic biomarker - 695LB
 - Immunologic failure - 502
 - Immunologic response - 347, 365, 473, 1015
 - Immunoprophylaxis - 90
 - Immunosenescence - 291, 709, 939
 - Immunotherapy - 77LB
 - Impact evaluation - 163
 - Impairment - 147
 - Implantable - 71
 - Implementation science - 869, 891, 981, 1019
 - Incidence - 166, 517, 563, 639
 - Assay - 511, 517, 895
 - Rate – 617, 896, 1007
 - Tuberculosis – 757
 - India - 918, 928, 1032
 - Inducible HIV-1 - 80, 377
 - Infant - 88, 440, 441, 807, 815, 803
 - Infant antiretroviral prophylaxis - 778, 801LB, 810
 - Infected CD4+ T cells - 208
 - Infection risk - 55
 - Inflammasome - 280, 880
 - Inflammation - 279, 283, 285, 350, 561, 609, 656, 711, 987
 - Inflammation markers - 44LB, 351, 412, 414, 428, 600, 653, 656, 854, 946
 - Inflammatory biomarkers - 234, 239, 264, 283, 293, 671, 695LB, 714, 717, 718, 825
 - Influenza vaccination – 324, 325
 - Inhibitors of tyrosin kinases - 468
 - Inhibitory quotient - 506
 - Injectable contraception - 861, 865
 - Injection drug use - 12, 152, 546, 597, 712, 898, 916, 918
 - Innate immunity - 256, 294, 371, 597
 - Innate lymphoid cells - 275LB
 - Insulin - 610
 - Insurance - 999, 1000, 1001
 - Integrase - 139, 507
 - Integrase Inhibitor (INI) - 106, 947, 961, 1034
 - Integrase Resistance - 481, 492LB, 501
 - Integrase strand transfer inhibitor - 438, 953
 - Integrated care – 534, 789
 - Integrated DNA - 204, 359, 362
 - Integration sites - 337
 - Interferon alpha - 133, 134, 290
 - Interferon gamma - 758
 - Interferon responses - 209LB
 - Interleukin 6 - 645
 - Interleukin-7 - 274
 - Internet - 889, 924
 - Intra-dermal immunization - 323
 - Intrauterine growth - 799
 - Invasive Pneumococcal Disease - 768
- K—**
- K65R - 503
 - Kaposi sarcoma - 618, 619, 631
 - Kenya - 562, 621, 909
 - Key populations – 220, 899, 979, 1032, 1046
 - Kidney - 685, 686, 689, 690, 693
 - Kidney function - 680, 681, 682, 686, 687
 - Killer-cell immunoglobulin-like receptor (KIR) - 256, 314, 315
 - KIR2D - 315
 - KIR3DL1/S1 - 178
 - Kynurenine-to-tryptophan (KT) ratio - 267, 326
- L—**
- Lamivudine - 563, 815
 - Language impairments - 813, 814
 - Late HIV diagnosis - 965, 1043
 - Latency – 359, 375
 - Latency models - 193, 204, 359, 367, 370, 373, 375, 378
 - Latency reversing agents - 81, 204, 371, 373, 374, 379

- Latent HIV - 80, 359
 Latent HIV-1 reactivation - 80, 363, 370, 378, 379
 Latent HIV-1 reservoir - 83, 375
 Latent reservoir - 336, 375
 Latin America - 958
 LDV/SOF - 588, 601
 LEDGF - 139, 363
 Ledipasvir - 573, 584
 Length of stay - 532
 Lesotho - 738, 988
 Levonorgestrel - 444
 Life expectancy - 54, 941
 Lifetime risk - 52
 Linear mixed models - 486
 Linkage - 220, 490
 Linkage to HIV care - 113LB, 176, 500, 531, 788, 974, 976, 983, 990, 1008, 1009
 Lipid - 553, 664, 672
 Lipid abnormalities - 644
 Lipid profile - 145, 666
 Lipoatrophy - 668, 855
 Lipodystrophy - 45, 123, 668, 707
 Lipohypertrophy - 45, 123, 707, 855
 Lithium - 419
 Liver - 528, 553, 562
 • Biopsies - 151, 556, 600
 • Cancer - 570
 • Cirrhosis - 10, 529, 530, 548, 586, 611, 712
 • Disease - 66, 422, 554, 558, 561, 594
 • Disease progression - 712
 • Enzyme elevation - 776
 • Fat - 553
 • Fibrosis - 527, 552, 555, 558, 560, 568, 606
 • Fuction test - 603
 • Histological steatosis - 10
 • Histology - 556, 557
 • Stiffness - 586
 • Transplantation - 11, 455, 571, 572
 • Related death - 612, 911
 Long-acting - 106
 Long-acting injections - 31LB, 71, 97, 442, 471
 Long-term follow-up - 1002
 Longitudinal study - 384, 388, 814, 826, 833, 859
 Lopinavir - 427
 Loss to follow-up - 34, 121, 796, 1021, 1022
 Low birth weight - 803
 Low-income countries - 512
 LRA - 95LB
 Lubiprostone - 234
 Lung cancer - 633
 Lung function - 255
 Lymph node - 127, 130, 245LB, 259LB 334, 343
 Lymphoid tissue - 23, 130, 184, 241, 242
 Lymphoma - 629, 630
- M-**
- M2-like macrophages - 372
 Macaque - 877
 Macaque model - 130, 405
 Macrophage - 182, 203, 255, 272, 330, 369, 394, 402
 Macrophage activation - 207, 273
 Macrophage tropism - 402
 Macrophage-specific adjunctive therapy - 273
 macrophages travel out of CNS - 141
 Magnetic resonance imaging - 385, 386, 390
 Magnetic resonance spectroscopy - 391
 Maintenance therapy - 31LB
 MAIT cell - 598
 Malaria - 101, 773
 Malawi - 118
 Male circumcision - 163, 165, 1059, 1060
 Male partners - 49, 790
 Mali - 921
 Mapping - 735
 Maraviroc - 103, 104, 147, 448, 694, 695LB, 818, 950, 1120
 MARCH8 - 203
 Marijuana - 257
 Mass Cytometry (CyTOF) - 411
 Mass media - 969
 Maternal Health - 772, 773
 Mathematical model - 51, 442, 466, 533, 786, 1046, 1047, 1049, 1051, 1052, 1055, 1057, 1063
 Maturation - 319
 Maturation inhibitor - 425, 464, 465, 466
 MDM2 - 202
 Measurement - 906
 Medicaid - 534, 1001
 Medical monitoring project - 53, 1037
 Medication Adherence - 952
 Memory B cells - 152
 Men - 935, 980
 Men who have sex with men (MSM) - 48LB, 108LB, 172, 216, 231, 286, 543, 546, 547, 628, 870, 884, 885, 888, 889, 896, 897, 898, 900, 913, 914, 922, 924, 925, 926, 927, 928, 929, 931, 933, 969, 970, 972, 1000, 1006, 1007, 1041, 1044, 1045, 1052, 1060
 Menopause - 650, 863, 872
 Mental health disorders - 920
 Meta-analysis - 383, 957
 Metabolic syndrome - 702
 Metabolism - 706
 Metabolomics - 595, 692, 693, 705, 706
 MHC-1 - 58, 373
 Microbial translocation - 21, 261, 275LB
 Microbicide - 109LB, 871, 872, 875, 876
 Microbiome - 6, 263, 264, 265, 701, 725
 Microbiota - 264, 267
 MicroRNA - 248, 559, 702
 Microtubules - 209LB
 Microvesicles - 250
 Migration - 738, 901, 902
 Minimal Hepatic Encephalopathy - 422
 Minority-resistant variants - 489
 Missed diagnosis - 965, 966
 Missing data imputation - 1013
 Mischondria - 144
 Mitochondrial injury - 670, 716
 Mitochondrial toxicity - 395, 668, 812, 855
 MK-150 - 875
 MK-8591 - 98
 Mobility - 169LB, 902
 Modeling - 115, 225, 481, 536, 1056
 Models of Care - 1031
 Modified CD4 T cells - 78, 357
 Modified CD4 T cells - 358LB
 Molecular dynamics - 208
 Molecular epidemiology - 218, 224, 542
 Monocyte - 184, 652, 711
 Monocyte activation - 44LB, 142, 239, 273, 645
 Monocyte cholesterol metabolism - 665
 Mortality - 37, 548, 549, 590, 611, 639, 691, 800, 803, 920, 941, 958, 994, 1016, 1020, 1021, 1027
 Mortuary surveillance - 297, 909
 Mother-to-child transmission (MTCT) - 33, 791, 794, 802, 806, 1023
 MRI - 148, 381, 389, 396
 MSM - 218, 886, 887
 mtDNA mutation - 716
 Mucosal - 6, 133
 • CD4+CCR5+ T cells - 287
 • Immunity - 263, 301, 880
 • Immunology - 188, 262, 286, 287
 • Protection - 263, 874
 Multi-trajectory modelling - 887
 Multicenter AIDS Cohort Study (MACS) - 283, 609, 685
 Multicohort study - 617, 618, 619
 Multidrug resistance - 479LB, 483, 848
 Multidrug resistance - 479LB
 Mutation - 716, 828

Mycobacterium tuberculosis - 157, 737
 Myocardial infarction - 42, 641, 661, 662, 671

-N-

NAFLD - 124, 553
 Naive CD4 T cell - 377
 Naive patients - 437LB, 461LB, 486, 946
 Nasopharynx-associated Lymphoid Tissue - 344
 Natural history and recovery - 855
 Natural Killer cells (NK) - 178, 179, 180, 315, 355
 NCDs - 703
 Needle-free technology - 323
 Needle-sharing - 916
 Nef - 57, 58, 136, 181, 190, 191, 253, 373
 Neisseria gonorrhoeae - 1004, 1006
 NeuroAIDS - 60, 61, 385, 423LB
 Neurocognition - 381, 416, 423LB
 Neurocognitive - 148, 175, 415

- Disorders - 63, 812
- Functioning - 386, 410, 418, 761
- Impairment - 145
- Performance - 147, 387
- Safety - 424LB

 Neuroimaging - 148, 381, 382, 383, 390, 423LB, 823
 Neuroinflammation - 391, 397, 407, 411, 413, 414
 Neurologic - 415
 Neuromotor dysfunction - 415, 820
 Neuronal injury - 395
 Neuropath - 402
 Neuropathogenesis - 394, 396, 405, 413
 Neuropsychological impairment - 401
 Neurosyphilis - 767
 Neurotoxicity - 63, 394, 395, 397
 Neutralization escape - 306, 309LB
 Neutralizing antibodies - 7, 88, 92, 301, 304, 307, 310LB, 400
 Neutropenia - 962
 Nevirapine - 444, 777, 815, 847
 New oral HCV drugs - 66, 525
 Next Generation Sequencing (NGS) - 192, 210, 213, 232, 260, 325, 399, 487, 490, 539LB, 602
 NF-kappaB - 463
 NHBS - 906, 933
 NNRTIs - 418
 Non liver-related death - 612
 Non-AIDS malignancy - 160, 616, 633
 Non-AIDS mortality - 616, 710
 Non-B subtype - 485
 Non-communicable diseases - 676, 678, 679

Non-Hodgkin lymphoma - 630
 Nonhuman primate models - 20, 24, 107, 258LB, 263, 333, 447
 Nonnucleoside reverse transcriptase inhibitor (NNRTI) - 456, 506, 668, 719
 Non-AIDS-defining cancers - 160, 620, 632
 NPC1L1 - 547
 NRTI - 30, 811, 951
 NRTI-free Antiretroviral Therapy - 30, 418, 951
 NSSA Drug Resistance - 578, 579
 NSSA inhibitor - 100
 NSSA mutation - 577
 Nuclear Import - 209LB
 Nucleoside reverse transcriptase inhibitor - 437LB
 Nuke-sparing - 45

-O-

OATP1B1/B3 - 460
 Obesity - 123, 645, 703
 Observational cohort - 708, 721, 778, 951, 962
 Older population - 705, 958
 Opioid prescriptions - 915, 916
 Opportunistic infection - 768
 Option B+ - 34, 757, 789, 792, 793, 796, 808
 Oral HPV infection - 161
 Oraquick - 519
 Orphanhood - 845
 Osteoporosis - 126
 Outbreak - 215, 221, 541, 916
 Outcomes - 174, 746, 842, 1030
 Oxidative stress - 255
 Oxidized LDL - 671, 673

-P-

p24 - 137
 P2X - 249
 P2X7 ATP receptors - 249, 663
 p38 MAPK - 467
 Partner notification - 978
 Partner services - 50, 224
 Partner testing - 49, 224
 Passive infusion - 309LB, 311LB
 Pathogenesis - 24, 243
 PCR - 339, 593, 785, 839
 Peak HIV viral load - 716
 Pediatric Antiretroviral Therapy - 39, 40, 735, 812, 816, 817, 849
 Pediatric HIV - 40, 324, 735, 780, 827, 828, 835
 Pediatric Tuberculosis - 735
 Pediatrics - 37, 735, 816, 818, 1120

People who inject drugs (PWID) - 27, 533
 Peptide - 667
 Pericardial fat - 649
 Perinatal HIV exposure - 796, 805, 825
 Perinatal HIV infection - 823, 825, 830, 834, 836, 838, 851, 856, 857
 Periodontitis - 713
 Peripheral blood mononuclear cells (PBMCs) - 730
 Peripheral neuropathy - 272, 415
 Persistence - 80, 86, 229, 340, 402
 Persistent replication - 333
 Persistent viremic control - 836
 Persons who inject drugs (PWID) - 132, 215, 535, 585, 899, 1032
 Pharmacodynamics - 104, 430
 Pharmacogenetics - 426, 429, 443, 445
 Pharmacogenomics - 443
 Pharmacokinetics - 98, 99, 104, 425, 426, 428, 431, 438, 441, 448, 453, 454, 455, 456, 457, 458, 574, 775, 818, 882LB, 1120
 Pharmacologic measures - 96
 Phase I - 876
 Phase I/II - 461LB, 816
 Phosphate - 651
 Phylodynamics - 216, 228
 Phylogenetic partitioning - 211
 Phylogenetics analysis - 210, 214, 217, 221, 223, 225, 232, 379, 400, 490, 541
 Phylogenomics - 140
 Physical function - 705
 Physical performance - 705
 PI-containing ARV regimens - 666
 Piperazine - 101
 Plasma - 250
 Plasmacytoid dendritic cell - 134
 Platelet function - 662
 Platelets - 44LB, 663
 PLWH - 434
 Pneumococcal vaccine - 328, 768
 PNPLA3 variants - 556
 Pnumococci - 724
 Point of care - 28, 512, 788
 Poly-ICLC - 322
 Polymerase - 223
 Polymorphism - 507
 Population based cohort - 116, 218, 917, 954, 982
 Population based intervention - 759, 982
 Population effectiveness - 1026
 Population level ART coverage - 114, 982
 Population level impact - 163
 Population survey methods - 937
 Population viral load - 1026

- Postpartum - 623, 791
 Posttreatment control - 87, 347, 352, 358LB
 Pre-ART - 346, 477
 Preexposure prophylaxis (PrEP) - 15, 48LB, 68, 69, 70, 71, 96, 103, 105, 106, 107, 109LB, 301, 333, 448, 471, 478, 521, 522, 524, 567, 479LB, 866, 868, 869, 870, 877, 878, 879, 881, 882LB, 883LB, 884, 885, 886, 887, 888, 889, 890, 891, 892, 894, 1051, 1052, 1055, 1056, 1057
 Pregnancy - 49, 433, 438, 439, 757, 770, 771, 772, 774, 775, 776, 791, 792, 794, 795, 798, 799, 804, 811, 862
 Prematurity - 799, 803
 Preterm - 798, 803
 Prevalence - 64, 483, 829, 860, 903, 905, 928
 Prevention - 4, 5, 79, 101, 103, 108LB, 844, 861, 870, 894, 934, 1025
 Prevention for Positives - 989, 997
 Prevention of mother-to-child transmission (PMTCT) - 34, 119, 433, 438, 441, 776, 777, 778, 790, 795, 805
 . and option B plus - 35LB, 757, 782
 Primary health care - 79, 585, 788, 1035
 Primary HIV infection - 142, 218
 Primary HIV-1 infection - 237, 522, 729
 Probiotics - 238, 263
 Program effectiveness - 163, 782
 Progression of HAND - 381
 Prophylaxis - 37, 768
 Prospective observational study - 762, 942
 Protease - 319
 • Cleavage sites - 319
 • Inhibitor - 498, 776, 1030
 • Inhibitor cross-resistance - 464
 • Inhibitor mutation - 427
 Protein-protein interaction - 202
 Proteome - 208
 Proteomics - 6, 279
 Provider education - 892
 Proximal tubule - 691, 868
 PTH - 700
 Puberty - 852
 Pulmonary tuberculosis - 158LB, 733, 736, 764, 995
 Pulse wave velocity - 658
 Purinergic - 249
 Pyroptosis - 240, 295
- Q-**
 Q-VOA - 341
 Q80K - 543
 Quality of care (QoC) - 994, 1035
 Quality of life - 475
- Quasispecies - 149
- R-**
 Racial disparities - 43, 476, 531, 700
 RAD51 - 246
 Radiotherapy - 620
 Raltegravir - 30, 508, 953
 Randomized clinical trial - 109LB, 424LB
 Randomized controlled trial - 27, 28, 41, 113LB, 470, 747, 790
 Randomized double-blind placebo-controlled trial - 79LB, 103, 419, 681, 682, 875
 Randomized trial - 475, 621, 980
 Rapid diagnostic tests - 519, 522, 968
 Rapid Pathway - 1017
 Radasvir - 153
 Re-engagement in Care - 27, 992
 Reactivation - 369
 Reactive oxygen species (ROS) - 282
 Real-time PCR - 812
 Rebound virus - 92
 Recency of HIV Infection - 485, 515
 Recombinants - 210, 213, 806
 Record linkage - 613
 Recreational substance use - 1034
 Rectal microbicides - 108LB, 880, 882LB
 Rectal tissue - 102LB
 Regression discontinuity - 960, 1011, 1012, 1048
 Regulatory T cells - 242
 Reinfection - 533
 Relapse - 573, 588, 601
 Renal
 • Function - 684, 866, 867
 • Function impairment - 153, 426, 682, 857
 • Toxicity - 452, 683
 • Tubular disease - 426, 683
 Repeat testing - 900, 977, 979
 Repertoire - 179
 Replication - 189
 Replication-competent virus - 82
 Replication-competent reservoir - 336
 Research data integrity - 1053
 Reservoir - 85, 258LB, 332, 353, 807
 Resistance - 434, 491LB, 575, 849, 940, 1029
 Resistance associated variants - 577, 580
 Resistance mutation - 490, 506
 Resistance testing - 493LB, 497
 Resource Limited Setting - 30, 493LB, 731, 787, 844, 899, 845, 907, 957, 960, 1013, 1031, 1027
 Respondent-driven sampling - 898
 Resting state fMRI - 390, 392
- Restriction factor - 57, 136, 199, 200
 Retention - 34, 789, 1011
 Retention in care - 116, 121, 790, 792, 844, 996, 1010, 1015, 1021, 1022, 1035, 1040
 Return to care - 992, 1021
 Reverse transcription - 468
 Rhesus macaque - 84, 105, 268, 272, 273
 Ribavirin - 99, 573
 Rif and INH Resistance - 749
 Rifabutin - 456, 753
 Rifampicin - 459, 754
 Rilpivirine - 31LB, 71, 453, 874, 945
 Risk behavior - 260, 770, 932
 Risk factor analysis - 215, 670, 913, 951
 Risk factors - 54, 55, 171, 630, 744, 833, 916, 936, 1046
 Risky sexual behavior - 898, 913, 973
 Ritonavir - 459
 Ritonavir-boosted lopinavir - 851
 RNA seq - 807, 880
 RNA splicing - 192
 Romidepsin - 26LB
 Rosuvastatin - 674
 Rural - 676, 965
 RV144 - 317
 Ryan White - 1001, 1002
- S-**
 Safety - 116, 461LB, 810, 818, 1120
 Safety - 461LB
 Salicylate - 463
 SAMHD1 - 205, 207, 468
 sCD14 - 239
 sCD163 - 690
 Screening - 156, 531, 532, 565, 622, 648, 740, 869, 966, 1005
 Second-line Antiretroviral Therapy - 498, 666, 752, 850, 1030
 Self-report - 704, 907, 954
 Self-reported condom use - 865
 Semen - 75LB, 164, 268, 285, 351, 730
 Semen biological marker - 864
 Seminal shedding - 727
 Senescence - 183
 Sensitive testing - 519
 Sequela - 73LB
 Sequencing - 201, 219
 Sequential Envs - 806
 Serious adverse events - 962
 Serious Non-AIDS Events - 559, 711
 Seroconversion - 519, 894
 Seroconverters - 519, 569
 Serodiscordant couples - 167, 200, 301, 1063
 Serology - 72LB

- Seroprevalence - 927
 Serosorting - 933
 Serum cholesterol - 854
 Set-point viral load - 346
 Severe immunodeficiency - 686
 Sex Difference - 43, 79, 416, 943
 Sex partners - 897
 Sex workers - 863, 922, 1046, 1059
 Sexual
 • Behavior - 890, 905, 925, 926, 930
 • Event coverage - 1055
 • Networks - 897, 964
 • Risk behavior - 863, 900, 1045
 • Transmission - 225, 987, 1045
 • Transmitted infection (STI) - 69, 770, 869, 870, 875, 878, 890, 900, 912, 923, 924, 932, 964, 1004, 1005, 1007
 SGA - 803
 SHIV - 229, 317, 321
 Shock and kill - 320
 Side effects - 756
 Sierra Leone - 72LB
 Simplification - 417
 Single cell analysis - 807
 Single genome sequencing - 86, 92, 348, 379, 400, 406, 806, 848
 Single-cell laser capture microdissection - 151
 siRNA - 182
 SIV - 21, 22, 23, 24, 84, 94, 95LB, 130, 270, 273, 352, 353, 877
 SIV coreceptor - 24
 SIV encephalitis - 273
 SIV/HIV chimeric viruses - 356
 Small-for-gestational-age - 803
 Smoking - 257, 387, 647, 674, 675
 SNP - 547
 Social media - 70
 Social network - 217, 924, 985
 Social support - 919
 Socioeconomic status - 476
 SOF/LDV - 452
 SOF/LDV - 154LB
 Sofosbuvir - 100, 573, 575, 577, 584, 585
 Solo LTR - 337
 Sooty mangabey - 20, 24, 827
 Sorafenib - 634
 South Africa - 14, 39, 115, 155, 157, 167, 169LB, 256, 523, 613, 631, 734, 756, 759, 783, 792, 845, 905, 907, 936, 981, 1010, 1011, 1014, 1016, 1028, 1048, 1057, 1061
 South Sudan - 510
 Spatial analysis - 972
 Spatial mapping - 1054
 Special populations - 496
 Speech impairments - 813
 Spontaneous clearance - 75LB, 152
 ST2 - 237
 State Space Models - 1042
 Statins - 421, 550, 553, 643, 673
 Statistics - 266
 Stem-cell transplantation - 357, 364, 365, 366, 367
 Stigma - 2, 606, 919, 925
 Stillbirth - 799
 Stool Xpert MTB/RIF - 748
 Stroke - 43, 636, 637, 638, 639
 Structure - 56, 58
 Sub-Saharan Africa - 498, 563, 658, 744, 751, 760, 786, 850, 861, 924, 925, 1049, 1054
 Subtype - 221, 219, 227
 Subtype B - 507
 Subtype C - 484
 Suppression - 1024
 Suppressive ART - 143, 276, 322, 710, 820
 Surveillance - 212, 477, 510, 520, 540, 908, 921
 Surveillance data - 53
 Survival - 54, 631, 688
 Survivor - 72LB, 73LB, 74LB, 75LB, 929
 Sustained virologic response (SVR) - 539LB
 SVR - 589, 604
 Swaziland - 1056
 Switching Antiretroviral Therapy - 680
 Symptoms - 518
 Synonymous mutations - 483
 Syphilis - 767, 870, 900, 929, 970, 1004, 1007
 Systems biology - 6, 324
- T-**
- T cell - 596
 T cell activation - 142, 190, 255
 T cell exhaustion - 596
 T cell subsets - 807
 T follicular - 94, 242, 378
 T follicular helper cells - 23, 82
 T-bet - 254
 TAF - 102LB, 050
 Tanzania - 978, 1025
 Targeted sequence capture - 360
 TasP - 1044
 Tat - 361, 396
 Tele-mentoring - 534
 Telomerase activity - 669
 Telomere length - 670
 Temporal trends - 888, 933
 Tenofovir - 46, 147, 426, 434, 452, 484, 503, 592, 669, 680, 681, 682, 695LB, 728, 813, 866, 867, 871
 • Alafenamide - 107, 680, 681, 682, 717
 • disoproxil fumarate - 36, 48LB, 104, 449, 683, 684, 685, 694, 728, 808, 819, 877
 • virological suppression, mortality, ART - 562
 Tenofovir/Emtricitabine - 103, 479LB, 867
 Test and treat - 168LB, 169LB, 842
 Testes - 867
 Testing - 841, 969, 985, 1006
 Testosterone Therapy - 914
 Tetherin - 58
 Text Messaging - 977, 993
 Tfh cells - 233, 245LB, 334
 TFV-DP - 102LB
 Th1 - 289
 Th17 cells - 188, 238, 280
 Thailand - 219, 384, 606, 857, 927, 956, 972
 The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) - 150, 684, 688
 Therapeutic vaccine - 26LB, 320, 322
 Third-Line - 493LB
 Thrombocytopenia - 962
 TIM-1 - 247
 Time to ART initiation - 790, 1010
 Tissue - 290, 345, 448
 Tissue Distribution - 84
 Tissue macrophages - 331, 402
 TLR - 196, 270, 322, 323
 TLR7 - 95LB
 Tolerability - 471
 Toxicity - 778, 867, 963
 Toxoplasma gondii prophylaxis - 765
 Traditional medicines - 434
 TRAIL - 372
 Transcription - 80
 Transcriptome - 208, 257, 725
 Transgender women - 48LB, 108LB
 Transgendered - 79, 884, 971
 Transient Elastography - 527, 529, 530, 560
 Transition to adult units - 177, 835
 Transitional-memory T cells - 332
 Transmission - 231, 736, 934
 • Cluster - 602
 • Group - 221, 943
 • Network - 149, 215, 221, 222
 • Risk - 221, 934, 1033
 Transmitted drug resistance - 477, 483, 486, 489
 Transmitted founder - 187, 231, 232, 394, 602

Transmitted HIV drug resistance - 478, 481, 482
 Transplantation - 264, 356
 Transport - 180
 Treatment - 146, 156, 605, 999
 • As prevention - 169LB, 167, 535, 989, 1054, 1063
 • Cascade - 172, 1048
 • Experienced - 472
 • Initiation - 112, 1048
 • Interruption - 332
 • Naive adults - 470, 509
 • Outcomes - 755
 TREG - 258LB
 Trends - 895
 TRIM22 - 246
 TRIM5alpha - 206
 TRIMCyp - 206
 Tropism - 509
 Truvada - 885, 888, 892, 894
 Tuberculosis - 115, 156, 743, 769
 • And HIV - 14, 157, 398, 457, 734, 738, 741LB, 744, 746, 747, 751, 753, 755, 756, 758, 1053
 • Diagnosis - 742, 746, 747, 749, 758
 • Drug resistance - 14
 • Incidence - 752
 • In pregnancy - 757, 758
 • Prophylaxis - 747
 • Surveillance - 1053
 Type 1 interferon - 135, 322, 781
 TZA-Assay - 341

-U-

Uganda - 444, 594
 Ultradeep sequencing - 489, 509, 827, 950
 Ultrasensitive viral load - 839
 UNAIDS 90-90-90 - 111
 United States - 216, 593, 772, 830, 935, 1006, 1051
 Universal ART coverage - 114, 117
 Unprotected intercourse - 286, 912
 Uptake - 883LB
 Urine biomarkers - 763
 Urine LAM testing - 747
 Urine lipoarabinomannan - 748
 USA - 883LB, 917
 Usage - 883LB

-V-

Vaccination - 161
 Vaccine - 76LB, 319, 321, 591
 Vaccine response - 325, 328, 825
 VACS - 645

Vaginal film - 871
 Vaginal gel - 875
 Vaginal mucosa - 288
 Vaginal ring - 872, 873, 877, 1057, 1058
 Validation study - 907
 Vascular disease - 41
 Vertical transmission - 839
 Veterans - 714
 Vif - 59, 199, 200, 202
 Viral
 • Decay - 751, 947
 • Diversity - 33, 215, 218
 • Fitness - 197
 • Hepatitis - 64, 545, 594, 609
 • Kinetics - 357, 956
 • Load - 304, 952, 993, 1024, 1027, 1029
 • Load monitoring - 795, 832
 • Outgrowth - 361
 • Persistence - 73LB, 333
 • Rebound - 32LB, 346, 831, 832
 • Replication - 151, 195, 378, 465, 592, 828
 • reservoir - 229, 333, 336, 356, 361, 372, 837
 • reservoir - 311LB
 • RNA agonist - 371
 • sequences - 331, 339
 • suppression - 27, 53, 111, 116, 832, 1002, 1027, 1028, 1035, 1037
 Viremia - 795
 Virologic
 • Control - 39, 209LB, 347
 • Failure - 484, 956, 1039
 • Monitoring - 502
 • Outcomes - 346, 502
 • Response - 796
 • Suppression - 391, 953, 1040
 Visceral adipose tissue - 704
 Vitamin D - 700, 798, 826, 859
 VMMC - 165
 Vorinostat - 355
 Vpr - 185
 Vulnerable populations - 79

-W-

Waist circumference - 704
 Weight gain - 858
 West Africa - 434, 568, 923, 961, 962, 1015, 1047
 West Africa - 75LB
 Western Blot - 515
 White matter abnormalities - 148
 World Health Organization (WHO) - 477
 World Health Organization (WHO) guidelines - 666, 1011, 1020, 1048

Women - 109LB, 162, 277, 593, 647, 650, 706, 720, 793, 794, 861, 1047, 1058

-X-




Xpert MTB/RIF - 742, 750

-Y-

Y chromosomal DNA - 865
 Yellow fever vaccine - 326
 Young adults - 177, 826, 830, 856, 859, 900
 Young black MSM - 217, 832, 930, 993

-Z-

Zidovudine - 205, 962
 Zinc finger nucleases - 356, 358LB
 Zoledronic acid - 47



Conference Schedule Overview

	Monday, February 22, 2016	Tuesday, February 23, 2016	Wednesday, February 24, 2016	Thursday, February 25, 2016
8:30 AM		PLENARY SESSION Auditorium PL1: Harnessing Antibodies for HIV-1 Prevention and Treatment	PLENARY SESSION Auditorium PL3: Progress in Gene Therapy for HIV Cure PL4: HIV in Transgender Populations: Charted and Uncharted Waters	PLENARY SESSION Auditorium PL5: Tuberculosis: Why Do I Have To Take So Many Pills? PL6: The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
9:00 AM	Program Committee Workshop for New Investigators and Trainees <i>Ballroom B/C</i>	PL2: Antiretroviral Therapy: Where Are We Now? Where Are We Going?		
9:30 AM				
10:00 AM		CONCURRENT ORAL ABSTRACT SESSIONS O-1: SIV and HIV Pathogenesis <i>Room 302</i> O-2: Viral Reservoirs/Antiretroviral Therapy Randomized Clinical Trials <i>Ballroom B/C</i> O-3: Prevention and Treatment of Pediatric HIV Infections <i>Room 304/306</i> O-4: Complications from Head to Toe <i>Auditorium</i> O-5: Strategies for Testing and Linkage to Care: Are We Closing the Gap? <i>Ballroom A</i>	CONCURRENT ORAL ABSTRACT SESSIONS O-6: Reservoirs, Relapse, and Remission <i>Ballroom B/C</i> O-7: Pushing Frontiers of Adaptive Immunity <i>Room 304/306</i> O-8: Drugs: From Discovery to Challenges in Clinical Use <i>Room 302</i> O-9: Expanding the Toolbox for Prevention <i>Auditorium</i> O-10: Getting to 90-90-90 <i>Ballroom A</i>	CONCURRENT ORAL ABSTRACT SESSIONS O-11: HIV Virology: Putting It All Together <i>Room 312</i> O-12: Central Nervous System: Viral Dynamics, Biomarkers, and Cognition <i>304/306</i> O-13: HCV: Curing the Patient but Not the Population <i>Ballroom B/C</i> O-14: Tuberculosis and Other Opportunistic Infections/Cancer Prevention: Hits and Misses <i>Ballroom A</i> O-15: Focus on HIV Acquisition and Challenges in the Cascade <i>Room 311</i>
12:00 PM	LUNCH 12:15 PM to 1:45 PM	LUNCH 12:15 PM to 1:45 PM	LUNCH 12:15 PM to 1:45 PM	
12:30 PM				
1:00 PM	Martin Delaney Presentation Panel on Stigma, Trauma, and Stress: Considerations for HIV Research and Programs <i>Ballroom B/C</i>	CONCURRENT THEMED DISCUSSION SESSIONS TD-1: Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions <i>Room 311</i> TD-2: Global Burden and Mortality of Cancer in HIV <i>Room 312</i> TD-3: Rants About HCV RAVS <i>Ballroom B/C</i> TD-4: Learning from Experience: Shaping the Future of Antiretroviral Therapy in Sub-Saharan Africa <i>Room 304/306</i> TD-5: HIV Testing: A Crucial Foundation <i>Room 302</i> TD-6: HIV Persistence and Latency Reversal <i>Ballroom A</i>	CONCURRENT THEMED DISCUSSION SESSIONS TD-7: Stroke: Incidence and Risk Factors <i>Room 304/306</i> TD-8: HIV and Microbiomes <i>Room 302</i> TD-9: Cryptococcal Disease: Detection and Complications <i>Room 312</i> TD-10: New Drugs for Kids: What's Taking so Long? <i>Room 311</i> TD-11: Innovations to Enhance Treatment Outcomes <i>Ballroom A</i> TD-12: It's Complicated: Renal Function and STIs in PrEP Users <i>Ballroom B/C</i>	CONCURRENT THEMED DISCUSSION SESSIONS TD-13: HIV Effects on Liver Fibrosis and Steatosis <i>Ballroom B/C</i> TD-14: Mind the Gaps: Optimizing the PMTCT Cascade <i>Room 302</i> TD-15: Pathways to Eliciting Antibody Responses <i>Room 312</i> TD-16: Going to Scale With ART and PrEP <i>Room 304/306</i> TD-17: MSM in Low- and Middle-Income Countries <i>Ballroom A</i> TD-18: Next Generation Sequencing for Detection of Transmitted or Linked Drug Resistance <i>Room 311</i>
2:00 PM				
2:30 PM	CONCURRENT WORKSHOPS Clinical Trial Design and Analysis <i>Ballroom B/C</i> Frontiers in Laboratory Science <i>Ballroom A</i> Interactive Case-Based Workshop on Hepatitis C <i>Room 304</i>	POSTER SESSIONS <i>Poster Halls A/B and D</i>	POSTER SESSIONS <i>Poster Halls A/B and D</i>	POSTER SESSIONS <i>Poster Halls A/B and D</i>
2:45 PM		CONCURRENT SYMPOSIA S-1: Molecular Interplay from Virus to Host <i>Room 304/306</i> S-2: A Beautiful Mind: Keeping It <i>Ballroom A</i> S-3: Global Impact of Hepatitis <i>Ballroom B/C</i> S-4: Innovations in PrEP <i>Auditorium</i>	CONCURRENT SYMPOSIA S-5: Reaching 90-90-90 and Beyond: Challenges and Innovations <i>Ballroom A</i> S-6: Pathogenesis and Consequences of Metabolic Complications <i>Ballroom B/C</i> S-7: Location, Location, Location: The Lymph Node <i>Room 304/306</i>	CONCURRENT SYMPOSIA S-8: Where Are the HIV Hot Spots? <i>Ballroom B/C</i> S-9: #HIV - Who Me? Adolescents at the Crossroads <i>Ballroom A</i> S-10: Natural Born(e) Killers <i>Room 304/306</i>
4:00 PM				
5:00 PM	Opening Session Auditorium Bernard Fields Lecture N'Galy-Mann Lecture CROI Foundation Special Event			
6:00 PM				
6:15 PM		SPECIAL SESSION 6:15 PM to 7:45 PM Ebola: One Year Later <i>Ballroom B/C</i>		
7:00 PM	Welcome Reception 7:00 PM to 9:30 PM <i>Prefunction area and Poster Hall</i>			